Association 21919924_3 0 11
of 21919924_3 12 14
alcohol 21919924_3 15 22
dependence 21919924_3 23 33
( 21919924_3 34 35
AD 21919924_3 36 38
) 21919924_3 39 40
with 21919924_3 41 45
markers 21919924_3 46 53
located 21919924_3 54 61
at 21919924_3 62 64
the 21919924_3 65 68
3 21919924_3 69 70
' 21919924_3 71 72
region 21919924_3 73 79
of 21919924_3 80 82
GABRA 21919924_3 83 88
2 21919924_3 88 89
has 21919924_3 90 93
been 21919924_3 94 98
replicated 21919924_3 99 109
in 21919924_3 110 112
several 21919924_3 113 120
studies 21919924_3 121 128
, 21919924_3 129 130
but 21919924_3 131 134
recent 21919924_3 135 141
studies 21919924_3 142 149
suggested 21919924_3 150 159
the 21919924_3 160 163
possibility 21919924_3 164 175
that 21919924_3 176 180
the 21919924_3 181 184
signal 21919924_3 185 191
may 21919924_3 192 195
be 21919924_3 196 198
attributable 21919924_3 199 211
to 21919924_3 212 214
the 21919924_3 215 218
adjacent 21919924_3 219 227
gene 21919924_3 228 232
, 21919924_3 233 234
GABRG 21919924_3 235 240
1 21919924_3 240 241
, 21919924_3 242 243
located 21919924_3 244 251
90 21919924_3 252 254
kb 21919924_3 255 257
distant 21919924_3 258 265
in 21919924_3 266 268
the 21919924_3 269 272
3 21919924_3 273 274
' 21919924_3 275 276
direction 21919924_3 277 286
. 21919924_3 287 288

The 22935916_9 0 3
COMT 22935916_9 4 8
gene 22935916_9 9 13
polymorphism 22935916_9 14 26
, 22935916_9 27 28
SNP 22935916_9 29 32
rs 22935916_9 33 35
9606186 22935916_9 35 42
, 22935916_9 43 44
is 22935916_9 45 47
associated 22935916_9 48 58
with 22935916_9 59 63
risperidone 22935916_9 64 75
therapy 22935916_9 76 83
efficiency 22935916_9 84 94
in 22935916_9 95 97
the 22935916_9 98 101
Chinese 22935916_9 102 109
population 22935916_9 110 120
. 22935916_9 121 122

Most 15188667_7 0 4
GISTs 15188667_7 5 10
respond 15188667_7 11 18
to 15188667_7 19 21
imatinib 15188667_7 22 30
mesylate 15188667_7 31 39
, 15188667_7 40 41
which 15188667_7 42 47
selectively 15188667_7 48 59
inhibits 15188667_7 60 68
both 15188667_7 69 73
KIT 15188667_7 74 77
and 15188667_7 78 81
PDGFRA 15188667_7 82 88
, 15188667_7 89 90
and 15188667_7 91 94
is 15188667_7 95 97
now 15188667_7 98 101
considered 15188667_7 102 112
as 15188667_7 113 115
the 15188667_7 116 119
standard 15188667_7 120 128
systemic 15188667_7 129 137
therapy 15188667_7 138 145
for 15188667_7 146 149
advanced 15188667_7 150 158
GIST 15188667_7 159 163
. 15188667_7 164 165

CONCLUSIONS 18568343_13 0 11
: 18568343_13 12 13
The 18568343_13 14 17
effect 18568343_13 18 24
of 18568343_13 25 27
UGT 18568343_13 28 31
1 18568343_13 31 32
A 18568343_13 32 33
8 18568343_13 33 34
and 18568343_13 35 38
UGT 18568343_13 39 42
1 18568343_13 42 43
A 18568343_13 43 44
9 18568343_13 44 45
variants 18568343_13 46 54
on 18568343_13 55 57
MPA 18568343_13 58 61
metabolism 18568343_13 62 72
appears 18568343_13 73 80
to 18568343_13 81 83
be 18568343_13 84 86
modified 18568343_13 87 95
by 18568343_13 96 98
concomitant 18568343_13 99 110
calcineurin 18568343_13 111 122
inhibitor 18568343_13 123 132
therapy 18568343_13 133 140
. 18568343_13 141 142

Withdrawal 11587712_3 0 10
precipitated 11587712_3 11 23
with 11587712_3 24 28
a 11587712_3 29 30
peripherally 11587712_3 31 43
acting 11587712_3 44 50
quaternary 11587712_3 51 61
opioid 11587712_3 62 68
antagonist 11587712_3 69 79
( 11587712_3 80 81
naloxone 11587712_3 82 90
methiodide 11587712_3 91 101
) 11587712_3 102 103
increased 11587712_3 104 113
Fos 11587712_3 114 117
expression 11587712_3 118 128
but 11587712_3 129 132
caused 11587712_3 133 139
a 11587712_3 140 141
more 11587712_3 142 146
restricted 11587712_3 147 157
pattern 11587712_3 158 165
of 11587712_3 166 168
neuronal 11587712_3 169 177
activation 11587712_3 178 188
than 11587712_3 189 193
systemic 11587712_3 194 202
withdrawal 11587712_3 203 213
( 11587712_3 214 215
precipitated 11587712_3 216 228
with 11587712_3 229 233
naloxone 11587712_3 234 242
which 11587712_3 243 248
enters 11587712_3 249 255
the 11587712_3 256 259
brain 11587712_3 260 265
) 11587712_3 266 267
. 11587712_3 268 269

One 26791794_9 0 3
patient 26791794_9 4 11
each 26791794_9 12 16
whose 26791794_9 17 22
advanced 26791794_9 23 31
tumors 26791794_9 32 38
harbored 26791794_9 39 47
high 26791794_9 48 52
level 26791794_9 53 58
MET 26791794_9 59 62
amplification 26791794_9 63 76
with 26791794_9 77 81
wild 26791794_9 82 86
- 26791794_9 86 87
type 26791794_9 87 91
PIK 26791794_9 92 95
3 26791794_9 95 96
CA 26791794_9 96 98
or 26791794_9 99 101
MET 26791794_9 102 105
exon 26791794_9 106 110
14 26791794_9 111 113
skipping 26791794_9 114 122
mutation 26791794_9 123 131
with 26791794_9 132 136
PIK 26791794_9 137 140
3 26791794_9 140 141
CA 26791794_9 141 143
- 26791794_9 144 145
p 26791794_9 146 147
. 26791794_9 147 148
Glu 26791794_9 148 151
542 26791794_9 151 154
Lys 26791794_9 154 157
had 26791794_9 158 161
significant 26791794_9 162 173
responses 26791794_9 174 183
to 26791794_9 184 186
crizotinib 26791794_9 187 197
; 26791794_9 198 199
suggesting 26791794_9 200 210
that 26791794_9 211 215
PIK 26791794_9 216 219
3 26791794_9 219 220
CA 26791794_9 220 222
co 26791794_9 223 225
- 26791794_9 225 226
mutation 26791794_9 226 234
did 26791794_9 235 238
not 26791794_9 239 242
affect 26791794_9 243 249
clinical 26791794_9 250 258
response 26791794_9 259 267
. 26791794_9 268 269

To 17559417_5 0 2
address 17559417_5 3 10
this 17559417_5 11 15
question 17559417_5 16 24
, 17559417_5 25 26
we 17559417_5 27 29
studied 17559417_5 30 37
the 17559417_5 38 41
effects 17559417_5 42 49
of 17559417_5 50 52
acute 17559417_5 53 58
and 17559417_5 59 62
chronic 17559417_5 63 70
intermittent 17559417_5 71 83
cocaine 17559417_5 84 91
administration 17559417_5 92 106
in 17559417_5 107 109
mice 17559417_5 110 114
with 17559417_5 115 119
a 17559417_5 120 121
targeted 17559417_5 122 130
deletion 17559417_5 131 139
of 17559417_5 140 142
the 17559417_5 143 146
gene 17559417_5 147 151
for 17559417_5 152 155
the 17559417_5 156 159
5 17559417_5 160 161
- 17559417_5 161 162
HT 17559417_5 162 164
( 17559417_5 164 165
3 17559417_5 165 166
A 17559417_5 166 167
) 17559417_5 168 169
- 17559417_5 170 171
receptor 17559417_5 172 180
subunit 17559417_5 181 188
( 17559417_5 189 190
5 17559417_5 191 192
- 17559417_5 192 193
HT 17559417_5 193 195
( 17559417_5 195 196
3 17559417_5 196 197
A 17559417_5 197 198
) 17559417_5 199 200
- 17559417_5 201 202
/ 17559417_5 203 204
- 17559417_5 205 206
) 17559417_5 207 208
. 17559417_5 209 210

MATERIAL 18355347_4 0 8
AND 18355347_4 9 12
METHODS 18355347_4 13 20
: 18355347_4 21 22
The 18355347_4 23 26
study 18355347_4 27 32
included 18355347_4 33 41
98 18355347_4 42 44
CsA 18355347_4 45 48
- 18355347_4 49 50
treated 18355347_4 50 57
renal 18355347_4 58 63
transplant 18355347_4 64 74
recipients 18355347_4 75 85
( 18355347_4 86 87
with 18355347_4 88 92
and 18355347_4 93 96
without 18355347_4 97 104
GO 18355347_4 105 107
) 18355347_4 108 109
and 18355347_4 110 113
44 18355347_4 114 116
tacrolimus 18355347_4 117 127
- 18355347_4 128 129
treated 18355347_4 129 136
transplant 18355347_4 137 147
patients 18355347_4 148 156
( 18355347_4 157 158
without 18355347_4 159 166
GO 18355347_4 167 169
) 18355347_4 170 171
. 18355347_4 172 173

Accordingly 25657029_9 0 11
, 25657029_9 12 13
PDAC 25657029_9 14 18
cell 25657029_9 19 23
lines 25657029_9 24 29
expressing 25657029_9 30 40
the 25657029_9 41 44
MIA 25657029_9 45 48
2 25657029_9 48 49
( 25657029_9 50 51
I 25657029_9 52 53
141 25657029_9 53 56
M 25657029_9 56 57
) 25657029_9 58 59
variant 25657029_9 60 67
expressed 25657029_9 68 77
high 25657029_9 78 82
levels 25657029_9 83 89
of 25657029_9 90 92
ERN 25657029_9 93 96
1 25657029_9 96 97
and 25657029_9 98 101
were 25657029_9 102 106
more 25657029_9 107 111
sensitive 25657029_9 112 121
to 25657029_9 122 124
gemcitabine 25657029_9 125 136
. 25657029_9 137 138

One 14654666_9 0 3
of 14654666_9 4 6
the 14654666_9 7 10
nonresponders 14654666_9 11 24
was 14654666_9 25 28
reinvestigated 14654666_9 29 43
at 14654666_9 44 46
3 14654666_9 47 48
years 14654666_9 49 54
of 14654666_9 55 57
age 14654666_9 58 61
, 14654666_9 62 63
showing 14654666_9 64 71
a 14654666_9 72 73
clear 14654666_9 74 79
response 14654666_9 80 88
( 14654666_9 89 90
genotype 14654666_9 91 99
Y 14654666_9 100 101
414 14654666_9 101 104
C 14654666_9 104 105
/ 14654666_9 106 107
R 14654666_9 108 109
408 14654666_9 109 112
W 14654666_9 112 113
) 14654666_9 114 115
: 14654666_9 116 117
BH 14654666_9 118 120
4 14654666_9 120 121
supplementation 14654666_9 122 137
resulted 14654666_9 138 146
in 14654666_9 147 149
a 14654666_9 150 151
much 14654666_9 152 156
higher 14654666_9 157 163
Phe 14654666_9 164 167
tolerance 14654666_9 168 177
( 14654666_9 178 179
500 14654666_9 180 183
instead 14654666_9 184 191
of 14654666_9 192 194
250 14654666_9 195 198
mg 14654666_9 199 201
/ 14654666_9 201 202
day 14654666_9 202 205
) 14654666_9 206 207
with 14654666_9 208 212
blood 14654666_9 213 218
Phe 14654666_9 219 222
levels 14654666_9 223 229
< 14654666_9 230 231
200 14654666_9 232 235
micromol 14654666_9 236 244
/ 14654666_9 244 245
L 14654666_9 245 246
. 14654666_9 247 248

Beta 16001112_10 0 4
2 16001112_10 4 5
- 16001112_10 6 7
/ 16001112_10 8 9
- 16001112_10 10 11
mice 16001112_10 12 16
treated 16001112_10 17 24
with 16001112_10 25 29
4 16001112_10 30 31
. 16001112_10 31 32
0 16001112_10 32 33
mg 16001112_10 34 36
/ 16001112_10 36 37
kg 16001112_10 37 39
/ 16001112_10 39 40
h 16001112_10 40 41
nicotine 16001112_10 42 50
were 16001112_10 51 55
no 16001112_10 56 58
longer 16001112_10 59 65
supersensitive 16001112_10 66 80
, 16001112_10 81 82
indicating 16001112_10 83 93
that 16001112_10 94 98
tolerance 16001112_10 99 108
developed 16001112_10 109 118
at 16001112_10 119 121
this 16001112_10 122 126
higher 16001112_10 127 133
dose 16001112_10 134 138
. 16001112_10 139 140

Here 19366808_3 0 4
, 19366808_3 5 6
we 19366808_3 7 9
show 19366808_3 10 14
that 19366808_3 15 19
the 19366808_3 20 23
multikinase 19366808_3 24 35
inhibitor 19366808_3 36 45
sorafenib 19366808_3 46 55
inhibits 19366808_3 56 64
proliferation 19366808_3 65 78
and 19366808_3 79 82
induces 19366808_3 83 90
apoptosis 19366808_3 91 100
at 19366808_3 101 103
much 19366808_3 104 108
lower 19366808_3 109 114
concentrations 19366808_3 115 129
in 19366808_3 130 132
Ton 19366808_3 133 136
. 19366808_3 136 137
B 19366808_3 137 138
210 19366808_3 138 141
cells 19366808_3 142 147
when 19366808_3 148 152
driven 19366808_3 153 159
by 19366808_3 160 162
inducibly 19366808_3 163 172
expressed 19366808_3 173 182
BCR 19366808_3 183 186
/ 19366808_3 186 187
ABL 19366808_3 187 190
than 19366808_3 191 195
when 19366808_3 196 200
driven 19366808_3 201 207
by 19366808_3 208 210
interleukin 19366808_3 211 222
- 19366808_3 222 223
3 19366808_3 223 224
. 19366808_3 225 226

The 12851836_12 0 3
apparently 12851836_12 4 14
high 12851836_12 15 19
prevalence 12851836_12 20 30
of 12851836_12 31 33
the 12851836_12 34 37
DPYD 12851836_12 38 42
mutation 12851836_12 43 51
associated 12851836_12 52 62
with 12851836_12 63 67
lack 12851836_12 68 72
of 12851836_12 73 75
DPD 12851836_12 76 79
activity 12851836_12 80 88
in 12851836_12 89 91
the 12851836_12 92 95
normal 12851836_12 96 102
population 12851836_12 103 113
warrants 12851836_12 114 122
genetic 12851836_12 123 130
screening 12851836_12 131 140
for 12851836_12 141 144
the 12851836_12 145 148
presence 12851836_12 149 157
of 12851836_12 158 160
these 12851836_12 161 166
mutations 12851836_12 167 176
in 12851836_12 177 179
cancer 12851836_12 180 186
patients 12851836_12 187 195
before 12851836_12 196 202
the 12851836_12 203 206
administration 12851836_12 207 221
of 12851836_12 222 224
5 12851836_12 225 226
- 12851836_12 226 227
FU 12851836_12 227 229
. 12851836_12 230 231

CONCLUSIONS 16818479_12 0 11
: 16818479_12 12 13
EGFR 16818479_12 14 18
mutations 16818479_12 19 28
did 16818479_12 29 32
not 16818479_12 33 36
affect 16818479_12 37 43
response 16818479_12 44 52
to 16818479_12 53 55
conventional 16818479_12 56 68
chemotherapeutic 16818479_12 69 85
agents 16818479_12 86 92
, 16818479_12 93 94
namely 16818479_12 95 101
platinums 16818479_12 102 111
, 16818479_12 112 113
paclitaxel 16818479_12 114 124
and 16818479_12 125 128
gemcitabine 16818479_12 129 140
. 16818479_12 141 142

The 14558439_3 0 3
JAK 14558439_3 4 7
3 14558439_3 7 8
inhibitor 14558439_3 9 18
4 14558439_3 19 20
- 14558439_3 20 21
( 14558439_3 21 22
4 14558439_3 22 23
' 14558439_3 23 24
- 14558439_3 24 25
hydroxyphenyl 14558439_3 25 38
) 14558439_3 38 39
- 14558439_3 39 40
amino 14558439_3 40 45
- 14558439_3 45 46
6 14558439_3 46 47
, 14558439_3 47 48
7 14558439_3 48 49
- 14558439_3 49 50
dimethoxyquinazoline 14558439_3 50 70
( 14558439_3 71 72
CAS 14558439_3 73 76
202475 14558439_3 77 83
- 14558439_3 83 84
60 14558439_3 84 86
- 14558439_3 86 87
3 14558439_3 87 88
, 14558439_3 89 90
JANEX 14558439_3 91 96
- 14558439_3 96 97
1 14558439_3 97 98
, 14558439_3 99 100
WHI 14558439_3 101 104
- 14558439_3 104 105
P 14558439_3 105 106
131 14558439_3 106 109
) 14558439_3 110 111
prevented 14558439_3 112 121
the 14558439_3 122 125
rejection 14558439_3 126 135
of 14558439_3 136 138
islet 14558439_3 139 144
allografts 14558439_3 145 155
in 14558439_3 156 158
mice 14558439_3 159 163
with 14558439_3 164 168
a 14558439_3 169 170
normal 14558439_3 171 177
JAK 14558439_3 178 181
3 14558439_3 181 182
expression 14558439_3 183 193
status 14558439_3 194 200
. 14558439_3 201 202

Effect 23543259_1 0 6
of 23543259_1 7 9
eNOS 23543259_1 10 14
polymorphisms 23543259_1 15 28
on 23543259_1 29 31
salbutamol 23543259_1 32 42
evoked 23543259_1 43 49
endothelium 23543259_1 50 61
dependent 23543259_1 62 71
vasodilation 23543259_1 72 84
in 23543259_1 85 87
South 23543259_1 88 93
Indian 23543259_1 94 100
healthy 23543259_1 101 108
subjects 23543259_1 109 117
. 23543259_1 118 119

In 15196685_4 0 2
contrast 15196685_4 3 11
to 15196685_4 12 14
the 15196685_4 15 18
control 15196685_4 19 26
group 15196685_4 27 32
( 15196685_4 33 34
n 15196685_4 35 36
= 15196685_4 37 38
3 15196685_4 39 40
) 15196685_4 41 42
, 15196685_4 43 44
2 15196685_4 45 46
h 15196685_4 47 48
after 15196685_4 49 54
intramuscular 15196685_4 55 68
capsaicin 15196685_4 69 78
injection 15196685_4 79 88
, 15196685_4 89 90
c 15196685_4 91 92
- 15196685_4 92 93
fos 15196685_4 93 96
expression 15196685_4 97 107
was 15196685_4 108 111
more 15196685_4 112 116
extensive 15196685_4 117 126
ipsilaterally 15196685_4 127 140
to 15196685_4 141 143
the 15196685_4 144 147
injected 15196685_4 148 156
side 15196685_4 157 161
in 15196685_4 162 164
the 15196685_4 165 168
C 15196685_4 169 170
3 15196685_4 170 171
- 15196685_4 171 172
C 15196685_4 172 173
6 15196685_4 173 174
segments 15196685_4 175 183
, 15196685_4 184 185
and 15196685_4 186 189
bilaterally 15196685_4 190 201
in 15196685_4 202 204
the 15196685_4 205 208
L 15196685_4 209 210
4 15196685_4 210 211
- 15196685_4 211 212
L 15196685_4 212 213
6 15196685_4 213 214
segments 15196685_4 215 223
. 15196685_4 224 225

METHODS 21192345_5 0 7
: 21192345_5 8 9
We 21192345_5 10 12
sequenced 21192345_5 13 22
the 21192345_5 23 26
exons 21192345_5 27 32
of 21192345_5 33 35
EPHX 21192345_5 36 40
1 21192345_5 40 41
using 21192345_5 42 47
PCR 21192345_5 48 51
and 21192345_5 52 55
direct 21192345_5 56 62
sequencing 21192345_5 63 73
in 21192345_5 74 76
279 21192345_5 77 80
patients 21192345_5 81 89
consisting 21192345_5 90 100
of 21192345_5 101 103
three 21192345_5 104 109
major 21192345_5 110 115
ethnic 21192345_5 116 122
groups 21192345_5 123 129
receiving 21192345_5 130 139
maintenance 21192345_5 140 151
warfarin 21192345_5 152 160
with 21192345_5 161 165
a 21192345_5 166 167
stable 21192345_5 168 174
international 21192345_5 175 188
normalized 21192345_5 189 199
ratio 21192345_5 200 205
. 21192345_5 206 207

Particularly 14582249_5 0 12
the 14582249_5 13 16
role 14582249_5 17 21
of 14582249_5 22 24
GSTT 14582249_5 25 29
1 14582249_5 29 30
and 14582249_5 31 34
GSTM 14582249_5 35 39
1 14582249_5 39 40
polymorphism 14582249_5 41 53
on 14582249_5 54 56
the 14582249_5 57 60
biological 14582249_5 61 71
indicators 14582249_5 72 82
of 14582249_5 83 85
1 14582249_5 86 87
, 14582249_5 87 88
3 14582249_5 88 89
- 14582249_5 89 90
butadiene 14582249_5 90 99
has 14582249_5 100 103
been 14582249_5 104 108
evaluated 14582249_5 109 118
. 14582249_5 119 120

The 26415139_12 0 3
effects 26415139_12 4 11
of 26415139_12 12 14
CYP 26415139_12 15 18
2 26415139_12 18 19
B 26415139_12 19 20
6 26415139_12 20 21
g 26415139_12 22 23
. 26415139_12 23 24
15582 26415139_12 24 29
C 26415139_12 29 30
> 26415139_12 30 31
T 26415139_12 31 32
on 26415139_12 33 35
plasma 26415139_12 36 42
EFV 26415139_12 43 46
concentration 26415139_12 47 60
were 26415139_12 61 65
further 26415139_12 66 73
evaluated 26415139_12 74 83
among 26415139_12 84 89
HIV 26415139_12 90 93
/ 26415139_12 94 95
AIDS 26415139_12 96 100
patients 26415139_12 101 109
. 26415139_12 110 111

Pharmacogenomics 16419387_1 0 16
as 16419387_1 17 19
molecular 16419387_1 20 29
autopsy 16419387_1 30 37
for 16419387_1 38 41
forensic 16419387_1 42 50
toxicology 16419387_1 51 61
: 16419387_1 62 63
genotyping 16419387_1 64 74
cytochrome 16419387_1 75 85
P 16419387_1 86 87
450 16419387_1 87 90
3 16419387_1 91 92
A 16419387_1 92 93
4 16419387_1 93 94
* 16419387_1 95 96
1 16419387_1 97 98
B 16419387_1 98 99
and 16419387_1 100 103
3 16419387_1 104 105
A 16419387_1 105 106
5 16419387_1 106 107
* 16419387_1 108 109
3 16419387_1 110 111
for 16419387_1 112 115
25 16419387_1 116 118
fentanyl 16419387_1 119 127
cases 16419387_1 128 133
. 16419387_1 134 135

The 25792135_8 0 3
graft 25792135_8 4 9
rs 25792135_8 10 12
2630578 25792135_8 12 19
BICD 25792135_8 20 24
1 25792135_8 24 25
gene 25792135_8 26 30
polymorphism 25792135_8 31 43
CC 25792135_8 44 46
genotype 25792135_8 47 55
was 25792135_8 56 59
associated 25792135_8 60 70
with 25792135_8 71 75
lower 25792135_8 76 81
creatinine 25792135_8 82 92
concentrations 25792135_8 93 107
in 25792135_8 108 110
the 25792135_8 111 114
first 25792135_8 115 120
month 25792135_8 121 126
( 25792135_8 127 128
CC 25792135_8 129 131
vs 25792135_8 132 134
. 25792135_8 134 135
GC 25792135_8 136 138
: 25792135_8 139 140
1 25792135_8 141 142
. 25792135_8 142 143
11 25792135_8 143 145
0 25792135_8 146 147
. 25792135_8 147 148
06 25792135_8 148 150
vs 25792135_8 151 153
. 25792135_8 153 154
2 25792135_8 155 156
. 25792135_8 156 157
0 25792135_8 157 158
1 25792135_8 159 160
. 25792135_8 160 161
25 25792135_8 161 163
mg 25792135_8 164 166
/ 25792135_8 166 167
dL 25792135_8 167 169
, 25792135_8 170 171
p 25792135_8 172 173
= 25792135_8 174 175
0 25792135_8 176 177
. 25792135_8 177 178
03 25792135_8 178 180
) 25792135_8 181 182
. 25792135_8 183 184

PURPOSE 25589624_2 0 7
: 25589624_2 8 9
Veliparib 25589624_2 10 19
, 25589624_2 20 21
a 25589624_2 22 23
PARP 25589624_2 24 28
inhibitor 25589624_2 29 38
, 25589624_2 39 40
demonstrated 25589624_2 41 53
clinical 25589624_2 54 62
activity 25589624_2 63 71
in 25589624_2 72 74
combination 25589624_2 75 86
with 25589624_2 87 91
oral 25589624_2 92 96
cyclophosphamide 25589624_2 97 113
in 25589624_2 114 116
patients 25589624_2 117 125
with 25589624_2 126 130
BRCA 25589624_2 131 135
- 25589624_2 136 137
mutant 25589624_2 137 143
solid 25589624_2 144 149
tumors 25589624_2 150 156
in 25589624_2 157 159
a 25589624_2 160 161
phase 25589624_2 162 167
I 25589624_2 168 169
trial 25589624_2 170 175
. 25589624_2 176 177

CONCLUSIONS 19396436_11 0 11
: 19396436_11 12 13
DRD 19396436_11 14 17
3 19396436_11 17 18
Ser 19396436_11 19 22
9 19396436_11 22 23
Gly 19396436_11 23 26
polymorphisms 19396436_11 27 40
are 19396436_11 41 44
significantly 19396436_11 45 58
associated 19396436_11 59 69
with 19396436_11 70 74
the 19396436_11 75 78
therapeutic 19396436_11 79 90
efficacy 19396436_11 91 99
of 19396436_11 100 102
pramipexole 19396436_11 103 114
in 19396436_11 115 117
Chinese 19396436_11 118 125
patients 19396436_11 126 134
with 19396436_11 135 139
PD 19396436_11 140 142
. 19396436_11 143 144

Green 16893904_1 0 5
tea 16893904_1 6 9
( 16893904_1 10 11
- 16893904_1 12 13
) 16893904_1 14 15
- 16893904_1 16 17
epigallocatechin 16893904_1 18 34
- 16893904_1 34 35
gallate 16893904_1 35 42
modulates 16893904_1 43 52
early 16893904_1 53 58
events 16893904_1 59 65
in 16893904_1 66 68
huntingtin 16893904_1 69 79
misfolding 16893904_1 80 90
and 16893904_1 91 94
reduces 16893904_1 95 102
toxicity 16893904_1 103 111
in 16893904_1 112 114
Huntington 16893904_1 115 125
' 16893904_1 125 126
s 16893904_1 126 127
disease 16893904_1 128 135
models 16893904_1 136 142
. 16893904_1 143 144

OBJECTIVE 25894531_2 0 9
: 25894531_2 10 11
To 25894531_2 12 14
determine 25894531_2 15 24
the 25894531_2 25 28
effects 25894531_2 29 36
of 25894531_2 37 39
single 25894531_2 40 46
nucleotide 25894531_2 47 57
polymorphisms 25894531_2 58 71
( 25894531_2 72 73
SNPs 25894531_2 74 78
) 25894531_2 79 80
in 25894531_2 81 83
the 25894531_2 84 87
adrenergic 25894531_2 88 98
b 25894531_2 99 100
2 25894531_2 100 101
- 25894531_2 101 102
receptor 25894531_2 102 110
gene 25894531_2 111 115
( 25894531_2 116 117
ADRB 25894531_2 118 122
2 25894531_2 122 123
, 25894531_2 124 125
rs 25894531_2 126 128
1042713 25894531_2 128 135
, 25894531_2 136 137
and 25894531_2 138 141
rs 25894531_2 142 144
1042714 25894531_2 144 151
) 25894531_2 152 153
and 25894531_2 154 157
epithelial 25894531_2 158 168
Na 25894531_2 169 171
channel 25894531_2 172 179
gene 25894531_2 180 184
( 25894531_2 185 186
SCNN 25894531_2 187 191
1 25894531_2 191 192
A 25894531_2 192 193
, 25894531_2 194 195
rs 25894531_2 196 198
2228576 25894531_2 198 205
) 25894531_2 206 207
on 25894531_2 208 210
cycling 25894531_2 211 218
performance 25894531_2 219 230
after 25894531_2 231 236
the 25894531_2 237 240
inhalation 25894531_2 241 251
of 25894531_2 252 254
salbutamol 25894531_2 255 265
. 25894531_2 266 267

Efficacy 25060417_1 0 8
of 25060417_1 9 11
diflunisal 25060417_1 12 22
on 25060417_1 23 25
autonomic 25060417_1 26 35
dysfunction 25060417_1 36 47
of 25060417_1 48 50
late 25060417_1 51 55
- 25060417_1 55 56
onset 25060417_1 56 61
familial 25060417_1 62 70
amyloid 25060417_1 71 78
polyneuropathy 25060417_1 79 93
( 25060417_1 94 95
TTR 25060417_1 96 99
Val 25060417_1 100 103
30 25060417_1 103 105
Met 25060417_1 105 108
) 25060417_1 109 110
in 25060417_1 111 113
a 25060417_1 114 115
Japanese 25060417_1 116 124
endemic 25060417_1 125 132
area 25060417_1 133 137
. 25060417_1 138 139

Oral 12518032_6 0 4
administration 12518032_6 5 19
to 12518032_6 20 22
mice 12518032_6 23 27
of 12518032_6 28 30
T 12518032_6 31 32
0901317 12518032_6 32 39
, 12518032_6 40 41
a 12518032_6 42 43
synthetic 12518032_6 44 53
LXR 12518032_6 54 57
- 12518032_6 58 59
selective 12518032_6 59 68
agonist 12518032_6 69 76
, 12518032_6 77 78
increases 12518032_6 79 88
levels 12518032_6 89 95
of 12518032_6 96 98
plasma 12518032_6 99 105
lipids 12518032_6 106 112
and 12518032_6 113 116
Angptl 12518032_6 117 123
3 12518032_6 123 124
mRNA 12518032_6 125 129
in 12518032_6 130 132
the 12518032_6 133 136
liver 12518032_6 137 142
. 12518032_6 143 144

RESULTS 24240480_7 0 7
: 24240480_7 8 9
The 24240480_7 10 13
ABCB 24240480_7 14 18
1 24240480_7 18 19
polymorphisms 24240480_7 20 33
including 24240480_7 34 43
c 24240480_7 44 45
. 24240480_7 45 46
1236 24240480_7 46 50
C 24240480_7 50 51
> 24240480_7 51 52
T 24240480_7 52 53
, 24240480_7 54 55
c 24240480_7 56 57
. 24240480_7 57 58
2677 24240480_7 58 62
G 24240480_7 62 63
> 24240480_7 63 64
T 24240480_7 64 65
/ 24240480_7 65 66
A 24240480_7 66 67
, 24240480_7 68 69
and 24240480_7 70 73
c 24240480_7 74 75
. 24240480_7 75 76
3435 24240480_7 76 80
C 24240480_7 80 81
> 24240480_7 81 82
T 24240480_7 82 83
did 24240480_7 84 87
not 24240480_7 88 91
affect 24240480_7 92 98
plasma 24240480_7 99 105
levels 24240480_7 106 112
of 24240480_7 113 115
quetiapine 24240480_7 116 126
, 24240480_7 127 128
and 24240480_7 129 132
its 24240480_7 133 136
pharmacokinetic 24240480_7 137 152
parameters 24240480_7 153 163
did 24240480_7 164 167
not 24240480_7 168 171
differ 24240480_7 172 178
among 24240480_7 179 184
ABCB 24240480_7 185 189
1 24240480_7 189 190
genotype 24240480_7 191 199
groups 24240480_7 200 206
. 24240480_7 207 208

SSRIs 23030234_8 0 5
can 23030234_8 6 9
increase 23030234_8 10 18
MDMA 23030234_8 19 23
plasma 23030234_8 24 30
levels 23030234_8 31 37
, 23030234_8 38 39
clinical 23030234_8 40 48
effects 23030234_8 49 56
( 23030234_8 57 58
e 23030234_8 59 60
. 23030234_8 60 61
g 23030234_8 61 62
. 23030234_8 62 63
blood 23030234_8 64 69
pressure 23030234_8 70 78
, 23030234_8 79 80
heart 23030234_8 81 86
rate 23030234_8 87 91
, 23030234_8 92 93
body 23030234_8 94 98
temperature 23030234_8 99 110
) 23030234_8 111 112
can 23030234_8 113 116
be 23030234_8 117 119
reduced 23030234_8 120 127
, 23030234_8 128 129
possibly 23030234_8 130 138
due 23030234_8 139 142
to 23030234_8 143 145
a 23030234_8 146 147
pharmacodynamic 23030234_8 148 163
interaction 23030234_8 164 175
at 23030234_8 176 178
the 23030234_8 179 182
serotonin 23030234_8 183 192
reuptake 23030234_8 193 201
transporter 23030234_8 202 213
( 23030234_8 214 215
SERT 23030234_8 216 220
) 23030234_8 221 222
. 23030234_8 223 224

Additionally 21880305_9 0 12
, 21880305_9 13 14
carriers 21880305_9 15 23
of 21880305_9 24 26
the 21880305_9 27 30
A 21880305_9 31 32
allele 21880305_9 33 39
of 21880305_9 40 42
rs 21880305_9 43 45
6265 21880305_9 45 49
responded 21880305_9 50 59
better 21880305_9 60 66
to 21880305_9 67 69
sertraline 21880305_9 70 80
treatment 21880305_9 81 90
( 21880305_9 91 92
p 21880305_9 93 94
= 21880305_9 95 96
0 21880305_9 97 98
. 21880305_9 98 99
001 21880305_9 99 102
) 21880305_9 103 104
. 21880305_9 105 106

BACKGROUND 22974536_2 0 10
: 22974536_2 11 12
A 22974536_2 13 14
recent 22974536_2 15 21
clinical 22974536_2 22 30
trial 22974536_2 31 36
has 22974536_2 37 40
demonstrated 22974536_2 41 53
that 22974536_2 54 58
patients 22974536_2 59 67
with 22974536_2 68 72
acute 22974536_2 73 78
coronary 22974536_2 79 87
syndromes 22974536_2 88 97
( 22974536_2 98 99
ACS 22974536_2 100 103
) 22974536_2 104 105
and 22974536_2 106 109
the 22974536_2 110 113
reduced 22974536_2 114 121
function 22974536_2 122 130
allele 22974536_2 131 137
CYP 22974536_2 138 141
2 22974536_2 141 142
C 22974536_2 142 143
19 22974536_2 143 145
* 22974536_2 146 147
2 22974536_2 148 149
( 22974536_2 150 151
* 22974536_2 152 153
2 22974536_2 154 155
allele 22974536_2 156 162
) 22974536_2 163 164
, 22974536_2 165 166
who 22974536_2 167 170
are 22974536_2 171 174
treated 22974536_2 175 182
with 22974536_2 183 187
thienopyridines 22974536_2 188 203
, 22974536_2 204 205
have 22974536_2 206 210
an 22974536_2 211 213
increased 22974536_2 214 223
risk 22974536_2 224 228
of 22974536_2 229 231
adverse 22974536_2 232 239
cardiac 22974536_2 240 247
events 22974536_2 248 254
with 22974536_2 255 259
clopidogrel 22974536_2 260 271
, 22974536_2 272 273
but 22974536_2 274 277
not 22974536_2 278 281
with 22974536_2 282 286
prasugrel 22974536_2 287 296
. 22974536_2 297 298

Few 28035401_6 0 3
studies 28035401_6 4 11
focused 28035401_6 12 19
on 28035401_6 20 22
the 28035401_6 23 26
role 28035401_6 27 31
of 28035401_6 32 34
HDAC 28035401_6 35 39
6 28035401_6 39 40
in 28035401_6 41 43
vemurafenib 28035401_6 44 55
resistance 28035401_6 56 66
. 28035401_6 67 68

A 18370849_5 0 1
strong 18370849_5 2 8
association 18370849_5 9 20
between 18370849_5 21 28
carbamazepine 18370849_5 29 42
hypersensitivity 18370849_5 43 59
and 18370849_5 60 63
HLA 18370849_5 64 67
- 18370849_5 67 68
B 18370849_5 68 69
* 18370849_5 70 71
1502 18370849_5 72 76
has 18370849_5 77 80
been 18370849_5 81 85
reported 18370849_5 86 94
in 18370849_5 95 97
Han 18370849_5 98 101
Chinese 18370849_5 102 109
. 18370849_5 110 111

Analogously 26013962_7 0 11
, 26013962_7 12 13
high 26013962_7 14 18
5 26013962_7 19 20
- 26013962_7 20 21
HTT 26013962_7 21 24
mRNA 26013962_7 25 29
levels 26013962_7 30 36
were 26013962_7 37 41
associated 26013962_7 42 52
with 26013962_7 53 57
worse 26013962_7 58 63
executive 26013962_7 64 73
WM 26013962_7 74 76
performance 26013962_7 77 88
in 26013962_7 89 91
cocaine 26013962_7 92 99
users 26013962_7 100 105
but 26013962_7 106 109
with 26013962_7 110 114
increased 26013962_7 115 124
performance 26013962_7 125 136
in 26013962_7 137 139
controls 26013962_7 140 148
. 26013962_7 149 150

The 10716965_3 0 3
cellular 10716965_3 4 12
retinol 10716965_3 13 20
- 10716965_3 21 22
binding 10716965_3 22 29
protein 10716965_3 30 37
( 10716965_3 38 39
CRBP 10716965_3 40 44
) 10716965_3 45 46
binds 10716965_3 47 52
vitamin 10716965_3 53 60
A 10716965_3 61 62
with 10716965_3 63 67
high 10716965_3 68 72
affinity 10716965_3 73 81
and 10716965_3 82 85
is 10716965_3 86 88
postulated 10716965_3 89 99
to 10716965_3 100 102
regulate 10716965_3 103 111
its 10716965_3 112 115
uptake 10716965_3 116 122
and 10716965_3 123 126
metabolism 10716965_3 127 137
. 10716965_3 138 139

We 24495780_6 0 2
genotyped 24495780_6 3 12
four 24495780_6 13 17
SNPs 24495780_6 18 22
( 24495780_6 23 24
rs 24495780_6 25 27
4795893 24495780_6 27 34
, 24495780_6 35 36
rs 24495780_6 37 39
1024611 24495780_6 39 46
, 24495780_6 47 48
rs 24495780_6 49 51
4586 24495780_6 51 55
and 24495780_6 56 59
rs 24495780_6 60 62
2857657 24495780_6 62 69
) 24495780_6 70 71
distributed 24495780_6 72 83
throughout 24495780_6 84 94
the 24495780_6 95 98
CCL 24495780_6 99 102
2 24495780_6 102 103
gene 24495780_6 104 108
and 24495780_6 109 112
examined 24495780_6 113 121
them 24495780_6 122 126
for 24495780_6 127 130
association 24495780_6 131 142
using 24495780_6 143 148
the 24495780_6 149 152
Positive 24495780_6 153 161
and 24495780_6 162 165
Negative 24495780_6 166 174
Syndrome 24495780_6 175 183
Scale 24495780_6 184 189
( 24495780_6 190 191
PANSS 24495780_6 192 197
) 24495780_6 198 199
score 24495780_6 200 205
in 24495780_6 206 208
two 24495780_6 209 212
independent 24495780_6 213 224
cohorts 24495780_6 225 232
of 24495780_6 233 235
Chinese 24495780_6 236 243
schizophrenic 24495780_6 244 257
patients 24495780_6 258 266
( 24495780_6 267 268
n 24495780_6 269 270
= 24495780_6 271 272
208 24495780_6 273 276
) 24495780_6 277 278
from 24495780_6 279 283
two 24495780_6 284 287
different 24495780_6 288 297
geographic 24495780_6 298 308
areas 24495780_6 309 314
, 24495780_6 315 316
following 24495780_6 317 326
an 24495780_6 327 329
8 24495780_6 330 331
- 24495780_6 331 332
week 24495780_6 332 336
period 24495780_6 337 343
of 24495780_6 344 346
risperidone 24495780_6 347 358
monotherapy 24495780_6 359 370
. 24495780_6 371 372

In 18429967_8 0 2
CYP 18429967_8 3 6
3 18429967_8 6 7
A 18429967_8 7 8
5 18429967_8 8 9
* 18429967_8 10 11
1 18429967_8 12 13
allele 18429967_8 14 20
carriers 18429967_8 21 29
( 18429967_8 30 31
CYP 18429967_8 32 35
3 18429967_8 35 36
A 18429967_8 36 37
5 18429967_8 37 38
expressers 18429967_8 39 49
) 18429967_8 50 51
, 18429967_8 52 53
body 18429967_8 54 58
weight 18429967_8 59 65
- 18429967_8 65 66
adjusted 18429967_8 66 74
oral 18429967_8 75 79
clearance 18429967_8 80 89
was 18429967_8 90 93
markedly 18429967_8 94 102
decreased 18429967_8 103 112
from 18429967_8 113 117
the 18429967_8 118 121
early 18429967_8 122 127
stage 18429967_8 128 133
to 18429967_8 134 136
the 18429967_8 137 140
maintenance 18429967_8 141 152
stage 18429967_8 153 158
[ 18429967_8 159 160
0 18429967_8 161 162
. 18429967_8 162 163
622 18429967_8 163 166
( 18429967_8 167 168
0 18429967_8 169 170
. 18429967_8 170 171
534 18429967_8 171 174
, 18429967_8 175 176
0 18429967_8 177 178
. 18429967_8 178 179
709 18429967_8 179 182
) 18429967_8 183 184
to 18429967_8 185 187
0 18429967_8 188 189
. 18429967_8 189 190
369 18429967_8 190 193
l 18429967_8 194 195
h 18429967_8 196 197
( 18429967_8 198 199
- 18429967_8 200 201
1 18429967_8 201 202
) 18429967_8 203 204
kg 18429967_8 205 207
( 18429967_8 208 209
- 18429967_8 210 211
1 18429967_8 211 212
) 18429967_8 213 214
( 18429967_8 215 216
0 18429967_8 217 218
. 18429967_8 218 219
314 18429967_8 219 222
, 18429967_8 223 224
0425 18429967_8 225 229
) 18429967_8 230 231
] 18429967_8 232 233
compared 18429967_8 234 242
with 18429967_8 243 247
a 18429967_8 248 249
smaller 18429967_8 250 257
decrease 18429967_8 258 266
[ 18429967_8 267 268
0 18429967_8 269 270
. 18429967_8 270 271
368 18429967_8 271 274
( 18429967_8 275 276
0 18429967_8 277 278
. 18429967_8 278 279
305 18429967_8 279 282
, 18429967_8 283 284
0 18429967_8 285 286
. 18429967_8 286 287
430 18429967_8 287 290
) 18429967_8 291 292
to 18429967_8 293 295
0 18429967_8 296 297
. 18429967_8 297 298
305 18429967_8 298 301
( 18429967_8 302 303
0 18429967_8 304 305
. 18429967_8 305 306
217 18429967_8 306 309
, 18429967_8 310 311
0 18429967_8 312 313
. 18429967_8 313 314
393 18429967_8 314 317
) 18429967_8 318 319
] 18429967_8 320 321
in 18429967_8 322 324
CYP 18429967_8 325 328
3 18429967_8 328 329
A 18429967_8 329 330
5 18429967_8 330 331
non 18429967_8 332 335
- 18429967_8 335 336
expressers 18429967_8 336 346
; 18429967_8 347 348
however 18429967_8 349 356
, 18429967_8 357 358
the 18429967_8 359 362
CYP 18429967_8 363 366
3 18429967_8 366 367
A 18429967_8 367 368
5 18429967_8 368 369
genetic 18429967_8 370 377
variation 18429967_8 378 387
did 18429967_8 388 391
not 18429967_8 392 395
influence 18429967_8 396 405
tacrolimus 18429967_8 406 416
chronopharmacokinetics 18429967_8 417 439
. 18429967_8 440 441

[ 12361551_1 0 1
Mutations 12361551_1 2 11
in 12361551_1 12 14
the 12361551_1 15 18
HFE 12361551_1 19 22
gene 12361551_1 23 27
( 12361551_1 28 29
C 12361551_1 30 31
282 12361551_1 31 34
Y 12361551_1 34 35
, 12361551_1 36 37
H 12361551_1 38 39
63 12361551_1 39 41
D 12361551_1 41 42
, 12361551_1 43 44
S 12361551_1 45 46
65 12361551_1 46 48
C 12361551_1 48 49
) 12361551_1 50 51
in 12361551_1 52 54
alcoholic 12361551_1 55 64
patients 12361551_1 65 73
with 12361551_1 74 78
finding 12361551_1 79 86
of 12361551_1 87 89
iron 12361551_1 90 94
overload 12361551_1 95 103
] 12361551_1 104 105
. 12361551_1 106 107

METHODS 19566775_5 0 7
: 19566775_5 8 9
The 19566775_5 10 13
single 19566775_5 14 20
nucleotide 19566775_5 21 31
polymorphisms 19566775_5 32 45
rs 19566775_5 46 48
16147 19566775_5 48 53
of 19566775_5 54 56
the 19566775_5 57 60
NPY 19566775_5 61 64
gene 19566775_5 65 69
( 19566775_5 70 71
- 19566775_5 72 73
485 19566775_5 73 76
C 19566775_5 76 77
> 19566775_5 77 78
T 19566775_5 78 79
) 19566775_5 80 81
and 19566775_5 82 85
rs 19566775_5 86 88
7687423 19566775_5 88 95
of 19566775_5 96 98
the 19566775_5 99 102
NPY 19566775_5 103 106
receptor 19566775_5 107 115
Y 19566775_5 116 117
1 19566775_5 117 118
( 19566775_5 119 120
NPY 19566775_5 121 124
1 19566775_5 124 125
R 19566775_5 125 126
) 19566775_5 127 128
gene 19566775_5 129 133
were 19566775_5 134 138
analyzed 19566775_5 139 147
in 19566775_5 148 150
222 19566775_5 151 154
patients 19566775_5 155 163
with 19566775_5 164 168
methamphetamine 19566775_5 169 184
dependence 19566775_5 185 195
and 19566775_5 196 199
psychosis 19566775_5 200 209
and 19566775_5 210 213
288 19566775_5 214 217
age 19566775_5 218 221
- 19566775_5 222 223
and 19566775_5 224 227
gender 19566775_5 228 234
- 19566775_5 234 235
matched 19566775_5 235 242
controls 19566775_5 243 251
. 19566775_5 252 253

CONCLUSIONS 10223459_12 0 11
: 10223459_12 12 13
The 10223459_12 14 17
present 10223459_12 18 25
study 10223459_12 26 31
indicates 10223459_12 32 41
that 10223459_12 42 46
clotrimazole 10223459_12 47 59
inhibits 10223459_12 60 68
cell 10223459_12 69 73
proliferation 10223459_12 74 87
accompanied 10223459_12 88 99
by 10223459_12 100 102
morphological 10223459_12 103 116
changes 10223459_12 117 124
toward 10223459_12 125 131
differentiation 10223459_12 132 147
of 10223459_12 148 150
glioblastoma 10223459_12 151 163
cells 10223459_12 164 169
and 10223459_12 170 173
that 10223459_12 174 178
this 10223459_12 179 183
drug 10223459_12 184 188
synergistically 10223459_12 189 204
enhances 10223459_12 205 213
the 10223459_12 214 217
antitumor 10223459_12 218 227
effect 10223459_12 228 234
of 10223459_12 235 237
cisplatin 10223459_12 238 247
by 10223459_12 248 250
inducing 10223459_12 251 259
wild 10223459_12 260 264
- 10223459_12 264 265
type 10223459_12 265 269
p 10223459_12 270 271
53 10223459_12 271 273
- 10223459_12 274 275
mediated 10223459_12 275 283
apoptosis 10223459_12 284 293
. 10223459_12 294 295

Treatment 15116260_11 0 9
with 15116260_11 10 14
the 15116260_11 15 18
HMG 15116260_11 19 22
CoA 15116260_11 23 26
reductase 15116260_11 27 36
inhibitor 15116260_11 37 46
pravastatin 15116260_11 47 58
reduced 15116260_11 59 66
progression 15116260_11 67 78
of 15116260_11 79 81
coronary 15116260_11 82 90
atherosclerosis 15116260_11 91 106
and 15116260_11 107 110
adverse 15116260_11 111 118
events 15116260_11 119 125
equally 15116260_11 126 133
for 15116260_11 134 137
all 15116260_11 138 141
genotypes 15116260_11 142 151
. 15116260_11 152 153

OBJECTIVE 17030231_4 0 9
: 17030231_4 10 11
We 17030231_4 12 14
sought 17030231_4 15 21
to 17030231_4 22 24
evaluate 17030231_4 25 33
the 17030231_4 34 37
effects 17030231_4 38 45
of 17030231_4 46 48
variation 17030231_4 49 58
in 17030231_4 59 61
the 17030231_4 62 65
beta 17030231_4 66 70
2 17030231_4 70 71
- 17030231_4 71 72
adrenergic 17030231_4 72 82
receptor 17030231_4 83 91
gene 17030231_4 92 96
( 17030231_4 97 98
ADRB 17030231_4 99 103
2 17030231_4 103 104
) 17030231_4 105 106
on 17030231_4 107 109
clinical 17030231_4 110 118
response 17030231_4 119 127
to 17030231_4 128 130
salmeterol 17030231_4 131 141
administered 17030231_4 142 154
with 17030231_4 155 159
fluticasone 17030231_4 160 171
propionate 17030231_4 172 182
. 17030231_4 183 184

PATIENTS 22753902_3 0 8
AND 22753902_3 9 12
METHODS 22753902_3 13 20
: 22753902_3 21 22
Younger 22753902_3 23 30
( 22753902_3 31 32
< 22753902_3 33 34
60 22753902_3 35 37
years 22753902_3 38 43
; 22753902_3 44 45
n 22753902_3 46 47
= 22753902_3 48 49
175 22753902_3 50 53
) 22753902_3 54 55
and 22753902_3 56 59
older 22753902_3 60 65
( 22753902_3 66 67
> 22753902_3 68 69
= 22753902_3 70 71
60 22753902_3 72 74
years 22753902_3 75 80
; 22753902_3 81 82
n 22753902_3 83 84
= 22753902_3 85 86
225 22753902_3 87 90
) 22753902_3 91 92
patients 22753902_3 93 101
with 22753902_3 102 106
CN 22753902_3 107 109
- 22753902_3 109 110
AML 22753902_3 110 113
treated 22753902_3 114 121
with 22753902_3 122 126
intensive 22753902_3 127 136
cytarabine 22753902_3 137 147
/ 22753902_3 148 149
anthracycline 22753902_3 150 163
- 22753902_3 164 165
based 22753902_3 165 170
first 22753902_3 171 176
- 22753902_3 176 177
line 22753902_3 177 181
therapy 22753902_3 182 189
on 22753902_3 190 192
Cancer 22753902_3 193 199
and 22753902_3 200 203
Leukemia 22753902_3 204 212
Group 22753902_3 213 218
B 22753902_3 219 220
protocols 22753902_3 221 230
were 22753902_3 231 235
centrally 22753902_3 236 245
analyzed 22753902_3 246 254
for 22753902_3 255 258
RUNX 22753902_3 259 263
1 22753902_3 263 264
mutations 22753902_3 265 274
by 22753902_3 275 277
polymerase 22753902_3 278 288
chain 22753902_3 289 294
reaction 22753902_3 295 303
and 22753902_3 304 307
direct 22753902_3 308 314
sequencing 22753902_3 315 325
and 22753902_3 326 329
for 22753902_3 330 333
established 22753902_3 334 345
prognostic 22753902_3 346 356
gene 22753902_3 357 361
mutations 22753902_3 362 371
. 22753902_3 372 373

Immunohistochemical 20015348_11 0 19
staining 20015348_11 20 28
further 20015348_11 29 36
demonstrated 20015348_11 37 49
that 20015348_11 50 54
the 20015348_11 55 58
BI 20015348_11 59 61
- 20015348_11 61 62
TK 20015348_11 62 64
/ 20015348_11 65 66
GCV 20015348_11 67 70
treatment 20015348_11 71 80
group 20015348_11 81 86
had 20015348_11 87 90
the 20015348_11 91 94
highest 20015348_11 95 102
level 20015348_11 103 108
of 20015348_11 109 111
caspase 20015348_11 112 119
3 20015348_11 119 120
protein 20015348_11 121 128
expression 20015348_11 129 139
than 20015348_11 140 144
that 20015348_11 145 149
of 20015348_11 150 152
the 20015348_11 153 156
empty 20015348_11 157 162
plasmid 20015348_11 163 170
group 20015348_11 171 176
and 20015348_11 177 180
normal 20015348_11 181 187
saline 20015348_11 188 194
group 20015348_11 195 200
( 20015348_11 201 202
p 20015348_11 203 204
< 20015348_11 205 206
0 20015348_11 207 208
. 20015348_11 208 209
05 20015348_11 209 211
) 20015348_11 212 213
. 20015348_11 214 215

CONCLUSION 18829024_9 0 10
( 18829024_9 11 12
S 18829024_9 13 14
) 18829024_9 15 16
: 18829024_9 17 18
Pregnancy 18829024_9 19 28
is 18829024_9 29 31
feasible 18829024_9 32 40
in 18829024_9 41 43
patients 18829024_9 44 52
with 18829024_9 53 57
StAR 18829024_9 58 62
gene 18829024_9 63 67
mutations 18829024_9 68 77
, 18829024_9 78 79
provided 18829024_9 80 88
that 18829024_9 89 93
extra 18829024_9 94 99
estrogens 18829024_9 100 109
are 18829024_9 110 113
offered 18829024_9 114 121
until 18829024_9 122 127
placental 18829024_9 128 137
function 18829024_9 138 146
ensues 18829024_9 147 153
. 18829024_9 154 155

We 27097364_3 0 2
analyzed 27097364_3 3 11
the 27097364_3 12 15
relations 27097364_3 16 25
between 27097364_3 26 33
plasma 27097364_3 34 40
raltegravir 27097364_3 41 52
concentrations 27097364_3 53 67
and 27097364_3 68 71
single 27097364_3 72 78
nucleotide 27097364_3 79 89
polymorphism 27097364_3 90 102
of 27097364_3 103 105
ABCB 27097364_3 106 110
1 27097364_3 110 111
and 27097364_3 112 115
ABCG 27097364_3 116 120
2 27097364_3 120 121
genes 27097364_3 122 127
. 27097364_3 128 129

Polymorphisms 20078613_12 0 13
of 20078613_12 14 16
genes 20078613_12 17 22
related 20078613_12 23 30
to 20078613_12 31 33
Oxa 20078613_12 34 37
pharmacodynamics 20078613_12 38 54
showed 20078613_12 55 61
an 20078613_12 62 64
influence 20078613_12 65 74
on 20078613_12 75 77
progression 20078613_12 78 89
- 20078613_12 89 90
free 20078613_12 90 94
survival 20078613_12 95 103
, 20078613_12 104 105
with 20078613_12 106 110
a 20078613_12 111 112
better 20078613_12 113 119
outcome 20078613_12 120 127
in 20078613_12 128 130
patients 20078613_12 131 139
bearing 20078613_12 140 147
GSTpi 20078613_12 148 153
105 20078613_12 154 157
Val 20078613_12 158 161
/ 20078613_12 162 163
Val 20078613_12 164 167
genotype 20078613_12 168 176
or 20078613_12 177 179
XPD 20078613_12 180 183
751 20078613_12 184 187
Lys 20078613_12 187 190
- 20078613_12 191 192
containing 20078613_12 192 202
genotype 20078613_12 203 211
( 20078613_12 212 213
P 20078613_12 214 215
= 20078613_12 216 217
0 20078613_12 218 219
. 20078613_12 219 220
054 20078613_12 220 223
) 20078613_12 224 225
. 20078613_12 226 227

To 26678339_4 0 2
identify 26678339_4 3 11
other 26678339_4 12 17
metabolic 26678339_4 18 27
therapeutic 26678339_4 28 39
targets 26678339_4 40 47
, 26678339_4 48 49
we 26678339_4 50 52
systematically 26678339_4 53 67
profiled 26678339_4 68 76
metabolites 26678339_4 77 88
in 26678339_4 89 91
endogenous 26678339_4 92 102
IDH 26678339_4 103 106
1 26678339_4 106 107
mutant 26678339_4 108 114
cancer 26678339_4 115 121
cells 26678339_4 122 127
after 26678339_4 128 133
mutant 26678339_4 134 140
IDH 26678339_4 141 144
1 26678339_4 144 145
inhibition 26678339_4 146 156
and 26678339_4 157 160
discovered 26678339_4 161 171
a 26678339_4 172 173
profound 26678339_4 174 182
vulnerability 26678339_4 183 196
to 26678339_4 197 199
depletion 26678339_4 200 209
of 26678339_4 210 212
the 26678339_4 213 216
coenzyme 26678339_4 217 225
NAD 26678339_4 226 229
+ 26678339_4 229 230
. 26678339_4 231 232

AIM 12846271_3 0 3
: 12846271_3 4 5
To 12846271_3 6 8
evaluate 12846271_3 9 17
whether 12846271_3 18 25
aromatase 12846271_3 26 35
gene 12846271_3 36 40
( 12846271_3 41 42
CYP 12846271_3 43 46
19 12846271_3 46 48
) 12846271_3 49 50
polymorphism 12846271_3 51 63
affects 12846271_3 64 71
circulating 12846271_3 72 83
estradiol 12846271_3 84 93
( 12846271_3 94 95
E 12846271_3 96 97
2 12846271_3 97 98
) 12846271_3 99 100
levels 12846271_3 101 107
, 12846271_3 108 109
bone 12846271_3 110 114
mineral 12846271_3 115 122
density 12846271_3 123 130
( 12846271_3 131 132
BMD 12846271_3 133 136
) 12846271_3 137 138
, 12846271_3 139 140
BMD 12846271_3 141 144
change 12846271_3 145 151
or 12846271_3 152 154
fracture 12846271_3 155 163
risk 12846271_3 164 168
. 12846271_3 169 170

The 7753410_9 0 3
angiotensin 7753410_9 4 15
II 7753410_9 16 18
- 7753410_9 19 20
AT 7753410_9 20 22
1 7753410_9 22 23
receptor 7753410_9 24 32
antagonist 7753410_9 33 43
, 7753410_9 44 45
losartan 7753410_9 46 54
, 7753410_9 55 56
applied 7753410_9 57 64
intracerebroventricular 7753410_9 65 88
five 7753410_9 89 93
minutes 7753410_9 94 101
prior 7753410_9 102 107
to 7753410_9 108 110
angiotensin 7753410_9 111 122
II 7753410_9 123 125
, 7753410_9 126 127
prevented 7753410_9 128 137
the 7753410_9 138 141
angiotensin 7753410_9 142 153
II 7753410_9 154 156
- 7753410_9 157 158
induced 7753410_9 158 165
immediate 7753410_9 166 175
early 7753410_9 176 181
gene 7753410_9 182 186
protein 7753410_9 187 194
expression 7753410_9 195 205
. 7753410_9 206 207

Phase 25902899_1 0 5
I 25902899_1 6 7
combination 25902899_1 8 19
of 25902899_1 20 22
pazopanib 25902899_1 23 32
and 25902899_1 33 36
everolimus 25902899_1 37 47
in 25902899_1 48 50
PIK 25902899_1 51 54
3 25902899_1 54 55
CA 25902899_1 55 57
mutation 25902899_1 58 66
positive 25902899_1 67 75
/ 25902899_1 75 76
PTEN 25902899_1 77 81
loss 25902899_1 82 86
patients 25902899_1 87 95
with 25902899_1 96 100
advanced 25902899_1 101 109
solid 25902899_1 110 115
tumors 25902899_1 116 122
refractory 25902899_1 123 133
to 25902899_1 134 136
standard 25902899_1 137 145
therapy 25902899_1 146 153
. 25902899_1 154 155

BACKGROUND 22708928_2 0 10
: 22708928_2 11 12
Sulfotransferase 22708928_2 13 29
1 22708928_2 30 31
A 22708928_2 31 32
1 22708928_2 32 33
( 22708928_2 34 35
SULT 22708928_2 36 40
1 22708928_2 40 41
A 22708928_2 41 42
1 22708928_2 42 43
) 22708928_2 44 45
participates 22708928_2 46 58
in 22708928_2 59 61
the 22708928_2 62 65
elimination 22708928_2 66 77
of 22708928_2 78 80
4 22708928_2 81 82
- 22708928_2 82 83
hydroxy 22708928_2 83 90
- 22708928_2 90 91
tamoxifen 22708928_2 91 100
( 22708928_2 101 102
4 22708928_2 103 104
- 22708928_2 104 105
OH 22708928_2 105 107
- 22708928_2 107 108
TAM 22708928_2 108 111
) 22708928_2 112 113
, 22708928_2 114 115
which 22708928_2 116 121
is 22708928_2 122 124
one 22708928_2 125 128
of 22708928_2 129 131
the 22708928_2 132 135
major 22708928_2 136 141
active 22708928_2 142 148
metabolites 22708928_2 149 160
of 22708928_2 161 163
tamoxifen 22708928_2 164 173
( 22708928_2 174 175
TAM 22708928_2 176 179
) 22708928_2 180 181
. 22708928_2 182 183

In 11923351_9 0 2
particular 11923351_9 3 13
, 11923351_9 14 15
the 11923351_9 16 19
frequency 11923351_9 20 29
of 11923351_9 30 32
T 11923351_9 33 34
69 11923351_9 34 36
N 11923351_9 36 37
/ 11923351_9 38 39
S 11923351_9 39 40
/ 11923351_9 40 41
A 11923351_9 41 42
increased 11923351_9 43 52
sharply 11923351_9 53 60
after 11923351_9 61 66
more 11923351_9 67 71
than 11923351_9 72 76
48 11923351_9 77 79
months 11923351_9 80 86
of 11923351_9 87 89
zidovudine 11923351_9 90 100
monotherapy 11923351_9 101 112
. 11923351_9 113 114

When 24638003_10 0 4
comparing 24638003_10 5 14
the 24638003_10 15 18
two 24638003_10 19 22
arms 24638003_10 23 27
, 24638003_10 28 29
imatinib 24638003_10 30 38
therapy 24638003_10 39 46
was 24638003_10 47 50
associated 24638003_10 51 61
with 24638003_10 62 66
higher 24638003_10 67 73
RFS 24638003_10 74 77
in 24638003_10 78 80
patients 24638003_10 81 89
with 24638003_10 90 94
a 24638003_10 95 96
KIT 24638003_10 97 100
exon 24638003_10 101 105
11 24638003_10 106 108
deletion 24638003_10 109 117
of 24638003_10 118 120
any 24638003_10 121 124
type 24638003_10 125 129
, 24638003_10 130 131
but 24638003_10 132 135
not 24638003_10 136 139
a 24638003_10 140 141
KIT 24638003_10 142 145
exon 24638003_10 146 150
11 24638003_10 151 153
insertion 24638003_10 154 163
or 24638003_10 164 166
point 24638003_10 167 172
mutation 24638003_10 173 181
, 24638003_10 182 183
KIT 24638003_10 184 187
exon 24638003_10 188 192
9 24638003_10 193 194
mutation 24638003_10 195 203
, 24638003_10 204 205
PDGFRA 24638003_10 206 212
mutation 24638003_10 213 221
, 24638003_10 222 223
or 24638003_10 224 226
wild 24638003_10 227 231
- 24638003_10 231 232
type 24638003_10 232 236
tumor 24638003_10 237 242
, 24638003_10 243 244
although 24638003_10 245 253
some 24638003_10 254 258
of 24638003_10 259 261
these 24638003_10 262 267
patient 24638003_10 268 275
groups 24638003_10 276 282
were 24638003_10 283 287
small 24638003_10 288 293
. 24638003_10 294 295

Despite 24152157_15 0 7
the 24152157_15 8 11
prevailing 24152157_15 12 22
dogma 24152157_15 23 28
that 24152157_15 29 33
Type 24152157_15 34 38
B 24152157_15 39 40
adverse 24152157_15 41 48
drug 24152157_15 49 53
reactions 24152157_15 54 63
are 24152157_15 64 67
dose 24152157_15 68 72
independent 24152157_15 73 84
, 24152157_15 85 86
allopurinol 24152157_15 87 98
hypersensitivity 24152157_15 99 115
is 24152157_15 116 118
primarily 24152157_15 119 128
driven 24152157_15 129 135
by 24152157_15 136 138
oxypurinol 24152157_15 139 149
- 24152157_15 150 151
specific 24152157_15 151 159
T 24152157_15 160 161
cell 24152157_15 162 166
response 24152157_15 167 175
in 24152157_15 176 178
a 24152157_15 179 180
dose 24152157_15 181 185
- 24152157_15 185 186
dependent 24152157_15 186 195
manner 24152157_15 196 202
, 24152157_15 203 204
particular 24152157_15 205 215
in 24152157_15 216 218
the 24152157_15 219 222
presence 24152157_15 223 231
of 24152157_15 232 234
HLA 24152157_15 235 238
- 24152157_15 238 239
B 24152157_15 239 240
* 24152157_15 241 242
58 24152157_15 243 245
: 24152157_15 245 246
01 24152157_15 246 248
allele 24152157_15 249 255
. 24152157_15 256 257

Sequence 17034599_14 0 8
variants 17034599_14 9 17
in 17034599_14 18 20
the 17034599_14 21 24
ATM 17034599_14 25 28
gene 17034599_14 29 33
, 17034599_14 34 35
particularly 17034599_14 36 48
those 17034599_14 49 54
that 17034599_14 55 59
encode 17034599_14 60 66
for 17034599_14 67 70
an 17034599_14 71 73
amino 17034599_14 74 79
- 17034599_14 79 80
acid 17034599_14 80 84
substitution 17034599_14 85 97
, 17034599_14 98 99
are 17034599_14 100 103
associated 17034599_14 104 114
with 17034599_14 115 119
adverse 17034599_14 120 127
radiotherapy 17034599_14 128 140
responses 17034599_14 141 150
among 17034599_14 151 156
patients 17034599_14 157 165
treated 17034599_14 166 173
with 17034599_14 174 178
125 17034599_14 179 182
I 17034599_14 182 183
prostate 17034599_14 184 192
brachytherapy 17034599_14 193 206
. 17034599_14 207 208

The 9259617_1 0 3
effect 9259617_1 4 10
of 9259617_1 11 13
aflatoxin 9259617_1 14 23
B 9259617_1 24 25
1 9259617_1 25 26
on 9259617_1 27 29
the 9259617_1 30 33
expression 9259617_1 34 44
of 9259617_1 45 47
early 9259617_1 48 53
response 9259617_1 54 62
genes 9259617_1 63 68
and 9259617_1 69 72
transforming 9259617_1 73 85
growth 9259617_1 86 92
factor 9259617_1 93 99
- 9259617_1 99 100
alpha 9259617_1 100 105
in 9259617_1 106 108
CCl 9259617_1 109 112
4 9259617_1 112 113
induced 9259617_1 114 121
rat 9259617_1 122 125
liver 9259617_1 126 131
injury 9259617_1 132 138
. 9259617_1 139 140

BACKGROUND 21723857_2 0 10
AND 21723857_2 11 14
AIMS 21723857_2 15 19
: 21723857_2 20 21
TPMT 21723857_2 22 26
deficiency 21723857_2 27 37
is 21723857_2 38 40
associated 21723857_2 41 51
with 21723857_2 52 56
azathioprine 21723857_2 57 69
( 21723857_2 70 71
AZA 21723857_2 72 75
) 21723857_2 76 77
- 21723857_2 78 79
induced 21723857_2 80 87
myelosuppression 21723857_2 88 104
( 21723857_2 105 106
MS 21723857_2 107 109
) 21723857_2 110 111
. 21723857_2 112 113

The 15834213_3 0 3
goal 15834213_3 4 8
of 15834213_3 9 11
this 15834213_3 12 16
study 15834213_3 17 22
was 15834213_3 23 26
to 15834213_3 27 29
test 15834213_3 30 34
whether 15834213_3 35 42
GABRA 15834213_3 43 48
2 15834213_3 48 49
is 15834213_3 50 52
associated 15834213_3 53 63
with 15834213_3 64 68
alcohol 15834213_3 69 76
dependence 15834213_3 77 87
in 15834213_3 88 90
a 15834213_3 91 92
sample 15834213_3 93 99
of 15834213_3 100 102
Russian 15834213_3 103 110
alcohol 15834213_3 111 118
- 15834213_3 119 120
dependent 15834213_3 120 129
men 15834213_3 130 133
. 15834213_3 134 135

The 19000371_7 0 3
levels 19000371_7 4 10
of 19000371_7 11 13
c 19000371_7 14 15
- 19000371_7 15 16
fos 19000371_7 16 19
, 19000371_7 20 21
c 19000371_7 22 23
- 19000371_7 23 24
jun 19000371_7 24 27
and 19000371_7 28 31
rsGFP 19000371_7 32 37
mRNA 19000371_7 38 42
, 19000371_7 43 44
as 19000371_7 45 47
well 19000371_7 48 52
as 19000371_7 53 55
the 19000371_7 56 59
levels 19000371_7 60 66
of 19000371_7 67 69
rsGFP 19000371_7 70 75
protein 19000371_7 76 83
, 19000371_7 84 85
in 19000371_7 86 88
the 19000371_7 89 92
FR 19000371_7 93 95
- 19000371_7 95 96
pQBI 19000371_7 96 100
25 19000371_7 100 102
cells 19000371_7 103 108
were 19000371_7 109 113
found 19000371_7 114 119
to 19000371_7 120 122
be 19000371_7 123 125
significantly 19000371_7 126 139
higher 19000371_7 140 146
following 19000371_7 147 156
exposure 19000371_7 157 165
to 19000371_7 166 168
doxorubicin 19000371_7 169 180
. 19000371_7 181 182

The 19784640_11 0 3
patients 19784640_11 4 12
with 19784640_11 13 17
the 19784640_11 18 21
CYP 19784640_11 22 25
3 19784640_11 25 26
A 19784640_11 26 27
4 19784640_11 27 28
* 19784640_11 29 30
1 19784640_11 31 32
G 19784640_11 32 33
/ 19784640_11 34 35
* 19784640_11 36 37
1 19784640_11 38 39
G 19784640_11 39 40
genotype 19784640_11 41 49
needed 19784640_11 50 56
less 19784640_11 57 61
fentanyl 19784640_11 62 70
( 19784640_11 71 72
227 19784640_11 73 76
. 19784640_11 76 77
8 19784640_11 77 78
+ 19784640_11 79 80
/ 19784640_11 81 82
- 19784640_11 83 84
55 19784640_11 85 87
. 19784640_11 87 88
2 19784640_11 88 89
microg 19784640_11 90 96
) 19784640_11 97 98
to 19784640_11 99 101
achieve 19784640_11 102 109
pain 19784640_11 110 114
control 19784640_11 115 122
than 19784640_11 123 127
patients 19784640_11 128 136
carrying 19784640_11 137 145
the 19784640_11 146 149
CYP 19784640_11 150 153
3 19784640_11 153 154
A 19784640_11 154 155
4 19784640_11 155 156
* 19784640_11 157 158
1 19784640_11 159 160
/ 19784640_11 161 162
* 19784640_11 163 164
1 19784640_11 165 166
( 19784640_11 167 168
381 19784640_11 169 172
. 19784640_11 172 173
6 19784640_11 173 174
+ 19784640_11 175 176
/ 19784640_11 177 178
- 19784640_11 179 180
163 19784640_11 181 184
. 19784640_11 184 185
6 19784640_11 185 186
microg 19784640_11 187 193
) 19784640_11 194 195
and 19784640_11 196 199
CYP 19784640_11 200 203
3 19784640_11 203 204
A 19784640_11 204 205
4 19784640_11 205 206
* 19784640_11 207 208
1 19784640_11 209 210
/ 19784640_11 211 212
* 19784640_11 213 214
1 19784640_11 215 216
G 19784640_11 216 217
( 19784640_11 218 219
371 19784640_11 220 223
. 19784640_11 223 224
9 19784640_11 224 225
+ 19784640_11 226 227
/ 19784640_11 228 229
- 19784640_11 230 231
180 19784640_11 232 235
. 19784640_11 235 236
1 19784640_11 236 237
microg 19784640_11 238 244
) 19784640_11 245 246
genotypes 19784640_11 247 256
( 19784640_11 257 258
P 19784640_11 259 260
< 19784640_11 261 262
0 19784640_11 263 264
. 19784640_11 264 265
05 19784640_11 265 267
) 19784640_11 268 269
during 19784640_11 270 276
the 19784640_11 277 280
first 19784640_11 281 286
24 19784640_11 287 289
h 19784640_11 290 291
postoperatively 19784640_11 292 307
. 19784640_11 308 309

CYP 18252229_3 0 3
2 18252229_3 3 4
C 18252229_3 4 5
9 18252229_3 5 6
( 18252229_3 7 8
* 18252229_3 9 10
) 18252229_3 11 12
2 18252229_3 13 14
( 18252229_3 15 16
p 18252229_3 17 18
. 18252229_3 18 19
R 18252229_3 19 20
144 18252229_3 20 23
C 18252229_3 23 24
) 18252229_3 25 26
, 18252229_3 27 28
CYP 18252229_3 29 32
2 18252229_3 32 33
C 18252229_3 33 34
9 18252229_3 34 35
( 18252229_3 36 37
* 18252229_3 38 39
) 18252229_3 40 41
3 18252229_3 42 43
( 18252229_3 44 45
p 18252229_3 46 47
. 18252229_3 47 48
I 18252229_3 48 49
359 18252229_3 49 52
L 18252229_3 52 53
) 18252229_3 54 55
, 18252229_3 56 57
and 18252229_3 58 61
the 18252229_3 62 65
VKORC 18252229_3 66 71
1 18252229_3 71 72
promoter 18252229_3 73 81
( 18252229_3 82 83
g 18252229_3 84 85
. 18252229_3 85 86
- 18252229_3 86 87
1639 18252229_3 87 91
G 18252229_3 91 92
- 18252229_3 92 93
- 18252229_3 93 94
> 18252229_3 94 95
A 18252229_3 95 96
) 18252229_3 97 98
polymorphisms 18252229_3 99 112
occur 18252229_3 113 118
frequently 18252229_3 119 129
in 18252229_3 130 132
patients 18252229_3 133 141
who 18252229_3 142 145
are 18252229_3 146 149
warfarin 18252229_3 150 158
" 18252229_3 159 160
sensitive 18252229_3 161 170
" 18252229_3 171 172
and 18252229_3 173 176
require 18252229_3 177 184
lower 18252229_3 185 190
doses 18252229_3 191 196
, 18252229_3 197 198
whereas 18252229_3 199 206
patients 18252229_3 207 215
with 18252229_3 216 220
VKORC 18252229_3 221 226
1 18252229_3 226 227
missense 18252229_3 228 236
mutations 18252229_3 237 246
are 18252229_3 247 250
warfarin 18252229_3 251 259
" 18252229_3 260 261
resistant 18252229_3 262 271
" 18252229_3 272 273
and 18252229_3 274 277
require 18252229_3 278 285
higher 18252229_3 286 292
doses 18252229_3 293 298
. 18252229_3 299 300

To 16084852_3 0 2
test 16084852_3 3 7
whether 16084852_3 8 15
certain 16084852_3 16 23
ABCB 16084852_3 24 28
1 16084852_3 28 29
haplotypes 16084852_3 30 40
contribute 16084852_3 41 51
to 16084852_3 52 54
interindividual 16084852_3 55 70
differences 16084852_3 71 82
in 16084852_3 83 85
central 16084852_3 86 93
nervous 16084852_3 94 101
system 16084852_3 102 108
drug 16084852_3 109 113
distribution 16084852_3 114 126
, 16084852_3 127 128
brain 16084852_3 129 134
distribution 16084852_3 135 147
of 16084852_3 148 150
a 16084852_3 151 152
model 16084852_3 153 158
P 16084852_3 159 160
- 16084852_3 160 161
glycoprotein 16084852_3 161 173
substrate 16084852_3 174 183
, 16084852_3 184 185
the 16084852_3 186 189
calcium 16084852_3 190 197
channel 16084852_3 198 205
inhibitor 16084852_3 206 215
verapamil 16084852_3 216 225
, 16084852_3 226 227
was 16084852_3 228 231
measured 16084852_3 232 240
by 16084852_3 241 243
positron 16084852_3 244 252
emission 16084852_3 253 261
tomography 16084852_3 262 272
( 16084852_3 273 274
PET 16084852_3 275 278
) 16084852_3 279 280
in 16084852_3 281 283
2 16084852_3 284 285
groups 16084852_3 286 292
of 16084852_3 293 295
healthy 16084852_3 296 303
volunteers 16084852_3 304 314
. 16084852_3 315 316

As 18433425_8 0 2
cytochrome 18433425_8 3 13
P 18433425_8 14 15
450 18433425_8 15 18
enzymes 18433425_8 19 26
metabolize 18433425_8 27 37
yohimbine 18433425_8 38 47
, 18433425_8 48 49
P 18433425_8 50 51
450 18433425_8 51 54
genotypes 18433425_8 55 64
( 18433425_8 65 66
CYP 18433425_8 67 70
2 18433425_8 70 71
D 18433425_8 71 72
6 18433425_8 72 73
and 18433425_8 74 77
CYP 18433425_8 78 81
3 18433425_8 81 82
A 18433425_8 82 83
4 18433425_8 83 84
) 18433425_8 85 86
were 18433425_8 87 91
determined 18433425_8 92 102
in 18433425_8 103 105
25 18433425_8 106 108
of 18433425_8 109 111
30 18433425_8 112 114
subjects 18433425_8 115 123
who 18433425_8 124 127
consented 18433425_8 128 137
to 18433425_8 138 140
genetic 18433425_8 141 148
studies 18433425_8 149 156
. 18433425_8 157 158

Another 24401102_11 0 7
SNP 24401102_11 8 11
in 24401102_11 12 14
the 24401102_11 15 18
region 24401102_11 19 25
, 24401102_11 26 27
rs 24401102_11 28 30
4952 24401102_11 30 34
, 24401102_11 35 36
remains 24401102_11 37 44
modestly 24401102_11 45 53
associated 24401102_11 54 64
with 24401102_11 65 69
nicotine 24401102_11 70 78
dependence 24401102_11 79 89
in 24401102_11 90 92
the 24401102_11 93 96
combined 24401102_11 97 105
data 24401102_11 106 110
after 24401102_11 111 116
conditioning 24401102_11 117 129
on 24401102_11 130 132
rs 24401102_11 133 135
13273442 24401102_11 135 143
. 24401102_11 144 145

When 24277619_9 0 4
rs 24277619_9 5 7
671 24277619_9 7 10
was 24277619_9 11 14
considered 24277619_9 15 25
as 24277619_9 26 28
a 24277619_9 29 30
candidate 24277619_9 31 40
SNP 24277619_9 41 44
in 24277619_9 45 47
females 24277619_9 48 55
, 24277619_9 56 57
it 24277619_9 58 60
explained 24277619_9 61 70
23 24277619_9 71 73
. 24277619_9 73 74
6 24277619_9 74 75
% 24277619_9 76 77
of 24277619_9 78 80
the 24277619_9 81 84
variation 24277619_9 85 94
in 24277619_9 95 97
flushing 24277619_9 98 106
response 24277619_9 107 115
, 24277619_9 116 117
but 24277619_9 118 121
alcohol 24277619_9 122 129
consumption 24277619_9 130 141
rates 24277619_9 142 147
were 24277619_9 148 152
too 24277619_9 153 156
low 24277619_9 157 160
among 24277619_9 161 166
females 24277619_9 167 174
- 24277619_9 174 175
despite 24277619_9 175 182
familial 24277619_9 183 191
enrichment 24277619_9 192 202
for 24277619_9 203 206
AD 24277619_9 207 209
- 24277619_9 210 211
for 24277619_9 211 214
an 24277619_9 215 217
adequate 24277619_9 218 226
test 24277619_9 227 231
of 24277619_9 232 234
association 24277619_9 235 246
for 24277619_9 247 250
either 24277619_9 251 257
AD 24277619_9 258 260
or 24277619_9 261 263
maximum 24277619_9 264 271
drinks 24277619_9 272 278
. 24277619_9 279 280

OBJECTIVE 21302482_2 0 9
: 21302482_2 10 11
To 21302482_2 12 14
study 21302482_2 15 20
the 21302482_2 21 24
relationships 21302482_2 25 38
of 21302482_2 39 41
blood 21302482_2 42 47
stasis 21302482_2 48 54
syndrome 21302482_2 55 63
( 21302482_2 64 65
BSS 21302482_2 66 69
) 21302482_2 70 71
, 21302482_2 72 73
CYP 21302482_2 74 77
2 21302482_2 77 78
C 21302482_2 78 79
19 21302482_2 79 81
gene 21302482_2 82 86
polymorphism 21302482_2 87 99
with 21302482_2 100 104
clopidogrel 21302482_2 105 116
resistance 21302482_2 117 127
( 21302482_2 128 129
CR 21302482_2 130 132
) 21302482_2 133 134
and 21302482_2 135 138
post 21302482_2 139 143
- 21302482_2 143 144
PCI 21302482_2 144 147
prognosis 21302482_2 148 157
. 21302482_2 158 159

A 17516068_1 0 1
phase 17516068_1 2 7
II 17516068_1 8 10
study 17516068_1 11 16
of 17516068_1 17 19
trastuzumab 17516068_1 20 31
and 17516068_1 32 35
capecitabine 17516068_1 36 48
for 17516068_1 49 52
patients 17516068_1 53 61
with 17516068_1 62 66
HER 17516068_1 67 70
2 17516068_1 70 71
- 17516068_1 72 73
overexpressing 17516068_1 73 87
metastatic 17516068_1 88 98
breast 17516068_1 99 105
cancer 17516068_1 106 112
: 17516068_1 113 114
Japan 17516068_1 115 120
Breast 17516068_1 121 127
Cancer 17516068_1 128 134
Research 17516068_1 135 143
Network 17516068_1 144 151
( 17516068_1 152 153
JBCRN 17516068_1 154 159
) 17516068_1 160 161
00 17516068_1 162 164
Trial 17516068_1 165 170
. 17516068_1 171 172

Luciferase 17121920_9 0 10
reporter 17121920_9 11 19
assay 17121920_9 20 25
and 17121920_9 26 29
the 17121920_9 30 33
chromatin 17121920_9 34 43
immunoprecipitation 17121920_9 44 63
assay 17121920_9 64 69
using 17121920_9 70 75
the 17121920_9 76 79
XIAP 17121920_9 80 84
promoter 17121920_9 85 93
constructs 17121920_9 94 104
show 17121920_9 105 109
that 17121920_9 110 114
mithramycin 17121920_9 115 126
A 17121920_9 127 128
down 17121920_9 129 133
- 17121920_9 133 134
regulates 17121920_9 134 143
the 17121920_9 144 147
transcription 17121920_9 148 161
of 17121920_9 162 164
XIAP 17121920_9 165 169
gene 17121920_9 170 174
through 17121920_9 175 182
inhibition 17121920_9 183 193
of 17121920_9 194 196
Sp 17121920_9 197 199
1 17121920_9 199 200
binding 17121920_9 201 208
to 17121920_9 209 211
its 17121920_9 212 215
promoter 17121920_9 216 224
. 17121920_9 225 226

CONCLUSIONS 22011650_9 0 11
: 22011650_9 12 13
HRQoL 22011650_9 14 19
and 22011650_9 20 23
symptom 22011650_9 24 31
endpoints 22011650_9 32 41
were 22011650_9 42 46
consistent 22011650_9 47 57
with 22011650_9 58 62
efficacy 22011650_9 63 71
outcomes 22011650_9 72 80
in 22011650_9 81 83
IPASS 22011650_9 84 89
and 22011650_9 90 93
favored 22011650_9 94 101
gefitinib 22011650_9 102 111
in 22011650_9 112 114
patients 22011650_9 115 123
with 22011650_9 124 128
EGFR 22011650_9 129 133
mutation 22011650_9 134 142
- 22011650_9 142 143
positive 22011650_9 143 151
tumors 22011650_9 152 158
and 22011650_9 159 162
carboplatin 22011650_9 163 174
/ 22011650_9 175 176
paclitaxel 22011650_9 177 187
in 22011650_9 188 190
patients 22011650_9 191 199
with 22011650_9 200 204
EGFR 22011650_9 205 209
mutation 22011650_9 210 218
- 22011650_9 218 219
negative 22011650_9 219 227
tumors 22011650_9 228 234
. 22011650_9 235 236

Using 15692831_8 0 5
plasma 15692831_8 6 12
CBZ 15692831_8 13 16
- 15692831_8 16 17
diol 15692831_8 17 21
/ 15692831_8 22 23
CBZ 15692831_8 24 27
- 15692831_8 27 28
epoxide 15692831_8 28 35
ratios 15692831_8 36 42
( 15692831_8 43 44
diol 15692831_8 45 49
/ 15692831_8 50 51
epoxide 15692831_8 52 59
ratios 15692831_8 60 66
) 15692831_8 67 68
indicative 15692831_8 69 79
of 15692831_8 80 82
the 15692831_8 83 86
mEH 15692831_8 87 90
activity 15692831_8 91 99
, 15692831_8 100 101
the 15692831_8 102 105
effects 15692831_8 106 113
of 15692831_8 114 116
the 15692831_8 117 120
diplotypes 15692831_8 121 131
in 15692831_8 132 134
each 15692831_8 135 139
EPHX 15692831_8 140 144
1 15692831_8 144 145
block 15692831_8 146 151
were 15692831_8 152 156
analyzed 15692831_8 157 165
on 15692831_8 166 168
CBZ 15692831_8 169 172
- 15692831_8 172 173
epoxide 15692831_8 173 180
metabolism 15692831_8 181 191
. 15692831_8 192 193

MATERIAL 22634097_7 0 8
AND 22634097_7 9 12
METHODS 22634097_7 13 20
: 22634097_7 21 22
We 22634097_7 23 25
analyzed 22634097_7 26 34
RAD 22634097_7 35 38
51 22634097_7 38 40
G 22634097_7 41 42
172 22634097_7 42 45
T 22634097_7 45 46
polymorphism 22634097_7 47 59
genotypes 22634097_7 60 69
in 22634097_7 70 72
cervical 22634097_7 73 81
cancer 22634097_7 82 88
patients 22634097_7 89 97
who 22634097_7 98 101
underwent 22634097_7 102 111
a 22634097_7 112 113
platinum 22634097_7 114 122
- 22634097_7 123 124
based 22634097_7 124 129
chemotherapy 22634097_7 130 142
in 22634097_7 143 145
combination 22634097_7 146 157
with 22634097_7 158 162
radiotherapy 22634097_7 163 175
. 22634097_7 176 177

Examining 23245376_1 0 9
the 23245376_1 10 13
association 23245376_1 14 25
of 23245376_1 26 28
NRXN 23245376_1 29 33
3 23245376_1 33 34
SNPs 23245376_1 35 39
with 23245376_1 40 44
borderline 23245376_1 45 55
personality 23245376_1 56 67
disorder 23245376_1 68 76
phenotypes 23245376_1 77 87
in 23245376_1 88 90
heroin 23245376_1 91 97
dependent 23245376_1 98 107
cases 23245376_1 108 113
and 23245376_1 114 117
socio 23245376_1 118 123
- 23245376_1 123 124
economically 23245376_1 124 136
disadvantaged 23245376_1 137 150
controls 23245376_1 151 159
. 23245376_1 160 161

Single 20374216_1 0 6
- 20374216_1 6 7
nucleotide 20374216_1 7 17
polymorphisms 20374216_1 18 31
in 20374216_1 32 34
corticotropin 20374216_1 35 48
releasing 20374216_1 49 58
hormone 20374216_1 59 66
receptor 20374216_1 67 75
1 20374216_1 76 77
gene 20374216_1 78 82
( 20374216_1 83 84
CRHR 20374216_1 85 89
1 20374216_1 89 90
) 20374216_1 91 92
are 20374216_1 93 96
associated 20374216_1 97 107
with 20374216_1 108 112
quantitative 20374216_1 113 125
trait 20374216_1 126 131
of 20374216_1 132 134
event 20374216_1 135 140
- 20374216_1 140 141
related 20374216_1 141 148
potential 20374216_1 149 158
and 20374216_1 159 162
alcohol 20374216_1 163 170
dependence 20374216_1 171 181
. 20374216_1 182 183

The 20871262_15 0 3
response 20871262_15 4 12
rate 20871262_15 13 17
in 20871262_15 18 20
patients 20871262_15 21 29
with 20871262_15 30 34
non 20871262_15 35 38
- 20871262_15 38 39
EGFR 20871262_15 40 44
mutant 20871262_15 45 51
tumors 20871262_15 52 58
was 20871262_15 59 62
8 20871262_15 63 64
% 20871262_15 65 66
, 20871262_15 67 68
likely 20871262_15 69 75
reflecting 20871262_15 76 86
activity 20871262_15 87 95
of 20871262_15 96 98
everolimus 20871262_15 99 109
. 20871262_15 110 111

rs 25589623_11 0 2
11085735 25589623_11 2 10
associated 25589623_11 11 21
with 25589623_11 22 26
RFS 25589623_11 27 30
also 25589623_11 31 35
among 25589623_11 36 41
tamoxifen 25589623_11 42 51
- 25589623_11 52 53
treated 25589623_11 53 60
cases 25589623_11 61 66
( 25589623_11 67 68
P 25589623_11 69 70
= 25589623_11 71 72
0 25589623_11 73 74
. 25589623_11 74 75
003 25589623_11 75 78
; 25589623_11 79 80
HR 25589623_11 81 83
, 25589623_11 84 85
3 25589623_11 86 87
. 25589623_11 87 88
517 25589623_11 88 91
) 25589623_11 92 93
. 25589623_11 94 95

It 23097010_11 0 2
suggested 23097010_11 3 12
that 23097010_11 13 17
the 23097010_11 18 21
POR 23097010_11 22 25
28 23097010_11 26 28
genetic 23097010_11 29 36
polymorphism 23097010_11 37 49
might 23097010_11 50 55
also 23097010_11 56 60
be 23097010_11 61 63
responsible 23097010_11 64 75
for 23097010_11 76 79
the 23097010_11 80 83
marked 23097010_11 84 90
interindividual 23097010_11 91 106
variability 23097010_11 107 118
of 23097010_11 119 121
tacrolimus 23097010_11 122 132
besides 23097010_11 133 140
the 23097010_11 141 144
CYP 23097010_11 145 148
3 23097010_11 148 149
A 23097010_11 149 150
5 23097010_11 150 151
3 23097010_11 152 153
genetic 23097010_11 154 161
polymorphism 23097010_11 162 174
. 23097010_11 175 176

Although 19429175_2 0 8
morphine 19429175_2 9 17
and 19429175_2 18 21
heroin 19429175_2 22 28
analgesia 19429175_2 29 38
is 19429175_2 39 41
mediated 19429175_2 42 50
by 19429175_2 51 53
mu 19429175_2 54 56
- 19429175_2 56 57
opioid 19429175_2 57 63
receptors 19429175_2 64 73
encoded 19429175_2 74 81
by 19429175_2 82 84
the 19429175_2 85 88
MOR 19429175_2 89 92
- 19429175_2 92 93
1 19429175_2 93 94
gene 19429175_2 95 99
, 19429175_2 100 101
distinct 19429175_2 102 110
isoforms 19429175_2 111 119
are 19429175_2 120 123
involved 19429175_2 124 132
. 19429175_2 133 134

With 15217301_7 0 4
regard 15217301_7 5 11
to 15217301_7 12 14
the 15217301_7 15 18
variability 15217301_7 19 30
, 15217301_7 31 32
polymorphisms 15217301_7 33 46
of 15217301_7 47 49
the 15217301_7 50 53
MDR 15217301_7 54 57
1 15217301_7 57 58
gene 15217301_7 59 63
have 15217301_7 64 68
recently 15217301_7 69 77
been 15217301_7 78 82
reported 15217301_7 83 91
to 15217301_7 92 94
be 15217301_7 95 97
associated 15217301_7 98 108
with 15217301_7 109 113
alterations 15217301_7 114 125
in 15217301_7 126 128
disposition 15217301_7 129 140
kinetics 15217301_7 141 149
and 15217301_7 150 153
interaction 15217301_7 154 165
profiles 15217301_7 166 174
of 15217301_7 175 177
clinically 15217301_7 178 188
useful 15217301_7 189 195
drugs 15217301_7 196 201
, 15217301_7 202 203
including 15217301_7 204 213
digoxin 15217301_7 214 221
, 15217301_7 222 223
fexofenadine 15217301_7 224 236
, 15217301_7 237 238
ciclosporin 15217301_7 239 250
and 15217301_7 251 254
talinolol 15217301_7 255 264
. 15217301_7 265 266

CONCLUSION 17358097_9 0 10
: 17358097_9 11 12
Our 17358097_9 13 16
findings 17358097_9 17 25
show 17358097_9 26 30
that 17358097_9 31 35
CYP 17358097_9 36 39
3 17358097_9 39 40
A 17358097_9 40 41
5 17358097_9 41 42
genotype 17358097_9 43 51
is 17358097_9 52 54
not 17358097_9 55 58
an 17358097_9 59 61
important 17358097_9 62 71
determinant 17358097_9 72 83
of 17358097_9 84 86
enantioselective 17358097_9 87 103
disposition 17358097_9 104 115
of 17358097_9 116 118
lansoprazole 17358097_9 119 131
. 17358097_9 132 133

The 7748323_2 0 3
expression 7748323_2 4 14
of 7748323_2 15 17
c 7748323_2 18 19
- 7748323_2 19 20
fos 7748323_2 20 23
mRNA 7748323_2 24 28
in 7748323_2 29 31
rat 7748323_2 32 35
brain 7748323_2 36 41
was 7748323_2 42 45
induced 7748323_2 46 53
by 7748323_2 54 56
intraperitoneal 7748323_2 57 72
( 7748323_2 73 74
ip 7748323_2 75 77
) 7748323_2 78 79
administration 7748323_2 80 94
of 7748323_2 95 97
N 7748323_2 98 99
- 7748323_2 99 100
methyl 7748323_2 100 106
- 7748323_2 106 107
D 7748323_2 107 108
- 7748323_2 108 109
aspartate 7748323_2 109 118
( 7748323_2 119 120
NMDA 7748323_2 121 125
) 7748323_2 126 127
and 7748323_2 128 131
kainic 7748323_2 132 138
acid 7748323_2 139 143
, 7748323_2 144 145
agonists 7748323_2 146 154
of 7748323_2 155 157
different 7748323_2 158 167
classes 7748323_2 168 175
of 7748323_2 176 178
glutamate 7748323_2 179 188
receptors 7748323_2 189 198
and 7748323_2 199 202
by 7748323_2 203 205
caffeine 7748323_2 206 214
, 7748323_2 215 216
an 7748323_2 217 219
antagonist 7748323_2 220 230
of 7748323_2 231 233
adenosine 7748323_2 234 243
receptors 7748323_2 244 253
. 7748323_2 254 255

For 26325438_9 0 3
tacrolimus 26325438_9 4 14
, 26325438_9 15 16
rs 26325438_9 17 19
776746 26325438_9 19 25
CYP 26325438_9 26 29
3 26325438_9 29 30
A 26325438_9 30 31
5 26325438_9 31 32
* 26325438_9 33 34
3 26325438_9 35 36
/ 26325438_9 37 38
* 26325438_9 39 40
3 26325438_9 41 42
and 26325438_9 43 46
CYP 26325438_9 47 50
3 26325438_9 50 51
A 26325438_9 51 52
5 26325438_9 52 53
* 26325438_9 54 55
3 26325438_9 56 57
/ 26325438_9 58 59
* 26325438_9 60 61
1 26325438_9 62 63
were 26325438_9 64 68
associated 26325438_9 69 79
with 26325438_9 80 84
higher 26325438_9 85 91
blood 26325438_9 92 97
levels 26325438_9 98 104
than 26325438_9 105 109
CYP 26325438_9 110 113
3 26325438_9 113 114
A 26325438_9 114 115
5 26325438_9 115 116
* 26325438_9 117 118
1 26325438_9 119 120
/ 26325438_9 121 122
* 26325438_9 123 124
1 26325438_9 125 126
( 26325438_9 127 128
P 26325438_9 129 130
= 26325438_9 131 132
. 26325438_9 133 134
002 26325438_9 134 137
) 26325438_9 138 139
. 26325438_9 140 141

Similar 18349701_12 0 7
to 18349701_12 8 10
the 18349701_12 11 14
observations 18349701_12 15 27
with 18349701_12 28 32
pindolol 18349701_12 33 41
, 18349701_12 42 43
s 18349701_12 44 45
/ 18349701_12 45 46
s 18349701_12 46 47
- 18349701_12 47 48
allele 18349701_12 48 54
patients 18349701_12 55 63
showed 18349701_12 64 70
a 18349701_12 71 72
higher 18349701_12 73 79
benefit 18349701_12 80 87
from 18349701_12 88 92
lithium 18349701_12 93 100
augmentation 18349701_12 101 113
than 18349701_12 114 118
did 18349701_12 119 122
patients 18349701_12 123 131
carrying 18349701_12 132 140
other 18349701_12 141 146
5 18349701_12 147 148
- 18349701_12 148 149
HTTLPR 18349701_12 149 155
genotypes 18349701_12 156 165
. 18349701_12 166 167

RESISTANCE 8970671_3 0 10
TO 8970671_3 11 13
SAQUINAVIR 8970671_3 14 24
: 8970671_3 25 26
Resistance 8970671_3 27 37
to 8970671_3 38 40
saquinavir 8970671_3 41 51
in 8970671_3 52 54
vitro 8970671_3 55 60
and 8970671_3 61 64
in 8970671_3 65 67
vivo 8970671_3 68 72
is 8970671_3 73 75
associated 8970671_3 76 86
with 8970671_3 87 91
mutations 8970671_3 92 101
L 8970671_3 102 103
90 8970671_3 103 105
M 8970671_3 105 106
and 8970671_3 107 110
G 8970671_3 111 112
48 8970671_3 112 114
V 8970671_3 114 115
in 8970671_3 116 118
HIV 8970671_3 119 122
protease 8970671_3 123 131
. 8970671_3 132 133

We 25319571_4 0 2
found 25319571_4 3 8
that 25319571_4 9 13
bath 25319571_4 14 18
application 25319571_4 19 30
of 25319571_4 31 33
group 25319571_4 34 39
I 25319571_4 40 41
mGluR 25319571_4 42 47
agonist 25319571_4 48 55
( 25319571_4 56 57
S 25319571_4 57 58
) 25319571_4 58 59
- 25319571_4 59 60
3 25319571_4 60 61
, 25319571_4 61 62
5 25319571_4 62 63
- 25319571_4 63 64
dihydroxyphenylglycine 25319571_4 64 86
( 25319571_4 87 88
DHPG 25319571_4 89 93
) 25319571_4 94 95
reliably 25319571_4 96 104
induced 25319571_4 105 112
LTD 25319571_4 113 116
in 25319571_4 117 119
both 25319571_4 120 124
NAc 25319571_4 125 128
shell 25319571_4 129 134
and 25319571_4 135 138
core 25319571_4 139 143
MSNs 25319571_4 144 148
of 25319571_4 149 151
wild 25319571_4 152 156
- 25319571_4 156 157
type 25319571_4 157 161
, 25319571_4 162 163
hemizygous 25319571_4 164 174
Drd 25319571_4 175 178
1 25319571_4 178 179
- 25319571_4 180 181
eGFP 25319571_4 181 185
, 25319571_4 186 187
and 25319571_4 188 191
Drd 25319571_4 192 195
2 25319571_4 195 196
- 25319571_4 197 198
eGFP 25319571_4 198 202
mice 25319571_4 203 207
. 25319571_4 208 209

We 16338277_3 0 2
hypothesized 16338277_3 3 15
that 16338277_3 16 20
clinical 16338277_3 21 29
resistance 16338277_3 30 40
to 16338277_3 41 43
5 16338277_3 44 45
- 16338277_3 45 46
HT 16338277_3 46 48
( 16338277_3 49 50
3 16338277_3 51 52
) 16338277_3 53 54
antagonists 16338277_3 55 66
is 16338277_3 67 69
associated 16338277_3 70 80
with 16338277_3 81 85
the 16338277_3 86 89
single 16338277_3 90 96
- 16338277_3 96 97
nucleotide 16338277_3 97 107
polymorphism 16338277_3 108 120
( 16338277_3 121 122
3435 16338277_3 123 127
C 16338277_3 127 128
> 16338277_3 128 129
T 16338277_3 129 130
) 16338277_3 131 132
in 16338277_3 133 135
the 16338277_3 136 139
gene 16338277_3 140 144
that 16338277_3 145 149
codes 16338277_3 150 155
for 16338277_3 156 159
the 16338277_3 160 163
drug 16338277_3 164 168
efflux 16338277_3 169 175
transporter 16338277_3 176 187
adenosine 16338277_3 188 197
triphosphate 16338277_3 198 210
- 16338277_3 211 212
binding 16338277_3 212 219
cassette 16338277_3 220 228
subfamily 16338277_3 229 238
B 16338277_3 239 240
member 16338277_3 241 247
1 16338277_3 248 249
( 16338277_3 250 251
ABCB 16338277_3 252 256
1 16338277_3 256 257
) 16338277_3 258 259
. 16338277_3 260 261

Consequently 19891556_6 0 12
, 19891556_6 13 14
the 19891556_6 15 18
US 19891556_6 19 21
FDA 19891556_6 22 25
has 19891556_6 26 29
recently 19891556_6 30 38
changed 19891556_6 39 46
clopidogrel 19891556_6 47 58
' 19891556_6 59 60
s 19891556_6 60 61
prescribing 19891556_6 62 73
information 19891556_6 74 85
to 19891556_6 86 88
highlight 19891556_6 89 98
the 19891556_6 99 102
impact 19891556_6 103 109
of 19891556_6 110 112
CYP 19891556_6 113 116
2 19891556_6 116 117
C 19891556_6 117 118
19 19891556_6 118 120
genotype 19891556_6 121 129
on 19891556_6 130 132
clopidogrel 19891556_6 133 144
pharmacokinetics 19891556_6 145 161
, 19891556_6 162 163
pharmacodynamics 19891556_6 164 180
and 19891556_6 181 184
clinical 19891556_6 185 193
response 19891556_6 194 202
. 19891556_6 203 204

The 12149232_3 0 3
mechanism 12149232_3 4 13
by 12149232_3 14 16
which 12149232_3 17 22
HFE 12149232_3 23 26
regulates 12149232_3 27 36
iron 12149232_3 37 41
absorption 12149232_3 42 52
is 12149232_3 53 55
not 12149232_3 56 59
known 12149232_3 60 65
, 12149232_3 66 67
but 12149232_3 68 71
the 12149232_3 72 75
C 12149232_3 76 77
282 12149232_3 77 80
Y 12149232_3 80 81
mutation 12149232_3 82 90
results 12149232_3 91 98
in 12149232_3 99 101
loss 12149232_3 102 106
of 12149232_3 107 109
cell 12149232_3 110 114
surface 12149232_3 115 122
expression 12149232_3 123 133
of 12149232_3 134 136
the 12149232_3 137 140
human 12149232_3 141 146
hemachromatosis 12149232_3 147 162
protein 12149232_3 163 170
( 12149232_3 171 172
HFE 12149232_3 173 176
) 12149232_3 177 178
and 12149232_3 179 182
hyperabsorption 12149232_3 183 198
of 12149232_3 199 201
iron 12149232_3 202 206
by 12149232_3 207 209
the 12149232_3 210 213
duodenal 12149232_3 214 222
enterocyte 12149232_3 223 233
. 12149232_3 234 235

RESULTS 16940443_5 0 7
: 16940443_5 8 9
Treatment 16940443_5 10 19
of 16940443_5 20 22
BAFs 16940443_5 23 27
with 16940443_5 28 32
prostaglandin 16940443_5 33 46
E 16940443_5 47 48
2 16940443_5 48 49
or 16940443_5 50 52
a 16940443_5 53 54
surrogate 16940443_5 55 64
hormonal 16940443_5 65 73
cocktail 16940443_5 74 82
of 16940443_5 83 85
dibutyryl 16940443_5 86 95
( 16940443_5 96 97
Bt 16940443_5 98 100
2 16940443_5 100 101
) 16940443_5 102 103
cAMP 16940443_5 104 108
plus 16940443_5 109 113
phorbol 16940443_5 114 121
12 16940443_5 122 124
, 16940443_5 124 125
13 16940443_5 126 128
- 16940443_5 128 129
diacetate 16940443_5 129 138
( 16940443_5 139 140
PDA 16940443_5 141 144
) 16940443_5 145 146
significantly 16940443_5 147 160
reduced 16940443_5 161 168
BRCA 16940443_5 169 173
1 16940443_5 173 174
levels 16940443_5 175 181
and 16940443_5 182 185
induced 16940443_5 186 193
aromatase 16940443_5 194 203
mRNA 16940443_5 204 208
levels 16940443_5 209 215
. 16940443_5 216 217

Prognostic 25474278_1 0 10
value 25474278_1 11 16
of 25474278_1 17 19
microsatellite 25474278_1 20 34
instability 25474278_1 35 46
and 25474278_1 47 50
p 25474278_1 51 52
53 25474278_1 52 54
expression 25474278_1 55 65
in 25474278_1 66 68
metastatic 25474278_1 69 79
colorectal 25474278_1 80 90
cancer 25474278_1 91 97
treated 25474278_1 98 105
with 25474278_1 106 110
oxaliplatin 25474278_1 111 122
and 25474278_1 123 126
fluoropyrimidine 25474278_1 127 143
- 25474278_1 144 145
based 25474278_1 145 150
chemotherapy 25474278_1 151 163
. 25474278_1 164 165

These 15063162_7 0 5
results 15063162_7 6 13
suggest 15063162_7 14 21
that 15063162_7 22 26
nitric 15063162_7 27 33
oxide 15063162_7 34 39
is 15063162_7 40 42
, 15063162_7 43 44
at 15063162_7 45 47
least 15063162_7 48 53
partly 15063162_7 54 60
, 15063162_7 61 62
involved 15063162_7 63 71
in 15063162_7 72 74
lithium 15063162_7 75 82
- 15063162_7 83 84
induced 15063162_7 84 91
c 15063162_7 92 93
- 15063162_7 93 94
Fos 15063162_7 94 97
/ 15063162_7 98 99
ICER 15063162_7 100 104
expression 15063162_7 105 115
in 15063162_7 116 118
the 15063162_7 119 122
adrenal 15063162_7 123 130
medulla 15063162_7 131 138
, 15063162_7 139 140
and 15063162_7 141 144
that 15063162_7 145 149
central 15063162_7 150 157
nitric 15063162_7 158 164
oxide 15063162_7 165 170
may 15063162_7 171 174
play 15063162_7 175 179
a 15063162_7 180 181
different 15063162_7 182 191
role 15063162_7 192 196
from 15063162_7 197 201
peripheral 15063162_7 202 212
nitric 15063162_7 213 219
oxide 15063162_7 220 225
in 15063162_7 226 228
lithium 15063162_7 229 236
- 15063162_7 237 238
induced 15063162_7 238 245
activation 15063162_7 246 256
of 15063162_7 257 259
adrenal 15063162_7 260 267
medulla 15063162_7 268 275
. 15063162_7 276 277

METHODS 15226679_4 0 7
: 15226679_4 8 9
In 15226679_4 10 12
this 15226679_4 13 17
study 15226679_4 18 23
, 15226679_4 24 25
we 15226679_4 26 28
have 15226679_4 29 33
evaluated 15226679_4 34 43
the 15226679_4 44 47
genotypes 15226679_4 48 57
of 15226679_4 58 60
MDR 15226679_4 61 64
1 15226679_4 64 65
and 15226679_4 66 69
cytochrome 15226679_4 70 80
P 15226679_4 81 82
450 15226679_4 82 85
( 15226679_4 86 87
CYP 15226679_4 87 90
) 15226679_4 90 91
3 15226679_4 92 93
A 15226679_4 93 94
in 15226679_4 95 97
donor 15226679_4 98 103
and 15226679_4 104 107
recipient 15226679_4 108 117
, 15226679_4 118 119
and 15226679_4 120 123
the 15226679_4 124 127
influence 15226679_4 128 137
of 15226679_4 138 140
polymorphisms 15226679_4 141 154
on 15226679_4 155 157
mRNA 15226679_4 158 162
expression 15226679_4 163 173
and 15226679_4 174 177
the 15226679_4 178 181
tacrolimus 15226679_4 182 192
concentration 15226679_4 193 206
/ 15226679_4 206 207
dose 15226679_4 207 211
( 15226679_4 212 213
C 15226679_4 214 215
/ 15226679_4 215 216
D 15226679_4 216 217
) 15226679_4 218 219
ratio 15226679_4 220 225
in 15226679_4 226 228
recipients 15226679_4 229 239
of 15226679_4 240 242
living 15226679_4 243 249
- 15226679_4 249 250
donor 15226679_4 250 255
liver 15226679_4 256 261
transplantation 15226679_4 262 277
( 15226679_4 278 279
LDLT 15226679_4 280 284
) 15226679_4 285 286
. 15226679_4 287 288

The 24322002_4 0 3
objective 24322002_4 4 13
of 24322002_4 14 16
the 24322002_4 17 20
present 24322002_4 21 28
study 24322002_4 29 34
was 24322002_4 35 38
to 24322002_4 39 41
confirm 24322002_4 42 49
the 24322002_4 50 53
influence 24322002_4 54 63
of 24322002_4 64 66
the 24322002_4 67 70
FCGR 24322002_4 71 75
3 24322002_4 75 76
A 24322002_4 76 77
polymorphism 24322002_4 78 90
on 24322002_4 91 93
the 24322002_4 94 97
extent 24322002_4 98 104
of 24322002_4 105 107
lymphocyte 24322002_4 108 118
depletion 24322002_4 119 128
in 24322002_4 129 131
kidney 24322002_4 132 138
transplant 24322002_4 139 149
patients 24322002_4 150 158
treated 24322002_4 159 166
with 24322002_4 167 171
rabbit 24322002_4 172 178
antithymocyte 24322002_4 179 192
globulin 24322002_4 193 201
( 24322002_4 202 203
r 24322002_4 204 205
- 24322002_4 205 206
ATG 24322002_4 206 209
) 24322002_4 210 211
. 24322002_4 212 213

In 10628896_5 0 2
studies 10628896_5 3 10
of 10628896_5 11 13
CYP 10628896_5 14 17
- 10628896_5 18 19
mediated 10628896_5 19 27
disposition 10628896_5 28 39
in 10628896_5 40 42
vitro 10628896_5 43 48
, 10628896_5 49 50
CYP 10628896_5 51 54
3 10628896_5 54 55
A 10628896_5 55 56
4 10628896_5 56 57
appears 10628896_5 58 65
to 10628896_5 66 68
be 10628896_5 69 71
the 10628896_5 72 75
major 10628896_5 76 81
isoform 10628896_5 82 89
responsible 10628896_5 90 101
for 10628896_5 102 105
the 10628896_5 106 109
metabolism 10628896_5 110 120
of 10628896_5 121 123
haloperidol 10628896_5 124 135
in 10628896_5 136 138
humans 10628896_5 139 145
. 10628896_5 146 147

BACKGROUND 23029188_2 0 10
: 23029188_2 11 12
Many 23029188_2 13 17
studies 23029188_2 18 25
have 23029188_2 26 30
been 23029188_2 31 35
published 23029188_2 36 45
on 23029188_2 46 48
the 23029188_2 49 52
association 23029188_2 53 64
between 23029188_2 65 72
single 23029188_2 73 79
nucleotide 23029188_2 80 90
polymorphisms 23029188_2 91 104
( 23029188_2 105 106
SNP 23029188_2 107 110
) 23029188_2 111 112
near 23029188_2 113 117
the 23029188_2 118 121
IL 23029188_2 122 124
28 23029188_2 124 126
B 23029188_2 126 127
gene 23029188_2 128 132
and 23029188_2 133 136
response 23029188_2 137 145
to 23029188_2 146 148
the 23029188_2 149 152
combined 23029188_2 153 161
treatments 23029188_2 162 172
of 23029188_2 173 175
pegylated 23029188_2 176 185
- 23029188_2 185 186
interferon 23029188_2 186 196
( 23029188_2 197 198
PegIFN 23029188_2 199 205
) 23029188_2 206 207
and 23029188_2 208 211
ribavirin 23029188_2 212 221
( 23029188_2 222 223
RBV 23029188_2 224 227
) 23029188_2 228 229
in 23029188_2 230 232
chronic 23029188_2 233 240
HCV 23029188_2 241 244
- 23029188_2 245 246
infected 23029188_2 246 254
patients 23029188_2 255 263
, 23029188_2 264 265
but 23029188_2 266 269
without 23029188_2 270 277
identical 23029188_2 278 287
conclusions 23029188_2 288 299
. 23029188_2 300 301

We 18525109_3 0 2
found 18525109_3 3 8
that 18525109_3 9 13
the 18525109_3 14 17
extract 18525109_3 18 25
of 18525109_3 26 28
C 18525109_3 29 30
. 18525109_3 30 31
sappan 18525109_3 32 38
L 18525109_3 39 40
. 18525109_3 40 41
and 18525109_3 42 45
brazilin 18525109_3 46 54
induced 18525109_3 55 62
antioxidant 18525109_3 63 74
response 18525109_3 75 83
element 18525109_3 84 91
( 18525109_3 92 93
ARE 18525109_3 94 97
) 18525109_3 98 99
- 18525109_3 100 101
luciferase 18525109_3 102 112
activity 18525109_3 113 121
and 18525109_3 122 125
heme 18525109_3 126 130
oxygenase 18525109_3 131 140
- 18525109_3 140 141
1 18525109_3 141 142
( 18525109_3 143 144
HO 18525109_3 145 147
- 18525109_3 147 148
1 18525109_3 148 149
) 18525109_3 150 151
expression 18525109_3 152 162
in 18525109_3 163 165
a 18525109_3 166 167
concentration 18525109_3 168 181
- 18525109_3 181 182
dependent 18525109_3 182 191
manner 18525109_3 192 198
. 18525109_3 199 200

Single 24966969_2 0 6
nucleotide 24966969_2 7 17
polymorphisms 24966969_2 18 31
( 24966969_2 32 33
SNPs 24966969_2 34 38
) 24966969_2 39 40
of 24966969_2 41 43
VKORC 24966969_2 44 49
( 24966969_2 50 51
1173 24966969_2 52 56
T 24966969_2 56 57
/ 24966969_2 57 58
C 24966969_2 58 59
, 24966969_2 60 61
rs 24966969_2 62 64
9934438 24966969_2 64 71
) 24966969_2 72 73
and 24966969_2 74 77
CYP 24966969_2 78 81
2 24966969_2 81 82
C 24966969_2 82 83
9 24966969_2 83 84
( 24966969_2 85 86
1075 24966969_2 87 91
A 24966969_2 91 92
/ 24966969_2 92 93
C 24966969_2 93 94
, 24966969_2 95 96
rs 24966969_2 97 99
1057910 24966969_2 99 106
) 24966969_2 107 108
are 24966969_2 109 112
major 24966969_2 113 118
contributory 24966969_2 119 131
factors 24966969_2 132 139
on 24966969_2 140 142
the 24966969_2 143 146
sensitivity 24966969_2 147 158
of 24966969_2 159 161
warfarin 24966969_2 162 170
in 24966969_2 171 173
Chinese 24966969_2 174 181
. 24966969_2 182 183

To 24651609_2 0 2
further 24651609_2 3 10
understand 24651609_2 11 21
the 24651609_2 22 25
pharmacological 24651609_2 26 41
properties 24651609_2 42 52
of 24651609_2 53 55
N 24651609_2 56 57
- 24651609_2 57 58
oleoylethanolamine 24651609_2 58 76
( 24651609_2 77 78
OEA 24651609_2 79 82
) 24651609_2 83 84
, 24651609_2 85 86
a 24651609_2 87 88
naturally 24651609_2 89 98
occurring 24651609_2 99 108
lipid 24651609_2 109 114
that 24651609_2 115 119
activates 24651609_2 120 129
peroxisome 24651609_2 130 140
proliferator 24651609_2 141 153
- 24651609_2 153 154
activated 24651609_2 154 163
receptor 24651609_2 164 172
alpha 24651609_2 173 178
( 24651609_2 179 180
PPARa 24651609_2 181 186
) 24651609_2 187 188
, 24651609_2 189 190
we 24651609_2 191 193
designed 24651609_2 194 202
sulfamoyl 24651609_2 203 212
analogs 24651609_2 213 220
based 24651609_2 221 226
on 24651609_2 227 229
its 24651609_2 230 233
structure 24651609_2 234 243
. 24651609_2 244 245

Association 16314758_1 0 11
of 16314758_1 12 14
a 16314758_1 15 16
polymorphism 16314758_1 17 29
in 16314758_1 30 32
the 16314758_1 33 36
Homer 16314758_1 37 42
1 16314758_1 42 43
gene 16314758_1 44 48
with 16314758_1 49 53
cocaine 16314758_1 54 61
dependence 16314758_1 62 72
in 16314758_1 73 75
an 16314758_1 76 78
African 16314758_1 79 86
American 16314758_1 87 95
population 16314758_1 96 106
. 16314758_1 107 108

Recently 20680652_3 0 8
, 20680652_3 9 10
we 20680652_3 11 13
identified 20680652_3 14 24
that 20680652_3 25 29
the 20680652_3 30 33
rs 20680652_3 34 36
622342 20680652_3 36 42
A 20680652_3 43 44
> 20680652_3 45 46
C 20680652_3 47 48
polymorphism 20680652_3 49 61
is 20680652_3 62 64
associated 20680652_3 65 75
with 20680652_3 76 80
the 20680652_3 81 84
HbA 20680652_3 85 88
1 20680652_3 88 89
c 20680652_3 89 90
lowering 20680652_3 91 99
effect 20680652_3 100 106
in 20680652_3 107 109
metformin 20680652_3 110 119
users 20680652_3 120 125
. 20680652_3 126 127

Although 18378882_9 0 8
the 18378882_9 9 12
MUT 18378882_9 13 16
+ 18378882_9 17 18
group 18378882_9 19 24
showed 18378882_9 25 31
more 18378882_9 32 36
severe 18378882_9 37 43
axial 18378882_9 44 49
signs 18378882_9 50 55
preoperatively 18378882_9 56 70
, 18378882_9 71 72
MUT 18378882_9 73 76
- 18378882_9 77 78
patients 18378882_9 79 87
developed 18378882_9 88 97
levodopa 18378882_9 98 106
- 18378882_9 107 108
and 18378882_9 109 112
deep 18378882_9 113 117
brain 18378882_9 118 123
stimulation 18378882_9 124 135
- 18378882_9 135 136
resistant 18378882_9 137 146
axial 18378882_9 147 152
signs 18378882_9 153 158
within 18378882_9 159 165
the 18378882_9 166 169
first 18378882_9 170 175
3 18378882_9 176 177
to 18378882_9 178 180
6 18378882_9 181 182
years 18378882_9 183 188
postoperatively 18378882_9 189 204
, 18378882_9 205 206
which 18378882_9 207 212
diminished 18378882_9 213 223
the 18378882_9 224 227
initial 18378882_9 228 235
benefit 18378882_9 236 243
soon 18378882_9 244 248
after 18378882_9 249 254
surgery 18378882_9 255 262
. 18378882_9 263 264

In 19114005_9 0 2
endothelial 19114005_9 3 14
as 19114005_9 15 17
well 19114005_9 18 22
as 19114005_9 23 25
glioma 19114005_9 26 32
cells 19114005_9 33 38
cilengitide 19114005_9 39 50
inhibited 19114005_9 51 60
phosphorylation 19114005_9 61 76
of 19114005_9 77 79
FAK 19114005_9 80 83
, 19114005_9 84 85
Src 19114005_9 86 89
and 19114005_9 90 93
Akt 19114005_9 94 97
. 19114005_9 98 99

CONCLUSION 26039043_12 0 10
: 26039043_12 11 12
Based 26039043_12 13 18
on 26039043_12 19 21
our 26039043_12 22 25
meta 26039043_12 26 30
- 26039043_12 30 31
analysis 26039043_12 31 39
, 26039043_12 40 41
the 26039043_12 42 45
CYP 26039043_12 46 49
3 26039043_12 49 50
A 26039043_12 50 51
4 26039043_12 51 52
* 26039043_12 53 54
1 26039043_12 55 56
B 26039043_12 56 57
genetic 26039043_12 58 65
polymorphism 26039043_12 66 78
affects 26039043_12 79 86
tacrolimus 26039043_12 87 97
dose 26039043_12 98 102
requirements 26039043_12 103 115
and 26039043_12 116 119
tacrolimus 26039043_12 120 130
trough 26039043_12 131 137
concentration 26039043_12 138 151
/ 26039043_12 151 152
weight 26039043_12 152 158
- 26039043_12 158 159
adjusted 26039043_12 159 167
tacrolimus 26039043_12 168 178
daily 26039043_12 179 184
dose 26039043_12 185 189
ratio 26039043_12 190 195
within 26039043_12 196 202
the 26039043_12 203 206
first 26039043_12 207 212
year 26039043_12 213 217
post 26039043_12 218 222
- 26039043_12 222 223
transplantation 26039043_12 224 239
in 26039043_12 240 242
adult 26039043_12 243 248
renal 26039043_12 249 254
transplant 26039043_12 255 265
recipients 26039043_12 266 276
, 26039043_12 277 278
especially 26039043_12 279 289
in 26039043_12 290 292
European 26039043_12 293 301
recipients 26039043_12 302 312
( 26039043_12 313 314
mostly 26039043_12 315 321
Caucasian 26039043_12 322 331
) 26039043_12 332 333
. 26039043_12 334 335

Importantly 22289787_11 0 11
, 22289787_11 12 13
VPA 22289787_11 14 17
/ 22289787_11 18 19
HU 22289787_11 20 22
treatment 22289787_11 23 32
additionally 22289787_11 33 45
reduces 22289787_11 46 53
expression 22289787_11 54 64
and 22289787_11 65 68
cell 22289787_11 69 73
surface 22289787_11 74 81
localization 22289787_11 82 94
of 22289787_11 95 97
EGFR 22289787_11 98 102
. 22289787_11 103 104

RESULTS 24782176_7 0 7
: 24782176_7 8 9
Among 24782176_7 10 15
the 24782176_7 16 19
87 24782176_7 20 22
identified 24782176_7 23 33
studies 24782176_7 34 41
examining 24782176_7 42 51
genetic 24782176_7 52 59
associations 24782176_7 60 72
with 24782176_7 73 77
MTX 24782176_7 78 81
efficacy 24782176_7 82 90
and 24782176_7 91 94
toxicity 24782176_7 95 103
, 24782176_7 104 105
the 24782176_7 106 109
reduced 24782176_7 110 117
folate 24782176_7 118 124
carrier 24782176_7 125 132
1 24782176_7 133 134
gene 24782176_7 135 139
( 24782176_7 140 141
RFC 24782176_7 142 145
1 24782176_7 145 146
) 24782176_7 147 148
variant 24782176_7 149 156
80 24782176_7 157 159
G 24782176_7 159 160
> 24782176_7 160 161
A 24782176_7 161 162
( 24782176_7 163 164
Arg 24782176_7 165 168
( 24782176_7 169 170
27 24782176_7 171 173
) 24782176_7 174 175
His 24782176_7 176 179
, 24782176_7 180 181
rs 24782176_7 182 184
1051266 24782176_7 184 191
) 24782176_7 192 193
was 24782176_7 194 197
selected 24782176_7 198 206
for 24782176_7 207 210
random 24782176_7 211 217
- 24782176_7 217 218
effects 24782176_7 218 225
meta 24782176_7 226 230
- 24782176_7 230 231
analysis 24782176_7 231 239
. 24782176_7 240 241

BACKGROUND 17555608_2 0 10
AND 17555608_2 11 14
OBJECTIVE 17555608_2 15 24
: 17555608_2 25 26
The 17555608_2 27 30
objectives 17555608_2 31 41
of 17555608_2 42 44
this 17555608_2 45 49
study 17555608_2 50 55
were 17555608_2 56 60
, 17555608_2 61 62
firstly 17555608_2 63 70
, 17555608_2 71 72
to 17555608_2 73 75
characterize 17555608_2 76 88
the 17555608_2 89 92
inter 17555608_2 93 98
- 17555608_2 98 99
patient 17555608_2 99 106
variability 17555608_2 107 118
in 17555608_2 119 121
the 17555608_2 122 125
dose 17555608_2 126 130
of 17555608_2 131 133
propofol 17555608_2 134 142
required 17555608_2 143 151
to 17555608_2 152 154
achieve 17555608_2 155 162
a 17555608_2 163 164
bispectral 17555608_2 165 175
index 17555608_2 176 181
< 17555608_2 182 183
70 17555608_2 184 186
and 17555608_2 187 190
' 17555608_2 191 192
time 17555608_2 193 197
to 17555608_2 198 200
eye 17555608_2 201 204
opening 17555608_2 205 212
' 17555608_2 213 214
following 17555608_2 215 224
propofol 17555608_2 225 233
infusion 17555608_2 234 242
and 17555608_2 243 246
, 17555608_2 247 248
secondly 17555608_2 249 257
, 17555608_2 258 259
to 17555608_2 260 262
determine 17555608_2 263 272
if 17555608_2 273 275
the 17555608_2 276 279
pharmacodynamic 17555608_2 280 295
parameter 17555608_2 296 305
' 17555608_2 306 307
time 17555608_2 308 312
to 17555608_2 313 315
achieve 17555608_2 316 323
bispectral 17555608_2 324 334
index 17555608_2 335 340
< 17555608_2 341 342
70 17555608_2 343 345
' 17555608_2 346 347
was 17555608_2 348 351
influenced 17555608_2 352 362
by 17555608_2 363 365
genotype 17555608_2 366 374
of 17555608_2 375 377
the 17555608_2 378 381
sex 17555608_2 382 385
- 17555608_2 385 386
linked 17555608_2 386 392
drug 17555608_2 393 397
receptor 17555608_2 398 406
gene 17555608_2 407 411
GABRE 17555608_2 412 417
or 17555608_2 418 420
if 17555608_2 421 423
pharmacokinetic 17555608_2 424 439
parameters 17555608_2 440 450
such 17555608_2 451 455
as 17555608_2 456 458
clearance 17555608_2 459 468
and 17555608_2 469 472
' 17555608_2 473 474
time 17555608_2 475 479
to 17555608_2 480 482
eye 17555608_2 483 486
opening 17555608_2 487 494
' 17555608_2 495 496
were 17555608_2 497 501
influenced 17555608_2 502 512
by 17555608_2 513 515
the 17555608_2 516 519
genotype 17555608_2 520 528
of 17555608_2 529 531
the 17555608_2 532 535
metabolizing 17555608_2 536 548
enzyme 17555608_2 549 555
CYP 17555608_2 556 559
2 17555608_2 559 560
B 17555608_2 560 561
6 17555608_2 561 562
. 17555608_2 563 564

In 21955998_9 0 2
conclusion 21955998_9 3 13
, 21955998_9 14 15
this 21955998_9 16 20
analysis 21955998_9 21 29
provides 21955998_9 30 38
confirmation 21955998_9 39 51
that 21955998_9 52 56
, 21955998_9 57 58
compared 21955998_9 59 67
with 21955998_9 68 72
chemotherapy 21955998_9 73 85
or 21955998_9 86 88
BSC 21955998_9 89 92
alone 21955998_9 93 98
, 21955998_9 99 100
anti 21955998_9 101 105
- 21955998_9 105 106
EGFR 21955998_9 107 111
mAb 21955998_9 112 115
with 21955998_9 116 120
chemotherapy 21955998_9 121 133
or 21955998_9 134 136
BSC 21955998_9 137 140
reduces 21955998_9 141 148
the 21955998_9 149 152
risk 21955998_9 153 157
of 21955998_9 158 160
progression 21955998_9 161 172
and 21955998_9 173 176
death 21955998_9 177 182
of 21955998_9 183 185
mCRC 21955998_9 186 190
and 21955998_9 191 194
that 21955998_9 195 199
this 21955998_9 200 204
benefit 21955998_9 205 212
is 21955998_9 213 215
seen 21955998_9 216 220
only 21955998_9 221 225
in 21955998_9 226 228
patients 21955998_9 229 237
with 21955998_9 238 242
wild 21955998_9 243 247
- 21955998_9 247 248
type 21955998_9 248 252
KRAS 21955998_9 253 257
tumors 21955998_9 258 264
. 21955998_9 265 266

In 22661198_3 0 2
the 22661198_3 3 6
present 22661198_3 7 14
study 22661198_3 15 20
, 22661198_3 21 22
a 22661198_3 23 24
potential 22661198_3 25 34
relationship 22661198_3 35 47
between 22661198_3 48 55
T 22661198_3 56 57
102 22661198_3 57 60
C 22661198_3 60 61
polymorphism 22661198_3 62 74
in 22661198_3 75 77
the 22661198_3 78 81
5 22661198_3 82 83
- 22661198_3 83 84
HT 22661198_3 84 86
receptor 22661198_3 87 95
subtype 22661198_3 96 103
2 22661198_3 104 105
A 22661198_3 105 106
gene 22661198_3 107 111
( 22661198_3 112 113
HTR 22661198_3 114 117
2 22661198_3 117 118
A 22661198_3 118 119
) 22661198_3 120 121
and 22661198_3 122 125
alcohol 22661198_3 126 133
dependence 22661198_3 134 144
was 22661198_3 145 148
examined 22661198_3 149 157
. 22661198_3 158 159

Sorafenib 26505133_3 0 9
, 26505133_3 10 11
an 26505133_3 12 14
oral 26505133_3 15 19
multikinase 26505133_3 20 31
inhibitor 26505133_3 32 41
, 26505133_3 42 43
can 26505133_3 44 47
inhibit 26505133_3 48 55
FLT 26505133_3 56 59
3 26505133_3 59 60
and 26505133_3 61 64
improve 26505133_3 65 72
clinical 26505133_3 73 81
outcome 26505133_3 82 89
of 26505133_3 90 92
FLT 26505133_3 93 96
3 26505133_3 96 97
mutated 26505133_3 98 105
leukemia 26505133_3 106 114
. 26505133_3 115 116

Moreover 22179112_4 0 8
, 22179112_4 9 10
Rhes 22179112_4 11 15
( 22179112_4 16 17
- 22179112_4 18 19
/ 22179112_4 20 21
- 22179112_4 22 23
) 22179112_4 24 25
mice 22179112_4 26 30
showed 22179112_4 31 37
reduced 22179112_4 38 45
striatal 22179112_4 46 54
mTOR 22179112_4 55 59
signaling 22179112_4 60 69
and 22179112_4 70 73
diminished 22179112_4 74 84
dyskinesia 22179112_4 85 95
, 22179112_4 96 97
but 22179112_4 98 101
maintained 22179112_4 102 112
motor 22179112_4 113 118
improvement 22179112_4 119 130
on 22179112_4 131 133
L 22179112_4 134 135
- 22179112_4 135 136
DOPA 22179112_4 136 140
treatment 22179112_4 141 150
, 22179112_4 151 152
suggesting 22179112_4 153 163
a 22179112_4 164 165
therapeutic 22179112_4 166 177
benefit 22179112_4 178 185
for 22179112_4 186 189
Rhes 22179112_4 190 194
- 22179112_4 195 196
binding 22179112_4 196 203
drugs 22179112_4 204 209
. 22179112_4 210 211

Homocysteine 17586618_1 0 12
induces 17586618_1 13 20
VCAM 17586618_1 21 25
- 17586618_1 25 26
1 17586618_1 26 27
gene 17586618_1 28 32
expression 17586618_1 33 43
through 17586618_1 44 51
NF 17586618_1 52 54
- 17586618_1 54 55
kappaB 17586618_1 55 61
and 17586618_1 62 65
NAD 17586618_1 66 69
( 17586618_1 69 70
P 17586618_1 70 71
) 17586618_1 71 72
H 17586618_1 72 73
oxidase 17586618_1 74 81
activation 17586618_1 82 92
: 17586618_1 93 94
protective 17586618_1 95 105
role 17586618_1 106 110
of 17586618_1 111 113
Mediterranean 17586618_1 114 127
diet 17586618_1 128 132
polyphenolic 17586618_1 133 145
antioxidants 17586618_1 146 158
. 17586618_1 159 160

We 19212337_5 0 2
describe 19212337_5 3 11
a 19212337_5 12 13
case 19212337_5 14 18
of 19212337_5 19 21
FIP 19212337_5 22 25
1 19212337_5 25 26
L 19212337_5 26 27
1 19212337_5 27 28
- 19212337_5 29 30
PDGFRalpha 19212337_5 30 40
T 19212337_5 41 42
674 19212337_5 42 45
I 19212337_5 45 46
CEL 19212337_5 47 50
in 19212337_5 51 53
blast 19212337_5 54 59
crisis 19212337_5 60 66
that 19212337_5 67 71
responded 19212337_5 72 81
to 19212337_5 82 84
sorafenib 19212337_5 85 94
( 19212337_5 95 96
Nexavar 19212337_5 97 104
) 19212337_5 105 106
. 19212337_5 107 108

Association 12966314_1 0 11
between 12966314_1 12 19
dopamine 12966314_1 20 28
receptor 12966314_1 29 37
D 12966314_1 38 39
1 12966314_1 39 40
gene 12966314_1 41 45
DdeI 12966314_1 46 50
polymorphism 12966314_1 51 63
and 12966314_1 64 67
sensation 12966314_1 68 77
seeking 12966314_1 78 85
in 12966314_1 86 88
alcohol 12966314_1 89 96
- 12966314_1 97 98
dependent 12966314_1 98 107
men 12966314_1 108 111
. 12966314_1 112 113

Although 20306339_17 0 8
the 20306339_17 9 12
study 20306339_17 13 18
was 20306339_17 19 22
closed 20306339_17 23 29
early 20306339_17 30 35
, 20306339_17 36 37
it 20306339_17 38 40
appears 20306339_17 41 48
capecitabine 20306339_17 49 61
therapy 20306339_17 62 69
in 20306339_17 70 72
pancreatic 20306339_17 73 83
cancer 20306339_17 84 90
patients 20306339_17 91 99
harboring 20306339_17 100 109
the 20306339_17 110 113
TYMS 20306339_17 114 118
* 20306339_17 119 120
2 20306339_17 121 122
/ 20306339_17 123 124
* 20306339_17 125 126
2 20306339_17 127 128
variant 20306339_17 129 136
may 20306339_17 137 140
be 20306339_17 141 143
associated 20306339_17 144 154
with 20306339_17 155 159
increased 20306339_17 160 169
non 20306339_17 170 173
- 20306339_17 173 174
hematologic 20306339_17 174 185
toxicity 20306339_17 186 194
. 20306339_17 195 196

Using 24830941_7 0 5
specific 24830941_7 6 14
kinase 24830941_7 15 21
inhibitors 24830941_7 22 32
for 24830941_7 33 36
mitogen 24830941_7 37 44
- 24830941_7 44 45
activated 24830941_7 45 54
protein 24830941_7 55 62
kinase 24830941_7 63 69
, 24830941_7 70 71
we 24830941_7 72 74
showed 24830941_7 75 81
that 24830941_7 82 86
extracellular 24830941_7 87 100
signal 24830941_7 101 107
- 24830941_7 107 108
regulated 24830941_7 108 117
kinase 24830941_7 118 124
and 24830941_7 125 128
Jun 24830941_7 129 132
N 24830941_7 133 134
- 24830941_7 134 135
terminal 24830941_7 135 143
kinase 24830941_7 144 150
are 24830941_7 151 154
essential 24830941_7 155 164
for 24830941_7 165 168
tBHQ 24830941_7 169 173
- 24830941_7 174 175
induced 24830941_7 175 182
expression 24830941_7 183 193
of 24830941_7 194 196
CYP 24830941_7 197 200
2 24830941_7 200 201
C 24830941_7 201 202
9 24830941_7 202 203
. 24830941_7 204 205

This 27040858_7 0 4
patient 27040858_7 5 12
had 27040858_7 13 16
an 27040858_7 17 19
excellent 27040858_7 20 29
response 27040858_7 30 38
to 27040858_7 39 41
Icotinib 27040858_7 42 50
but 27040858_7 51 54
not 27040858_7 55 58
crizotinib 27040858_7 59 69
, 27040858_7 70 71
suggesting 27040858_7 72 82
that 27040858_7 83 87
the 27040858_7 88 91
EGFR 27040858_7 92 96
mutation 27040858_7 97 105
was 27040858_7 106 109
the 27040858_7 110 113
oncogenic 27040858_7 114 123
driver 27040858_7 124 130
but 27040858_7 131 134
ROS 27040858_7 135 138
1 27040858_7 138 139
fusion 27040858_7 140 146
and 27040858_7 147 150
KRAS 27040858_7 151 155
mutation 27040858_7 156 164
not 27040858_7 165 168
. 27040858_7 169 170

Patients 17559964_9 0 8
with 17559964_9 9 13
a 17559964_9 14 15
GNB 17559964_9 16 19
3 17559964_9 19 20
CC 17559964_9 21 23
genotype 17559964_9 24 32
had 17559964_9 33 36
significantly 17559964_9 37 50
lower 17559964_9 51 56
SVR 17559964_9 57 60
rates 17559964_9 61 66
as 17559964_9 67 69
compared 17559964_9 70 78
to 17559964_9 79 81
carriers 17559964_9 82 90
of 17559964_9 91 93
a 17559964_9 94 95
non 17559964_9 96 99
- 17559964_9 99 100
CC 17559964_9 101 103
genotype 17559964_9 104 112
( 17559964_9 113 114
52 17559964_9 115 117
% 17559964_9 118 119
versus 17559964_9 120 126
77 17559964_9 127 129
% 17559964_9 130 131
; 17559964_9 132 133
p 17559964_9 134 135
= 17559964_9 136 137
0 17559964_9 138 139
. 17559964_9 139 140
018 17559964_9 140 143
) 17559964_9 144 145
. 17559964_9 146 147

We 18186959_9 0 2
hypothesize 18186959_9 3 14
that 18186959_9 15 19
cell 18186959_9 20 24
cycle 18186959_9 25 30
arrest 18186959_9 31 37
induced 18186959_9 38 45
by 18186959_9 46 48
erlotinib 18186959_9 49 58
accounts 18186959_9 59 67
for 18186959_9 68 71
these 18186959_9 72 77
findings 18186959_9 78 86
in 18186959_9 87 89
the 18186959_9 90 93
presence 18186959_9 94 102
of 18186959_9 103 105
wild 18186959_9 106 110
- 18186959_9 110 111
type 18186959_9 111 115
EGFR 18186959_9 116 120
and 18186959_9 121 124
that 18186959_9 125 129
pharmacodynamic 18186959_9 130 145
separation 18186959_9 146 156
of 18186959_9 157 159
the 18186959_9 160 163
2 18186959_9 164 165
drug 18186959_9 166 170
classes 18186959_9 171 178
will 18186959_9 179 183
ameliorate 18186959_9 184 194
these 18186959_9 195 200
effects 18186959_9 201 208
. 18186959_9 209 210

Phase 24947927_1 0 5
I 24947927_1 6 7
expansion 24947927_1 8 17
and 24947927_1 18 21
pharmacodynamic 24947927_1 22 37
study 24947927_1 38 43
of 24947927_1 44 46
the 24947927_1 47 50
oral 24947927_1 51 55
MEK 24947927_1 56 59
inhibitor 24947927_1 60 69
RO 24947927_1 70 72
4987655 24947927_1 72 79
( 24947927_1 80 81
CH 24947927_1 82 84
4987655 24947927_1 84 91
) 24947927_1 92 93
in 24947927_1 94 96
selected 24947927_1 97 105
patients 24947927_1 106 114
with 24947927_1 115 119
advanced 24947927_1 120 128
cancer 24947927_1 129 135
with 24947927_1 136 140
RAS 24947927_1 141 144
- 24947927_1 144 145
RAF 24947927_1 146 149
mutations 24947927_1 150 159
. 24947927_1 160 161

However 27217047_10 0 7
, 27217047_10 8 9
in 27217047_10 10 12
patients 27217047_10 13 21
who 27217047_10 22 25
were 27217047_10 26 30
co 27217047_10 31 33
- 27217047_10 33 34
administered 27217047_10 34 46
AZ 27217047_10 47 49
, 27217047_10 50 51
the 27217047_10 52 55
C 27217047_10 56 57
0 27217047_10 57 58
values 27217047_10 59 65
of 27217047_10 66 68
tacrolimus 27217047_10 69 79
were 27217047_10 80 84
higher 27217047_10 85 91
in 27217047_10 92 94
patients 27217047_10 95 103
with 27217047_10 104 108
the 27217047_10 109 112
CYP 27217047_10 113 116
3 27217047_10 116 117
A 27217047_10 117 118
5 27217047_10 118 119
* 27217047_10 120 121
3 27217047_10 122 123
/ 27217047_10 124 125
* 27217047_10 126 127
3 27217047_10 128 129
allele 27217047_10 130 136
than 27217047_10 137 141
with 27217047_10 142 146
the 27217047_10 147 150
CYP 27217047_10 151 154
3 27217047_10 154 155
A 27217047_10 155 156
5 27217047_10 156 157
* 27217047_10 158 159
1 27217047_10 160 161
allele 27217047_10 162 168
( 27217047_10 169 170
P 27217047_10 171 172
= 27217047_10 173 174
0 27217047_10 175 176
. 27217047_10 176 177
034 27217047_10 177 180
) 27217047_10 181 182
, 27217047_10 183 184
although 27217047_10 185 193
daily 27217047_10 194 199
doses 27217047_10 200 205
of 27217047_10 206 208
Tac 27217047_10 209 212
- 27217047_10 212 213
QD 27217047_10 213 215
in 27217047_10 216 218
patients 27217047_10 219 227
with 27217047_10 228 232
CYP 27217047_10 233 236
3 27217047_10 236 237
A 27217047_10 237 238
5 27217047_10 238 239
* 27217047_10 240 241
3 27217047_10 242 243
/ 27217047_10 244 245
* 27217047_10 246 247
3 27217047_10 248 249
were 27217047_10 250 254
significantly 27217047_10 255 268
lower 27217047_10 269 274
than 27217047_10 275 279
those 27217047_10 280 285
with 27217047_10 286 290
the 27217047_10 291 294
CYP 27217047_10 295 298
3 27217047_10 298 299
A 27217047_10 299 300
5 27217047_10 300 301
* 27217047_10 302 303
1 27217047_10 304 305
allele 27217047_10 306 312
( 27217047_10 313 314
P 27217047_10 315 316
= 27217047_10 317 318
0 27217047_10 319 320
. 27217047_10 320 321
041 27217047_10 321 324
) 27217047_10 325 326
. 27217047_10 327 328

Using 12165570_5 0 5
viral 12165570_5 6 11
- 12165570_5 11 12
mediated 12165570_5 12 20
gene 12165570_5 21 25
transfer 12165570_5 26 34
to 12165570_5 35 37
locally 12165570_5 38 45
alter 12165570_5 46 51
the 12165570_5 52 55
activity 12165570_5 56 64
of 12165570_5 65 67
CREB 12165570_5 68 72
, 12165570_5 73 74
we 12165570_5 75 77
show 12165570_5 78 82
that 12165570_5 83 87
this 12165570_5 88 92
manipulation 12165570_5 93 105
affects 12165570_5 106 113
morphine 12165570_5 114 122
reward 12165570_5 123 129
, 12165570_5 130 131
as 12165570_5 132 134
well 12165570_5 135 139
as 12165570_5 140 142
the 12165570_5 143 146
preference 12165570_5 147 157
for 12165570_5 158 161
sucrose 12165570_5 162 169
, 12165570_5 170 171
a 12165570_5 172 173
more 12165570_5 174 178
natural 12165570_5 179 186
reward 12165570_5 187 193
. 12165570_5 194 195

The 18855539_7 0 3
heterogeneity 18855539_7 4 17
in 18855539_7 18 20
the 18855539_7 21 24
prevalence 18855539_7 25 35
of 18855539_7 36 38
HLA 18855539_7 39 42
- 18855539_7 42 43
B 18855539_7 43 44
* 18855539_7 45 46
5701 18855539_7 47 51
across 18855539_7 52 58
distinct 18855539_7 59 67
ethnicities 18855539_7 68 79
accounts 18855539_7 80 88
for 18855539_7 89 92
differences 18855539_7 93 104
in 18855539_7 105 107
the 18855539_7 108 111
risk 18855539_7 112 116
of 18855539_7 117 119
abacavir 18855539_7 120 128
hypersensitivity 18855539_7 129 145
reactions 18855539_7 146 155
in 18855539_7 156 158
distinct 18855539_7 159 167
populations 18855539_7 168 179
. 18855539_7 180 181

They 19442155_5 0 4
are 19442155_5 5 8
all 19442155_5 9 12
inhibited 19442155_5 13 22
by 19442155_5 23 25
lithium 19442155_5 26 33
at 19442155_5 34 36
therapeutic 19442155_5 37 48
concentrations 19442155_5 49 63
and 19442155_5 64 67
are 19442155_5 68 71
representative 19442155_5 72 86
of 19442155_5 87 89
the 19442155_5 90 93
inositol 19442155_5 94 102
depletion 19442155_5 103 112
and 19442155_5 113 116
of 19442155_5 117 119
the 19442155_5 120 123
GSK 19442155_5 124 127
- 19442155_5 127 128
3 19442155_5 128 129
beta 19442155_5 130 134
based 19442155_5 135 140
theories 19442155_5 141 149
of 19442155_5 150 152
lithium 19442155_5 153 160
action 19442155_5 161 167
. 19442155_5 168 169

Many 22348413_12 0 4
interactions 22348413_12 5 17
affecting 22348413_12 18 27
statins 22348413_12 28 35
are 22348413_12 36 39
CYP 22348413_12 40 43
3 22348413_12 43 44
A 22348413_12 44 45
4 22348413_12 45 46
- 22348413_12 47 48
mediated 22348413_12 48 56
, 22348413_12 57 58
but 22348413_12 59 62
transporters 22348413_12 63 75
are 22348413_12 76 79
important 22348413_12 80 89
in 22348413_12 90 92
certain 22348413_12 93 100
interactions 22348413_12 101 113
. 22348413_12 114 115

The 15000558_1 0 3
reverse 15000558_1 4 11
transcriptase 15000558_1 12 25
( 15000558_1 26 27
RT 15000558_1 28 30
) 15000558_1 31 32
mutation 15000558_1 33 41
V 15000558_1 42 43
118 15000558_1 43 46
I 15000558_1 46 47
is 15000558_1 48 50
associated 15000558_1 51 61
with 15000558_1 62 66
virologic 15000558_1 67 76
failure 15000558_1 77 84
on 15000558_1 85 87
abacavir 15000558_1 88 96
- 15000558_1 97 98
based 15000558_1 98 103
antiretroviral 15000558_1 104 118
treatment 15000558_1 119 128
( 15000558_1 129 130
ART 15000558_1 131 134
) 15000558_1 135 136
in 15000558_1 137 139
HIV 15000558_1 140 143
- 15000558_1 143 144
1 15000558_1 144 145
infection 15000558_1 146 155
. 15000558_1 156 157

In 18760346_3 0 2
alcoholic 18760346_3 3 12
cirrhotic 18760346_3 13 22
patients 18760346_3 23 31
, 18760346_3 32 33
the 18760346_3 34 37
Ala 18760346_3 38 41
- 18760346_3 41 42
MnSOD 18760346_3 43 48
allele 18760346_3 49 55
is 18760346_3 56 58
associated 18760346_3 59 69
with 18760346_3 70 74
hepatic 18760346_3 75 82
iron 18760346_3 83 87
accumulation 18760346_3 88 100
and 18760346_3 101 104
an 18760346_3 105 107
increased 18760346_3 108 117
risk 18760346_3 118 122
of 18760346_3 123 125
hepatocellular 18760346_3 126 140
carcinoma 18760346_3 141 150
. 18760346_3 151 152

CONCLUSIONS 9205829_7 0 11
: 9205829_7 12 13
Proguanil 9205829_7 14 23
may 9205829_7 24 27
be 9205829_7 28 30
a 9205829_7 31 32
suitable 9205829_7 33 41
phenotyping 9205829_7 42 53
probe 9205829_7 54 59
for 9205829_7 60 63
the 9205829_7 64 67
CYP 9205829_7 68 71
2 9205829_7 71 72
C 9205829_7 72 73
19 9205829_7 73 75
genetic 9205829_7 76 83
polymorphism 9205829_7 84 96
, 9205829_7 97 98
however 9205829_7 99 106
the 9205829_7 107 110
exact 9205829_7 111 116
antimode 9205829_7 117 125
of 9205829_7 126 128
the 9205829_7 129 132
urinary 9205829_7 133 140
metabolic 9205829_7 141 150
ratio 9205829_7 151 156
chosen 9205829_7 157 163
to 9205829_7 164 166
separate 9205829_7 167 175
poor 9205829_7 176 180
and 9205829_7 181 184
extensive 9205829_7 185 194
metabolisers 9205829_7 195 207
needs 9205829_7 208 213
further 9205829_7 214 221
investigation 9205829_7 222 235
. 9205829_7 236 237

Pharmacokinetic 22948856_1 0 15
and 22948856_1 16 19
tolerability 22948856_1 20 32
profile 22948856_1 33 40
of 22948856_1 41 43
pridopidine 22948856_1 44 55
in 22948856_1 56 58
healthy 22948856_1 59 66
- 22948856_1 66 67
volunteer 22948856_1 67 76
poor 22948856_1 77 81
and 22948856_1 82 85
extensive 22948856_1 86 95
CYP 22948856_1 96 99
2 22948856_1 99 100
D 22948856_1 100 101
6 22948856_1 101 102
metabolizers 22948856_1 103 115
, 22948856_1 116 117
following 22948856_1 118 127
single 22948856_1 128 134
and 22948856_1 135 138
multiple 22948856_1 139 147
dosing 22948856_1 148 154
. 22948856_1 155 156

Our 21995595_10 0 3
data 21995595_10 4 8
suggest 21995595_10 9 16
that 21995595_10 17 21
the 21995595_10 22 25
ENO 21995595_10 26 29
2 21995595_10 29 30
gene 21995595_10 31 35
might 21995595_10 36 41
be 21995595_10 42 44
associated 21995595_10 45 55
with 21995595_10 56 60
heroin 21995595_10 61 67
dependence 21995595_10 68 78
, 21995595_10 79 80
and 21995595_10 81 84
reduced 21995595_10 85 92
ENO 21995595_10 93 96
2 21995595_10 96 97
gene 21995595_10 98 102
expression 21995595_10 103 113
may 21995595_10 114 117
confer 21995595_10 118 124
increased 21995595_10 125 134
risk 21995595_10 135 139
to 21995595_10 140 142
heroin 21995595_10 143 149
dependence 21995595_10 150 160
. 21995595_10 161 162

Our 22842957_3 0 3
objective 22842957_3 4 13
was 22842957_3 14 17
to 22842957_3 18 20
assess 22842957_3 21 27
the 22842957_3 28 31
association 22842957_3 32 43
between 22842957_3 44 51
CYP 22842957_3 52 55
2 22842957_3 55 56
C 22842957_3 56 57
9 22842957_3 57 58
and 22842957_3 59 62
SLCO 22842957_3 63 67
1 22842957_3 67 68
B 22842957_3 68 69
1 22842957_3 69 70
polymorphisms 22842957_3 71 84
and 22842957_3 85 88
the 22842957_3 89 92
metabolism 22842957_3 93 103
of 22842957_3 104 106
nateglinide 22842957_3 107 118
in 22842957_3 119 121
healthy 22842957_3 122 129
Chinese 22842957_3 130 137
male 22842957_3 138 142
volunteers 22842957_3 143 153
. 22842957_3 154 155

Cyclin 18006783_9 0 6
D 18006783_9 7 8
1 18006783_9 8 9
is 18006783_9 10 12
up 18006783_9 13 15
- 18006783_9 15 16
regulated 18006783_9 16 25
under 18006783_9 26 31
the 18006783_9 32 35
Ras 18006783_9 36 39
pathway 18006783_9 40 47
and 18006783_9 48 51
is 18006783_9 52 54
down 18006783_9 55 59
- 18006783_9 59 60
regulated 18006783_9 60 69
by 18006783_9 70 72
celecoxib 18006783_9 73 82
. 18006783_9 83 84

It 15163695_4 0 2
was 15163695_4 3 6
found 15163695_4 7 12
that 15163695_4 13 17
CREB 15163695_4 18 22
- 15163695_4 23 24
haplodeficient 15163695_4 24 38
( 15163695_4 39 40
+ 15163695_4 41 42
/ 15163695_4 43 44
- 15163695_4 45 46
) 15163695_4 47 48
mice 15163695_4 49 53
have 15163695_4 54 58
higher 15163695_4 59 65
preference 15163695_4 66 76
for 15163695_4 77 80
ethanol 15163695_4 81 88
but 15163695_4 89 92
not 15163695_4 93 96
for 15163695_4 97 100
sucrose 15163695_4 101 108
solution 15163695_4 109 117
than 15163695_4 118 122
wild 15163695_4 123 127
- 15163695_4 127 128
type 15163695_4 128 132
( 15163695_4 133 134
+ 15163695_4 135 136
/ 15163695_4 137 138
+ 15163695_4 139 140
) 15163695_4 141 142
littermates 15163695_4 143 154
. 15163695_4 155 156

Patients 17961161_11 0 8
with 17961161_11 9 13
ERCC 17961161_11 14 18
1 17961161_11 18 19
- 17961161_11 20 21
negative 17961161_11 21 29
tumors 17961161_11 30 36
appear 17961161_11 37 43
to 17961161_11 44 46
have 17961161_11 47 51
significantly 17961161_11 52 65
better 17961161_11 66 72
response 17961161_11 73 81
to 17961161_11 82 84
platinum 17961161_11 85 93
- 17961161_11 94 95
based 17961161_11 95 100
chemotherapy 17961161_11 101 113
compared 17961161_11 114 122
to 17961161_11 123 125
patients 17961161_11 126 134
with 17961161_11 135 139
ERCC 17961161_11 140 144
1 17961161_11 144 145
- 17961161_11 146 147
positive 17961161_11 147 155
tumors 17961161_11 156 162
, 17961161_11 163 164
but 17961161_11 165 168
the 17961161_11 169 172
differences 17961161_11 173 184
in 17961161_11 185 187
response 17961161_11 188 196
rates 17961161_11 197 202
did 17961161_11 203 206
not 17961161_11 207 210
translate 17961161_11 211 220
into 17961161_11 221 225
differences 17961161_11 226 237
in 17961161_11 238 240
survival 17961161_11 241 249
. 17961161_11 250 251

GGCX 20694283_8 0 4
rs 20694283_8 5 7
11676382 20694283_8 7 15
is 20694283_8 16 18
a 20694283_8 19 20
statistically 20694283_8 21 34
significant 20694283_8 35 46
predictor 20694283_8 47 56
of 20694283_8 57 59
warfarin 20694283_8 60 68
dose 20694283_8 69 73
, 20694283_8 74 75
but 20694283_8 76 79
the 20694283_8 80 83
clinical 20694283_8 84 92
relevance 20694283_8 93 102
is 20694283_8 103 105
modest 20694283_8 106 112
. 20694283_8 113 114

Additionally 20442314_9 0 12
, 20442314_9 13 14
Bcr 20442314_9 15 18
- 20442314_9 18 19
Abl 20442314_9 19 22
- 20442314_9 23 24
expressing 20442314_9 24 34
cells 20442314_9 35 40
showed 20442314_9 41 47
resistance 20442314_9 48 58
to 20442314_9 59 61
death 20442314_9 62 67
activated 20442314_9 68 77
by 20442314_9 78 80
spindle 20442314_9 81 88
defects 20442314_9 89 96
, 20442314_9 97 98
reversed 20442314_9 99 107
by 20442314_9 108 110
imatinib 20442314_9 111 119
. 20442314_9 120 121

Capecitabine 27569869_5 0 12
is 27569869_5 13 15
activated 27569869_5 16 25
to 27569869_5 26 28
5 27569869_5 29 30
- 27569869_5 30 31
FU 27569869_5 31 33
by 27569869_5 34 36
CES 27569869_5 37 40
, 27569869_5 41 42
CDA 27569869_5 43 46
and 27569869_5 47 50
TYMP 27569869_5 51 55
, 27569869_5 56 57
of 27569869_5 58 60
which 27569869_5 61 66
SNPs 27569869_5 67 71
in 27569869_5 72 74
CDA 27569869_5 75 78
and 27569869_5 79 82
CES 27569869_5 83 86
2 27569869_5 86 87
were 27569869_5 88 92
found 27569869_5 93 98
to 27569869_5 99 101
be 27569869_5 102 104
associated 27569869_5 105 115
with 27569869_5 116 120
efficacy 27569869_5 121 129
and 27569869_5 130 133
toxicity 27569869_5 134 142
. 27569869_5 143 144

In 26984388_6 0 2
conclusion 26984388_6 3 13
, 26984388_6 14 15
cobimetinib 26984388_6 16 27
plus 26984388_6 28 32
vemurafenib 26984388_6 33 44
is 26984388_6 45 47
a 26984388_6 48 49
valuable 26984388_6 50 58
option 26984388_6 59 65
for 26984388_6 66 69
use 26984388_6 70 73
in 26984388_6 74 76
BRAF 26984388_6 77 81
( 26984388_6 82 83
V 26984388_6 84 85
600 26984388_6 85 88
) 26984388_6 89 90
mutation 26984388_6 91 99
- 26984388_6 99 100
positive 26984388_6 100 108
unresectable 26984388_6 109 121
or 26984388_6 122 124
metastatic 26984388_6 125 135
melanoma 26984388_6 136 144
. 26984388_6 145 146

Trabectedin 27710871_1 0 11
as 27710871_1 12 14
a 27710871_1 15 16
chemotherapy 27710871_1 17 29
option 27710871_1 30 36
for 27710871_1 37 40
patients 27710871_1 41 49
with 27710871_1 50 54
BRCA 27710871_1 55 59
deficiency 27710871_1 60 70
. 27710871_1 71 72

Moreover 25696877_6 0 8
, 25696877_6 9 10
in 25696877_6 11 13
patients 25696877_6 14 22
treated 25696877_6 23 30
with 25696877_6 31 35
clopidogrel 25696877_6 36 47
predominantly 25696877_6 48 61
for 25696877_6 62 65
percutaneous 25696877_6 66 78
coronary 25696877_6 79 87
intervention 25696877_6 88 100
, 25696877_6 101 102
carriers 25696877_6 103 111
of 25696877_6 112 114
1 25696877_6 115 116
or 25696877_6 117 119
2 25696877_6 120 121
CYP 25696877_6 122 125
2 25696877_6 125 126
C 25696877_6 126 127
19 25696877_6 127 129
loss 25696877_6 130 134
- 25696877_6 134 135
of 25696877_6 135 137
- 25696877_6 137 138
function 25696877_6 138 146
alleles 25696877_6 147 154
are 25696877_6 155 158
at 25696877_6 159 161
increased 25696877_6 162 171
risk 25696877_6 172 176
for 25696877_6 177 180
major 25696877_6 181 186
adverse 25696877_6 187 194
cardiovascular 25696877_6 195 209
outcomes 25696877_6 210 218
, 25696877_6 219 220
with 25696877_6 221 225
an 25696877_6 226 228
1 25696877_6 229 230
. 25696877_6 230 231
5 25696877_6 231 232
- 25696877_6 232 233
fold 25696877_6 233 237
increase 25696877_6 238 246
in 25696877_6 247 249
the 25696877_6 250 253
risk 25696877_6 254 258
of 25696877_6 259 261
cardiovascular 25696877_6 262 276
death 25696877_6 277 282
, 25696877_6 283 284
myocardial 25696877_6 285 295
infarction 25696877_6 296 306
, 25696877_6 307 308
or 25696877_6 309 311
stroke 25696877_6 312 318
as 25696877_6 319 321
well 25696877_6 322 326
as 25696877_6 327 329
an 25696877_6 330 332
3 25696877_6 333 334
- 25696877_6 334 335
fold 25696877_6 335 339
increase 25696877_6 340 348
in 25696877_6 349 351
risk 25696877_6 352 356
for 25696877_6 357 360
stent 25696877_6 361 366
thrombosis 25696877_6 367 377
. 25696877_6 378 379

METHODS 18573584_4 0 7
: 18573584_4 8 9
In 18573584_4 10 12
total 18573584_4 13 18
56 18573584_4 19 21
patients 18573584_4 22 30
acutely 18573584_4 31 38
treated 18573584_4 39 46
with 18573584_4 47 51
haloperidol 18573584_4 52 63
or 18573584_4 64 66
risperidone 18573584_4 67 78
either 18573584_4 79 85
for 18573584_4 86 89
the 18573584_4 90 93
first 18573584_4 94 99
episode 18573584_4 100 107
of 18573584_4 108 110
schizophrenia 18573584_4 111 124
, 18573584_4 125 126
schizophreniform 18573584_4 127 143
or 18573584_4 144 146
schizoaffective 18573584_4 147 162
disorders 18573584_4 163 172
, 18573584_4 173 174
or 18573584_4 175 177
for 18573584_4 178 181
the 18573584_4 182 185
relapse 18573584_4 186 193
of 18573584_4 194 196
these 18573584_4 197 202
psychotic 18573584_4 203 212
disorders 18573584_4 213 222
after 18573584_4 223 228
tapering 18573584_4 229 237
their 18573584_4 238 243
maintenance 18573584_4 244 255
treatment 18573584_4 256 265
, 18573584_4 266 267
were 18573584_4 268 272
genotyped 18573584_4 273 282
for 18573584_4 283 286
the 18573584_4 287 290
5 18573584_4 291 292
- 18573584_4 292 293
HTTLPR 18573584_4 293 299
L 18573584_4 300 301
and 18573584_4 302 305
S 18573584_4 306 307
alleles 18573584_4 308 315
and 18573584_4 316 319
for 18573584_4 320 323
the 18573584_4 324 327
new 18573584_4 328 331
A 18573584_4 332 333
/ 18573584_4 333 334
G 18573584_4 334 335
functional 18573584_4 336 346
variant 18573584_4 347 354
within 18573584_4 355 361
the 18573584_4 362 365
L 18573584_4 366 367
alelle 18573584_4 368 374
( 18573584_4 375 376
La 18573584_4 377 379
/ 18573584_4 379 380
g 18573584_4 380 381
) 18573584_4 382 383
. 18573584_4 384 385

We 15379981_6 0 2
found 15379981_6 3 8
that 15379981_6 9 13
lycopene 15379981_6 14 22
down 15379981_6 23 27
- 15379981_6 27 28
regulates 15379981_6 28 37
the 15379981_6 38 41
expression 15379981_6 42 52
of 15379981_6 53 55
costimulatory 15379981_6 56 69
molecules 15379981_6 70 79
( 15379981_6 80 81
CD 15379981_6 82 84
80 15379981_6 84 86
and 15379981_6 87 90
CD 15379981_6 91 93
86 15379981_6 93 95
) 15379981_6 96 97
and 15379981_6 98 101
major 15379981_6 102 107
histocompatibility 15379981_6 108 126
complex 15379981_6 127 134
type 15379981_6 135 139
II 15379981_6 140 142
molecules 15379981_6 143 152
. 15379981_6 153 154

Sorafenib 23792568_2 0 9
, 23792568_2 10 11
the 23792568_2 12 15
first 23792568_2 16 21
agent 23792568_2 22 27
developed 23792568_2 28 37
to 23792568_2 38 40
target 23792568_2 41 47
BRAF 23792568_2 48 52
mutant 23792568_2 53 59
melanoma 23792568_2 60 68
, 23792568_2 69 70
is 23792568_2 71 73
a 23792568_2 74 75
multi 23792568_2 76 81
- 23792568_2 81 82
kinase 23792568_2 82 88
inhibitor 23792568_2 89 98
that 23792568_2 99 103
was 23792568_2 104 107
approved 23792568_2 108 116
by 23792568_2 117 119
the 23792568_2 120 123
FDA 23792568_2 124 127
for 23792568_2 128 131
therapy 23792568_2 132 139
of 23792568_2 140 142
kidney 23792568_2 143 149
and 23792568_2 150 153
subsequently 23792568_2 154 166
liver 23792568_2 167 172
cancer 23792568_2 173 179
, 23792568_2 180 181
and 23792568_2 182 185
is 23792568_2 186 188
currently 23792568_2 189 198
in 23792568_2 199 201
clinical 23792568_2 202 210
trials 23792568_2 211 217
for 23792568_2 218 221
thyroid 23792568_2 222 229
, 23792568_2 230 231
lung 23792568_2 232 236
and 23792568_2 237 240
brain 23792568_2 241 246
cancer 23792568_2 247 253
. 23792568_2 254 255

Selective 23186157_3 0 9
Abl 23186157_3 10 13
kinase 23186157_3 14 20
inhibitors 23186157_3 21 31
have 23186157_3 32 36
been 23186157_3 37 41
successfully 23186157_3 42 54
established 23186157_3 55 66
for 23186157_3 67 70
the 23186157_3 71 74
treatment 23186157_3 75 84
of 23186157_3 85 87
Ph 23186157_3 88 90
( 23186157_3 91 92
+ 23186157_3 92 93
) 23186157_3 93 94
leukemias 23186157_3 95 104
. 23186157_3 105 106

CONCLUSION 21418871_10 0 10
: 21418871_10 11 12
Gastric 21418871_10 13 20
cancer 21418871_10 21 27
patients 21418871_10 28 36
with 21418871_10 37 41
ERCC 21418871_10 42 46
1 21418871_10 46 47
- 21418871_10 48 49
118 21418871_10 49 52
C 21418871_10 53 54
/ 21418871_10 54 55
C 21418871_10 55 56
genotype 21418871_10 57 65
and 21418871_10 66 69
XRCC 21418871_10 70 74
1 21418871_10 74 75
- 21418871_10 76 77
399 21418871_10 77 80
A 21418871_10 80 81
/ 21418871_10 82 83
G 21418871_10 84 85
or 21418871_10 86 88
A 21418871_10 89 90
/ 21418871_10 90 91
A 21418871_10 91 92
genotype 21418871_10 93 101
may 21418871_10 102 105
benefit 21418871_10 106 113
from 21418871_10 114 118
an 21418871_10 119 121
oxaliplatin 21418871_10 122 133
- 21418871_10 134 135
based 21418871_10 135 140
adjuvant 21418871_10 141 149
chemotherapy 21418871_10 150 162
. 21418871_10 163 164

Cytochrome 15790782_1 0 10
P 15790782_1 11 12
450 15790782_1 12 15
2 15790782_1 16 17
C 15790782_1 17 18
9 15790782_1 18 19
( 15790782_1 20 21
CYP 15790782_1 22 25
2 15790782_1 25 26
C 15790782_1 26 27
9 15790782_1 27 28
) 15790782_1 29 30
and 15790782_1 31 34
vitamin 15790782_1 35 42
K 15790782_1 43 44
epoxide 15790782_1 45 52
reductase 15790782_1 53 62
( 15790782_1 63 64
VKORC 15790782_1 65 70
1 15790782_1 70 71
) 15790782_1 72 73
genotypes 15790782_1 74 83
as 15790782_1 84 86
determinants 15790782_1 87 99
of 15790782_1 100 102
acenocoumarol 15790782_1 103 116
sensitivity 15790782_1 117 128
. 15790782_1 129 130

However 21790903_11 0 7
, 21790903_11 8 9
because 21790903_11 10 17
there 21790903_11 18 23
is 21790903_11 24 26
considerable 21790903_11 27 39
co 21790903_11 40 42
- 21790903_11 42 43
morbidity 21790903_11 43 52
of 21790903_11 53 55
CD 21790903_11 56 58
with 21790903_11 59 63
other 21790903_11 64 69
drugs 21790903_11 70 75
of 21790903_11 76 78
abuse 21790903_11 79 84
, 21790903_11 85 86
additional 21790903_11 87 97
studies 21790903_11 98 105
are 21790903_11 106 109
necessary 21790903_11 110 119
to 21790903_11 120 122
determine 21790903_11 123 132
whether 21790903_11 133 140
polymorphisms 21790903_11 141 154
in 21790903_11 155 157
CNR 21790903_11 158 161
1 21790903_11 161 162
induce 21790903_11 163 169
a 21790903_11 170 171
general 21790903_11 172 179
susceptibility 21790903_11 180 194
to 21790903_11 195 197
substance 21790903_11 198 207
dependence 21790903_11 208 218
or 21790903_11 219 221
are 21790903_11 222 225
specific 21790903_11 226 234
to 21790903_11 235 237
cocaine 21790903_11 238 245
addiction 21790903_11 246 255
. 21790903_11 256 257

Enzyme 22935222_7 0 6
inhibition 22935222_7 7 17
assays 22935222_7 18 24
revealed 22935222_7 25 33
that 22935222_7 34 38
naringenin 22935222_7 39 49
inhibited 22935222_7 50 59
CYP 22935222_7 60 63
1 22935222_7 63 64
B 22935222_7 64 65
1 22935222_7 65 66
at 22935222_7 67 69
or 22935222_7 70 72
above 22935222_7 73 78
5 22935222_7 79 80
m 22935222_7 81 82
but 22935222_7 83 86
not 22935222_7 87 90
CYP 22935222_7 91 94
1 22935222_7 94 95
A 22935222_7 95 96
1 22935222_7 96 97
activity 22935222_7 98 106
. 22935222_7 107 108

It 20528747_6 0 2
reduced 20528747_6 3 10
the 20528747_6 11 14
mRNA 20528747_6 15 19
and 20528747_6 20 23
protein 20528747_6 24 31
expression 20528747_6 32 42
of 20528747_6 43 45
membrane 20528747_6 46 54
type 20528747_6 55 59
- 20528747_6 59 60
1 20528747_6 60 61
MMP 20528747_6 62 65
( 20528747_6 66 67
MT 20528747_6 68 70
1 20528747_6 70 71
- 20528747_6 71 72
MMP 20528747_6 72 75
) 20528747_6 76 77
and 20528747_6 78 81
induced 20528747_6 82 89
mRNA 20528747_6 90 94
and 20528747_6 95 98
protein 20528747_6 99 106
expression 20528747_6 107 117
of 20528747_6 118 120
tissue 20528747_6 121 127
inhibitor 20528747_6 128 137
of 20528747_6 138 140
MMP 20528747_6 141 144
- 20528747_6 144 145
2 20528747_6 145 146
( 20528747_6 147 148
TIMP 20528747_6 149 153
- 20528747_6 153 154
2 20528747_6 154 155
) 20528747_6 156 157
, 20528747_6 158 159
suggesting 20528747_6 160 170
theaflavin 20528747_6 171 181
' 20528747_6 182 183
s 20528747_6 183 184
inhibitory 20528747_6 185 195
effect 20528747_6 196 202
on 20528747_6 203 205
MMP 20528747_6 206 209
- 20528747_6 209 210
2 20528747_6 210 211
activation 20528747_6 212 222
. 20528747_6 223 224

Presence 25270523_1 0 8
of 25270523_1 9 11
anaplastic 25270523_1 12 22
lymphoma 25270523_1 23 31
kinase 25270523_1 32 38
translocation 25270523_1 39 52
in 25270523_1 53 55
sarcomatoid 25270523_1 56 67
carcinoma 25270523_1 68 77
of 25270523_1 78 80
head 25270523_1 81 85
and 25270523_1 86 89
neck 25270523_1 90 94
and 25270523_1 95 98
treatment 25270523_1 99 108
effect 25270523_1 109 115
of 25270523_1 116 118
crizotinib 25270523_1 119 129
: 25270523_1 130 131
A 25270523_1 132 133
case 25270523_1 134 138
series 25270523_1 139 145
. 25270523_1 146 147

To 16963807_2 0 2
investigate 16963807_2 3 14
the 16963807_2 15 18
molecular 16963807_2 19 28
mechanisms 16963807_2 29 39
of 16963807_2 40 42
the 16963807_2 43 46
effect 16963807_2 47 53
of 16963807_2 54 56
curcumin 16963807_2 57 65
on 16963807_2 66 68
up 16963807_2 69 71
- 16963807_2 71 72
regulation 16963807_2 72 82
of 16963807_2 83 85
LDL 16963807_2 86 89
receptor 16963807_2 90 98
expression 16963807_2 99 109
, 16963807_2 110 111
a 16963807_2 112 113
sterol 16963807_2 114 120
regulatory 16963807_2 121 131
report 16963807_2 132 138
system 16963807_2 139 145
was 16963807_2 146 149
established 16963807_2 150 161
in 16963807_2 162 164
Xenopus 16963807_2 165 172
laevis 16963807_2 173 179
oocytes 16963807_2 180 187
by 16963807_2 188 190
microinjection 16963807_2 191 205
of 16963807_2 206 208
a 16963807_2 209 210
plasmid 16963807_2 211 218
pLXRN 16963807_2 219 224
- 16963807_2 224 225
4 16963807_2 225 226
SRE 16963807_2 226 229
- 16963807_2 229 230
fPA 16963807_2 230 233
, 16963807_2 234 235
in 16963807_2 236 238
which 16963807_2 239 244
green 16963807_2 245 250
fluorescence 16963807_2 251 263
protein 16963807_2 264 271
( 16963807_2 272 273
GFP 16963807_2 274 277
) 16963807_2 278 279
gene 16963807_2 280 284
was 16963807_2 285 288
constructed 16963807_2 289 300
downstream 16963807_2 301 311
from 16963807_2 312 316
the 16963807_2 317 320
sterol 16963807_2 321 327
regulatory 16963807_2 328 338
element 16963807_2 339 346
- 16963807_2 346 347
1 16963807_2 347 348
( 16963807_2 349 350
SRE 16963807_2 351 354
- 16963807_2 354 355
1 16963807_2 355 356
) 16963807_2 357 358
, 16963807_2 359 360
in 16963807_2 361 363
the 16963807_2 364 367
nucleus 16963807_2 368 375
of 16963807_2 376 378
the 16963807_2 379 382
oocytes 16963807_2 383 390
. 16963807_2 391 392

In 19179882_9 0 2
both 19179882_9 3 7
TPN 19179882_9 8 11
groups 19179882_9 12 18
, 19179882_9 19 20
MDR 19179882_9 21 24
2 19179882_9 24 25
expression 19179882_9 26 36
was 19179882_9 37 40
significantly 19179882_9 41 54
( 19179882_9 55 56
68 19179882_9 57 59
% 19179882_9 60 61
) 19179882_9 62 63
lower 19179882_9 64 69
than 19179882_9 70 74
controls 19179882_9 75 83
and 19179882_9 84 87
bile 19179882_9 88 92
phosphatidylcholine 19179882_9 93 112
content 19179882_9 113 120
, 19179882_9 121 122
a 19179882_9 123 124
functional 19179882_9 125 135
measure 19179882_9 136 143
of 19179882_9 144 146
MDR 19179882_9 147 150
2 19179882_9 150 151
, 19179882_9 152 153
was 19179882_9 154 157
40 19179882_9 158 160
% 19179882_9 161 162
less 19179882_9 163 167
than 19179882_9 168 172
controls 19179882_9 173 181
. 19179882_9 182 183

The 24681963_1 0 3
effects 24681963_1 4 11
of 24681963_1 12 14
a 24681963_1 15 16
Gly 24681963_1 17 20
16 24681963_1 20 22
Arg 24681963_1 22 25
ADRB 24681963_1 26 30
2 24681963_1 30 31
polymorphism 24681963_1 32 44
on 24681963_1 45 47
responses 24681963_1 48 57
to 24681963_1 58 60
salmeterol 24681963_1 61 71
or 24681963_1 72 74
montelukast 24681963_1 75 86
in 24681963_1 87 89
Japanese 24681963_1 90 98
patients 24681963_1 99 107
with 24681963_1 108 112
mild 24681963_1 113 117
persistent 24681963_1 118 128
asthma 24681963_1 129 135
. 24681963_1 136 137

A 12166950_3 0 1
series 12166950_3 2 8
of 12166950_3 9 11
highly 12166950_3 12 18
potent 12166950_3 19 25
, 12166950_3 26 27
specific 12166950_3 28 36
, 12166950_3 37 38
orally 12166950_3 39 45
active 12166950_3 46 52
, 12166950_3 53 54
small 12166950_3 55 60
molecule 12166950_3 61 69
kinase 12166950_3 70 76
inhibitors 12166950_3 77 87
directed 12166950_3 88 96
against 12166950_3 97 104
members 12166950_3 105 112
of 12166950_3 113 115
PDGFR 12166950_3 116 121
receptor 12166950_3 122 130
have 12166950_3 131 135
been 12166950_3 136 140
developed 12166950_3 141 150
through 12166950_3 151 158
modifications 12166950_3 159 172
of 12166950_3 173 175
the 12166950_3 176 179
novel 12166950_3 180 185
quinazoline 12166950_3 186 197
template 12166950_3 198 206
I 12166950_3 207 208
. 12166950_3 209 210

In 11287760_4 0 2
addition 11287760_4 3 11
, 11287760_4 12 13
we 11287760_4 14 16
investigated 11287760_4 17 29
the 11287760_4 30 33
relationship 11287760_4 34 46
between 11287760_4 47 54
the 11287760_4 55 58
MTHFR 11287760_4 59 64
gene 11287760_4 65 69
polymorphism 11287760_4 70 82
and 11287760_4 83 86
the 11287760_4 87 90
plasma 11287760_4 91 97
homocysteine 11287760_4 98 110
( 11287760_4 111 112
Hcy 11287760_4 113 116
) 11287760_4 117 118
level 11287760_4 119 124
as 11287760_4 125 127
well 11287760_4 128 132
as 11287760_4 133 135
the 11287760_4 136 139
intima 11287760_4 140 146
- 11287760_4 146 147
media 11287760_4 147 152
thickness 11287760_4 153 162
of 11287760_4 163 165
common 11287760_4 166 172
carotid 11287760_4 173 180
artery 11287760_4 181 187
( 11287760_4 188 189
CC 11287760_4 190 192
- 11287760_4 192 193
IMT 11287760_4 193 196
) 11287760_4 197 198
in 11287760_4 199 201
these 11287760_4 202 207
patients 11287760_4 208 216
. 11287760_4 217 218

This 27350677_12 0 4
study 27350677_12 5 10
provides 27350677_12 11 19
evidence 27350677_12 20 28
of 27350677_12 29 31
common 27350677_12 32 38
genetic 27350677_12 39 46
variants 27350677_12 47 55
within 27350677_12 56 62
the 27350677_12 63 66
PDLIM 27350677_12 67 72
5 27350677_12 72 73
gene 27350677_12 74 78
and 27350677_12 79 82
interactions 27350677_12 83 95
between 27350677_12 96 103
PLDIM 27350677_12 104 109
5 27350677_12 109 110
gene 27350677_12 111 115
polymorphisms 27350677_12 116 129
and 27350677_12 130 133
steroid 27350677_12 134 141
use 27350677_12 142 145
influencing 27350677_12 146 157
cancer 27350677_12 158 164
. 27350677_12 165 166

CYP 24465960_12 0 3
3 24465960_12 3 4
A 24465960_12 4 5
5 24465960_12 5 6
* 24465960_12 7 8
3 24465960_12 9 10
, 24465960_12 11 12
CYP 24465960_12 13 16
3 24465960_12 16 17
A 24465960_12 17 18
4 24465960_12 18 19
* 24465960_12 20 21
1 24465960_12 22 23
G 24465960_12 23 24
, 24465960_12 25 26
CYP 24465960_12 27 30
3 24465960_12 30 31
A 24465960_12 31 32
4 24465960_12 32 33
rs 24465960_12 34 36
4646437 24465960_12 36 43
T 24465960_12 44 45
> 24465960_12 45 46
C 24465960_12 46 47
and 24465960_12 48 51
IL 24465960_12 52 54
- 24465960_12 54 55
10 24465960_12 55 57
rs 24465960_12 58 60
1800871 24465960_12 60 67
C 24465960_12 68 69
> 24465960_12 69 70
T 24465960_12 70 71
might 24465960_12 72 77
be 24465960_12 78 80
potential 24465960_12 81 90
polymorphisms 24465960_12 91 104
affecting 24465960_12 105 114
the 24465960_12 115 118
interindividual 24465960_12 119 134
variability 24465960_12 135 146
in 24465960_12 147 149
tacrolimus 24465960_12 150 160
metabolism 24465960_12 161 171
among 24465960_12 172 177
Chinese 24465960_12 178 185
renal 24465960_12 186 191
transplant 24465960_12 192 202
recipients 24465960_12 203 213
. 24465960_12 214 215

The 16473917_1 0 3
canine 16473917_1 4 10
CYP 16473917_1 11 14
1 16473917_1 14 15
A 16473917_1 15 16
2 16473917_1 16 17
deficiency 16473917_1 18 28
polymorphism 16473917_1 29 41
dramatically 16473917_1 42 54
affects 16473917_1 55 62
the 16473917_1 63 66
pharmacokinetics 16473917_1 67 83
of 16473917_1 84 86
4 16473917_1 87 88
- 16473917_1 88 89
cyclohexyl 16473917_1 89 99
- 16473917_1 99 100
1 16473917_1 100 101
- 16473917_1 101 102
ethyl 16473917_1 102 107
- 16473917_1 107 108
7 16473917_1 108 109
- 16473917_1 109 110
methylpyrido 16473917_1 110 122
[ 16473917_1 122 123
2 16473917_1 123 124
, 16473917_1 124 125
3 16473917_1 125 126
- 16473917_1 126 127
D 16473917_1 127 128
] 16473917_1 128 129
- 16473917_1 129 130
pyrimidine 16473917_1 130 140
- 16473917_1 140 141
2 16473917_1 141 142
- 16473917_1 142 143
( 16473917_1 143 144
1 16473917_1 144 145
H 16473917_1 145 146
) 16473917_1 146 147
- 16473917_1 147 148
one 16473917_1 148 151
( 16473917_1 152 153
YM 16473917_1 154 156
- 16473917_1 156 157
64227 16473917_1 157 162
) 16473917_1 163 164
, 16473917_1 165 166
a 16473917_1 167 168
phosphodiesterase 16473917_1 169 186
type 16473917_1 187 191
4 16473917_1 192 193
inhibitor 16473917_1 194 203
. 16473917_1 204 205

Therefore 28423012_11 0 9
, 28423012_11 10 11
induction 28423012_11 12 21
of 28423012_11 22 24
15 28423012_11 25 27
- 28423012_11 27 28
PGDH 28423012_11 28 32
expression 28423012_11 33 43
or 28423012_11 44 46
utilization 28423012_11 47 58
of 28423012_11 59 61
15 28423012_11 62 64
- 28423012_11 64 65
keto 28423012_11 65 69
- 28423012_11 69 70
PGE 28423012_11 70 73
2 28423012_11 73 74
analogue 28423012_11 75 83
may 28423012_11 84 87
have 28423012_11 88 92
therapeutic 28423012_11 93 104
benefits 28423012_11 105 113
for 28423012_11 114 117
the 28423012_11 118 121
treatment 28423012_11 122 131
of 28423012_11 132 134
endotoxin 28423012_11 135 144
- 28423012_11 144 145
associated 28423012_11 145 155
liver 28423012_11 156 161
inflammation 28423012_11 162 174
/ 28423012_11 175 176
injury 28423012_11 176 182
. 28423012_11 183 184

The 11320258_10 0 3
serotonin 11320258_10 4 13
dependence 11320258_10 14 24
of 11320258_10 25 27
cocaine 11320258_10 28 35
reward 11320258_10 36 42
in 11320258_10 43 45
DAT 11320258_10 46 49
knockout 11320258_10 50 58
mice 11320258_10 59 63
is 11320258_10 64 66
thus 11320258_10 67 71
confirmed 11320258_10 72 81
by 11320258_10 82 84
the 11320258_10 85 88
elimination 11320258_10 89 100
of 11320258_10 101 103
cocaine 11320258_10 104 111
place 11320258_10 112 117
preference 11320258_10 118 128
in 11320258_10 129 131
DAT 11320258_10 132 135
/ 11320258_10 136 137
SERT 11320258_10 138 142
double 11320258_10 143 149
knockout 11320258_10 150 158
mice 11320258_10 159 163
. 11320258_10 164 165

CONCLUSION 19695401_17 0 10
: 19695401_17 11 12
In 19695401_17 13 15
these 19695401_17 16 21
kidney 19695401_17 22 28
transplant 19695401_17 29 39
recipients 19695401_17 40 50
, 19695401_17 51 52
patients 19695401_17 53 61
who 19695401_17 62 65
carried 19695401_17 66 73
the 19695401_17 74 77
TPMT 19695401_17 78 82
* 19695401_17 83 84
3 19695401_17 85 86
C 19695401_17 86 87
allele 19695401_17 88 94
were 19695401_17 95 99
at 19695401_17 100 102
a 19695401_17 103 104
higher 19695401_17 105 111
risk 19695401_17 112 116
for 19695401_17 117 120
azathioprine 19695401_17 121 133
- 19695401_17 134 135
induced 19695401_17 135 142
myelosuppression 19695401_17 143 159
than 19695401_17 160 164
noncarriers 19695401_17 165 176
. 19695401_17 177 178

There 11555846_6 0 5
were 11555846_6 6 10
no 11555846_6 11 13
significant 11555846_6 14 25
associations 11555846_6 26 38
between 11555846_6 39 46
Gln 11555846_6 47 50
27 11555846_6 50 52
Glu 11555846_6 52 55
beta 11555846_6 56 60
( 11555846_6 61 62
2 11555846_6 63 64
) 11555846_6 65 66
- 11555846_6 67 68
adrenergic 11555846_6 69 79
receptor 11555846_6 80 88
or 11555846_6 89 91
Pro 11555846_6 92 95
12 11555846_6 95 97
Ala 11555846_6 97 100
peroxisome 11555846_6 101 111
proliferator 11555846_6 112 124
- 11555846_6 124 125
activated 11555846_6 125 134
receptor 11555846_6 135 143
gamma 11555846_6 144 149
variants 11555846_6 150 158
and 11555846_6 159 162
glucose 11555846_6 163 170
or 11555846_6 171 173
insulin 11555846_6 174 181
kinetic 11555846_6 182 189
parameters 11555846_6 190 200
. 11555846_6 201 202

Drugs 19813492_5 0 5
that 19813492_5 6 10
are 19813492_5 11 14
substrates 19813492_5 15 25
of 19813492_5 26 28
cytochrome 19813492_5 29 39
P 19813492_5 40 41
450 19813492_5 41 44
3 19813492_5 45 46
A 19813492_5 46 47
4 19813492_5 47 48
, 19813492_5 49 50
as 19813492_5 51 53
well 19813492_5 54 58
as 19813492_5 59 61
inhibitors 19813492_5 62 72
and 19813492_5 73 76
inducers 19813492_5 77 85
of 19813492_5 86 88
cytochrome 19813492_5 89 99
P 19813492_5 100 101
450 19813492_5 101 104
3 19813492_5 105 106
A 19813492_5 106 107
4 19813492_5 107 108
, 19813492_5 109 110
can 19813492_5 111 114
cause 19813492_5 115 120
significant 19813492_5 121 132
interactions 19813492_5 133 145
with 19813492_5 146 150
tacrolimus 19813492_5 151 161
. 19813492_5 162 163

This 25034231_6 0 4
xanthone 25034231_6 5 13
down 25034231_6 14 18
- 25034231_6 18 19
regulates 25034231_6 19 28
the 25034231_6 29 32
expression 25034231_6 33 43
of 25034231_6 44 46
CXCR 25034231_6 47 51
4 25034231_6 51 52
on 25034231_6 53 55
MM 25034231_6 56 58
cells 25034231_6 59 64
in 25034231_6 65 67
a 25034231_6 68 69
dose 25034231_6 70 74
- 25034231_6 75 76
and 25034231_6 77 80
time 25034231_6 81 85
- 25034231_6 85 86
dependent 25034231_6 86 95
manner 25034231_6 96 102
. 25034231_6 103 104

In 24265703_7 0 2
contrast 24265703_7 3 11
, 24265703_7 12 13
RB 24265703_7 14 16
1 24265703_7 16 17
status 24265703_7 18 24
did 24265703_7 25 28
not 24265703_7 29 32
affect 24265703_7 33 39
sensitivity 24265703_7 40 51
of 24265703_7 52 54
TNBC 24265703_7 55 59
cells 24265703_7 60 65
to 24265703_7 66 68
multiple 24265703_7 69 77
other 24265703_7 78 83
drugs 24265703_7 84 89
including 24265703_7 90 99
cisplatin 24265703_7 100 109
( 24265703_7 110 111
CDDP 24265703_7 112 116
) 24265703_7 117 118
, 24265703_7 119 120
5 24265703_7 121 122
- 24265703_7 122 123
fluorouracil 24265703_7 123 135
, 24265703_7 136 137
idarubicin 24265703_7 138 148
, 24265703_7 149 150
epirubicin 24265703_7 151 161
, 24265703_7 162 163
PRIMA 24265703_7 164 169
- 24265703_7 169 170
1 24265703_7 170 171
( 24265703_7 172 173
met 24265703_7 174 177
) 24265703_7 178 179
, 24265703_7 180 181
fludarabine 24265703_7 182 193
and 24265703_7 194 197
PD 24265703_7 198 200
- 24265703_7 200 201
0332991 24265703_7 201 208
, 24265703_7 209 210
some 24265703_7 211 215
of 24265703_7 216 218
which 24265703_7 219 224
are 24265703_7 225 228
used 24265703_7 229 233
to 24265703_7 234 236
treat 24265703_7 237 242
TNBC 24265703_7 243 247
patients 24265703_7 248 256
. 24265703_7 257 258

A 22900031_3 0 1
mouse 22900031_3 2 7
model 22900031_3 8 13
with 22900031_3 14 18
a 22900031_3 19 20
genetic 22900031_3 21 28
deletion 22900031_3 29 37
of 22900031_3 38 40
Pak 22900031_3 41 44
1 22900031_3 44 45
( 22900031_3 46 47
Pak 22900031_3 48 51
1 22900031_3 51 52
( 22900031_3 53 54
- 22900031_3 55 56
/ 22900031_3 57 58
- 22900031_3 59 60
) 22900031_3 61 62
) 22900031_3 63 64
was 22900031_3 65 68
used 22900031_3 69 73
to 22900031_3 74 76
determine 22900031_3 77 86
the 22900031_3 87 90
role 22900031_3 91 95
of 22900031_3 96 98
Pak 22900031_3 99 102
in 22900031_3 103 105
the 22900031_3 106 109
response 22900031_3 110 118
of 22900031_3 119 121
the 22900031_3 122 125
airways 22900031_3 126 133
in 22900031_3 134 136
vivo 22900031_3 137 141
to 22900031_3 142 144
challenge 22900031_3 145 154
with 22900031_3 155 159
inhaled 22900031_3 160 167
or 22900031_3 168 170
intravenous 22900031_3 171 182
acetylcholine 22900031_3 183 196
( 22900031_3 197 198
ACh 22900031_3 199 202
) 22900031_3 203 204
. 22900031_3 205 206

In 10911933_8 0 2
human 10911933_8 3 8
experimental 10911933_8 9 21
studies 10911933_8 22 29
, 10911933_8 30 31
we 10911933_8 32 34
have 10911933_8 35 39
shown 10911933_8 40 45
that 10911933_8 46 50
CYP 10911933_8 51 54
phenotype 10911933_8 55 64
and 10911933_8 65 68
genotype 10911933_8 69 77
affect 10911933_8 78 84
abuse 10911933_8 85 90
liability 10911933_8 91 100
of 10911933_8 101 103
CYP 10911933_8 104 107
2 10911933_8 107 108
D 10911933_8 108 109
6 10911933_8 109 110
metabolized 10911933_8 111 122
drugs 10911933_8 123 128
of 10911933_8 129 131
abuse 10911933_8 132 137
. 10911933_8 138 139

The 22175791_7 0 3
results 22175791_7 4 11
suggest 22175791_7 12 19
that 22175791_7 20 24
the 22175791_7 25 28
GSTT 22175791_7 29 33
1 22175791_7 33 34
homozygous 22175791_7 35 45
deletion 22175791_7 46 54
genotype 22175791_7 55 63
may 22175791_7 64 67
be 22175791_7 68 70
associated 22175791_7 71 81
with 22175791_7 82 86
a 22175791_7 87 88
better 22175791_7 89 95
prognosis 22175791_7 96 105
after 22175791_7 106 111
APAP 22175791_7 112 116
poisoning 22175791_7 117 126
and 22175791_7 127 130
that 22175791_7 131 135
carriers 22175791_7 136 144
of 22175791_7 145 147
the 22175791_7 148 151
GSTP 22175791_7 152 156
1 22175791_7 156 157
homozygous 22175791_7 158 168
variant 22175791_7 169 176
genotype 22175791_7 177 185
may 22175791_7 186 189
have 22175791_7 190 194
a 22175791_7 195 196
decreased 22175791_7 197 206
risk 22175791_7 207 211
of 22175791_7 212 214
being 22175791_7 215 220
APAP 22175791_7 221 225
poisoned 22175791_7 226 234
. 22175791_7 235 236

This 12052467_7 0 4
review 12052467_7 5 11
aims 12052467_7 12 16
to 12052467_7 17 19
give 12052467_7 20 24
an 12052467_7 25 27
overview 12052467_7 28 36
of 12052467_7 37 39
the 12052467_7 40 43
known 12052467_7 44 49
polymorphisms 12052467_7 50 63
( 12052467_7 64 65
Cholesteryl 12052467_7 66 77
Ester 12052467_7 78 83
Transfer 12052467_7 84 92
Protein 12052467_7 93 100
polymorphism 12052467_7 101 113
, 12052467_7 114 115
Stromelysin 12052467_7 116 127
- 12052467_7 127 128
1 12052467_7 128 129
polymorphism 12052467_7 130 142
, 12052467_7 143 144
- 12052467_7 145 146
455 12052467_7 146 149
G 12052467_7 149 150
/ 12052467_7 150 151
A 12052467_7 151 152
and 12052467_7 153 156
TaqI 12052467_7 157 161
polymorphisms 12052467_7 162 175
of 12052467_7 176 178
the 12052467_7 179 182
beta 12052467_7 183 187
- 12052467_7 187 188
fibrinogen 12052467_7 188 198
gene 12052467_7 199 203
, 12052467_7 204 205
apoE 12052467_7 206 210
4 12052467_7 210 211
, 12052467_7 212 213
Asp 12052467_7 214 217
( 12052467_7 217 218
9 12052467_7 218 219
) 12052467_7 219 220
Asn 12052467_7 220 223
mutation 12052467_7 224 232
in 12052467_7 233 235
the 12052467_7 236 239
lipoprotein 12052467_7 240 251
lipase 12052467_7 252 258
gene 12052467_7 259 263
, 12052467_7 264 265
the 12052467_7 266 269
- 12052467_7 270 271
514 12052467_7 271 274
CT 12052467_7 275 277
polymorphism 12052467_7 278 290
in 12052467_7 291 293
the 12052467_7 294 297
hepatic 12052467_7 298 305
lipase 12052467_7 306 312
gene 12052467_7 313 317
and 12052467_7 318 321
the 12052467_7 322 325
ACE 12052467_7 326 329
deletion 12052467_7 330 338
type 12052467_7 339 343
gene 12052467_7 344 348
) 12052467_7 349 350
that 12052467_7 351 355
have 12052467_7 356 360
an 12052467_7 361 363
influence 12052467_7 364 373
on 12052467_7 374 376
the 12052467_7 377 380
effects 12052467_7 381 388
of 12052467_7 389 391
statins 12052467_7 392 399
in 12052467_7 400 402
the 12052467_7 403 406
general 12052467_7 407 414
population 12052467_7 415 425
. 12052467_7 426 427

The 15967990_10 0 3
results 15967990_10 4 11
of 15967990_10 12 14
these 15967990_10 15 20
experiments 15967990_10 21 32
provide 15967990_10 33 40
insight 15967990_10 41 48
into 15967990_10 49 53
a 15967990_10 54 55
unique 15967990_10 56 62
pharmacogenetic 15967990_10 63 78
mechanism 15967990_10 79 88
by 15967990_10 89 91
which 15967990_10 92 97
common 15967990_10 98 104
polymorphisms 15967990_10 105 118
affect 15967990_10 119 125
TPMT 15967990_10 126 130
protein 15967990_10 131 138
function 15967990_10 139 147
and 15967990_10 148 151
, 15967990_10 152 153
as 15967990_10 154 156
a 15967990_10 157 158
result 15967990_10 159 165
, 15967990_10 166 167
therapeutic 15967990_10 168 179
response 15967990_10 180 188
to 15967990_10 189 191
thiopurine 15967990_10 192 202
drugs 15967990_10 203 208
. 15967990_10 209 210

UGT 17529886_13 0 3
1 17529886_13 3 4
A 17529886_13 4 5
7 17529886_13 5 6
and 17529886_13 7 10
UGT 17529886_13 11 14
1 17529886_13 14 15
A 17529886_13 15 16
9 17529886_13 16 17
I 17529886_13 18 19
399 17529886_13 19 22
polymorphisms 17529886_13 23 36
do 17529886_13 37 39
not 17529886_13 40 43
contribute 17529886_13 44 54
to 17529886_13 55 57
interindividual 17529886_13 58 73
differences 17529886_13 74 85
in 17529886_13 86 88
MPA 17529886_13 89 92
pharmacokinetics 17529886_13 93 109
. 17529886_13 110 111

CYP 22528326_10 0 3
4 22528326_10 3 4
F 22528326_10 4 5
2 22528326_10 5 6
rs 22528326_10 7 9
2108622 22528326_10 9 16
has 22528326_10 17 20
a 22528326_10 21 22
small 22528326_10 23 28
but 22528326_10 29 32
significant 22528326_10 33 44
association 22528326_10 45 56
with 22528326_10 57 61
warfarin 22528326_10 62 70
stable 22528326_10 71 77
dose 22528326_10 78 82
in 22528326_10 83 85
Han 22528326_10 86 89
- 22528326_10 89 90
Chinese 22528326_10 90 97
population 22528326_10 98 108
. 22528326_10 109 110

We 23503720_9 0 2
further 23503720_9 3 10
demonstrated 23503720_9 11 23
that 23503720_9 24 28
silibinin 23503720_9 29 38
attenuated 23503720_9 39 49
the 23503720_9 50 53
translocation 23503720_9 54 67
of 23503720_9 68 70
Smad 23503720_9 71 75
2 23503720_9 75 76
and 23503720_9 77 80
Smad 23503720_9 81 85
3 23503720_9 85 86
to 23503720_9 87 89
the 23503720_9 90 93
nucleus 23503720_9 94 101
in 23503720_9 102 104
the 23503720_9 105 108
TGF 23503720_9 109 112
- 23503720_9 112 113
b 23503720_9 113 114
1 23503720_9 114 115
- 23503720_9 116 117
treated 23503720_9 117 124
HSFs 23503720_9 125 129
. 23503720_9 130 131

METHODS 17558305_5 0 7
: 17558305_5 8 9
Associations 17558305_5 10 22
between 17558305_5 23 30
UGT 17558305_5 31 34
1 17558305_5 34 35
A 17558305_5 35 36
haplotypes 17558305_5 37 47
and 17558305_5 48 51
the 17558305_5 52 55
area 17558305_5 56 60
under 17558305_5 61 66
concentration 17558305_5 67 80
curve 17558305_5 81 86
ratio 17558305_5 87 92
( 17558305_5 93 94
SN 17558305_5 95 97
- 17558305_5 97 98
38 17558305_5 98 100
glucuronide 17558305_5 101 112
/ 17558305_5 113 114
SN 17558305_5 115 117
- 17558305_5 118 119
38 17558305_5 119 121
) 17558305_5 122 123
or 17558305_5 124 126
toxicities 17558305_5 127 137
were 17558305_5 138 142
analyzed 17558305_5 143 151
in 17558305_5 152 154
177 17558305_5 155 158
Japanese 17558305_5 159 167
cancer 17558305_5 168 174
patients 17558305_5 175 183
treated 17558305_5 184 191
with 17558305_5 192 196
irinotecan 17558305_5 197 207
as 17558305_5 208 210
a 17558305_5 211 212
single 17558305_5 213 219
agent 17558305_5 220 225
or 17558305_5 226 228
in 17558305_5 229 231
combination 17558305_5 232 243
chemotherapy 17558305_5 244 256
. 17558305_5 257 258

We 11849656_2 0 2
studied 11849656_2 3 10
the 11849656_2 11 14
relation 11849656_2 15 23
between 11849656_2 24 31
renin 11849656_2 32 37
- 11849656_2 37 38
angiotensin 11849656_2 38 49
system 11849656_2 50 56
( 11849656_2 57 58
RAS 11849656_2 59 62
) 11849656_2 63 64
related 11849656_2 65 72
gene 11849656_2 73 77
polymorphisms 11849656_2 78 91
, 11849656_2 92 93
such 11849656_2 94 98
as 11849656_2 99 101
angiotensin 11849656_2 102 113
converting 11849656_2 114 124
enzyme 11849656_2 125 131
( 11849656_2 132 133
ACE 11849656_2 134 137
) 11849656_2 138 139
insertion 11849656_2 140 149
/ 11849656_2 149 150
deletion 11849656_2 150 158
( 11849656_2 159 160
I 11849656_2 161 162
/ 11849656_2 162 163
D 11849656_2 163 164
) 11849656_2 165 166
, 11849656_2 167 168
angiotensinogen 11849656_2 169 184
( 11849656_2 185 186
AGT 11849656_2 187 190
) 11849656_2 191 192
M 11849656_2 193 194
253 11849656_2 194 197
T 11849656_2 197 198
and 11849656_2 199 202
angiotensin 11849656_2 203 214
II 11849656_2 215 217
type 11849656_2 218 222
1 11849656_2 223 224
receptor 11849656_2 225 233
( 11849656_2 234 235
AT 11849656_2 236 238
1 11849656_2 238 239
R 11849656_2 239 240
) 11849656_2 241 242
A 11849656_2 243 244
1166 11849656_2 244 248
C 11849656_2 248 249
, 11849656_2 250 251
and 11849656_2 252 255
the 11849656_2 256 259
effect 11849656_2 260 266
of 11849656_2 267 269
quinapril 11849656_2 270 279
, 11849656_2 280 281
an 11849656_2 282 284
ACE 11849656_2 285 288
inhibitor 11849656_2 289 298
with 11849656_2 299 303
high 11849656_2 304 308
tissue 11849656_2 309 315
- 11849656_2 315 316
binding 11849656_2 316 323
affinity 11849656_2 324 332
, 11849656_2 333 334
on 11849656_2 335 337
preventing 11849656_2 338 348
restenosis 11849656_2 349 359
after 11849656_2 360 365
percutaneous 11849656_2 366 378
coronary 11849656_2 379 387
intervention 11849656_2 388 400
( 11849656_2 401 402
PCI 11849656_2 403 406
) 11849656_2 407 408
. 11849656_2 409 410

Thiopurines 25885881_4 0 11
inhibit 25885881_4 12 19
Rac 25885881_4 20 23
1 25885881_4 23 24
, 25885881_4 25 26
a 25885881_4 27 28
GTPase 25885881_4 29 35
that 25885881_4 36 40
exerts 25885881_4 41 47
an 25885881_4 48 50
antiapoptotic 25885881_4 51 64
effect 25885881_4 65 71
on 25885881_4 72 74
T 25885881_4 75 76
- 25885881_4 76 77
lymphocytes 25885881_4 77 88
. 25885881_4 89 90

Among 16475678_9 0 5
12 16475678_9 6 8
patients 16475678_9 9 17
treated 16475678_9 18 25
with 16475678_9 26 30
paclitaxel 16475678_9 31 41
alone 16475678_9 42 47
, 16475678_9 48 49
only 16475678_9 50 54
1 16475678_9 55 56
( 16475678_9 57 58
20 16475678_9 59 61
. 16475678_9 61 62
0 16475678_9 62 63
% 16475678_9 64 65
) 16475678_9 66 67
of 16475678_9 68 70
the 16475678_9 71 74
5 16475678_9 75 76
patients 16475678_9 77 85
with 16475678_9 86 90
CHFR 16475678_9 91 95
methylation 16475678_9 96 107
had 16475678_9 108 111
a 16475678_9 112 113
partial 16475678_9 114 121
response 16475678_9 122 130
( 16475678_9 131 132
PR 16475678_9 133 135
) 16475678_9 136 137
to 16475678_9 138 140
paclitaxel 16475678_9 141 151
, 16475678_9 152 153
whereas 16475678_9 154 161
3 16475678_9 162 163
( 16475678_9 164 165
42 16475678_9 166 168
. 16475678_9 168 169
9 16475678_9 169 170
% 16475678_9 171 172
) 16475678_9 173 174
of 16475678_9 175 177
the 16475678_9 178 181
7 16475678_9 182 183
patients 16475678_9 184 192
without 16475678_9 193 200
CHFR 16475678_9 201 205
methylation 16475678_9 206 217
had 16475678_9 218 221
a 16475678_9 222 223
PR 16475678_9 224 226
to 16475678_9 227 229
paclitaxel 16475678_9 230 240
( 16475678_9 241 242
p 16475678_9 243 244
= 16475678_9 245 246
0 16475678_9 247 248
. 16475678_9 248 249
836 16475678_9 249 252
) 16475678_9 253 254
. 16475678_9 255 256

Conversely 19299582_7 0 10
, 19299582_7 11 12
addition 19299582_7 13 21
of 19299582_7 22 24
sirtinol 19299582_7 25 33
( 19299582_7 34 35
a 19299582_7 36 37
known 19299582_7 38 43
SIRT 19299582_7 44 48
1 19299582_7 48 49
inhibitor 19299582_7 50 59
) 19299582_7 60 61
or 19299582_7 62 64
knocking 19299582_7 65 73
down 19299582_7 74 78
SIRT 19299582_7 79 83
1 19299582_7 83 84
by 19299582_7 85 87
the 19299582_7 88 91
small 19299582_7 92 97
silencing 19299582_7 98 107
SIRT 19299582_7 108 112
1 19299582_7 112 113
plasmid 19299582_7 114 121
( 19299582_7 122 123
SIRT 19299582_7 124 128
1 19299582_7 128 129
shRNA 19299582_7 130 135
) 19299582_7 136 137
augmented 19299582_7 138 147
TNF 19299582_7 148 151
- 19299582_7 151 152
alpha 19299582_7 152 157
release 19299582_7 158 165
, 19299582_7 166 167
suggesting 19299582_7 168 178
that 19299582_7 179 183
impairment 19299582_7 184 194
of 19299582_7 195 197
SIRT 19299582_7 198 202
1 19299582_7 202 203
may 19299582_7 204 207
contribute 19299582_7 208 218
to 19299582_7 219 221
TNF 19299582_7 222 225
- 19299582_7 225 226
alpha 19299582_7 226 231
secretion 19299582_7 232 241
. 19299582_7 242 243

OBJECTIVE 23756537_2 0 9
: 23756537_2 10 11
To 23756537_2 12 14
investigate 23756537_2 15 26
the 23756537_2 27 30
occurrence 23756537_2 31 41
of 23756537_2 42 44
MDR 23756537_2 45 48
1 23756537_2 48 49
C 23756537_2 50 51
3435 23756537_2 51 55
T 23756537_2 55 56
gene 23756537_2 57 61
polymorphisms 23756537_2 62 75
in 23756537_2 76 78
the 23756537_2 79 82
Turkish 23756537_2 83 90
renal 23756537_2 91 96
transplant 23756537_2 97 107
patients 23756537_2 108 116
treated 23756537_2 117 124
with 23756537_2 125 129
cyclosporine 23756537_2 130 142
( 23756537_2 143 144
CsA 23756537_2 145 148
) 23756537_2 149 150
, 23756537_2 151 152
and 23756537_2 153 156
correlate 23756537_2 157 166
these 23756537_2 167 172
findings 23756537_2 173 181
with 23756537_2 182 186
prevalence 23756537_2 187 197
and 23756537_2 198 201
degree 23756537_2 202 208
of 23756537_2 209 211
gingival 23756537_2 212 220
hyperplasia 23756537_2 221 232
( 23756537_2 233 234
GH 23756537_2 235 237
) 23756537_2 238 239
. 23756537_2 240 241

We 25499099_6 0 2
found 25499099_6 3 8
oral 25499099_6 9 13
clearance 25499099_6 14 23
of 25499099_6 24 26
S 25499099_6 27 28
- 25499099_6 28 29
warfarin 25499099_6 29 37
to 25499099_6 38 40
be 25499099_6 41 43
higher 25499099_6 44 50
among 25499099_6 51 56
carriers 25499099_6 57 65
of 25499099_6 66 68
the 25499099_6 69 72
minor 25499099_6 73 78
rs 25499099_6 79 81
7089580 25499099_6 81 88
allele 25499099_6 89 95
( 25499099_6 96 97
T 25499099_6 98 99
) 25499099_6 100 101
compared 25499099_6 102 110
with 25499099_6 111 115
wild 25499099_6 116 120
- 25499099_6 120 121
type 25499099_6 121 125
homozygotes 25499099_6 126 137
( 25499099_6 138 139
3 25499099_6 140 141
. 25499099_6 141 142
73 25499099_6 142 144
1 25499099_6 145 146
. 25499099_6 146 147
46 25499099_6 147 149
vs 25499099_6 150 152
2 25499099_6 153 154
. 25499099_6 154 155
95 25499099_6 155 157
1 25499099_6 158 159
. 25499099_6 159 160
39 25499099_6 160 162
mL 25499099_6 163 165
/ 25499099_6 165 166
min 25499099_6 166 169
; 25499099_6 170 171
P 25499099_6 172 173
= 25499099_6 174 175
0 25499099_6 176 177
. 25499099_6 177 178
04 25499099_6 178 180
) 25499099_6 181 182
. 25499099_6 183 184

One 11016647_4 0 3
future 11016647_4 4 10
approach 11016647_4 11 19
to 11016647_4 20 22
treatment 11016647_4 23 32
of 11016647_4 33 35
these 11016647_4 36 41
tumors 11016647_4 42 48
may 11016647_4 49 52
rely 11016647_4 53 57
on 11016647_4 58 60
concurrent 11016647_4 61 71
pharmacological 11016647_4 72 87
depletion 11016647_4 88 97
of 11016647_4 98 100
tumor 11016647_4 101 106
MGMT 11016647_4 107 111
with 11016647_4 112 116
O 11016647_4 117 118
6 11016647_4 118 119
- 11016647_4 119 120
benzylguanine 11016647_4 120 133
( 11016647_4 134 135
6 11016647_4 136 137
- 11016647_4 137 138
BG 11016647_4 138 140
) 11016647_4 141 142
and 11016647_4 143 146
protection 11016647_4 147 157
of 11016647_4 158 160
sensitive 11016647_4 161 170
tissues 11016647_4 171 178
, 11016647_4 179 180
such 11016647_4 181 185
as 11016647_4 186 188
hematopoietic 11016647_4 189 202
stem 11016647_4 203 207
and 11016647_4 208 211
progenitor 11016647_4 212 222
cells 11016647_4 223 228
, 11016647_4 229 230
using 11016647_4 231 236
genetic 11016647_4 237 244
modification 11016647_4 245 257
with 11016647_4 258 262
6 11016647_4 263 264
- 11016647_4 264 265
BG 11016647_4 265 267
- 11016647_4 268 269
resistant 11016647_4 269 278
MGMT 11016647_4 279 283
mutants 11016647_4 284 291
. 11016647_4 292 293

We 15349717_10 0 2
concluded 15349717_10 3 12
that 15349717_10 13 17
when 15349717_10 18 22
azathioprine 15349717_10 23 35
is 15349717_10 36 38
administered 15349717_10 39 51
at 15349717_10 52 54
an 15349717_10 55 57
initial 15349717_10 58 65
dose 15349717_10 66 70
of 15349717_10 71 73
1 15349717_10 74 75
. 15349717_10 75 76
5 15349717_10 76 77
mg 15349717_10 78 80
/ 15349717_10 80 81
kg 15349717_10 81 83
per 15349717_10 84 87
day 15349717_10 88 91
, 15349717_10 92 93
both 15349717_10 94 98
coding 15349717_10 99 105
and 15349717_10 106 109
promoter 15349717_10 110 118
TPMT 15349717_10 119 123
polymorphisms 15349717_10 124 137
influence 15349717_10 138 147
the 15349717_10 148 151
dose 15349717_10 152 156
tolerated 15349717_10 157 166
. 15349717_10 167 168

AIMS 25841872_2 0 4
: 25841872_2 5 6
Ezetimibe 25841872_2 7 16
reduces 25841872_2 17 24
plasma 25841872_2 25 31
levels 25841872_2 32 38
of 25841872_2 39 41
low 25841872_2 42 45
- 25841872_2 45 46
density 25841872_2 46 53
lipoprotein 25841872_2 54 65
( 25841872_2 66 67
LDL 25841872_2 68 71
) 25841872_2 72 73
cholesterol 25841872_2 74 85
by 25841872_2 86 88
inhibiting 25841872_2 89 99
Niemann 25841872_2 100 107
- 25841872_2 107 108
Pick 25841872_2 108 112
C 25841872_2 113 114
1 25841872_2 114 115
- 25841872_2 115 116
Like 25841872_2 116 120
protein 25841872_2 121 128
1 25841872_2 129 130
( 25841872_2 131 132
NPC 25841872_2 133 136
1 25841872_2 136 137
L 25841872_2 137 138
1 25841872_2 138 139
) 25841872_2 140 141
, 25841872_2 142 143
the 25841872_2 144 147
transporter 25841872_2 148 159
responsible 25841872_2 160 171
for 25841872_2 172 175
cholesterol 25841872_2 176 187
uptake 25841872_2 188 194
from 25841872_2 195 199
the 25841872_2 200 203
intestine 25841872_2 204 213
into 25841872_2 214 218
enterocytes 25841872_2 219 230
and 25841872_2 231 234
from 25841872_2 235 239
the 25841872_2 240 243
bile 25841872_2 244 248
into 25841872_2 249 253
hepatocytes 25841872_2 254 265
. 25841872_2 266 267

Detection 15345592_1 0 9
of 15345592_1 10 12
BCR 15345592_1 13 16
- 15345592_1 16 17
ABL 15345592_1 17 20
kinase 15345592_1 21 27
mutations 15345592_1 28 37
in 15345592_1 38 40
CD 15345592_1 41 43
34 15345592_1 43 45
+ 15345592_1 46 47
cells 15345592_1 48 53
from 15345592_1 54 58
chronic 15345592_1 59 66
myelogenous 15345592_1 67 78
leukemia 15345592_1 79 87
patients 15345592_1 88 96
in 15345592_1 97 99
complete 15345592_1 100 108
c 15345592_1 109 110
ytogenetic 15345592_1 111 121
remission 15345592_1 122 131
on 15345592_1 132 134
imatinib 15345592_1 135 143
mesylate 15345592_1 144 152
treatment 15345592_1 153 162
. 15345592_1 163 164

Alcohol 15099407_2 0 7
dehydrogenase 15099407_2 8 21
( 15099407_2 22 23
ADH 15099407_2 24 27
) 15099407_2 28 29
and 15099407_2 30 33
mitochondrial 15099407_2 34 47
aldehyde 15099407_2 48 56
dehydrogenase 15099407_2 57 70
( 15099407_2 71 72
ALDH 15099407_2 73 77
2 15099407_2 77 78
) 15099407_2 79 80
are 15099407_2 81 84
responsible 15099407_2 85 96
for 15099407_2 97 100
metabolizing 15099407_2 101 113
the 15099407_2 114 117
bulk 15099407_2 118 122
of 15099407_2 123 125
ethanol 15099407_2 126 133
consumed 15099407_2 134 142
as 15099407_2 143 145
part 15099407_2 146 150
of 15099407_2 151 153
the 15099407_2 154 157
diet 15099407_2 158 162
and 15099407_2 163 166
their 15099407_2 167 172
activities 15099407_2 173 183
contribute 15099407_2 184 194
to 15099407_2 195 197
the 15099407_2 198 201
rate 15099407_2 202 206
of 15099407_2 207 209
ethanol 15099407_2 210 217
elimination 15099407_2 218 229
from 15099407_2 230 234
the 15099407_2 235 238
blood 15099407_2 239 244
. 15099407_2 245 246

CONCLUSION 26086150_11 0 10
: 26086150_11 11 12
Evidence 26086150_11 13 21
of 26086150_11 22 24
associations 26086150_11 25 37
between 26086150_11 38 45
co 26086150_11 46 48
- 26086150_11 48 49
trimoxazole 26086150_11 49 60
- 26086150_11 61 62
induced 26086150_11 62 69
SJS 26086150_11 70 73
/ 26086150_11 74 75
TEN 26086150_11 76 79
and 26086150_11 80 83
HLA 26086150_11 84 87
alleles 26086150_11 88 95
including 26086150_11 96 105
HLA 26086150_11 106 109
- 26086150_11 109 110
B 26086150_11 110 111
* 26086150_11 112 113
15 26086150_11 114 116
: 26086150_11 116 117
02 26086150_11 117 119
, 26086150_11 120 121
HLA 26086150_11 122 125
- 26086150_11 125 126
C 26086150_11 126 127
* 26086150_11 128 129
06 26086150_11 130 132
: 26086150_11 132 133
02 26086150_11 133 135
, 26086150_11 136 137
and 26086150_11 138 141
HLA 26086150_11 142 145
- 26086150_11 145 146
C 26086150_11 146 147
* 26086150_11 148 149
08 26086150_11 150 152
: 26086150_11 152 153
01 26086150_11 153 155
were 26086150_11 156 160
found 26086150_11 161 166
in 26086150_11 167 169
the 26086150_11 170 173
study 26086150_11 174 179
population 26086150_11 180 190
. 26086150_11 191 192

BRAF 21351275_1 0 4
mutation 21351275_1 5 13
- 21351275_1 14 15
selective 21351275_1 15 24
inhibition 21351275_1 25 35
of 21351275_1 36 38
thyroid 21351275_1 39 46
cancer 21351275_1 47 53
cells 21351275_1 54 59
by 21351275_1 60 62
the 21351275_1 63 66
novel 21351275_1 67 72
MEK 21351275_1 73 76
inhibitor 21351275_1 77 86
RDEA 21351275_1 87 91
119 21351275_1 91 94
and 21351275_1 95 98
genetic 21351275_1 99 106
- 21351275_1 106 107
potentiated 21351275_1 107 118
synergism 21351275_1 119 128
with 21351275_1 129 133
the 21351275_1 134 137
mTOR 21351275_1 138 142
inhibitor 21351275_1 143 152
temsirolimus 21351275_1 153 165
. 21351275_1 166 167

PXR 18805405_1 0 3
- 18805405_1 4 5
mediated 18805405_1 5 13
transcriptional 18805405_1 14 29
activation 18805405_1 30 40
of 18805405_1 41 43
CYP 18805405_1 44 47
3 18805405_1 47 48
A 18805405_1 48 49
4 18805405_1 49 50
by 18805405_1 51 53
cryptotanshinone 18805405_1 54 70
and 18805405_1 71 74
tanshinone 18805405_1 75 85
IIA 18805405_1 86 89
. 18805405_1 90 91

Is 24092646_1 0 2
there 24092646_1 3 8
a 24092646_1 9 10
role 24092646_1 11 15
for 24092646_1 16 19
MDR 24092646_1 20 23
1 24092646_1 23 24
, 24092646_1 25 26
EPHX 24092646_1 27 31
1 24092646_1 31 32
and 24092646_1 33 36
protein 24092646_1 37 44
Z 24092646_1 45 46
gene 24092646_1 47 51
variants 24092646_1 52 60
in 24092646_1 61 63
modulation 24092646_1 64 74
of 24092646_1 75 77
warfarin 24092646_1 78 86
dosage 24092646_1 87 93
? 24092646_1 94 95
a 24092646_1 96 97
study 24092646_1 98 103
on 24092646_1 104 106
a 24092646_1 107 108
cohort 24092646_1 109 115
of 24092646_1 116 118
the 24092646_1 119 122
Egyptian 24092646_1 123 131
population 24092646_1 132 142
. 24092646_1 143 144

Among 10070957_8 0 5
controls 10070957_8 6 14
, 10070957_8 15 16
we 10070957_8 17 19
found 10070957_8 20 25
women 10070957_8 26 31
with 10070957_8 32 36
the 10070957_8 37 40
A 10070957_8 41 42
2 10070957_8 42 43
/ 10070957_8 43 44
A 10070957_8 44 45
2 10070957_8 45 46
genotype 10070957_8 47 55
to 10070957_8 56 58
have 10070957_8 59 63
elevated 10070957_8 64 72
levels 10070957_8 73 79
of 10070957_8 80 82
estrone 10070957_8 83 90
( 10070957_8 91 92
+ 10070957_8 93 94
14 10070957_8 94 96
. 10070957_8 96 97
3 10070957_8 97 98
% 10070957_8 99 100
, 10070957_8 101 102
P 10070957_8 103 104
= 10070957_8 105 106
0 10070957_8 107 108
. 10070957_8 108 109
01 10070957_8 109 111
) 10070957_8 112 113
, 10070957_8 114 115
estradiol 10070957_8 116 125
( 10070957_8 126 127
+ 10070957_8 128 129
13 10070957_8 129 131
. 10070957_8 131 132
8 10070957_8 132 133
% 10070957_8 134 135
, 10070957_8 136 137
P 10070957_8 138 139
= 10070957_8 140 141
0 10070957_8 142 143
. 10070957_8 143 144
08 10070957_8 144 146
) 10070957_8 147 148
, 10070957_8 149 150
testosterone 10070957_8 151 163
( 10070957_8 164 165
+ 10070957_8 166 167
8 10070957_8 167 168
. 10070957_8 168 169
6 10070957_8 169 170
% 10070957_8 171 172
, 10070957_8 173 174
P 10070957_8 175 176
= 10070957_8 177 178
0 10070957_8 179 180
. 10070957_8 180 181
34 10070957_8 181 183
) 10070957_8 184 185
, 10070957_8 186 187
androstenedione 10070957_8 188 203
( 10070957_8 204 205
+ 10070957_8 206 207
17 10070957_8 207 209
. 10070957_8 209 210
1 10070957_8 210 211
% 10070957_8 212 213
, 10070957_8 214 215
P 10070957_8 216 217
= 10070957_8 218 219
0 10070957_8 220 221
. 10070957_8 221 222
06 10070957_8 222 224
) 10070957_8 225 226
, 10070957_8 227 228
dehydroepiandrosterone 10070957_8 229 251
( 10070957_8 252 253
+ 10070957_8 254 255
14 10070957_8 255 257
. 10070957_8 257 258
4 10070957_8 258 259
% 10070957_8 260 261
, 10070957_8 262 263
P 10070957_8 264 265
= 10070957_8 266 267
0 10070957_8 268 269
. 10070957_8 269 270
02 10070957_8 270 272
) 10070957_8 273 274
, 10070957_8 275 276
and 10070957_8 277 280
dehydroepiandrosterone 10070957_8 281 303
sulfate 10070957_8 304 311
( 10070957_8 312 313
+ 10070957_8 314 315
7 10070957_8 315 316
. 10070957_8 316 317
2 10070957_8 317 318
% 10070957_8 319 320
, 10070957_8 321 322
P 10070957_8 323 324
= 10070957_8 325 326
0 10070957_8 327 328
. 10070957_8 328 329
26 10070957_8 329 331
) 10070957_8 332 333
compared 10070957_8 334 342
with 10070957_8 343 347
women 10070957_8 348 353
with 10070957_8 354 358
the 10070957_8 359 362
A 10070957_8 363 364
1 10070957_8 364 365
/ 10070957_8 365 366
A 10070957_8 366 367
1 10070957_8 367 368
genotype 10070957_8 369 377
. 10070957_8 378 379

A 9607827_2 0 1
set 9607827_2 2 5
of 9607827_2 6 8
five 9607827_2 9 13
reverse 9607827_2 14 21
transcriptase 9607827_2 22 35
mutations 9607827_2 36 45
, 9607827_2 46 47
which 9607827_2 48 53
include 9607827_2 54 61
Q 9607827_2 62 63
151 9607827_2 63 66
M 9607827_2 66 67
, 9607827_2 68 69
is 9607827_2 70 72
known 9607827_2 73 78
to 9607827_2 79 81
confer 9607827_2 82 88
multi 9607827_2 89 94
- 9607827_2 94 95
dideoxynucleoside 9607827_2 96 113
resistance 9607827_2 114 124
( 9607827_2 125 126
MDR 9607827_2 127 130
) 9607827_2 131 132
in 9607827_2 133 135
human 9607827_2 136 141
immunodeficiency 9607827_2 142 158
virus 9607827_2 159 164
type 9607827_2 165 169
1 9607827_2 170 171
( 9607827_2 172 173
HIV 9607827_2 174 177
- 9607827_2 177 178
1 9607827_2 178 179
) 9607827_2 180 181
. 9607827_2 182 183

CONCLUSION 14654539_7 0 10
: 14654539_7 11 12
This 14654539_7 13 17
study 14654539_7 18 23
revealed 14654539_7 24 32
a 14654539_7 33 34
significant 14654539_7 35 46
association 14654539_7 47 58
between 14654539_7 59 66
lack 14654539_7 67 71
of 14654539_7 72 74
response 14654539_7 75 83
to 14654539_7 84 86
5 14654539_7 87 88
- 14654539_7 88 89
fluorouracil 14654539_7 89 101
and 14654539_7 102 105
mitomycin 14654539_7 106 115
and 14654539_7 116 119
mutations 14654539_7 120 129
affecting 14654539_7 130 139
the 14654539_7 140 143
L 14654539_7 144 145
2 14654539_7 145 146
/ 14654539_7 146 147
L 14654539_7 147 148
3 14654539_7 148 149
domains 14654539_7 150 157
of 14654539_7 158 160
the 14654539_7 161 164
p 14654539_7 165 166
53 14654539_7 166 168
protein 14654539_7 169 176
. 14654539_7 177 178

A 18589587_5 0 1
population 18589587_5 2 12
with 18589587_5 13 17
slow 18589587_5 18 22
acetylation 18589587_5 23 34
has 18589587_5 35 38
a 18589587_5 39 40
higher 18589587_5 41 47
risk 18589587_5 48 52
of 18589587_5 53 55
toxicity 18589587_5 56 64
, 18589587_5 65 66
as 18589587_5 67 69
that 18589587_5 70 74
potent 18589587_5 75 81
inhibition 18589587_5 82 92
of 18589587_5 93 95
cytochrome 18589587_5 96 106
P 18589587_5 107 108
450 18589587_5 108 111
( 18589587_5 112 113
CYP 18589587_5 114 117
450 18589587_5 117 120
) 18589587_5 121 122
isoforms 18589587_5 123 131
by 18589587_5 132 134
isoniazid 18589587_5 135 144
( 18589587_5 145 146
CYP 18589587_5 147 150
2 18589587_5 150 151
C 18589587_5 151 152
19 18589587_5 152 154
y 18589587_5 155 156
CYP 18589587_5 157 160
3 18589587_5 160 161
A 18589587_5 161 162
) 18589587_5 163 164
are 18589587_5 165 168
dependent 18589587_5 169 178
of 18589587_5 179 181
INH 18589587_5 182 185
plasmatic 18589587_5 186 195
concentration 18589587_5 196 209
. 18589587_5 210 211

In 20205660_5 0 2
this 20205660_5 3 7
in 20205660_5 8 10
- 20205660_5 10 11
depth 20205660_5 11 16
review 20205660_5 17 23
we 20205660_5 24 26
discuss 20205660_5 27 34
the 20205660_5 35 38
genetic 20205660_5 39 46
polymorphisms 20205660_5 47 60
of 20205660_5 61 63
genes 20205660_5 64 69
encoding 20205660_5 70 78
for 20205660_5 79 82
glutathione 20205660_5 83 94
S 20205660_5 95 96
- 20205660_5 97 98
tranferases 20205660_5 98 109
, 20205660_5 110 111
xanthine 20205660_5 112 120
oxidase 20205660_5 121 128
, 20205660_5 129 130
thiopurine 20205660_5 131 141
S 20205660_5 142 143
- 20205660_5 143 144
methyltransferase 20205660_5 144 161
, 20205660_5 162 163
inosine 20205660_5 164 171
triphosphate 20205660_5 172 184
pyrophosphatase 20205660_5 185 200
, 20205660_5 201 202
hypoxanthine 20205660_5 203 215
phosphoribosyltransferase 20205660_5 216 241
, 20205660_5 242 243
inosine 20205660_5 244 251
monophosphate 20205660_5 252 265
dehydrogenase 20205660_5 266 279
and 20205660_5 280 283
multidrug 20205660_5 284 293
resistance 20205660_5 294 304
proteins 20205660_5 305 313
. 20205660_5 314 315

None 26946441_13 0 4
of 26946441_13 5 7
the 26946441_13 8 11
selected 26946441_13 12 20
polymorphisms 26946441_13 21 34
were 26946441_13 35 39
significantly 26946441_13 40 53
associated 26946441_13 54 64
with 26946441_13 65 69
analgesic 26946441_13 70 79
response 26946441_13 80 88
of 26946441_13 89 91
oxycodone 26946441_13 92 101
, 26946441_13 102 103
but 26946441_13 104 107
an 26946441_13 108 110
association 26946441_13 111 122
of 26946441_13 123 125
baseline 26946441_13 126 134
response 26946441_13 135 143
in 26946441_13 144 146
muscle 26946441_13 147 153
cuff 26946441_13 154 158
pressure 26946441_13 159 167
with 26946441_13 168 172
two 26946441_13 173 176
OPRK 26946441_13 177 181
1 26946441_13 181 182
SNPs 26946441_13 183 187
was 26946441_13 188 191
identified 26946441_13 192 202
. 26946441_13 203 204

There 27457818_7 0 5
were 27457818_7 6 10
no 27457818_7 11 13
differences 27457818_7 14 25
between 27457818_7 26 33
clonidine 27457818_7 34 43
and 27457818_7 44 47
placebo 27457818_7 48 55
among 27457818_7 56 61
patients 27457818_7 62 70
with 27457818_7 71 75
COMT 27457818_7 76 80
low 27457818_7 81 84
- 27457818_7 84 85
activity 27457818_7 85 93
alleles 27457818_7 94 101
. 27457818_7 102 103

Previous 10678749_3 0 8
studies 10678749_3 9 16
have 10678749_3 17 21
also 10678749_3 22 26
shown 10678749_3 27 32
that 10678749_3 33 37
pretreatment 10678749_3 38 50
with 10678749_3 51 55
the 10678749_3 56 59
D 10678749_3 60 61
2 10678749_3 61 62
- 10678749_3 62 63
like 10678749_3 63 67
dopamine 10678749_3 68 76
agonist 10678749_3 77 84
quinpirole 10678749_3 85 95
virtually 10678749_3 96 105
abolishes 10678749_3 106 115
RU 10678749_3 116 118
- 10678749_3 118 119
24969 10678749_3 119 124
- 10678749_3 125 126
induced 10678749_3 126 133
striatal 10678749_3 134 142
c 10678749_3 143 144
- 10678749_3 144 145
Fos 10678749_3 145 148
expression 10678749_3 149 159
. 10678749_3 160 161

AC 27573423_1 0 2
0010 27573423_1 2 6
, 27573423_1 7 8
an 27573423_1 9 11
Irreversible 27573423_1 12 24
EGFR 27573423_1 25 29
Inhibitor 27573423_1 30 39
Selectively 27573423_1 40 51
Targeting 27573423_1 52 61
Mutated 27573423_1 62 69
EGFR 27573423_1 70 74
and 27573423_1 75 78
Overcoming 27573423_1 79 89
T 27573423_1 90 91
790 27573423_1 91 94
M 27573423_1 94 95
- 27573423_1 96 97
Induced 27573423_1 97 104
Resistance 27573423_1 105 115
in 27573423_1 116 118
Animal 27573423_1 119 125
Models 27573423_1 126 132
and 27573423_1 133 136
Lung 27573423_1 137 141
Cancer 27573423_1 142 148
Patients 27573423_1 149 157
. 27573423_1 158 159

The 23358500_5 0 3
present 23358500_5 4 11
study 23358500_5 12 17
investigated 23358500_5 18 30
the 23358500_5 31 34
association 23358500_5 35 46
of 23358500_5 47 49
CHRNA 23358500_5 50 55
5 23358500_5 55 56
polymorphisms 23358500_5 57 70
and 23358500_5 71 74
smoking 23358500_5 75 82
topography 23358500_5 83 93
in 23358500_5 94 96
66 23358500_5 97 99
smokers 23358500_5 100 107
asked 23358500_5 108 113
to 23358500_5 114 116
smoke 23358500_5 117 122
four 23358500_5 123 127
nicotine 23358500_5 128 136
- 23358500_5 137 138
containing 23358500_5 138 148
( 23358500_5 149 150
nicotine 23358500_5 151 159
yield 23358500_5 160 165
= 23358500_5 166 167
0 23358500_5 168 169
. 23358500_5 169 170
60 23358500_5 170 172
mg 23358500_5 173 175
) 23358500_5 176 177
and 23358500_5 178 181
four 23358500_5 182 186
placebo 23358500_5 187 194
( 23358500_5 195 196
nicotine 23358500_5 197 205
yield 23358500_5 206 211
< 23358500_5 212 213
0 23358500_5 214 215
. 23358500_5 215 216
05 23358500_5 216 218
mg 23358500_5 219 221
) 23358500_5 222 223
cigarettes 23358500_5 224 234
, 23358500_5 235 236
during 23358500_5 237 243
separate 23358500_5 244 252
experimental 23358500_5 253 265
sessions 23358500_5 266 274
. 23358500_5 275 276

Thus 19636338_15 0 4
, 19636338_15 5 6
CYP 19636338_15 7 10
1 19636338_15 10 11
A 19636338_15 11 12
2 19636338_15 12 13
* 19636338_15 14 15
1 19636338_15 16 17
F 19636338_15 17 18
genotyping 19636338_15 19 29
may 19636338_15 30 33
be 19636338_15 34 36
useful 19636338_15 37 43
for 19636338_15 44 47
clinical 19636338_15 48 56
treatment 19636338_15 57 66
decisions 19636338_15 67 76
given 19636338_15 77 82
the 19636338_15 83 86
fact 19636338_15 87 91
that 19636338_15 92 96
olanzapine 19636338_15 97 107
serum 19636338_15 108 113
concentrations 19636338_15 114 128
correlated 19636338_15 129 139
with 19636338_15 140 144
treatment 19636338_15 145 154
response 19636338_15 155 163
. 19636338_15 164 165

The 16407894_3 0 3
Ras 16407894_3 4 7
- 16407894_3 8 9
controlled 16407894_3 9 19
Raf 16407894_3 20 23
- 16407894_3 24 25
MEK 16407894_3 26 29
- 16407894_3 30 31
ERK 16407894_3 32 35
protein 16407894_3 36 43
kinase 16407894_3 44 50
signaling 16407894_3 51 60
cascade 16407894_3 61 68
has 16407894_3 69 72
been 16407894_3 73 77
implicated 16407894_3 78 88
in 16407894_3 89 91
the 16407894_3 92 95
behavioral 16407894_3 96 106
and 16407894_3 107 110
neurobiological 16407894_3 111 126
actions 16407894_3 127 134
of 16407894_3 135 137
cocaine 16407894_3 138 145
in 16407894_3 146 148
animals 16407894_3 149 156
. 16407894_3 157 158

CONCLUSION 21288822_9 0 10
: 21288822_9 11 12
Because 21288822_9 13 20
of 21288822_9 21 23
the 21288822_9 24 27
possible 21288822_9 28 36
role 21288822_9 37 41
of 21288822_9 42 44
pfmdr 21288822_9 45 50
1 21288822_9 50 51
in 21288822_9 52 54
amodiaquine 21288822_9 55 66
and 21288822_9 67 70
mefloquine 21288822_9 71 81
resistance 21288822_9 82 92
, 21288822_9 93 94
demonstrating 21288822_9 95 108
selection 21288822_9 109 118
on 21288822_9 119 121
pfmdr 21288822_9 122 127
1 21288822_9 127 128
and 21288822_9 129 132
defining 21288822_9 133 141
lineages 21288822_9 142 150
of 21288822_9 151 153
resistant 21288822_9 154 163
alleles 21288822_9 164 171
in 21288822_9 172 174
an 21288822_9 175 177
African 21288822_9 178 185
population 21288822_9 186 196
holds 21288822_9 197 202
great 21288822_9 203 208
importance 21288822_9 209 219
. 21288822_9 220 221

Phase 25351929_1 0 5
II 25351929_1 6 8
, 25351929_1 9 10
open 25351929_1 11 15
- 25351929_1 15 16
label 25351929_1 16 21
trial 25351929_1 22 27
of 25351929_1 28 30
lapatinib 25351929_1 31 40
and 25351929_1 41 44
vinorelbine 25351929_1 45 56
in 25351929_1 57 59
women 25351929_1 60 65
with 25351929_1 66 70
previously 25351929_1 71 81
treated 25351929_1 82 89
HER 25351929_1 90 93
2 25351929_1 93 94
- 25351929_1 95 96
positive 25351929_1 96 104
metastatic 25351929_1 105 115
breast 25351929_1 116 122
cancer 25351929_1 123 129
. 25351929_1 130 131

RESULTS 24585043_5 0 7
: 24585043_5 8 9
We 24585043_5 10 12
found 24585043_5 13 18
highly 24585043_5 19 25
significant 24585043_5 26 37
differences 24585043_5 38 49
in 24585043_5 50 52
allele 24585043_5 53 59
and 24585043_5 60 63
genotype 24585043_5 64 72
frequencies 24585043_5 73 84
of 24585043_5 85 87
rs 24585043_5 88 90
6465084 24585043_5 90 97
between 24585043_5 98 105
the 24585043_5 106 109
alcohol 24585043_5 110 117
- 24585043_5 118 119
dependent 24585043_5 119 128
and 24585043_5 129 132
control 24585043_5 133 140
group 24585043_5 141 146
, 24585043_5 147 148
with 24585043_5 149 153
the 24585043_5 154 157
greater 24585043_5 158 165
frequency 24585043_5 166 175
of 24585043_5 176 178
A 24585043_5 179 180
allele 24585043_5 181 187
of 24585043_5 188 190
SNP 24585043_5 191 194
rs 24585043_5 195 197
6465084 24585043_5 197 204
in 24585043_5 205 207
alcohol 24585043_5 208 215
- 24585043_5 216 217
dependent 24585043_5 217 226
group 24585043_5 227 232
. 24585043_5 233 234

Although 21635144_12 0 8
its 21635144_12 9 12
effect 21635144_12 13 19
on 21635144_12 20 22
CYP 21635144_12 23 26
3 21635144_12 26 27
A 21635144_12 27 28
4 21635144_12 28 29
activity 21635144_12 30 38
is 21635144_12 39 41
not 21635144_12 42 45
clear 21635144_12 46 51
, 21635144_12 52 53
CYP 21635144_12 54 57
3 21635144_12 57 58
A 21635144_12 58 59
4 21635144_12 59 60
* 21635144_12 61 62
1 21635144_12 63 64
/ 21635144_12 65 66
* 21635144_12 67 68
1 21635144_12 69 70
G 21635144_12 70 71
may 21635144_12 72 75
be 21635144_12 76 78
a 21635144_12 79 80
candidate 21635144_12 81 90
for 21635144_12 91 94
a 21635144_12 95 96
polymorphism 21635144_12 97 109
affecting 21635144_12 110 119
the 21635144_12 120 123
interindividual 21635144_12 124 139
variability 21635144_12 140 151
in 21635144_12 152 154
tacrolimus 21635144_12 155 165
pharmacokinetics 21635144_12 166 182
among 21635144_12 183 188
CYP 21635144_12 189 192
3 21635144_12 192 193
A 21635144_12 193 194
5 21635144_12 194 195
expressers 21635144_12 196 206
. 21635144_12 207 208

Age 24601977_7 0 3
, 24601977_7 4 5
CYP 24601977_7 6 9
2 24601977_7 9 10
C 24601977_7 10 11
9 24601977_7 11 12
genotype 24601977_7 13 21
, 24601977_7 22 23
VKORC 24601977_7 24 29
1 24601977_7 29 30
genotype 24601977_7 31 39
and 24601977_7 40 43
age 24601977_7 44 47
: 24601977_7 48 49
VKORC 24601977_7 50 55
1 24601977_7 55 56
interaction 24601977_7 57 68
accounted 24601977_7 69 78
for 24601977_7 79 82
53 24601977_7 83 85
% 24601977_7 86 87
of 24601977_7 88 90
warfarin 24601977_7 91 99
dose 24601977_7 100 104
variability 24601977_7 105 116
. 24601977_7 117 118

Yin 26556583_1 0 3
and 26556583_1 4 7
yang 26556583_1 8 12
of 26556583_1 13 15
cytidine 26556583_1 16 24
deaminase 26556583_1 25 34
roles 26556583_1 35 40
in 26556583_1 41 43
clinical 26556583_1 44 52
response 26556583_1 53 61
to 26556583_1 62 64
azacitidine 26556583_1 65 76
in 26556583_1 77 79
the 26556583_1 80 83
elderly 26556583_1 84 91
: 26556583_1 92 93
a 26556583_1 94 95
pharmacogenetics 26556583_1 96 112
tale 26556583_1 113 117
. 26556583_1 118 119

METHODS 26940072_6 0 7
: 26940072_6 8 9
Kuwaiti 26940072_6 10 17
patients 26940072_6 18 26
who 26940072_6 27 30
were 26940072_6 31 35
taking 26940072_6 36 42
a 26940072_6 43 44
maintenance 26940072_6 45 56
dose 26940072_6 57 61
of 26940072_6 62 64
warfarin 26940072_6 65 73
were 26940072_6 74 78
genotyped 26940072_6 79 88
for 26940072_6 89 92
CYP 26940072_6 93 96
2 26940072_6 96 97
C 26940072_6 97 98
9 26940072_6 98 99
* 26940072_6 100 101
1 26940072_6 102 103
, 26940072_6 104 105
* 26940072_6 106 107
2 26940072_6 108 109
and 26940072_6 110 113
* 26940072_6 114 115
3 26940072_6 116 117
and 26940072_6 118 121
VKORC 26940072_6 122 127
1 26940072_6 127 128
rs 26940072_6 129 131
9923231 26940072_6 131 138
, 26940072_6 139 140
rs 26940072_6 141 143
9934438 26940072_6 143 150
, 26940072_6 151 152
rs 26940072_6 153 155
7294 26940072_6 155 159
and 26940072_6 160 163
rs 26940072_6 164 166
2884737 26940072_6 166 173
. 26940072_6 174 175

Our 22588330_3 0 3
results 22588330_3 4 11
indicated 22588330_3 12 21
that 22588330_3 22 26
LDF 22588330_3 27 30
inhibited 22588330_3 31 40
LPS 22588330_3 41 44
- 22588330_3 45 46
induced 22588330_3 46 53
nitric 22588330_3 54 60
oxide 22588330_3 61 66
and 22588330_3 67 70
prostaglandin 22588330_3 71 84
E 22588330_3 85 86
( 22588330_3 86 87
2 22588330_3 87 88
) 22588330_3 88 89
production 22588330_3 90 100
in 22588330_3 101 103
a 22588330_3 104 105
dose 22588330_3 106 110
- 22588330_3 110 111
dependent 22588330_3 111 120
manner 22588330_3 121 127
and 22588330_3 128 131
suppressed 22588330_3 132 142
the 22588330_3 143 146
expression 22588330_3 147 157
of 22588330_3 158 160
inducible 22588330_3 161 170
nitric 22588330_3 171 177
oxide 22588330_3 178 183
synthase 22588330_3 184 192
( 22588330_3 193 194
iNOS 22588330_3 195 199
) 22588330_3 200 201
and 22588330_3 202 205
cyclooxygenase 22588330_3 206 220
2 22588330_3 221 222
( 22588330_3 223 224
COX 22588330_3 225 228
- 22588330_3 228 229
2 22588330_3 229 230
) 22588330_3 231 232
in 22588330_3 233 235
RAW 22588330_3 236 239
264 22588330_3 240 243
. 22588330_3 243 244
7 22588330_3 244 245
cells 22588330_3 246 251
. 22588330_3 252 253

OBJECTIVE 12796525_2 0 9
: 12796525_2 10 11
To 12796525_2 12 14
assess 12796525_2 15 21
whether 12796525_2 22 29
polymorphisms 12796525_2 30 43
in 12796525_2 44 46
the 12796525_2 47 50
dopamine 12796525_2 51 59
receptor 12796525_2 60 68
genes 12796525_2 69 74
and 12796525_2 75 78
in 12796525_2 79 81
the 12796525_2 82 85
dopamine 12796525_2 86 94
transporter 12796525_2 95 106
gene 12796525_2 107 111
( 12796525_2 112 113
DAT 12796525_2 114 117
) 12796525_2 118 119
are 12796525_2 120 123
predictors 12796525_2 124 134
of 12796525_2 135 137
adverse 12796525_2 138 145
effects 12796525_2 146 153
of 12796525_2 154 156
L 12796525_2 157 158
- 12796525_2 159 160
dopa 12796525_2 161 165
. 12796525_2 166 167

Phase 27883280_1 0 5
I 27883280_1 6 7
study 27883280_1 8 13
of 27883280_1 14 16
irinotecan 27883280_1 17 27
for 27883280_1 28 31
previously 27883280_1 32 42
treated 27883280_1 43 50
lung 27883280_1 51 55
cancer 27883280_1 56 62
patients 27883280_1 63 71
with 27883280_1 72 76
the 27883280_1 77 80
UGT 27883280_1 81 84
1 27883280_1 84 85
A 27883280_1 85 86
1 27883280_1 86 87
* 27883280_1 88 89
28 27883280_1 90 92
or 27883280_1 93 95
* 27883280_1 96 97
6 27883280_1 98 99
polymorphism 27883280_1 100 112
: 27883280_1 113 114
Results 27883280_1 115 122
of 27883280_1 123 125
the 27883280_1 126 129
Lung 27883280_1 130 134
Oncology 27883280_1 135 143
Group 27883280_1 144 149
in 27883280_1 150 152
Kyushu 27883280_1 153 159
( 27883280_1 160 161
LOGIK 27883280_1 162 167
1004 27883280_1 167 171
A 27883280_1 171 172
) 27883280_1 173 174
. 27883280_1 175 176

Temsirolimus 15998902_8 0 12
peak 15998902_8 13 17
concentration 15998902_8 18 31
( 15998902_8 32 33
Cmax 15998902_8 34 38
) 15998902_8 39 40
, 15998902_8 41 42
and 15998902_8 43 46
sirolimus 15998902_8 47 56
Cmax 15998902_8 57 61
and 15998902_8 62 65
area 15998902_8 66 70
under 15998902_8 71 76
the 15998902_8 77 80
concentration 15998902_8 81 94
- 15998902_8 94 95
time 15998902_8 95 99
curve 15998902_8 100 105
were 15998902_8 106 110
decreased 15998902_8 111 120
in 15998902_8 121 123
patients 15998902_8 124 132
receiving 15998902_8 133 142
p 15998902_8 143 144
450 15998902_8 144 147
enzyme 15998902_8 148 154
- 15998902_8 154 155
inducing 15998902_8 155 163
anticonvulsants 15998902_8 164 179
( 15998902_8 180 181
EIACs 15998902_8 182 187
) 15998902_8 188 189
by 15998902_8 190 192
73 15998902_8 193 195
% 15998902_8 196 197
, 15998902_8 198 199
47 15998902_8 200 202
% 15998902_8 203 204
, 15998902_8 205 206
and 15998902_8 207 210
50 15998902_8 211 213
% 15998902_8 214 215
, 15998902_8 216 217
respectively 15998902_8 218 230
, 15998902_8 231 232
but 15998902_8 233 236
were 15998902_8 237 241
still 15998902_8 242 247
within 15998902_8 248 254
the 15998902_8 255 258
therapeutic 15998902_8 259 270
range 15998902_8 271 276
of 15998902_8 277 279
preclinical 15998902_8 280 291
models 15998902_8 292 298
. 15998902_8 299 300

The 22085575_9 0 3
final 22085575_9 4 9
patient 22085575_9 10 17
, 22085575_9 18 19
a 22085575_9 20 21
47 22085575_9 22 24
- 22085575_9 24 25
year 22085575_9 25 29
- 22085575_9 29 30
old 22085575_9 30 33
woman 22085575_9 34 39
, 22085575_9 40 41
had 22085575_9 42 45
an 22085575_9 46 48
EML 22085575_9 49 52
4 22085575_9 52 53
- 22085575_9 54 55
ALK 22085575_9 56 59
translocation 22085575_9 60 73
and 22085575_9 74 77
responded 22085575_9 78 87
remarkably 22085575_9 88 98
well 22085575_9 99 103
to 22085575_9 104 106
an 22085575_9 107 109
ALK 22085575_9 110 113
inhibitor 22085575_9 114 123
, 22085575_9 124 125
crozotinib 22085575_9 126 136
. 22085575_9 137 138

CYP 17112802_1 0 3
2 17112802_1 3 4
A 17112802_1 4 5
6 17112802_1 5 6
genotype 17112802_1 7 15
and 17112802_1 16 19
the 17112802_1 20 23
metabolism 17112802_1 24 34
and 17112802_1 35 38
disposition 17112802_1 39 50
kinetics 17112802_1 51 59
of 17112802_1 60 62
nicotine 17112802_1 63 71
. 17112802_1 72 73

RESULTS 21047202_5 0 7
: 21047202_5 8 9
Four 21047202_5 10 14
polymorphisms 21047202_5 15 28
in 21047202_5 29 31
CYP 21047202_5 32 35
3 21047202_5 35 36
A 21047202_5 36 37
5 21047202_5 37 38
and 21047202_5 39 42
one 21047202_5 43 46
polymorphism 21047202_5 47 59
in 21047202_5 60 62
CYP 21047202_5 63 66
3 21047202_5 66 67
A 21047202_5 67 68
4 21047202_5 68 69
were 21047202_5 70 74
identified 21047202_5 75 85
to 21047202_5 86 88
be 21047202_5 89 91
significantly 21047202_5 92 105
associated 21047202_5 106 116
with 21047202_5 117 121
tacrolimus 21047202_5 122 132
stable 21047202_5 133 139
dose 21047202_5 140 144
( 21047202_5 145 146
p 21047202_5 147 148
< 21047202_5 149 150
8 21047202_5 151 152
. 21047202_5 152 153
46 21047202_5 153 155
10 21047202_5 156 158
( 21047202_5 159 160
- 21047202_5 161 162
5 21047202_5 162 163
) 21047202_5 164 165
) 21047202_5 166 167
. 21047202_5 168 169

Previous 12855658_2 0 8
studies 12855658_2 9 16
directed 12855658_2 17 25
at 12855658_2 26 28
identifying 12855658_2 29 40
paclitaxel 12855658_2 41 51
resistance 12855658_2 52 62
genes 12855658_2 63 68
in 12855658_2 69 71
a 12855658_2 72 73
paclitaxel 12855658_2 74 84
- 12855658_2 85 86
resistant 12855658_2 86 95
subclone 12855658_2 96 104
of 12855658_2 105 107
the 12855658_2 108 111
human 12855658_2 112 117
ovarian 12855658_2 118 125
cancer 12855658_2 126 132
cell 12855658_2 133 137
line 12855658_2 138 142
SKOV 12855658_2 143 147
- 12855658_2 147 148
3 12855658_2 148 149
identified 12855658_2 150 160
a 12855658_2 161 162
novel 12855658_2 163 168
cancer 12855658_2 169 175
testis 12855658_2 176 182
antigen 12855658_2 183 190
, 12855658_2 191 192
Taxol 12855658_2 193 198
resistance 12855658_2 199 209
- 12855658_2 210 211
associated 12855658_2 211 221
gene 12855658_2 222 226
3 12855658_2 227 228
( 12855658_2 229 230
TRAG 12855658_2 231 235
- 12855658_2 235 236
3 12855658_2 236 237
) 12855658_2 238 239
. 12855658_2 240 241

In 24387766_10 0 2
conclusion 24387766_10 3 13
, 24387766_10 14 15
these 24387766_10 16 21
results 24387766_10 22 29
indicate 24387766_10 30 38
that 24387766_10 39 43
black 24387766_10 44 49
soyabean 24387766_10 50 58
extract 24387766_10 59 66
regulates 24387766_10 67 76
Fe 24387766_10 77 79
metabolism 24387766_10 80 90
by 24387766_10 91 93
inhibiting 24387766_10 94 104
the 24387766_10 105 108
expression 24387766_10 109 119
of 24387766_10 120 122
hepcidin 24387766_10 123 131
. 24387766_10 132 133

Although 16467864_3 0 8
AML 16467864_3 9 12
1 16467864_3 12 13
mutations 16467864_3 14 23
are 16467864_3 24 27
suspected 16467864_3 28 37
to 16467864_3 38 40
play 16467864_3 41 45
a 16467864_3 46 47
pivotal 16467864_3 48 55
role 16467864_3 56 60
in 16467864_3 61 63
the 16467864_3 64 67
development 16467864_3 68 79
of 16467864_3 80 82
MDS 16467864_3 83 86
/ 16467864_3 87 88
AML 16467864_3 88 91
, 16467864_3 92 93
acquisition 16467864_3 94 105
of 16467864_3 106 108
additional 16467864_3 109 119
genetic 16467864_3 120 127
alterations 16467864_3 128 139
is 16467864_3 140 142
also 16467864_3 143 147
necessary 16467864_3 148 157
. 16467864_3 158 159

To 22948856_4 0 2
further 22948856_4 3 10
investigate 22948856_4 11 22
the 22948856_4 23 26
pharmacokinetic 22948856_4 27 42
profile 22948856_4 43 50
of 22948856_4 51 53
pridopidine 22948856_4 54 65
and 22948856_4 66 69
to 22948856_4 70 72
establish 22948856_4 73 82
whether 22948856_4 83 90
dose 22948856_4 91 95
adjustment 22948856_4 96 106
is 22948856_4 107 109
needed 22948856_4 110 116
in 22948856_4 117 119
poor 22948856_4 120 124
CYP 22948856_4 125 128
2 22948856_4 128 129
D 22948856_4 129 130
6 22948856_4 130 131
metabolizers 22948856_4 132 144
, 22948856_4 145 146
a 22948856_4 147 148
single 22948856_4 149 155
- 22948856_4 155 156
centre 22948856_4 156 162
, 22948856_4 163 164
open 22948856_4 165 169
- 22948856_4 169 170
label 22948856_4 170 175
, 22948856_4 176 177
multiple 22948856_4 178 186
- 22948856_4 186 187
dose 22948856_4 187 191
study 22948856_4 192 197
in 22948856_4 198 200
healthy 22948856_4 201 208
volunteers 22948856_4 209 219
was 22948856_4 220 223
performed 22948856_4 224 233
. 22948856_4 234 235

Effects 14570538_1 0 7
of 14570538_1 8 10
dopamine 14570538_1 11 19
transporter 14570538_1 20 31
and 14570538_1 32 35
receptor 14570538_1 36 44
polymorphisms 14570538_1 45 58
on 14570538_1 59 61
smoking 14570538_1 62 69
cessation 14570538_1 70 79
in 14570538_1 80 82
a 14570538_1 83 84
bupropion 14570538_1 85 94
clinical 14570538_1 95 103
trial 14570538_1 104 109
. 14570538_1 110 111

Interactions 17708140_6 0 12
with 17708140_6 13 17
warfarin 17708140_6 18 26
, 17708140_6 27 28
antidepressants 17708140_6 29 44
, 17708140_6 45 46
antiepileptic 17708140_6 47 60
drugs 17708140_6 61 66
, 17708140_6 67 68
and 17708140_6 69 72
statins 17708140_6 73 80
often 17708140_6 81 86
involve 17708140_6 87 94
the 17708140_6 95 98
cytochrome 17708140_6 99 109
P 17708140_6 110 111
450 17708140_6 111 114
enzymes 17708140_6 115 122
. 17708140_6 123 124

Influence 18377430_1 0 9
of 18377430_1 10 12
ABCB 18377430_1 13 17
1 18377430_1 17 18
and 18377430_1 19 22
ABCG 18377430_1 23 27
2 18377430_1 27 28
polymorphisms 18377430_1 29 42
on 18377430_1 43 45
doxorubicin 18377430_1 46 57
disposition 18377430_1 58 69
in 18377430_1 70 72
Asian 18377430_1 73 78
breast 18377430_1 79 85
cancer 18377430_1 86 92
patients 18377430_1 93 101
. 18377430_1 102 103

Similarly 11491416_8 0 9
, 11491416_8 10 11
the 11491416_8 12 15
in 11491416_8 16 18
vitro 11491416_8 19 24
replication 11491416_8 25 36
capacity 11491416_8 37 45
of 11491416_8 46 48
a 11491416_8 49 50
mutant 11491416_8 51 57
virus 11491416_8 58 63
expressing 11491416_8 64 74
a 11491416_8 75 76
zidovudine 11491416_8 77 87
- 11491416_8 88 89
associated 11491416_8 89 99
mutation 11491416_8 100 108
and 11491416_8 109 112
M 11491416_8 113 114
184 11491416_8 114 117
V 11491416_8 117 118
was 11491416_8 119 122
significantly 11491416_8 123 136
reduced 11491416_8 137 144
compared 11491416_8 145 153
with 11491416_8 154 158
wild 11491416_8 159 163
- 11491416_8 163 164
type 11491416_8 164 168
virus 11491416_8 169 174
. 11491416_8 175 176

Nutlin 19147553_3 0 6
- 19147553_3 6 7
3 19147553_3 7 8
is 19147553_3 9 11
a 19147553_3 12 13
MDM 19147553_3 14 17
2 19147553_3 17 18
inhibitor 19147553_3 19 28
under 19147553_3 29 34
preclinical 19147553_3 35 46
investigation 19147553_3 47 60
as 19147553_3 61 63
nongenotoxic 19147553_3 64 76
activator 19147553_3 77 86
of 19147553_3 87 89
the 19147553_3 90 93
p 19147553_3 94 95
53 19147553_3 95 97
pathway 19147553_3 98 105
for 19147553_3 106 109
cancer 19147553_3 110 116
therapy 19147553_3 117 124
. 19147553_3 125 126

Discovery 21561767_1 0 9
of 21561767_1 10 12
5 21561767_1 13 14
- 21561767_1 14 15
( 21561767_1 15 16
arenethynyl 21561767_1 16 27
) 21561767_1 27 28
hetero 21561767_1 29 35
- 21561767_1 35 36
monocyclic 21561767_1 36 46
derivatives 21561767_1 47 58
as 21561767_1 59 61
potent 21561767_1 62 68
inhibitors 21561767_1 69 79
of 21561767_1 80 82
BCR 21561767_1 83 86
- 21561767_1 86 87
ABL 21561767_1 87 90
including 21561767_1 91 100
the 21561767_1 101 104
T 21561767_1 105 106
315 21561767_1 106 109
I 21561767_1 109 110
gatekeeper 21561767_1 111 121
mutant 21561767_1 122 128
. 21561767_1 129 130

RESULTS 22418828_5 0 7
: 22418828_5 8 9
Carriers 22418828_5 10 18
of 22418828_5 19 21
CYP 22418828_5 22 25
2 22418828_5 25 26
C 22418828_5 26 27
19 22418828_5 27 29
* 22418828_5 30 31
2 22418828_5 32 33
/ 22418828_5 34 35
* 22418828_5 36 37
2 22418828_5 38 39
( 22418828_5 40 41
n 22418828_5 42 43
= 22418828_5 44 45
2 22418828_5 46 47
) 22418828_5 48 49
were 22418828_5 50 54
characterized 22418828_5 55 68
by 22418828_5 69 71
higher 22418828_5 72 78
, 22418828_5 79 80
starting 22418828_5 81 89
from 22418828_5 90 94
3 22418828_5 95 96
. 22418828_5 96 97
5 22418828_5 97 98
h 22418828_5 99 100
post 22418828_5 101 105
dose 22418828_5 106 110
, 22418828_5 111 112
plasma 22418828_5 113 119
concentrations 22418828_5 120 134
of 22418828_5 135 137
pantoprazole 22418828_5 138 150
in 22418828_5 151 153
comparison 22418828_5 154 164
to 22418828_5 165 167
wild 22418828_5 168 172
- 22418828_5 172 173
type 22418828_5 173 177
( 22418828_5 178 179
CYP 22418828_5 180 183
2 22418828_5 183 184
C 22418828_5 184 185
19 22418828_5 185 187
* 22418828_5 188 189
1 22418828_5 190 191
/ 22418828_5 192 193
* 22418828_5 194 195
1 22418828_5 196 197
, 22418828_5 198 199
n 22418828_5 200 201
= 22418828_5 202 203
6 22418828_5 204 205
) 22418828_5 206 207
volunteers 22418828_5 208 218
. 22418828_5 219 220

Prediction 23306941_1 0 10
of 23306941_1 11 13
sustained 23306941_1 14 23
virologic 23306941_1 24 33
response 23306941_1 34 42
based 23306941_1 43 48
on 23306941_1 49 51
week 23306941_1 52 56
4 23306941_1 57 58
and 23306941_1 59 62
week 23306941_1 63 67
12 23306941_1 68 70
response 23306941_1 71 79
in 23306941_1 80 82
hepatitis 23306941_1 83 92
C 23306941_1 93 94
virus 23306941_1 95 100
genotype 23306941_1 101 109
1 23306941_1 110 111
patients 23306941_1 112 120
treated 23306941_1 121 128
with 23306941_1 129 133
peginterferon 23306941_1 134 147
and 23306941_1 148 151
ribavirin 23306941_1 152 161
: 23306941_1 162 163
assessment 23306941_1 164 174
in 23306941_1 175 177
a 23306941_1 178 179
favorable 23306941_1 180 189
IL 23306941_1 190 192
28 23306941_1 192 194
B 23306941_1 194 195
allele 23306941_1 196 202
- 23306941_1 203 204
prevalent 23306941_1 204 213
area 23306941_1 214 218
. 23306941_1 219 220

Comparison 9006118_1 0 10
of 9006118_1 11 13
transformation 9006118_1 14 28
by 9006118_1 29 31
manganese 9006118_1 32 41
sulfate 9006118_1 42 49
and 9006118_1 50 53
5 9006118_1 54 55
- 9006118_1 55 56
azacytidine 9006118_1 56 67
in 9006118_1 68 70
Rat 9006118_1 71 74
6 9006118_1 75 76
cells 9006118_1 77 82
overexpressing 9006118_1 83 97
the 9006118_1 98 101
c 9006118_1 102 103
- 9006118_1 103 104
myc 9006118_1 104 107
oncogene 9006118_1 108 116
. 9006118_1 117 118

In 19932784_15 0 2
conclusion 19932784_15 3 13
, 19932784_15 14 15
high 19932784_15 16 20
BMI 19932784_15 21 24
, 19932784_15 25 26
acute 19932784_15 27 32
coronary 19932784_15 33 41
syndrome 19932784_15 42 50
, 19932784_15 51 52
diabetes 19932784_15 53 61
mellitus 19932784_15 62 70
, 19932784_15 71 72
and 19932784_15 73 76
CYP 19932784_15 77 80
2 19932784_15 80 81
C 19932784_15 81 82
19 19932784_15 82 84
2 19932784_15 85 86
are 19932784_15 87 90
associated 19932784_15 91 101
with 19932784_15 102 106
HTPR 19932784_15 107 111
after 19932784_15 112 117
a 19932784_15 118 119
600 19932784_15 120 123
- 19932784_15 123 124
mg 19932784_15 124 126
loading 19932784_15 127 134
dose 19932784_15 135 139
of 19932784_15 140 142
clopidogrel 19932784_15 143 154
. 19932784_15 155 156

Catechol 19037200_5 0 8
- 19037200_5 8 9
O 19037200_5 9 10
- 19037200_5 10 11
methyltransferase 19037200_5 11 28
( 19037200_5 29 30
COMT 19037200_5 31 35
) 19037200_5 36 37
catalyzes 19037200_5 38 47
the 19037200_5 48 51
breakdown 19037200_5 52 61
of 19037200_5 62 64
cerebral 19037200_5 65 73
dopamine 19037200_5 74 82
. 19037200_5 83 84

A 15896496_1 0 1
study 15896496_1 2 7
of 15896496_1 8 10
the 15896496_1 11 14
association 15896496_1 15 26
of 15896496_1 27 29
( 15896496_1 30 31
Val 15896496_1 32 35
66 15896496_1 35 37
Met 15896496_1 37 40
) 15896496_1 41 42
polymorphism 15896496_1 43 55
in 15896496_1 56 58
the 15896496_1 59 62
brain 15896496_1 63 68
- 15896496_1 68 69
derived 15896496_1 69 76
neurotrophic 15896496_1 77 89
factor 15896496_1 90 96
gene 15896496_1 97 101
with 15896496_1 102 106
alcohol 15896496_1 107 114
dependence 15896496_1 115 125
and 15896496_1 126 129
extreme 15896496_1 130 137
violence 15896496_1 138 146
in 15896496_1 147 149
Chinese 15896496_1 150 157
males 15896496_1 158 163
. 15896496_1 164 165

However 26791794_6 0 7
, 26791794_6 8 9
a 26791794_6 10 11
commercially 26791794_6 12 24
- 26791794_6 24 25
available 26791794_6 25 34
cell 26791794_6 35 39
line 26791794_6 40 44
with 26791794_6 45 49
MET 26791794_6 50 53
exon 26791794_6 54 58
14 26791794_6 59 61
skipping 26791794_6 62 70
mutation 26791794_6 71 79
and 26791794_6 80 83
co 26791794_6 84 86
- 26791794_6 86 87
occurring 26791794_6 87 96
PIK 26791794_6 97 100
3 26791794_6 100 101
CA 26791794_6 101 103
- 26791794_6 104 105
p 26791794_6 106 107
. 26791794_6 107 108
Glu 26791794_6 108 111
545 26791794_6 111 114
Lys 26791794_6 114 117
mutation 26791794_6 118 126
did 26791794_6 127 130
not 26791794_6 131 134
respond 26791794_6 135 142
to 26791794_6 143 145
crizotinib 26791794_6 146 156
; 26791794_6 157 158
suggesting 26791794_6 159 169
the 26791794_6 170 173
latter 26791794_6 174 180
abrogated 26791794_6 181 190
response 26791794_6 191 199
. 26791794_6 200 201

Adjusted 17548696_4 0 8
odds 17548696_4 9 13
ratios 17548696_4 14 20
( 17548696_4 21 22
OR 17548696_4 23 25
) 17548696_4 26 27
for 17548696_4 28 31
skin 17548696_4 32 36
lesions 17548696_4 37 44
were 17548696_4 45 49
estimated 17548696_4 50 59
in 17548696_4 60 62
relation 17548696_4 63 71
to 17548696_4 72 74
the 17548696_4 75 78
polymorphisms 17548696_4 79 92
in 17548696_4 93 95
the 17548696_4 96 99
glutathione 17548696_4 100 111
S 17548696_4 112 113
- 17548696_4 113 114
transferase 17548696_4 114 125
omega 17548696_4 126 131
1 17548696_4 131 132
and 17548696_4 133 136
methylenetetrahydrofolate 17548696_4 137 162
reductase 17548696_4 163 172
genes 17548696_4 173 178
, 17548696_4 179 180
the 17548696_4 181 184
percentage 17548696_4 185 195
of 17548696_4 196 198
monomethylarsonous 17548696_4 199 217
acid 17548696_4 218 222
( 17548696_4 223 224
% 17548696_4 225 226
MMA 17548696_4 227 230
) 17548696_4 231 232
and 17548696_4 233 236
dimethylarsinic 17548696_4 237 252
acid 17548696_4 253 257
( 17548696_4 258 259
% 17548696_4 260 261
DMA 17548696_4 262 265
) 17548696_4 266 267
in 17548696_4 268 270
urine 17548696_4 271 276
, 17548696_4 277 278
and 17548696_4 279 282
the 17548696_4 283 286
ratios 17548696_4 287 293
of 17548696_4 294 296
MMA 17548696_4 297 300
to 17548696_4 301 303
inorganic 17548696_4 304 313
arsenic 17548696_4 314 321
and 17548696_4 322 325
DMA 17548696_4 326 329
to 17548696_4 330 332
MMA 17548696_4 333 336
. 17548696_4 337 338

Toll 21890455_1 0 4
- 21890455_1 4 5
like 21890455_1 5 9
receptor 21890455_1 10 18
9 21890455_1 19 20
agonist 21890455_1 21 28
IMO 21890455_1 29 32
cooperates 21890455_1 33 43
with 21890455_1 44 48
cetuximab 21890455_1 49 58
in 21890455_1 59 61
K 21890455_1 62 63
- 21890455_1 63 64
ras 21890455_1 64 67
mutant 21890455_1 68 74
colorectal 21890455_1 75 85
and 21890455_1 86 89
pancreatic 21890455_1 90 100
cancers 21890455_1 101 108
. 21890455_1 109 110

Altogether 18084327_10 0 10
, 18084327_10 11 12
these 18084327_10 13 18
data 18084327_10 19 23
indicate 18084327_10 24 32
that 18084327_10 33 37
AZD 18084327_10 38 41
1152 18084327_10 41 45
can 18084327_10 46 49
radiosensitize 18084327_10 50 64
tumor 18084327_10 65 70
cell 18084327_10 71 75
lines 18084327_10 76 81
in 18084327_10 82 84
vitro 18084327_10 85 90
and 18084327_10 91 94
in 18084327_10 95 97
vivo 18084327_10 98 102
, 18084327_10 103 104
the 18084327_10 105 108
fact 18084327_10 109 113
that 18084327_10 114 118
these 18084327_10 119 124
effects 18084327_10 125 132
are 18084327_10 133 136
exacerbated 18084327_10 137 148
in 18084327_10 149 151
p 18084327_10 152 153
53 18084327_10 153 155
- 18084327_10 156 157
deficient 18084327_10 157 166
cancer 18084327_10 167 173
cells 18084327_10 174 179
is 18084327_10 180 182
of 18084327_10 183 185
potential 18084327_10 186 195
interest 18084327_10 196 204
for 18084327_10 205 208
further 18084327_10 209 216
clinical 18084327_10 217 225
development 18084327_10 226 237
. 18084327_10 238 239

Bupropion 15083067_2 0 9
is 15083067_2 10 12
primarily 15083067_2 13 22
metabolized 15083067_2 23 34
in 15083067_2 35 37
human 15083067_2 38 43
liver 15083067_2 44 49
by 15083067_2 50 52
cytochrome 15083067_2 53 63
P 15083067_2 64 65
450 15083067_2 65 68
( 15083067_2 69 70
CYP 15083067_2 71 74
) 15083067_2 75 76
2 15083067_2 77 78
B 15083067_2 78 79
6 15083067_2 79 80
, 15083067_2 81 82
an 15083067_2 83 85
isoform 15083067_2 86 93
that 15083067_2 94 98
shows 15083067_2 99 104
high 15083067_2 105 109
interindividual 15083067_2 110 125
variability 15083067_2 126 137
in 15083067_2 138 140
expression 15083067_2 141 151
and 15083067_2 152 155
catalysis 15083067_2 156 165
. 15083067_2 166 167

We 12150448_4 0 2
pre 12150448_4 3 6
- 12150448_4 6 7
selected 12150448_4 7 15
patients 12150448_4 16 24
with 12150448_4 25 29
advanced 12150448_4 30 38
HER 12150448_4 39 42
- 12150448_4 42 43
2 12150448_4 43 44
/ 12150448_4 44 45
neu 12150448_4 45 48
( 12150448_4 49 50
HER 12150448_4 51 54
2 12150448_4 54 55
) 12150448_4 56 57
overexpressing 12150448_4 58 72
breast 12150448_4 73 79
and 12150448_4 80 83
ovarian 12150448_4 84 91
cancers 12150448_4 92 99
for 12150448_4 100 103
enrolment 12150448_4 104 113
into 12150448_4 114 118
a 12150448_4 119 120
phase 12150448_4 121 126
I 12150448_4 127 128
trial 12150448_4 129 134
designed 12150448_4 135 143
to 12150448_4 144 146
evaluate 12150448_4 147 155
the 12150448_4 156 159
immunogenicity 12150448_4 160 174
of 12150448_4 175 177
a 12150448_4 178 179
HER 12150448_4 180 183
2 12150448_4 183 184
peptide 12150448_4 185 192
vaccine 12150448_4 193 200
based 12150448_4 201 206
on 12150448_4 207 209
the 12150448_4 210 213
patient 12150448_4 214 221
' 12150448_4 222 223
s 12150448_4 223 224
immune 12150448_4 225 231
competence 12150448_4 232 242
as 12150448_4 243 245
assessed 12150448_4 246 254
by 12150448_4 255 257
DTH 12150448_4 258 261
skin 12150448_4 262 266
testing 12150448_4 267 274
to 12150448_4 275 277
common 12150448_4 278 284
recall 12150448_4 285 291
antigens 12150448_4 292 300
( 12150448_4 301 302
Multitest 12150448_4 303 312
CMI 12150448_4 313 316
, 12150448_4 317 318
Institut 12150448_4 319 327
Merieux 12150448_4 328 335
, 12150448_4 336 337
Lyon 12150448_4 338 342
, 12150448_4 343 344
France 12150448_4 345 351
) 12150448_4 352 353
. 12150448_4 354 355

CONCLUSION 24519039_8 0 10
: 24519039_8 11 12
These 24519039_8 13 18
findings 24519039_8 19 27
demonstrate 24519039_8 28 39
a 24519039_8 40 41
novel 24519039_8 42 47
ribavirin 24519039_8 48 57
- 24519039_8 58 59
like 24519039_8 59 63
association 24519039_8 64 75
between 24519039_8 76 83
polymorphisms 24519039_8 84 97
at 24519039_8 98 100
ITPA 24519039_8 101 105
and 24519039_8 106 109
treatment 24519039_8 110 119
efficacy 24519039_8 120 128
in 24519039_8 129 131
chronic 24519039_8 132 139
hepatitis 24519039_8 140 149
C 24519039_8 150 151
mediated 24519039_8 152 160
by 24519039_8 161 163
reduced 24519039_8 164 171
relapse 24519039_8 172 179
risk 24519039_8 180 184
. 24519039_8 185 186

CONCLUSION 21849660_11 0 10
: 21849660_11 11 12
Statin 21849660_11 13 19
use 21849660_11 20 23
during 21849660_11 24 30
and 21849660_11 31 34
after 21849660_11 35 40
adjuvant 21849660_11 41 49
chemotherapy 21849660_11 50 62
was 21849660_11 63 66
not 21849660_11 67 70
associated 21849660_11 71 81
with 21849660_11 82 86
improved 21849660_11 87 95
DFS 21849660_11 96 99
, 21849660_11 100 101
RFS 21849660_11 102 105
, 21849660_11 106 107
or 21849660_11 108 110
OS 21849660_11 111 113
in 21849660_11 114 116
patients 21849660_11 117 125
with 21849660_11 126 130
stage 21849660_11 131 136
III 21849660_11 137 140
colon 21849660_11 141 146
cancer 21849660_11 147 153
, 21849660_11 154 155
regardless 21849660_11 156 166
of 21849660_11 167 169
KRAS 21849660_11 170 174
mutation 21849660_11 175 183
status 21849660_11 184 190
. 21849660_11 191 192

Our 23752130_11 0 3
novel 23752130_11 4 9
findings 23752130_11 10 18
suggest 23752130_11 19 26
that 23752130_11 27 31
butyric 23752130_11 32 39
acid 23752130_11 40 44
has 23752130_11 45 48
significant 23752130_11 49 60
anti 23752130_11 61 65
- 23752130_11 65 66
inflammatory 23752130_11 66 78
effects 23752130_11 79 86
partly 23752130_11 87 93
via 23752130_11 94 97
MFG 23752130_11 98 101
- 23752130_11 101 102
E 23752130_11 102 103
8 23752130_11 103 104
on 23752130_11 105 107
DSS 23752130_11 108 111
- 23752130_11 112 113
induced 23752130_11 113 120
murine 23752130_11 121 127
experimental 23752130_11 128 140
colitis 23752130_11 141 148
. 23752130_11 149 150

Moreover 20127344_13 0 8
, 20127344_13 9 10
mutated 20127344_13 11 18
IDH 20127344_13 19 22
1 20127344_13 22 23
consumes 20127344_13 24 32
rather 20127344_13 33 39
than 20127344_13 40 44
produces 20127344_13 45 53
NADPH 20127344_13 54 59
, 20127344_13 60 61
thus 20127344_13 62 66
likely 20127344_13 67 73
lowering 20127344_13 74 82
NADPH 20127344_13 83 88
levels 20127344_13 89 95
even 20127344_13 96 100
further 20127344_13 101 108
. 20127344_13 109 110

CONCLUSIONS 26471290_13 0 11
: 26471290_13 12 13
KRAS 26471290_13 14 18
MT 26471290_13 19 21
are 26471290_13 22 25
not 26471290_13 26 29
associated 26471290_13 30 40
with 26471290_13 41 45
inferior 26471290_13 46 54
progression 26471290_13 55 66
- 26471290_13 66 67
free 26471290_13 67 71
and 26471290_13 72 75
overall 26471290_13 76 83
survival 26471290_13 84 92
in 26471290_13 93 95
advanced 26471290_13 96 104
NSCLC 26471290_13 105 110
patients 26471290_13 111 119
treated 26471290_13 120 127
with 26471290_13 128 132
standard 26471290_13 133 141
first 26471290_13 142 147
- 26471290_13 147 148
line 26471290_13 148 152
platinum 26471290_13 153 161
- 26471290_13 162 163
based 26471290_13 163 168
chemotherapy 26471290_13 169 181
. 26471290_13 182 183

Inter 25121365_3 0 5
- 25121365_3 5 6
individual 25121365_3 6 16
variability 25121365_3 17 28
in 25121365_3 29 31
drug 25121365_3 32 36
response 25121365_3 37 45
can 25121365_3 46 49
be 25121365_3 50 52
attributed 25121365_3 53 63
to 25121365_3 64 66
genetic 25121365_3 67 74
polymorphism 25121365_3 75 87
in 25121365_3 88 90
genes 25121365_3 91 96
encoding 25121365_3 97 105
different 25121365_3 106 115
drug 25121365_3 116 120
metabolizing 25121365_3 121 133
enzymes 25121365_3 134 141
, 25121365_3 142 143
drug 25121365_3 144 148
transporters 25121365_3 149 161
( 25121365_3 162 163
P 25121365_3 164 165
- 25121365_3 165 166
gp 25121365_3 166 168
) 25121365_3 169 170
, 25121365_3 171 172
and 25121365_3 173 176
enzymes 25121365_3 177 184
involved 25121365_3 185 193
in 25121365_3 194 196
sodium 25121365_3 197 203
channel 25121365_3 204 211
biosynthesis 25121365_3 212 224
. 25121365_3 225 226

In 24597986_7 0 2
conclusion 24597986_7 3 13
, 24597986_7 14 15
the 24597986_7 16 19
RFC 24597986_7 20 23
1 24597986_7 23 24
G 24597986_7 25 26
80 24597986_7 26 28
A 24597986_7 28 29
polymorphism 24597986_7 30 42
does 24597986_7 43 47
not 24597986_7 48 51
seem 24597986_7 52 56
to 24597986_7 57 59
be 24597986_7 60 62
a 24597986_7 63 64
good 24597986_7 65 69
marker 24597986_7 70 76
of 24597986_7 77 79
MTX 24597986_7 80 83
- 24597986_7 84 85
related 24597986_7 85 92
toxicity 24597986_7 93 101
in 24597986_7 102 104
pediatric 24597986_7 105 114
ALL 24597986_7 115 118
. 24597986_7 119 120

The 22137367_6 0 3
mean 22137367_6 4 8
SDS 22137367_6 9 12
baseline 22137367_6 13 21
IGF 22137367_6 22 25
- 22137367_6 25 26
1 22137367_6 26 27
value 22137367_6 28 33
was 22137367_6 34 37
- 22137367_6 38 39
1 22137367_6 39 40
. 22137367_6 40 41
6 22137367_6 41 42
0 22137367_6 43 44
. 22137367_6 44 45
5 22137367_6 45 46
before 22137367_6 47 53
rGH 22137367_6 54 57
treatment 22137367_6 58 67
and 22137367_6 68 71
1 22137367_6 72 73
. 22137367_6 73 74
4 22137367_6 74 75
0 22137367_6 76 77
. 22137367_6 77 78
3 22137367_6 78 79
during 22137367_6 80 86
the 22137367_6 87 90
last 22137367_6 91 95
year 22137367_6 96 100
of 22137367_6 101 103
observation 22137367_6 104 115
. 22137367_6 116 117

A 21111586_1 0 1
methylene 21111586_1 2 11
chloride 21111586_1 12 20
fraction 21111586_1 21 29
of 21111586_1 30 32
Saururus 21111586_1 33 41
chinensis 21111586_1 42 51
induces 21111586_1 52 59
apoptosis 21111586_1 60 69
through 21111586_1 70 77
the 21111586_1 78 81
activation 21111586_1 82 92
of 21111586_1 93 95
caspase 21111586_1 96 103
- 21111586_1 103 104
3 21111586_1 104 105
in 21111586_1 106 108
prostate 21111586_1 109 117
and 21111586_1 118 121
breast 21111586_1 122 128
cancer 21111586_1 129 135
cells 21111586_1 136 141
. 21111586_1 142 143

RESULTS 25303981_7 0 7
: 25303981_7 8 9
Our 25303981_7 10 13
results 25303981_7 14 21
indicated 25303981_7 22 31
that 25303981_7 32 36
the 25303981_7 37 40
DTNBP 25303981_7 41 46
1 25303981_7 46 47
rs 25303981_7 48 50
3213207 25303981_7 50 57
polymorphism 25303981_7 58 70
did 25303981_7 71 74
not 25303981_7 75 78
show 25303981_7 79 83
any 25303981_7 84 87
significant 25303981_7 88 99
association 25303981_7 100 111
with 25303981_7 112 116
risk 25303981_7 117 121
of 25303981_7 122 124
methamphetamine 25303981_7 125 140
dependence 25303981_7 141 151
, 25303981_7 152 153
either 25303981_7 154 160
in 25303981_7 161 163
the 25303981_7 164 167
pooled 25303981_7 168 174
subjects 25303981_7 175 183
or 25303981_7 184 186
after 25303981_7 187 192
stratification 25303981_7 193 207
into 25303981_7 208 212
the 25303981_7 213 216
4 25303981_7 217 218
different 25303981_7 219 228
ethnic 25303981_7 229 235
groups 25303981_7 236 242
( 25303981_7 243 244
P 25303981_7 245 246
> 25303981_7 247 248
0 25303981_7 249 250
. 25303981_7 250 251
05 25303981_7 251 253
) 25303981_7 254 255
. 25303981_7 256 257

AIMS 26411491_2 0 4
: 26411491_2 5 6
6 26411491_2 7 8
- 26411491_2 8 9
mercaptopurine 26411491_2 9 23
influences 26411491_2 24 34
in 26411491_2 35 37
vitro 26411491_2 38 43
TPMT 26411491_2 44 48
gene 26411491_2 49 53
expression 26411491_2 54 64
in 26411491_2 65 67
a 26411491_2 68 69
TPMT 26411491_2 70 74
promoter 26411491_2 75 83
variable 26411491_2 84 92
number 26411491_2 93 99
of 26411491_2 100 102
tandem 26411491_2 103 109
repeats 26411491_2 110 117
( 26411491_2 118 119
VNTR 26411491_2 120 124
) 26411491_2 125 126
- 26411491_2 127 128
dependent 26411491_2 129 138
manner 26411491_2 139 145
. 26411491_2 146 147

Confirmation 16395124_1 0 12
of 16395124_1 13 15
association 16395124_1 16 27
of 16395124_1 28 30
the 16395124_1 31 34
GABRA 16395124_1 35 40
2 16395124_1 40 41
gene 16395124_1 42 46
with 16395124_1 47 51
alcohol 16395124_1 52 59
dependence 16395124_1 60 70
by 16395124_1 71 73
subtype 16395124_1 74 81
- 16395124_1 81 82
specific 16395124_1 82 90
analysis 16395124_1 91 99
. 16395124_1 100 101

Substituting 24342753_5 0 12
F 24342753_5 13 14
617 24342753_5 14 17
, 24342753_5 18 19
Y 24342753_5 20 21
621 24342753_5 21 24
or 24342753_5 25 27
F 24342753_5 28 29
624 24342753_5 29 32
in 24342753_5 33 35
TM 24342753_5 36 38
5 24342753_5 38 39
with 24342753_5 40 44
leucine 24342753_5 45 52
reduced 24342753_5 53 60
channel 24342753_5 61 68
sensitivity 24342753_5 69 80
to 24342753_5 81 83
the 24342753_5 84 87
agonist 24342753_5 88 95
4 24342753_5 96 97
a 24342753_5 97 98
- 24342753_5 98 99
PDD 24342753_5 100 103
and 24342753_5 104 107
heat 24342753_5 108 112
, 24342753_5 113 114
yet 24342753_5 115 118
two 24342753_5 119 122
of 24342753_5 123 125
these 24342753_5 126 131
mutants 24342753_5 132 139
- 24342753_5 140 141
F 24342753_5 142 143
617 24342753_5 143 146
L 24342753_5 146 147
and 24342753_5 148 151
Y 24342753_5 152 153
621 24342753_5 153 156
L 24342753_5 156 157
- 24342753_5 158 159
showed 24342753_5 160 166
increased 24342753_5 167 176
activation 24342753_5 177 187
in 24342753_5 188 190
response 24342753_5 191 199
to 24342753_5 200 202
cell 24342753_5 203 207
swelling 24342753_5 208 216
. 24342753_5 217 218

Arg 18075464_1 0 3
389 18075464_1 3 6
Gly 18075464_1 6 9
- 18075464_1 9 10
beta 18075464_1 11 15
1 18075464_1 15 16
- 18075464_1 17 18
adrenergic 18075464_1 18 28
receptors 18075464_1 29 38
determine 18075464_1 39 48
improvement 18075464_1 49 60
in 18075464_1 61 63
left 18075464_1 64 68
ventricular 18075464_1 69 80
systolic 18075464_1 81 89
function 18075464_1 90 98
in 18075464_1 99 101
nonischemic 18075464_1 102 113
cardiomyopathy 18075464_1 114 128
patients 18075464_1 129 137
with 18075464_1 138 142
heart 18075464_1 143 148
failure 18075464_1 149 156
after 18075464_1 157 162
chronic 18075464_1 163 170
treatment 18075464_1 171 180
with 18075464_1 181 185
carvedilol 18075464_1 186 196
. 18075464_1 197 198

Lipoprotein 23415432_1 0 11
abnormalities 23415432_1 12 25
in 23415432_1 26 28
compound 23415432_1 29 37
heterozygous 23415432_1 38 50
lipoprotein 23415432_1 51 62
lipase 23415432_1 63 69
deficiency 23415432_1 70 80
after 23415432_1 81 86
treatment 23415432_1 87 96
with 23415432_1 97 101
a 23415432_1 102 103
low 23415432_1 104 107
- 23415432_1 107 108
fat 23415432_1 108 111
diet 23415432_1 112 116
and 23415432_1 117 120
orlistat 23415432_1 121 129
. 23415432_1 130 131

The 22118006_7 0 3
CYP 22118006_7 4 7
2 22118006_7 7 8
C 22118006_7 8 9
19 22118006_7 9 11
* 22118006_7 12 13
2 22118006_7 14 15
genotype 22118006_7 16 24
is 22118006_7 25 27
associated 22118006_7 28 38
with 22118006_7 39 43
an 22118006_7 44 46
increased 22118006_7 47 56
risk 22118006_7 57 61
of 22118006_7 62 64
definite 22118006_7 65 73
ST 22118006_7 74 76
following 22118006_7 77 86
coronary 22118006_7 87 95
stent 22118006_7 96 101
placement 22118006_7 102 111
among 22118006_7 112 117
Chinese 22118006_7 118 125
patients 22118006_7 126 134
with 22118006_7 135 139
coronary 22118006_7 140 148
artery 22118006_7 149 155
disease 22118006_7 156 163
receiving 22118006_7 164 173
clopidogrel 22118006_7 174 185
. 22118006_7 186 187

CONCLUSION 19796663_8 0 10
: 19796663_8 11 12
This 19796663_8 13 17
has 19796663_8 18 21
been 19796663_8 22 26
the 19796663_8 27 30
first 19796663_8 31 36
study 19796663_8 37 42
showing 19796663_8 43 50
significant 19796663_8 51 62
associations 19796663_8 63 75
between 19796663_8 76 83
apomorphine 19796663_8 84 95
- 19796663_8 96 97
induced 19796663_8 97 104
GH 19796663_8 105 107
response 19796663_8 108 116
and 19796663_8 117 120
SNPs 19796663_8 121 125
in 19796663_8 126 128
DRD 19796663_8 129 132
2 19796663_8 132 133
and 19796663_8 134 137
ANKK 19796663_8 138 142
1 19796663_8 142 143
in 19796663_8 144 146
alcohol 19796663_8 147 154
- 19796663_8 155 156
dependent 19796663_8 156 165
patients 19796663_8 166 174
. 19796663_8 175 176

No 22298798_1 0 2
association 22298798_1 3 14
of 22298798_1 15 17
ABCB 22298798_1 18 22
1 22298798_1 22 23
C 22298798_1 24 25
3435 22298798_1 25 29
T 22298798_1 29 30
genotype 22298798_1 31 39
with 22298798_1 40 44
clopidogrel 22298798_1 45 56
response 22298798_1 57 65
or 22298798_1 66 68
risk 22298798_1 69 73
of 22298798_1 74 76
stent 22298798_1 77 82
thrombosis 22298798_1 83 93
in 22298798_1 94 96
patients 22298798_1 97 105
undergoing 22298798_1 106 116
coronary 22298798_1 117 125
stenting 22298798_1 126 134
. 22298798_1 135 136

UNASSIGNED 26056325_2 0 10
: 26056325_2 11 12
Vemurafenib 26056325_2 13 24
and 26056325_2 25 28
dabrafenib 26056325_2 29 39
are 26056325_2 40 43
both 26056325_2 44 48
orally 26056325_2 49 55
bioavailable 26056325_2 56 68
small 26056325_2 69 74
molecule 26056325_2 75 83
agents 26056325_2 84 90
that 26056325_2 91 95
block 26056325_2 96 101
mitogen 26056325_2 102 109
activated 26056325_2 110 119
protein 26056325_2 120 127
kinase 26056325_2 128 134
signalling 26056325_2 135 145
in 26056325_2 146 148
patients 26056325_2 149 157
with 26056325_2 158 162
melanoma 26056325_2 163 171
and 26056325_2 172 175
BRAF 26056325_2 176 180
( 26056325_2 181 182
V 26056325_2 182 183
600 26056325_2 183 186
E 26056325_2 186 187
) 26056325_2 188 189
mutation 26056325_2 190 198
. 26056325_2 199 200

These 18058343_7 0 5
data 18058343_7 6 10
suggest 18058343_7 11 18
that 18058343_7 19 23
bupropion 18058343_7 24 33
may 18058343_7 34 37
be 18058343_7 38 40
effective 18058343_7 41 50
for 18058343_7 51 54
smoking 18058343_7 55 62
cessation 18058343_7 63 72
only 18058343_7 73 77
in 18058343_7 78 80
a 18058343_7 81 82
subgroup 18058343_7 83 91
of 18058343_7 92 94
smokers 18058343_7 95 102
with 18058343_7 103 107
the 18058343_7 108 111
DRD 18058343_7 112 115
2 18058343_7 115 116
Taq 18058343_7 117 120
1 18058343_7 120 121
A 18058343_7 122 123
2 18058343_7 123 124
/ 18058343_7 124 125
A 18058343_7 125 126
2 18058343_7 126 127
genotype 18058343_7 128 136
. 18058343_7 137 138

The 8834233_1 0 3
contribution 8834233_1 4 16
of 8834233_1 17 19
polymorphism 8834233_1 20 32
in 8834233_1 33 35
the 8834233_1 36 39
alcohol 8834233_1 40 47
dehydrogenase 8834233_1 48 61
beta 8834233_1 62 66
subunit 8834233_1 67 74
to 8834233_1 75 77
alcohol 8834233_1 78 85
sensitivity 8834233_1 86 97
in 8834233_1 98 100
a 8834233_1 101 102
Japanese 8834233_1 103 111
population 8834233_1 112 122
. 8834233_1 123 124

Catechol 19042106_4 0 8
- 19042106_4 8 9
O 19042106_4 9 10
- 19042106_4 10 11
methyltransferase 19042106_4 11 28
( 19042106_4 29 30
COMT 19042106_4 31 35
) 19042106_4 36 37
is 19042106_4 38 40
involved 19042106_4 41 49
in 19042106_4 50 52
the 19042106_4 53 56
catabolism 19042106_4 57 67
of 19042106_4 68 70
Ecstasy 19042106_4 71 78
. 19042106_4 79 80

Sensitization 11167824_1 0 13
by 11167824_1 14 16
5 11167824_1 17 18
- 11167824_1 18 19
aza 11167824_1 19 22
- 11167824_1 22 23
2 11167824_1 23 24
' 11167824_1 24 25
- 11167824_1 25 26
deoxycytidine 11167824_1 26 39
of 11167824_1 40 42
leukaemia 11167824_1 43 52
cells 11167824_1 53 58
with 11167824_1 59 63
MLL 11167824_1 64 67
abnormalities 11167824_1 68 81
to 11167824_1 82 84
induction 11167824_1 85 94
of 11167824_1 95 97
differentiation 11167824_1 98 113
by 11167824_1 114 116
all 11167824_1 117 120
- 11167824_1 120 121
trans 11167824_1 121 126
retinoic 11167824_1 127 135
acid 11167824_1 136 140
and 11167824_1 141 144
1 11167824_1 145 146
alpha 11167824_1 146 151
, 11167824_1 151 152
25 11167824_1 152 154
- 11167824_1 154 155
dihydroxyvitamin 11167824_1 155 171
D 11167824_1 172 173
3 11167824_1 173 174
. 11167824_1 175 176

Evodiamine 15710601_1 0 10
abolishes 15710601_1 11 20
constitutive 15710601_1 21 33
and 15710601_1 34 37
inducible 15710601_1 38 47
NF 15710601_1 48 50
- 15710601_1 50 51
kappaB 15710601_1 51 57
activation 15710601_1 58 68
by 15710601_1 69 71
inhibiting 15710601_1 72 82
IkappaBalpha 15710601_1 83 95
kinase 15710601_1 96 102
activation 15710601_1 103 113
, 15710601_1 114 115
thereby 15710601_1 116 123
suppressing 15710601_1 124 135
NF 15710601_1 136 138
- 15710601_1 138 139
kappaB 15710601_1 139 145
- 15710601_1 146 147
regulated 15710601_1 147 156
antiapoptotic 15710601_1 157 170
and 15710601_1 171 174
metastatic 15710601_1 175 185
gene 15710601_1 186 190
expression 15710601_1 191 201
, 15710601_1 202 203
up 15710601_1 204 206
- 15710601_1 206 207
regulating 15710601_1 207 217
apoptosis 15710601_1 218 227
, 15710601_1 228 229
and 15710601_1 230 233
inhibiting 15710601_1 234 244
invasion 15710601_1 245 253
. 15710601_1 254 255

At 19067682_7 0 2
1 19067682_7 3 4
- 19067682_7 4 5
month 19067682_7 5 10
post 19067682_7 11 15
- 19067682_7 15 16
transplantation 19067682_7 17 32
, 19067682_7 33 34
tacrolimus 19067682_7 35 45
daily 19067682_7 46 51
dose 19067682_7 52 56
was 19067682_7 57 60
higher 19067682_7 61 67
for 19067682_7 68 71
patients 19067682_7 72 80
with 19067682_7 81 85
CYP 19067682_7 86 89
3 19067682_7 89 90
A 19067682_7 90 91
5 19067682_7 91 92
* 19067682_7 93 94
1 19067682_7 95 96
/ 19067682_7 97 98
* 19067682_7 99 100
1 19067682_7 101 102
genotype 19067682_7 103 111
compared 19067682_7 112 120
to 19067682_7 121 123
CYP 19067682_7 124 127
3 19067682_7 127 128
A 19067682_7 128 129
5 19067682_7 129 130
* 19067682_7 131 132
3 19067682_7 133 134
/ 19067682_7 135 136
* 19067682_7 137 138
3 19067682_7 139 140
genotype 19067682_7 141 149
( 19067682_7 150 151
0 19067682_7 152 153
. 19067682_7 153 154
26 19067682_7 154 156
+ 19067682_7 157 158
/ 19067682_7 159 160
- 19067682_7 161 162
0 19067682_7 163 164
. 19067682_7 164 165
03 19067682_7 165 167
versus 19067682_7 168 174
0 19067682_7 175 176
. 19067682_7 176 177
16 19067682_7 177 179
+ 19067682_7 180 181
/ 19067682_7 182 183
- 19067682_7 184 185
0 19067682_7 186 187
. 19067682_7 187 188
01 19067682_7 188 190
mg 19067682_7 191 193
/ 19067682_7 193 194
kg 19067682_7 194 196
/ 19067682_7 196 197
day 19067682_7 197 200
, 19067682_7 201 202
respectively 19067682_7 203 215
, 19067682_7 216 217
P 19067682_7 218 219
< 19067682_7 220 221
0 19067682_7 222 223
. 19067682_7 223 224
0001 19067682_7 224 228
) 19067682_7 229 230
. 19067682_7 231 232

The 24394004_5 0 3
relationship 24394004_5 4 16
between 24394004_5 17 24
the 24394004_5 25 28
MSI 24394004_5 29 32
status 24394004_5 33 39
and 24394004_5 40 43
the 24394004_5 44 47
efficacy 24394004_5 48 56
of 24394004_5 57 59
first 24394004_5 60 65
- 24394004_5 66 67
line 24394004_5 68 72
oxaliplatin 24394004_5 73 84
- 24394004_5 85 86
based 24394004_5 86 91
chemotherapy 24394004_5 92 104
was 24394004_5 105 108
retrospectively 24394004_5 109 124
examined 24394004_5 125 133
. 24394004_5 134 135

BRCA 19615284_8 0 4
1 19615284_8 4 5
methylation 19615284_8 6 17
status 19615284_8 18 24
may 19615284_8 25 28
be 19615284_8 29 31
a 19615284_8 32 33
useful 19615284_8 34 40
predictor 19615284_8 41 50
for 19615284_8 51 54
anthracycline 19615284_8 55 68
- 19615284_8 69 70
based 19615284_8 70 75
neoadjuvant 19615284_8 76 87
chemotherapy 19615284_8 88 100
in 19615284_8 101 103
primary 19615284_8 104 111
breast 19615284_8 112 118
cancer 19615284_8 119 125
patients 19615284_8 126 134
. 19615284_8 135 136

CONCLUSION 24993285_12 0 10
: 24993285_12 11 12
We 24993285_12 13 15
conclude 24993285_12 16 24
that 24993285_12 25 29
these 24993285_12 30 35
BDNF 24993285_12 36 40
SNPs 24993285_12 41 45
play 24993285_12 46 50
a 24993285_12 51 52
role 24993285_12 53 57
in 24993285_12 58 60
development 24993285_12 61 72
of 24993285_12 73 75
comorbid 24993285_12 76 84
alcohol 24993285_12 85 92
dependence 24993285_12 93 103
in 24993285_12 104 106
schizophrenia 24993285_12 107 120
while 24993285_12 121 126
our 24993285_12 127 130
data 24993285_12 131 135
do 24993285_12 136 138
not 24993285_12 139 142
indicate 24993285_12 143 151
that 24993285_12 152 156
they 24993285_12 157 161
play 24993285_12 162 166
a 24993285_12 167 168
role 24993285_12 169 173
in 24993285_12 174 176
alcohol 24993285_12 177 184
- 24993285_12 185 186
dependent 24993285_12 186 195
patients 24993285_12 196 204
who 24993285_12 205 208
do 24993285_12 209 211
not 24993285_12 212 215
have 24993285_12 216 220
schizophrenia 24993285_12 221 234
. 24993285_12 235 236

The 17558310_2 0 3
1976 17558310_2 4 8
C 17558310_2 8 9
> 17558310_2 9 10
T 17558310_2 10 11
polymorphism 17558310_2 12 24
in 17558310_2 25 27
the 17558310_2 28 31
adenosine 17558310_2 32 41
A 17558310_2 42 43
2 17558310_2 43 44
A 17558310_2 44 45
receptor 17558310_2 46 54
gene 17558310_2 55 59
( 17558310_2 60 61
ADORA 17558310_2 62 67
2 17558310_2 67 68
A 17558310_2 68 69
) 17558310_2 70 71
modulates 17558310_2 72 81
the 17558310_2 82 85
psychological 17558310_2 86 99
response 17558310_2 100 108
to 17558310_2 109 111
administration 17558310_2 112 126
of 17558310_2 127 129
the 17558310_2 130 133
adenosine 17558310_2 134 143
receptor 17558310_2 144 152
antagonist 17558310_2 153 163
caffeine 17558310_2 164 172
. 17558310_2 173 174

These 19183407_9 0 5
results 19183407_9 6 13
suggest 19183407_9 14 21
that 19183407_9 22 26
AKR 19183407_9 27 30
- 19183407_9 30 31
501 19183407_9 31 34
is 19183407_9 35 37
an 19183407_9 38 40
orally 19183407_9 41 47
- 19183407_9 47 48
active 19183407_9 48 54
TPO 19183407_9 55 58
receptor 19183407_9 59 67
agonist 19183407_9 68 75
that 19183407_9 76 80
may 19183407_9 81 84
be 19183407_9 85 87
useful 19183407_9 88 94
in 19183407_9 95 97
the 19183407_9 98 101
treatment 19183407_9 102 111
of 19183407_9 112 114
patients 19183407_9 115 123
with 19183407_9 124 128
thrombocytopenia 19183407_9 129 145
. 19183407_9 146 147

CONCLUSIONS 21642685_12 0 11
: 21642685_12 12 13
Among 21642685_12 14 19
patients 21642685_12 20 28
with 21642685_12 29 33
advanced 21642685_12 34 42
melanoma 21642685_12 43 51
harboring 21642685_12 52 61
KIT 21642685_12 62 65
alterations 21642685_12 66 77
, 21642685_12 78 79
treatment 21642685_12 80 89
with 21642685_12 90 94
imatinib 21642685_12 95 103
mesylate 21642685_12 104 112
results 21642685_12 113 120
in 21642685_12 121 123
significant 21642685_12 124 135
clinical 21642685_12 136 144
responses 21642685_12 145 154
in 21642685_12 155 157
a 21642685_12 158 159
subset 21642685_12 160 166
of 21642685_12 167 169
patients 21642685_12 170 178
. 21642685_12 179 180

Nebivolol 19330906_1 0 9
decreases 19330906_1 10 19
endothelial 19330906_1 20 31
cell 19330906_1 32 36
stiffness 19330906_1 37 46
via 19330906_1 47 50
the 19330906_1 51 54
estrogen 19330906_1 55 63
receptor 19330906_1 64 72
beta 19330906_1 73 77
: 19330906_1 78 79
a 19330906_1 80 81
nano 19330906_1 82 86
- 19330906_1 86 87
imaging 19330906_1 87 94
study 19330906_1 95 100
. 19330906_1 101 102

In 22206814_8 0 2
contrast 22206814_8 3 11
, 22206814_8 12 13
human 22206814_8 14 19
PXR 22206814_8 20 23
was 22206814_8 24 27
activated 22206814_8 28 37
by 22206814_8 38 40
okadaic 22206814_8 41 48
acid 22206814_8 49 53
at 22206814_8 54 56
similar 22206814_8 57 64
concentrations 22206814_8 65 79
to 22206814_8 80 82
CiVDR 22206814_8 83 88
/ 22206814_8 88 89
PXRa 22206814_8 89 93
( 22206814_8 94 95
EC 22206814_8 96 98
50 22206814_8 98 100
= 22206814_8 101 102
7 22206814_8 103 104
. 22206814_8 104 105
2 22206814_8 105 106
1 22206814_8 107 108
. 22206814_8 108 109
1 22206814_8 109 110
nM 22206814_8 111 113
) 22206814_8 114 115
but 22206814_8 116 119
not 22206814_8 120 123
by 22206814_8 124 126
pectenotoxin 22206814_8 127 139
- 22206814_8 139 140
2 22206814_8 140 141
. 22206814_8 142 143

Age 15947090_8 0 3
, 15947090_8 4 5
height 15947090_8 6 12
, 15947090_8 13 14
and 15947090_8 15 18
CYP 15947090_8 19 22
2 15947090_8 22 23
C 15947090_8 23 24
9 15947090_8 24 25
genotype 15947090_8 26 34
significantly 15947090_8 35 48
contributed 15947090_8 49 60
to 15947090_8 61 63
S 15947090_8 64 65
- 15947090_8 65 66
warfarin 15947090_8 66 74
and 15947090_8 75 78
total 15947090_8 79 84
warfarin 15947090_8 85 93
clearance 15947090_8 94 103
, 15947090_8 104 105
whereas 15947090_8 106 113
only 15947090_8 114 118
age 15947090_8 119 122
and 15947090_8 123 126
body 15947090_8 127 131
size 15947090_8 132 136
significantly 15947090_8 137 150
contributed 15947090_8 151 162
to 15947090_8 163 165
R 15947090_8 166 167
- 15947090_8 167 168
warfarin 15947090_8 169 177
clearance 15947090_8 178 187
. 15947090_8 188 189

In 9795138_10 0 2
the 9795138_10 3 6
arcuate 9795138_10 7 14
nucleus 9795138_10 15 22
, 9795138_10 23 24
there 9795138_10 25 30
was 9795138_10 31 34
a 9795138_10 35 36
modest 9795138_10 37 43
increase 9795138_10 44 52
in 9795138_10 53 55
the 9795138_10 56 59
average 9795138_10 60 67
number 9795138_10 68 74
of 9795138_10 75 77
cells 9795138_10 78 83
/ 9795138_10 83 84
animal 9795138_10 84 90
which 9795138_10 91 96
expressed 9795138_10 97 106
zif 9795138_10 107 110
/ 9795138_10 110 111
268 9795138_10 111 114
mRNA 9795138_10 115 119
following 9795138_10 120 129
the 9795138_10 130 133
injection 9795138_10 134 143
of 9795138_10 144 146
PVP 9795138_10 147 150
and 9795138_10 151 154
oPRL 9795138_10 155 159
at 9795138_10 160 162
all 9795138_10 163 166
times 9795138_10 167 172
studied 9795138_10 173 180
. 9795138_10 181 182

In 20878066_6 0 2
this 20878066_6 3 7
report 20878066_6 8 14
, 20878066_6 15 16
using 20878066_6 17 22
a 20878066_6 23 24
cell 20878066_6 25 29
line 20878066_6 30 34
with 20878066_6 35 39
knock 20878066_6 40 45
- 20878066_6 45 46
down 20878066_6 46 50
p 20878066_6 51 52
53 20878066_6 52 54
expression 20878066_6 55 65
through 20878066_6 66 73
siRNA 20878066_6 74 79
, 20878066_6 80 81
we 20878066_6 82 84
found 20878066_6 85 90
that 20878066_6 91 95
amifostine 20878066_6 96 106
enhancement 20878066_6 107 118
of 20878066_6 119 121
paclitaxel 20878066_6 122 132
' 20878066_6 133 134
s 20878066_6 134 135
anticancer 20878066_6 136 146
effect 20878066_6 147 153
is 20878066_6 154 156
p 20878066_6 157 158
53 20878066_6 158 160
status 20878066_6 161 167
- 20878066_6 168 169
dependent 20878066_6 169 178
. 20878066_6 179 180

Screening 25565175_4 0 9
for 25565175_4 10 13
HLA 25565175_4 14 17
- 25565175_4 17 18
B 25565175_4 18 19
5701 25565175_4 20 24
to 25565175_4 25 27
avoid 25565175_4 28 33
abacavir 25565175_4 34 42
hypersensitivity 25565175_4 43 59
reactions 25565175_4 60 69
has 25565175_4 70 73
become 25565175_4 74 80
a 25565175_4 81 82
routine 25565175_4 83 90
part 25565175_4 91 95
of 25565175_4 96 98
clinical 25565175_4 99 107
care 25565175_4 108 112
, 25565175_4 113 114
and 25565175_4 115 118
has 25565175_4 119 122
markedly 25565175_4 123 131
improved 25565175_4 132 140
drug 25565175_4 141 145
safety 25565175_4 146 152
. 25565175_4 153 154

INTRODUCTION 27027150_2 0 12
: 27027150_2 13 14
In 27027150_2 15 17
the 27027150_2 18 21
40 27027150_2 22 24
- 27027150_2 24 25
50 27027150_2 25 27
% 27027150_2 28 29
of 27027150_2 30 32
advanced 27027150_2 33 41
melanoma 27027150_2 42 50
patients 27027150_2 51 59
with 27027150_2 60 64
tumors 27027150_2 65 71
harboring 27027150_2 72 81
BRAF 27027150_2 82 86
V 27027150_2 87 88
600 27027150_2 88 91
E 27027150_2 91 92
and 27027150_2 93 96
V 27027150_2 97 98
600 27027150_2 98 101
K 27027150_2 101 102
mutations 27027150_2 103 112
, 27027150_2 113 114
BRAF 27027150_2 115 119
inhibitors 27027150_2 120 130
such 27027150_2 131 135
as 27027150_2 136 138
dabrafenib 27027150_2 139 149
are 27027150_2 150 153
a 27027150_2 154 155
highly 27027150_2 156 162
effective 27027150_2 163 172
treatment 27027150_2 173 182
. 27027150_2 183 184

There 8904964_10 0 5
was 8904964_10 6 9
also 8904964_10 10 14
a 8904964_10 15 16
nonsignificant 8904964_10 17 31
trend 8904964_10 32 37
for 8904964_10 38 41
subjects 8904964_10 42 50
with 8904964_10 51 55
an 8904964_10 56 58
ADH 8904964_10 59 62
2 8904964_10 62 63
* 8904964_10 64 65
3 8904964_10 66 67
allele 8904964_10 68 74
( 8904964_10 75 76
n 8904964_10 77 78
= 8904964_10 79 80
6 8904964_10 81 82
) 8904964_10 83 84
to 8904964_10 85 87
have 8904964_10 88 92
faster 8904964_10 93 99
rates 8904964_10 100 105
of 8904964_10 106 108
alcohol 8904964_10 109 116
elimination 8904964_10 117 128
than 8904964_10 129 133
those 8904964_10 134 139
with 8904964_10 140 144
ADH 8904964_10 145 148
2 8904964_10 148 149
* 8904964_10 150 151
1 8904964_10 152 153
alleles 8904964_10 154 161
only 8904964_10 162 166
( 8904964_10 167 168
n 8904964_10 169 170
= 8904964_10 171 172
33 8904964_10 173 175
) 8904964_10 176 177
. 8904964_10 178 179

These 22394227_9 0 5
results 22394227_9 6 13
suggest 22394227_9 14 21
that 22394227_9 22 26
the 22394227_9 27 30
Ainu 22394227_9 31 35
- 22394227_9 35 36
selected 22394227_9 36 44
traditional 22394227_9 45 56
beneficial 22394227_9 57 67
plants 22394227_9 68 74
are 22394227_9 75 78
useful 22394227_9 79 85
source 22394227_9 86 92
for 22394227_9 93 96
findings 22394227_9 97 105
of 22394227_9 106 108
novel 22394227_9 109 114
AhR 22394227_9 115 118
antagonists 22394227_9 119 130
, 22394227_9 131 132
and 22394227_9 133 136
the 22394227_9 137 140
antagonistic 22394227_9 141 153
activity 22394227_9 154 162
of 22394227_9 163 165
these 22394227_9 166 171
plants 22394227_9 172 178
may 22394227_9 179 182
be 22394227_9 183 185
independent 22394227_9 186 197
on 22394227_9 198 200
their 22394227_9 201 206
antioxidative 22394227_9 207 220
activity 22394227_9 221 229
and 22394227_9 230 233
polyphenol 22394227_9 234 244
content 22394227_9 245 252
. 22394227_9 253 254

In 21596890_6 0 2
HepG 21596890_6 3 7
2 21596890_6 7 8
cells 21596890_6 9 14
, 21596890_6 15 16
CDCA 21596890_6 17 21
treatment 21596890_6 22 31
activated 21596890_6 32 41
C 21596890_6 42 43
/ 21596890_6 44 45
EBPb 21596890_6 45 49
, 21596890_6 50 51
as 21596890_6 52 54
shown 21596890_6 55 60
by 21596890_6 61 63
increases 21596890_6 64 73
in 21596890_6 74 76
its 21596890_6 77 80
phosphorylation 21596890_6 81 96
, 21596890_6 97 98
nuclear 21596890_6 99 106
accumulation 21596890_6 107 119
, 21596890_6 120 121
and 21596890_6 122 125
expression 21596890_6 126 136
. 21596890_6 137 138

UNASSIGNED 26369533_2 0 10
: 26369533_2 11 12
Breast 26369533_2 13 19
cancer 26369533_2 20 26
patients 26369533_2 27 35
with 26369533_2 36 40
absent 26369533_2 41 47
or 26369533_2 48 50
reduced 26369533_2 51 58
CYP 26369533_2 59 62
2 26369533_2 62 63
D 26369533_2 63 64
6 26369533_2 64 65
activity 26369533_2 66 74
and 26369533_2 75 78
consequently 26369533_2 79 91
low 26369533_2 92 95
endoxifen 26369533_2 96 105
levels 26369533_2 106 112
may 26369533_2 113 116
benefit 26369533_2 117 124
less 26369533_2 125 129
from 26369533_2 130 134
tamoxifen 26369533_2 135 144
treatment 26369533_2 145 154
. 26369533_2 155 156

Using 16357205_4 0 5
an 16357205_4 6 8
embryonic 16357205_4 9 18
stem 16357205_4 19 23
cell 16357205_4 24 28
line 16357205_4 29 33
engineered 16357205_4 34 44
with 16357205_4 45 49
tetracycline 16357205_4 50 62
- 16357205_4 63 64
inducible 16357205_4 64 73
Cdx 16357205_4 74 77
4 16357205_4 77 78
, 16357205_4 79 80
we 16357205_4 81 83
demonstrate 16357205_4 84 95
that 16357205_4 96 100
ectopic 16357205_4 101 108
Cdx 16357205_4 109 112
4 16357205_4 112 113
expression 16357205_4 114 124
promotes 16357205_4 125 133
hematopoietic 16357205_4 134 147
mesoderm 16357205_4 148 156
specification 16357205_4 157 170
, 16357205_4 171 172
increases 16357205_4 173 182
hematopoietic 16357205_4 183 196
progenitor 16357205_4 197 207
formation 16357205_4 208 217
, 16357205_4 218 219
and 16357205_4 220 223
, 16357205_4 224 225
together 16357205_4 226 234
with 16357205_4 235 239
HoxB 16357205_4 240 244
4 16357205_4 244 245
, 16357205_4 246 247
enhances 16357205_4 248 256
multilineage 16357205_4 257 269
hematopoietic 16357205_4 270 283
engraftment 16357205_4 284 295
of 16357205_4 296 298
lethally 16357205_4 299 307
irradiated 16357205_4 308 318
adult 16357205_4 319 324
mice 16357205_4 325 329
. 16357205_4 330 331

Pharmacogenetics 25391641_1 0 16
of 25391641_1 17 19
CYP 25391641_1 20 23
2 25391641_1 23 24
B 25391641_1 24 25
6 25391641_1 25 26
, 25391641_1 27 28
CYP 25391641_1 29 32
2 25391641_1 32 33
A 25391641_1 33 34
6 25391641_1 34 35
and 25391641_1 36 39
UGT 25391641_1 40 43
2 25391641_1 43 44
B 25391641_1 44 45
7 25391641_1 45 46
in 25391641_1 47 49
HIV 25391641_1 50 53
treatment 25391641_1 54 63
in 25391641_1 64 66
African 25391641_1 67 74
populations 25391641_1 75 86
: 25391641_1 87 88
focus 25391641_1 89 94
on 25391641_1 95 97
efavirenz 25391641_1 98 107
and 25391641_1 108 111
nevirapine 25391641_1 112 122
. 25391641_1 123 124

Monitoring 19820367_1 0 10
of 19820367_1 11 13
endometrial 19820367_1 14 25
K 19820367_1 26 27
- 19820367_1 27 28
ras 19820367_1 28 31
mutation 19820367_1 32 40
in 19820367_1 41 43
tamoxifen 19820367_1 44 53
- 19820367_1 54 55
treated 19820367_1 55 62
patients 19820367_1 63 71
with 19820367_1 72 76
breast 19820367_1 77 83
cancer 19820367_1 84 90
. 19820367_1 91 92

CREB 16359811_6 0 4
antisense 16359811_6 5 14
also 16359811_6 15 19
increased 16359811_6 20 29
the 16359811_6 30 33
threshold 16359811_6 34 43
dose 16359811_6 44 48
of 16359811_6 49 51
cocaine 16359811_6 52 59
required 16359811_6 60 68
for 16359811_6 69 72
reinstating 16359811_6 73 84
cocaine 16359811_6 85 92
self 16359811_6 93 97
- 16359811_6 97 98
administration 16359811_6 98 112
, 16359811_6 113 114
indicating 16359811_6 115 125
that 16359811_6 126 130
nucleus 16359811_6 131 138
accumbens 16359811_6 139 148
CREB 16359811_6 149 153
levels 16359811_6 154 160
regulate 16359811_6 161 169
the 16359811_6 170 173
incentive 16359811_6 174 183
properties 16359811_6 184 194
of 16359811_6 195 197
cocaine 16359811_6 198 205
. 16359811_6 206 207

The 21912425_8 0 3
ease 21912425_8 4 8
of 21912425_8 9 11
typing 21912425_8 12 18
rs 21912425_8 19 21
9263726 21912425_8 21 28
makes 21912425_8 29 34
it 21912425_8 35 37
a 21912425_8 38 39
useful 21912425_8 40 46
biomarker 21912425_8 47 56
for 21912425_8 57 60
allopurinol 21912425_8 61 72
- 21912425_8 73 74
related 21912425_8 74 81
SJS 21912425_8 82 85
/ 21912425_8 86 87
TEN 21912425_8 88 91
in 21912425_8 92 94
Japanese 21912425_8 95 103
. 21912425_8 104 105

Based 10877911_6 0 5
on 10877911_6 6 8
these 10877911_6 9 14
results 10877911_6 15 22
, 10877911_6 23 24
glial 10877911_6 25 30
cell 10877911_6 31 35
line 10877911_6 36 40
- 10877911_6 40 41
derived 10877911_6 41 48
neurotrophic 10877911_6 49 61
factor 10877911_6 62 68
( 10877911_6 69 70
GDNF 10877911_6 71 75
) 10877911_6 76 77
was 10877911_6 78 81
assessed 10877911_6 82 90
as 10877911_6 91 93
a 10877911_6 94 95
neuroprotective 10877911_6 96 111
molecule 10877911_6 112 120
in 10877911_6 121 123
a 10877911_6 124 125
6 10877911_6 126 127
- 10877911_6 127 128
hydroxydopamine 10877911_6 128 143
model 10877911_6 144 149
of 10877911_6 150 152
Parkinson 10877911_6 153 162
' 10877911_6 162 163
s 10877911_6 163 164
disease 10877911_6 165 172
. 10877911_6 173 174

METHODS 16041239_4 0 7
: 16041239_4 8 9
A 16041239_4 10 11
comprehensive 16041239_4 12 25
evaluation 16041239_4 26 36
of 16041239_4 37 39
single 16041239_4 40 46
nucleotide 16041239_4 47 57
polymorphisms 16041239_4 58 71
( 16041239_4 72 73
39 16041239_4 74 76
SNPs 16041239_4 77 81
in 16041239_4 82 84
ABCB 16041239_4 85 89
1 16041239_4 89 90
, 16041239_4 91 92
7 16041239_4 93 94
in 16041239_4 95 97
ABCC 16041239_4 98 102
1 16041239_4 102 103
, 16041239_4 104 105
27 16041239_4 106 108
in 16041239_4 109 111
ABCC 16041239_4 112 116
2 16041239_4 116 117
, 16041239_4 118 119
and 16041239_4 120 123
16 16041239_4 124 126
in 16041239_4 127 129
ABCG 16041239_4 130 134
2 16041239_4 134 135
) 16041239_4 136 137
, 16041239_4 138 139
and 16041239_4 140 143
inferred 16041239_4 144 152
haplotypes 16041239_4 153 163
was 16041239_4 164 167
done 16041239_4 168 172
to 16041239_4 173 175
assess 16041239_4 176 182
possible 16041239_4 183 191
associations 16041239_4 192 204
of 16041239_4 205 207
genetic 16041239_4 208 215
variants 16041239_4 216 224
with 16041239_4 225 229
cellular 16041239_4 230 238
exposure 16041239_4 239 247
of 16041239_4 248 250
nelfinavir 16041239_4 251 261
in 16041239_4 262 264
vivo 16041239_4 265 269
. 16041239_4 270 271

Toxic 19031955_1 0 5
encephalopathy 19031955_1 6 20
and 19031955_1 21 24
delayed 19031955_1 25 32
MTX 19031955_1 33 36
clearance 19031955_1 37 46
after 19031955_1 47 52
high 19031955_1 53 57
- 19031955_1 57 58
dose 19031955_1 58 62
methotrexate 19031955_1 63 75
therapy 19031955_1 76 83
in 19031955_1 84 86
a 19031955_1 87 88
child 19031955_1 89 94
homozygous 19031955_1 95 105
for 19031955_1 106 109
the 19031955_1 110 113
MTHFR 19031955_1 114 119
C 19031955_1 120 121
677 19031955_1 121 124
T 19031955_1 124 125
polymorphism 19031955_1 126 138
. 19031955_1 139 140

Our 22862823_4 0 3
analyses 22862823_4 4 12
demonstrate 22862823_4 13 24
significant 22862823_4 25 36
association 22862823_4 37 48
between 22862823_4 49 56
GATA 22862823_4 57 61
4 22862823_4 61 62
and 22862823_4 63 66
alcohol 22862823_4 67 74
dependence 22862823_4 75 85
at 22862823_4 86 88
the 22862823_4 89 92
gene 22862823_4 93 97
level 22862823_4 98 103
( 22862823_4 104 105
P 22862823_4 106 107
= 22862823_4 108 109
0 22862823_4 110 111
. 22862823_4 111 112
009 22862823_4 112 115
) 22862823_4 116 117
but 22862823_4 118 121
no 22862823_4 122 124
association 22862823_4 125 136
with 22862823_4 137 141
rs 22862823_4 142 144
13273672 22862823_4 144 152
. 22862823_4 153 154

BACKGROUND 25007187_2 0 10
: 25007187_2 11 12
The 25007187_2 13 16
aim 25007187_2 17 20
of 25007187_2 21 23
this 25007187_2 24 28
study 25007187_2 29 34
is 25007187_2 35 37
to 25007187_2 38 40
analyze 25007187_2 41 48
polymorphisms 25007187_2 49 62
in 25007187_2 63 65
genes 25007187_2 66 71
involved 25007187_2 72 80
in 25007187_2 81 83
6 25007187_2 84 85
- 25007187_2 85 86
mercaptopurine 25007187_2 86 100
detoxification 25007187_2 101 115
( 25007187_2 116 117
TPMT 25007187_2 118 122
) 25007187_2 123 124
; 25007187_2 125 126
methotrexate 25007187_2 127 139
( 25007187_2 140 141
MTX 25007187_2 142 145
) 25007187_2 146 147
metabolism 25007187_2 148 158
including 25007187_2 159 168
ABCB 25007187_2 169 173
1 25007187_2 173 174
( 25007187_2 175 176
or 25007187_2 177 179
MDR 25007187_2 180 183
1 25007187_2 183 184
) 25007187_2 185 186
, 25007187_2 187 188
ABCC 25007187_2 189 193
2 25007187_2 193 194
, 25007187_2 195 196
SLC 25007187_2 197 200
19 25007187_2 200 202
A 25007187_2 202 203
1 25007187_2 203 204
( 25007187_2 205 206
or 25007187_2 207 209
RFC 25007187_2 210 213
1 25007187_2 213 214
) 25007187_2 215 216
, 25007187_2 217 218
and 25007187_2 219 222
SLCO 25007187_2 223 227
1 25007187_2 227 228
B 25007187_2 228 229
1 25007187_2 229 230
; 25007187_2 231 232
and 25007187_2 233 236
the 25007187_2 237 240
MTX 25007187_2 241 244
effect 25007187_2 245 251
mainly 25007187_2 252 258
MTHFR 25007187_2 259 264
and 25007187_2 265 268
TYMS 25007187_2 269 273
, 25007187_2 274 275
and 25007187_2 276 279
to 25007187_2 280 282
assess 25007187_2 283 289
whether 25007187_2 290 297
these 25007187_2 298 303
polymorphisms 25007187_2 304 317
are 25007187_2 318 321
predictors 25007187_2 322 332
of 25007187_2 333 335
treatment 25007187_2 336 345
toxicity 25007187_2 346 354
and 25007187_2 355 358
/ 25007187_2 358 359
or 25007187_2 359 361
MTX 25007187_2 362 365
clearance 25007187_2 366 375
. 25007187_2 376 377

We 15610939_3 0 2
compared 15610939_3 3 11
5 15610939_3 12 13
- 15610939_3 13 14
HTT 15610939_3 14 17
uptake 15610939_3 18 24
( 15610939_3 25 26
function 15610939_3 27 35
) 15610939_3 36 37
level 15610939_3 38 43
and 15610939_3 44 47
paroxetine 15610939_3 48 58
binding 15610939_3 59 66
( 15610939_3 67 68
density 15610939_3 69 76
) 15610939_3 77 78
in 15610939_3 79 81
platelets 15610939_3 82 91
of 15610939_3 92 94
alcoholics 15610939_3 95 105
as 15610939_3 106 108
indices 15610939_3 109 116
of 15610939_3 117 119
5 15610939_3 120 121
- 15610939_3 121 122
HTT 15610939_3 122 125
expression 15610939_3 126 136
rate 15610939_3 137 141
among 15610939_3 142 147
LL 15610939_3 148 150
, 15610939_3 151 152
LS 15610939_3 153 155
, 15610939_3 156 157
and 15610939_3 158 161
SS 15610939_3 162 164
genotypes 15610939_3 165 174
. 15610939_3 175 176

Thiopurine 27498738_5 0 10
S 27498738_5 11 12
- 27498738_5 12 13
methyl 27498738_5 13 19
transferase 27498738_5 20 31
( 27498738_5 32 33
TPMT 27498738_5 34 38
) 27498738_5 39 40
is 27498738_5 41 43
a 27498738_5 44 45
useful 27498738_5 46 52
test 27498738_5 53 57
for 27498738_5 58 61
predicting 27498738_5 62 72
6 27498738_5 73 74
- 27498738_5 74 75
mercaptopurine 27498738_5 75 89
( 27498738_5 90 91
6 27498738_5 92 93
- 27498738_5 93 94
MP 27498738_5 94 96
) 27498738_5 97 98
sensitivity 27498738_5 99 110
in 27498738_5 111 113
Caucasians 27498738_5 114 124
. 27498738_5 125 126

RESULTS 18645163_6 0 7
: 18645163_6 8 9
Seven 18645163_6 10 15
patients 18645163_6 16 24
with 18645163_6 25 29
CPT 18645163_6 30 33
II 18645163_6 34 36
deficiency 18645163_6 37 47
were 18645163_6 48 52
studied 18645163_6 53 60
from 18645163_6 61 65
7 18645163_6 66 67
to 18645163_6 68 70
61 18645163_6 71 73
months 18645163_6 74 80
on 18645163_6 81 83
the 18645163_6 84 87
triheptanoin 18645163_6 88 100
( 18645163_6 101 102
anaplerotic 18645163_6 103 114
) 18645163_6 115 116
diet 18645163_6 117 121
. 18645163_6 122 123

The 18628428_8 0 3
increased 18628428_8 4 13
risk 18628428_8 14 18
of 18628428_8 19 21
breast 18628428_8 22 28
cancer 18628428_8 29 35
associated 18628428_8 36 46
with 18628428_8 47 51
E 18628428_8 52 53
+ 18628428_8 53 54
P 18628428_8 54 55
use 18628428_8 56 59
was 18628428_8 60 63
greater 18628428_8 64 71
among 18628428_8 72 77
women 18628428_8 78 83
with 18628428_8 84 88
at 18628428_8 89 91
least 18628428_8 92 97
one 18628428_8 98 101
rare 18628428_8 102 106
allele 18628428_8 107 113
of 18628428_8 114 116
the 18628428_8 117 120
CYP 18628428_8 121 124
1 18628428_8 124 125
A 18628428_8 125 126
1 18628428_8 126 127
Ile 18628428_8 128 131
( 18628428_8 131 132
462 18628428_8 132 135
) 18628428_8 135 136
Val 18628428_8 136 139
, 18628428_8 140 141
CYP 18628428_8 142 145
1 18628428_8 145 146
A 18628428_8 146 147
1 18628428_8 147 148
MspI 18628428_8 149 153
, 18628428_8 154 155
CYP 18628428_8 156 159
1 18628428_8 159 160
B 18628428_8 160 161
1 18628428_8 161 162
Asn 18628428_8 163 166
( 18628428_8 166 167
453 18628428_8 167 170
) 18628428_8 170 171
Ser 18628428_8 171 174
, 18628428_8 175 176
and 18628428_8 177 180
PGR 18628428_8 181 184
Val 18628428_8 185 188
( 18628428_8 188 189
660 18628428_8 189 192
) 18628428_8 192 193
Leu 18628428_8 193 196
polymorphisms 18628428_8 197 210
than 18628428_8 211 215
among 18628428_8 216 221
women 18628428_8 222 227
homozygous 18628428_8 228 238
for 18628428_8 239 242
the 18628428_8 243 246
common 18628428_8 247 253
allele 18628428_8 254 260
of 18628428_8 261 263
these 18628428_8 264 269
polymorphisms 18628428_8 270 283
. 18628428_8 284 285

COMT 21280081_10 0 4
inhibition 21280081_10 5 15
by 21280081_10 16 18
entacapone 21280081_10 19 29
was 21280081_10 30 33
higher 21280081_10 34 40
in 21280081_10 41 43
COMT 21280081_10 44 48
( 21280081_10 49 50
HH 21280081_10 51 53
) 21280081_10 54 55
than 21280081_10 56 60
in 21280081_10 61 63
COMT 21280081_10 64 68
( 21280081_10 69 70
LL 21280081_10 71 73
) 21280081_10 74 75
patients 21280081_10 76 84
( 21280081_10 85 86
- 21280081_10 87 88
0 21280081_10 88 89
. 21280081_10 89 90
54 21280081_10 90 92
0 21280081_10 93 94
. 21280081_10 94 95
07 21280081_10 95 97
vs 21280081_10 98 100
- 21280081_10 101 102
0 21280081_10 102 103
. 21280081_10 103 104
31 21280081_10 104 106
0 21280081_10 107 108
. 21280081_10 108 109
06 21280081_10 109 111
pmol 21280081_10 112 116
/ 21280081_10 116 117
min 21280081_10 117 120
/ 21280081_10 120 121
mg 21280081_10 121 123
protein 21280081_10 124 131
, 21280081_10 132 133
p 21280081_10 134 135
= 21280081_10 136 137
0 21280081_10 138 139
. 21280081_10 139 140
02 21280081_10 140 142
) 21280081_10 143 144
. 21280081_10 145 146

Itraconazole 22348413_9 0 12
and 22348413_9 13 16
other 22348413_9 17 22
potent 22348413_9 23 29
inhibitors 22348413_9 30 40
of 22348413_9 41 43
CYP 22348413_9 44 47
3 22348413_9 47 48
A 22348413_9 48 49
4 22348413_9 49 50
could 22348413_9 51 56
drastically 22348413_9 57 68
increase 22348413_9 69 77
exposure 22348413_9 78 86
to 22348413_9 87 89
drugs 22348413_9 90 95
like 22348413_9 96 100
midazolam 22348413_9 101 110
, 22348413_9 111 112
triazolam 22348413_9 113 122
, 22348413_9 123 124
buspirone 22348413_9 125 134
, 22348413_9 135 136
lovastatin 22348413_9 137 147
, 22348413_9 148 149
simvastatin 22348413_9 150 161
and 22348413_9 162 165
oxycodone 22348413_9 166 175
, 22348413_9 176 177
whereas 22348413_9 178 185
rifampicin 22348413_9 186 196
greatly 22348413_9 197 204
reduced 22348413_9 205 212
their 22348413_9 213 218
plasma 22348413_9 219 225
concentrations 22348413_9 226 240
. 22348413_9 241 242

These 21562147_9 0 5
results 21562147_9 6 13
indicate 21562147_9 14 22
, 21562147_9 23 24
for 21562147_9 25 28
the 21562147_9 29 32
first 21562147_9 33 38
time 21562147_9 39 43
, 21562147_9 44 45
that 21562147_9 46 50
three 21562147_9 51 56
common 21562147_9 57 63
SNPs 21562147_9 64 68
in 21562147_9 69 71
the 21562147_9 72 75
POR 21562147_9 76 79
gene 21562147_9 80 84
may 21562147_9 85 88
contribute 21562147_9 89 99
to 21562147_9 100 102
the 21562147_9 103 106
interindividual 21562147_9 107 122
variability 21562147_9 123 134
in 21562147_9 135 137
warfarin 21562147_9 138 146
maintenance 21562147_9 147 158
dose 21562147_9 159 163
. 21562147_9 164 165

The 16800828_1 0 3
polymorphism 16800828_1 4 16
GABABR 16800828_1 17 23
1 16800828_1 23 24
T 16800828_1 25 26
1974 16800828_1 26 30
C 16800828_1 30 31
[ 16800828_1 32 33
rs 16800828_1 34 36
29230 16800828_1 36 41
] 16800828_1 42 43
of 16800828_1 44 46
the 16800828_1 47 50
GABAB 16800828_1 51 56
receptor 16800828_1 57 65
gene 16800828_1 66 70
is 16800828_1 71 73
not 16800828_1 74 77
associated 16800828_1 78 88
with 16800828_1 89 93
the 16800828_1 94 97
diagnosis 16800828_1 98 107
of 16800828_1 108 110
alcoholism 16800828_1 111 121
or 16800828_1 122 124
alcohol 16800828_1 125 132
withdrawal 16800828_1 133 143
seizures 16800828_1 144 152
. 16800828_1 153 154

For 26940072_9 0 3
VKORC 26940072_9 4 9
1 26940072_9 9 10
, 26940072_9 11 12
the 26940072_9 13 16
daily 26940072_9 17 22
warfarin 26940072_9 23 31
dose 26940072_9 32 36
was 26940072_9 37 40
significantly 26940072_9 41 54
different 26940072_9 55 64
( 26940072_9 65 66
p 26940072_9 67 68
= 26940072_9 69 70
0 26940072_9 71 72
. 26940072_9 72 73
001 26940072_9 73 76
) 26940072_9 77 78
among 26940072_9 79 84
the 26940072_9 85 88
three 26940072_9 89 94
genotypes 26940072_9 95 104
of 26940072_9 105 107
rs 26940072_9 108 110
9923231 26940072_9 110 117
, 26940072_9 118 119
rs 26940072_9 120 122
9934438 26940072_9 122 129
and 26940072_9 130 133
rs 26940072_9 134 136
2884737 26940072_9 136 143
, 26940072_9 144 145
with 26940072_9 146 150
carriers 26940072_9 151 159
of 26940072_9 160 162
the 26940072_9 163 166
wild 26940072_9 167 171
- 26940072_9 171 172
type 26940072_9 172 176
genotype 26940072_9 177 185
requiring 26940072_9 186 195
the 26940072_9 196 199
highest 26940072_9 200 207
dose 26940072_9 208 212
compared 26940072_9 213 221
to 26940072_9 222 224
variant 26940072_9 225 232
allele 26940072_9 233 239
carriers 26940072_9 240 248
( 26940072_9 249 250
p 26940072_9 251 252
< 26940072_9 253 254
= 26940072_9 255 256
0 26940072_9 257 258
. 26940072_9 258 259
001 26940072_9 259 262
- 26940072_9 262 263
0 26940072_9 263 264
. 26940072_9 265 266
002 26940072_9 266 269
) 26940072_9 270 271
. 26940072_9 272 273

Acquired 23569304_9 0 8
resistance 23569304_9 9 19
to 23569304_9 20 22
vemurafenib 23569304_9 23 34
associated 23569304_9 35 45
with 23569304_9 46 50
reactivation 23569304_9 51 63
of 23569304_9 64 66
MAPK 23569304_9 67 71
signaling 23569304_9 72 81
as 23569304_9 82 84
observed 23569304_9 85 93
by 23569304_9 94 96
elevated 23569304_9 97 105
ERK 23569304_9 106 109
1 23569304_9 109 110
/ 23569304_9 110 111
2 23569304_9 111 112
phosphorylation 23569304_9 113 128
levels 23569304_9 129 135
in 23569304_9 136 138
progressive 23569304_9 139 150
lesions 23569304_9 151 158
and 23569304_9 159 162
the 23569304_9 163 166
appearance 23569304_9 167 177
of 23569304_9 178 180
secondary 23569304_9 181 190
NRAS 23569304_9 191 195
( 23569304_9 196 197
Q 23569304_9 198 199
61 23569304_9 199 201
) 23569304_9 202 203
mutations 23569304_9 204 213
or 23569304_9 214 216
MEK 23569304_9 217 220
1 23569304_9 220 221
( 23569304_9 222 223
Q 23569304_9 224 225
56 23569304_9 225 227
P 23569304_9 227 228
) 23569304_9 229 230
or 23569304_9 231 233
MEK 23569304_9 234 237
1 23569304_9 237 238
( 23569304_9 238 239
E 23569304_9 239 240
203 23569304_9 240 243
K 23569304_9 243 244
) 23569304_9 245 246
mutations 23569304_9 247 256
. 23569304_9 257 258

PACAP 10087449_9 0 5
- 10087449_9 6 7
induced 10087449_9 7 14
expression 10087449_9 15 25
of 10087449_9 26 28
the 10087449_9 29 32
c 10087449_9 33 34
- 10087449_9 34 35
fos 10087449_9 35 38
gene 10087449_9 39 43
was 10087449_9 44 47
significantly 10087449_9 48 61
reduced 10087449_9 62 69
by 10087449_9 70 72
pretreatment 10087449_9 73 85
with 10087449_9 86 90
a 10087449_9 91 92
PACAP 10087449_9 93 98
receptor 10087449_9 99 107
antagonist 10087449_9 108 118
, 10087449_9 119 120
PACAP 10087449_9 121 126
- 10087449_9 127 128
( 10087449_9 129 130
6 10087449_9 131 132
- 10087449_9 132 133
38 10087449_9 133 135
) 10087449_9 136 137
- 10087449_9 138 139
NH 10087449_9 140 142
2 10087449_9 142 143
. 10087449_9 144 145

Codeine 24458010_2 0 7
is 24458010_2 8 10
bioactivated 24458010_2 11 23
to 24458010_2 24 26
morphine 24458010_2 27 35
, 24458010_2 36 37
a 24458010_2 38 39
strong 24458010_2 40 46
opioid 24458010_2 47 53
agonist 24458010_2 54 61
, 24458010_2 62 63
by 24458010_2 64 66
the 24458010_2 67 70
hepatic 24458010_2 71 78
cytochrome 24458010_2 79 89
P 24458010_2 90 91
450 24458010_2 91 94
2 24458010_2 95 96
D 24458010_2 96 97
6 24458010_2 97 98
( 24458010_2 99 100
CYP 24458010_2 101 104
2 24458010_2 104 105
D 24458010_2 105 106
6 24458010_2 106 107
) 24458010_2 108 109
; 24458010_2 110 111
hence 24458010_2 112 117
, 24458010_2 118 119
the 24458010_2 120 123
efficacy 24458010_2 124 132
and 24458010_2 133 136
safety 24458010_2 137 143
of 24458010_2 144 146
codeine 24458010_2 147 154
are 24458010_2 155 158
governed 24458010_2 159 167
by 24458010_2 168 170
CYP 24458010_2 171 174
2 24458010_2 174 175
D 24458010_2 175 176
6 24458010_2 176 177
activity 24458010_2 178 186
. 24458010_2 187 188

UNASSIGNED 25687192_2 0 10
: 25687192_2 11 12
Although 25687192_2 13 21
the 25687192_2 22 25
single 25687192_2 26 32
- 25687192_2 32 33
nucleotide 25687192_2 33 43
polymorphism 25687192_2 44 56
( 25687192_2 57 58
SNP 25687192_2 59 62
) 25687192_2 63 64
rs 25687192_2 65 67
12979860 25687192_2 67 75
in 25687192_2 76 78
the 25687192_2 79 82
IL 25687192_2 83 85
28 25687192_2 85 87
B 25687192_2 87 88
gene 25687192_2 89 93
is 25687192_2 94 96
a 25687192_2 97 98
better 25687192_2 99 105
predictor 25687192_2 106 115
of 25687192_2 116 118
sustained 25687192_2 119 128
virological 25687192_2 129 140
response 25687192_2 141 149
to 25687192_2 150 152
treatment 25687192_2 153 162
of 25687192_2 163 165
chronic 25687192_2 166 173
hepatitis 25687192_2 174 183
C 25687192_2 184 185
( 25687192_2 186 187
CHC 25687192_2 188 191
) 25687192_2 192 193
than 25687192_2 194 198
other 25687192_2 199 204
baseline 25687192_2 205 213
factors 25687192_2 214 221
, 25687192_2 222 223
some 25687192_2 224 228
CHC 25687192_2 229 232
patients 25687192_2 233 241
with 25687192_2 242 246
the 25687192_2 247 250
favorable 25687192_2 251 260
C 25687192_2 261 262
allele 25687192_2 263 269
can 25687192_2 270 273
not 25687192_2 274 277
achieve 25687192_2 278 285
a 25687192_2 286 287
sustained 25687192_2 288 297
virological 25687192_2 298 309
response 25687192_2 310 318
when 25687192_2 319 323
treated 25687192_2 324 331
with 25687192_2 332 336
peginterferon 25687192_2 337 350
plus 25687192_2 351 355
ribavirin 25687192_2 356 365
. 25687192_2 366 367

PATIENTS 24733796_3 0 8
AND 24733796_3 9 12
METHODS 24733796_3 13 20
: 24733796_3 21 22
Patients 24733796_3 23 31
with 24733796_3 32 36
HER 24733796_3 37 40
2 24733796_3 40 41
- 24733796_3 42 43
positive 24733796_3 43 51
locally 24733796_3 52 59
advanced 24733796_3 60 68
breast 24733796_3 69 75
cancer 24733796_3 76 82
or 24733796_3 83 85
MBC 24733796_3 86 89
were 24733796_3 90 94
treated 24733796_3 95 102
with 24733796_3 103 107
3 24733796_3 108 109
. 24733796_3 109 110
6 24733796_3 110 111
mg 24733796_3 112 114
/ 24733796_3 114 115
kg 24733796_3 115 117
T 24733796_3 118 119
- 24733796_3 119 120
DM 24733796_3 121 123
1 24733796_3 123 124
plus 24733796_3 125 129
pertuzumab 24733796_3 130 140
( 24733796_3 141 142
840 24733796_3 143 146
- 24733796_3 146 147
mg 24733796_3 147 149
loading 24733796_3 150 157
dose 24733796_3 158 162
, 24733796_3 163 164
then 24733796_3 165 169
420 24733796_3 170 173
mg 24733796_3 174 176
subsequently 24733796_3 177 189
) 24733796_3 190 191
once 24733796_3 192 196
every 24733796_3 197 202
3 24733796_3 203 204
weeks 24733796_3 205 210
. 24733796_3 211 212

INTERVENTIONS 18784465_7 0 13
: 18784465_7 14 15
The 18784465_7 16 19
interventions 18784465_7 20 33
are 18784465_7 34 37
first 18784465_7 38 43
- 18784465_7 43 44
line 18784465_7 44 48
abacavir 18784465_7 49 57
, 18784465_7 58 59
lamivudine 18784465_7 60 70
, 18784465_7 71 72
and 18784465_7 73 76
efavirenz 18784465_7 77 86
without 18784465_7 87 94
pretreatment 18784465_7 95 107
HLA 18784465_7 108 111
- 18784465_7 111 112
B 18784465_7 112 113
* 18784465_7 114 115
5701 18784465_7 116 120
testing 18784465_7 121 128
; 18784465_7 129 130
the 18784465_7 131 134
same 18784465_7 135 139
regimen 18784465_7 140 147
with 18784465_7 148 152
HLA 18784465_7 153 156
- 18784465_7 156 157
B 18784465_7 157 158
* 18784465_7 159 160
5701 18784465_7 161 165
testing 18784465_7 166 173
; 18784465_7 174 175
and 18784465_7 176 179
first 18784465_7 180 185
- 18784465_7 185 186
line 18784465_7 186 190
tenofovir 18784465_7 191 200
, 18784465_7 201 202
emtricitabine 18784465_7 203 216
, 18784465_7 217 218
and 18784465_7 219 222
efavirenz 18784465_7 223 232
. 18784465_7 233 234

It 14631118_5 0 2
was 14631118_5 3 6
found 14631118_5 7 12
that 14631118_5 13 17
the 14631118_5 18 21
EA 14631118_5 22 24
extract 14631118_5 25 32
of 14631118_5 33 35
bitter 14631118_5 36 42
gourd 14631118_5 43 48
( 14631118_5 49 50
Momordica 14631118_5 51 60
charantia 14631118_5 61 70
) 14631118_5 71 72
, 14631118_5 73 74
a 14631118_5 75 76
common 14631118_5 77 83
oriental 14631118_5 84 92
vegetable 14631118_5 93 102
, 14631118_5 103 104
activated 14631118_5 105 114
PPARalpha 14631118_5 115 124
to 14631118_5 125 127
an 14631118_5 128 130
extent 14631118_5 131 137
that 14631118_5 138 142
was 14631118_5 143 146
equivalent 14631118_5 147 157
to 14631118_5 158 160
or 14631118_5 161 163
even 14631118_5 164 168
higher 14631118_5 169 175
than 14631118_5 176 180
10 14631118_5 181 183
microM 14631118_5 184 190
Wy 14631118_5 191 193
- 14631118_5 193 194
14643 14631118_5 194 199
, 14631118_5 200 201
a 14631118_5 202 203
known 14631118_5 204 209
ligand 14631118_5 210 216
of 14631118_5 217 219
PPARalpha 14631118_5 220 229
. 14631118_5 230 231

This 25039301_4 0 4
study 25039301_4 5 10
used 25039301_4 11 15
computer 25039301_4 16 24
- 25039301_4 24 25
assisted 25039301_4 25 33
self 25039301_4 34 38
- 25039301_4 38 39
infusion 25039301_4 39 47
of 25039301_4 48 50
ethanol 25039301_4 51 58
( 25039301_4 59 60
CASE 25039301_4 61 65
) 25039301_4 66 67
to 25039301_4 68 70
examine 25039301_4 71 78
associations 25039301_4 79 91
among 25039301_4 92 97
OPRM 25039301_4 98 102
1 25039301_4 102 103
A 25039301_4 104 105
118 25039301_4 105 108
G 25039301_4 108 109
genotype 25039301_4 110 118
, 25039301_4 119 120
subjective 25039301_4 121 131
responses 25039301_4 132 141
to 25039301_4 142 144
alcohol 25039301_4 145 152
and 25039301_4 153 156
intravenous 25039301_4 157 168
alcohol 25039301_4 169 176
self 25039301_4 177 181
- 25039301_4 181 182
administration 25039301_4 182 196
in 25039301_4 197 199
young 25039301_4 200 205
heavy 25039301_4 206 211
drinkers 25039301_4 212 220
( 25039301_4 221 222
n 25039301_4 223 224
= 25039301_4 225 226
40 25039301_4 227 229
, 25039301_4 230 231
mean 25039301_4 232 236
age 25039301_4 237 240
= 25039301_4 241 242
19 25039301_4 243 245
. 25039301_4 245 246
95 25039301_4 246 248
years 25039301_4 249 254
, 25039301_4 255 256
SD 25039301_4 257 259
= 25039301_4 260 261
0 25039301_4 262 263
. 25039301_4 263 264
82 25039301_4 264 266
) 25039301_4 267 268
. 25039301_4 269 270

BRAF 26045855_1 0 4
( 26045855_1 5 6
V 26045855_1 6 7
600 26045855_1 7 10
) 26045855_1 11 12
mutant 26045855_1 13 19
non 26045855_1 20 23
- 26045855_1 23 24
small 26045855_1 24 29
- 26045855_1 29 30
cell 26045855_1 30 34
lung 26045855_1 35 39
cancer 26045855_1 40 46
resistant 26045855_1 47 56
to 26045855_1 57 59
Vemurafenib 26045855_1 60 71
. 26045855_1 72 73

Triallelic 26352193_12 0 10
5 26352193_12 11 12
- 26352193_12 12 13
HTTLPR 26352193_12 13 19
was 26352193_12 20 23
associated 26352193_12 24 34
with 26352193_12 35 39
social 26352193_12 40 46
anxiety 26352193_12 47 54
, 26352193_12 55 56
anxiety 26352193_12 57 64
, 26352193_12 65 66
and 26352193_12 67 70
depressive 26352193_12 71 81
traits 26352193_12 82 88
in 26352193_12 89 91
alcohol 26352193_12 92 99
- 26352193_12 100 101
dependent 26352193_12 101 110
subjects 26352193_12 111 119
. 26352193_12 120 121

RESULTS 23570465_7 0 7
_ 23570465_7 8 9
CONCLUSION 23570465_7 10 20
: 23570465_7 21 22
In 23570465_7 23 25
patients 23570465_7 26 34
adherent 23570465_7 35 43
to 23570465_7 44 46
tamoxifen 23570465_7 47 56
for 23570465_7 57 60
at 23570465_7 61 63
least 23570465_7 64 69
one 23570465_7 70 73
year 23570465_7 74 78
( 23570465_7 79 80
n 23570465_7 81 82
= 23570465_7 83 84
313 23570465_7 85 88
) 23570465_7 89 90
there 23570465_7 91 96
was 23570465_7 97 100
an 23570465_7 101 103
association 23570465_7 104 115
between 23570465_7 116 123
reduced 23570465_7 124 131
CYP 23570465_7 132 135
2 23570465_7 135 136
D 23570465_7 136 137
6 23570465_7 137 138
activity 23570465_7 139 147
( 23570465_7 148 149
< 23570465_7 150 151
= 23570465_7 152 153
50 23570465_7 154 156
% 23570465_7 157 158
of 23570465_7 159 161
normal 23570465_7 162 168
) 23570465_7 169 170
and 23570465_7 171 174
recurrence 23570465_7 175 185
( 23570465_7 186 187
p 23570465_7 188 189
= 23570465_7 190 191
0 23570465_7 192 193
. 23570465_7 193 194
025 23570465_7 194 197
) 23570465_7 198 199
and 23570465_7 200 203
breast 23570465_7 204 210
cancer 23570465_7 211 217
- 23570465_7 218 219
specific 23570465_7 219 227
mortality 23570465_7 228 237
( 23570465_7 238 239
p 23570465_7 240 241
= 23570465_7 242 243
0 23570465_7 244 245
. 23570465_7 245 246
034 23570465_7 246 249
) 23570465_7 250 251
. 23570465_7 252 253

The 17986837_5 0 3
TPH 17986837_5 4 7
1 17986837_5 7 8
779 17986837_5 9 12
A 17986837_5 12 13
/ 17986837_5 13 14
C 17986837_5 14 15
was 17986837_5 16 19
only 17986837_5 20 24
investigated 17986837_5 25 37
in 17986837_5 38 40
sample 17986837_5 41 47
2 17986837_5 48 49
where 17986837_5 50 55
additional 17986837_5 56 66
data 17986837_5 67 71
with 17986837_5 72 76
respect 17986837_5 77 84
to 17986837_5 85 87
the 17986837_5 88 91
degree 17986837_5 92 98
of 17986837_5 99 101
nicotine 17986837_5 102 110
dependence 17986837_5 111 121
were 17986837_5 122 126
assessed 17986837_5 127 135
. 17986837_5 136 137

GACI 21932012_4 0 4
is 21932012_4 5 7
linked 21932012_4 8 14
to 21932012_4 15 17
mutations 21932012_4 18 27
in 21932012_4 28 30
the 21932012_4 31 34
ENPP 21932012_4 35 39
1 21932012_4 39 40
gene 21932012_4 41 45
, 21932012_4 46 47
which 21932012_4 48 53
encodes 21932012_4 54 61
for 21932012_4 62 65
an 21932012_4 66 68
enzyme 21932012_4 69 75
that 21932012_4 76 80
generates 21932012_4 81 90
inorganic 21932012_4 91 100
pyrophosphate 21932012_4 101 114
( 21932012_4 115 116
PP 21932012_4 117 119
( 21932012_4 119 120
i 21932012_4 120 121
) 21932012_4 121 122
) 21932012_4 123 124
, 21932012_4 125 126
a 21932012_4 127 128
potent 21932012_4 129 135
inhibitor 21932012_4 136 145
of 21932012_4 146 148
hydroxyapatite 21932012_4 149 163
crystal 21932012_4 164 171
formation 21932012_4 172 181
. 21932012_4 182 183

A 11712813_1 0 1
polymorphism 11712813_1 2 14
of 11712813_1 15 17
the 11712813_1 18 21
XRCC 11712813_1 22 26
1 11712813_1 26 27
gene 11712813_1 28 32
predicts 11712813_1 33 41
for 11712813_1 42 45
response 11712813_1 46 54
to 11712813_1 55 57
platinum 11712813_1 58 66
based 11712813_1 67 72
treatment 11712813_1 73 82
in 11712813_1 83 85
advanced 11712813_1 86 94
colorectal 11712813_1 95 105
cancer 11712813_1 106 112
. 11712813_1 113 114

Wogonin 25264278_1 0 7
reverses 25264278_1 8 16
multi 25264278_1 17 22
- 25264278_1 22 23
drug 25264278_1 23 27
resistance 25264278_1 28 38
of 25264278_1 39 41
human 25264278_1 42 47
myelogenous 25264278_1 48 59
leukemia 25264278_1 60 68
K 25264278_1 69 70
562 25264278_1 70 73
/ 25264278_1 73 74
A 25264278_1 74 75
02 25264278_1 75 77
cells 25264278_1 78 83
via 25264278_1 84 87
downregulation 25264278_1 88 102
of 25264278_1 103 105
MRP 25264278_1 106 109
1 25264278_1 109 110
expression 25264278_1 111 121
by 25264278_1 122 124
inhibiting 25264278_1 125 135
Nrf 25264278_1 136 139
2 25264278_1 139 140
/ 25264278_1 141 142
ARE 25264278_1 142 145
signaling 25264278_1 146 155
pathway 25264278_1 156 163
. 25264278_1 164 165

Therefore 26299806_7 0 9
, 26299806_7 10 11
we 26299806_7 12 14
investigated 26299806_7 15 27
the 26299806_7 28 31
effect 26299806_7 32 38
of 26299806_7 39 41
fisetin 26299806_7 42 49
and 26299806_7 50 53
sorafenib 26299806_7 54 63
( 26299806_7 64 65
an 26299806_7 66 68
RAF 26299806_7 69 72
inhibitor 26299806_7 73 82
) 26299806_7 83 84
alone 26299806_7 85 90
and 26299806_7 91 94
in 26299806_7 95 97
combination 26299806_7 98 109
on 26299806_7 110 112
cell 26299806_7 113 117
proliferation 26299806_7 118 131
, 26299806_7 132 133
apoptosis 26299806_7 134 143
and 26299806_7 144 147
tumor 26299806_7 148 153
growth 26299806_7 154 160
. 26299806_7 161 162

Preliminary 19564049_1 0 11
evidence 19564049_1 12 20
on 19564049_1 21 23
the 19564049_1 24 27
association 19564049_1 28 39
between 19564049_1 40 47
XBP 19564049_1 48 51
1 19564049_1 51 52
- 19564049_1 53 54
116 19564049_1 54 57
C 19564049_1 57 58
/ 19564049_1 58 59
G 19564049_1 59 60
polymorphism 19564049_1 61 73
and 19564049_1 74 77
response 19564049_1 78 86
to 19564049_1 87 89
prophylactic 19564049_1 90 102
treatment 19564049_1 103 112
with 19564049_1 113 117
valproate 19564049_1 118 127
in 19564049_1 128 130
bipolar 19564049_1 131 138
disorders 19564049_1 139 148
. 19564049_1 149 150

The 23127338_3 0 3
purpose 23127338_3 4 11
of 23127338_3 12 14
this 23127338_3 15 19
study 23127338_3 20 25
was 23127338_3 26 29
to 23127338_3 30 32
investigate 23127338_3 33 44
possible 23127338_3 45 53
mutations 23127338_3 54 63
in 23127338_3 64 66
promoter 23127338_3 67 75
and 23127338_3 76 79
exon 23127338_3 80 84
regions 23127338_3 85 92
of 23127338_3 93 95
eIF 23127338_3 96 99
3 23127338_3 99 100
a 23127338_3 100 101
gene 23127338_3 102 106
and 23127338_3 107 110
to 23127338_3 111 113
assess 23127338_3 114 120
whether 23127338_3 121 128
eIF 23127338_3 129 132
3 23127338_3 132 133
a 23127338_3 133 134
mutation 23127338_3 135 143
status 23127338_3 144 150
have 23127338_3 151 155
prognostic 23127338_3 156 166
and 23127338_3 167 170
predictive 23127338_3 171 181
significance 23127338_3 182 194
in 23127338_3 195 197
platinum 23127338_3 198 206
- 23127338_3 207 208
based 23127338_3 208 213
chemotherapeutic 23127338_3 214 230
lung 23127338_3 231 235
cancer 23127338_3 236 242
patients 23127338_3 243 251
. 23127338_3 252 253

Transforming 10750555_2 0 12
growth 10750555_2 13 19
factor 10750555_2 20 26
beta 10750555_2 27 31
( 10750555_2 32 33
TGF 10750555_2 34 37
- 10750555_2 37 38
beta 10750555_2 38 42
) 10750555_2 43 44
is 10750555_2 45 47
an 10750555_2 48 50
important 10750555_2 51 60
regulator 10750555_2 61 70
of 10750555_2 71 73
bone 10750555_2 74 78
metabolism 10750555_2 79 89
, 10750555_2 90 91
its 10750555_2 92 95
effects 10750555_2 96 103
being 10750555_2 104 109
intertwined 10750555_2 110 121
with 10750555_2 122 126
those 10750555_2 127 132
of 10750555_2 133 135
estrogen 10750555_2 136 144
and 10750555_2 145 148
vitamin 10750555_2 149 156
D 10750555_2 157 158
. 10750555_2 159 160

injection 15016420_6 0 9
of 15016420_6 10 12
propranolol 15016420_6 13 24
also 15016420_6 25 29
reversed 15016420_6 30 38
the 15016420_6 39 42
cold 15016420_6 43 47
stress 15016420_6 48 54
- 15016420_6 54 55
induced 15016420_6 55 62
suppression 15016420_6 63 74
of 15016420_6 75 77
NK 15016420_6 78 80
cytotoxicity 15016420_6 81 93
, 15016420_6 94 95
but 15016420_6 96 99
without 15016420_6 100 107
significant 15016420_6 108 119
effect 15016420_6 120 126
on 15016420_6 127 129
Fos 15016420_6 130 133
expression 15016420_6 134 144
in 15016420_6 145 147
the 15016420_6 148 151
brain 15016420_6 152 157
. 15016420_6 158 159

On 22077505_8 0 2
the 22077505_8 3 6
other 22077505_8 7 12
hand 22077505_8 13 17
, 22077505_8 18 19
Chinese 22077505_8 20 27
and 22077505_8 28 31
Japanese 22077505_8 32 40
are 22077505_8 41 44
at 22077505_8 45 47
an 22077505_8 48 50
elevated 22077505_8 51 59
risk 22077505_8 60 64
of 22077505_8 65 67
irinotecan 22077505_8 68 78
- 22077505_8 79 80
induced 22077505_8 80 87
neutropenia 22077505_8 88 99
associated 22077505_8 100 110
with 22077505_8 111 115
UGT 22077505_8 116 119
1 22077505_8 119 120
A 22077505_8 120 121
1 22077505_8 121 122
* 22077505_8 123 124
6 22077505_8 125 126
relative 22077505_8 127 135
to 22077505_8 136 138
Indians 22077505_8 139 146
in 22077505_8 147 149
Singapore 22077505_8 150 159
or 22077505_8 160 162
North 22077505_8 163 168
American 22077505_8 169 177
Caucasians 22077505_8 178 188
. 22077505_8 189 190

These 26116794_11 0 5
findings 26116794_11 6 14
support 26116794_11 15 22
the 26116794_11 23 26
involvement 26116794_11 27 38
of 26116794_11 39 41
GABRA 26116794_11 42 47
2 26116794_11 47 48
gene 26116794_11 49 53
in 26116794_11 54 56
alcohol 26116794_11 57 64
dependence 26116794_11 65 75
- 26116794_11 76 77
related 26116794_11 77 84
aggressive 26116794_11 85 95
behavior 26116794_11 96 104
. 26116794_11 105 106

Conditional 21995462_17 0 11
haplotype 21995462_17 12 21
analyses 21995462_17 22 30
revealed 21995462_17 31 39
that 21995462_17 40 44
the 21995462_17 45 48
haplotypic 21995462_17 49 59
constructs 21995462_17 60 70
comprising 21995462_17 71 81
the 21995462_17 82 85
IVS 21995462_17 86 89
4 21995462_17 89 90
+ 21995462_17 90 91
76 21995462_17 91 93
G 21995462_17 93 94
> 21995462_17 94 95
A 21995462_17 95 96
, 21995462_17 97 98
699 21995462_17 99 102
G 21995462_17 102 103
> 21995462_17 103 104
A 21995462_17 104 105
( 21995462_17 106 107
Met 21995462_17 108 111
233 21995462_17 111 114
Ile 21995462_17 114 117
) 21995462_17 118 119
, 21995462_17 120 121
IVS 21995462_17 122 125
12 21995462_17 125 127
- 21995462_17 127 128
5676 21995462_17 128 132
A 21995462_17 132 133
> 21995462_17 133 134
G 21995462_17 134 135
, 21995462_17 136 137
and 21995462_17 138 141
* 21995462_17 142 143
347 21995462_17 143 146
_ 21995462_17 146 147
* 21995462_17 147 148
348 21995462_17 148 151
insA 21995462_17 151 155
polymorphisms 21995462_17 156 169
were 21995462_17 170 174
critical 21995462_17 175 183
determinants 21995462_17 184 196
of 21995462_17 197 199
variability 21995462_17 200 211
in 21995462_17 212 214
docetaxel 21995462_17 215 224
disposition 21995462_17 225 236
[ 21995462_17 237 238
clearance 21995462_17 239 248
and 21995462_17 249 252
area 21995462_17 253 257
under 21995462_17 258 263
the 21995462_17 264 267
plasma 21995462_17 268 274
concentration 21995462_17 275 288
- 21995462_17 288 289
time 21995462_17 289 293
curve 21995462_17 294 299
( 21995462_17 300 301
AUC 21995462_17 302 305
( 21995462_17 306 307
0 21995462_17 308 309
, 21995462_17 310 311
) 21995462_17 312 313
) 21995462_17 314 315
: 21995462_17 316 317
r 21995462_17 318 319
( 21995462_17 320 321
2 21995462_17 322 323
) 21995462_17 324 325
= 21995462_17 326 327
29 21995462_17 328 330
% 21995462_17 331 332
and 21995462_17 333 336
22 21995462_17 337 339
% 21995462_17 340 341
, 21995462_17 342 343
respectively 21995462_17 344 356
] 21995462_17 357 358
. 21995462_17 359 360

CONCLUSIONS 16144943_13 0 11
: 16144943_13 12 13
These 16144943_13 14 19
preclinical 16144943_13 20 31
findings 16144943_13 32 40
support 16144943_13 41 48
the 16144943_13 49 52
development 16144943_13 53 64
of 16144943_13 65 67
SAHA 16144943_13 68 72
in 16144943_13 73 75
combination 16144943_13 76 87
with 16144943_13 88 92
docetaxel 16144943_13 93 102
and 16144943_13 103 106
/ 16144943_13 106 107
or 16144943_13 107 109
trastuzumab 16144943_13 110 121
against 16144943_13 122 129
Her 16144943_13 130 133
- 16144943_13 133 134
2 16144943_13 134 135
- 16144943_13 136 137
amplified 16144943_13 137 146
breast 16144943_13 147 153
cancer 16144943_13 154 160
. 16144943_13 161 162

Pooled 20973798_3 0 6
data 20973798_3 7 11
from 20973798_3 12 16
several 20973798_3 17 24
phase 20973798_3 25 30
II 20973798_3 31 33
studies 20973798_3 34 41
show 20973798_3 42 46
that 20973798_3 47 51
gefitinib 20973798_3 52 61
and 20973798_3 62 65
erlotinib 20973798_3 66 75
induce 20973798_3 76 82
responses 20973798_3 83 92
in 20973798_3 93 95
over 20973798_3 96 100
70 20973798_3 101 103
% 20973798_3 104 105
of 20973798_3 106 108
NSCLC 20973798_3 109 114
patients 20973798_3 115 123
harboring 20973798_3 124 133
EGFR 20973798_3 134 138
mutations 20973798_3 139 148
, 20973798_3 149 150
with 20973798_3 151 155
progression 20973798_3 156 167
- 20973798_3 167 168
free 20973798_3 168 172
survival 20973798_3 173 181
( 20973798_3 182 183
PFS 20973798_3 184 187
) 20973798_3 188 189
ranging 20973798_3 190 197
from 20973798_3 198 202
9 20973798_3 203 204
to 20973798_3 205 207
13 20973798_3 208 210
months 20973798_3 211 217
. 20973798_3 218 219

Available 15983922_3 0 9
data 15983922_3 10 14
suggest 15983922_3 15 22
that 15983922_3 23 27
lamivudine 15983922_3 28 38
contributes 15983922_3 39 50
to 15983922_3 51 53
partial 15983922_3 54 61
viral 15983922_3 62 67
suppression 15983922_3 68 79
, 15983922_3 80 81
despite 15983922_3 82 89
the 15983922_3 90 93
presence 15983922_3 94 102
of 15983922_3 103 105
M 15983922_3 106 107
184 15983922_3 107 110
V 15983922_3 110 111
mutations 15983922_3 112 121
and 15983922_3 122 125
high 15983922_3 126 130
- 15983922_3 130 131
level 15983922_3 131 136
phenotypic 15983922_3 137 147
lamivudine 15983922_3 148 158
resistance 15983922_3 159 169
. 15983922_3 170 171

CYP 15094935_9 0 3
2 15094935_9 3 4
C 15094935_9 4 5
9 15094935_9 5 6
genotyping 15094935_9 7 17
in 15094935_9 18 20
these 15094935_9 21 26
patients 15094935_9 27 35
provided 15094935_9 36 44
a 15094935_9 45 46
likely 15094935_9 47 53
explanation 15094935_9 54 65
for 15094935_9 66 69
their 15094935_9 70 75
continued 15094935_9 76 85
low 15094935_9 86 89
warfarin 15094935_9 90 98
dosage 15094935_9 99 105
requirements 15094935_9 106 118
. 15094935_9 119 120

We 16929515_2 0 2
evaluated 16929515_2 3 12
DNA 16929515_2 13 16
polymorphisms 16929515_2 17 30
in 16929515_2 31 33
the 16929515_2 34 37
thymidylate 16929515_2 38 49
synthase 16929515_2 50 58
( 16929515_2 59 60
TS 16929515_2 61 63
) 16929515_2 64 65
and 16929515_2 66 69
5 16929515_2 70 71
, 16929515_2 71 72
10 16929515_2 72 74
- 16929515_2 74 75
methylene 16929515_2 75 84
- 16929515_2 84 85
tetrahydrofolate 16929515_2 85 101
reductase 16929515_2 102 111
( 16929515_2 112 113
MTHFR 16929515_2 114 119
) 16929515_2 120 121
genes 16929515_2 122 127
for 16929515_2 128 131
an 16929515_2 132 134
association 16929515_2 135 146
with 16929515_2 147 151
response 16929515_2 152 160
and 16929515_2 161 164
survival 16929515_2 165 173
in 16929515_2 174 176
locally 16929515_2 177 184
advanced 16929515_2 185 193
gastric 16929515_2 194 201
cancer 16929515_2 202 208
treated 16929515_2 209 216
with 16929515_2 217 221
5 16929515_2 222 223
- 16929515_2 223 224
FU 16929515_2 224 226
based 16929515_2 227 232
preoperative 16929515_2 233 245
chemotherapy 16929515_2 246 258
( 16929515_2 259 260
CTx 16929515_2 261 264
) 16929515_2 265 266
. 16929515_2 267 268

The 19712599_4 0 3
purpose 19712599_4 4 11
of 19712599_4 12 14
this 19712599_4 15 19
study 19712599_4 20 25
is 19712599_4 26 28
to 19712599_4 29 31
identify 19712599_4 32 40
the 19712599_4 41 44
cases 19712599_4 45 50
where 19712599_4 51 56
a 19712599_4 57 58
probable 19712599_4 59 67
hypersensitivity 19712599_4 68 84
reaction 19712599_4 85 93
to 19712599_4 94 96
abacavir 19712599_4 97 105
presented 19712599_4 106 115
the 19712599_4 116 119
HLA 19712599_4 120 123
- 19712599_4 123 124
B 19712599_4 124 125
* 19712599_4 126 127
5701 19712599_4 128 132
allele 19712599_4 133 139
. 19712599_4 140 141

In 20303013_3 0 2
this 20303013_3 3 7
study 20303013_3 8 13
, 20303013_3 14 15
we 20303013_3 16 18
investigated 20303013_3 19 31
the 20303013_3 32 35
influence 20303013_3 36 45
of 20303013_3 46 48
the 20303013_3 49 52
genetic 20303013_3 53 60
polymorphisms 20303013_3 61 74
GSTM 20303013_3 75 79
1 20303013_3 79 80
, 20303013_3 81 82
GSTT 20303013_3 83 87
1 20303013_3 87 88
, 20303013_3 89 90
and 20303013_3 91 94
GSTP 20303013_3 95 99
1 20303013_3 99 100
on 20303013_3 101 103
treatment 20303013_3 104 113
response 20303013_3 114 122
in 20303013_3 123 125
94 20303013_3 126 128
Korean 20303013_3 129 135
patients 20303013_3 136 144
with 20303013_3 145 149
de 20303013_3 150 152
novo 20303013_3 153 157
diffuse 20303013_3 158 165
large 20303013_3 166 171
B 20303013_3 172 173
- 20303013_3 173 174
cell 20303013_3 174 178
lymphoma 20303013_3 179 187
, 20303013_3 188 189
who 20303013_3 190 193
had 20303013_3 194 197
received 20303013_3 198 206
rituximab 20303013_3 207 216
plus 20303013_3 217 221
cyclophosphamide 20303013_3 222 238
/ 20303013_3 239 240
doxorubicin 20303013_3 241 252
/ 20303013_3 253 254
vincristine 20303013_3 255 266
/ 20303013_3 267 268
prednisone 20303013_3 269 279
( 20303013_3 280 281
R 20303013_3 282 283
- 20303013_3 283 284
CHOP 20303013_3 285 289
) 20303013_3 290 291
as 20303013_3 292 294
a 20303013_3 295 296
front 20303013_3 297 302
- 20303013_3 302 303
line 20303013_3 303 307
regimen 20303013_3 308 315
. 20303013_3 316 317

Diagnostic 24956250_1 0 10
accuracy 24956250_1 11 19
of 24956250_1 20 22
HLA 24956250_1 23 26
- 24956250_1 26 27
B 24956250_1 27 28
* 24956250_1 29 30
57 24956250_1 31 33
: 24956250_1 33 34
01 24956250_1 34 36
screening 24956250_1 37 46
for 24956250_1 47 50
the 24956250_1 51 54
prediction 24956250_1 55 65
of 24956250_1 66 68
abacavir 24956250_1 69 77
hypersensitivity 24956250_1 78 94
and 24956250_1 95 98
clinical 24956250_1 99 107
utility 24956250_1 108 115
of 24956250_1 116 118
the 24956250_1 119 122
test 24956250_1 123 127
: 24956250_1 128 129
a 24956250_1 130 131
meta 24956250_1 132 136
- 24956250_1 136 137
analytic 24956250_1 137 145
review 24956250_1 146 152
. 24956250_1 153 154

The 20121554_4 0 3
authors 20121554_4 4 11
describe 20121554_4 12 20
the 20121554_4 21 24
case 20121554_4 25 29
of 20121554_4 30 32
a 20121554_4 33 34
12 20121554_4 35 37
- 20121554_4 37 38
year 20121554_4 38 42
- 20121554_4 42 43
old 20121554_4 43 46
male 20121554_4 47 51
with 20121554_4 52 56
acute 20121554_4 57 62
lymphoblastic 20121554_4 63 76
leukemia 20121554_4 77 85
and 20121554_4 86 89
a 20121554_4 90 91
homozygous 20121554_4 92 102
methylenetetrahydrofolate 20121554_4 103 128
reductase 20121554_4 129 138
C 20121554_4 139 140
677 20121554_4 140 143
T 20121554_4 143 144
mutation 20121554_4 145 153
, 20121554_4 154 155
who 20121554_4 156 159
developed 20121554_4 160 169
subacute 20121554_4 170 178
methotrexate 20121554_4 179 191
- 20121554_4 192 193
induced 20121554_4 193 200
toxicity 20121554_4 201 209
and 20121554_4 210 213
cerebral 20121554_4 214 222
venous 20121554_4 223 229
thrombosis 20121554_4 230 240
after 20121554_4 241 246
receiving 20121554_4 247 256
intrathecal 20121554_4 257 268
methotrexate 20121554_4 269 281
. 20121554_4 282 283

Specifically 12777962_9 0 12
, 12777962_9 13 14
Canadian 12777962_9 15 23
Native 12777962_9 24 30
Indians 12777962_9 31 38
dependent 12777962_9 39 48
on 12777962_9 49 51
nicotine 12777962_9 52 60
alone 12777962_9 61 66
or 12777962_9 67 69
alcohol 12777962_9 70 77
alone 12777962_9 78 83
exhibited 12777962_9 84 93
significantly 12777962_9 94 107
greater 12777962_9 108 115
CYP 12777962_9 116 119
2 12777962_9 119 120
E 12777962_9 120 121
1 12777962_9 121 122
* 12777962_9 123 124
1 12777962_9 125 126
D 12777962_9 126 127
frequencies 12777962_9 128 139
compared 12777962_9 140 148
to 12777962_9 149 151
non 12777962_9 152 155
- 12777962_9 155 156
drug 12777962_9 156 160
dependent 12777962_9 161 170
controls 12777962_9 171 179
, 12777962_9 180 181
while 12777962_9 182 187
the 12777962_9 188 191
variant 12777962_9 192 199
frequency 12777962_9 200 209
among 12777962_9 210 215
Southeast 12777962_9 216 225
Asians 12777962_9 226 232
dependent 12777962_9 233 242
on 12777962_9 243 245
nicotine 12777962_9 246 254
was 12777962_9 255 258
greater 12777962_9 259 266
than 12777962_9 267 271
their 12777962_9 272 277
non 12777962_9 278 281
- 12777962_9 281 282
drug 12777962_9 282 286
dependent 12777962_9 287 296
counterparts 12777962_9 297 309
. 12777962_9 310 311

A 23982262_11 0 1
trend 23982262_11 2 7
toward 23982262_11 8 14
higher 23982262_11 15 21
nevirapine 23982262_11 22 32
AUC 23982262_11 33 36
( 23982262_11 37 38
0 23982262_11 39 40
- 23982262_11 40 41
6 23982262_11 41 42
h 23982262_11 43 44
) 23982262_11 45 46
for 23982262_11 47 50
the 23982262_11 51 54
CYP 23982262_11 55 58
2 23982262_11 58 59
B 23982262_11 59 60
6 23982262_11 60 61
516 23982262_11 62 65
TT 23982262_11 65 67
( 23982262_11 68 69
rs 23982262_11 70 72
3745274 23982262_11 72 79
; 23982262_11 80 81
Q 23982262_11 82 83
172 23982262_11 83 86
H 23982262_11 86 87
) 23982262_11 88 89
genotype 23982262_11 90 98
was 23982262_11 99 102
observed 23982262_11 103 111
in 23982262_11 112 114
European 23982262_11 115 123
Americans 23982262_11 124 133
( 23982262_11 134 135
P 23982262_11 136 137
= 23982262_11 138 139
0 23982262_11 140 141
. 23982262_11 141 142
19 23982262_11 142 144
) 23982262_11 145 146
. 23982262_11 147 148

Small 24921970_1 0 5
- 24921970_1 5 6
molecule 24921970_1 6 14
EGFR 24921970_1 15 19
tyrosine 24921970_1 20 28
kinase 24921970_1 29 35
inhibitors 24921970_1 36 46
for 24921970_1 47 50
the 24921970_1 51 54
treatment 24921970_1 55 64
of 24921970_1 65 67
cancer 24921970_1 68 74
. 24921970_1 75 76

Finally 10677041_7 0 7
, 10677041_7 8 9
DOR 10677041_7 10 13
- 10677041_7 13 14
1 10677041_7 14 15
mutant 10677041_7 16 22
mice 10677041_7 23 27
do 10677041_7 28 30
not 10677041_7 31 34
develop 10677041_7 35 42
analgesic 10677041_7 43 52
tolerance 10677041_7 53 62
to 10677041_7 63 65
morphine 10677041_7 66 74
, 10677041_7 75 76
genetically 10677041_7 77 88
demonstrating 10677041_7 89 102
a 10677041_7 103 104
central 10677041_7 105 112
role 10677041_7 113 117
for 10677041_7 118 121
DOR 10677041_7 122 125
- 10677041_7 125 126
1 10677041_7 126 127
in 10677041_7 128 130
this 10677041_7 131 135
process 10677041_7 136 143
. 10677041_7 144 145

CYP 12777962_1 0 3
2 12777962_1 3 4
E 12777962_1 4 5
1 12777962_1 5 6
* 12777962_1 7 8
1 12777962_1 9 10
D 12777962_1 10 11
regulatory 12777962_1 12 22
polymorphism 12777962_1 23 35
: 12777962_1 36 37
association 12777962_1 38 49
with 12777962_1 50 54
alcohol 12777962_1 55 62
and 12777962_1 63 66
nicotine 12777962_1 67 75
dependence 12777962_1 76 86
. 12777962_1 87 88

Within 11888582_12 0 6
the 11888582_12 7 10
entire 11888582_12 11 17
abacavir 11888582_12 18 26
- 11888582_12 27 28
exposed 11888582_12 28 35
cohort 11888582_12 36 42
( 11888582_12 43 44
n 11888582_12 45 46
= 11888582_12 47 48
200 11888582_12 49 52
) 11888582_12 53 54
, 11888582_12 55 56
presence 11888582_12 57 65
of 11888582_12 66 68
HLA 11888582_12 69 72
- 11888582_12 72 73
B 11888582_12 73 74
* 11888582_12 75 76
5701 11888582_12 77 81
, 11888582_12 82 83
HLA 11888582_12 84 87
- 11888582_12 87 88
DR 11888582_12 88 90
7 11888582_12 91 92
, 11888582_12 93 94
and 11888582_12 95 98
HLA 11888582_12 99 102
- 11888582_12 102 103
DQ 11888582_12 103 105
3 11888582_12 106 107
had 11888582_12 108 111
a 11888582_12 112 113
positive 11888582_12 114 122
predictive 11888582_12 123 133
value 11888582_12 134 139
for 11888582_12 140 143
hypersensitivity 11888582_12 144 160
of 11888582_12 161 163
100 11888582_12 164 167
% 11888582_12 168 169
, 11888582_12 170 171
and 11888582_12 172 175
a 11888582_12 176 177
negative 11888582_12 178 186
predictive 11888582_12 187 197
value 11888582_12 198 203
of 11888582_12 204 206
97 11888582_12 207 209
% 11888582_12 210 211
. 11888582_12 212 213

However 23666583_9 0 7
, 23666583_9 8 9
intraindividual 23666583_9 10 25
variability 23666583_9 26 37
of 23666583_9 38 40
tacrolimus 23666583_9 41 51
clearance 23666583_9 52 61
was 23666583_9 62 65
not 23666583_9 66 69
related 23666583_9 70 77
to 23666583_9 78 80
CYP 23666583_9 81 84
3 23666583_9 84 85
A 23666583_9 85 86
5 23666583_9 86 87
genotype 23666583_9 88 96
( 23666583_9 97 98
P 23666583_9 99 100
= 23666583_9 101 102
0 23666583_9 103 104
. 23666583_9 104 105
3331 23666583_9 105 109
) 23666583_9 110 111
. 23666583_9 112 113

We 22942289_9 0 2
studied 22942289_9 3 10
the 22942289_9 11 14
consequences 22942289_9 15 27
of 22942289_9 28 30
VX 22942289_9 31 33
- 22942289_9 33 34
770 22942289_9 34 37
interaction 22942289_9 38 49
with 22942289_9 50 54
CFTR 22942289_9 55 59
incorporated 22942289_9 60 72
in 22942289_9 73 75
planar 22942289_9 76 82
lipid 22942289_9 83 88
bilayers 22942289_9 89 97
and 22942289_9 98 101
in 22942289_9 102 104
proteoliposomes 22942289_9 105 120
, 22942289_9 121 122
using 22942289_9 123 128
a 22942289_9 129 130
novel 22942289_9 131 136
flux 22942289_9 137 141
- 22942289_9 141 142
based 22942289_9 142 147
assay 22942289_9 148 153
. 22942289_9 154 155

DNA 20191296_1 0 3
methylation 20191296_1 4 15
of 20191296_1 16 18
the 20191296_1 19 22
POMC 20191296_1 23 27
gene 20191296_1 28 32
promoter 20191296_1 33 41
is 20191296_1 42 44
associated 20191296_1 45 55
with 20191296_1 56 60
craving 20191296_1 61 68
in 20191296_1 69 71
alcohol 20191296_1 72 79
dependence 20191296_1 80 90
. 20191296_1 91 92

CONCLUSIONS 21817190_8 0 11
: 21817190_8 12 13
The 21817190_8 14 17
variants 21817190_8 18 26
of 21817190_8 27 29
the 21817190_8 30 33
ITPA 21817190_8 34 38
gene 21817190_8 39 43
, 21817190_8 44 45
which 21817190_8 46 51
could 21817190_8 52 57
protect 21817190_8 58 65
against 21817190_8 66 73
haemolytic 21817190_8 74 84
anaemia 21817190_8 85 92
and 21817190_8 93 96
RBV 21817190_8 97 100
dose 21817190_8 101 105
reduction 21817190_8 106 115
, 21817190_8 116 117
were 21817190_8 118 122
associated 21817190_8 123 133
with 21817190_8 134 138
a 21817190_8 139 140
high 21817190_8 141 145
rate 21817190_8 146 150
of 21817190_8 151 153
SVR 21817190_8 154 157
by 21817190_8 158 160
standard 21817190_8 161 169
PEG 21817190_8 170 173
- 21817190_8 173 174
IFN 21817190_8 174 177
and 21817190_8 178 181
RBV 21817190_8 182 185
therapy 21817190_8 186 193
in 21817190_8 194 196
a 21817190_8 197 198
subset 21817190_8 199 205
of 21817190_8 206 208
Japanese 21817190_8 209 217
patients 21817190_8 218 226
with 21817190_8 227 231
the 21817190_8 232 235
favourable 21817190_8 236 246
TT 21817190_8 247 249
genotype 21817190_8 250 258
at 21817190_8 259 261
rs 21817190_8 262 264
8099917 21817190_8 264 271
of 21817190_8 272 274
IL 21817190_8 275 277
28 21817190_8 277 279
B 21817190_8 279 280
. 21817190_8 281 282

While 18675355_8 0 5
anti 18675355_8 6 10
- 18675355_8 10 11
CD 18675355_8 12 14
40 18675355_8 14 16
L 18675355_8 16 17
did 18675355_8 18 21
not 18675355_8 22 25
impair 18675355_8 26 32
T 18675355_8 33 34
cell 18675355_8 35 39
proliferation 18675355_8 40 53
, 18675355_8 54 55
anti 18675355_8 56 60
- 18675355_8 60 61
LFA 18675355_8 62 65
- 18675355_8 65 66
1 18675355_8 66 67
reduced 18675355_8 68 75
both 18675355_8 76 80
CD 18675355_8 81 83
4 18675355_8 83 84
and 18675355_8 85 88
CD 18675355_8 89 91
8 18675355_8 91 92
T 18675355_8 93 94
cell 18675355_8 95 99
proliferation 18675355_8 100 113
, 18675355_8 114 115
and 18675355_8 116 119
combining 18675355_8 120 129
anti 18675355_8 130 134
- 18675355_8 134 135
LFA 18675355_8 136 139
- 18675355_8 139 140
1 18675355_8 140 141
with 18675355_8 142 146
everolimus 18675355_8 147 157
or 18675355_8 158 160
DSG 18675355_8 161 164
had 18675355_8 165 168
an 18675355_8 169 171
additive 18675355_8 172 180
inhibitory 18675355_8 181 191
effect 18675355_8 192 198
on 18675355_8 199 201
CD 18675355_8 202 204
4 18675355_8 204 205
T 18675355_8 206 207
cell 18675355_8 208 212
proliferation 18675355_8 213 226
. 18675355_8 227 228

HER 21676217_3 0 3
2 21676217_3 3 4
- 21676217_3 5 6
related 21676217_3 6 13
target 21676217_3 14 20
drugs 21676217_3 21 26
trastuzumab 21676217_3 27 38
and 21676217_3 39 42
lapatinib 21676217_3 43 52
have 21676217_3 53 57
been 21676217_3 58 62
the 21676217_3 63 66
foundation 21676217_3 67 77
of 21676217_3 78 80
treatment 21676217_3 81 90
of 21676217_3 91 93
HER 21676217_3 94 97
2 21676217_3 97 98
- 21676217_3 99 100
- 21676217_3 100 101
positive 21676217_3 102 110
breast 21676217_3 111 117
cancer 21676217_3 118 124
. 21676217_3 125 126

CONCLUSIONS 18382665_13 0 11
/ 18382665_13 11 12
SIGNIFICANCE 18382665_13 12 24
: 18382665_13 25 26
The 18382665_13 27 30
selection 18382665_13 31 40
distribution 18382665_13 41 53
is 18382665_13 54 56
more 18382665_13 57 61
significantly 18382665_13 62 75
correlated 18382665_13 76 86
with 18382665_13 87 91
the 18382665_13 92 95
frequency 18382665_13 96 105
of 18382665_13 106 108
the 18382665_13 109 112
derived 18382665_13 113 120
ADH 18382665_13 121 124
1 18382665_13 124 125
B 18382665_13 125 126
regulatory 18382665_13 127 137
region 18382665_13 138 144
polymorphism 18382665_13 145 157
than 18382665_13 158 162
the 18382665_13 163 166
derived 18382665_13 167 174
amino 18382665_13 175 180
- 18382665_13 180 181
acid 18382665_13 181 185
altering 18382665_13 186 194
allele 18382665_13 195 201
ADH 18382665_13 202 205
1 18382665_13 205 206
B 18382665_13 206 207
* 18382665_13 208 209
47 18382665_13 210 212
His 18382665_13 212 215
. 18382665_13 216 217

OBJECTIVE 24325099_2 0 9
: 24325099_2 10 11
To 24325099_2 12 14
investigate 24325099_2 15 26
the 24325099_2 27 30
role 24325099_2 31 35
of 24325099_2 36 38
the 24325099_2 39 42
- 24325099_2 43 44
250 24325099_2 45 48
G 24325099_2 48 49
/ 24325099_2 49 50
A 24325099_2 50 51
polymorphism 24325099_2 52 64
in 24325099_2 65 67
the 24325099_2 68 71
promoter 24325099_2 72 80
region 24325099_2 81 87
of 24325099_2 88 90
hepatic 24325099_2 91 98
lipase 24325099_2 99 105
gene 24325099_2 106 110
( 24325099_2 111 112
LIPC 24325099_2 113 117
) 24325099_2 118 119
on 24325099_2 120 122
serum 24325099_2 123 128
lipid 24325099_2 129 134
profile 24325099_2 135 142
and 24325099_2 143 146
its 24325099_2 147 150
interactions 24325099_2 151 163
with 24325099_2 164 168
a 24325099_2 169 170
high 24325099_2 171 175
- 24325099_2 175 176
carbohydrate 24325099_2 177 189
/ 24325099_2 190 191
low 24325099_2 191 194
- 24325099_2 194 195
fat 24325099_2 195 198
( 24325099_2 199 200
HC 24325099_2 201 203
/ 24325099_2 203 204
LF 24325099_2 204 206
) 24325099_2 207 208
diet 24325099_2 209 213
on 24325099_2 214 216
serum 24325099_2 217 222
lipid 24325099_2 223 228
profiles 24325099_2 229 237
in 24325099_2 238 240
a 24325099_2 241 242
young 24325099_2 243 248
healthy 24325099_2 249 256
Chinese 24325099_2 257 264
population 24325099_2 265 275
. 24325099_2 276 277

CONCLUSION 21052032_12 0 10
: 21052032_12 11 12
The 21052032_12 13 16
MC 21052032_12 17 19
1 21052032_12 19 20
R 21052032_12 20 21
gene 21052032_12 22 26
might 21052032_12 27 32
be 21052032_12 33 35
associated 21052032_12 36 46
with 21052032_12 47 51
major 21052032_12 52 57
depressive 21052032_12 58 68
disorder 21052032_12 69 77
and 21052032_12 78 81
with 21052032_12 82 86
treatment 21052032_12 87 96
response 21052032_12 97 105
to 21052032_12 106 108
desipramine 21052032_12 109 120
. 21052032_12 121 122

In 22394056_8 0 2
contrast 22394056_8 3 11
to 22394056_8 12 14
the 22394056_8 15 18
deficit 22394056_8 19 26
in 22394056_8 27 29
fear 22394056_8 30 34
extinction 22394056_8 35 45
previously 22394056_8 46 56
demonstrated 22394056_8 57 69
in 22394056_8 70 72
these 22394056_8 73 78
mice 22394056_8 79 83
, 22394056_8 84 85
we 22394056_8 86 88
found 22394056_8 89 94
that 22394056_8 95 99
BDNF 22394056_8 100 104
( 22394056_8 105 106
Val 22394056_8 107 110
/ 22394056_8 111 112
Met 22394056_8 112 115
) 22394056_8 116 117
mice 22394056_8 118 122
exhibited 22394056_8 123 132
more 22394056_8 133 137
rapid 22394056_8 138 143
extinction 22394056_8 144 154
of 22394056_8 155 157
cocaine 22394056_8 158 165
responding 22394056_8 166 176
compared 22394056_8 177 185
to 22394056_8 186 188
wildtype 22394056_8 189 197
mice 22394056_8 198 202
. 22394056_8 203 204

Newly 17952745_4 0 5
launched 17952745_4 6 14
and 17952745_4 15 18
planned 17952745_4 19 26
phase 17952745_4 27 32
III 17952745_4 33 36
trials 17952745_4 37 43
will 17952745_4 44 48
explore 17952745_4 49 56
whether 17952745_4 57 64
the 17952745_4 65 68
addition 17952745_4 69 77
of 17952745_4 78 80
temozolomide 17952745_4 81 93
to 17952745_4 94 96
radiotherapy 17952745_4 97 109
improves 17952745_4 110 118
overall 17952745_4 119 126
survival 17952745_4 127 135
in 17952745_4 136 138
grade 17952745_4 139 144
II 17952745_4 145 147
/ 17952745_4 147 148
III 17952745_4 148 151
as 17952745_4 152 154
well 17952745_4 155 159
as 17952745_4 160 162
the 17952745_4 163 166
prognostic 17952745_4 167 177
and 17952745_4 178 181
predictive 17952745_4 182 192
value 17952745_4 193 198
of 17952745_4 199 201
1 17952745_4 202 203
p 17952745_4 203 204
/ 17952745_4 204 205
19 17952745_4 205 207
q 17952745_4 207 208
analyses 17952745_4 209 217
and 17952745_4 218 221
MGMT 17952745_4 222 226
promotor 17952745_4 227 235
methylation 17952745_4 236 247
status 17952745_4 248 254
. 17952745_4 255 256

RRM 20226083_1 0 3
1 20226083_1 3 4
single 20226083_1 5 11
nucleotide 20226083_1 12 22
polymorphism 20226083_1 23 35
- 20226083_1 36 37
37 20226083_1 37 39
C 20226083_1 39 40
- 20226083_1 40 41
- 20226083_1 41 42
> 20226083_1 42 43
A 20226083_1 43 44
correlates 20226083_1 45 55
with 20226083_1 56 60
progression 20226083_1 61 72
- 20226083_1 72 73
free 20226083_1 73 77
survival 20226083_1 78 86
in 20226083_1 87 89
NSCLC 20226083_1 90 95
patients 20226083_1 96 104
after 20226083_1 105 110
gemcitabine 20226083_1 111 122
- 20226083_1 123 124
based 20226083_1 124 129
chemotherapy 20226083_1 130 142
. 20226083_1 143 144

These 8099817_5 0 5
results 8099817_5 6 13
indicate 8099817_5 14 22
that 8099817_5 23 27
the 8099817_5 28 31
expression 8099817_5 32 42
of 8099817_5 43 45
preprodynorphin 8099817_5 46 61
, 8099817_5 62 63
but 8099817_5 64 67
not 8099817_5 68 71
c 8099817_5 72 73
- 8099817_5 73 74
fos 8099817_5 74 77
, 8099817_5 78 79
is 8099817_5 80 82
upregulated 8099817_5 83 94
in 8099817_5 95 97
rat 8099817_5 98 101
striatum 8099817_5 102 110
as 8099817_5 111 113
a 8099817_5 114 115
consequence 8099817_5 116 127
of 8099817_5 128 130
cocaine 8099817_5 131 138
self 8099817_5 139 143
- 8099817_5 143 144
administration 8099817_5 144 158
. 8099817_5 159 160

By 18079739_5 0 2
western 18079739_5 3 10
blotting 18079739_5 11 19
we 18079739_5 20 22
showed 18079739_5 23 29
that 18079739_5 30 34
in 18079739_5 35 37
HEL 18079739_5 38 41
cells 18079739_5 42 47
, 18079739_5 48 49
ITF 18079739_5 50 53
2357 18079739_5 53 57
led 18079739_5 58 61
to 18079739_5 62 64
the 18079739_5 65 68
disappearance 18079739_5 69 82
of 18079739_5 83 85
total 18079739_5 86 91
and 18079739_5 92 95
phosphorylated 18079739_5 96 110
JAK 18079739_5 111 114
2 18079739_5 114 115
( 18079739_5 116 117
V 18079739_5 117 118
617 18079739_5 118 121
F 18079739_5 121 122
) 18079739_5 123 124
as 18079739_5 125 127
well 18079739_5 128 132
as 18079739_5 133 135
pSTAT 18079739_5 136 141
5 18079739_5 141 142
and 18079739_5 143 146
pSTAT 18079739_5 147 152
3 18079739_5 152 153
, 18079739_5 154 155
but 18079739_5 156 159
it 18079739_5 160 162
did 18079739_5 163 166
not 18079739_5 167 170
affect 18079739_5 171 177
the 18079739_5 178 181
wild 18079739_5 182 186
- 18079739_5 186 187
type 18079739_5 187 191
JAK 18079739_5 192 195
2 18079739_5 195 196
or 18079739_5 197 199
STAT 18079739_5 200 204
proteins 18079739_5 205 213
in 18079739_5 214 216
the 18079739_5 217 220
control 18079739_5 221 228
K 18079739_5 229 230
562 18079739_5 230 233
cell 18079739_5 234 238
line 18079739_5 239 243
. 18079739_5 244 245

This 19377049_12 0 4
work 19377049_12 5 9
suggests 19377049_12 10 18
a 19377049_12 19 20
role 19377049_12 21 25
for 19377049_12 26 29
DHFR 19377049_12 30 34
inhibitors 19377049_12 35 45
and 19377049_12 46 49
corticosteroids 19377049_12 50 65
in 19377049_12 66 68
treating 19377049_12 69 77
patients 19377049_12 78 86
with 19377049_12 87 91
AML 19377049_12 92 95
1 19377049_12 95 96
- 19377049_12 97 98
ETO 19377049_12 99 102
- 19377049_12 103 104
positive 19377049_12 104 112
disease 19377049_12 113 120
. 19377049_12 121 122

Polymorphisms 23020798_1 0 13
in 23020798_1 14 16
ERCC 23020798_1 17 21
1 23020798_1 21 22
, 23020798_1 23 24
GSTs 23020798_1 25 29
, 23020798_1 30 31
TS 23020798_1 32 34
and 23020798_1 35 38
MTHFR 23020798_1 39 44
predict 23020798_1 45 52
clinical 23020798_1 53 61
outcomes 23020798_1 62 70
of 23020798_1 71 73
gastric 23020798_1 74 81
cancer 23020798_1 82 88
patients 23020798_1 89 97
treated 23020798_1 98 105
with 23020798_1 106 110
platinum 23020798_1 111 119
/ 23020798_1 120 121
5 23020798_1 121 122
- 23020798_1 122 123
Fu 23020798_1 123 125
- 23020798_1 126 127
based 23020798_1 127 132
chemotherapy 23020798_1 133 145
: 23020798_1 146 147
a 23020798_1 148 149
systematic 23020798_1 150 160
review 23020798_1 161 167
. 23020798_1 168 169

RESULTS 24123531_7 0 7
: 24123531_7 8 9
All 24123531_7 10 13
7 24123531_7 14 15
cell 24123531_7 16 20
lines 24123531_7 21 26
were 24123531_7 27 31
wild 24123531_7 32 36
- 24123531_7 36 37
type 24123531_7 37 41
for 24123531_7 42 45
EGFR 24123531_7 46 50
and 24123531_7 51 54
KRAS 24123531_7 55 59
regardless 24123531_7 60 70
of 24123531_7 71 73
erlotinib 24123531_7 74 83
sensitivity 24123531_7 84 95
; 24123531_7 96 97
however 24123531_7 98 105
, 24123531_7 106 107
1 24123531_7 108 109
erlotinib 24123531_7 110 119
- 24123531_7 120 121
resistant 24123531_7 121 130
cell 24123531_7 131 135
line 24123531_7 136 140
( 24123531_7 141 142
HN 24123531_7 143 145
31 24123531_7 145 147
) 24123531_7 148 149
harbored 24123531_7 150 158
an 24123531_7 159 161
HRAS 24123531_7 162 166
G 24123531_7 167 168
12 24123531_7 168 170
D 24123531_7 170 171
mutation 24123531_7 172 180
. 24123531_7 181 182

When 11054768_9 0 4
we 11054768_9 5 7
compared 11054768_9 8 16
the 11054768_9 17 20
heroin 11054768_9 21 27
- 11054768_9 28 29
abuse 11054768_9 29 34
group 11054768_9 35 40
with 11054768_9 41 45
controls 11054768_9 46 54
, 11054768_9 55 56
we 11054768_9 57 59
found 11054768_9 60 65
no 11054768_9 66 68
significant 11054768_9 69 80
difference 11054768_9 81 91
between 11054768_9 92 99
the 11054768_9 100 103
patients 11054768_9 104 112
and 11054768_9 113 116
controls 11054768_9 117 125
for 11054768_9 126 129
either 11054768_9 130 136
polymorphism 11054768_9 137 149
in 11054768_9 150 152
the 11054768_9 153 156
DRD 11054768_9 157 160
4 11054768_9 160 161
gene 11054768_9 162 166
or 11054768_9 167 169
their 11054768_9 170 175
haplotypes 11054768_9 176 186
. 11054768_9 187 188

Nicotine 16485141_1 0 8
self 16485141_1 9 13
- 16485141_1 13 14
administration 16485141_1 14 28
in 16485141_1 29 31
mice 16485141_1 32 36
is 16485141_1 37 39
associated 16485141_1 40 50
with 16485141_1 51 55
rates 16485141_1 56 61
of 16485141_1 62 64
nicotine 16485141_1 65 73
inactivation 16485141_1 74 86
by 16485141_1 87 89
CYP 16485141_1 90 93
2 16485141_1 93 94
A 16485141_1 94 95
5 16485141_1 95 96
. 16485141_1 97 98

Evidence 8807668_1 0 8
that 8807668_1 9 13
poor 8807668_1 14 18
metabolizers 8807668_1 19 31
of 8807668_1 32 34
( 8807668_1 35 36
S 8807668_1 36 37
) 8807668_1 37 38
- 8807668_1 38 39
mephenytoin 8807668_1 39 50
could 8807668_1 51 56
be 8807668_1 57 59
identified 8807668_1 60 70
by 8807668_1 71 73
haplotypes 8807668_1 74 84
of 8807668_1 85 87
CYP 8807668_1 88 91
2 8807668_1 91 92
C 8807668_1 92 93
19 8807668_1 93 95
in 8807668_1 96 98
Japanese 8807668_1 99 107
. 8807668_1 108 109

The 11368834_10 0 3
results 11368834_10 4 11
suggest 11368834_10 12 19
that 11368834_10 20 24
CCK 11368834_10 25 28
- 11368834_10 29 30
45 11368834_10 30 32
C 11368834_10 32 33
> 11368834_10 33 34
T 11368834_10 34 35
and 11368834_10 36 39
CCKBR 11368834_10 40 45
Val 11368834_10 46 49
125 11368834_10 49 52
Ile 11368834_10 52 55
polymorphisms 11368834_10 56 69
do 11368834_10 70 72
not 11368834_10 73 76
have 11368834_10 77 81
a 11368834_10 82 83
major 11368834_10 84 89
role 11368834_10 90 94
in 11368834_10 95 97
alcohol 11368834_10 98 105
dependence 11368834_10 106 116
in 11368834_10 117 119
the 11368834_10 120 123
population 11368834_10 124 134
studied 11368834_10 135 142
. 11368834_10 143 144

The 17412797_15 0 3
specificity 17412797_15 4 15
of 17412797_15 16 18
N 17412797_15 19 20
Latex 17412797_15 21 26
CDT 17412797_15 27 30
for 17412797_15 31 34
identifying 17412797_15 35 46
alcohol 17412797_15 47 54
abuse 17412797_15 55 60
may 17412797_15 61 64
be 17412797_15 65 67
higher 17412797_15 68 74
than 17412797_15 75 79
for 17412797_15 80 83
immunoassays 17412797_15 84 96
that 17412797_15 97 101
use 17412797_15 102 105
column 17412797_15 106 112
separation 17412797_15 113 123
, 17412797_15 124 125
because 17412797_15 126 133
transferrin 17412797_15 134 145
genetic 17412797_15 146 153
variants 17412797_15 154 162
do 17412797_15 163 165
not 17412797_15 166 169
interfere 17412797_15 170 179
with 17412797_15 180 184
measurements 17412797_15 185 197
. 17412797_15 198 199

Maintenance 25643589_10 0 11
lenalidomide 25643589_10 12 24
/ 25643589_10 25 26
azacitidine 25643589_10 27 38
augmented 25643589_10 39 48
the 25643589_10 49 52
function 25643589_10 53 61
of 25643589_10 62 64
cytotoxic 25643589_10 65 74
T 25643589_10 75 76
lymphocytes 25643589_10 77 88
, 25643589_10 89 90
particularly 25643589_10 91 103
in 25643589_10 104 106
patients 25643589_10 107 115
with 25643589_10 116 120
NPM 25643589_10 121 124
1 25643589_10 124 125
mutation 25643589_10 126 134
. 25643589_10 135 136

The 15944732_4 0 3
association 15944732_4 4 15
of 15944732_4 16 18
a 15944732_4 19 20
DNA 15944732_4 21 24
vaccine 15944732_4 25 32
encoding 15944732_4 33 41
a 15944732_4 42 43
portion 15944732_4 44 51
of 15944732_4 52 54
rat 15944732_4 55 58
HER 15944732_4 59 62
2 15944732_4 62 63
/ 15944732_4 64 65
neu 15944732_4 66 69
with 15944732_4 70 74
either 15944732_4 75 81
Imiquimod 15944732_4 82 91
or 15944732_4 92 94
S 15944732_4 95 96
- 15944732_4 96 97
27609 15944732_4 97 102
was 15944732_4 103 106
found 15944732_4 107 112
to 15944732_4 113 115
delay 15944732_4 116 121
the 15944732_4 122 125
development 15944732_4 126 137
of 15944732_4 138 140
spontaneous 15944732_4 141 152
mammary 15944732_4 153 160
tumours 15944732_4 161 168
and 15944732_4 169 172
to 15944732_4 173 175
reduce 15944732_4 176 182
their 15944732_4 183 188
incidence 15944732_4 189 198
, 15944732_4 199 200
in 15944732_4 201 203
comparison 15944732_4 204 214
with 15944732_4 215 219
DNA 15944732_4 220 223
vaccination 15944732_4 224 235
alone 15944732_4 236 241
. 15944732_4 242 243

Here 11967152_6 0 4
, 11967152_6 5 6
we 11967152_6 7 9
show 11967152_6 10 14
that 11967152_6 15 19
pretetanic 11967152_6 20 30
application 11967152_6 31 42
of 11967152_6 43 45
a 11967152_6 46 47
concentration 11967152_6 48 61
of 11967152_6 62 64
CPP 11967152_6 65 68
( 11967152_6 69 70
0 11967152_6 71 72
. 11967152_6 72 73
1 11967152_6 73 74
microM 11967152_6 75 81
) 11967152_6 82 83
ineffective 11967152_6 84 95
in 11967152_6 96 98
WT 11967152_6 99 101
hippocampal 11967152_6 102 113
slices 11967152_6 114 120
induced 11967152_6 121 128
deficits 11967152_6 129 137
in 11967152_6 138 140
alpha 11967152_6 141 146
CaMKII 11967152_6 147 153
( 11967152_6 154 155
T 11967152_6 156 157
286 11967152_6 157 160
A 11967152_6 160 161
+ 11967152_6 162 163
/ 11967152_6 164 165
- 11967152_6 166 167
) 11967152_6 168 169
slices 11967152_6 170 176
in 11967152_6 177 179
hippocampal 11967152_6 180 191
long 11967152_6 192 196
- 11967152_6 196 197
term 11967152_6 197 201
potentiation 11967152_6 202 214
( 11967152_6 215 216
LTP 11967152_6 217 220
) 11967152_6 221 222
, 11967152_6 223 224
a 11967152_6 225 226
mechanism 11967152_6 227 236
thought 11967152_6 237 244
to 11967152_6 245 247
be 11967152_6 248 250
involved 11967152_6 251 259
in 11967152_6 260 262
learning 11967152_6 263 271
and 11967152_6 272 275
memory 11967152_6 276 282
. 11967152_6 283 284

A 18729643_4 0 1
coding 18729643_4 2 8
variant 18729643_4 9 16
in 18729643_4 17 19
one 18729643_4 20 23
such 18729643_4 24 28
gene 18729643_4 29 33
, 18729643_4 34 35
encoding 18729643_4 36 44
the 18729643_4 45 48
dopamine 18729643_4 49 57
catabolic 18729643_4 58 67
enzyme 18729643_4 68 74
catechol 18729643_4 75 83
- 18729643_4 83 84
O 18729643_4 84 85
- 18729643_4 85 86
methyltransferase 18729643_4 86 103
( 18729643_4 104 105
COMT 18729643_4 106 110
Val 18729643_4 111 114
158 18729643_4 114 117
Met 18729643_4 117 120
) 18729643_4 121 122
, 18729643_4 123 124
has 18729643_4 125 128
previously 18729643_4 129 139
been 18729643_4 140 144
associated 18729643_4 145 155
with 18729643_4 156 160
anxiety 18729643_4 161 168
and 18729643_4 169 172
with 18729643_4 173 177
anxiety 18729643_4 178 185
- 18729643_4 186 187
related 18729643_4 187 194
temperament 18729643_4 195 206
and 18729643_4 207 210
altered 18729643_4 211 218
neural 18729643_4 219 225
responses 18729643_4 226 235
to 18729643_4 236 238
affective 18729643_4 239 248
stimuli 18729643_4 249 256
in 18729643_4 257 259
healthy 18729643_4 260 267
individuals 18729643_4 268 279
. 18729643_4 280 281

In 22995765_7 0 2
the 22995765_7 3 6
genetic 22995765_7 7 14
association 22995765_7 15 26
analysis 22995765_7 27 35
, 22995765_7 36 37
we 22995765_7 38 40
found 22995765_7 41 46
that 22995765_7 47 51
AA 22995765_7 52 54
homozygotes 22995765_7 55 66
of 22995765_7 67 69
rs 22995765_7 70 72
6943555 22995765_7 72 79
were 22995765_7 80 84
significantly 22995765_7 85 98
over 22995765_7 99 103
- 22995765_7 103 104
represented 22995765_7 104 115
in 22995765_7 116 118
the 22995765_7 119 122
heroin 22995765_7 123 129
dependent 22995765_7 130 139
subjects 22995765_7 140 148
compared 22995765_7 149 157
with 22995765_7 158 162
the 22995765_7 163 166
control 22995765_7 167 174
subjects 22995765_7 175 183
( 22995765_7 184 185
odds 22995765_7 186 190
ratio 22995765_7 191 196
= 22995765_7 197 198
1 22995765_7 199 200
. 22995765_7 200 201
7 22995765_7 201 202
, 22995765_7 203 204
95 22995765_7 205 207
% 22995765_7 208 209
confidence 22995765_7 210 220
interval 22995765_7 221 229
: 22995765_7 230 231
1 22995765_7 232 233
. 22995765_7 233 234
08 22995765_7 234 236
- 22995765_7 236 237
2 22995765_7 237 238
. 22995765_7 239 240
74 22995765_7 240 242
, 22995765_7 243 244
p 22995765_7 245 246
= 22995765_7 247 248
0 22995765_7 249 250
. 22995765_7 250 251
017 22995765_7 251 254
) 22995765_7 255 256
. 22995765_7 257 258

A 12824799_5 0 1
previously 12824799_5 2 12
unnoticed 12824799_5 13 22
role 12824799_5 23 27
of 12824799_5 28 30
Y 12824799_5 31 32
181 12824799_5 32 35
I 12824799_5 35 36
/ 12824799_5 37 38
C 12824799_5 38 39
RT 12824799_5 40 42
changes 12824799_5 43 50
selected 12824799_5 51 59
by 12824799_5 60 62
nevirapine 12824799_5 63 73
or 12824799_5 74 76
other 12824799_5 77 82
NNRTI 12824799_5 83 88
in 12824799_5 89 91
determining 12824799_5 92 103
stavudine 12824799_5 104 113
resistance 12824799_5 114 124
is 12824799_5 125 127
documented 12824799_5 128 138
. 12824799_5 139 140

The 19328219_11 0 3
association 19328219_11 4 15
of 19328219_11 16 18
- 19328219_11 19 20
1438 19328219_11 20 24
A 19328219_11 24 25
/ 19328219_11 25 26
G 19328219_11 26 27
with 19328219_11 28 32
alcohol 19328219_11 33 40
dependence 19328219_11 41 51
was 19328219_11 52 55
especially 19328219_11 56 66
pronounced 19328219_11 67 77
in 19328219_11 78 80
the 19328219_11 81 84
presence 19328219_11 85 93
of 19328219_11 94 96
5 19328219_11 97 98
- 19328219_11 98 99
HTTLPR 19328219_11 99 105
S 19328219_11 106 107
/ 19328219_11 107 108
S 19328219_11 108 109
, 19328219_11 110 111
less 19328219_11 112 116
evident 19328219_11 117 124
with 19328219_11 125 129
5 19328219_11 130 131
- 19328219_11 131 132
HTTLPR 19328219_11 132 138
L 19328219_11 139 140
/ 19328219_11 140 141
S 19328219_11 141 142
and 19328219_11 143 146
not 19328219_11 147 150
present 19328219_11 151 158
with 19328219_11 159 163
5 19328219_11 164 165
- 19328219_11 165 166
HTTLPR 19328219_11 166 172
L 19328219_11 173 174
/ 19328219_11 174 175
L 19328219_11 175 176
. 19328219_11 177 178

The 10656431_13 0 3
efficiency 10656431_13 4 14
of 10656431_13 15 17
paclitaxel 10656431_13 18 28
during 10656431_13 29 35
mitosis 10656431_13 36 43
might 10656431_13 44 49
be 10656431_13 50 52
supported 10656431_13 53 62
by 10656431_13 63 65
lack 10656431_13 66 70
of 10656431_13 71 73
G 10656431_13 74 75
1 10656431_13 75 76
arrest 10656431_13 77 83
due 10656431_13 84 87
to 10656431_13 88 90
p 10656431_13 91 92
53 10656431_13 92 94
deficiency 10656431_13 95 105
. 10656431_13 106 107

Further 20922562_4 0 7
logistic 20922562_4 8 16
analyses 20922562_4 17 25
revealed 20922562_4 26 34
that 20922562_4 35 39
most 20922562_4 40 44
polymorphisms 20922562_4 45 58
of 20922562_4 59 61
KIF 20922562_4 62 65
3 20922562_4 65 66
A 20922562_4 66 67
were 20922562_4 68 72
significantly 20922562_4 73 86
associated 20922562_4 87 97
with 20922562_4 98 102
AIA 20922562_4 103 106
( 20922562_4 107 108
P 20922562_4 109 110
= 20922562_4 111 112
0 20922562_4 113 114
. 20922562_4 114 115
0004 20922562_4 115 119
- 20922562_4 119 120
0 20922562_4 120 121
. 20922562_4 122 123
02 20922562_4 123 125
; 20922562_4 126 127
P 20922562_4 128 129
( 20922562_4 130 131
corr 20922562_4 132 136
) 20922562_4 137 138
= 20922562_4 139 140
0 20922562_4 141 142
. 20922562_4 142 143
004 20922562_4 143 146
- 20922562_4 146 147
0 20922562_4 147 148
. 20922562_4 149 150
04 20922562_4 150 152
) 20922562_4 153 154
and 20922562_4 155 158
the 20922562_4 159 162
decline 20922562_4 163 170
of 20922562_4 171 173
forced 20922562_4 174 180
expiratory 20922562_4 181 191
volume 20922562_4 192 198
at 20922562_4 199 201
1 20922562_4 202 203
s 20922562_4 204 205
( 20922562_4 206 207
FEV 20922562_4 208 211
( 20922562_4 212 213
1 20922562_4 214 215
) 20922562_4 216 217
) 20922562_4 218 219
% 20922562_4 220 221
by 20922562_4 222 224
aspirin 20922562_4 225 232
provocation 20922562_4 233 244
( 20922562_4 245 246
P 20922562_4 247 248
= 20922562_4 249 250
0 20922562_4 251 252
. 20922562_4 252 253
004 20922562_4 253 256
- 20922562_4 256 257
0 20922562_4 257 258
. 20922562_4 259 260
04 20922562_4 260 262
; 20922562_4 263 264
P 20922562_4 265 266
( 20922562_4 267 268
corr 20922562_4 269 273
) 20922562_4 274 275
= 20922562_4 276 277
0 20922562_4 278 279
. 20922562_4 279 280
03 20922562_4 280 282
) 20922562_4 283 284
. 20922562_4 285 286

To 25286744_4 0 2
quantify 25286744_4 3 11
changes 25286744_4 12 19
of 25286744_4 20 22
CYP 25286744_4 23 26
3 25286744_4 26 27
A 25286744_4 27 28
4 25286744_4 28 29
activity 25286744_4 30 38
, 25286744_4 39 40
midazolam 25286744_4 41 50
( 25286744_4 51 52
3 25286744_4 53 54
mg 25286744_4 55 57
po 25286744_4 58 60
) 25286744_4 61 62
as 25286744_4 63 65
a 25286744_4 66 67
probe 25286744_4 68 73
drug 25286744_4 74 78
was 25286744_4 79 82
used 25286744_4 83 87
. 25286744_4 88 89

In 23959853_1 0 2
vivo 23959853_1 3 7
absorption 23959853_1 8 18
and 23959853_1 19 22
disposition 23959853_1 23 34
of 23959853_1 35 37
cefadroxil 23959853_1 38 48
after 23959853_1 49 54
escalating 23959853_1 55 65
oral 23959853_1 66 70
doses 23959853_1 71 76
in 23959853_1 77 79
wild 23959853_1 80 84
- 23959853_1 84 85
type 23959853_1 85 89
and 23959853_1 90 93
PepT 23959853_1 94 98
1 23959853_1 98 99
knockout 23959853_1 100 108
mice 23959853_1 109 113
. 23959853_1 114 115

This 22509987_5 0 4
study 22509987_5 5 10
tested 22509987_5 11 17
the 22509987_5 18 21
hypothesis 22509987_5 22 32
that 22509987_5 33 37
genetic 22509987_5 38 45
variation 22509987_5 46 55
in 22509987_5 56 58
COMT 22509987_5 59 63
Val 22509987_5 64 67
158 22509987_5 67 70
Met 22509987_5 70 73
and 22509987_5 74 77
DRD 22509987_5 78 81
2 22509987_5 81 82
/ 22509987_5 83 84
ANKK 22509987_5 85 89
1 22509987_5 89 90
Taq 22509987_5 91 94
1 22509987_5 94 95
A 22509987_5 95 96
interacts 22509987_5 97 106
with 22509987_5 107 111
childhood 22509987_5 112 121
adverse 22509987_5 122 129
experiences 22509987_5 130 141
to 22509987_5 142 144
predict 22509987_5 145 152
alcohol 22509987_5 153 160
dependence 22509987_5 161 171
. 22509987_5 172 173

CONCLUSION 20022477_10 0 10
: 20022477_10 11 12
This 20022477_10 13 17
result 20022477_10 18 24
suggests 20022477_10 25 33
that 20022477_10 34 38
the 20022477_10 39 42
CCR 20022477_10 43 46
3 20022477_10 46 47
genetic 20022477_10 48 55
polymorphisms 20022477_10 56 69
may 20022477_10 70 73
contribute 20022477_10 74 84
to 20022477_10 85 87
the 20022477_10 88 91
development 20022477_10 92 103
of 20022477_10 104 106
the 20022477_10 107 110
AERD 20022477_10 111 115
phenotype 20022477_10 116 125
and 20022477_10 126 129
may 20022477_10 130 133
be 20022477_10 134 136
used 20022477_10 137 141
as 20022477_10 142 144
a 20022477_10 145 146
genetic 20022477_10 147 154
marker 20022477_10 155 161
for 20022477_10 162 165
differentiating 20022477_10 166 181
between 20022477_10 182 189
the 20022477_10 190 193
two 20022477_10 194 197
major 20022477_10 198 203
aspirin 20022477_10 204 211
hypersensitivity 20022477_10 212 228
phenotypes 20022477_10 229 239
. 20022477_10 240 241

Association 20597903_1 0 11
of 20597903_1 12 14
SLC 20597903_1 15 18
6 20597903_1 18 19
A 20597903_1 19 20
12 20597903_1 20 22
variants 20597903_1 23 31
with 20597903_1 32 36
aspirin 20597903_1 37 44
- 20597903_1 45 46
intolerant 20597903_1 46 56
asthma 20597903_1 57 63
in 20597903_1 64 66
a 20597903_1 67 68
Korean 20597903_1 69 75
population 20597903_1 76 86
. 20597903_1 87 88

RESULTS 20947785_6 0 7
: 20947785_6 8 9
Compound 20947785_6 10 18
heterozygous 20947785_6 19 31
or 20947785_6 32 34
homozygous 20947785_6 35 45
NPHS 20947785_6 46 50
2 20947785_6 50 51
pathogenic 20947785_6 52 62
mutations 20947785_6 63 72
were 20947785_6 73 77
identified 20947785_6 78 88
in 20947785_6 89 91
seven 20947785_6 92 97
childhood 20947785_6 98 107
- 20947785_6 107 108
onset 20947785_6 108 113
steroid 20947785_6 114 121
- 20947785_6 122 123
resistant 20947785_6 123 132
nephrotic 20947785_6 133 142
syndrome 20947785_6 143 151
( 20947785_6 152 153
SRNS 20947785_6 154 158
) 20947785_6 159 160
cases 20947785_6 161 166
. 20947785_6 167 168

To 17719176_3 0 2
test 17719176_3 3 7
the 17719176_3 8 11
influence 17719176_3 12 21
of 17719176_3 22 24
WFS 17719176_3 25 28
1 17719176_3 28 29
polymorphisms 17719176_3 30 43
on 17719176_3 44 46
medication 17719176_3 47 57
overuse 17719176_3 58 65
headache 17719176_3 66 74
( 17719176_3 75 76
MOH 17719176_3 77 80
) 17719176_3 81 82
, 17719176_3 83 84
a 17719176_3 85 86
chronic 17719176_3 87 94
headache 17719176_3 95 103
condition 17719176_3 104 113
related 17719176_3 114 121
to 17719176_3 122 124
symptomatic 17719176_3 125 136
drugs 17719176_3 137 142
overuse 17719176_3 143 150
, 17719176_3 151 152
we 17719176_3 153 155
analyzed 17719176_3 156 164
82 17719176_3 165 167
MOH 17719176_3 168 171
patients 17719176_3 172 180
for 17719176_3 181 184
the 17719176_3 185 188
WFS 17719176_3 189 192
1 17719176_3 192 193
His 17719176_3 194 197
611 17719176_3 197 200
Arg 17719176_3 200 203
polymorphism 17719176_3 204 216
, 17719176_3 217 218
and 17719176_3 219 222
performed 17719176_3 223 232
a 17719176_3 233 234
comparison 17719176_3 235 245
between 17719176_3 246 253
clinical 17719176_3 254 262
features 17719176_3 263 271
of 17719176_3 272 274
Arg 17719176_3 275 278
/ 17719176_3 279 280
Arg 17719176_3 281 284
( 17719176_3 285 286
R 17719176_3 287 288
/ 17719176_3 288 289
R 17719176_3 289 290
) 17719176_3 291 292
and 17719176_3 293 296
non 17719176_3 297 300
- 17719176_3 300 301
R 17719176_3 301 302
/ 17719176_3 302 303
R 17719176_3 303 304
individuals 17719176_3 305 316
. 17719176_3 317 318

BACKGROUND 22217332_2 0 10
: 22217332_2 11 12
Since 22217332_2 13 18
subepithelial 22217332_2 19 32
fibrosis 22217332_2 33 41
and 22217332_2 42 45
protruded 22217332_2 46 55
extracellular 22217332_2 56 69
matrix 22217332_2 70 76
are 22217332_2 77 80
among 22217332_2 81 86
the 22217332_2 87 90
histological 22217332_2 91 103
characteristics 22217332_2 104 119
of 22217332_2 120 122
polyps 22217332_2 123 129
, 22217332_2 130 131
the 22217332_2 132 135
emilin 22217332_2 136 142
/ 22217332_2 142 143
multimerin 22217332_2 143 153
domain 22217332_2 154 160
- 22217332_2 160 161
containing 22217332_2 161 171
protein 22217332_2 172 179
2 22217332_2 180 181
( 22217332_2 182 183
EMID 22217332_2 184 188
2 22217332_2 188 189
) 22217332_2 190 191
gene 22217332_2 192 196
is 22217332_2 197 199
speculated 22217332_2 200 210
to 22217332_2 211 213
be 22217332_2 214 216
involved 22217332_2 217 225
in 22217332_2 226 228
the 22217332_2 229 232
presence 22217332_2 233 241
of 22217332_2 242 244
nasal 22217332_2 245 250
polyps 22217332_2 251 257
in 22217332_2 258 260
asthma 22217332_2 261 267
and 22217332_2 268 271
aspirin 22217332_2 272 279
- 22217332_2 280 281
hypersensitive 22217332_2 281 295
patients 22217332_2 296 304
. 22217332_2 305 306

We 26566708_5 0 2
prospectively 26566708_5 3 16
investigated 26566708_5 17 29
the 26566708_5 30 33
associations 26566708_5 34 46
between 26566708_5 47 54
HO 26566708_5 55 57
- 26566708_5 57 58
1 26566708_5 58 59
( 26566708_5 60 61
GT 26566708_5 62 64
) 26566708_5 65 66
n 26566708_5 67 68
polymorphism 26566708_5 69 81
and 26566708_5 82 85
cancer 26566708_5 86 92
risk 26566708_5 93 97
related 26566708_5 98 105
to 26566708_5 106 108
arsenic 26566708_5 109 116
from 26566708_5 117 121
drinking 26566708_5 122 130
water 26566708_5 131 136
. 26566708_5 137 138

The 21172311_2 0 3
human 21172311_2 4 9
serotonin 21172311_2 10 19
receptor 21172311_2 20 28
1 21172311_2 29 30
B 21172311_2 30 31
( 21172311_2 32 33
HRT 21172311_2 34 37
1 21172311_2 37 38
B 21172311_2 38 39
) 21172311_2 40 41
plays 21172311_2 42 47
an 21172311_2 48 50
important 21172311_2 51 60
role 21172311_2 61 65
in 21172311_2 66 68
regulating 21172311_2 69 79
serotonin 21172311_2 80 89
release 21172311_2 90 97
. 21172311_2 98 99

We 22821000_4 0 2
examined 22821000_4 3 11
the 22821000_4 12 15
role 22821000_4 16 20
of 22821000_4 21 23
Ranbp 22821000_4 24 29
2 22821000_4 29 30
haploinsufficiency 22821000_4 31 49
on 22821000_4 50 52
cellular 22821000_4 53 61
and 22821000_4 62 65
metabolic 22821000_4 66 75
manifestations 22821000_4 76 90
linked 22821000_4 91 97
to 22821000_4 98 100
tyrosine 22821000_4 101 109
- 22821000_4 110 111
hydroxylase 22821000_4 111 122
( 22821000_4 123 124
TH 22821000_4 125 127
( 22821000_4 128 129
+ 22821000_4 130 131
) 22821000_4 132 133
) 22821000_4 134 135
dopaminergic 22821000_4 136 148
neurons 22821000_4 149 156
and 22821000_4 157 160
glial 22821000_4 161 166
cells 22821000_4 167 172
of 22821000_4 173 175
the 22821000_4 176 179
brain 22821000_4 180 185
and 22821000_4 186 189
retina 22821000_4 190 196
upon 22821000_4 197 201
acute 22821000_4 202 207
challenge 22821000_4 208 217
to 22821000_4 218 220
1 22821000_4 221 222
- 22821000_4 222 223
methyl 22821000_4 223 229
- 22821000_4 229 230
4 22821000_4 230 231
- 22821000_4 231 232
phenyl 22821000_4 232 238
- 22821000_4 238 239
1 22821000_4 239 240
, 22821000_4 240 241
2 22821000_4 241 242
, 22821000_4 242 243
3 22821000_4 243 244
, 22821000_4 244 245
6 22821000_4 245 246
- 22821000_4 246 247
tetrahydropyridine 22821000_4 247 265
( 22821000_4 266 267
MPTP 22821000_4 268 272
) 22821000_4 273 274
, 22821000_4 275 276
a 22821000_4 277 278
parkinsonian 22821000_4 279 291
neurotoxin 22821000_4 292 302
, 22821000_4 303 304
which 22821000_4 305 310
models 22821000_4 311 317
facets 22821000_4 318 324
of 22821000_4 325 327
Parkinson 22821000_4 328 337
disease 22821000_4 338 345
. 22821000_4 346 347

A 12070798_4 0 1
significant 12070798_4 2 13
association 12070798_4 14 25
between 12070798_4 26 33
expression 12070798_4 34 44
of 12070798_4 45 47
c 12070798_4 48 49
- 12070798_4 49 50
erbB 12070798_4 50 54
- 12070798_4 54 55
2 12070798_4 55 56
mRNA 12070798_4 57 61
und 12070798_4 62 65
survival 12070798_4 66 74
was 12070798_4 75 78
obtained 12070798_4 79 87
for 12070798_4 88 91
the 12070798_4 92 95
subgroup 12070798_4 96 104
of 12070798_4 105 107
patients 12070798_4 108 116
who 12070798_4 117 120
received 12070798_4 121 129
a 12070798_4 130 131
standard 12070798_4 132 140
chemotherapy 12070798_4 141 153
with 12070798_4 154 158
carboplatin 12070798_4 159 170
or 12070798_4 171 173
cisplatin 12070798_4 174 183
and 12070798_4 184 187
cyclophosphamide 12070798_4 188 204
( 12070798_4 205 206
P 12070798_4 207 208
= 12070798_4 209 210
0 12070798_4 211 212
. 12070798_4 212 213
0003 12070798_4 213 217
) 12070798_4 218 219
. 12070798_4 220 221

Also 22572645_4 0 4
, 22572645_4 5 6
we 22572645_4 7 9
examined 22572645_4 10 18
whether 22572645_4 19 26
any 22572645_4 27 30
association 22572645_4 31 42
between 22572645_4 43 50
folate 22572645_4 51 57
status 22572645_4 58 64
and 22572645_4 65 68
child 22572645_4 69 74
problems 22572645_4 75 83
is 22572645_4 84 86
a 22572645_4 87 88
consequence 22572645_4 89 100
of 22572645_4 101 103
maternal 22572645_4 104 112
folic 22572645_4 113 118
acid 22572645_4 119 123
supplement 22572645_4 124 134
use 22572645_4 135 138
or 22572645_4 139 141
variation 22572645_4 142 151
in 22572645_4 152 154
maternal 22572645_4 155 163
MTHFR 22572645_4 164 169
genotype 22572645_4 170 178
. 22572645_4 179 180

CONCLUSIONS 21692767_12 0 11
: 21692767_12 12 13
The 21692767_12 14 17
high 21692767_12 18 22
transcript 21692767_12 23 33
haplotype 21692767_12 34 43
ht 21692767_12 44 46
1 21692767_12 46 47
[ 21692767_12 48 49
CG 21692767_12 50 52
] 21692767_12 53 54
of 21692767_12 55 57
the 21692767_12 58 61
IL 21692767_12 62 64
18 21692767_12 64 66
gene 21692767_12 67 71
may 21692767_12 72 75
contribute 21692767_12 76 86
to 21692767_12 87 89
the 21692767_12 90 93
development 21692767_12 94 105
of 21692767_12 106 108
acute 21692767_12 109 114
cutaneous 21692767_12 115 124
inflammation 21692767_12 125 137
sensitive 21692767_12 138 147
to 21692767_12 148 150
aspirin 21692767_12 151 158
, 21692767_12 159 160
leading 21692767_12 161 168
to 21692767_12 169 171
the 21692767_12 172 175
clinical 21692767_12 176 184
presentation 21692767_12 185 197
of 21692767_12 198 200
AIAU 21692767_12 201 205
. 21692767_12 206 207

Our 22684019_11 0 3
findings 22684019_11 4 12
suggest 22684019_11 13 20
that 22684019_11 21 25
IM 22684019_11 26 28
3829 22684019_11 28 32
could 22684019_11 33 38
be 22684019_11 39 41
a 22684019_11 42 43
promising 22684019_11 44 53
radiosensitizer 22684019_11 54 69
in 22684019_11 70 72
lung 22684019_11 73 77
cancer 22684019_11 78 84
patients 22684019_11 85 93
, 22684019_11 94 95
particularly 22684019_11 96 108
those 22684019_11 109 114
with 22684019_11 115 119
high 22684019_11 120 124
expression 22684019_11 125 135
of 22684019_11 136 138
Nrf 22684019_11 139 142
2 22684019_11 142 143
. 22684019_11 144 145

( 2491158_6 0 1
NZB 2491158_6 2 5
x 2491158_6 6 7
NZW 2491158_6 8 11
) 2491158_6 12 13
F 2491158_6 14 15
1 2491158_6 15 16
mice 2491158_6 17 21
respond 2491158_6 22 29
to 2491158_6 30 32
immunization 2491158_6 33 45
with 2491158_6 46 50
phosphorylcholine 2491158_6 51 68
with 2491158_6 69 73
a 2491158_6 74 75
response 2491158_6 76 84
that 2491158_6 85 89
is 2491158_6 90 92
largely 2491158_6 93 100
encoded 2491158_6 101 108
by 2491158_6 109 111
the 2491158_6 112 115
VH 2491158_6 116 118
1 2491158_6 118 119
gene 2491158_6 120 124
of 2491158_6 125 127
the 2491158_6 128 131
S 2491158_6 132 133
107 2491158_6 133 136
family 2491158_6 137 143
. 2491158_6 144 145

The 15386371_15 0 3
selection 15386371_15 4 13
of 15386371_15 14 16
patients 15386371_15 17 25
who 15386371_15 26 29
are 15386371_15 30 33
likely 15386371_15 34 40
to 15386371_15 41 43
respond 15386371_15 44 51
to 15386371_15 52 54
5 15386371_15 55 56
- 15386371_15 56 57
FU 15386371_15 57 59
therapy 15386371_15 60 67
may 15386371_15 68 71
be 15386371_15 72 74
considerably 15386371_15 75 87
improved 15386371_15 88 96
if 15386371_15 97 99
the 15386371_15 100 103
TS 15386371_15 104 106
genotype 15386371_15 107 115
were 15386371_15 116 120
to 15386371_15 121 123
include 15386371_15 124 131
both 15386371_15 132 136
the 15386371_15 137 140
VNTR 15386371_15 141 145
and 15386371_15 146 149
the 15386371_15 150 153
SNP 15386371_15 154 157
located 15386371_15 158 165
within 15386371_15 166 172
the 15386371_15 173 176
promoter 15386371_15 177 185
region 15386371_15 186 192
of 15386371_15 193 195
the 15386371_15 196 199
gene 15386371_15 200 204
. 15386371_15 205 206

A 19300499_1 0 1
genome 19300499_1 2 8
- 19300499_1 8 9
wide 19300499_1 9 13
association 19300499_1 14 25
study 19300499_1 26 31
confirms 19300499_1 32 40
VKORC 19300499_1 41 46
1 19300499_1 46 47
, 19300499_1 48 49
CYP 19300499_1 50 53
2 19300499_1 53 54
C 19300499_1 54 55
9 19300499_1 55 56
, 19300499_1 57 58
and 19300499_1 59 62
CYP 19300499_1 63 66
4 19300499_1 66 67
F 19300499_1 67 68
2 19300499_1 68 69
as 19300499_1 70 72
principal 19300499_1 73 82
genetic 19300499_1 83 90
determinants 19300499_1 91 103
of 19300499_1 104 106
warfarin 19300499_1 107 115
dose 19300499_1 116 120
. 19300499_1 121 122

RY 26716652_7 0 2
10 26716652_7 2 4
- 26716652_7 4 5
4 26716652_7 5 6
plus 26716652_7 7 11
DAPT 26716652_7 12 16
increases 26716652_7 17 26
apoptosis 26716652_7 27 36
in 26716652_7 37 39
both 26716652_7 40 44
HER 26716652_7 45 48
2 26716652_7 48 49
- 26716652_7 50 51
overexpressing 26716652_7 51 65
cell 26716652_7 66 70
lines 26716652_7 71 76
by 26716652_7 77 79
two 26716652_7 80 83
- 26716652_7 83 84
fold 26716652_7 84 88
compared 26716652_7 89 97
to 26716652_7 98 100
RY 26716652_7 101 103
10 26716652_7 103 105
- 26716652_7 105 106
4 26716652_7 106 107
alone 26716652_7 108 113
, 26716652_7 114 115
while 26716652_7 116 121
DAPT 26716652_7 122 126
alone 26716652_7 127 132
has 26716652_7 133 136
no 26716652_7 137 139
significant 26716652_7 140 151
effects 26716652_7 152 159
on 26716652_7 160 162
apoptosis 26716652_7 163 172
. 26716652_7 173 174

Pompe 21109266_2 0 5
disease 21109266_2 6 13
is 21109266_2 14 16
caused 21109266_2 17 23
by 21109266_2 24 26
the 21109266_2 27 30
deficiency 21109266_2 31 41
of 21109266_2 42 44
acid 21109266_2 45 49
a 21109266_2 50 51
- 21109266_2 51 52
glucosidase 21109266_2 52 63
( 21109266_2 64 65
GAA 21109266_2 66 69
) 21109266_2 70 71
, 21109266_2 72 73
which 21109266_2 74 79
degrades 21109266_2 80 88
glycogen 21109266_2 89 97
into 21109266_2 98 102
glucose 21109266_2 103 110
. 21109266_2 111 112

AIMS 18754843_2 0 4
: 18754843_2 5 6
The 18754843_2 7 10
objectives 18754843_2 11 21
were 18754843_2 22 26
to 18754843_2 27 29
evaluate 18754843_2 30 38
the 18754843_2 39 42
effect 18754843_2 43 49
of 18754843_2 50 52
CYP 18754843_2 53 56
2 18754843_2 56 57
D 18754843_2 57 58
6 18754843_2 58 59
genetic 18754843_2 60 67
polymorphism 18754843_2 68 80
on 18754843_2 81 83
the 18754843_2 84 87
pharmacokinetics 18754843_2 88 104
of 18754843_2 105 107
flecainide 18754843_2 108 118
, 18754843_2 119 120
and 18754843_2 121 124
also 18754843_2 125 129
on 18754843_2 130 132
the 18754843_2 133 136
extent 18754843_2 137 143
of 18754843_2 144 146
drug 18754843_2 147 151
interaction 18754843_2 152 163
with 18754843_2 164 168
paroxetine 18754843_2 169 179
as 18754843_2 180 182
a 18754843_2 183 184
CYP 18754843_2 185 188
2 18754843_2 188 189
D 18754843_2 189 190
6 18754843_2 190 191
inhibitor 18754843_2 192 201
after 18754843_2 202 207
a 18754843_2 208 209
single 18754843_2 210 216
oral 18754843_2 217 221
administration 18754843_2 222 236
in 18754843_2 237 239
healthy 18754843_2 240 247
subjects 18754843_2 248 256
. 18754843_2 257 258

METHODS 19229528_4 0 7
: 19229528_4 8 9
The 19229528_4 10 13
aim 19229528_4 14 17
of 19229528_4 18 20
the 19229528_4 21 24
current 19229528_4 25 32
study 19229528_4 33 38
was 19229528_4 39 42
to 19229528_4 43 45
evaluate 19229528_4 46 54
an 19229528_4 55 57
association 19229528_4 58 69
between 19229528_4 70 77
TPMT 19229528_4 78 82
and 19229528_4 83 86
ITPA 19229528_4 87 91
gene 19229528_4 92 96
polymorphisms 19229528_4 97 110
and 19229528_4 111 114
drug 19229528_4 115 119
intolerance 19229528_4 120 131
in 19229528_4 132 134
a 19229528_4 135 136
cohort 19229528_4 137 143
of 19229528_4 144 146
157 19229528_4 147 150
renal 19229528_4 151 156
transplant 19229528_4 157 167
recipients 19229528_4 168 178
treated 19229528_4 179 186
with 19229528_4 187 191
azathioprine 19229528_4 192 204
( 19229528_4 205 206
AZA 19229528_4 207 210
) 19229528_4 211 212
. 19229528_4 213 214

Considering 24022708_2 0 11
that 24022708_2 12 16
the 24022708_2 17 20
genotypes 24022708_2 21 30
of 24022708_2 31 33
CYP 24022708_2 34 37
2 24022708_2 37 38
C 24022708_2 38 39
19 24022708_2 39 41
and 24022708_2 42 45
MDRI 24022708_2 46 50
C 24022708_2 51 52
3435 24022708_2 52 56
T 24022708_2 56 57
are 24022708_2 58 61
two 24022708_2 62 65
major 24022708_2 66 71
factors 24022708_2 72 79
attributed 24022708_2 80 90
to 24022708_2 91 93
the 24022708_2 94 97
inter 24022708_2 98 103
- 24022708_2 103 104
individual 24022708_2 104 114
pharmacokinetic 24022708_2 115 130
variability 24022708_2 131 142
of 24022708_2 143 145
lansoprazole 24022708_2 146 158
( 24022708_2 159 160
LSZ 24022708_2 161 164
) 24022708_2 165 166
, 24022708_2 167 168
the 24022708_2 169 172
aim 24022708_2 173 176
of 24022708_2 177 179
the 24022708_2 180 183
study 24022708_2 184 189
was 24022708_2 190 193
to 24022708_2 194 196
simultaneously 24022708_2 197 211
elucidate 24022708_2 212 221
the 24022708_2 222 225
effects 24022708_2 226 233
of 24022708_2 234 236
CYP 24022708_2 237 240
2 24022708_2 240 241
C 24022708_2 241 242
19 24022708_2 242 244
and 24022708_2 245 248
MDRI 24022708_2 249 253
C 24022708_2 254 255
3435 24022708_2 255 259
T 24022708_2 259 260
polymorphisms 24022708_2 261 274
on 24022708_2 275 277
the 24022708_2 278 281
pharmacokinetics 24022708_2 282 298
difference 24022708_2 299 309
of 24022708_2 310 312
LSZ 24022708_2 313 316
and 24022708_2 317 320
its 24022708_2 321 324
metabolites 24022708_2 325 336
5 24022708_2 337 338
' 24022708_2 338 339
- 24022708_2 339 340
hydroxy 24022708_2 340 347
lansoprazole 24022708_2 348 360
( 24022708_2 361 362
HLSZ 24022708_2 363 367
) 24022708_2 368 369
and 24022708_2 370 373
lansoprazole 24022708_2 374 386
sulphone 24022708_2 387 395
( 24022708_2 396 397
LSZS 24022708_2 398 402
) 24022708_2 403 404
following 24022708_2 405 414
oral 24022708_2 415 419
administration 24022708_2 420 434
of 24022708_2 435 437
LSZ 24022708_2 438 441
tablets 24022708_2 442 449
in 24022708_2 450 452
healthy 24022708_2 453 460
Chinese 24022708_2 461 468
subjects 24022708_2 469 477
. 24022708_2 478 479

We 19620488_3 0 2
determined 19620488_3 3 13
the 19620488_3 14 17
status 19620488_3 18 24
of 19620488_3 25 27
the 19620488_3 28 31
HER 19620488_3 32 35
2 19620488_3 35 36
and 19620488_3 37 40
TOP 19620488_3 41 44
2 19620488_3 44 45
A 19620488_3 45 46
genes 19620488_3 47 52
in 19620488_3 53 55
a 19620488_3 56 57
large 19620488_3 58 63
cohort 19620488_3 64 70
of 19620488_3 71 73
breast 19620488_3 74 80
cancer 19620488_3 81 87
patients 19620488_3 88 96
treated 19620488_3 97 104
with 19620488_3 105 109
adjuvant 19620488_3 110 118
doxorubicin 19620488_3 119 130
( 19620488_3 131 132
A 19620488_3 133 134
) 19620488_3 135 136
and 19620488_3 137 140
cyclophosphamide 19620488_3 141 157
( 19620488_3 158 159
C 19620488_3 160 161
) 19620488_3 162 163
. 19620488_3 164 165

Hepatoprotective 28213291_1 0 16
effect 28213291_1 17 23
of 28213291_1 24 26
2 28213291_1 27 28
' 28213291_1 28 29
- 28213291_1 29 30
O 28213291_1 30 31
- 28213291_1 31 32
galloylhyperin 28213291_1 32 46
against 28213291_1 47 54
oxidative 28213291_1 55 64
stress 28213291_1 65 71
- 28213291_1 72 73
induced 28213291_1 73 80
liver 28213291_1 81 86
damage 28213291_1 87 93
through 28213291_1 94 101
induction 28213291_1 102 111
of 28213291_1 112 114
Nrf 28213291_1 115 118
2 28213291_1 118 119
/ 28213291_1 120 121
ARE 28213291_1 122 125
- 28213291_1 126 127
mediated 28213291_1 127 135
antioxidant 28213291_1 136 147
pathway 28213291_1 148 155
. 28213291_1 156 157

Patients 25227813_15 0 8
with 25227813_15 9 13
mutant 25227813_15 14 20
EGFR 25227813_15 21 25
genotype 25227813_15 26 34
and 25227813_15 35 38
higher 25227813_15 39 45
icotinib 25227813_15 46 54
concentration 25227813_15 55 68
might 25227813_15 69 74
have 25227813_15 75 79
increased 25227813_15 80 89
PFS 25227813_15 90 93
and 25227813_15 94 97
OS 25227813_15 98 100
and 25227813_15 101 104
lower 25227813_15 105 110
tumor 25227813_15 111 116
metastasis 25227813_15 117 127
. 25227813_15 128 129

Since 11692082_6 0 5
ivermectin 11692082_6 6 16
is 11692082_6 17 19
a 11692082_6 20 21
substrate 11692082_6 22 31
for 11692082_6 32 35
P 11692082_6 36 37
- 11692082_6 37 38
gp 11692082_6 38 40
, 11692082_6 41 42
we 11692082_6 43 45
hypothesized 11692082_6 46 58
that 11692082_6 59 63
ivermectin 11692082_6 64 74
- 11692082_6 75 76
sensitive 11692082_6 76 85
collies 11692082_6 86 93
had 11692082_6 94 97
altered 11692082_6 98 105
mdr 11692082_6 106 109
1 11692082_6 109 110
expression 11692082_6 111 121
compared 11692082_6 122 130
with 11692082_6 131 135
unaffected 11692082_6 136 146
collies 11692082_6 147 154
. 11692082_6 155 156

RESULTS 23702428_7 0 7
: 23702428_7 8 9
A 23702428_7 10 11
characteristic 23702428_7 12 26
feature 23702428_7 27 34
of 23702428_7 35 37
heroin 23702428_7 38 44
abusers 23702428_7 45 52
was 23702428_7 53 56
decreased 23702428_7 57 66
expression 23702428_7 67 77
of 23702428_7 78 80
MOR 23702428_7 81 84
and 23702428_7 85 88
extracellular 23702428_7 89 102
regulated 23702428_7 103 112
kinase 23702428_7 113 119
signaling 23702428_7 120 129
networks 23702428_7 130 138
, 23702428_7 139 140
concomitant 23702428_7 141 152
with 23702428_7 153 157
dysregulation 23702428_7 158 171
of 23702428_7 172 174
the 23702428_7 175 178
downstream 23702428_7 179 189
transcription 23702428_7 190 203
factor 23702428_7 204 210
ELK 23702428_7 211 214
1 23702428_7 214 215
. 23702428_7 216 217

Furthermore 15544431_6 0 11
, 15544431_6 12 13
in 15544431_6 14 16
our 15544431_6 17 20
recent 15544431_6 21 27
study 15544431_6 28 33
, 15544431_6 34 35
it 15544431_6 36 38
was 15544431_6 39 42
also 15544431_6 43 47
shown 15544431_6 48 53
that 15544431_6 54 58
cigarette 15544431_6 59 68
smoke 15544431_6 69 74
exposure 15544431_6 75 83
induces 15544431_6 84 91
hepatic 15544431_6 92 99
CYP 15544431_6 100 103
2 15544431_6 103 104
A 15544431_6 104 105
8 15544431_6 105 106
in 15544431_6 107 109
hamsters 15544431_6 110 118
, 15544431_6 119 120
which 15544431_6 121 126
is 15544431_6 127 129
homologous 15544431_6 130 140
to 15544431_6 141 143
CYP 15544431_6 144 147
2 15544431_6 147 148
A 15544431_6 148 149
6 15544431_6 149 150
in 15544431_6 151 153
human 15544431_6 154 159
, 15544431_6 160 161
and 15544431_6 162 165
hepatic 15544431_6 166 173
S 15544431_6 174 175
9 15544431_6 175 176
fraction 15544431_6 177 185
exposed 15544431_6 186 193
to 15544431_6 194 196
cigarette 15544431_6 197 206
smoke 15544431_6 207 212
increases 15544431_6 213 222
the 15544431_6 223 226
mutagenicity 15544431_6 227 239
of 15544431_6 240 242
4 15544431_6 243 244
- 15544431_6 244 245
( 15544431_6 245 246
methylnitrosamino 15544431_6 246 263
) 15544431_6 263 264
- 15544431_6 264 265
1 15544431_6 265 266
- 15544431_6 266 267
( 15544431_6 267 268
3 15544431_6 268 269
- 15544431_6 269 270
pyridyl 15544431_6 270 277
) 15544431_6 277 278
- 15544431_6 278 279
1 15544431_6 279 280
- 15544431_6 280 281
butanone 15544431_6 281 289
( 15544431_6 290 291
NNK 15544431_6 292 295
) 15544431_6 296 297
, 15544431_6 298 299
a 15544431_6 300 301
tobacco 15544431_6 302 309
specific 15544431_6 310 318
nitrosamine 15544431_6 319 330
, 15544431_6 331 332
which 15544431_6 333 338
is 15544431_6 339 341
in 15544431_6 342 344
line 15544431_6 345 349
with 15544431_6 350 354
the 15544431_6 355 358
fact 15544431_6 359 363
that 15544431_6 364 368
NNK 15544431_6 369 372
is 15544431_6 373 375
metabolically 15544431_6 376 389
activated 15544431_6 390 399
by 15544431_6 400 402
CYP 15544431_6 403 406
2 15544431_6 406 407
A 15544431_6 407 408
6 15544431_6 408 409
. 15544431_6 410 411

Patients 19682085_14 0 8
with 19682085_14 9 13
ITPA 19682085_14 14 18
94 19682085_14 19 21
C 19682085_14 21 22
> 19682085_14 22 23
A 19682085_14 23 24
homozygous 19682085_14 25 35
allele 19682085_14 36 42
are 19682085_14 43 46
at 19682085_14 47 49
high 19682085_14 50 54
risk 19682085_14 55 59
to 19682085_14 60 62
develop 19682085_14 63 70
AZA 19682085_14 71 74
- 19682085_14 75 76
related 19682085_14 76 83
gastrointestinal 19682085_14 84 100
toxicity 19682085_14 101 109
and 19682085_14 110 113
flu 19682085_14 114 117
- 19682085_14 118 119
like 19682085_14 119 123
symptoms 19682085_14 124 132
( 19682085_14 133 134
P 19682085_14 135 136
< 19682085_14 137 138
0 19682085_14 139 140
. 19682085_14 140 141
01 19682085_14 141 143
) 19682085_14 144 145
. 19682085_14 146 147

The 16719540_4 0 3
reasons 16719540_4 4 11
why 16719540_4 12 15
doses 16719540_4 16 21
are 16719540_4 22 25
not 16719540_4 26 29
individualised 16719540_4 30 44
routinely 16719540_4 45 54
are 16719540_4 55 58
difficulties 16719540_4 59 71
in 16719540_4 72 74
defining 16719540_4 75 83
, 16719540_4 84 85
predicting 16719540_4 86 96
and 16719540_4 97 100
achieving 16719540_4 101 110
an 16719540_4 111 113
optimal 16719540_4 114 121
fluorouracil 16719540_4 122 134
exposure 16719540_4 135 143
or 16719540_4 144 146
dose 16719540_4 147 151
because 16719540_4 152 159
of 16719540_4 160 162
a 16719540_4 163 164
narrow 16719540_4 165 171
therapeutic 16719540_4 172 183
index 16719540_4 184 189
, 16719540_4 190 191
nonlinear 16719540_4 192 201
pharmacokinetics 16719540_4 202 218
, 16719540_4 219 220
variabilities 16719540_4 221 234
in 16719540_4 235 237
administration 16719540_4 238 252
rates 16719540_4 253 258
and 16719540_4 259 262
metabolism 16719540_4 263 273
, 16719540_4 274 275
and 16719540_4 276 279
in 16719540_4 280 282
targets 16719540_4 283 290
like 16719540_4 291 295
thymidylate 16719540_4 296 307
synthase 16719540_4 308 316
. 16719540_4 317 318

Effect 1734875_1 0 6
of 1734875_1 7 9
extracellular 1734875_1 10 23
phosphatidylinositol 1734875_1 24 44
on 1734875_1 45 47
c 1734875_1 48 49
- 1734875_1 49 50
myc 1734875_1 50 53
gene 1734875_1 54 58
- 1734875_1 58 59
expressed 1734875_1 59 68
human 1734875_1 69 74
renal 1734875_1 75 80
cancer 1734875_1 81 87
cell 1734875_1 88 92
line 1734875_1 93 97
. 1734875_1 98 99

CONCLUSIONS 19884861_11 0 11
: 19884861_11 12 13
Activating 19884861_11 14 24
EGFR 19884861_11 25 29
mutations 19884861_11 30 39
detected 19884861_11 40 48
in 19884861_11 49 51
shed 19884861_11 52 56
DNA 19884861_11 57 60
in 19884861_11 61 63
plasma 19884861_11 64 70
are 19884861_11 71 74
significantly 19884861_11 75 88
associated 19884861_11 89 99
with 19884861_11 100 104
favorable 19884861_11 105 114
outcomes 19884861_11 115 123
in 19884861_11 124 126
patients 19884861_11 127 135
with 19884861_11 136 140
advanced 19884861_11 141 149
NSCLC 19884861_11 150 155
receiving 19884861_11 156 165
docetaxel 19884861_11 166 175
plus 19884861_11 176 180
intercalated 19884861_11 181 193
erlotinib 19884861_11 194 203
. 19884861_11 204 205

The 16819620_6 0 3
present 16819620_6 4 11
study 16819620_6 12 17
was 16819620_6 18 21
designed 16819620_6 22 30
to 16819620_6 31 33
examine 16819620_6 34 41
the 16819620_6 42 45
influence 16819620_6 46 55
of 16819620_6 56 58
the 16819620_6 59 62
DA 16819620_6 63 65
D 16819620_6 66 67
4 16819620_6 67 68
receptor 16819620_6 69 77
( 16819620_6 78 79
DRD 16819620_6 80 83
4 16819620_6 83 84
) 16819620_6 85 86
and 16819620_6 87 90
the 16819620_6 91 94
serotonin 16819620_6 95 104
transporter 16819620_6 105 116
( 16819620_6 117 118
5 16819620_6 119 120
- 16819620_6 120 121
HTT 16819620_6 121 124
) 16819620_6 125 126
genotype 16819620_6 127 135
and 16819620_6 136 139
their 16819620_6 140 145
interaction 16819620_6 146 157
on 16819620_6 158 160
adolescent 16819620_6 161 171
alcohol 16819620_6 172 179
and 16819620_6 180 183
tobacco 16819620_6 184 191
experimentation 16819620_6 192 207
. 16819620_6 208 209

The 17899045_8 0 3
multiple 17899045_8 4 12
linear 17899045_8 13 19
regression 17899045_8 20 30
model 17899045_8 31 36
for 17899045_8 37 40
warfarin 17899045_8 41 49
dose 17899045_8 50 54
indicated 17899045_8 55 64
significant 17899045_8 65 76
contributions 17899045_8 77 90
from 17899045_8 91 95
age 17899045_8 96 99
( 17899045_8 100 101
r 17899045_8 102 103
( 17899045_8 104 105
2 17899045_8 106 107
) 17899045_8 108 109
= 17899045_8 110 111
0 17899045_8 112 113
. 17899045_8 113 114
084 17899045_8 114 117
; 17899045_8 118 119
P 17899045_8 120 121
< 17899045_8 122 123
0 17899045_8 124 125
. 17899045_8 125 126
001 17899045_8 126 129
) 17899045_8 130 131
, 17899045_8 132 133
weight 17899045_8 134 140
( 17899045_8 141 142
r 17899045_8 143 144
( 17899045_8 145 146
2 17899045_8 147 148
) 17899045_8 149 150
= 17899045_8 151 152
0 17899045_8 153 154
. 17899045_8 154 155
063 17899045_8 155 158
; 17899045_8 159 160
P 17899045_8 161 162
< 17899045_8 163 164
0 17899045_8 165 166
. 17899045_8 166 167
001 17899045_8 167 170
) 17899045_8 171 172
, 17899045_8 173 174
VKORC 17899045_8 175 180
1 17899045_8 180 181
genotype 17899045_8 182 190
( 17899045_8 191 192
r 17899045_8 193 194
( 17899045_8 195 196
2 17899045_8 197 198
) 17899045_8 199 200
= 17899045_8 201 202
0 17899045_8 203 204
. 17899045_8 204 205
494 17899045_8 205 208
; 17899045_8 209 210
P 17899045_8 211 212
< 17899045_8 213 214
0 17899045_8 215 216
. 17899045_8 216 217
001 17899045_8 217 220
) 17899045_8 221 222
, 17899045_8 223 224
and 17899045_8 225 228
age 17899045_8 229 232
, 17899045_8 233 234
weight 17899045_8 235 241
, 17899045_8 242 243
and 17899045_8 244 247
CYP 17899045_8 248 251
2 17899045_8 251 252
C 17899045_8 252 253
9 17899045_8 253 254
and 17899045_8 255 258
VKORC 17899045_8 259 264
1 17899045_8 264 265
genotype 17899045_8 266 274
together 17899045_8 275 283
( 17899045_8 284 285
r 17899045_8 286 287
( 17899045_8 288 289
2 17899045_8 290 291
) 17899045_8 292 293
= 17899045_8 294 295
0 17899045_8 296 297
. 17899045_8 297 298
628 17899045_8 298 301
; 17899045_8 302 303
P 17899045_8 304 305
< 17899045_8 306 307
0 17899045_8 308 309
. 17899045_8 309 310
001 17899045_8 310 313
) 17899045_8 314 315
. 17899045_8 316 317

Elucidation 12057079_3 0 11
of 12057079_3 12 14
HER 12057079_3 15 18
2 12057079_3 18 19
and 12057079_3 20 23
its 12057079_3 24 27
role 12057079_3 28 32
in 12057079_3 33 35
malignant 12057079_3 36 45
transformation 12057079_3 46 60
has 12057079_3 61 64
helped 12057079_3 65 71
define 12057079_3 72 78
a 12057079_3 79 80
subset 12057079_3 81 87
of 12057079_3 88 90
aggressive 12057079_3 91 101
breast 12057079_3 102 108
cancer 12057079_3 109 115
that 12057079_3 116 120
may 12057079_3 121 124
be 12057079_3 125 127
relatively 12057079_3 128 138
resistant 12057079_3 139 148
to 12057079_3 149 151
non 12057079_3 152 155
- 12057079_3 155 156
anthracycline 12057079_3 157 170
- 12057079_3 171 172
based 12057079_3 172 177
therapies 12057079_3 178 187
and 12057079_3 188 191
hormonal 12057079_3 192 200
agents 12057079_3 201 207
, 12057079_3 208 209
but 12057079_3 210 213
responds 12057079_3 214 222
to 12057079_3 223 225
targeted 12057079_3 226 234
molecular 12057079_3 235 244
therapy 12057079_3 245 252
. 12057079_3 253 254

At 16242410_4 0 2
the 16242410_4 3 6
cFos 16242410_4 7 11
promoter 16242410_4 12 20
, 16242410_4 21 22
H 16242410_4 23 24
4 16242410_4 24 25
hyperacetylation 16242410_4 26 42
is 16242410_4 43 45
seen 16242410_4 46 50
within 16242410_4 51 57
30 16242410_4 58 60
min 16242410_4 61 64
of 16242410_4 65 67
a 16242410_4 68 69
single 16242410_4 70 76
cocaine 16242410_4 77 84
injection 16242410_4 85 94
, 16242410_4 95 96
whereas 16242410_4 97 104
no 16242410_4 105 107
histone 16242410_4 108 115
modifications 16242410_4 116 129
were 16242410_4 130 134
seen 16242410_4 135 139
with 16242410_4 140 144
chronic 16242410_4 145 152
cocaine 16242410_4 153 160
, 16242410_4 161 162
consistent 16242410_4 163 173
with 16242410_4 174 178
cocaine 16242410_4 179 186
' 16242410_4 187 188
s 16242410_4 188 189
ability 16242410_4 190 197
to 16242410_4 198 200
induce 16242410_4 201 207
cFos 16242410_4 208 212
acutely 16242410_4 213 220
, 16242410_4 221 222
but 16242410_4 223 226
not 16242410_4 227 230
chronically 16242410_4 231 242
. 16242410_4 243 244

For 19817501_20 0 3
example 19817501_20 4 11
, 19817501_20 12 13
CYP 19817501_20 14 17
2 19817501_20 17 18
D 19817501_20 18 19
6 19817501_20 19 20
* 19817501_20 21 22
17 19817501_20 23 25
is 19817501_20 26 28
generally 19817501_20 29 38
considered 19817501_20 39 49
as 19817501_20 50 52
an 19817501_20 53 55
allele 19817501_20 56 62
with 19817501_20 63 67
reduced 19817501_20 68 75
function 19817501_20 76 84
, 19817501_20 85 86
but 19817501_20 87 90
it 19817501_20 91 93
displays 19817501_20 94 102
remarkable 19817501_20 103 113
variability 19817501_20 114 125
in 19817501_20 126 128
its 19817501_20 129 132
activity 19817501_20 133 141
towards 19817501_20 142 149
substrates 19817501_20 150 160
such 19817501_20 161 165
as 19817501_20 166 168
dextromethorphan 19817501_20 169 185
, 19817501_20 186 187
risperidone 19817501_20 188 199
, 19817501_20 200 201
codeine 19817501_20 202 209
and 19817501_20 210 213
haloperidol 19817501_20 214 225
. 19817501_20 226 227

The 20159992_1 0 3
FLT 20159992_1 4 7
3 20159992_1 7 8
internal 20159992_1 9 17
tandem 20159992_1 18 24
duplication 20159992_1 25 36
mutation 20159992_1 37 45
is 20159992_1 46 48
a 20159992_1 49 50
secondary 20159992_1 51 60
target 20159992_1 61 67
of 20159992_1 68 70
the 20159992_1 71 74
aurora 20159992_1 75 81
B 20159992_1 82 83
kinase 20159992_1 84 90
inhibitor 20159992_1 91 100
AZD 20159992_1 101 104
1152 20159992_1 104 108
- 20159992_1 108 109
HQPA 20159992_1 109 113
in 20159992_1 114 116
acute 20159992_1 117 122
myelogenous 20159992_1 123 134
leukemia 20159992_1 135 143
cells 20159992_1 144 149
. 20159992_1 150 151

Our 26239294_9 0 3
results 26239294_9 4 11
indicate 26239294_9 12 20
that 26239294_9 21 25
common 26239294_9 26 32
, 26239294_9 33 34
low 26239294_9 35 38
frequency 26239294_9 39 48
and 26239294_9 49 52
rare 26239294_9 53 57
CHRNA 26239294_9 58 63
5 26239294_9 63 64
coding 26239294_9 65 71
variants 26239294_9 72 80
are 26239294_9 81 84
independently 26239294_9 85 98
associated 26239294_9 99 109
with 26239294_9 110 114
nicotine 26239294_9 115 123
dependence 26239294_9 124 134
risk 26239294_9 135 139
. 26239294_9 140 141

Genomewide 26485092_1 0 10
Association 26485092_1 11 22
Study 26485092_1 23 28
of 26485092_1 29 31
Tacrolimus 26485092_1 32 42
Concentrations 26485092_1 43 57
in 26485092_1 58 60
African 26485092_1 61 68
American 26485092_1 69 77
Kidney 26485092_1 78 84
Transplant 26485092_1 85 95
Recipients 26485092_1 96 106
Identifies 26485092_1 107 117
Multiple 26485092_1 118 126
CYP 26485092_1 127 130
3 26485092_1 130 131
A 26485092_1 131 132
5 26485092_1 132 133
Alleles 26485092_1 134 141
. 26485092_1 142 143

OBJECTIVE 26698676_2 0 9
: 26698676_2 10 11
To 26698676_2 12 14
evaluate 26698676_2 15 23
the 26698676_2 24 27
relationship 26698676_2 28 40
between 26698676_2 41 48
use 26698676_2 49 52
of 26698676_2 53 55
fertility 26698676_2 56 65
medication 26698676_2 66 76
( 26698676_2 77 78
i 26698676_2 79 80
. 26698676_2 80 81
e 26698676_2 81 82
. 26698676_2 82 83
, 26698676_2 84 85
selective 26698676_2 86 95
estrogen 26698676_2 96 104
receptor 26698676_2 105 113
[ 26698676_2 114 115
ER 26698676_2 116 118
] 26698676_2 119 120
modulator 26698676_2 121 130
, 26698676_2 131 132
gonadotropin 26698676_2 133 145
, 26698676_2 146 147
or 26698676_2 148 150
other 26698676_2 151 156
) 26698676_2 157 158
or 26698676_2 159 161
infertility 26698676_2 162 173
treatment 26698676_2 174 183
( 26698676_2 184 185
i 26698676_2 186 187
. 26698676_2 187 188
e 26698676_2 188 189
. 26698676_2 189 190
, 26698676_2 191 192
IVF 26698676_2 193 196
or 26698676_2 197 199
IUI 26698676_2 200 203
) 26698676_2 204 205
and 26698676_2 206 209
the 26698676_2 210 213
risk 26698676_2 214 218
of 26698676_2 219 221
ovarian 26698676_2 222 229
cancer 26698676_2 230 236
among 26698676_2 237 242
women 26698676_2 243 248
with 26698676_2 249 253
a 26698676_2 254 255
BRCA 26698676_2 256 260
1 26698676_2 260 261
or 26698676_2 262 264
BRCA 26698676_2 265 269
2 26698676_2 269 270
mutation 26698676_2 271 279
. 26698676_2 280 281

The 23082737_9 0 3
second 23082737_9 4 10
is 23082737_9 11 13
vemurafenib 23082737_9 14 25
, 23082737_9 26 27
an 23082737_9 28 30
inhibitor 23082737_9 31 40
that 23082737_9 41 45
blocks 23082737_9 46 52
the 23082737_9 53 56
abnormal 23082737_9 57 65
signaling 23082737_9 66 75
for 23082737_9 76 79
melanoma 23082737_9 80 88
cellular 23082737_9 89 97
growth 23082737_9 98 104
in 23082737_9 105 107
tumors 23082737_9 108 114
that 23082737_9 115 119
carry 23082737_9 120 125
the 23082737_9 126 129
BRAF 23082737_9 130 134
( 23082737_9 135 136
V 23082737_9 136 137
600 23082737_9 137 140
E 23082737_9 140 141
) 23082737_9 142 143
mutation 23082737_9 144 152
. 23082737_9 153 154

We 23275005_7 0 2
chose 23275005_7 3 8
a 23275005_7 9 10
30 23275005_7 11 13
M 23275005_7 14 15
concentration 23275005_7 16 29
of 23275005_7 30 32
4 23275005_7 33 34
- 23275005_7 34 35
HNE 23275005_7 35 38
, 23275005_7 39 40
which 23275005_7 41 46
produced 23275005_7 47 55
an 23275005_7 56 58
approximately 23275005_7 59 72
50 23275005_7 73 75
% 23275005_7 76 77
inhibition 23275005_7 78 88
of 23275005_7 89 91
complex 23275005_7 92 99
I 23275005_7 100 101
- 23275005_7 102 103
or 23275005_7 104 106
complex 23275005_7 107 114
II 23275005_7 115 117
- 23275005_7 117 118
driven 23275005_7 119 125
respiration 23275005_7 126 137
, 23275005_7 138 139
to 23275005_7 140 142
assess 23275005_7 143 149
whether 23275005_7 150 157
prior 23275005_7 158 163
in 23275005_7 164 166
vivo 23275005_7 167 171
Nrf 23275005_7 172 175
2 23275005_7 175 176
- 23275005_7 177 178
ARE 23275005_7 179 182
- 23275005_7 183 184
activating 23275005_7 184 194
compounds 23275005_7 195 204
would 23275005_7 205 210
increase 23275005_7 211 219
the 23275005_7 220 223
resistance 23275005_7 224 234
of 23275005_7 235 237
the 23275005_7 238 241
isolated 23275005_7 242 250
cortical 23275005_7 251 259
mitochondria 23275005_7 260 272
to 23275005_7 273 275
4 23275005_7 276 277
- 23275005_7 277 278
HNE 23275005_7 278 281
' 23275005_7 282 283
s 23275005_7 283 284
mitotoxic 23275005_7 285 294
effects 23275005_7 295 302
. 23275005_7 303 304

A 22095536_2 0 1
study 22095536_2 2 7
was 22095536_2 8 11
carried 22095536_2 12 19
out 22095536_2 20 23
to 22095536_2 24 26
determine 22095536_2 27 36
whether 22095536_2 37 44
early 22095536_2 45 50
viral 22095536_2 51 56
dynamics 22095536_2 57 65
retain 22095536_2 66 72
prediction 22095536_2 73 83
of 22095536_2 84 86
the 22095536_2 87 90
outcome 22095536_2 91 98
of 22095536_2 99 101
peginterferon 22095536_2 102 115
( 22095536_2 116 117
PEG 22095536_2 118 121
- 22095536_2 121 122
IFN 22095536_2 122 125
) 22095536_2 126 127
and 22095536_2 128 131
ribavirin 22095536_2 132 141
combination 22095536_2 142 153
therapy 22095536_2 154 161
based 22095536_2 162 167
on 22095536_2 168 170
different 22095536_2 171 180
genetic 22095536_2 181 188
polymorphisms 22095536_2 189 202
near 22095536_2 203 207
the 22095536_2 208 211
IL 22095536_2 212 214
28 22095536_2 214 216
B 22095536_2 216 217
gene 22095536_2 218 222
, 22095536_2 223 224
the 22095536_2 225 228
strongest 22095536_2 229 238
baseline 22095536_2 239 247
predictor 22095536_2 248 257
of 22095536_2 258 260
response 22095536_2 261 269
to 22095536_2 270 272
this 22095536_2 273 277
therapy 22095536_2 278 285
. 22095536_2 286 287

BACKGROUND 23501331_2 0 10
: 23501331_2 11 12
Variability 23501331_2 13 24
of 23501331_2 25 27
response 23501331_2 28 36
to 23501331_2 37 39
statins 23501331_2 40 47
has 23501331_2 48 51
been 23501331_2 52 56
related 23501331_2 57 64
to 23501331_2 65 67
polymorphisms 23501331_2 68 81
in 23501331_2 82 84
genes 23501331_2 85 90
involved 23501331_2 91 99
in 23501331_2 100 102
cholesterol 23501331_2 103 114
homeostasis 23501331_2 115 126
and 23501331_2 127 130
statin 23501331_2 131 137
metabolism 23501331_2 138 148
, 23501331_2 149 150
such 23501331_2 151 155
as 23501331_2 156 158
CYP 23501331_2 159 162
3 23501331_2 162 163
A 23501331_2 163 164
4 23501331_2 164 165
and 23501331_2 166 169
CYP 23501331_2 170 173
3 23501331_2 173 174
A 23501331_2 174 175
5 23501331_2 175 176
. 23501331_2 177 178

Our 21844885_11 0 3
results 21844885_11 4 11
support 21844885_11 12 19
the 21844885_11 20 23
potential 21844885_11 24 33
predictive 21844885_11 34 44
ability 21844885_11 45 52
of 21844885_11 53 55
VEGF 21844885_11 56 60
genotypes 21844885_11 61 70
in 21844885_11 71 73
patients 21844885_11 74 82
with 21844885_11 83 87
metastatic 21844885_11 88 98
colorectal 21844885_11 99 109
cancer 21844885_11 110 116
receiving 21844885_11 117 126
irinotecan 21844885_11 127 137
- 21844885_11 138 139
based 21844885_11 139 144
chemotherapy 21844885_11 145 157
plus 21844885_11 158 162
bevacizumab 21844885_11 163 174
, 21844885_11 175 176
in 21844885_11 177 179
terms 21844885_11 180 185
of 21844885_11 186 188
RR 21844885_11 189 191
and 21844885_11 192 195
OS 21844885_11 196 198
. 21844885_11 199 200

Bucindolol 23071495_3 0 10
is 23071495_3 11 13
a 23071495_3 14 15
b 23071495_3 16 17
- 23071495_3 17 18
blocker 23071495_3 18 25
/ 23071495_3 26 27
sympatholytic 23071495_3 28 41
agent 23071495_3 42 47
whose 23071495_3 48 53
efficacy 23071495_3 54 62
is 23071495_3 63 65
modulated 23071495_3 66 75
by 23071495_3 76 78
polymorphisms 23071495_3 79 92
in 23071495_3 93 95
the 23071495_3 96 99
primary 23071495_3 100 107
target 23071495_3 108 114
( 23071495_3 115 116
b 23071495_3 117 118
( 23071495_3 119 120
1 23071495_3 121 122
) 23071495_3 123 124
adrenergic 23071495_3 125 135
receptor 23071495_3 136 144
[ 23071495_3 145 146
AR 23071495_3 147 149
] 23071495_3 150 151
Arg 23071495_3 152 155
389 23071495_3 155 158
Gly 23071495_3 159 162
on 23071495_3 163 165
cardiac 23071495_3 166 173
myocytes 23071495_3 174 182
) 23071495_3 183 184
and 23071495_3 185 188
a 23071495_3 189 190
secondary 23071495_3 191 200
target 23071495_3 201 207
modifier 23071495_3 208 216
( 23071495_3 217 218
a 23071495_3 219 220
( 23071495_3 221 222
2 23071495_3 223 224
C 23071495_3 224 225
) 23071495_3 226 227
AR 23071495_3 228 230
Ins 23071495_3 231 234
[ 23071495_3 235 236
wild 23071495_3 237 241
- 23071495_3 241 242
type 23071495_3 242 246
( 23071495_3 247 248
Wt 23071495_3 249 251
) 23071495_3 252 253
] 23071495_3 254 255
322 23071495_3 256 259
- 23071495_3 259 260
325 23071495_3 260 263
deletion 23071495_3 264 272
[ 23071495_3 273 274
Del 23071495_3 275 278
] 23071495_3 279 280
on 23071495_3 281 283
cardiac 23071495_3 284 291
adrenergic 23071495_3 292 302
neurons 23071495_3 303 310
) 23071495_3 311 312
. 23071495_3 313 314

PURPOSE 15020609_2 0 7
: 15020609_2 8 9
To 15020609_2 10 12
determine 15020609_2 13 22
whether 15020609_2 23 30
adding 15020609_2 31 37
the 15020609_2 38 41
multidrug 15020609_2 42 51
resistance 15020609_2 52 62
gene 15020609_2 63 67
- 15020609_2 67 68
1 15020609_2 68 69
( 15020609_2 70 71
MDR 15020609_2 72 75
- 15020609_2 75 76
1 15020609_2 76 77
) 15020609_2 78 79
modulator 15020609_2 80 89
valspodar 15020609_2 90 99
( 15020609_2 100 101
PSC 15020609_2 102 105
833 15020609_2 106 109
; 15020609_2 110 111
Novartis 15020609_2 112 120
Pharmaceuticals 15020609_2 121 136
, 15020609_2 137 138
Hanover 15020609_2 139 146
, 15020609_2 147 148
NJ 15020609_2 149 151
) 15020609_2 152 153
to 15020609_2 154 156
chemotherapy 15020609_2 157 169
provided 15020609_2 170 178
clinical 15020609_2 179 187
benefit 15020609_2 188 195
to 15020609_2 196 198
patients 15020609_2 199 207
with 15020609_2 208 212
poor 15020609_2 213 217
- 15020609_2 217 218
risk 15020609_2 218 222
acute 15020609_2 223 228
myeloid 15020609_2 229 236
leukemia 15020609_2 237 245
( 15020609_2 246 247
AML 15020609_2 248 251
) 15020609_2 252 253
and 15020609_2 254 257
high 15020609_2 258 262
- 15020609_2 262 263
risk 15020609_2 263 267
myelodysplastic 15020609_2 268 283
syndrome 15020609_2 284 292
( 15020609_2 293 294
MDS 15020609_2 295 298
) 15020609_2 299 300
. 15020609_2 301 302

The 16257348_2 0 3
purpose 16257348_2 4 11
of 16257348_2 12 14
this 16257348_2 15 19
study 16257348_2 20 25
was 16257348_2 26 29
to 16257348_2 30 32
explore 16257348_2 33 40
the 16257348_2 41 44
association 16257348_2 45 56
of 16257348_2 57 59
a 16257348_2 60 61
tryptophan 16257348_2 62 72
hydroxylase 16257348_2 73 84
gene 16257348_2 85 89
polymorphism 16257348_2 90 102
( 16257348_2 103 104
TPH 16257348_2 105 108
1 16257348_2 108 109
A 16257348_2 110 111
218 16257348_2 111 114
C 16257348_2 114 115
) 16257348_2 116 117
with 16257348_2 118 122
the 16257348_2 123 126
age 16257348_2 127 130
of 16257348_2 131 133
alcoholism 16257348_2 134 144
onset 16257348_2 145 150
in 16257348_2 151 153
a 16257348_2 154 155
Korean 16257348_2 156 162
population 16257348_2 163 173
. 16257348_2 174 175

Analysing 22300961_11 0 9
combined 22300961_11 10 18
effects 22300961_11 19 26
, 22300961_11 27 28
a 22300961_11 29 30
significant 22300961_11 31 42
impact 22300961_11 43 49
of 22300961_11 50 52
low 22300961_11 53 56
25 22300961_11 57 59
- 22300961_11 59 60
OH 22300961_11 60 62
vitamin 22300961_11 63 70
D 22300961_11 71 72
levels 22300961_11 73 79
on 22300961_11 80 82
sustained 22300961_11 83 92
virological 22300961_11 93 104
response 22300961_11 105 113
were 22300961_11 114 118
only 22300961_11 119 123
seen 22300961_11 124 128
in 22300961_11 129 131
patients 22300961_11 132 140
with 22300961_11 141 145
the 22300961_11 146 149
unfavourable 22300961_11 150 162
NR 22300961_11 163 165
1 22300961_11 165 166
I 22300961_11 166 167
1 22300961_11 167 168
CCA 22300961_11 169 172
( 22300961_11 173 174
bAt 22300961_11 175 178
) 22300961_11 179 180
haplotype 22300961_11 181 190
( 22300961_11 191 192
OR 22300961_11 193 195
for 22300961_11 196 199
non 22300961_11 200 203
- 22300961_11 203 204
SVR 22300961_11 204 207
3 22300961_11 208 209
. 22300961_11 209 210
55 22300961_11 210 212
; 22300961_11 213 214
95 22300961_11 215 217
% 22300961_11 218 219
CI 22300961_11 220 222
1 22300961_11 223 224
. 22300961_11 224 225
005 22300961_11 225 228
, 22300961_11 229 230
12 22300961_11 231 233
. 22300961_11 233 234
57 22300961_11 234 236
; 22300961_11 237 238
P 22300961_11 239 240
= 22300961_11 241 242
0 22300961_11 243 244
. 22300961_11 244 245
049 22300961_11 245 248
) 22300961_11 249 250
. 22300961_11 251 252

Polymorphisms 17563401_7 0 13
in 17563401_7 14 16
3 17563401_7 17 18
- 17563401_7 18 19
hydroxy 17563401_7 19 26
- 17563401_7 26 27
3 17563401_7 27 28
- 17563401_7 28 29
methylglutaryl 17563401_7 29 43
- 17563401_7 43 44
coenzyme 17563401_7 44 52
A 17563401_7 53 54
reductase 17563401_7 55 64
( 17563401_7 65 66
HMGCR 17563401_7 67 72
) 17563401_7 73 74
previously 17563401_7 75 85
reported 17563401_7 86 94
to 17563401_7 95 97
affect 17563401_7 98 104
the 17563401_7 105 108
efficacy 17563401_7 109 117
of 17563401_7 118 120
pravastatin 17563401_7 121 132
did 17563401_7 133 136
not 17563401_7 137 140
show 17563401_7 141 145
a 17563401_7 146 147
similar 17563401_7 148 155
effect 17563401_7 156 162
on 17563401_7 163 165
the 17563401_7 166 169
reduction 17563401_7 170 179
of 17563401_7 180 182
LDL 17563401_7 183 186
cholesterol 17563401_7 187 198
by 17563401_7 199 201
fluvastatin 17563401_7 202 213
. 17563401_7 214 215

Using 20107067_3 0 5
mice 20107067_3 6 10
with 20107067_3 11 15
targeted 20107067_3 16 24
deletion 20107067_3 25 33
of 20107067_3 34 36
SR 20107067_3 37 39
, 20107067_3 40 41
we 20107067_3 42 44
demonstrate 20107067_3 45 56
a 20107067_3 57 58
role 20107067_3 59 63
for 20107067_3 64 67
D 20107067_3 68 69
- 20107067_3 69 70
serine 20107067_3 70 76
in 20107067_3 77 79
NMDA 20107067_3 80 84
receptor 20107067_3 85 93
- 20107067_3 94 95
mediated 20107067_3 95 103
neurotoxicity 20107067_3 104 117
and 20107067_3 118 121
stroke 20107067_3 122 128
. 20107067_3 129 130

Clinical 22205192_1 0 8
Pharmacogenetics 22205192_1 9 25
Implementation 22205192_1 26 40
Consortium 22205192_1 41 51
( 22205192_1 52 53
CPIC 22205192_1 54 58
) 22205192_1 59 60
guidelines 22205192_1 61 71
for 22205192_1 72 75
codeine 22205192_1 76 83
therapy 22205192_1 84 91
in 22205192_1 92 94
the 22205192_1 95 98
context 22205192_1 99 106
of 22205192_1 107 109
cytochrome 22205192_1 110 120
P 22205192_1 121 122
450 22205192_1 122 125
2 22205192_1 126 127
D 22205192_1 127 128
6 22205192_1 128 129
( 22205192_1 130 131
CYP 22205192_1 132 135
2 22205192_1 135 136
D 22205192_1 136 137
6 22205192_1 137 138
) 22205192_1 139 140
genotype 22205192_1 141 149
. 22205192_1 150 151

IMO 21890455_6 0 3
interfered 21890455_6 4 14
with 21890455_6 15 19
EGFR 21890455_6 20 24
- 21890455_6 25 26
dependent 21890455_6 26 35
signaling 21890455_6 36 45
, 21890455_6 46 47
modulating 21890455_6 48 58
the 21890455_6 59 62
functional 21890455_6 63 73
interaction 21890455_6 74 85
between 21890455_6 86 93
TLR 21890455_6 94 97
9 21890455_6 97 98
and 21890455_6 99 102
EGFR 21890455_6 103 107
. 21890455_6 108 109

RESULTS 24886060_7 0 7
: 24886060_7 8 9
Expression 24886060_7 10 20
of 24886060_7 21 23
NQO 24886060_7 24 27
1 24886060_7 27 28
markedly 24886060_7 29 37
increased 24886060_7 38 47
sensitivity 24886060_7 48 59
to 24886060_7 60 62
17 24886060_7 63 65
- 24886060_7 65 66
AAG 24886060_7 66 69
in 24886060_7 70 72
the 24886060_7 73 76
OSCC 24886060_7 77 81
cell 24886060_7 82 86
lines 24886060_7 87 92
, 24886060_7 93 94
while 24886060_7 95 100
normal 24886060_7 101 107
fibroblasts 24886060_7 108 119
, 24886060_7 120 121
which 24886060_7 122 127
expressed 24886060_7 128 137
HSP 24886060_7 138 141
90 24886060_7 141 143
at 24886060_7 144 146
much 24886060_7 147 151
lower 24886060_7 152 157
levels 24886060_7 158 164
, 24886060_7 165 166
were 24886060_7 167 171
more 24886060_7 172 176
resistant 24886060_7 177 186
to 24886060_7 187 189
17 24886060_7 190 192
- 24886060_7 192 193
AAG 24886060_7 193 196
. 24886060_7 197 198

Sorafenib 19366808_1 0 9
induces 19366808_1 10 17
apoptosis 19366808_1 18 27
specifically 19366808_1 28 40
in 19366808_1 41 43
cells 19366808_1 44 49
expressing 19366808_1 50 60
BCR 19366808_1 61 64
/ 19366808_1 64 65
ABL 19366808_1 65 68
by 19366808_1 69 71
inhibiting 19366808_1 72 82
its 19366808_1 83 86
kinase 19366808_1 87 93
activity 19366808_1 94 102
to 19366808_1 103 105
activate 19366808_1 106 114
the 19366808_1 115 118
intrinsic 19366808_1 119 128
mitochondrial 19366808_1 129 142
pathway 19366808_1 143 150
. 19366808_1 151 152

Phase 20028383_1 0 5
I 20028383_1 6 7
study 20028383_1 8 13
of 20028383_1 14 16
irinotecan 20028383_1 17 27
and 20028383_1 28 31
doxifluridine 20028383_1 32 45
for 20028383_1 46 49
metastatic 20028383_1 50 60
colorectal 20028383_1 61 71
cancer 20028383_1 72 78
focusing 20028383_1 79 87
on 20028383_1 88 90
the 20028383_1 91 94
UGT 20028383_1 95 98
1 20028383_1 98 99
A 20028383_1 99 100
1 20028383_1 100 101
* 20028383_1 102 103
28 20028383_1 104 106
polymorphism 20028383_1 107 119
. 20028383_1 120 121

BACKGROUND 17412797_2 0 10
: 17412797_2 11 12
Carbohydrate 17412797_2 13 25
- 17412797_2 26 27
deficient 17412797_2 27 36
transferrin 17412797_2 37 48
( 17412797_2 49 50
CDT 17412797_2 51 54
) 17412797_2 55 56
is 17412797_2 57 59
a 17412797_2 60 61
promising 17412797_2 62 71
biomarker 17412797_2 72 81
of 17412797_2 82 84
alcohol 17412797_2 85 92
abuse 17412797_2 93 98
. 17412797_2 99 100

Therefore 15707696_5 0 9
, 15707696_5 10 11
these 15707696_5 12 17
observations 15707696_5 18 30
indicate 15707696_5 31 39
that 15707696_5 40 44
chronic 15707696_5 45 52
ethanol 15707696_5 53 60
causes 15707696_5 61 67
demethylation 15707696_5 68 81
in 15707696_5 82 84
CpG 15707696_5 85 88
islands 15707696_5 89 96
in 15707696_5 97 99
the 15707696_5 100 103
regions 15707696_5 104 111
( 15707696_5 112 113
5843 15707696_5 114 118
- 15707696_5 118 119
6276 15707696_5 119 123
) 15707696_5 124 125
and 15707696_5 126 129
( 15707696_5 130 131
6477 15707696_5 132 136
- 15707696_5 136 137
6763 15707696_5 137 141
) 15707696_5 142 143
, 15707696_5 144 145
thereby 15707696_5 146 153
probably 15707696_5 154 162
resulting 15707696_5 163 172
in 15707696_5 173 175
increased 15707696_5 176 185
expression 15707696_5 186 196
of 15707696_5 197 199
the 15707696_5 200 203
NR 15707696_5 204 206
2 15707696_5 206 207
B 15707696_5 207 208
gene 15707696_5 209 213
. 15707696_5 214 215

CONCLUSIONS 25939871_12 0 11
: 25939871_12 12 13
Polymorphism 25939871_12 14 26
of 25939871_12 27 29
SLCO 25939871_12 30 34
1 25939871_12 34 35
B 25939871_12 35 36
1 25939871_12 36 37
c 25939871_12 38 39
. 25939871_12 39 40
521 25939871_12 40 43
T 25939871_12 44 45
> 25939871_12 46 47
C 25939871_12 48 49
could 25939871_12 50 55
be 25939871_12 56 58
a 25939871_12 59 60
strong 25939871_12 61 67
predictor 25939871_12 68 77
of 25939871_12 78 80
dose 25939871_12 81 85
reduction 25939871_12 86 95
of 25939871_12 96 98
6 25939871_12 99 100
- 25939871_12 100 101
MP 25939871_12 101 103
in 25939871_12 104 106
maintenance 25939871_12 107 118
chemotherapy 25939871_12 119 131
in 25939871_12 132 134
childhood 25939871_12 135 144
ALL 25939871_12 145 148
. 25939871_12 149 150

PATIENTS 25242669_6 0 8
AND 25242669_6 9 12
METHODS 25242669_6 13 20
: 25242669_6 21 22
The 25242669_6 23 26
IRENE 25242669_6 27 32
( 25242669_6 33 34
Iressa 25242669_6 35 41
RE 25242669_6 42 44
- 25242669_6 44 45
challenge 25242669_6 45 54
in 25242669_6 55 57
advanced 25242669_6 58 66
, 25242669_6 67 68
EGFR 25242669_6 69 73
- 25242669_6 74 75
mutated 25242669_6 75 82
NSCLC 25242669_6 83 88
patients 25242669_6 89 97
who 25242669_6 98 101
responded 25242669_6 102 111
to 25242669_6 112 114
an 25242669_6 115 117
EGFR 25242669_6 118 122
- 25242669_6 123 124
TKI 25242669_6 124 127
used 25242669_6 128 132
as 25242669_6 133 135
first 25242669_6 136 141
- 25242669_6 141 142
line 25242669_6 142 146
or 25242669_6 147 149
previous 25242669_6 150 158
treatment 25242669_6 159 168
) 25242669_6 169 170
( 25242669_6 171 172
Dutch 25242669_6 173 178
association 25242669_6 179 190
for 25242669_6 191 194
pulmonologists 25242669_6 195 209
[ 25242669_6 210 211
NVALT 25242669_6 212 217
] 25242669_6 218 219
- 25242669_6 220 221
16 25242669_6 221 223
) 25242669_6 224 225
trial 25242669_6 226 231
is 25242669_6 232 234
a 25242669_6 235 236
multicenter 25242669_6 237 248
, 25242669_6 249 250
open 25242669_6 251 255
- 25242669_6 255 256
label 25242669_6 256 261
, 25242669_6 262 263
single 25242669_6 264 270
- 25242669_6 270 271
arm 25242669_6 271 274
, 25242669_6 275 276
single 25242669_6 277 283
- 25242669_6 283 284
stage 25242669_6 284 289
, 25242669_6 290 291
phase 25242669_6 292 297
II 25242669_6 298 300
study 25242669_6 301 306
to 25242669_6 307 309
evaluate 25242669_6 310 318
gefitinib 25242669_6 319 328
rechallenge 25242669_6 329 340
in 25242669_6 341 343
EGFR 25242669_6 344 348
- 25242669_6 349 350
mutated 25242669_6 350 357
NSCLC 25242669_6 358 363
patients 25242669_6 364 372
who 25242669_6 373 376
were 25242669_6 377 381
previously 25242669_6 382 392
treated 25242669_6 393 400
with 25242669_6 401 405
a 25242669_6 406 407
TKI 25242669_6 408 411
followed 25242669_6 412 420
by 25242669_6 421 423
a 25242669_6 424 425
subsequent 25242669_6 426 436
line 25242669_6 437 441
of 25242669_6 442 444
treatment 25242669_6 445 454
( 25242669_6 455 456
excluding 25242669_6 457 466
EGFR 25242669_6 467 471
- 25242669_6 472 473
TKIs 25242669_6 473 477
) 25242669_6 478 479
. 25242669_6 480 481

Metoprolol 7875180_1 0 10
alpha 7875180_1 11 16
- 7875180_1 16 17
hydroxylation 7875180_1 17 30
is 7875180_1 31 33
a 7875180_1 34 35
poor 7875180_1 36 40
probe 7875180_1 41 46
for 7875180_1 47 50
debrizoquine 7875180_1 51 63
oxidation 7875180_1 64 73
( 7875180_1 74 75
CYP 7875180_1 76 79
2 7875180_1 79 80
D 7875180_1 80 81
6 7875180_1 81 82
) 7875180_1 83 84
polymorphism 7875180_1 85 97
in 7875180_1 98 100
Jordanians 7875180_1 101 111
. 7875180_1 112 113

Although 22835516_5 0 8
malignant 22835516_5 9 18
pleural 22835516_5 19 26
effusions 22835516_5 27 36
carried 22835516_5 37 44
the 22835516_5 45 48
same 22835516_5 49 53
EGFR 22835516_5 54 58
mutation 22835516_5 59 67
, 22835516_5 68 69
progressive 22835516_5 70 81
pleural 22835516_5 82 89
effusions 22835516_5 90 99
after 22835516_5 100 105
treatment 22835516_5 106 115
with 22835516_5 116 120
chemotherapy 22835516_5 121 133
, 22835516_5 134 135
gefitinib 22835516_5 136 145
, 22835516_5 146 147
and 22835516_5 148 151
erlotinib 22835516_5 152 161
did 22835516_5 162 165
not 22835516_5 166 169
show 22835516_5 170 174
any 22835516_5 175 178
EGFR 22835516_5 179 183
mutation 22835516_5 184 192
. 22835516_5 193 194

Moreover 19147553_8 0 8
, 19147553_8 9 10
nutlin 19147553_8 11 17
- 19147553_8 17 18
3 19147553_8 18 19
reduced 19147553_8 20 27
efflux 19147553_8 28 34
of 19147553_8 35 37
rhodamine 19147553_8 38 47
123 19147553_8 48 51
and 19147553_8 52 55
other 19147553_8 56 61
fluorescence 19147553_8 62 74
dyes 19147553_8 75 79
that 19147553_8 80 84
are 19147553_8 85 88
effluxed 19147553_8 89 97
by 19147553_8 98 100
P 19147553_8 101 102
- 19147553_8 102 103
gp 19147553_8 103 105
. 19147553_8 106 107

Twenty 10655277_2 0 6
- 10655277_2 6 7
four 10655277_2 7 11
patients 10655277_2 12 20
with 10655277_2 21 25
chronic 10655277_2 26 33
hepatitis 10655277_2 34 43
B 10655277_2 44 45
virus 10655277_2 46 51
( 10655277_2 52 53
HBV 10655277_2 54 57
) 10655277_2 58 59
, 10655277_2 60 61
antibody 10655277_2 62 70
to 10655277_2 71 73
hepatitis 10655277_2 74 83
B 10655277_2 84 85
e 10655277_2 86 87
antigen 10655277_2 88 95
( 10655277_2 96 97
anti 10655277_2 98 102
- 10655277_2 102 103
HBe 10655277_2 103 106
) 10655277_2 107 108
, 10655277_2 109 110
HBV 10655277_2 111 114
DNA 10655277_2 115 118
positivity 10655277_2 119 129
, 10655277_2 130 131
and 10655277_2 132 135
alanine 10655277_2 136 143
transaminase 10655277_2 144 156
( 10655277_2 157 158
ALT 10655277_2 159 162
) 10655277_2 163 164
elevation 10655277_2 165 174
who 10655277_2 175 178
failed 10655277_2 179 185
previous 10655277_2 186 194
interferon 10655277_2 195 205
alfa 10655277_2 206 210
( 10655277_2 211 212
IFN 10655277_2 213 216
- 10655277_2 216 217
alpha 10655277_2 217 222
) 10655277_2 223 224
therapy 10655277_2 225 232
were 10655277_2 233 237
included 10655277_2 238 246
in 10655277_2 247 249
a 10655277_2 250 251
pilot 10655277_2 252 257
study 10655277_2 258 263
of 10655277_2 264 266
combination 10655277_2 267 278
therapy 10655277_2 279 286
with 10655277_2 287 291
ribavirin 10655277_2 292 301
and 10655277_2 302 305
IFN 10655277_2 306 309
- 10655277_2 309 310
alpha 10655277_2 310 315
. 10655277_2 316 317

CONCLUSIONS 20308030_10 0 11
: 20308030_10 12 13
We 20308030_10 14 16
found 20308030_10 17 22
no 20308030_10 23 25
significant 20308030_10 26 37
association 20308030_10 38 49
between 20308030_10 50 57
oxaliplatin 20308030_10 58 69
- 20308030_10 70 71
induced 20308030_10 71 78
neuropathy 20308030_10 79 89
and 20308030_10 90 93
the 20308030_10 94 97
GSTP 20308030_10 98 102
1 20308030_10 102 103
Ile 20308030_10 104 107
( 20308030_10 108 109
105 20308030_10 110 113
) 20308030_10 114 115
Val 20308030_10 116 119
and 20308030_10 120 123
AGXT 20308030_10 124 128
Ile 20308030_10 129 132
( 20308030_10 133 134
340 20308030_10 135 138
) 20308030_10 139 140
Met 20308030_10 141 144
polymorphisms 20308030_10 145 158
. 20308030_10 159 160

We 20621700_3 0 2
evaluated 20621700_3 3 12
the 20621700_3 13 16
effects 20621700_3 17 24
of 20621700_3 25 27
IL 20621700_3 28 30
- 20621700_3 30 31
28 20621700_3 31 33
B 20621700_3 33 34
polymorphisms 20621700_3 35 48
on 20621700_3 49 51
response 20621700_3 52 60
to 20621700_3 61 63
treatment 20621700_3 64 73
with 20621700_3 74 78
peginterferon 20621700_3 79 92
and 20621700_3 93 96
ribavirin 20621700_3 97 106
in 20621700_3 107 109
a 20621700_3 110 111
well 20621700_3 112 116
- 20621700_3 116 117
characterized 20621700_3 117 130
cohort 20621700_3 131 137
of 20621700_3 138 140
genotype 20621700_3 141 149
2 20621700_3 150 151
/ 20621700_3 151 152
3 20621700_3 152 153
patients 20621700_3 154 162
. 20621700_3 163 164

A 21187469_8 0 1
positive 21187469_8 2 10
control 21187469_8 11 18
using 21187469_8 19 24
5 21187469_8 25 26
- 21187469_8 26 27
azacytidine 21187469_8 27 38
also 21187469_8 39 43
reactivated 21187469_8 44 55
p 21187469_8 56 57
16 21187469_8 57 59
INK 21187469_8 59 62
4 21187469_8 62 63
a 21187469_8 63 64
. 21187469_8 65 66

Compared 22179630_14 0 8
to 22179630_14 9 11
patients 22179630_14 12 20
carrying 22179630_14 21 29
the 22179630_14 30 33
C 22179630_14 34 35
/ 22179630_14 35 36
T 22179630_14 36 37
genotype 22179630_14 38 46
of 22179630_14 47 49
BAG 22179630_14 50 53
- 22179630_14 53 54
1 22179630_14 54 55
, 22179630_14 56 57
patients 22179630_14 58 66
carrying 22179630_14 67 75
the 22179630_14 76 79
C 22179630_14 80 81
/ 22179630_14 81 82
C 22179630_14 82 83
genotype 22179630_14 84 92
at 22179630_14 93 95
Bag 22179630_14 96 99
- 22179630_14 99 100
1 22179630_14 100 101
codon 22179630_14 102 107
324 22179630_14 108 111
exhibited 22179630_14 112 121
better 22179630_14 122 128
responses 22179630_14 129 138
to 22179630_14 139 141
platinum 22179630_14 142 150
- 22179630_14 151 152
based 22179630_14 152 157
chemotherapy 22179630_14 158 170
. 22179630_14 171 172

Results 8947308_9 0 7
of 8947308_9 8 10
the 8947308_9 11 14
present 8947308_9 15 22
Finnish 8947308_9 23 30
association 8947308_9 31 42
study 8947308_9 43 48
suggest 8947308_9 49 56
that 8947308_9 57 61
homozygous 8947308_9 62 72
deletion 8947308_9 73 81
of 8947308_9 82 84
the 8947308_9 85 88
GST 8947308_9 89 92
M 8947308_9 93 94
1 8947308_9 94 95
gene 8947308_9 96 100
may 8947308_9 101 104
indicate 8947308_9 105 113
increased 8947308_9 114 123
susceptibility 8947308_9 124 138
to 8947308_9 139 141
develop 8947308_9 142 149
irreversible 8947308_9 150 162
liver 8947308_9 163 168
damage 8947308_9 169 175
in 8947308_9 176 178
response 8947308_9 179 187
to 8947308_9 188 190
the 8947308_9 191 194
toxic 8947308_9 195 200
effects 8947308_9 201 208
of 8947308_9 209 211
ethanol 8947308_9 212 219
. 8947308_9 220 221

In 19442155_4 0 2
the 19442155_4 3 6
present 19442155_4 7 14
paper 19442155_4 15 20
, 19442155_4 21 22
we 19442155_4 23 25
focused 19442155_4 26 33
on 19442155_4 34 36
the 19442155_4 37 40
most 19442155_4 41 45
direct 19442155_4 46 52
biochemical 19442155_4 53 64
lithium 19442155_4 65 72
targets 19442155_4 73 80
at 19442155_4 81 83
therapeutic 19442155_4 84 95
concentration 19442155_4 96 109
, 19442155_4 110 111
for 19442155_4 112 115
which 19442155_4 116 121
some 19442155_4 122 126
pharmacogenetic 19442155_4 127 142
finding 19442155_4 143 150
is 19442155_4 151 153
present 19442155_4 154 161
( 19442155_4 162 163
i 19442155_4 164 165
. 19442155_4 165 166
e 19442155_4 166 167
. 19442155_4 167 168
inositol 19442155_4 169 177
mono 19442155_4 178 182
phosphatase 19442155_4 183 194
( 19442155_4 195 196
IMPase 19442155_4 197 203
) 19442155_4 204 205
, 19442155_4 206 207
inositol 19442155_4 208 216
polyphosphate 19442155_4 217 230
- 19442155_4 230 231
1 19442155_4 231 232
- 19442155_4 232 233
phosphatase 19442155_4 233 244
( 19442155_4 245 246
IPPase 19442155_4 247 253
) 19442155_4 254 255
and 19442155_4 256 259
glycogen 19442155_4 260 268
sinthase 19442155_4 269 277
kinase 19442155_4 278 284
3 19442155_4 285 286
beta 19442155_4 287 291
( 19442155_4 292 293
GSK 19442155_4 294 297
- 19442155_4 297 298
3 19442155_4 298 299
beta 19442155_4 300 304
) 19442155_4 305 306
) 19442155_4 307 308
. 19442155_4 309 310

A 24728879_2 0 1
strong 24728879_2 2 8
association 24728879_2 9 20
between 24728879_2 21 28
the 24728879_2 29 32
human 24728879_2 33 38
leucocyte 24728879_2 39 48
antigen 24728879_2 49 56
( 24728879_2 57 58
HLA 24728879_2 58 61
) 24728879_2 61 62
- 24728879_2 62 63
B 24728879_2 63 64
* 24728879_2 65 66
58 24728879_2 67 69
: 24728879_2 69 70
01 24728879_2 70 72
allele 24728879_2 73 79
and 24728879_2 80 83
allopurinol 24728879_2 84 95
- 24728879_2 96 97
associated 24728879_2 97 107
severe 24728879_2 108 114
cutaneous 24728879_2 115 124
adverse 24728879_2 125 132
reactions 24728879_2 133 142
( 24728879_2 143 144
SCAR 24728879_2 145 149
) 24728879_2 150 151
has 24728879_2 152 155
been 24728879_2 156 160
reported 24728879_2 161 169
. 24728879_2 170 171

The 23515680_8 0 3
SNPs 23515680_8 4 8
C 23515680_8 9 10
1236 23515680_8 10 14
T 23515680_8 14 15
and 23515680_8 16 19
C 23515680_8 20 21
3435 23515680_8 21 25
T 23515680_8 25 26
in 23515680_8 27 29
venlafaxine 23515680_8 30 41
- 23515680_8 42 43
positive 23515680_8 43 51
cases 23515680_8 52 57
were 23515680_8 58 62
significantly 23515680_8 63 76
different 23515680_8 77 86
between 23515680_8 87 94
the 23515680_8 95 98
intoxication 23515680_8 99 111
cases 23515680_8 112 117
and 23515680_8 118 121
non 23515680_8 122 125
- 23515680_8 125 126
intoxications 23515680_8 126 139
. 23515680_8 140 141

Intracerebroventricular 19179437_6 0 23
treatment 19179437_6 24 33
with 19179437_6 34 38
4 19179437_6 39 40
mug 19179437_6 41 44
leptin 19179437_6 45 51
- 19179437_6 52 53
induced 19179437_6 53 60
robust 19179437_6 61 67
signal 19179437_6 68 74
transducer 19179437_6 75 85
and 19179437_6 86 89
activator 19179437_6 90 99
of 19179437_6 100 102
transcription 19179437_6 103 116
- 19179437_6 116 117
3 19179437_6 117 118
expression 19179437_6 119 129
within 19179437_6 130 136
the 19179437_6 137 140
anteroventral 19179437_6 141 154
periventricular 19179437_6 155 170
nucleus 19179437_6 171 178
but 19179437_6 179 182
not 19179437_6 183 186
in 19179437_6 187 189
GnRH 19179437_6 190 194
neurons 19179437_6 195 202
. 19179437_6 203 204

RESULTS 23736108_9 0 7
: 23736108_9 8 9
Logistic 23736108_9 10 18
regression 23736108_9 19 29
analysis 23736108_9 30 38
showed 23736108_9 39 45
that 23736108_9 46 50
the 23736108_9 51 54
minor 23736108_9 55 60
allele 23736108_9 61 67
frequencies 23736108_9 68 79
of 23736108_9 80 82
TAPBP 23736108_9 83 88
rs 23736108_9 89 91
2071888 23736108_9 91 98
C 23736108_9 99 100
> 23736108_9 100 101
G 23736108_9 101 102
( 23736108_9 103 104
Thr 23736108_9 105 108
260 23736108_9 108 111
Arg 23736108_9 111 114
) 23736108_9 115 116
on 23736108_9 117 119
exon 23736108_9 120 124
4 23736108_9 125 126
( 23736108_9 127 128
P 23736108_9 129 130
> 23736108_9 131 132
0 23736108_9 133 134
. 23736108_9 134 135
05 23736108_9 135 137
) 23736108_9 138 139
, 23736108_9 140 141
which 23736108_9 142 147
was 23736108_9 148 151
in 23736108_9 152 154
absolute 23736108_9 155 163
linkage 23736108_9 164 171
disequilibrium 23736108_9 172 186
with 23736108_9 187 191
rs 23736108_9 192 194
1059288 23736108_9 194 201
T 23736108_9 202 203
> 23736108_9 203 204
C 23736108_9 204 205
on 23736108_9 206 208
3 23736108_9 209 210
' 23736108_9 211 212
UTR 23736108_9 213 216
, 23736108_9 217 218
were 23736108_9 219 223
significantly 23736108_9 224 237
higher 23736108_9 238 244
in 23736108_9 245 247
the 23736108_9 248 251
AERD 23736108_9 252 256
group 23736108_9 257 262
than 23736108_9 263 267
in 23736108_9 268 270
the 23736108_9 271 274
aspirin 23736108_9 275 282
- 23736108_9 283 284
tolerant 23736108_9 284 292
asthma 23736108_9 293 299
group 23736108_9 300 305
, 23736108_9 306 307
and 23736108_9 308 311
the 23736108_9 312 315
P 23736108_9 316 317
values 23736108_9 318 324
remained 23736108_9 325 333
significant 23736108_9 334 345
after 23736108_9 346 351
multiple 23736108_9 352 360
comparisons 23736108_9 361 372
( 23736108_9 373 374
Pcorr 23736108_9 375 380
= 23736108_9 381 382
0 23736108_9 383 384
. 23736108_9 384 385
006 23736108_9 385 388
, 23736108_9 389 390
odds 23736108_9 391 395
ratio 23736108_9 396 401
: 23736108_9 402 403
1 23736108_9 404 405
. 23736108_9 405 406
37 23736108_9 406 408
, 23736108_9 409 410
95 23736108_9 411 413
% 23736108_9 414 415
confidence 23736108_9 416 426
interval 23736108_9 427 435
: 23736108_9 436 437
1 23736108_9 438 439
. 23736108_9 439 440
11 23736108_9 440 442
- 23736108_9 442 443
1 23736108_9 443 444
. 23736108_9 445 446
69 23736108_9 446 448
, 23736108_9 449 450
additive 23736108_9 451 459
model 23736108_9 460 465
; 23736108_9 466 467
Pcorr 23736108_9 468 473
= 23736108_9 474 475
0 23736108_9 476 477
. 23736108_9 477 478
009 23736108_9 478 481
, 23736108_9 482 483
odds 23736108_9 484 488
ratio 23736108_9 489 494
: 23736108_9 495 496
1 23736108_9 497 498
. 23736108_9 498 499
52 23736108_9 499 501
, 23736108_9 502 503
95 23736108_9 504 506
% 23736108_9 507 508
confidence 23736108_9 509 519
interval 23736108_9 520 528
: 23736108_9 529 530
1 23736108_9 531 532
. 23736108_9 532 533
14 23736108_9 533 535
- 23736108_9 535 536
2 23736108_9 536 537
. 23736108_9 538 539
03 23736108_9 539 541
, 23736108_9 542 543
dominant 23736108_9 544 552
model 23736108_9 553 558
) 23736108_9 559 560
. 23736108_9 561 562

CONCLUSIONS 19531897_9 0 11
: 19531897_9 12 13
CYP 19531897_9 14 17
2 19531897_9 17 18
C 19531897_9 18 19
19 19531897_9 19 21
polymorphisms 19531897_9 22 35
are 19531897_9 36 39
frequent 19531897_9 40 48
in 19531897_9 49 51
Japanese 19531897_9 52 60
, 19531897_9 61 62
and 19531897_9 63 66
the 19531897_9 67 70
antiplatelet 19531897_9 71 83
effect 19531897_9 84 90
of 19531897_9 91 93
clopidogrel 19531897_9 94 105
is 19531897_9 106 108
strongly 19531897_9 109 117
affected 19531897_9 118 126
by 19531897_9 127 129
them 19531897_9 130 134
in 19531897_9 135 137
the 19531897_9 138 141
real 19531897_9 142 146
- 19531897_9 146 147
world 19531897_9 147 152
clinical 19531897_9 153 161
setting 19531897_9 162 169
. 19531897_9 170 171

In 6938173_4 0 2
order 6938173_4 3 8
to 6938173_4 9 11
find 6938173_4 12 16
out 6938173_4 17 20
genetic 6938173_4 21 28
variability 6938173_4 29 40
and 6938173_4 41 44
its 6938173_4 45 48
possible 6938173_4 49 57
association 6938173_4 58 69
with 6938173_4 70 74
chromosomic 6938173_4 75 86
damage 6938173_4 87 93
, 6938173_4 94 95
we 6938173_4 96 98
studied 6938173_4 99 106
the 6938173_4 107 110
ABO 6938173_4 111 114
, 6938173_4 115 116
Rh 6938173_4 117 119
and 6938173_4 120 123
MN 6938173_4 124 126
blood 6938173_4 127 132
groups 6938173_4 133 139
as 6938173_4 140 142
well 6938173_4 143 147
as 6938173_4 148 150
the 6938173_4 151 154
ability 6938173_4 155 162
to 6938173_4 163 165
taste 6938173_4 166 171
PTC 6938173_4 172 175
, 6938173_4 176 177
ear 6938173_4 178 181
lobe 6938173_4 182 186
type 6938173_4 187 191
and 6938173_4 192 195
mid 6938173_4 196 199
- 6938173_4 199 200
digital 6938173_4 200 207
hair 6938173_4 208 212
, 6938173_4 213 214
in 6938173_4 215 217
77 6938173_4 218 220
workers 6938173_4 221 228
exposed 6938173_4 229 236
to 6938173_4 237 239
lead 6938173_4 240 244
oxides 6938173_4 245 251
. 6938173_4 252 253

The 23147740_4 0 3
current 23147740_4 4 11
study 23147740_4 12 17
explored 23147740_4 18 26
the 23147740_4 27 30
PD 23147740_4 31 33
target 23147740_4 34 40
of 23147740_4 41 43
posaconazole 23147740_4 44 56
in 23147740_4 57 59
an 23147740_4 60 62
immunocompromised 23147740_4 63 80
murine 23147740_4 81 87
model 23147740_4 88 93
of 23147740_4 94 96
IPA 23147740_4 97 100
against 23147740_4 101 108
10 23147740_4 109 111
A 23147740_4 112 113
. 23147740_4 113 114
fumigatus 23147740_4 115 124
isolates 23147740_4 125 133
, 23147740_4 134 135
including 23147740_4 136 145
4 23147740_4 146 147
Cyp 23147740_4 148 151
51 23147740_4 151 153
wild 23147740_4 154 158
- 23147740_4 158 159
type 23147740_4 159 163
isolates 23147740_4 164 172
and 23147740_4 173 176
6 23147740_4 177 178
isolates 23147740_4 179 187
carrying 23147740_4 188 196
Cyp 23147740_4 197 200
51 23147740_4 200 202
mutations 23147740_4 203 212
conferring 23147740_4 213 223
azole 23147740_4 224 229
resistance 23147740_4 230 240
. 23147740_4 241 242

CONCLUSION 17445431_11 0 10
: 17445431_11 11 12
DPYD 17445431_11 13 17
* 17445431_11 18 19
5 17445431_11 20 21
gene 17445431_11 22 26
mutation 17445431_11 27 35
contributes 17445431_11 36 47
to 17445431_11 48 50
reduced 17445431_11 51 58
DPYD 17445431_11 59 63
enzyme 17445431_11 64 70
activity 17445431_11 71 79
and 17445431_11 80 83
5 17445431_11 84 85
- 17445431_11 85 86
FU 17445431_11 86 88
dyes 17445431_11 89 93
metabolism 17445431_11 94 104
, 17445431_11 105 106
which 17445431_11 107 112
is 17445431_11 113 115
associated 17445431_11 116 126
with 17445431_11 127 131
accumulation 17445431_11 132 144
of 17445431_11 145 147
5 17445431_11 148 149
- 17445431_11 149 150
FU 17445431_11 150 152
and 17445431_11 153 156
chemotherapeutic 17445431_11 157 173
toxicity 17445431_11 174 182
in 17445431_11 183 185
patients 17445431_11 186 194
with 17445431_11 195 199
gastric 17445431_11 200 207
and 17445431_11 208 211
colonic 17445431_11 212 219
carcinoma 17445431_11 220 229
. 17445431_11 230 231

We 8834564_2 0 2
examined 8834564_2 3 11
the 8834564_2 12 15
relation 8834564_2 16 24
between 8834564_2 25 32
spontaneous 8834564_2 33 44
abortion 8834564_2 45 53
and 8834564_2 54 57
polymorphisms 8834564_2 58 71
in 8834564_2 72 74
two 8834564_2 75 78
genes 8834564_2 79 84
, 8834564_2 85 86
glutathione 8834564_2 87 98
S 8834564_2 99 100
- 8834564_2 100 101
transferase 8834564_2 101 112
( 8834564_2 113 114
GSTM 8834564_2 115 119
1 8834564_2 119 120
) 8834564_2 121 122
and 8834564_2 123 126
N 8834564_2 127 128
- 8834564_2 129 130
acetyltransferase 8834564_2 130 147
( 8834564_2 148 149
NAT 8834564_2 150 153
2 8834564_2 153 154
) 8834564_2 155 156
, 8834564_2 157 158
which 8834564_2 159 164
are 8834564_2 165 168
involved 8834564_2 169 177
in 8834564_2 178 180
the 8834564_2 181 184
metabolism 8834564_2 185 195
of 8834564_2 196 198
xenobiotics 8834564_2 199 210
. 8834564_2 211 212

CONCLUSIONS 23246478_11 0 11
: 23246478_11 12 13
Our 23246478_11 14 17
results 23246478_11 18 25
suggest 23246478_11 26 33
that 23246478_11 34 38
4 23246478_11 39 40
single 23246478_11 41 47
nucleotide 23246478_11 48 58
polymorphisms 23246478_11 59 72
can 23246478_11 73 76
be 23246478_11 77 79
used 23246478_11 80 84
to 23246478_11 85 87
adjust 23246478_11 88 94
a 23246478_11 95 96
man 23246478_11 97 100
' 23246478_11 101 102
s 23246478_11 102 103
measured 23246478_11 104 112
prostate 23246478_11 113 121
specific 23246478_11 122 130
antigen 23246478_11 131 138
concentration 23246478_11 139 152
and 23246478_11 153 156
potentially 23246478_11 157 168
delay 23246478_11 169 174
or 23246478_11 175 177
prevent 23246478_11 178 185
unnecessary 23246478_11 186 197
prostate 23246478_11 198 206
biopsies 23246478_11 207 215
in 23246478_11 216 218
Caucasian 23246478_11 219 228
men 23246478_11 229 232
. 23246478_11 233 234

Also 2887298_6 0 4
pretreatment 2887298_6 5 17
with 2887298_6 18 22
cyclophosphamide 2887298_6 23 39
or 2887298_6 40 42
irradiation 2887298_6 43 54
abolished 2887298_6 55 64
the 2887298_6 65 68
capacity 2887298_6 69 77
of 2887298_6 78 80
adult 2887298_6 81 86
mice 2887298_6 87 91
to 2887298_6 92 94
increase 2887298_6 95 103
cell 2887298_6 104 108
surface 2887298_6 109 116
H 2887298_6 117 118
- 2887298_6 118 119
2 2887298_6 119 120
on 2887298_6 121 123
YAC 2887298_6 124 127
- 2887298_6 127 128
1 2887298_6 128 129
cells 2887298_6 130 135
. 2887298_6 136 137

METHODS 27864013_5 0 7
: 27864013_5 8 9
We 27864013_5 10 12
did 27864013_5 13 16
a 27864013_5 17 18
retrospective 27864013_5 19 32
individual 27864013_5 33 43
data 27864013_5 44 48
analysis 27864013_5 49 57
based 27864013_5 58 63
on 27864013_5 64 66
all 27864013_5 67 70
published 27864013_5 71 80
randomised 27864013_5 81 91
trials 27864013_5 92 98
that 27864013_5 99 103
included 27864013_5 104 112
treatment 27864013_5 113 122
- 27864013_5 122 123
naive 27864013_5 123 128
patients 27864013_5 129 137
with 27864013_5 138 142
BRAF 27864013_5 143 147
( 27864013_5 148 149
V 27864013_5 150 151
600 27864013_5 151 154
E 27864013_5 154 155
) 27864013_5 156 157
- 27864013_5 158 159
mutant 27864013_5 160 166
or 27864013_5 167 169
BRAF 27864013_5 170 174
( 27864013_5 175 176
V 27864013_5 177 178
600 27864013_5 178 181
K 27864013_5 181 182
) 27864013_5 183 184
- 27864013_5 185 186
mutant 27864013_5 187 193
metastatic 27864013_5 194 204
melanoma 27864013_5 205 213
who 27864013_5 214 217
received 27864013_5 218 226
the 27864013_5 227 230
approved 27864013_5 231 239
dose 27864013_5 240 244
of 27864013_5 245 247
dabrafenib 27864013_5 248 258
150 27864013_5 259 262
mg 27864013_5 263 265
twice 27864013_5 266 271
daily 27864013_5 272 277
plus 27864013_5 278 282
trametinib 27864013_5 283 293
2 27864013_5 294 295
mg 27864013_5 296 298
once 27864013_5 299 303
daily 27864013_5 304 309
. 27864013_5 310 311

The 8873217_7 0 3
intron 8873217_7 4 10
6 8873217_7 11 12
G 8873217_7 12 13
- 8873217_7 13 14
- 8873217_7 14 15
> 8873217_7 15 16
T 8873217_7 16 17
variant 8873217_7 18 25
was 8873217_7 26 29
significantly 8873217_7 30 43
associated 8873217_7 44 54
with 8873217_7 55 59
platelet 8873217_7 60 68
serotonin 8873217_7 69 78
levels 8873217_7 79 85
. 8873217_7 86 87

Our 23617284_5 0 3
previous 23617284_5 4 12
studies 23617284_5 13 20
have 23617284_5 21 25
demonstrated 23617284_5 26 38
the 23617284_5 39 42
involvement 23617284_5 43 54
of 23617284_5 55 57
xeroderma 23617284_5 58 67
pigmentosum 23617284_5 68 79
group 23617284_5 80 85
A 23617284_5 86 87
( 23617284_5 88 89
XPA 23617284_5 90 93
) 23617284_5 94 95
codon 23617284_5 96 101
23 23617284_5 101 103
and 23617284_5 104 107
xeroderma 23617284_5 108 117
pigmentosum 23617284_5 118 129
group 23617284_5 130 135
D 23617284_5 136 137
( 23617284_5 138 139
XPD 23617284_5 140 143
) 23617284_5 144 145
codon 23617284_5 146 151
751 23617284_5 151 154
single 23617284_5 155 161
- 23617284_5 161 162
nucleotide 23617284_5 162 172
polymorphisms 23617284_5 173 186
( 23617284_5 187 188
SNPs 23617284_5 189 193
) 23617284_5 194 195
in 23617284_5 196 198
clinical 23617284_5 199 207
response 23617284_5 208 216
to 23617284_5 217 219
platinum 23617284_5 220 228
based 23617284_5 229 234
chemotherapy 23617284_5 235 247
in 23617284_5 248 250
advanced 23617284_5 251 259
NSCLC 23617284_5 260 265
patients 23617284_5 266 274
. 23617284_5 275 276

An 19273354_4 0 2
aetiological 19273354_4 3 15
approach 19273354_4 16 24
has 19273354_4 25 28
identified 19273354_4 29 39
monogenic 19273354_4 40 49
patients 19273354_4 50 58
with 19273354_4 59 63
diabetes 19273354_4 64 72
due 19273354_4 73 76
to 19273354_4 77 79
TCF 19273354_4 80 83
1 19273354_4 83 84
mutations 19273354_4 85 94
who 19273354_4 95 98
are 19273354_4 99 102
particularly 19273354_4 103 115
sensitive 19273354_4 116 125
to 19273354_4 126 128
the 19273354_4 129 132
hypoglycaemic 19273354_4 133 146
effects 19273354_4 147 154
of 19273354_4 155 157
sulphonylureas 19273354_4 158 172
, 19273354_4 173 174
and 19273354_4 175 178
KCNJ 19273354_4 179 183
11 19273354_4 183 185
or 19273354_4 186 188
ABCC 19273354_4 189 193
8 19273354_4 193 194
mutations 19273354_4 195 204
in 19273354_4 205 207
which 19273354_4 208 213
sulphonylureas 19273354_4 214 228
can 19273354_4 229 232
be 19273354_4 233 235
used 19273354_4 236 240
in 19273354_4 241 243
place 19273354_4 244 249
of 19273354_4 250 252
insulin 19273354_4 253 260
treatment 19273354_4 261 270
. 19273354_4 271 272

Patients 18666383_8 0 8
who 18666383_8 9 12
inherited 18666383_8 13 22
very 18666383_8 23 27
low 18666383_8 28 31
levels 18666383_8 32 38
of 18666383_8 39 41
TPMT 18666383_8 42 46
activity 18666383_8 47 55
are 18666383_8 56 59
at 18666383_8 60 62
greatly 18666383_8 63 70
increased 18666383_8 71 80
risk 18666383_8 81 85
for 18666383_8 86 89
thiopurine 18666383_8 90 100
- 18666383_8 101 102
induced 18666383_8 102 109
toxicity 18666383_8 110 118
such 18666383_8 119 123
as 18666383_8 124 126
myelosuppression 18666383_8 127 143
, 18666383_8 144 145
when 18666383_8 146 150
treated 18666383_8 151 158
with 18666383_8 159 163
standard 18666383_8 164 172
doses 18666383_8 173 178
of 18666383_8 179 181
these 18666383_8 182 187
drugs 18666383_8 188 193
, 18666383_8 194 195
while 18666383_8 196 201
subjects 18666383_8 202 210
with 18666383_8 211 215
very 18666383_8 216 220
high 18666383_8 221 225
activity 18666383_8 226 234
may 18666383_8 235 238
be 18666383_8 239 241
undertreated 18666383_8 242 254
. 18666383_8 255 256

These 25871911_11 0 5
surprising 25871911_11 6 16
findings 25871911_11 17 25
in 25871911_11 26 28
a 25871911_11 29 30
group 25871911_11 31 36
of 25871911_11 37 39
phenotypically 25871911_11 40 54
similar 25871911_11 55 62
patients 25871911_11 63 71
with 25871911_11 72 76
ER 25871911_11 77 79
- 25871911_11 80 81
positive 25871911_11 81 89
, 25871911_11 90 91
endocrine 25871911_11 92 101
therapy 25871911_11 102 109
- 25871911_11 110 111
pretreated 25871911_11 111 121
, 25871911_11 122 123
HER 25871911_11 124 127
2 25871911_11 127 128
- 25871911_11 129 130
negative 25871911_11 130 138
metastases 25871911_11 139 149
, 25871911_11 150 151
are 25871911_11 152 155
supported 25871911_11 156 165
by 25871911_11 166 168
preclinical 25871911_11 169 180
data 25871911_11 181 185
showing 25871911_11 186 193
that 25871911_11 194 198
sensitivity 25871911_11 199 210
to 25871911_11 211 213
5 25871911_11 214 215
- 25871911_11 215 216
fluorouracil 25871911_11 216 228
is 25871911_11 229 231
enhanced 25871911_11 232 240
by 25871911_11 241 243
deficiencies 25871911_11 244 256
in 25871911_11 257 259
chromatin 25871911_11 260 269
remodeling 25871911_11 270 280
and 25871911_11 281 284
homologous 25871911_11 285 295
recombination 25871911_11 296 309
genes 25871911_11 310 315
. 25871911_11 316 317

EXPERIMENTAL 18980981_6 0 12
DESIGN 18980981_6 13 19
: 18980981_6 20 21
In 18980981_6 22 24
a 18980981_6 25 26
cell 18980981_6 27 31
culture 18980981_6 32 39
model 18980981_6 40 45
of 18980981_6 46 48
an 18980981_6 49 51
erlotinib 18980981_6 52 61
- 18980981_6 62 63
sensitive 18980981_6 63 72
EGFR 18980981_6 73 77
- 18980981_6 78 79
mutant 18980981_6 79 85
NSCLC 18980981_6 86 91
cell 18980981_6 92 96
line 18980981_6 97 101
, 18980981_6 102 103
we 18980981_6 104 106
tested 18980981_6 107 113
the 18980981_6 114 117
hypothesis 18980981_6 118 128
that 18980981_6 129 133
prior 18980981_6 134 139
exposure 18980981_6 140 148
to 18980981_6 149 151
platinum 18980981_6 152 160
agents 18980981_6 161 167
, 18980981_6 168 169
a 18980981_6 170 171
standard 18980981_6 172 180
component 18980981_6 181 190
of 18980981_6 191 193
NSCLC 18980981_6 194 199
chemotherapy 18980981_6 200 212
treatment 18980981_6 213 222
, 18980981_6 223 224
affects 18980981_6 225 232
the 18980981_6 233 236
subsequent 18980981_6 237 247
response 18980981_6 248 256
to 18980981_6 257 259
erlotinib 18980981_6 260 269
. 18980981_6 270 271

CONCLUSIONS 22026499_9 0 11
: 22026499_9 12 13
This 22026499_9 14 18
report 22026499_9 19 25
presents 22026499_9 26 34
a 22026499_9 35 36
novel 22026499_9 37 42
mutation 22026499_9 43 51
in 22026499_9 52 54
the 22026499_9 55 58
SGCE 22026499_9 59 63
gene 22026499_9 64 68
causing 22026499_9 69 76
myoclonus 22026499_9 77 86
dystonia 22026499_9 87 95
and 22026499_9 96 99
extends 22026499_9 100 107
the 22026499_9 108 111
phenotype 22026499_9 112 121
of 22026499_9 122 124
myoclonus 22026499_9 125 134
dystonia 22026499_9 135 143
to 22026499_9 144 146
also 22026499_9 147 151
include 22026499_9 152 159
alcohol 22026499_9 160 167
- 22026499_9 168 169
induced 22026499_9 169 176
dystonia 22026499_9 177 185
. 22026499_9 186 187

We 21747412_4 0 2
investigated 21747412_4 3 15
the 21747412_4 16 19
usefulness 21747412_4 20 30
of 21747412_4 31 33
the 21747412_4 34 37
MTHFR 21747412_4 38 43
genotype 21747412_4 44 52
to 21747412_4 53 55
increase 21747412_4 56 64
the 21747412_4 65 68
MTX 21747412_4 69 72
dosage 21747412_4 73 79
in 21747412_4 80 82
the 21747412_4 83 86
consolidation 21747412_4 87 100
phase 21747412_4 101 106
in 21747412_4 107 109
141 21747412_4 110 113
childhood 21747412_4 114 123
ALL 21747412_4 124 127
patients 21747412_4 128 136
enrolled 21747412_4 137 145
in 21747412_4 146 148
the 21747412_4 149 152
ALL 21747412_4 153 156
/ 21747412_4 157 158
SHOP 21747412_4 158 162
- 21747412_4 163 164
2005 21747412_4 164 168
protocol 21747412_4 169 177
. 21747412_4 178 179

Moreover 19481104_8 0 8
, 19481104_8 9 10
we 19481104_8 11 13
demonstrated 19481104_8 14 26
that 19481104_8 27 31
the 19481104_8 32 35
genes 19481104_8 36 41
such 19481104_8 42 46
as 19481104_8 47 49
Gsta 19481104_8 50 54
2 19481104_8 54 55
, 19481104_8 56 57
Sult 19481104_8 58 62
2 19481104_8 62 63
a 19481104_8 63 64
1 19481104_8 64 65
, 19481104_8 66 67
Fgl 19481104_8 68 71
1 19481104_8 71 72
and 19481104_8 73 76
C 19481104_8 77 78
6 19481104_8 78 79
were 19481104_8 80 84
newly 19481104_8 85 90
found 19481104_8 91 96
to 19481104_8 97 99
be 19481104_8 100 102
innately 19481104_8 103 111
lower 19481104_8 112 117
in 19481104_8 118 120
the 19481104_8 121 124
susceptible 19481104_8 125 136
animals 19481104_8 137 144
to 19481104_8 145 147
CCl 19481104_8 148 151
( 19481104_8 151 152
4 19481104_8 152 153
) 19481104_8 153 154
- 19481104_8 155 156
hepatotoxicity 19481104_8 157 171
. 19481104_8 172 173

Experimental 19671633_2 0 12
studies 19671633_2 13 20
in 19671633_2 21 23
our 19671633_2 24 27
laboratory 19671633_2 28 38
have 19671633_2 39 43
established 19671633_2 44 55
the 19671633_2 56 59
role 19671633_2 60 64
of 19671633_2 65 67
delta 19671633_2 68 73
- 19671633_2 73 74
aminolevulinic 19671633_2 74 88
acid 19671633_2 89 93
dehydratase 19671633_2 94 105
( 19671633_2 106 107
ALAD 19671633_2 108 112
) 19671633_2 113 114
and 19671633_2 115 118
matrix 19671633_2 119 125
gamma 19671633_2 126 131
- 19671633_2 131 132
carboxyglutamic 19671633_2 132 147
acid 19671633_2 148 152
( 19671633_2 153 154
MGP 19671633_2 155 158
) 19671633_2 159 160
gene 19671633_2 161 165
polymorphisms 19671633_2 166 179
in 19671633_2 180 182
the 19671633_2 183 186
etiology 19671633_2 187 195
of 19671633_2 196 198
lead 19671633_2 199 203
toxicity 19671633_2 204 212
. 19671633_2 213 214

It 23012624_2 0 2
has 23012624_2 3 6
been 23012624_2 7 11
reported 23012624_2 12 20
that 23012624_2 21 25
inosine 23012624_2 26 33
triphosphatase 23012624_2 34 48
( 23012624_2 49 50
ITPA 23012624_2 51 55
) 23012624_2 56 57
gene 23012624_2 58 62
variants 23012624_2 63 71
protect 23012624_2 72 79
against 23012624_2 80 87
ribavirin 23012624_2 88 97
- 23012624_2 98 99
induced 23012624_2 99 106
anemia 23012624_2 107 113
in 23012624_2 114 116
patients 23012624_2 117 125
treated 23012624_2 126 133
for 23012624_2 134 137
chronic 23012624_2 138 145
hepatitis 23012624_2 146 155
C 23012624_2 156 157
. 23012624_2 158 159

Common 19190113_1 0 6
variation 19190113_1 7 16
in 19190113_1 17 19
the 19190113_1 20 23
DIO 19190113_1 24 27
2 19190113_1 27 28
gene 19190113_1 29 33
predicts 19190113_1 34 42
baseline 19190113_1 43 51
psychological 19190113_1 52 65
well 19190113_1 66 70
- 19190113_1 70 71
being 19190113_1 71 76
and 19190113_1 77 80
response 19190113_1 81 89
to 19190113_1 90 92
combination 19190113_1 93 104
thyroxine 19190113_1 105 114
plus 19190113_1 115 119
triiodothyronine 19190113_1 120 136
therapy 19190113_1 137 144
in 19190113_1 145 147
hypothyroid 19190113_1 148 159
patients 19190113_1 160 168
. 19190113_1 169 170

Moreover 10529724_11 0 8
, 10529724_11 9 10
in 10529724_11 11 13
contrast 10529724_11 14 22
to 10529724_11 23 25
nNOS 10529724_11 26 30
deficiency 10529724_11 31 41
, 10529724_11 42 43
iNOS 10529724_11 44 48
deficiency 10529724_11 49 59
did 10529724_11 60 63
not 10529724_11 64 67
affect 10529724_11 68 74
METH 10529724_11 75 79
- 10529724_11 80 81
induced 10529724_11 81 88
behavioral 10529724_11 89 99
sensitization 10529724_11 100 113
. 10529724_11 114 115

At 26103436_16 0 2
the 26103436_16 3 6
time 26103436_16 7 11
of 26103436_16 12 14
relapse 26103436_16 15 22
, 26103436_16 23 24
agents 26103436_16 25 31
directed 26103436_16 32 40
at 26103436_16 41 43
activated 26103436_16 44 53
pathways 26103436_16 54 62
in 26103436_16 63 65
MCL 26103436_16 66 69
cells 26103436_16 70 75
such 26103436_16 76 80
as 26103436_16 81 83
bortezomib 26103436_16 84 94
( 26103436_16 95 96
NFkB 26103436_16 97 101
inhibitor 26103436_16 102 111
) 26103436_16 112 113
, 26103436_16 114 115
lenalidamide 26103436_16 116 128
( 26103436_16 129 130
anti 26103436_16 131 135
- 26103436_16 135 136
angiogenesis 26103436_16 136 148
) 26103436_16 149 150
and 26103436_16 151 154
Ibruitinib 26103436_16 155 165
( 26103436_16 166 167
Bruton 26103436_16 168 174
' 26103436_16 174 175
s 26103436_16 175 176
Tyrosine 26103436_16 177 185
Kinase 26103436_16 186 192
[ 26103436_16 193 194
BTK 26103436_16 195 198
] 26103436_16 199 200
inhibitor 26103436_16 201 210
) 26103436_16 211 212
have 26103436_16 213 217
demonstrated 26103436_16 218 230
excellent 26103436_16 231 240
clinical 26103436_16 241 249
activity 26103436_16 250 258
in 26103436_16 259 261
MCL 26103436_16 262 265
patients 26103436_16 266 274
. 26103436_16 275 276

We 20655300_4 0 2
conducted 20655300_4 3 12
an 20655300_4 13 15
exploratory 20655300_4 16 27
research 20655300_4 28 36
to 20655300_4 37 39
investigate 20655300_4 40 51
the 20655300_4 52 55
association 20655300_4 56 67
of 20655300_4 68 70
BDNF 20655300_4 71 75
val 20655300_4 76 79
66 20655300_4 79 81
met 20655300_4 81 84
genetic 20655300_4 85 92
polymorphism 20655300_4 93 105
with 20655300_4 106 110
the 20655300_4 111 114
ages 20655300_4 115 119
of 20655300_4 120 122
onset 20655300_4 123 128
for 20655300_4 129 132
heroin 20655300_4 133 139
abuse 20655300_4 140 145
in 20655300_4 146 148
males 20655300_4 149 154
. 20655300_4 155 156

BACKGROUND 22252093_2 0 10
: 22252093_2 11 12
The 22252093_2 13 16
required 22252093_2 17 25
acenocoumarol 22252093_2 26 39
dose 22252093_2 40 44
and 22252093_2 45 48
the 22252093_2 49 52
risk 22252093_2 53 57
of 22252093_2 58 60
underanticoagulation 22252093_2 61 81
and 22252093_2 82 85
overanticoagulation 22252093_2 86 105
are 22252093_2 106 109
associated 22252093_2 110 120
with 22252093_2 121 125
the 22252093_2 126 129
CYP 22252093_2 130 133
2 22252093_2 133 134
C 22252093_2 134 135
9 22252093_2 135 136
and 22252093_2 137 140
VKORC 22252093_2 141 146
1 22252093_2 146 147
genotypes 22252093_2 148 157
. 22252093_2 158 159

LAM 20648600_11 0 3
resistance 20648600_11 4 14
substitutions 20648600_11 15 28
( 20648600_11 29 30
rt 20648600_11 31 33
L 20648600_11 34 35
180 20648600_11 35 38
M 20648600_11 38 39
+ 20648600_11 40 41
rt 20648600_11 42 44
M 20648600_11 45 46
204 20648600_11 46 49
V 20648600_11 49 50
) 20648600_11 51 52
were 20648600_11 53 57
detected 20648600_11 58 66
in 20648600_11 67 69
10 20648600_11 70 72
( 20648600_11 73 74
50 20648600_11 75 77
% 20648600_11 78 79
) 20648600_11 80 81
of 20648600_11 82 84
the 20648600_11 85 88
20 20648600_11 89 91
patients 20648600_11 92 100
with 20648600_11 101 105
viremia 20648600_11 106 113
. 20648600_11 114 115

These 15265979_11 0 5
results 15265979_11 6 13
provide 15265979_11 14 21
important 15265979_11 22 31
new 15265979_11 32 35
mechanistic 15265979_11 36 47
information 15265979_11 48 59
regarding 15265979_11 60 69
the 15265979_11 70 73
hepatotoxic 15265979_11 74 85
effects 15265979_11 86 93
of 15265979_11 94 96
amiodarone 15265979_11 97 107
and 15265979_11 108 111
indicate 15265979_11 112 120
that 15265979_11 121 125
PPARalpha 15265979_11 126 135
protects 15265979_11 136 144
against 15265979_11 145 152
amiodarone 15265979_11 153 163
- 15265979_11 164 165
induced 15265979_11 165 172
hepatotoxicity 15265979_11 173 187
. 15265979_11 188 189

The 20153935_3 0 3
A 20153935_3 4 5
118 20153935_3 5 8
G 20153935_3 8 9
( 20153935_3 10 11
N 20153935_3 12 13
40 20153935_3 13 15
D 20153935_3 15 16
) 20153935_3 17 18
polymorphism 20153935_3 19 31
in 20153935_3 32 34
humans 20153935_3 35 41
is 20153935_3 42 44
functionally 20153935_3 45 57
mimicked 20153935_3 58 66
by 20153935_3 67 69
the 20153935_3 70 73
C 20153935_3 74 75
77 20153935_3 75 77
G 20153935_3 77 78
( 20153935_3 79 80
P 20153935_3 81 82
26 20153935_3 82 84
R 20153935_3 84 85
) 20153935_3 86 87
polymorphism 20153935_3 88 100
in 20153935_3 101 103
rhesus 20153935_3 104 110
monkeys 20153935_3 111 118
; 20153935_3 119 120
both 20153935_3 121 125
show 20153935_3 126 130
similar 20153935_3 131 138
in 20153935_3 139 141
vitro 20153935_3 142 147
influences 20153935_3 148 158
on 20153935_3 159 161
ligand 20153935_3 162 168
binding 20153935_3 169 176
and 20153935_3 177 180
in 20153935_3 181 183
vivo 20153935_3 184 188
correlations 20153935_3 189 201
with 20153935_3 202 206
physiological 20153935_3 207 220
measures 20153935_3 221 229
as 20153935_3 230 232
well 20153935_3 233 237
as 20153935_3 238 240
behavioral 20153935_3 241 251
measures 20153935_3 252 260
including 20153935_3 261 270
predilection 20153935_3 271 283
towards 20153935_3 284 291
alcohol 20153935_3 292 299
consumption 20153935_3 300 311
. 20153935_3 312 313

A 22486182_10 0 1
final 22486182_10 2 7
multivariate 22486182_10 8 20
regression 22486182_10 21 31
model 22486182_10 32 37
that 22486182_10 38 42
included 22486182_10 43 51
the 22486182_10 52 55
target 22486182_10 56 62
International 22486182_10 63 76
Normalized 22486182_10 77 87
Ratio 22486182_10 88 93
, 22486182_10 94 95
VKORC 22486182_10 96 101
1 22486182_10 101 102
and 22486182_10 103 106
CYP 22486182_10 107 110
2 22486182_10 110 111
C 22486182_10 111 112
9 22486182_10 112 113
genotypes 22486182_10 114 123
explained 22486182_10 124 133
36 22486182_10 134 136
2 22486182_10 137 138
% 22486182_10 139 140
of 22486182_10 141 143
the 22486182_10 144 147
overall 22486182_10 148 155
interindividual 22486182_10 156 171
variability 22486182_10 172 183
in 22486182_10 184 186
acenocoumarol 22486182_10 187 200
dose 22486182_10 201 205
requirement 22486182_10 206 217
. 22486182_10 218 219

The 21908221_3 0 3
present 21908221_3 4 11
study 21908221_3 12 17
aimed 21908221_3 18 23
at 21908221_3 24 26
investigating 21908221_3 27 40
whether 21908221_3 41 48
hormone 21908221_3 49 56
therapy 21908221_3 57 64
( 21908221_3 65 66
HT 21908221_3 67 69
) 21908221_3 70 71
may 21908221_3 72 75
influence 21908221_3 76 85
on 21908221_3 86 88
the 21908221_3 89 92
blood 21908221_3 93 98
/ 21908221_3 99 100
urinary 21908221_3 101 108
8 21908221_3 109 110
- 21908221_3 110 111
OHdG 21908221_3 111 115
levels 21908221_3 116 122
and 21908221_3 123 126
whether 21908221_3 127 134
the 21908221_3 135 138
level 21908221_3 139 144
of 21908221_3 145 147
8 21908221_3 148 149
- 21908221_3 149 150
OHdG 21908221_3 150 154
is 21908221_3 155 157
different 21908221_3 158 167
according 21908221_3 168 177
to 21908221_3 178 180
OGG 21908221_3 181 184
1 21908221_3 184 185
S 21908221_3 186 187
326 21908221_3 187 190
C 21908221_3 190 191
polymorphism 21908221_3 192 204
in 21908221_3 205 207
postmenopausal 21908221_3 208 222
women 21908221_3 223 228
receiving 21908221_3 229 238
HT 21908221_3 239 241
. 21908221_3 242 243

Potential 23942539_1 0 9
of 23942539_1 10 12
dihydropyrimidine 23942539_1 13 30
dehydrogenase 23942539_1 31 44
genotypes 23942539_1 45 54
in 23942539_1 55 57
personalizing 23942539_1 58 71
5 23942539_1 72 73
- 23942539_1 73 74
fluorouracil 23942539_1 74 86
therapy 23942539_1 87 94
among 23942539_1 95 100
colorectal 23942539_1 101 111
cancer 23942539_1 112 118
patients 23942539_1 119 127
. 23942539_1 128 129

Fourteen 24766650_6 0 8
SNPs 24766650_6 9 13
showed 24766650_6 14 20
nominally 24766650_6 21 30
significant 24766650_6 31 42
association 24766650_6 43 54
with 24766650_6 55 59
heroin 24766650_6 60 66
addiction 24766650_6 67 76
( 24766650_6 77 78
p 24766650_6 79 80
< 24766650_6 81 82
0 24766650_6 83 84
. 24766650_6 84 85
05 24766650_6 85 87
) 24766650_6 88 89
, 24766650_6 90 91
including 24766650_6 92 101
the 24766650_6 102 105
African 24766650_6 106 113
- 24766650_6 113 114
specific 24766650_6 114 122
, 24766650_6 123 124
missense 24766650_6 125 133
SNP 24766650_6 134 137
rs 24766650_6 138 140
5376 24766650_6 140 144
( 24766650_6 145 146
Asn 24766650_6 147 150
334 24766650_6 150 153
Ser 24766650_6 153 156
) 24766650_6 157 158
in 24766650_6 159 161
the 24766650_6 162 165
galanin 24766650_6 166 173
receptor 24766650_6 174 182
type 24766650_6 183 187
1 24766650_6 188 189
gene 24766650_6 190 194
( 24766650_6 195 196
GALR 24766650_6 197 201
1 24766650_6 201 202
) 24766650_6 203 204
and 24766650_6 205 208
the 24766650_6 209 212
functional 24766650_6 213 223
FKBP 24766650_6 224 228
5 24766650_6 228 229
intronic 24766650_6 230 238
SNP 24766650_6 239 242
rs 24766650_6 243 245
1360780 24766650_6 245 252
. 24766650_6 253 254

It 11361019_12 0 2
was 11361019_12 3 6
also 11361019_12 7 11
found 11361019_12 12 17
that 11361019_12 18 22
the 11361019_12 23 26
cell 11361019_12 27 31
survival 11361019_12 32 40
upon 11361019_12 41 45
the 11361019_12 46 49
treatment 11361019_12 50 59
of 11361019_12 60 62
CB 11361019_12 63 65
1954 11361019_12 66 70
was 11361019_12 71 74
related 11361019_12 75 82
to 11361019_12 83 85
the 11361019_12 86 89
expressed 11361019_12 90 99
DT 11361019_12 100 102
- 11361019_12 102 103
diaphorase 11361019_12 103 113
activity 11361019_12 114 122
in 11361019_12 123 125
these 11361019_12 126 131
cells 11361019_12 132 137
. 11361019_12 138 139

METHODS 18977767_5 0 7
AND 18977767_5 8 11
RESULTS 18977767_5 12 19
: 18977767_5 20 21
The 18977767_5 22 25
skeletal 18977767_5 26 34
Na 18977767_5 35 37
( 18977767_5 37 38
+ 18977767_5 38 39
) 18977767_5 39 40
channel 18977767_5 41 48
isoform 18977767_5 49 56
( 18977767_5 57 58
SkM 18977767_5 59 62
1 18977767_5 62 63
) 18977767_5 64 65
and 18977767_5 66 69
the 18977767_5 70 73
cardiac 18977767_5 74 81
Na 18977767_5 82 84
( 18977767_5 84 85
+ 18977767_5 85 86
) 18977767_5 86 87
channel 18977767_5 88 95
isoform 18977767_5 96 103
( 18977767_5 104 105
Nav 18977767_5 106 109
1 18977767_5 109 110
. 18977767_5 110 111
5 18977767_5 111 112
) 18977767_5 113 114
were 18977767_5 115 119
expressed 18977767_5 120 129
in 18977767_5 130 132
newborn 18977767_5 133 140
rat 18977767_5 141 144
ventricular 18977767_5 145 156
myocyte 18977767_5 157 164
cultures 18977767_5 165 173
with 18977767_5 174 178
a 18977767_5 179 180
point 18977767_5 181 186
mutation 18977767_5 187 195
introduced 18977767_5 196 206
in 18977767_5 207 209
Nav 18977767_5 210 213
1 18977767_5 213 214
. 18977767_5 214 215
5 18977767_5 215 216
to 18977767_5 217 219
increase 18977767_5 220 228
tetrodotoxin 18977767_5 229 241
( 18977767_5 242 243
TTX 18977767_5 244 247
) 18977767_5 248 249
sensitivity 18977767_5 250 261
so 18977767_5 262 264
native 18977767_5 265 271
and 18977767_5 272 275
expressed 18977767_5 276 285
currents 18977767_5 286 294
could 18977767_5 295 300
be 18977767_5 301 303
distinguished 18977767_5 304 317
. 18977767_5 318 319

Therefore 21946895_6 0 9
, 21946895_6 10 11
while 21946895_6 12 17
naltrexone 21946895_6 18 28
was 21946895_6 29 32
an 21946895_6 33 35
effective 21946895_6 36 45
treatment 21946895_6 46 55
for 21946895_6 56 59
alcohol 21946895_6 60 67
dependence 21946895_6 68 78
, 21946895_6 79 80
the 21946895_6 81 84
OPRM 21946895_6 85 89
1 21946895_6 89 90
A 21946895_6 91 92
118 21946895_6 92 95
G 21946895_6 95 96
genotype 21946895_6 97 105
was 21946895_6 106 109
not 21946895_6 110 113
a 21946895_6 114 115
predictor 21946895_6 116 125
of 21946895_6 126 128
success 21946895_6 129 136
. 21946895_6 137 138

In 12419746_1 0 2
vitro 12419746_1 3 8
comparative 12419746_1 9 20
evaluation 12419746_1 21 31
of 12419746_1 32 34
trastuzumab 12419746_1 35 46
( 12419746_1 47 48
Herceptin 12419746_1 49 58
) 12419746_1 59 60
combined 12419746_1 61 69
with 12419746_1 70 74
paclitaxel 12419746_1 75 85
( 12419746_1 86 87
Taxol 12419746_1 88 93
) 12419746_1 94 95
or 12419746_1 96 98
docetaxel 12419746_1 99 108
( 12419746_1 109 110
Taxotere 12419746_1 111 119
) 12419746_1 120 121
in 12419746_1 122 124
HER 12419746_1 125 128
2 12419746_1 128 129
- 12419746_1 130 131
expressing 12419746_1 131 141
human 12419746_1 142 147
breast 12419746_1 148 154
cancer 12419746_1 155 161
cell 12419746_1 162 166
lines 12419746_1 167 172
. 12419746_1 173 174

Previous 15589566_3 0 8
studies 15589566_3 9 16
have 15589566_3 17 21
demonstrated 15589566_3 22 34
an 15589566_3 35 37
association 15589566_3 38 49
between 15589566_3 50 57
suicide 15589566_3 58 65
attempts 15589566_3 66 74
and 15589566_3 75 78
the 15589566_3 79 82
5 15589566_3 83 84
- 15589566_3 84 85
HTTLPR 15589566_3 85 91
S 15589566_3 92 93
allele 15589566_3 94 100
in 15589566_3 101 103
alcohol 15589566_3 104 111
- 15589566_3 112 113
dependent 15589566_3 113 122
subjects 15589566_3 123 131
. 15589566_3 132 133

However 23360489_5 0 7
, 23360489_5 8 9
a 23360489_5 10 11
lung 23360489_5 12 16
cancer 23360489_5 17 23
cell 23360489_5 24 28
line 23360489_5 29 33
harboring 23360489_5 34 43
gene 23360489_5 44 48
amplification 23360489_5 49 62
of 23360489_5 63 65
c 23360489_5 66 67
- 23360489_5 67 68
Met 23360489_5 68 71
is 23360489_5 72 74
sensitive 23360489_5 75 84
to 23360489_5 85 87
the 23360489_5 88 91
c 23360489_5 92 93
- 23360489_5 93 94
Met 23360489_5 94 97
- 23360489_5 98 99
targeted 23360489_5 99 107
drug 23360489_5 108 112
SU 23360489_5 113 115
11274 23360489_5 115 120
but 23360489_5 121 124
not 23360489_5 125 128
to 23360489_5 129 131
EGFR 23360489_5 132 136
- 23360489_5 137 138
targeted 23360489_5 138 146
drugs 23360489_5 147 152
. 23360489_5 153 154

We 24088005_4 0 2
found 24088005_4 3 8
association 24088005_4 9 20
between 24088005_4 21 28
polymorphic 24088005_4 29 40
variant 24088005_4 41 48
CYP 24088005_4 49 52
2 24088005_4 52 53
C 24088005_4 53 54
19 24088005_4 54 56
* 24088005_4 57 58
2 24088005_4 59 60
with 24088005_4 61 65
changes 24088005_4 66 73
of 24088005_4 74 76
platelet 24088005_4 77 85
aggregation 24088005_4 86 97
after 24088005_4 98 103
administration 24088005_4 104 118
of 24088005_4 119 121
clopidogrel 24088005_4 122 133
. 24088005_4 134 135

Selumetinib 27467210_4 0 11
( 27467210_4 12 13
AZD 27467210_4 14 17
6244 27467210_4 17 21
, 27467210_4 22 23
ARRY 27467210_4 24 28
- 27467210_4 28 29
142886 27467210_4 29 35
) 27467210_4 36 37
is 27467210_4 38 40
a 27467210_4 41 42
potent 27467210_4 43 49
and 27467210_4 50 53
selective 27467210_4 54 63
inhibitor 27467210_4 64 73
of 27467210_4 74 76
MEK 27467210_4 77 80
1 27467210_4 80 81
/ 27467210_4 81 82
2 27467210_4 82 83
which 27467210_4 84 89
has 27467210_4 90 93
demonstrated 27467210_4 94 106
significant 27467210_4 107 118
efficacy 27467210_4 119 127
in 27467210_4 128 130
combination 27467210_4 131 142
with 27467210_4 143 147
docetaxel 27467210_4 148 157
in 27467210_4 158 160
patients 27467210_4 161 169
with 27467210_4 170 174
KRAS 27467210_4 175 179
mutant 27467210_4 180 186
pretreated 27467210_4 187 197
advanced 27467210_4 198 206
NSCLC 27467210_4 207 212
. 27467210_4 213 214

Combinational 26450467_1 0 13
Effect 26450467_1 14 20
of 26450467_1 21 23
CYP 26450467_1 24 27
3 26450467_1 27 28
A 26450467_1 28 29
5 26450467_1 29 30
and 26450467_1 31 34
MDR 26450467_1 35 38
- 26450467_1 38 39
1 26450467_1 39 40
Polymorphisms 26450467_1 41 54
on 26450467_1 55 57
Tacrolimus 26450467_1 58 68
Pharmacokinetics 26450467_1 69 85
in 26450467_1 86 88
Liver 26450467_1 89 94
Transplant 26450467_1 95 105
Patients 26450467_1 106 114
. 26450467_1 115 116

The 17495880_6 0 3
lack 17495880_6 4 8
of 17495880_6 9 11
a 17495880_6 12 13
time 17495880_6 14 18
- 17495880_6 18 19
related 17495880_6 19 26
increase 17495880_6 27 35
in 17495880_6 36 38
dose 17495880_6 39 43
- 17495880_6 43 44
corrected 17495880_6 44 53
tacrolimus 17495880_6 54 64
exposure 17495880_6 65 73
observed 17495880_6 74 82
with 17495880_6 83 87
the 17495880_6 88 91
CYP 17495880_6 92 95
3 17495880_6 95 96
A 17495880_6 96 97
4 17495880_6 97 98
* 17495880_6 99 100
1 17495880_6 101 102
/ 17495880_6 103 104
CYP 17495880_6 105 108
3 17495880_6 108 109
A 17495880_6 109 110
5 17495880_6 110 111
* 17495880_6 112 113
1 17495880_6 114 115
and 17495880_6 116 119
CYP 17495880_6 120 123
3 17495880_6 123 124
A 17495880_6 124 125
4 17495880_6 125 126
* 17495880_6 127 128
1 17495880_6 129 130
B 17495880_6 130 131
/ 17495880_6 132 133
CYP 17495880_6 134 137
3 17495880_6 137 138
A 17495880_6 138 139
5 17495880_6 139 140
* 17495880_6 141 142
1 17495880_6 143 144
genotypes 17495880_6 145 154
is 17495880_6 155 157
associated 17495880_6 158 168
with 17495880_6 169 173
tacrolimus 17495880_6 174 184
- 17495880_6 185 186
related 17495880_6 186 193
nephrotoxicity 17495880_6 194 208
, 17495880_6 209 210
possibly 17495880_6 211 219
as 17495880_6 220 222
a 17495880_6 223 224
result 17495880_6 225 231
of 17495880_6 232 234
higher 17495880_6 235 241
concentrations 17495880_6 242 256
of 17495880_6 257 259
toxic 17495880_6 260 265
metabolites 17495880_6 266 277
. 17495880_6 278 279

CYP 18978522_8 0 3
3 18978522_8 3 4
A 18978522_8 4 5
7 18978522_8 5 6
* 18978522_8 7 8
1 18978522_8 9 10
C 18978522_8 10 11
carriers 18978522_8 12 20
required 18978522_8 21 29
a 18978522_8 30 31
1 18978522_8 32 33
. 18978522_8 33 34
4 18978522_8 34 35
- 18978522_8 35 36
fold 18978522_8 36 40
to 18978522_8 41 43
1 18978522_8 44 45
. 18978522_8 45 46
6 18978522_8 46 47
- 18978522_8 47 48
fold 18978522_8 48 52
higher 18978522_8 53 59
cyclosporine 18978522_8 60 72
daily 18978522_8 73 78
dose 18978522_8 79 83
during 18978522_8 84 90
the 18978522_8 91 94
first 18978522_8 95 100
year 18978522_8 101 105
after 18978522_8 106 111
transplantation 18978522_8 112 127
( 18978522_8 128 129
P 18978522_8 130 131
< 18978522_8 132 133
0 18978522_8 134 135
. 18978522_8 135 136
05 18978522_8 136 138
) 18978522_8 139 140
. 18978522_8 141 142

METHODS 23679233_4 0 7
: 23679233_4 8 9
Genomic 23679233_4 10 17
alterations 23679233_4 18 29
were 23679233_4 30 34
analyzed 23679233_4 35 43
using 23679233_4 44 49
single 23679233_4 50 56
- 23679233_4 56 57
nucleotide 23679233_4 57 67
polymorphism 23679233_4 68 80
arrays 23679233_4 81 87
in 23679233_4 88 90
46 23679233_4 91 93
HER 23679233_4 94 97
2 23679233_4 97 98
immunohistochemistry 23679233_4 99 119
( 23679233_4 120 121
IHC 23679233_4 122 125
) 23679233_4 126 127
3 23679233_4 128 129
+ 23679233_4 130 131
or 23679233_4 132 134
2 23679233_4 135 136
+ 23679233_4 137 138
/ 23679233_4 139 140
fluorescent 23679233_4 141 152
in 23679233_4 153 155
situ 23679233_4 156 160
hybridization 23679233_4 161 174
( 23679233_4 175 176
FISH 23679233_4 177 181
) 23679233_4 182 183
+ 23679233_4 184 185
breast 23679233_4 186 192
cancers 23679233_4 193 200
that 23679233_4 201 205
were 23679233_4 206 210
treated 23679233_4 211 218
with 23679233_4 219 223
neoadjuvant 23679233_4 224 235
chemotherapy 23679233_4 236 248
with 23679233_4 249 253
paclitaxel 23679233_4 254 264
, 23679233_4 265 266
cyclophosphamid 23679233_4 267 282
, 23679233_4 283 284
epirubicin 23679233_4 285 295
, 23679233_4 296 297
fluorouracil 23679233_4 298 310
, 23679233_4 311 312
and 23679233_4 313 316
trastuzumab 23679233_4 317 328
. 23679233_4 329 330

No 18377430_8 0 2
significant 18377430_8 3 14
influences 18377430_8 15 25
on 18377430_8 26 28
doxorubicin 18377430_8 29 40
pharmacokinetic 18377430_8 41 56
parameters 18377430_8 57 67
were 18377430_8 68 72
observed 18377430_8 73 81
in 18377430_8 82 84
relation 18377430_8 85 93
to 18377430_8 94 96
the 18377430_8 97 100
ABCG 18377430_8 101 105
2 18377430_8 105 106
c 18377430_8 107 108
. 18377430_8 108 109
421 18377430_8 109 112
C 18377430_8 112 113
> 18377430_8 113 114
A 18377430_8 114 115
polymorphism 18377430_8 116 128
. 18377430_8 129 130

BACKGROUND 24692733_2 0 10
: 24692733_2 11 12
This 24692733_2 13 17
study 24692733_2 18 23
was 24692733_2 24 27
the 24692733_2 28 31
first 24692733_2 32 37
multicenter 24692733_2 38 49
phase 24692733_2 50 55
II 24692733_2 56 58
study 24692733_2 59 64
of 24692733_2 65 67
cetuximab 24692733_2 68 77
plus 24692733_2 78 82
folinic 24692733_2 83 90
acid 24692733_2 91 95
/ 24692733_2 96 97
5 24692733_2 98 99
- 24692733_2 99 100
fluorouracil 24692733_2 100 112
/ 24692733_2 113 114
irinotecan 24692733_2 115 125
( 24692733_2 126 127
FOLFIRI 24692733_2 128 135
) 24692733_2 136 137
in 24692733_2 138 140
KRAS 24692733_2 141 145
wild 24692733_2 146 150
- 24692733_2 150 151
type 24692733_2 151 155
mCRC 24692733_2 156 160
as 24692733_2 161 163
a 24692733_2 164 165
second 24692733_2 166 172
- 24692733_2 172 173
line 24692733_2 173 177
treatment 24692733_2 178 187
in 24692733_2 188 190
Japan 24692733_2 191 196
including 24692733_2 197 206
BRAF 24692733_2 207 211
and 24692733_2 212 215
PIK 24692733_2 216 219
3 24692733_2 219 220
CA 24692733_2 220 222
genotyping 24692733_2 223 233
. 24692733_2 234 235

CONCLUSIONS 23237192_10 0 11
: 23237192_10 12 13
Mitochondrial 23237192_10 14 27
1494 23237192_10 28 32
C 23237192_10 32 33
> 23237192_10 33 34
T 23237192_10 35 36
mutation 23237192_10 37 45
is 23237192_10 46 48
the 23237192_10 49 52
molecular 23237192_10 53 62
basis 23237192_10 63 68
responsible 23237192_10 69 80
for 23237192_10 81 84
the 23237192_10 85 88
NSHL 23237192_10 89 93
of 23237192_10 94 96
two 23237192_10 97 100
families 23237192_10 101 109
, 23237192_10 110 111
and 23237192_10 112 115
the 23237192_10 116 119
use 23237192_10 120 123
of 23237192_10 124 126
aminoglycoside 23237192_10 127 141
antibiotics 23237192_10 142 153
can 23237192_10 154 157
worsen 23237192_10 158 164
the 23237192_10 165 168
hearing 23237192_10 169 176
of 23237192_10 177 179
the 23237192_10 180 183
mutation 23237192_10 184 192
carriers 23237192_10 193 201
. 23237192_10 202 203

OBJECTIVES 18983505_3 0 10
: 18983505_3 11 12
To 18983505_3 13 15
prospectively 18983505_3 16 29
quantify 18983505_3 30 38
the 18983505_3 39 42
dose 18983505_3 43 47
- 18983505_3 47 48
response 18983505_3 48 56
effects 18983505_3 57 64
of 18983505_3 65 67
paroxetine 18983505_3 68 78
and 18983505_3 79 82
the 18983505_3 83 86
influence 18983505_3 87 96
of 18983505_3 97 99
the 18983505_3 100 103
serotonin 18983505_3 104 113
transporter 18983505_3 114 125
gene 18983505_3 126 130
( 18983505_3 131 132
SLC 18983505_3 133 136
6 18983505_3 136 137
A 18983505_3 137 138
4 18983505_3 138 139
) 18983505_3 140 141
promoter 18983505_3 142 150
polymorphism 18983505_3 151 163
( 18983505_3 164 165
5 18983505_3 166 167
- 18983505_3 167 168
HTTLPR 18983505_3 168 174
) 18983505_3 175 176
on 18983505_3 177 179
platelet 18983505_3 180 188
function 18983505_3 189 197
. 18983505_3 198 199

No 24285256_8 0 2
significant 24285256_8 3 14
differences 24285256_8 15 26
of 24285256_8 27 29
sirolimus 24285256_8 30 39
C 24285256_8 40 41
0 24285256_8 41 42
/ 24285256_8 42 43
D 24285256_8 43 44
ratios 24285256_8 45 51
were 24285256_8 52 56
observed 24285256_8 57 65
among 24285256_8 66 71
various 24285256_8 72 79
ABCB 24285256_8 80 84
1 24285256_8 84 85
1236 24285256_8 86 90
C 24285256_8 90 91
> 24285256_8 91 92
T 24285256_8 92 93
, 24285256_8 94 95
2677 24285256_8 96 100
G 24285256_8 100 101
> 24285256_8 101 102
T 24285256_8 102 103
/ 24285256_8 104 105
A 24285256_8 105 106
and 24285256_8 107 110
3435 24285256_8 111 115
C 24285256_8 115 116
> 24285256_8 116 117
T 24285256_8 117 118
genotype 24285256_8 119 127
groups 24285256_8 128 134
. 24285256_8 135 136

COMT 21309949_1 0 4
and 21309949_1 5 8
ALDH 21309949_1 9 13
2 21309949_1 13 14
polymorphisms 21309949_1 15 28
moderate 21309949_1 29 37
associations 21309949_1 38 50
of 21309949_1 51 53
implicit 21309949_1 54 62
drinking 21309949_1 63 71
motives 21309949_1 72 79
with 21309949_1 80 84
alcohol 21309949_1 85 92
use 21309949_1 93 96
. 21309949_1 97 98

Variation 22955794_3 0 9
in 22955794_3 10 12
the 22955794_3 13 16
cytochrome 22955794_3 17 27
P 22955794_3 28 29
450 22955794_3 29 32
2 22955794_3 33 34
C 22955794_3 34 35
19 22955794_3 35 37
( 22955794_3 38 39
CYP 22955794_3 40 43
2 22955794_3 43 44
C 22955794_3 44 45
19 22955794_3 45 47
) 22955794_3 48 49
gene 22955794_3 50 54
coding 22955794_3 55 61
for 22955794_3 62 65
the 22955794_3 66 69
CYP 22955794_3 70 73
2 22955794_3 73 74
C 22955794_3 74 75
19 22955794_3 75 77
enzyme 22955794_3 78 84
is 22955794_3 85 87
one 22955794_3 88 91
of 22955794_3 92 94
the 22955794_3 95 98
major 22955794_3 99 104
determinants 22955794_3 105 117
of 22955794_3 118 120
this 22955794_3 121 125
variable 22955794_3 126 134
response 22955794_3 135 143
to 22955794_3 144 146
clopidogrel 22955794_3 147 158
. 22955794_3 159 160

Diplotypes 17217931_1 0 10
of 17217931_1 11 13
the 17217931_1 14 17
human 17217931_1 18 23
serotonin 17217931_1 24 33
1 17217931_1 34 35
B 17217931_1 35 36
receptor 17217931_1 37 45
promoter 17217931_1 46 54
predict 17217931_1 55 62
growth 17217931_1 63 69
hormone 17217931_1 70 77
responses 17217931_1 78 87
to 17217931_1 88 90
sumatriptan 17217931_1 91 102
in 17217931_1 103 105
abstinent 17217931_1 106 115
alcohol 17217931_1 116 123
- 17217931_1 124 125
dependent 17217931_1 125 134
men 17217931_1 135 138
. 17217931_1 139 140

Phenotypic 11122156_8 0 10
severity 11122156_8 11 19
was 11122156_8 20 23
not 11122156_8 24 27
simply 11122156_8 28 34
related 11122156_8 35 42
to 11122156_8 43 45
the 11122156_8 46 49
degree 11122156_8 50 56
of 11122156_8 57 59
alpha 11122156_8 60 65
- 11122156_8 65 66
globin 11122156_8 66 72
deficiency 11122156_8 73 83
: 11122156_8 84 85
high 11122156_8 86 90
Hb 11122156_8 91 93
H 11122156_8 94 95
levels 11122156_8 96 102
were 11122156_8 103 107
found 11122156_8 108 113
to 11122156_8 114 116
exacerbate 11122156_8 117 127
anaemia 11122156_8 128 135
by 11122156_8 136 138
negatively 11122156_8 139 149
influencing 11122156_8 150 161
tissue 11122156_8 162 168
oxygenation 11122156_8 169 180
, 11122156_8 181 182
and 11122156_8 183 186
both 11122156_8 187 191
Hb 11122156_8 192 194
H 11122156_8 195 196
and 11122156_8 197 200
alpha 11122156_8 201 206
- 11122156_8 206 207
thalassaemic 11122156_8 207 219
haemoglobin 11122156_8 220 231
variants 11122156_8 232 240
appear 11122156_8 241 247
to 11122156_8 248 250
reduce 11122156_8 251 257
red 11122156_8 258 261
cell 11122156_8 262 266
survival 11122156_8 267 275
within 11122156_8 276 282
the 11122156_8 283 286
bone 11122156_8 287 291
marrow 11122156_8 292 298
and 11122156_8 299 302
circulation 11122156_8 303 314
. 11122156_8 315 316

Here 17989208_5 0 4
, 17989208_5 5 6
we 17989208_5 7 9
systematically 17989208_5 10 24
introduced 17989208_5 25 35
cysteine 17989208_5 36 44
- 17989208_5 45 46
scanning 17989208_5 46 54
substitutions 17989208_5 55 68
into 17989208_5 69 73
the 17989208_5 74 77
descending 17989208_5 78 88
portion 17989208_5 89 96
of 17989208_5 97 99
the 17989208_5 100 103
P 17989208_5 104 105
loop 17989208_5 106 110
( 17989208_5 111 112
residues 17989208_5 113 121
339 17989208_5 122 125
- 17989208_5 125 126
345 17989208_5 126 129
) 17989208_5 130 131
of 17989208_5 132 134
HCN 17989208_5 135 138
1 17989208_5 138 139
- 17989208_5 140 141
R 17989208_5 141 142
( 17989208_5 143 144
where 17989208_5 145 150
R 17989208_5 151 152
is 17989208_5 153 155
resistance 17989208_5 156 166
to 17989208_5 167 169
sulfhydryl 17989208_5 170 180
- 17989208_5 181 182
reactive 17989208_5 182 190
agents 17989208_5 191 197
) 17989208_5 198 199
channels 17989208_5 200 208
, 17989208_5 209 210
in 17989208_5 211 213
which 17989208_5 214 219
all 17989208_5 220 223
endogenous 17989208_5 224 234
cysteines 17989208_5 235 244
except 17989208_5 245 251
C 17989208_5 252 253
303 17989208_5 253 256
have 17989208_5 257 261
been 17989208_5 262 266
removed 17989208_5 267 274
or 17989208_5 275 277
replaced 17989208_5 278 286
. 17989208_5 287 288

Identification 25404639_1 0 14
and 25404639_1 15 18
validation 25404639_1 19 29
of 25404639_1 30 32
p 25404639_1 33 34
50 25404639_1 34 36
as 25404639_1 37 39
the 25404639_1 40 43
cellular 25404639_1 44 52
target 25404639_1 53 59
of 25404639_1 60 62
eriocalyxin 25404639_1 63 74
B 25404639_1 75 76
. 25404639_1 77 78

Poly 19383921_1 0 4
( 19383921_1 4 5
ADP 19383921_1 5 8
- 19383921_1 8 9
ribose 19383921_1 9 15
) 19383921_1 15 16
polymerase 19383921_1 17 27
- 19383921_1 27 28
1 19383921_1 28 29
inhibitor 19383921_1 30 39
treatment 19383921_1 40 49
regresses 19383921_1 50 59
autochthonous 19383921_1 60 73
Brca 19383921_1 74 78
2 19383921_1 78 79
/ 19383921_1 80 81
p 19383921_1 82 83
53 19383921_1 83 85
- 19383921_1 86 87
mutant 19383921_1 87 93
mammary 19383921_1 94 101
tumors 19383921_1 102 108
in 19383921_1 109 111
vivo 19383921_1 112 116
and 19383921_1 117 120
delays 19383921_1 121 127
tumor 19383921_1 128 133
relapse 19383921_1 134 141
in 19383921_1 142 144
combination 19383921_1 145 156
with 19383921_1 157 161
carboplatin 19383921_1 162 173
. 19383921_1 174 175

[ 21829065_1 0 1
Analysis 21829065_1 2 10
of 21829065_1 11 13
the 21829065_1 14 17
correlation 21829065_1 18 29
with 21829065_1 30 34
KRAS 21829065_1 35 39
gene 21829065_1 40 44
mutation 21829065_1 45 53
status 21829065_1 54 60
and 21829065_1 61 64
the 21829065_1 65 68
benefit 21829065_1 69 76
of 21829065_1 77 79
cetuximab 21829065_1 80 89
plus 21829065_1 90 94
irinotecan 21829065_1 95 105
as 21829065_1 106 108
third 21829065_1 109 114
- 21829065_1 115 116
line 21829065_1 117 121
chemotherapy 21829065_1 122 134
for 21829065_1 135 138
the 21829065_1 139 142
Treatment 21829065_1 143 152
of 21829065_1 153 155
unresectable 21829065_1 156 168
metastatic 21829065_1 169 179
colorectal 21829065_1 180 190
cancer 21829065_1 191 197
] 21829065_1 198 199
. 21829065_1 200 201

Identification 23301703_1 0 14
of 23301703_1 15 17
GZD 23301703_1 18 21
824 23301703_1 21 24
as 23301703_1 25 27
an 23301703_1 28 30
orally 23301703_1 31 37
bioavailable 23301703_1 38 50
inhibitor 23301703_1 51 60
that 23301703_1 61 65
targets 23301703_1 66 73
phosphorylated 23301703_1 74 88
and 23301703_1 89 92
nonphosphorylated 23301703_1 93 110
breakpoint 23301703_1 111 121
cluster 23301703_1 122 129
region 23301703_1 130 136
- 23301703_1 136 137
Abelson 23301703_1 137 144
( 23301703_1 145 146
Bcr 23301703_1 147 150
- 23301703_1 150 151
Abl 23301703_1 151 154
) 23301703_1 155 156
kinase 23301703_1 157 163
and 23301703_1 164 167
overcomes 23301703_1 168 177
clinically 23301703_1 178 188
acquired 23301703_1 189 197
mutation 23301703_1 198 206
- 23301703_1 207 208
induced 23301703_1 208 215
resistance 23301703_1 216 226
against 23301703_1 227 234
imatinib 23301703_1 235 243
. 23301703_1 244 245

Acetaminophen 17898154_8 0 13
, 17898154_8 14 15
3 17898154_8 16 17
' 17898154_8 17 18
- 17898154_8 18 19
azido 17898154_8 19 24
- 17898154_8 24 25
3 17898154_8 25 26
' 17898154_8 26 27
- 17898154_8 27 28
deoxythymidine 17898154_8 28 42
, 17898154_8 43 44
muraglitazar 17898154_8 45 57
, 17898154_8 58 59
estradiol 17898154_8 60 69
( 17898154_8 70 71
17 17898154_8 72 74
- 17898154_8 74 75
OH 17898154_8 75 77
) 17898154_8 78 79
, 17898154_8 80 81
and 17898154_8 82 85
ethinyl 17898154_8 86 93
estradiol 17898154_8 94 103
( 17898154_8 104 105
17 17898154_8 106 108
- 17898154_8 108 109
OH 17898154_8 109 111
) 17898154_8 112 113
were 17898154_8 114 118
all 17898154_8 119 122
found 17898154_8 123 128
to 17898154_8 129 131
show 17898154_8 132 136
similar 17898154_8 137 144
rates 17898154_8 145 150
of 17898154_8 151 153
metabolism 17898154_8 154 164
regardless 17898154_8 165 175
of 17898154_8 176 178
UGT 17898154_8 179 182
1 17898154_8 182 183
A 17898154_8 183 184
1 17898154_8 184 185
genotype 17898154_8 186 194
. 17898154_8 195 196

Cumulatively 16402341_5 0 12
these 16402341_5 13 18
findings 16402341_5 19 27
suggested 16402341_5 28 37
that 16402341_5 38 42
TD 16402341_5 43 45
was 16402341_5 46 49
related 16402341_5 50 57
to 16402341_5 58 60
phenylalanine 16402341_5 61 74
metabolism 16402341_5 75 85
and 16402341_5 86 89
thus 16402341_5 90 94
that 16402341_5 95 99
sequence 16402341_5 100 108
variants 16402341_5 109 117
in 16402341_5 118 120
the 16402341_5 121 124
gene 16402341_5 125 129
for 16402341_5 130 133
phenylalanine 16402341_5 134 147
hydroxylase 16402341_5 148 159
( 16402341_5 160 161
PAH 16402341_5 162 165
) 16402341_5 166 167
, 16402341_5 168 169
the 16402341_5 170 173
rate 16402341_5 174 178
- 16402341_5 178 179
limiting 16402341_5 179 187
enzyme 16402341_5 188 194
in 16402341_5 195 197
the 16402341_5 198 201
catabolism 16402341_5 202 212
of 16402341_5 213 215
phenylalanine 16402341_5 216 229
, 16402341_5 230 231
could 16402341_5 232 237
be 16402341_5 238 240
associated 16402341_5 241 251
with 16402341_5 252 256
TD 16402341_5 257 259
susceptibility 16402341_5 260 274
. 16402341_5 275 276

DESIGN 22102708_4 0 6
AND 22102708_4 7 10
METHODS 22102708_4 11 18
: 22102708_4 19 20
We 22102708_4 21 23
compared 22102708_4 24 32
the 22102708_4 33 36
clinical 22102708_4 37 45
and 22102708_4 46 49
hematologic 22102708_4 50 61
responses 22102708_4 62 71
to 22102708_4 72 74
change 22102708_4 75 81
in 22102708_4 82 84
% 22102708_4 85 86
V 22102708_4 87 88
617 22102708_4 88 91
F 22102708_4 91 92
( 22102708_4 93 94
molecular 22102708_4 95 104
response 22102708_4 105 113
) 22102708_4 114 115
in 22102708_4 116 118
73 22102708_4 119 121
patients 22102708_4 122 130
with 22102708_4 131 135
polycythemia 22102708_4 136 148
vera 22102708_4 149 153
treated 22102708_4 154 161
with 22102708_4 162 166
either 22102708_4 167 173
interferon 22102708_4 174 184
( 22102708_4 185 186
rIFNa 22102708_4 187 192
- 22102708_4 192 193
2 22102708_4 193 194
b 22102708_4 194 195
: 22102708_4 196 197
28 22102708_4 198 200
, 22102708_4 201 202
Peg 22102708_4 203 206
- 22102708_4 206 207
rIFNa 22102708_4 207 212
- 22102708_4 212 213
2 22102708_4 213 214
a 22102708_4 214 215
: 22102708_4 216 217
18 22102708_4 218 220
) 22102708_4 221 222
or 22102708_4 223 225
non 22102708_4 226 229
- 22102708_4 229 230
interferon 22102708_4 230 240
drugs 22102708_4 241 246
( 22102708_4 247 248
n 22102708_4 249 250
= 22102708_4 251 252
27 22102708_4 253 255
) 22102708_4 256 257
, 22102708_4 258 259
which 22102708_4 260 265
included 22102708_4 266 274
hydroxyurea 22102708_4 275 286
( 22102708_4 287 288
n 22102708_4 289 290
= 22102708_4 291 292
8 22102708_4 293 294
) 22102708_4 295 296
, 22102708_4 297 298
imatinib 22102708_4 299 307
( 22102708_4 308 309
n 22102708_4 310 311
= 22102708_4 312 313
12 22102708_4 314 316
) 22102708_4 317 318
, 22102708_4 319 320
dasatinib 22102708_4 321 330
( 22102708_4 331 332
n 22102708_4 333 334
= 22102708_4 335 336
5 22102708_4 337 338
) 22102708_4 339 340
, 22102708_4 341 342
busulfan 22102708_4 343 351
( 22102708_4 352 353
n 22102708_4 354 355
= 22102708_4 356 357
1 22102708_4 358 359
) 22102708_4 360 361
, 22102708_4 362 363
and 22102708_4 364 367
radioactive 22102708_4 368 379
phosphorus 22102708_4 380 390
( 22102708_4 391 392
n 22102708_4 393 394
= 22102708_4 395 396
1 22102708_4 397 398
) 22102708_4 399 400
. 22102708_4 401 402

Cyclosporine 11956176_1 0 12
a 11956176_1 13 14
and 11956176_1 15 18
FK 11956176_1 19 21
506 11956176_1 21 24
inhibit 11956176_1 25 32
transcriptional 11956176_1 33 48
activity 11956176_1 49 57
of 11956176_1 58 60
the 11956176_1 61 64
human 11956176_1 65 70
mineralocorticoid 11956176_1 71 88
receptor 11956176_1 89 97
: 11956176_1 98 99
a 11956176_1 100 101
cell 11956176_1 102 106
- 11956176_1 106 107
based 11956176_1 107 112
model 11956176_1 113 118
to 11956176_1 119 121
investigate 11956176_1 122 133
partial 11956176_1 134 141
aldosterone 11956176_1 142 153
resistance 11956176_1 154 164
in 11956176_1 165 167
kidney 11956176_1 168 174
transplantation 11956176_1 175 190
. 11956176_1 191 192

Vemurafenib 23909652_2 0 11
, 23909652_2 12 13
a 23909652_2 14 15
selective 23909652_2 16 25
BRAF 23909652_2 26 30
( 23909652_2 31 32
v 23909652_2 33 34
- 23909652_2 34 35
raf 23909652_2 35 38
murine 23909652_2 39 45
sarcoma 23909652_2 46 53
viral 23909652_2 54 59
oncogene 23909652_2 60 68
homologue 23909652_2 69 78
B 23909652_2 79 80
1 23909652_2 80 81
) 23909652_2 82 83
kinase 23909652_2 84 90
inhibitor 23909652_2 91 100
, 23909652_2 101 102
is 23909652_2 103 105
a 23909652_2 106 107
new 23909652_2 108 111
targeted 23909652_2 112 120
biotherapy 23909652_2 121 131
that 23909652_2 132 136
improves 23909652_2 137 145
survival 23909652_2 146 154
in 23909652_2 155 157
patients 23909652_2 158 166
with 23909652_2 167 171
metastatic 23909652_2 172 182
melanomas 23909652_2 183 192
harbouring 23909652_2 193 203
the 23909652_2 204 207
BRAF 23909652_2 208 212
V 23909652_2 213 214
600 23909652_2 214 217
E 23909652_2 217 218
mutation 23909652_2 219 227
. 23909652_2 228 229

Results 18940228_4 0 7
revealed 18940228_4 8 16
that 18940228_4 17 21
HCH 18940228_4 22 25
administration 18940228_4 26 40
lead 18940228_4 41 45
to 18940228_4 46 48
an 18940228_4 49 51
increase 18940228_4 52 60
in 18940228_4 61 63
hepatic 18940228_4 64 71
lipid 18940228_4 72 77
peroxidation 18940228_4 78 90
associated 18940228_4 91 101
with 18940228_4 102 106
reduction 18940228_4 107 116
in 18940228_4 117 119
, 18940228_4 120 121
levels 18940228_4 122 128
of 18940228_4 129 131
glutathione 18940228_4 132 143
( 18940228_4 144 145
GSH 18940228_4 146 149
) 18940228_4 150 151
, 18940228_4 152 153
activity 18940228_4 154 162
of 18940228_4 163 165
superoxide 18940228_4 166 176
dismutase 18940228_4 177 186
( 18940228_4 187 188
SOD 18940228_4 189 192
) 18940228_4 193 194
, 18940228_4 195 196
catalase 18940228_4 197 205
and 18940228_4 206 209
glucose 18940228_4 210 217
- 18940228_4 217 218
6 18940228_4 218 219
- 18940228_4 219 220
phosphate 18940228_4 220 229
dehydrogenase 18940228_4 230 243
. 18940228_4 244 245

KEY 20663035_7 0 3
FINDINGS 20663035_7 4 12
: 20663035_7 13 14
Kainic 20663035_7 15 21
acid 20663035_7 22 26
treatment 20663035_7 27 36
significiantly 20663035_7 37 51
upregulated 20663035_7 52 63
the 20663035_7 64 67
expression 20663035_7 68 78
of 20663035_7 79 81
c 20663035_7 82 83
- 20663035_7 83 84
fos 20663035_7 84 87
mRNA 20663035_7 88 92
in 20663035_7 93 95
the 20663035_7 96 99
hippocampus 20663035_7 100 111
and 20663035_7 112 115
cortex 20663035_7 116 122
when 20663035_7 123 127
compared 20663035_7 128 136
to 20663035_7 137 139
the 20663035_7 140 143
control 20663035_7 144 151
group 20663035_7 152 157
. 20663035_7 158 159

Association 21172311_1 0 11
between 21172311_1 12 19
the 21172311_1 20 23
5 21172311_1 24 25
- 21172311_1 25 26
HTR 21172311_1 27 30
1 21172311_1 30 31
B 21172311_1 31 32
gene 21172311_1 33 37
polymorphisms 21172311_1 38 51
and 21172311_1 52 55
alcohol 21172311_1 56 63
dependence 21172311_1 64 74
in 21172311_1 75 77
a 21172311_1 78 79
Han 21172311_1 80 83
Chinese 21172311_1 84 91
population 21172311_1 92 102
. 21172311_1 103 104

CONCLUSIONS 23258095_8 0 11
: 23258095_8 12 13
Maintenance 23258095_8 14 25
therapy 23258095_8 26 33
with 23258095_8 34 38
the 23258095_8 39 42
use 23258095_8 43 46
of 23258095_8 47 49
long 23258095_8 50 54
- 23258095_8 54 55
term 23258095_8 55 59
low 23258095_8 60 63
- 23258095_8 63 64
dose 23258095_8 64 68
PEG 23258095_8 69 72
- 23258095_8 73 74
IFNa 23258095_8 75 79
- 23258095_8 79 80
2 23258095_8 80 81
a 23258095_8 82 83
is 23258095_8 84 86
effective 23258095_8 87 96
for 23258095_8 97 100
preventing 23258095_8 101 111
HCC 23258095_8 112 115
occurrence 23258095_8 116 126
irrespective 23258095_8 127 139
of 23258095_8 140 142
the 23258095_8 143 146
IL 23258095_8 147 149
28 23258095_8 149 151
B 23258095_8 151 152
SNP 23258095_8 153 156
, 23258095_8 157 158
at 23258095_8 159 161
least 23258095_8 162 167
for 23258095_8 168 171
a 23258095_8 172 173
subset 23258095_8 174 180
of 23258095_8 181 183
CHC 23258095_8 184 187
patients 23258095_8 188 196
. 23258095_8 197 198

Five 21531995_4 0 4
SCARB 21531995_4 5 10
1 21531995_4 10 11
SNPs 21531995_4 12 16
were 21531995_4 17 21
sequenced 21531995_4 22 31
and 21531995_4 32 35
progesterone 21531995_4 36 48
levels 21531995_4 49 55
were 21531995_4 56 60
measured 21531995_4 61 69
in 21531995_4 70 72
the 21531995_4 73 76
follicular 21531995_4 77 87
fluid 21531995_4 88 93
. 21531995_4 94 95

In 18602406_7 0 2
beta 18602406_7 3 7
3 18602406_7 7 8
( 18602406_7 9 10
N 18602406_7 11 12
265 18602406_7 12 15
M 18602406_7 15 16
) 18602406_7 17 18
point 18602406_7 19 24
- 18602406_7 24 25
mutated 18602406_7 25 32
mice 18602406_7 33 37
the 18602406_7 38 41
anxiolytic 18602406_7 42 52
activity 18602406_7 53 61
of 18602406_7 62 64
valerenic 18602406_7 65 74
acid 18602406_7 75 79
was 18602406_7 80 83
absent 18602406_7 84 90
. 18602406_7 91 92

rs 25594941_4 0 2
9923231 25594941_4 2 9
( 25594941_4 10 11
VKORC 25594941_4 12 17
1 25594941_4 17 18
) 25594941_4 19 20
, 25594941_4 21 22
rs 25594941_4 23 25
7294 25594941_4 25 29
( 25594941_4 30 31
VKORC 25594941_4 32 37
1 25594941_4 37 38
) 25594941_4 39 40
, 25594941_4 41 42
rs 25594941_4 43 45
1057910 25594941_4 45 52
( 25594941_4 53 54
CYP 25594941_4 55 58
2 25594941_4 58 59
C 25594941_4 59 60
9 25594941_4 60 61
) 25594941_4 62 63
, 25594941_4 64 65
rs 25594941_4 66 68
2108622 25594941_4 68 75
( 25594941_4 76 77
CYP 25594941_4 78 81
4 25594941_4 81 82
F 25594941_4 82 83
2 25594941_4 83 84
) 25594941_4 85 86
, 25594941_4 87 88
and 25594941_4 89 92
rs 25594941_4 93 95
699664 25594941_4 95 101
( 25594941_4 102 103
GGCX 25594941_4 104 108
) 25594941_4 109 110
involved 25594941_4 111 119
in 25594941_4 120 122
the 25594941_4 123 126
warfarin 25594941_4 127 135
action 25594941_4 136 142
mechanism 25594941_4 143 152
and 25594941_4 153 156
the 25594941_4 157 160
circulatory 25594941_4 161 172
vitamin 25594941_4 173 180
K 25594941_4 181 182
were 25594941_4 183 187
selected 25594941_4 188 196
to 25594941_4 197 199
investigate 25594941_4 200 211
their 25594941_4 212 217
polymorphism 25594941_4 218 230
characteristics 25594941_4 231 246
and 25594941_4 247 250
their 25594941_4 251 256
effects 25594941_4 257 264
on 25594941_4 265 267
the 25594941_4 268 271
pharmacodynamics 25594941_4 272 288
and 25594941_4 289 292
pharmacokinetics 25594941_4 293 309
of 25594941_4 310 312
warfarin 25594941_4 313 321
in 25594941_4 322 324
Chinese 25594941_4 325 332
population 25594941_4 333 343
. 25594941_4 344 345

Phase 25870087_1 0 5
I 25870087_1 6 7
/ 25870087_1 7 8
II 25870087_1 8 10
Study 25870087_1 11 16
of 25870087_1 17 19
HSP 25870087_1 20 23
90 25870087_1 23 25
Inhibitor 25870087_1 26 35
AUY 25870087_1 36 39
922 25870087_1 39 42
and 25870087_1 43 46
Erlotinib 25870087_1 47 56
for 25870087_1 57 60
EGFR 25870087_1 61 65
- 25870087_1 66 67
Mutant 25870087_1 67 73
Lung 25870087_1 74 78
Cancer 25870087_1 79 85
With 25870087_1 86 90
Acquired 25870087_1 91 99
Resistance 25870087_1 100 110
to 25870087_1 111 113
Epidermal 25870087_1 114 123
Growth 25870087_1 124 130
Factor 25870087_1 131 137
Receptor 25870087_1 138 146
Tyrosine 25870087_1 147 155
Kinase 25870087_1 156 162
Inhibitors 25870087_1 163 173
. 25870087_1 174 175

Following 18324624_6 0 9
transient 18324624_6 10 19
expression 18324624_6 20 30
of 18324624_6 31 33
MDR 18324624_6 34 37
- 18324624_6 37 38
1 18324624_6 38 39
and 18324624_6 40 43
MCJ 18324624_6 44 47
, 18324624_6 48 49
changes 18324624_6 50 57
in 18324624_6 58 60
the 18324624_6 61 64
sensitivity 18324624_6 65 76
of 18324624_6 77 79
Sk 18324624_6 80 82
- 18324624_6 82 83
Ov 18324624_6 83 85
- 18324624_6 85 86
3 18324624_6 86 87
cells 18324624_6 88 93
to 18324624_6 94 96
paclitaxel 18324624_6 97 107
were 18324624_6 108 112
detected 18324624_6 113 121
whereas 18324624_6 122 129
expression 18324624_6 130 140
of 18324624_6 141 143
Src 18324624_6 144 147
, 18324624_6 148 149
Bcl 18324624_6 150 153
- 18324624_6 153 154
2 18324624_6 154 155
and 18324624_6 156 159
Bcl 18324624_6 160 163
- 18324624_6 163 164
X 18324624_6 164 165
( 18324624_6 165 166
L 18324624_6 166 167
) 18324624_6 167 168
decreased 18324624_6 169 178
the 18324624_6 179 182
sensitivity 18324624_6 183 194
of 18324624_6 195 197
Sk 18324624_6 198 200
- 18324624_6 200 201
Ov 18324624_6 201 203
- 18324624_6 203 204
3 18324624_6 204 205
cells 18324624_6 206 211
to 18324624_6 212 214
carboplatin 18324624_6 215 226
. 18324624_6 227 228

CONCLUSION 21139584_10 0 10
: 21139584_10 11 12
GUT 21139584_10 13 16
- 21139584_10 16 17
70 21139584_10 17 19
has 21139584_10 20 23
pronounced 21139584_10 24 34
antiproliferative 21139584_10 35 52
effects 21139584_10 53 60
in 21139584_10 61 63
MCL 21139584_10 64 67
with 21139584_10 68 72
mt 21139584_10 73 75
- 21139584_10 75 76
p 21139584_10 77 78
53 21139584_10 78 80
, 21139584_10 81 82
a 21139584_10 83 84
known 21139584_10 85 90
negative 21139584_10 91 99
prognostic 21139584_10 100 110
factor 21139584_10 111 117
for 21139584_10 118 121
MCL 21139584_10 122 125
, 21139584_10 126 127
through 21139584_10 128 135
Hsp 21139584_10 136 139
90 21139584_10 139 141
inhibition 21139584_10 142 152
. 21139584_10 153 154

Functionalized 18647087_1 0 14
PEG 18647087_1 15 18
- 18647087_1 19 20
PEI 18647087_1 21 24
copolymers 18647087_1 25 35
complexed 18647087_1 36 45
to 18647087_1 46 48
exon 18647087_1 49 53
- 18647087_1 53 54
skipping 18647087_1 54 62
oligonucleotides 18647087_1 63 79
improve 18647087_1 80 87
dystrophin 18647087_1 88 98
expression 18647087_1 99 109
in 18647087_1 110 112
mdx 18647087_1 113 116
mice 18647087_1 117 121
. 18647087_1 122 123

No 19912163_13 0 2
significant 19912163_13 3 14
differences 19912163_13 15 26
were 19912163_13 27 31
observed 19912163_13 32 40
in 19912163_13 41 43
the 19912163_13 44 47
dose 19912163_13 48 52
- 19912163_13 52 53
normalized 19912163_13 53 63
C 19912163_13 64 65
( 19912163_13 66 67
12 19912163_13 68 70
) 19912163_13 71 72
of 19912163_13 73 75
mizoribine 19912163_13 76 86
and 19912163_13 87 90
substitute 19912163_13 91 101
CL 19912163_13 102 104
( 19912163_13 105 106
MZ 19912163_13 107 109
) 19912163_13 110 111
between 19912163_13 112 119
the 19912163_13 120 123
G 19912163_13 124 125
565 19912163_13 125 128
A 19912163_13 128 129
genotypes 19912163_13 130 139
. 19912163_13 140 141

CONCLUSIONS 16944116_13 0 11
: 16944116_13 12 13
CYP 16944116_13 14 17
2 16944116_13 17 18
D 16944116_13 18 19
6 16944116_13 19 20
genotype 16944116_13 21 29
, 16944116_13 30 31
even 16944116_13 32 36
in 16944116_13 37 39
IMs 16944116_13 40 43
, 16944116_13 44 45
as 16944116_13 46 48
well 16944116_13 49 53
as 16944116_13 54 56
body 16944116_13 57 61
weight 16944116_13 62 68
, 16944116_13 69 70
age 16944116_13 71 74
, 16944116_13 75 76
sex 16944116_13 77 80
, 16944116_13 81 82
and 16944116_13 83 86
Scr 16944116_13 87 90
influence 16944116_13 91 100
flecainide 16944116_13 101 111
pharmacokinetics 16944116_13 112 128
in 16944116_13 129 131
Japanese 16944116_13 132 140
patients 16944116_13 141 149
with 16944116_13 150 154
supraventricular 16944116_13 155 171
tachyarrhythmia 16944116_13 172 187
. 16944116_13 188 189

Exposure 21107535_6 0 8
of 21107535_6 9 11
PC 21107535_6 12 14
12 21107535_6 14 16
cells 21107535_6 17 22
to 21107535_6 23 25
MnCl 21107535_6 26 30
( 21107535_6 30 31
2 21107535_6 31 32
) 21107535_6 32 33
for 21107535_6 34 37
24 21107535_6 38 40
h 21107535_6 41 42
promoted 21107535_6 43 51
an 21107535_6 52 54
increased 21107535_6 55 64
cytosolic 21107535_6 65 74
and 21107535_6 75 78
nuclear 21107535_6 79 86
accumulation 21107535_6 87 99
of 21107535_6 100 102
Nrf 21107535_6 103 106
2 21107535_6 106 107
and 21107535_6 108 111
enhanced 21107535_6 112 120
the 21107535_6 121 124
binding 21107535_6 125 132
of 21107535_6 133 135
Nrf 21107535_6 136 139
2 21107535_6 139 140
to 21107535_6 141 143
the 21107535_6 144 147
HO 21107535_6 148 150
- 21107535_6 150 151
1 21107535_6 151 152
gene 21107535_6 153 157
ARE 21107535_6 158 161
, 21107535_6 162 163
thereby 21107535_6 164 171
inducing 21107535_6 172 180
the 21107535_6 181 184
expression 21107535_6 185 195
of 21107535_6 196 198
an 21107535_6 199 201
Nrf 21107535_6 202 205
2 21107535_6 205 206
- 21107535_6 207 208
regulated 21107535_6 208 217
gene 21107535_6 218 222
, 21107535_6 223 224
HO 21107535_6 225 227
- 21107535_6 227 228
1 21107535_6 228 229
. 21107535_6 230 231

We 18794726_7 0 2
also 18794726_7 3 7
measured 18794726_7 8 16
plasma 18794726_7 17 23
atenolol 18794726_7 24 32
concentrations 18794726_7 33 47
and 18794726_7 48 51
determined 18794726_7 52 62
genotypes 18794726_7 63 72
for 18794726_7 73 76
variants 18794726_7 77 85
of 18794726_7 86 88
the 18794726_7 89 92
beta 18794726_7 93 97
1 18794726_7 97 98
- 18794726_7 98 99
AR 18794726_7 99 101
( 18794726_7 102 103
Ser 18794726_7 104 107
49 18794726_7 107 109
Gly 18794726_7 109 112
, 18794726_7 113 114
Arg 18794726_7 115 118
389 18794726_7 118 121
Gly 18794726_7 121 124
) 18794726_7 125 126
and 18794726_7 127 130
alpha 18794726_7 131 136
2 18794726_7 136 137
C 18794726_7 137 138
- 18794726_7 138 139
AR 18794726_7 139 141
( 18794726_7 142 143
del 18794726_7 144 147
322 18794726_7 147 150
- 18794726_7 150 151
325 18794726_7 151 154
) 18794726_7 155 156
. 18794726_7 157 158

We 22134241_7 0 2
found 22134241_7 3 8
that 22134241_7 9 13
the 22134241_7 14 17
combination 22134241_7 18 29
of 22134241_7 30 32
AZD 22134241_7 33 36
7762 22134241_7 36 40
and 22134241_7 41 44
olaparib 22134241_7 45 53
produced 22134241_7 54 62
significant 22134241_7 63 74
radiosensitization 22134241_7 75 93
in 22134241_7 94 96
p 22134241_7 97 98
53 22134241_7 98 100
mutant 22134241_7 101 107
pancreatic 22134241_7 108 118
cancer 22134241_7 119 125
cells 22134241_7 126 131
and 22134241_7 132 135
in 22134241_7 136 138
all 22134241_7 139 142
of 22134241_7 143 145
the 22134241_7 146 149
isogenic 22134241_7 150 158
cancer 22134241_7 159 165
cell 22134241_7 166 170
lines 22134241_7 171 176
. 22134241_7 177 178

CYP 21975350_4 0 3
2 21975350_4 3 4
A 21975350_4 4 5
6 21975350_4 5 6
and 21975350_4 7 10
CYP 21975350_4 11 14
3 21975350_4 14 15
A 21975350_4 15 16
showed 21975350_4 17 23
effects 21975350_4 24 31
on 21975350_4 32 34
letrozole 21975350_4 35 44
metabolism 21975350_4 45 55
in 21975350_4 56 58
vitro 21975350_4 59 64
. 21975350_4 65 66

Multiple 19448895_12 0 8
linear 19448895_12 9 15
regression 19448895_12 16 26
analyses 19448895_12 27 35
showed 19448895_12 36 42
that 19448895_12 43 47
the 19448895_12 48 51
AC 19448895_12 52 54
and 19448895_12 55 58
CC 19448895_12 59 61
CYP 19448895_12 62 65
7 19448895_12 65 66
A 19448895_12 66 67
1 19448895_12 67 68
genotypes 19448895_12 69 78
accounted 19448895_12 79 88
for 19448895_12 89 92
5 19448895_12 93 94
. 19448895_12 94 95
2 19448895_12 95 96
and 19448895_12 97 100
6 19448895_12 101 102
. 19448895_12 102 103
2 19448895_12 103 104
% 19448895_12 105 106
of 19448895_12 107 109
triglyceride 19448895_12 110 122
concentration 19448895_12 123 136
during 19448895_12 137 143
follow 19448895_12 144 150
- 19448895_12 150 151
up 19448895_12 151 153
and 19448895_12 154 157
adjusted 19448895_12 158 166
percent 19448895_12 167 174
of 19448895_12 175 177
change 19448895_12 178 184
of 19448895_12 185 187
triglyceride 19448895_12 188 200
concentration 19448895_12 201 214
, 19448895_12 215 216
respectively 19448895_12 217 229
. 19448895_12 230 231

A 20179610_15 0 1
2143 20179610_15 1 5
G 20179610_15 5 6
was 20179610_15 7 10
an 20179610_15 11 13
important 20179610_15 14 23
23 20179610_15 24 26
S 20179610_15 26 27
rRNA 20179610_15 28 32
mutation 20179610_15 33 41
associated 20179610_15 42 52
with 20179610_15 53 57
clarithromycin 20179610_15 58 72
resistance 20179610_15 73 83
and 20179610_15 84 87
affected 20179610_15 88 96
the 20179610_15 97 100
H 20179610_15 101 102
. 20179610_15 102 103
pylori 20179610_15 104 110
eradication 20179610_15 111 122
efficacy 20179610_15 123 131
. 20179610_15 132 133

METHODS 24521898_3 0 7
: 24521898_3 8 9
Genomic 24521898_3 10 17
DNAs 24521898_3 18 22
were 24521898_3 23 27
extracted 24521898_3 28 37
from 24521898_3 38 42
the 24521898_3 43 46
warfarin 24521898_3 47 55
hypersensitive 24521898_3 56 70
patient 24521898_3 71 78
and 24521898_3 79 82
used 24521898_3 83 87
for 24521898_3 88 91
genetic 24521898_3 92 99
screening 24521898_3 100 109
of 24521898_3 110 112
CYP 24521898_3 113 116
2 24521898_3 116 117
C 24521898_3 117 118
9 24521898_3 118 119
, 24521898_3 120 121
VKORC 24521898_3 122 127
1 24521898_3 127 128
and 24521898_3 129 132
CYP 24521898_3 133 136
4 24521898_3 136 137
F 24521898_3 137 138
2 24521898_3 138 139
by 24521898_3 140 142
direct 24521898_3 143 149
sequencing 24521898_3 150 160
. 24521898_3 161 162

Lack 18429967_1 0 4
of 18429967_1 5 7
tacrolimus 18429967_1 8 18
circadian 18429967_1 19 28
pharmacokinetics 18429967_1 29 45
and 18429967_1 46 49
CYP 18429967_1 50 53
3 18429967_1 53 54
A 18429967_1 54 55
5 18429967_1 55 56
pharmacogenetics 18429967_1 57 73
in 18429967_1 74 76
the 18429967_1 77 80
early 18429967_1 81 86
and 18429967_1 87 90
maintenance 18429967_1 91 102
stages 18429967_1 103 109
in 18429967_1 110 112
Japanese 18429967_1 113 121
renal 18429967_1 122 127
transplant 18429967_1 128 138
recipients 18429967_1 139 149
. 18429967_1 150 151

CONCLUSIONS 17700364_10 0 11
: 17700364_10 12 13
Single 17700364_10 14 20
nucleotide 17700364_10 21 31
polymorphisms 17700364_10 32 45
of 17700364_10 46 48
ABCA 17700364_10 49 53
1 17700364_10 53 54
, 17700364_10 55 56
APOA 17700364_10 57 61
5 17700364_10 61 62
, 17700364_10 63 64
APOC 17700364_10 65 69
3 17700364_10 69 70
, 17700364_10 71 72
APOE 17700364_10 73 77
, 17700364_10 78 79
and 17700364_10 80 83
CETP 17700364_10 84 88
contribute 17700364_10 89 99
to 17700364_10 100 102
plasma 17700364_10 103 109
triglyceride 17700364_10 110 122
and 17700364_10 123 126
high 17700364_10 127 131
- 17700364_10 131 132
density 17700364_10 132 139
lipoprotein 17700364_10 140 151
- 17700364_10 151 152
cholesterol 17700364_10 153 164
levels 17700364_10 165 171
during 17700364_10 172 178
antiretroviral 17700364_10 179 193
therapy 17700364_10 194 201
exposure 17700364_10 202 210
. 17700364_10 211 212

In 11417444_12 0 2
patients 11417444_12 3 11
treated 11417444_12 12 19
with 11417444_12 20 24
azathioprine 11417444_12 25 37
, 11417444_12 38 39
the 11417444_12 40 43
TPMT 11417444_12 44 48
activity 11417444_12 49 57
showed 11417444_12 58 64
a 11417444_12 65 66
slow 11417444_12 67 71
increase 11417444_12 72 80
that 11417444_12 81 85
declined 11417444_12 86 94
to 11417444_12 95 97
pre 11417444_12 98 101
- 11417444_12 101 102
treatment 11417444_12 102 111
values 11417444_12 112 118
when 11417444_12 119 123
azathioprine 11417444_12 124 136
was 11417444_12 137 140
withdrawn 11417444_12 141 150
. 11417444_12 151 152

Patients 16043828_13 0 8
with 16043828_13 9 13
KRAS 16043828_13 14 18
- 16043828_13 19 20
mutant 16043828_13 20 26
NSCLC 16043828_13 27 32
showed 16043828_13 33 39
poorer 16043828_13 40 46
clinical 16043828_13 47 55
outcomes 16043828_13 56 64
when 16043828_13 65 69
treated 16043828_13 70 77
with 16043828_13 78 82
erlotinib 16043828_13 83 92
and 16043828_13 93 96
chemotherapy 16043828_13 97 109
. 16043828_13 110 111

In 27228223_9 0 2
summary 27228223_9 3 10
, 27228223_9 11 12
the 27228223_9 13 16
results 27228223_9 17 24
suggest 27228223_9 25 32
that 27228223_9 33 37
hepatic 27228223_9 38 45
oseltamivir 27228223_9 46 57
activation 27228223_9 58 68
appears 27228223_9 69 76
to 27228223_9 77 79
be 27228223_9 80 82
more 27228223_9 83 87
efficient 27228223_9 88 97
in 27228223_9 98 100
females 27228223_9 101 108
than 27228223_9 109 113
that 27228223_9 114 118
in 27228223_9 119 121
males 27228223_9 122 127
, 27228223_9 128 129
and 27228223_9 130 133
the 27228223_9 134 137
activation 27228223_9 138 148
can 27228223_9 149 152
be 27228223_9 153 155
impaired 27228223_9 156 164
by 27228223_9 165 167
functional 27228223_9 168 178
CES 27228223_9 179 182
1 27228223_9 182 183
variants 27228223_9 184 192
, 27228223_9 193 194
such 27228223_9 195 199
as 27228223_9 200 202
the 27228223_9 203 206
G 27228223_9 207 208
143 27228223_9 208 211
E 27228223_9 211 212
. 27228223_9 213 214

In 11888518_8 0 2
terms 11888518_8 3 8
of 11888518_8 9 11
gene 11888518_8 12 16
expression 11888518_8 17 27
, 11888518_8 28 29
BO 11888518_8 30 32
- 11888518_8 32 33
653 11888518_8 33 36
, 11888518_8 37 38
but 11888518_8 39 42
not 11888518_8 43 46
probucol 11888518_8 47 55
, 11888518_8 56 57
significantly 11888518_8 58 71
inhibited 11888518_8 72 81
c 11888518_8 82 83
- 11888518_8 83 84
myc 11888518_8 84 87
induction 11888518_8 88 97
. 11888518_8 98 99

In 20401433_11 0 2
the 20401433_11 3 6
Polish 20401433_11 7 13
men 20401433_11 14 17
examined 20401433_11 18 26
, 20401433_11 27 28
ADH 20401433_11 29 32
1 20401433_11 32 33
C 20401433_11 33 34
* 20401433_11 35 36
1 20401433_11 37 38
and 20401433_11 39 42
ADH 20401433_11 43 46
1 20401433_11 46 47
B 20401433_11 47 48
* 20401433_11 49 50
1 20401433_11 51 52
alleles 20401433_11 53 60
and 20401433_11 61 64
ADH 20401433_11 65 68
1 20401433_11 68 69
C 20401433_11 69 70
* 20401433_11 71 72
1 20401433_11 73 74
/ 20401433_11 75 76
* 20401433_11 77 78
1 20401433_11 79 80
and 20401433_11 81 84
ADH 20401433_11 85 88
1 20401433_11 88 89
B 20401433_11 89 90
* 20401433_11 91 92
1 20401433_11 93 94
/ 20401433_11 95 96
* 20401433_11 97 98
1 20401433_11 99 100
genotypes 20401433_11 101 110
favor 20401433_11 111 116
alcohol 20401433_11 117 124
dependence 20401433_11 125 135
. 20401433_11 136 137

The 26773964_3 0 3
aim 26773964_3 4 7
of 26773964_3 8 10
this 26773964_3 11 15
study 26773964_3 16 21
was 26773964_3 22 25
to 26773964_3 26 28
evaluate 26773964_3 29 37
the 26773964_3 38 41
influence 26773964_3 42 51
of 26773964_3 52 54
CYP 26773964_3 55 58
3 26773964_3 58 59
A 26773964_3 59 60
5 26773964_3 60 61
polymorphism 26773964_3 62 74
on 26773964_3 75 77
the 26773964_3 78 81
increase 26773964_3 82 90
in 26773964_3 91 93
CYP 26773964_3 94 97
3 26773964_3 97 98
A 26773964_3 98 99
activity 26773964_3 100 108
after 26773964_3 109 114
living 26773964_3 115 121
kidney 26773964_3 122 128
transplantation 26773964_3 129 144
, 26773964_3 145 146
by 26773964_3 147 149
measuring 26773964_3 150 159
the 26773964_3 160 163
plasma 26773964_3 164 170
concentration 26773964_3 171 184
of 26773964_3 185 187
4 26773964_3 188 189
b 26773964_3 189 190
- 26773964_3 190 191
hydroxycholesterol 26773964_3 191 209
. 26773964_3 210 211

A 15910869_1 0 1
promoter 15910869_1 2 10
polymorphism 15910869_1 11 23
in 15910869_1 24 26
cholesterol 15910869_1 27 38
7 15910869_1 39 40
alpha 15910869_1 40 45
- 15910869_1 45 46
hydroxylase 15910869_1 46 57
interacts 15910869_1 58 67
with 15910869_1 68 72
apolipoprotein 15910869_1 73 87
E 15910869_1 88 89
genotype 15910869_1 90 98
in 15910869_1 99 101
the 15910869_1 102 105
LDL 15910869_1 106 109
- 15910869_1 109 110
lowering 15910869_1 110 118
response 15910869_1 119 127
to 15910869_1 128 130
atorvastatin 15910869_1 131 143
. 15910869_1 144 145

CONCLUSIONS 26240276_10 0 11
: 26240276_10 12 13
HAGE 26240276_10 14 18
expression 26240276_10 19 29
is 26240276_10 30 32
a 26240276_10 33 34
potential 26240276_10 35 44
prognostic 26240276_10 45 55
marker 26240276_10 56 62
and 26240276_10 63 66
a 26240276_10 67 68
predictor 26240276_10 69 78
of 26240276_10 79 81
response 26240276_10 82 90
to 26240276_10 91 93
anthracycline 26240276_10 94 107
treatment 26240276_10 108 117
in 26240276_10 118 120
TNBC 26240276_10 121 125
. 26240276_10 126 127

OBJECTIVE 24040330_2 0 9
: 24040330_2 10 11
To 24040330_2 12 14
examine 24040330_2 15 22
the 24040330_2 23 26
association 24040330_2 27 38
of 24040330_2 39 41
six 24040330_2 42 45
glutathione 24040330_2 46 57
transferase 24040330_2 58 69
( 24040330_2 70 71
GST 24040330_2 72 75
) 24040330_2 76 77
gene 24040330_2 78 82
polymorphisms 24040330_2 83 96
( 24040330_2 97 98
GSTT 24040330_2 99 103
1 24040330_2 103 104
, 24040330_2 105 106
GSTP 24040330_2 107 111
1 24040330_2 111 112
/ 24040330_2 113 114
rs 24040330_2 115 117
1695 24040330_2 117 121
, 24040330_2 122 123
GSTO 24040330_2 124 128
1 24040330_2 128 129
/ 24040330_2 130 131
rs 24040330_2 132 134
4925 24040330_2 134 138
, 24040330_2 139 140
GSTO 24040330_2 141 145
2 24040330_2 145 146
/ 24040330_2 147 148
rs 24040330_2 149 151
156697 24040330_2 151 157
, 24040330_2 158 159
GSTM 24040330_2 160 164
1 24040330_2 164 165
, 24040330_2 166 167
GSTA 24040330_2 168 172
1 24040330_2 172 173
/ 24040330_2 174 175
rs 24040330_2 176 178
3957357 24040330_2 178 185
) 24040330_2 186 187
with 24040330_2 188 192
the 24040330_2 193 196
survival 24040330_2 197 205
of 24040330_2 206 208
patients 24040330_2 209 217
with 24040330_2 218 222
muscle 24040330_2 223 229
invasive 24040330_2 230 238
bladder 24040330_2 239 246
cancer 24040330_2 247 253
and 24040330_2 254 257
the 24040330_2 258 261
genotype 24040330_2 262 270
modifying 24040330_2 271 280
effect 24040330_2 281 287
on 24040330_2 288 290
chemotherapy 24040330_2 291 303
. 24040330_2 304 305

CONCLUSION 18654768_9 0 10
: 18654768_9 11 12
Based 18654768_9 13 18
on 18654768_9 19 21
our 18654768_9 22 25
investigation 18654768_9 26 39
using 18654768_9 40 45
two 18654768_9 46 49
different 18654768_9 50 59
CYP 18654768_9 60 63
2 18654768_9 63 64
C 18654768_9 64 65
19 18654768_9 65 67
substrates 18654768_9 68 78
, 18654768_9 79 80
we 18654768_9 81 83
concluded 18654768_9 84 93
that 18654768_9 94 98
a 18654768_9 99 100
clinically 18654768_9 101 111
significant 18654768_9 112 123
difference 18654768_9 124 134
in 18654768_9 135 137
escitalopram 18654768_9 138 150
or 18654768_9 151 153
omeprazole 18654768_9 154 164
kinetics 18654768_9 165 173
between 18654768_9 174 181
the 18654768_9 182 185
genotypes 18654768_9 186 195
appears 18654768_9 196 203
unlikely 18654768_9 204 212
. 18654768_9 213 214

Patients 25303299_10 0 8
with 25303299_10 9 13
MTHFR 25303299_10 14 19
C 25303299_10 20 21
677 25303299_10 21 24
T 25303299_10 24 25
and 25303299_10 26 29
ABCB 25303299_10 30 34
1 25303299_10 34 35
C 25303299_10 36 37
3435 25303299_10 37 41
T 25303299_10 41 42
polymorphisms 25303299_10 43 56
appear 25303299_10 57 63
to 25303299_10 64 66
have 25303299_10 67 71
significantly 25303299_10 72 85
higher 25303299_10 86 92
MTX 25303299_10 93 96
plasma 25303299_10 97 103
concentrations 25303299_10 104 118
( 25303299_10 119 120
p 25303299_10 121 122
< 25303299_10 123 124
0 25303299_10 125 126
. 25303299_10 126 127
05 25303299_10 127 129
) 25303299_10 130 131
. 25303299_10 132 133

Here 17267549_4 0 4
, 17267549_4 5 6
we 17267549_4 7 9
report 17267549_4 10 16
that 17267549_4 17 21
overexpression 17267549_4 22 36
of 17267549_4 37 39
the 17267549_4 40 43
Kv 17267549_4 44 46
1 17267549_4 46 47
. 17267549_4 47 48
5 17267549_4 48 49
channel 17267549_4 50 57
gene 17267549_4 58 62
( 17267549_4 63 64
KCNA 17267549_4 65 69
5 17267549_4 69 70
) 17267549_4 71 72
in 17267549_4 73 75
human 17267549_4 76 81
PASMC 17267549_4 82 87
and 17267549_4 88 91
other 17267549_4 92 97
cell 17267549_4 98 102
lines 17267549_4 103 108
produced 17267549_4 109 117
a 17267549_4 118 119
15 17267549_4 120 122
- 17267549_4 122 123
pS 17267549_4 123 125
single 17267549_4 126 132
channel 17267549_4 133 140
current 17267549_4 141 148
and 17267549_4 149 152
a 17267549_4 153 154
large 17267549_4 155 160
whole 17267549_4 161 166
cell 17267549_4 167 171
current 17267549_4 172 179
that 17267549_4 180 184
was 17267549_4 185 188
sensitive 17267549_4 189 198
to 17267549_4 199 201
4 17267549_4 202 203
- 17267549_4 203 204
aminopyridine 17267549_4 204 217
. 17267549_4 218 219

Our 17105675_6 0 3
results 17105675_6 4 11
show 17105675_6 12 16
that 17105675_6 17 21
genotyping 17105675_6 22 32
A 17105675_6 33 34
- 17105675_6 34 35
241 17105675_6 35 38
G 17105675_6 38 39
may 17105675_6 40 43
help 17105675_6 44 48
to 17105675_6 49 51
predict 17105675_6 52 59
the 17105675_6 60 63
efficacy 17105675_6 64 72
of 17105675_6 73 75
risperidone 17105675_6 76 87
treatment 17105675_6 88 97
on 17105675_6 98 100
the 17105675_6 101 104
basis 17105675_6 105 110
that 17105675_6 111 115
patients 17105675_6 116 124
with 17105675_6 125 129
the 17105675_6 130 133
A 17105675_6 134 135
allele 17105675_6 136 142
showed 17105675_6 143 149
greater 17105675_6 150 157
improvement 17105675_6 158 169
than 17105675_6 170 174
those 17105675_6 175 180
with 17105675_6 181 185
the 17105675_6 186 189
G 17105675_6 190 191
allele 17105675_6 192 198
on 17105675_6 199 201
the 17105675_6 202 205
overall 17105675_6 206 213
BPRS 17105675_6 214 218
( 17105675_6 219 220
chi 17105675_6 221 224
2 17105675_6 224 225
= 17105675_6 226 227
7 17105675_6 228 229
. 17105675_6 229 230
19 17105675_6 230 232
, 17105675_6 233 234
p 17105675_6 235 236
= 17105675_6 237 238
0 17105675_6 239 240
. 17105675_6 240 241
007 17105675_6 241 244
, 17105675_6 245 246
p 17105675_6 247 248
= 17105675_6 249 250
0 17105675_6 251 252
. 17105675_6 252 253
031 17105675_6 253 256
after 17105675_6 257 262
correction 17105675_6 263 273
by 17105675_6 274 276
the 17105675_6 277 280
program 17105675_6 281 288
SNPSpD 17105675_6 289 295
) 17105675_6 296 297
, 17105675_6 298 299
while 17105675_6 300 305
other 17105675_6 306 311
polymorphisms 17105675_6 312 325
, 17105675_6 326 327
including 17105675_6 328 337
- 17105675_6 338 339
141 17105675_6 339 342
C 17105675_6 343 344
Ins 17105675_6 345 348
/ 17105675_6 348 349
Del 17105675_6 349 352
, 17105675_6 353 354
TaqIB 17105675_6 355 360
, 17105675_6 361 362
rs 17105675_6 363 365
1076562 17105675_6 365 372
, 17105675_6 373 374
T 17105675_6 375 376
939 17105675_6 376 379
C 17105675_6 379 380
and 17105675_6 381 384
TaqIA 17105675_6 385 390
, 17105675_6 391 392
did 17105675_6 393 396
not 17105675_6 397 400
show 17105675_6 401 405
any 17105675_6 406 409
association 17105675_6 410 421
with 17105675_6 422 426
the 17105675_6 427 430
response 17105675_6 431 439
to 17105675_6 440 442
risperidone 17105675_6 443 454
. 17105675_6 455 456

Homozygosity 22571356_5 0 12
for 22571356_5 13 16
the 22571356_5 17 20
- 22571356_5 21 22
1639 22571356_5 22 26
G 22571356_5 27 28
> 22571356_5 28 29
A 22571356_5 29 30
single 22571356_5 31 37
nucleotide 22571356_5 38 48
functional 22571356_5 49 59
promoter 22571356_5 60 68
polymorphism 22571356_5 69 81
of 22571356_5 82 84
the 22571356_5 85 88
VKORC 22571356_5 89 94
1 22571356_5 94 95
gene 22571356_5 96 100
( 22571356_5 101 102
genotype 22571356_5 103 111
AA 22571356_5 112 114
; 22571356_5 115 116
14 22571356_5 117 119
5 22571356_5 120 121
% 22571356_5 122 123
of 22571356_5 124 126
cases 22571356_5 127 132
) 22571356_5 133 134
was 22571356_5 135 138
associated 22571356_5 139 149
with 22571356_5 150 154
a 22571356_5 155 156
significantly 22571356_5 157 170
shortened 22571356_5 171 180
time 22571356_5 181 185
to 22571356_5 186 188
therapeutic 22571356_5 189 200
INR 22571356_5 201 204
> 22571356_5 205 206
= 22571356_5 207 208
2 22571356_5 209 210
( 22571356_5 211 212
P 22571356_5 213 214
< 22571356_5 215 216
0 22571356_5 217 218
01 22571356_5 219 221
) 22571356_5 222 223
, 22571356_5 224 225
reduced 22571356_5 226 233
stable 22571356_5 234 240
warfarin 22571356_5 241 249
dose 22571356_5 250 254
( 22571356_5 255 256
P 22571356_5 257 258
< 22571356_5 259 260
0 22571356_5 261 262
01 22571356_5 263 265
) 22571356_5 266 267
, 22571356_5 268 269
and 22571356_5 270 273
an 22571356_5 274 276
increased 22571356_5 277 286
number 22571356_5 287 293
of 22571356_5 294 296
INRs 22571356_5 297 301
> 22571356_5 302 303
5 22571356_5 304 305
( 22571356_5 306 307
P 22571356_5 308 309
< 22571356_5 310 311
0 22571356_5 312 313
001 22571356_5 314 317
) 22571356_5 318 319
and 22571356_5 320 323
occurrence 22571356_5 324 334
of 22571356_5 335 337
bleeding 22571356_5 338 346
events 22571356_5 347 353
( 22571356_5 354 355
P 22571356_5 356 357
< 22571356_5 358 359
0 22571356_5 360 361
01 22571356_5 362 364
) 22571356_5 365 366
during 22571356_5 367 373
the 22571356_5 374 377
first 22571356_5 378 383
month 22571356_5 384 389
, 22571356_5 390 391
as 22571356_5 392 394
compared 22571356_5 395 403
to 22571356_5 404 406
the 22571356_5 407 410
GG 22571356_5 411 413
genotype 22571356_5 414 422
. 22571356_5 423 424

The 17884271_6 0 3
present 17884271_6 4 11
results 17884271_6 12 19
suggest 17884271_6 20 27
that 17884271_6 28 32
high 17884271_6 33 37
- 17884271_6 37 38
activity 17884271_6 38 46
MAO 17884271_6 47 50
- 17884271_6 50 51
A 17884271_6 51 52
genotypes 17884271_6 53 62
possibly 17884271_6 63 71
by 17884271_6 72 74
consecutively 17884271_6 75 88
decreased 17884271_6 89 98
serotonin 17884271_6 99 108
and 17884271_6 109 112
/ 17884271_6 112 113
or 17884271_6 113 115
norepinephrine 17884271_6 116 130
availability 17884271_6 131 143
negatively 17884271_6 144 154
influence 17884271_6 155 164
antidepressant 17884271_6 165 179
treatment 17884271_6 180 189
response 17884271_6 190 198
during 17884271_6 199 205
the 17884271_6 206 209
first 17884271_6 210 215
six 17884271_6 216 219
weeks 17884271_6 220 225
of 17884271_6 226 228
pharmacological 17884271_6 229 244
treatment 17884271_6 245 254
in 17884271_6 255 257
female 17884271_6 258 264
patients 17884271_6 265 273
with 17884271_6 274 278
Major 17884271_6 279 284
Depression 17884271_6 285 295
. 17884271_6 296 297

BACKGROUND 22521649_2 0 10
: 22521649_2 11 12
Epidermal 22521649_2 13 22
growth 22521649_2 23 29
factor 22521649_2 30 36
receptor 22521649_2 37 45
( 22521649_2 46 47
EGFR 22521649_2 48 52
) 22521649_2 53 54
mutations 22521649_2 55 64
in 22521649_2 65 67
non 22521649_2 68 71
- 22521649_2 71 72
small 22521649_2 72 77
cell 22521649_2 78 82
lung 22521649_2 83 87
cancer 22521649_2 88 94
( 22521649_2 95 96
NSCLC 22521649_2 97 102
) 22521649_2 103 104
are 22521649_2 105 108
important 22521649_2 109 118
predictive 22521649_2 119 129
markers 22521649_2 130 137
for 22521649_2 138 141
the 22521649_2 142 145
response 22521649_2 146 154
to 22521649_2 155 157
EGFR 22521649_2 158 162
- 22521649_2 163 164
tyrosine 22521649_2 165 173
kinase 22521649_2 174 180
inhibitors 22521649_2 181 191
( 22521649_2 192 193
EGFR 22521649_2 194 198
- 22521649_2 199 200
TKIs 22521649_2 200 204
) 22521649_2 205 206
. 22521649_2 207 208

We 9142901_2 0 2
reported 9142901_2 3 11
previously 9142901_2 12 22
that 9142901_2 23 27
somatostatin 9142901_2 28 40
inhibits 9142901_2 41 49
the 9142901_2 50 53
expression 9142901_2 54 64
of 9142901_2 65 67
the 9142901_2 68 71
immediate 9142901_2 72 81
early 9142901_2 82 87
gene 9142901_2 88 92
c 9142901_2 93 94
- 9142901_2 94 95
fos 9142901_2 95 98
. 9142901_2 99 100

Currently 21623265_3 0 9
, 21623265_3 10 11
clinical 21623265_3 12 20
development 21623265_3 21 32
of 21623265_3 33 35
crizotinib 21623265_3 36 46
is 21623265_3 47 49
focused 21623265_3 50 57
primarily 21623265_3 58 67
on 21623265_3 68 70
ALK 21623265_3 71 74
rearranged 21623265_3 75 85
non 21623265_3 86 89
- 21623265_3 89 90
small 21623265_3 90 95
cell 21623265_3 96 100
lung 21623265_3 101 105
cancer 21623265_3 106 112
( 21623265_3 113 114
NSCLC 21623265_3 115 120
) 21623265_3 121 122
. 21623265_3 123 124

CONCLUSIONS 17492376_9 0 11
: 17492376_9 12 13
Breast 17492376_9 14 20
cancers 17492376_9 21 28
among 17492376_9 29 34
BRCA 17492376_9 35 39
1 17492376_9 39 40
carriers 17492376_9 41 49
frequently 17492376_9 50 60
do 17492376_9 61 63
not 17492376_9 64 67
exhibit 17492376_9 68 75
sensitivity 17492376_9 76 87
to 17492376_9 88 90
docetaxel 17492376_9 91 100
in 17492376_9 101 103
the 17492376_9 104 107
neo 17492376_9 108 111
- 17492376_9 111 112
adjuvant 17492376_9 112 120
setting 17492376_9 121 128
. 17492376_9 129 130

In 17680654_7 0 2
the 17680654_7 3 6
remaining 17680654_7 7 16
12 17680654_7 17 19
patients 17680654_7 20 28
given 17680654_7 29 34
telaprevir 17680654_7 35 45
alone 17680654_7 46 51
or 17680654_7 52 54
with 17680654_7 55 59
telaprevir 17680654_7 60 70
/ 17680654_7 71 72
PEG 17680654_7 73 76
- 17680654_7 76 77
IFN 17680654_7 77 80
- 17680654_7 80 81
alpha 17680654_7 81 86
- 17680654_7 86 87
2 17680654_7 87 88
a 17680654_7 88 89
, 17680654_7 90 91
the 17680654_7 92 95
A 17680654_7 96 97
156 17680654_7 97 100
V 17680654_7 100 101
/ 17680654_7 102 103
T 17680654_7 103 104
variant 17680654_7 105 112
was 17680654_7 113 116
detected 17680654_7 117 125
in 17680654_7 126 128
some 17680654_7 129 133
patients 17680654_7 134 142
, 17680654_7 143 144
but 17680654_7 145 148
viral 17680654_7 149 154
levels 17680654_7 155 161
continued 17680654_7 162 171
to 17680654_7 172 174
decline 17680654_7 175 182
in 17680654_7 183 185
all 17680654_7 186 189
patients 17680654_7 190 198
. 17680654_7 199 200

No 20731819_13 0 2
other 20731819_13 3 8
variants 20731819_13 9 17
, 20731819_13 18 19
including 20731819_13 20 29
CYP 20731819_13 30 33
2 20731819_13 33 34
D 20731819_13 34 35
6 20731819_13 35 36
* 20731819_13 37 38
4 20731819_13 39 40
( 20731819_13 41 42
MAF 20731819_13 43 46
= 20731819_13 47 48
0 20731819_13 49 50
. 20731819_13 50 51
20 20731819_13 51 53
) 20731819_13 54 55
, 20731819_13 56 57
previously 20731819_13 58 68
reported 20731819_13 69 77
to 20731819_13 78 80
be 20731819_13 81 83
associated 20731819_13 84 94
with 20731819_13 95 99
poorer 20731819_13 100 106
clinical 20731819_13 107 115
outcomes 20731819_13 116 124
, 20731819_13 125 126
were 20731819_13 127 131
associated 20731819_13 132 142
with 20731819_13 143 147
differences 20731819_13 148 159
in 20731819_13 160 162
BCSS 20731819_13 163 167
, 20731819_13 168 169
in 20731819_13 170 172
either 20731819_13 173 179
the 20731819_13 180 183
tamoxifen 20731819_13 184 193
or 20731819_13 194 196
non 20731819_13 197 200
- 20731819_13 200 201
tamoxifen 20731819_13 202 211
groups 20731819_13 212 218
. 20731819_13 219 220

Both 26481697_2 0 4
chemotherapy 26481697_2 5 17
and 26481697_2 18 21
epidermal 26481697_2 22 31
growth 26481697_2 32 38
factor 26481697_2 39 45
receptor 26481697_2 46 54
tyrosine 26481697_2 55 63
kinase 26481697_2 64 70
inhibitors 26481697_2 71 81
( 26481697_2 82 83
EGFR 26481697_2 84 88
TKIs 26481697_2 89 93
) 26481697_2 94 95
are 26481697_2 96 99
widely 26481697_2 100 106
applied 26481697_2 107 114
for 26481697_2 115 118
the 26481697_2 119 122
treatment 26481697_2 123 132
of 26481697_2 133 135
non 26481697_2 136 139
- 26481697_2 139 140
small 26481697_2 140 145
cell 26481697_2 146 150
lung 26481697_2 151 155
cancer 26481697_2 156 162
( 26481697_2 163 164
NSCLC 26481697_2 165 170
) 26481697_2 171 172
, 26481697_2 173 174
but 26481697_2 175 178
the 26481697_2 179 182
efficacy 26481697_2 183 191
of 26481697_2 192 194
these 26481697_2 195 200
two 26481697_2 201 204
treatments 26481697_2 205 215
in 26481697_2 216 218
combination 26481697_2 219 230
is 26481697_2 231 233
not 26481697_2 234 237
yet 26481697_2 238 241
clear 26481697_2 242 247
. 26481697_2 248 249

OBJECTIVES 20510210_2 0 10
: 20510210_2 11 12
The 20510210_2 13 16
aim 20510210_2 17 20
of 20510210_2 21 23
this 20510210_2 24 28
study 20510210_2 29 34
was 20510210_2 35 38
to 20510210_2 39 41
evaluate 20510210_2 42 50
the 20510210_2 51 54
relative 20510210_2 55 63
impact 20510210_2 64 70
of 20510210_2 71 73
demographic 20510210_2 74 85
and 20510210_2 86 89
clinical 20510210_2 90 98
variables 20510210_2 99 108
versus 20510210_2 109 115
the 20510210_2 116 119
cytochrome 20510210_2 120 130
P 20510210_2 131 132
450 20510210_2 132 135
2 20510210_2 136 137
C 20510210_2 137 138
19 20510210_2 138 140
( 20510210_2 141 142
CYP 20510210_2 143 146
2 20510210_2 146 147
C 20510210_2 147 148
19 20510210_2 148 150
) 20510210_2 151 152
polymorphism 20510210_2 153 165
on 20510210_2 166 168
antiplatelet 20510210_2 169 181
effects 20510210_2 182 189
of 20510210_2 190 192
clopidogrel 20510210_2 193 204
. 20510210_2 205 206

Tamoxifen 16297086_5 0 9
reduces 16297086_5 10 17
the 16297086_5 18 21
risk 16297086_5 22 26
of 16297086_5 27 29
breast 16297086_5 30 36
cancer 16297086_5 37 43
in 16297086_5 44 46
BRCA 16297086_5 47 51
- 16297086_5 51 52
2 16297086_5 52 53
mutation 16297086_5 54 62
carriers 16297086_5 63 71
, 16297086_5 72 73
but 16297086_5 74 77
not 16297086_5 78 81
in 16297086_5 82 84
BRCA 16297086_5 85 89
- 16297086_5 89 90
1 16297086_5 90 91
mutation 16297086_5 92 100
carriers 16297086_5 101 109
. 16297086_5 110 111

Genetic 21114867_1 0 7
polymorphisms 21114867_1 8 21
in 21114867_1 22 24
the 21114867_1 25 28
endothelial 21114867_1 29 40
nitric 21114867_1 41 47
oxide 21114867_1 48 53
synthase 21114867_1 54 62
gene 21114867_1 63 67
correlate 21114867_1 68 77
with 21114867_1 78 82
overall 21114867_1 83 90
survival 21114867_1 91 99
in 21114867_1 100 102
advanced 21114867_1 103 111
non 21114867_1 112 115
- 21114867_1 115 116
small 21114867_1 116 121
- 21114867_1 121 122
cell 21114867_1 122 126
lung 21114867_1 127 131
cancer 21114867_1 132 138
patients 21114867_1 139 147
treated 21114867_1 148 155
with 21114867_1 156 160
platinum 21114867_1 161 169
- 21114867_1 170 171
based 21114867_1 171 176
doublet 21114867_1 177 184
chemotherapy 21114867_1 185 197
. 21114867_1 198 199

In 8487953_6 0 2
contrast 8487953_6 3 11
, 8487953_6 12 13
strong 8487953_6 14 20
neocortical 8487953_6 21 32
constitutive 8487953_6 33 45
expression 8487953_6 46 56
of 8487953_6 57 59
KROX 8487953_6 60 64
- 8487953_6 64 65
24 8487953_6 65 67
was 8487953_6 68 71
almost 8487953_6 72 78
abolished 8487953_6 79 88
by 8487953_6 89 91
MK 8487953_6 92 94
- 8487953_6 94 95
801 8487953_6 95 98
administration 8487953_6 99 113
, 8487953_6 114 115
and 8487953_6 116 119
replaced 8487953_6 120 128
by 8487953_6 129 131
an 8487953_6 132 134
expression 8487953_6 135 145
pattern 8487953_6 146 153
similar 8487953_6 154 161
to 8487953_6 162 164
that 8487953_6 165 169
of 8487953_6 170 172
FOS 8487953_6 173 176
and 8487953_6 177 180
JUN 8487953_6 181 184
proteins 8487953_6 185 193
. 8487953_6 194 195

Apoptosis 25712669_5 0 9
- 25712669_5 9 10
related 25712669_5 10 17
molecular 25712669_5 18 27
changes 25712669_5 28 35
and 25712669_5 36 39
STAT 25712669_5 40 44
3 25712669_5 44 45
phosphorylation 25712669_5 46 61
and 25712669_5 62 65
transcriptional 25712669_5 66 81
activities 25712669_5 82 92
were 25712669_5 93 97
measured 25712669_5 98 106
after 25712669_5 107 112
matrine 25712669_5 113 120
treatment 25712669_5 121 130
for 25712669_5 131 134
48 25712669_5 135 137
h 25712669_5 137 138
. 25712669_5 139 140

MATERIALS 19663671_7 0 9
_ 19663671_7 10 11
METHODS 19663671_7 12 19
: 19663671_7 20 21
c 19663671_7 22 23
. 19663671_7 23 24
1236 19663671_7 24 28
C 19663671_7 28 29
> 19663671_7 29 30
T 19663671_7 30 31
( 19663671_7 32 33
exon 19663671_7 34 38
12 19663671_7 39 41
) 19663671_7 42 43
, 19663671_7 44 45
c 19663671_7 46 47
. 19663671_7 47 48
2677 19663671_7 48 52
G 19663671_7 52 53
> 19663671_7 53 54
T 19663671_7 54 55
( 19663671_7 56 57
exon 19663671_7 58 62
21 19663671_7 63 65
) 19663671_7 66 67
and 19663671_7 68 71
c 19663671_7 72 73
. 19663671_7 73 74
3435 19663671_7 74 78
C 19663671_7 78 79
> 19663671_7 79 80
T 19663671_7 80 81
( 19663671_7 82 83
exon 19663671_7 84 88
26 19663671_7 89 91
) 19663671_7 92 93
SNPs 19663671_7 94 98
of 19663671_7 99 101
ABCB 19663671_7 102 106
1 19663671_7 106 107
were 19663671_7 108 112
evaluated 19663671_7 113 122
by 19663671_7 123 125
PCR 19663671_7 126 129
techniques 19663671_7 130 140
, 19663671_7 141 142
while 19663671_7 143 148
plasma 19663671_7 149 155
levels 19663671_7 156 162
of 19663671_7 163 165
clozapine 19663671_7 166 175
and 19663671_7 176 179
norclozapine 19663671_7 180 192
were 19663671_7 193 197
measured 19663671_7 198 206
by 19663671_7 207 209
HPLC 19663671_7 210 214
in 19663671_7 215 217
40 19663671_7 218 220
men 19663671_7 221 224
( 19663671_7 225 226
aged 19663671_7 227 231
, 19663671_7 232 233
47 19663671_7 234 236
. 19663671_7 236 237
6 19663671_7 237 238
+ 19663671_7 239 240
/ 19663671_7 241 242
- 19663671_7 243 244
16 19663671_7 245 247
. 19663671_7 247 248
6 19663671_7 248 249
years 19663671_7 250 255
, 19663671_7 256 257
median 19663671_7 258 264
: 19663671_7 265 266
42 19663671_7 267 269
years 19663671_7 270 275
) 19663671_7 276 277
and 19663671_7 278 281
20 19663671_7 282 284
women 19663671_7 285 290
( 19663671_7 291 292
aged 19663671_7 293 297
40 19663671_7 298 300
. 19663671_7 300 301
7 19663671_7 301 302
+ 19663671_7 303 304
/ 19663671_7 305 306
- 19663671_7 307 308
11 19663671_7 309 311
. 19663671_7 311 312
4 19663671_7 312 313
years 19663671_7 314 319
, 19663671_7 320 321
median 19663671_7 322 328
: 19663671_7 329 330
38 19663671_7 331 333
years 19663671_7 334 339
) 19663671_7 340 341
1 19663671_7 342 343
month 19663671_7 344 349
after 19663671_7 350 355
the 19663671_7 356 359
start 19663671_7 360 365
of 19663671_7 366 368
clozapine 19663671_7 369 378
administration 19663671_7 379 393
. 19663671_7 394 395

Of 16595709_5 0 2
all 16595709_5 3 6
the 16595709_5 7 10
variants 16595709_5 11 19
, 16595709_5 20 21
the 16595709_5 22 25
UGT 16595709_5 26 29
1 16595709_5 29 30
A 16595709_5 30 31
9 16595709_5 31 32
I 16595709_5 33 34
399 16595709_5 34 37
C 16595709_5 37 38
> 16595709_5 38 39
T 16595709_5 39 40
was 16595709_5 41 44
associated 16595709_5 45 55
with 16595709_5 56 60
the 16595709_5 61 64
most 16595709_5 65 69
dramatic 16595709_5 70 78
change 16595709_5 79 85
in 16595709_5 86 88
SN 16595709_5 89 91
- 16595709_5 91 92
38 16595709_5 92 94
- 16595709_5 94 95
glucuronide 16595709_5 95 106
( 16595709_5 107 108
SN 16595709_5 109 111
- 16595709_5 111 112
38 16595709_5 112 114
G 16595709_5 114 115
) 16595709_5 116 117
( 16595709_5 118 119
2 16595709_5 120 121
. 16595709_5 121 122
64 16595709_5 122 124
- 16595709_5 124 125
fold 16595709_5 125 129
; 16595709_5 130 131
p 16595709_5 132 133
= 16595709_5 134 135
0 16595709_5 136 137
. 16595709_5 137 138
0007 16595709_5 138 142
) 16595709_5 143 144
. 16595709_5 145 146

IFN 23739923_9 0 3
- 23739923_9 3 4
a 23739923_9 4 5
production 23739923_9 6 16
was 23739923_9 17 20
significantly 23739923_9 21 34
enhanced 23739923_9 35 43
by 23739923_9 44 46
the 23739923_9 47 50
hypoxia 23739923_9 51 58
- 23739923_9 59 60
mimicking 23739923_9 60 69
agent 23739923_9 70 75
deferoxamine 23739923_9 76 88
mesylate 23739923_9 89 97
in 23739923_9 98 100
cell 23739923_9 101 105
lines 23739923_9 106 111
expressing 23739923_9 112 122
the 23739923_9 123 126
wild 23739923_9 127 131
- 23739923_9 131 132
type 23739923_9 132 136
von 23739923_9 137 140
Hippel 23739923_9 141 147
- 23739923_9 147 148
Lindau 23739923_9 148 154
( 23739923_9 155 156
VHL 23739923_9 157 160
) 23739923_9 161 162
gene 23739923_9 163 167
( 23739923_9 168 169
KU 23739923_9 170 172
19 23739923_9 172 174
- 23739923_9 174 175
20 23739923_9 175 177
and 23739923_9 178 181
ACHN 23739923_9 182 186
) 23739923_9 187 188
compared 23739923_9 189 197
with 23739923_9 198 202
cells 23739923_9 203 208
expressing 23739923_9 209 219
the 23739923_9 220 223
mutant 23739923_9 224 230
VHL 23739923_9 231 234
gene 23739923_9 235 239
( 23739923_9 240 241
786 23739923_9 242 245
- 23739923_9 245 246
O 23739923_9 246 247
) 23739923_9 248 249
. 23739923_9 250 251

The 22076562_5 0 3
aim 22076562_5 4 7
of 22076562_5 8 10
this 22076562_5 11 15
study 22076562_5 16 21
was 22076562_5 22 25
to 22076562_5 26 28
evaluate 22076562_5 29 37
lansoprazole 22076562_5 38 50
as 22076562_5 51 53
an 22076562_5 54 56
in 22076562_5 57 59
vivo 22076562_5 60 64
phenotyping 22076562_5 65 76
probe 22076562_5 77 82
for 22076562_5 83 86
assessing 22076562_5 87 96
CYP 22076562_5 97 100
2 22076562_5 100 101
C 22076562_5 101 102
19 22076562_5 102 104
activity 22076562_5 105 113
in 22076562_5 114 116
children 22076562_5 117 125
. 22076562_5 126 127

In 23175182_5 0 2
contrast 23175182_5 3 11
, 23175182_5 12 13
mGlu 23175182_5 14 18
3 23175182_5 18 19
receptor 23175182_5 20 28
blockade 23175182_5 29 37
did 23175182_5 38 41
not 23175182_5 42 45
affect 23175182_5 46 52
the 23175182_5 53 56
action 23175182_5 57 63
of 23175182_5 64 66
paclitaxel 23175182_5 67 77
, 23175182_5 78 79
etoposide 23175182_5 80 89
, 23175182_5 90 91
cis 23175182_5 92 95
- 23175182_5 95 96
platinum 23175182_5 96 104
, 23175182_5 105 106
and 23175182_5 107 110
irinotecan 23175182_5 111 121
. 23175182_5 122 123

Solute 21346370_3 0 6
carrier 21346370_3 7 14
family 21346370_3 15 21
22 21346370_3 22 24
, 21346370_3 24 25
member 21346370_3 26 32
2 21346370_3 33 34
( 21346370_3 35 36
SLC 21346370_3 37 40
22 21346370_3 40 42
A 21346370_3 42 43
2 21346370_3 43 44
) 21346370_3 45 46
, 21346370_3 47 48
also 21346370_3 49 53
known 21346370_3 54 59
as 21346370_3 60 62
organic 21346370_3 63 70
cation 21346370_3 71 77
transporter 21346370_3 78 89
2 21346370_3 90 91
( 21346370_3 92 93
OCT 21346370_3 94 97
2 21346370_3 97 98
) 21346370_3 99 100
, 21346370_3 101 102
is 21346370_3 103 105
predominantly 21346370_3 106 119
expressed 21346370_3 120 129
in 21346370_3 130 132
the 21346370_3 133 136
luminal 21346370_3 137 144
membrane 21346370_3 145 153
of 21346370_3 154 156
airway 21346370_3 157 163
epithelial 21346370_3 164 174
cells 21346370_3 175 180
and 21346370_3 181 184
has 21346370_3 185 188
been 21346370_3 189 193
shown 21346370_3 194 199
to 21346370_3 200 202
mediate 21346370_3 203 210
the 21346370_3 211 214
transport 21346370_3 215 224
of 21346370_3 225 227
prostaglandins 21346370_3 228 242
on 21346370_3 243 245
the 21346370_3 246 249
cyclooxygenase 21346370_3 250 264
pathway 21346370_3 265 272
which 21346370_3 273 278
is 21346370_3 279 281
regulated 21346370_3 282 291
by 21346370_3 292 294
aspirin 21346370_3 295 302
blockage 21346370_3 303 311
. 21346370_3 312 313

One 24704376_7 0 3
SNP 24704376_7 4 7
in 24704376_7 8 10
exon 24704376_7 11 15
3 24704376_7 16 17
, 24704376_7 18 19
rs 24704376_7 20 22
35349697 24704376_7 22 30
, 24704376_7 31 32
demonstrated 24704376_7 33 45
a 24704376_7 46 47
significant 24704376_7 48 59
correlation 24704376_7 60 71
with 24704376_7 72 76
opioid 24704376_7 77 83
addiction 24704376_7 84 93
as 24704376_7 94 96
well 24704376_7 97 101
as 24704376_7 102 104
with 24704376_7 105 109
alcohol 24704376_7 110 117
addiction 24704376_7 118 127
. 24704376_7 128 129

Studies 23467639_5 0 7
of 23467639_5 8 10
aspirin 23467639_5 11 18
, 23467639_5 19 20
P 23467639_5 21 22
2 23467639_5 22 23
Y 23467639_5 23 24
12 23467639_5 24 26
inhibitors 23467639_5 27 37
and 23467639_5 38 41
other 23467639_5 42 47
antiplatelet 23467639_5 48 60
drugs 23467639_5 61 66
clearly 23467639_5 67 74
demonstrate 23467639_5 75 86
how 23467639_5 87 90
inhibition 23467639_5 91 101
of 23467639_5 102 104
platelet 23467639_5 105 113
function 23467639_5 114 122
increases 23467639_5 123 132
bleeding 23467639_5 133 141
risk 23467639_5 142 146
. 23467639_5 147 148

To 10098858_5 0 2
examine 10098858_5 3 10
the 10098858_5 11 14
effects 10098858_5 15 22
of 10098858_5 23 25
repeated 10098858_5 26 34
amphetamine 10098858_5 35 46
on 10098858_5 47 49
RGS 10098858_5 50 53
2 10098858_5 53 54
expression 10098858_5 55 65
, 10098858_5 66 67
rats 10098858_5 68 72
were 10098858_5 73 77
treated 10098858_5 78 85
with 10098858_5 86 90
escalating 10098858_5 91 101
doses 10098858_5 102 107
of 10098858_5 108 110
amphetamine 10098858_5 111 122
( 10098858_5 123 124
1 10098858_5 125 126
. 10098858_5 126 127
0 10098858_5 127 128
- 10098858_5 128 129
7 10098858_5 129 130
. 10098858_5 131 132
5 10098858_5 132 133
mg 10098858_5 134 136
/ 10098858_5 136 137
kg 10098858_5 137 139
) 10098858_5 140 141
for 10098858_5 142 145
4 10098858_5 146 147
days 10098858_5 148 152
, 10098858_5 153 154
followed 10098858_5 155 163
by 10098858_5 164 166
8 10098858_5 167 168
days 10098858_5 169 173
of 10098858_5 174 176
multiple 10098858_5 177 185
daily 10098858_5 186 191
injections 10098858_5 192 202
( 10098858_5 203 204
7 10098858_5 205 206
. 10098858_5 206 207
5 10098858_5 207 208
mg 10098858_5 209 211
/ 10098858_5 211 212
kg 10098858_5 212 214
/ 10098858_5 214 215
2 10098858_5 215 216
h 10098858_5 217 218
x 10098858_5 219 220
four 10098858_5 221 225
injections 10098858_5 226 236
) 10098858_5 237 238
. 10098858_5 239 240

To 21338584_3 0 2
address 21338584_3 3 10
this 21338584_3 11 15
hypothesis 21338584_3 16 26
we 21338584_3 27 29
analyzed 21338584_3 30 38
PDYN 21338584_3 39 43
mRNA 21338584_3 44 48
levels 21338584_3 49 55
in 21338584_3 56 58
the 21338584_3 59 62
dorsolateral 21338584_3 63 75
prefrontal 21338584_3 76 86
cortex 21338584_3 87 93
( 21338584_3 94 95
dl 21338584_3 96 98
- 21338584_3 98 99
PFC 21338584_3 99 102
) 21338584_3 103 104
and 21338584_3 105 108
hippocampus 21338584_3 109 120
, 21338584_3 121 122
both 21338584_3 123 127
involved 21338584_3 128 136
in 21338584_3 137 139
cognitive 21338584_3 140 149
control 21338584_3 150 157
of 21338584_3 158 160
addictive 21338584_3 161 170
behavior 21338584_3 171 179
and 21338584_3 180 183
PDYN 21338584_3 184 188
promoter 21338584_3 189 197
SNP 21338584_3 198 201
genotype 21338584_3 202 210
in 21338584_3 211 213
alcohol 21338584_3 214 221
- 21338584_3 222 223
dependent 21338584_3 223 232
and 21338584_3 233 236
control 21338584_3 237 244
human 21338584_3 245 250
subjects 21338584_3 251 259
. 21338584_3 260 261

Preventive 22819302_1 0 10
and 22819302_1 11 14
protective 22819302_1 15 25
effects 22819302_1 26 33
of 22819302_1 34 36
silymarin 22819302_1 37 46
on 22819302_1 47 49
doxorubicin 22819302_1 50 61
- 22819302_1 62 63
induced 22819302_1 63 70
testicular 22819302_1 71 81
damages 22819302_1 82 89
correlate 22819302_1 90 99
with 22819302_1 100 104
changes 22819302_1 105 112
in 22819302_1 113 115
c 22819302_1 116 117
- 22819302_1 117 118
myc 22819302_1 118 121
gene 22819302_1 122 126
expression 22819302_1 127 137
. 22819302_1 138 139

Bisacurone 18602074_4 0 10
dose 18602074_4 11 15
- 18602074_4 15 16
dependently 18602074_4 16 27
inhibited 18602074_4 28 37
TNF 18602074_4 38 41
- 18602074_4 41 42
alpha 18602074_4 42 47
- 18602074_4 48 49
mediated 18602074_4 49 57
expression 18602074_4 58 68
of 18602074_4 69 71
VCAM 18602074_4 72 76
- 18602074_4 76 77
1 18602074_4 77 78
. 18602074_4 79 80

The 19536092_9 0 3
results 19536092_9 4 11
suggest 19536092_9 12 19
that 19536092_9 20 24
the 19536092_9 25 28
ATM 19536092_9 29 32
and 19536092_9 33 36
ERCC 19536092_9 37 41
5 19536092_9 41 42
genes 19536092_9 43 48
may 19536092_9 49 52
be 19536092_9 53 55
associated 19536092_9 56 66
with 19536092_9 67 71
oxaliplatin 19536092_9 72 83
efficacy 19536092_9 84 92
in 19536092_9 93 95
ACC 19536092_9 96 99
. 19536092_9 100 101

Furthermore 15154117_7 0 11
, 15154117_7 12 13
the 15154117_7 14 17
haplotype 15154117_7 18 27
- 15154117_7 27 28
specific 15154117_7 28 36
FBAT 15154117_7 37 41
showed 15154117_7 42 48
a 15154117_7 49 50
common 15154117_7 51 57
( 15154117_7 58 59
22 15154117_7 60 62
. 15154117_7 62 63
5 15154117_7 63 64
% 15154117_7 65 66
) 15154117_7 67 68
CHRNA 15154117_7 69 74
4 15154117_7 74 75
haplotype 15154117_7 76 85
, 15154117_7 86 87
GCTATA 15154117_7 88 94
, 15154117_7 95 96
which 15154117_7 97 102
was 15154117_7 103 106
significantly 15154117_7 107 120
associated 15154117_7 121 131
with 15154117_7 132 136
both 15154117_7 137 141
a 15154117_7 142 143
protective 15154117_7 144 154
effect 15154117_7 155 161
against 15154117_7 162 169
nicotine 15154117_7 170 178
addiction 15154117_7 179 188
as 15154117_7 189 191
a 15154117_7 192 193
dichotomized 15154117_7 194 206
trait 15154117_7 207 212
( 15154117_7 213 214
Z 15154117_7 215 216
= 15154117_7 217 218
- 15154117_7 219 220
3 15154117_7 220 221
. 15154117_7 221 222
04 15154117_7 222 224
, 15154117_7 225 226
P 15154117_7 227 228
< 15154117_7 229 230
. 15154117_7 231 232
005 15154117_7 232 235
) 15154117_7 236 237
and 15154117_7 238 241
significant 15154117_7 242 253
decreases 15154117_7 254 263
of 15154117_7 264 266
age 15154117_7 267 270
- 15154117_7 270 271
adjusted 15154117_7 271 279
FTND 15154117_7 280 284
( 15154117_7 285 286
Z 15154117_7 287 288
= 15154117_7 289 290
- 15154117_7 291 292
3 15154117_7 292 293
. 15154117_7 293 294
31 15154117_7 294 296
, 15154117_7 297 298
P 15154117_7 299 300
< 15154117_7 301 302
. 15154117_7 303 304
005 15154117_7 304 307
) 15154117_7 308 309
or 15154117_7 310 312
RTQ 15154117_7 313 316
scores 15154117_7 317 323
( 15154117_7 324 325
Z 15154117_7 326 327
= 15154117_7 328 329
- 15154117_7 330 331
2 15154117_7 331 332
. 15154117_7 332 333
73 15154117_7 333 335
, 15154117_7 336 337
P 15154117_7 338 339
= 15154117_7 340 341
. 15154117_7 342 343
006 15154117_7 343 346
) 15154117_7 347 348
. 15154117_7 349 350

METHODS 23774940_5 0 7
: 23774940_5 8 9
Twenty 23774940_5 10 16
- 23774940_5 16 17
seven 23774940_5 17 22
patients 23774940_5 23 31
with 23774940_5 32 36
NVP 23774940_5 37 40
- 23774940_5 41 42
induced 23774940_5 42 49
SJS 23774940_5 50 53
/ 23774940_5 54 55
TEN 23774940_5 56 59
and 23774940_5 60 63
78 23774940_5 64 66
controls 23774940_5 67 75
, 23774940_5 76 77
all 23774940_5 78 81
from 23774940_5 82 86
Mozambique 23774940_5 87 97
, 23774940_5 98 99
were 23774940_5 100 104
genotyped 23774940_5 105 114
for 23774940_5 115 118
the 23774940_5 119 122
ABCB 23774940_5 123 127
1 23774940_5 127 128
and 23774940_5 129 132
ABCC 23774940_5 133 137
10 23774940_5 137 139
transporter 23774940_5 140 151
genes 23774940_5 152 157
and 23774940_5 158 161
for 23774940_5 162 165
CYP 23774940_5 166 169
2 23774940_5 169 170
B 23774940_5 170 171
6 23774940_5 171 172
, 23774940_5 173 174
CYP 23774940_5 175 178
3 23774940_5 178 179
A 23774940_5 179 180
4 23774940_5 180 181
and 23774940_5 182 185
CYP 23774940_5 186 189
3 23774940_5 189 190
A 23774940_5 190 191
5 23774940_5 191 192
cytochrome 23774940_5 193 203
gene 23774940_5 204 208
variants 23774940_5 209 217
. 23774940_5 218 219

After 27916449_4 0 5
identification 27916449_4 6 20
of 27916449_4 21 23
a 27916449_4 24 25
GNAO 27916449_4 26 30
1 27916449_4 30 31
missense 27916449_4 32 40
mutation 27916449_4 41 49
at 27916449_4 50 52
the 27916449_4 53 56
age 27916449_4 57 60
of 27916449_4 61 63
18 27916449_4 64 66
years 27916449_4 66 71
, 27916449_4 72 73
topiramate 27916449_4 74 84
treatment 27916449_4 85 94
was 27916449_4 95 98
initiated 27916449_4 99 108
and 27916449_4 109 112
the 27916449_4 113 116
frequency 27916449_4 117 126
of 27916449_4 127 129
chorea 27916449_4 130 136
decreased 27916449_4 137 146
dramatically 27916449_4 147 159
. 27916449_4 160 161

When 20216107_11 0 4
stratified 20216107_11 5 15
by 20216107_11 16 18
the 20216107_11 19 22
COMT 20216107_11 23 27
high 20216107_11 28 32
activity 20216107_11 33 41
haplotype 20216107_11 42 51
, 20216107_11 52 53
a 20216107_11 54 55
beneficial 20216107_11 56 66
effect 20216107_11 67 73
of 20216107_11 74 76
propranolol 20216107_11 77 88
on 20216107_11 89 91
pain 20216107_11 92 96
perception 20216107_11 97 107
was 20216107_11 108 111
noted 20216107_11 112 117
in 20216107_11 118 120
patients 20216107_11 121 129
not 20216107_11 130 133
carrying 20216107_11 134 142
this 20216107_11 143 147
haplotype 20216107_11 148 157
, 20216107_11 158 159
a 20216107_11 160 161
diminished 20216107_11 162 172
benefit 20216107_11 173 180
was 20216107_11 181 184
observed 20216107_11 185 193
in 20216107_11 194 196
the 20216107_11 197 200
heterozygotes 20216107_11 201 214
, 20216107_11 215 216
and 20216107_11 217 220
no 20216107_11 221 223
benefit 20216107_11 224 231
was 20216107_11 232 235
noted 20216107_11 236 241
in 20216107_11 242 244
the 20216107_11 245 248
homozygotes 20216107_11 249 260
. 20216107_11 261 262

The 15650426_10 0 3
second 15650426_10 4 10
MVA 15650426_10 11 14
booster 15650426_10 15 22
dose 15650426_10 23 27
did 15650426_10 28 31
not 15650426_10 32 35
increase 15650426_10 36 44
the 15650426_10 45 48
peak 15650426_10 49 53
CD 15650426_10 54 56
4 15650426_10 56 57
and 15650426_10 58 61
CD 15650426_10 62 64
8 15650426_10 64 65
T 15650426_10 66 67
cell 15650426_10 68 72
responses 15650426_10 73 82
, 15650426_10 83 84
but 15650426_10 85 88
increased 15650426_10 89 98
anti 15650426_10 99 103
- 15650426_10 103 104
Env 15650426_10 105 108
Ab 15650426_10 109 111
titers 15650426_10 112 118
by 15650426_10 119 121
40 15650426_10 122 124
- 15650426_10 125 126
to 15650426_10 127 129
90 15650426_10 130 132
- 15650426_10 132 133
fold 15650426_10 133 137
. 15650426_10 138 139

We 17151111_6 0 2
showed 17151111_6 3 9
that 17151111_6 10 14
mutation 17151111_6 15 23
of 17151111_6 24 26
one 17151111_6 27 30
of 17151111_6 31 33
the 17151111_6 34 37
two 17151111_6 38 41
N 17151111_6 42 43
- 17151111_6 44 45
linked 17151111_6 45 51
GP 17151111_6 52 54
2 17151111_6 54 55
glycosylation 17151111_6 56 69
sites 17151111_6 70 75
was 17151111_6 76 79
highly 17151111_6 80 86
detrimental 17151111_6 87 98
to 17151111_6 99 101
the 17151111_6 102 105
antigenicity 17151111_6 106 118
and 17151111_6 119 122
immunogenicity 17151111_6 123 137
of 17151111_6 138 140
GP 17151111_6 141 143
. 17151111_6 144 145

This 22921020_3 0 4
steroid 22921020_3 5 12
response 22921020_3 13 21
appears 22921020_3 22 29
to 22921020_3 30 32
be 22921020_3 33 35
heritable 22921020_3 36 45
and 22921020_3 46 49
alleles 22921020_3 50 57
in 22921020_3 58 60
the 22921020_3 61 64
SFRS 22921020_3 65 69
3 22921020_3 69 70
and 22921020_3 71 74
FKBP 22921020_3 75 79
4 22921020_3 79 80
genes 22921020_3 81 86
have 22921020_3 87 91
recently 22921020_3 92 100
been 22921020_3 101 105
suggested 22921020_3 106 115
to 22921020_3 116 118
play 22921020_3 119 123
a 22921020_3 124 125
role 22921020_3 126 130
. 22921020_3 131 132

CONCLUSIONS 25726043_14 0 11
: 25726043_14 12 13
NSCLC 25726043_14 14 19
patients 25726043_14 20 28
with 25726043_14 29 33
a 25726043_14 34 35
smoking 25726043_14 36 43
history 25726043_14 44 51
or 25726043_14 52 54
the 25726043_14 55 58
EGFR 25726043_14 59 63
L 25726043_14 64 65
858 25726043_14 65 68
R 25726043_14 68 69
mutation 25726043_14 70 78
may 25726043_14 79 82
demonstrate 25726043_14 83 94
a 25726043_14 95 96
poorer 25726043_14 97 103
response 25726043_14 104 112
to 25726043_14 113 115
gefitinib 25726043_14 116 125
treatment 25726043_14 126 135
. 25726043_14 136 137

Cocaine 17596442_8 0 7
- 17596442_8 8 9
induced 17596442_8 9 16
c 17596442_8 17 18
AMP 17596442_8 19 22
- 17596442_8 23 24
dependent 17596442_8 24 33
phosphorylation 17596442_8 34 49
of 17596442_8 50 52
glutamate 17596442_8 53 62
receptor 17596442_8 63 71
1 17596442_8 72 73
was 17596442_8 74 77
altered 17596442_8 78 85
in 17596442_8 86 88
the 17596442_8 89 92
striatum 17596442_8 93 101
of 17596442_8 102 104
CB 17596442_8 105 107
1 17596442_8 107 108
- 17596442_8 108 109
R 17596442_8 109 110
mutant 17596442_8 111 117
mice 17596442_8 118 122
but 17596442_8 123 126
not 17596442_8 127 130
of 17596442_8 131 133
AM 17596442_8 134 136
251 17596442_8 136 139
- 17596442_8 140 141
treated 17596442_8 141 148
mice 17596442_8 149 153
. 17596442_8 154 155

RESULTS 16390351_6 0 7
: 16390351_6 8 9
Neither 16390351_6 10 17
the 16390351_6 18 21
mean 16390351_6 22 26
AUC 16390351_6 27 30
( 16390351_6 31 32
0 16390351_6 33 34
- 16390351_6 34 35
infinity 16390351_6 35 43
) 16390351_6 44 45
( 16390351_6 46 47
geometric 16390351_6 48 57
mean 16390351_6 58 62
ratio 16390351_6 63 68
: 16390351_6 69 70
1 16390351_6 71 72
. 16390351_6 72 73
01 16390351_6 73 75
; 16390351_6 76 77
95 16390351_6 78 80
% 16390351_6 81 82
CI 16390351_6 83 85
: 16390351_6 86 87
0 16390351_6 88 89
. 16390351_6 89 90
93 16390351_6 90 92
- 16390351_6 92 93
1 16390351_6 93 94
. 16390351_6 95 96
1 16390351_6 96 97
, 16390351_6 98 99
P 16390351_6 100 101
= 16390351_6 102 103
0 16390351_6 104 105
. 16390351_6 105 106
88 16390351_6 106 108
) 16390351_6 109 110
nor 16390351_6 111 114
the 16390351_6 115 118
mean 16390351_6 119 123
C 16390351_6 124 125
( 16390351_6 126 127
max 16390351_6 128 131
) 16390351_6 132 133
( 16390351_6 134 135
geometric 16390351_6 136 145
mean 16390351_6 146 150
ratio 16390351_6 151 156
: 16390351_6 157 158
1 16390351_6 159 160
. 16390351_6 160 161
05 16390351_6 161 163
; 16390351_6 164 165
95 16390351_6 166 168
% 16390351_6 169 170
CI 16390351_6 171 173
: 16390351_6 174 175
0 16390351_6 176 177
. 16390351_6 177 178
94 16390351_6 178 180
- 16390351_6 180 181
1 16390351_6 181 182
. 16390351_6 183 184
2 16390351_6 184 185
, 16390351_6 186 187
P 16390351_6 188 189
= 16390351_6 190 191
0 16390351_6 192 193
. 16390351_6 193 194
35 16390351_6 194 196
) 16390351_6 197 198
of 16390351_6 199 201
repaglinide 16390351_6 202 213
were 16390351_6 214 218
statistically 16390351_6 219 232
significantly 16390351_6 233 246
different 16390351_6 247 256
in 16390351_6 257 259
the 16390351_6 260 263
group 16390351_6 264 269
carrying 16390351_6 270 278
the 16390351_6 279 282
CYP 16390351_6 283 286
2 16390351_6 286 287
C 16390351_6 287 288
8 16390351_6 288 289
* 16390351_6 290 291
3 16390351_6 292 293
mutant 16390351_6 294 300
allele 16390351_6 301 307
compared 16390351_6 308 316
with 16390351_6 317 321
wild 16390351_6 322 326
- 16390351_6 326 327
types 16390351_6 327 332
. 16390351_6 333 334

This 26216193_4 0 4
study 26216193_4 5 10
aimed 26216193_4 11 16
to 26216193_4 17 19
correlate 26216193_4 20 29
a 26216193_4 30 31
phenotypic 26216193_4 32 42
marker 26216193_4 43 49
of 26216193_4 50 52
5 26216193_4 53 54
- 26216193_4 54 55
fluorouracil 26216193_4 55 67
metabolism 26216193_4 68 78
( 26216193_4 79 80
the 26216193_4 81 84
individual 26216193_4 85 95
degradation 26216193_4 96 107
rate 26216193_4 108 112
of 26216193_4 113 115
5 26216193_4 116 117
- 26216193_4 117 118
fluorouracil 26216193_4 118 130
- 26216193_4 130 131
5 26216193_4 131 132
- 26216193_4 132 133
FUDR 26216193_4 133 137
) 26216193_4 138 139
with 26216193_4 140 144
15 26216193_4 145 147
functional 26216193_4 148 158
polymorphisms 26216193_4 159 172
in 26216193_4 173 175
the 26216193_4 176 179
dihydropyrimidine 26216193_4 180 197
dehydrogenase 26216193_4 198 211
gene 26216193_4 212 216
( 26216193_4 217 218
DPYD 26216193_4 219 223
) 26216193_4 224 225
. 26216193_4 226 227

Egfr 23894460_7 0 4
mutant 23894460_7 5 11
follicles 23894460_7 12 21
responded 23894460_7 22 31
with 23894460_7 32 36
less 23894460_7 37 41
proliferation 23894460_7 42 55
, 23894460_7 56 57
apoptosis 23894460_7 58 67
, 23894460_7 68 69
and 23894460_7 70 73
fewer 23894460_7 74 79
p 23894460_7 80 81
53 23894460_7 81 83
- 23894460_7 84 85
positive 23894460_7 85 93
cells 23894460_7 94 99
after 23894460_7 100 105
cyclophosphamide 23894460_7 106 122
. 23894460_7 123 124

The 20555338_2 0 3
aim 20555338_2 4 7
of 20555338_2 8 10
the 20555338_2 11 14
study 20555338_2 15 20
is 20555338_2 21 23
to 20555338_2 24 26
improve 20555338_2 27 34
our 20555338_2 35 38
understanding 20555338_2 39 52
of 20555338_2 53 55
the 20555338_2 56 59
worldwide 20555338_2 60 69
allele 20555338_2 70 76
frequency 20555338_2 77 86
distribution 20555338_2 87 99
of 20555338_2 100 102
four 20555338_2 103 107
genetic 20555338_2 108 115
polymorphisms 20555338_2 116 129
known 20555338_2 130 135
to 20555338_2 136 138
influence 20555338_2 139 148
warfarin 20555338_2 149 157
dosing 20555338_2 158 164
( 20555338_2 165 166
VKORC 20555338_2 167 172
1 20555338_2 172 173
rs 20555338_2 174 176
9923231 20555338_2 176 183
, 20555338_2 184 185
CYP 20555338_2 186 189
2 20555338_2 189 190
C 20555338_2 190 191
9 20555338_2 191 192
rs 20555338_2 193 195
1799853 20555338_2 195 202
, 20555338_2 203 204
CYP 20555338_2 205 208
2 20555338_2 208 209
C 20555338_2 209 210
9 20555338_2 210 211
rs 20555338_2 212 214
1057910 20555338_2 214 221
and 20555338_2 222 225
CYP 20555338_2 226 229
4 20555338_2 229 230
F 20555338_2 230 231
2 20555338_2 231 232
rs 20555338_2 233 235
2108622 20555338_2 235 242
) 20555338_2 243 244
. 20555338_2 245 246

Association 25035107_1 0 11
of 25035107_1 12 14
gene 25035107_1 15 19
polymorphisms 25035107_1 20 33
encoding 25035107_1 34 42
dopaminergic 25035107_1 43 55
system 25035107_1 56 62
components 25035107_1 63 73
and 25035107_1 74 77
platelet 25035107_1 78 86
MAO 25035107_1 87 90
- 25035107_1 90 91
B 25035107_1 91 92
activity 25035107_1 93 101
with 25035107_1 102 106
alcohol 25035107_1 107 114
dependence 25035107_1 115 125
and 25035107_1 126 129
alcohol 25035107_1 130 137
dependence 25035107_1 138 148
- 25035107_1 149 150
related 25035107_1 150 157
phenotypes 25035107_1 158 168
. 25035107_1 169 170

BACKGROUND 20628391_2 0 10
: 20628391_2 11 12
The 20628391_2 13 16
impact 20628391_2 17 23
of 20628391_2 24 26
thymidylate 20628391_2 27 38
synthase 20628391_2 39 47
( 20628391_2 48 49
TYMS 20628391_2 50 54
) 20628391_2 55 56
and 20628391_2 57 60
UDP 20628391_2 61 64
- 20628391_2 64 65
glucoronosyltransferase 20628391_2 65 88
1 20628391_2 89 90
A 20628391_2 90 91
( 20628391_2 92 93
UGT 20628391_2 94 97
1 20628391_2 97 98
A 20628391_2 98 99
) 20628391_2 100 101
germline 20628391_2 102 110
polymorphisms 20628391_2 111 124
on 20628391_2 125 127
the 20628391_2 128 131
outcome 20628391_2 132 139
of 20628391_2 140 142
colorectal 20628391_2 143 153
cancer 20628391_2 154 160
( 20628391_2 161 162
CRC 20628391_2 163 166
) 20628391_2 167 168
patients 20628391_2 169 177
treated 20628391_2 178 185
with 20628391_2 186 190
irinotecan 20628391_2 191 201
plus 20628391_2 202 206
5 20628391_2 207 208
- 20628391_2 208 209
fluorouracil 20628391_2 209 221
( 20628391_2 222 223
irinotecan 20628391_2 224 234
/ 20628391_2 235 236
5 20628391_2 237 238
FU 20628391_2 238 240
) 20628391_2 241 242
is 20628391_2 243 245
still 20628391_2 246 251
controversial 20628391_2 252 265
. 20628391_2 266 267

In 16146333_7 0 2
addition 16146333_7 3 11
to 16146333_7 12 14
its 16146333_7 15 18
role 16146333_7 19 23
to 16146333_7 24 26
confer 16146333_7 27 33
resistance 16146333_7 34 44
against 16146333_7 45 52
chemotherapeutic 16146333_7 53 69
agents 16146333_7 70 76
, 16146333_7 77 78
BCRP 16146333_7 79 83
actively 16146333_7 84 92
transports 16146333_7 93 103
structurally 16146333_7 104 116
diverse 16146333_7 117 124
organic 16146333_7 125 132
molecules 16146333_7 133 142
, 16146333_7 143 144
conjugated 16146333_7 145 155
or 16146333_7 156 158
unconjugated 16146333_7 159 171
, 16146333_7 172 173
such 16146333_7 174 178
as 16146333_7 179 181
estrone 16146333_7 182 189
- 16146333_7 189 190
3 16146333_7 190 191
- 16146333_7 191 192
sulfate 16146333_7 192 199
, 16146333_7 200 201
17 16146333_7 202 204
beta 16146333_7 204 208
- 16146333_7 208 209
estradiol 16146333_7 209 218
17 16146333_7 219 221
- 16146333_7 221 222
( 16146333_7 222 223
beta 16146333_7 223 227
- 16146333_7 227 228
D 16146333_7 228 229
- 16146333_7 229 230
glucuronide 16146333_7 230 241
) 16146333_7 242 243
, 16146333_7 244 245
and 16146333_7 246 249
methotrexate 16146333_7 250 262
. 16146333_7 263 264

Mutations 17062187_6 0 9
at 17062187_6 10 12
codons 17062187_6 13 19
M 17062187_6 20 21
184 17062187_6 21 24
V 17062187_6 24 25
and 17062187_6 26 29
Q 17062187_6 30 31
151 17062187_6 31 34
M 17062187_6 34 35
conferring 17062187_6 36 46
resistance 17062187_6 47 57
to 17062187_6 58 60
nucleoside 17062187_6 61 71
reverse 17062187_6 72 79
transcriptase 17062187_6 80 93
inhibitors 17062187_6 94 104
( 17062187_6 105 106
NRTIs 17062187_6 107 112
) 17062187_6 113 114
in 17062187_6 115 117
HIV 17062187_6 118 121
- 17062187_6 121 122
1 17062187_6 122 123
infection 17062187_6 124 133
were 17062187_6 134 138
detected 17062187_6 139 147
, 17062187_6 148 149
as 17062187_6 150 152
were 17062187_6 153 157
mutations 17062187_6 158 167
at 17062187_6 168 170
codons 17062187_6 171 177
V 17062187_6 178 179
71 17062187_6 179 181
I 17062187_6 181 182
and 17062187_6 183 186
L 17062187_6 187 188
90 17062187_6 188 190
M 17062187_6 190 191
implying 17062187_6 192 200
indinavir 17062187_6 201 210
and 17062187_6 211 214
nelfinavir 17062187_6 215 225
resistance 17062187_6 226 236
as 17062187_6 237 239
well 17062187_6 240 244
. 17062187_6 245 246

In 16184603_4 0 2
order 16184603_4 3 8
to 16184603_4 9 11
confirm 16184603_4 12 19
this 16184603_4 20 24
finding 16184603_4 25 32
, 16184603_4 33 34
we 16184603_4 35 37
genotyped 16184603_4 38 47
the 16184603_4 48 51
prodynorphin 16184603_4 52 64
promoter 16184603_4 65 73
polymorphism 16184603_4 74 86
in 16184603_4 87 89
cocaine 16184603_4 90 97
dependent 16184603_4 98 107
( 16184603_4 108 109
n 16184603_4 110 111
= 16184603_4 112 113
167 16184603_4 114 117
) 16184603_4 118 119
and 16184603_4 120 123
control 16184603_4 124 131
( 16184603_4 132 133
n 16184603_4 134 135
= 16184603_4 136 137
88 16184603_4 138 140
) 16184603_4 141 142
individuals 16184603_4 143 154
of 16184603_4 155 157
African 16184603_4 158 165
descent 16184603_4 166 173
. 16184603_4 174 175

This 12804863_11 0 4
indicates 12804863_11 5 14
that 12804863_11 15 19
a 12804863_11 20 21
close 12804863_11 22 27
association 12804863_11 28 39
of 12804863_11 40 42
HER 12804863_11 43 46
- 12804863_11 46 47
2 12804863_11 47 48
/ 12804863_11 49 50
neu 12804863_11 51 54
peptide 12804863_11 55 62
and 12804863_11 63 66
CpG 12804863_11 67 70
ODN 12804863_11 71 74
inside 12804863_11 75 81
liposomes 12804863_11 82 91
enhances 12804863_11 92 100
the 12804863_11 101 104
CTL 12804863_11 105 108
epitope 12804863_11 109 116
delivery 12804863_11 117 125
and 12804863_11 126 129
induces 12804863_11 130 137
CD 12804863_11 138 140
8 12804863_11 140 141
+ 12804863_11 142 143
mediated 12804863_11 144 152
immune 12804863_11 153 159
response 12804863_11 160 168
. 12804863_11 169 170

Chronic 9488225_8 0 7
administration 9488225_8 8 22
of 9488225_8 23 25
captopril 9488225_8 26 35
( 9488225_8 36 37
approximately 9488225_8 38 51
120 9488225_8 52 55
mg 9488225_8 56 58
/ 9488225_8 58 59
kg 9488225_8 59 61
body 9488225_8 62 66
weight 9488225_8 67 73
per 9488225_8 74 77
day 9488225_8 78 81
for 9488225_8 82 85
2 9488225_8 86 87
weeks 9488225_8 88 93
in 9488225_8 94 96
drinking 9488225_8 97 105
water 9488225_8 106 111
) 9488225_8 112 113
reduced 9488225_8 114 121
SBP 9488225_8 122 125
in 9488225_8 126 128
either 9488225_8 129 135
Bk 9488225_8 136 138
2 9488225_8 138 139
r 9488225_8 139 140
- 9488225_8 141 142
/ 9488225_8 143 144
- 9488225_8 145 146
or 9488225_8 147 149
J 9488225_8 150 151
129 9488225_8 151 154
Sv 9488225_8 155 157
. 9488225_8 158 159

C 12021632_1 0 1
3435 12021632_1 1 5
T 12021632_1 5 6
mutation 12021632_1 7 15
in 12021632_1 16 18
exon 12021632_1 19 23
26 12021632_1 24 26
of 12021632_1 27 29
the 12021632_1 30 33
human 12021632_1 34 39
MDR 12021632_1 40 43
1 12021632_1 43 44
gene 12021632_1 45 49
and 12021632_1 50 53
cyclosporine 12021632_1 54 66
pharmacokinetics 12021632_1 67 83
in 12021632_1 84 86
healthy 12021632_1 87 94
subjects 12021632_1 95 103
. 12021632_1 104 105

CONCLUSIONS 25658497_11 0 11
: 25658497_11 12 13
This 25658497_11 14 18
study 25658497_11 19 24
argues 25658497_11 25 31
for 25658497_11 32 35
a 25658497_11 36 37
personalized 25658497_11 38 50
prescription 25658497_11 51 63
of 25658497_11 64 66
antidepressants 25658497_11 67 82
in 25658497_11 83 85
Caucasian 25658497_11 86 95
patients 25658497_11 96 104
with 25658497_11 105 109
major 25658497_11 110 115
depressive 25658497_11 116 126
disorder 25658497_11 127 135
, 25658497_11 136 137
based 25658497_11 138 143
on 25658497_11 144 146
the 25658497_11 147 150
BDNF 25658497_11 151 155
Val 25658497_11 156 159
66 25658497_11 159 161
Met 25658497_11 161 164
polymorphism 25658497_11 165 177
: 25658497_11 178 179
SSRI 25658497_11 180 184
should 25658497_11 185 191
be 25658497_11 192 194
preferred 25658497_11 195 204
for 25658497_11 205 208
Val 25658497_11 209 212
/ 25658497_11 213 214
Val 25658497_11 215 218
patients 25658497_11 219 227
and 25658497_11 228 231
SNRI 25658497_11 232 236
/ 25658497_11 236 237
TCA 25658497_11 238 241
for 25658497_11 242 245
Met 25658497_11 246 249
patients 25658497_11 250 258
. 25658497_11 259 260

That 16550163_3 0 4
is 16550163_3 5 7
true 16550163_3 8 12
because 16550163_3 13 20
of 16550163_3 21 23
its 16550163_3 24 27
importance 16550163_3 28 38
clinically 16550163_3 39 49
for 16550163_3 50 53
the 16550163_3 54 57
individualization 16550163_3 58 75
of 16550163_3 76 78
thiopurine 16550163_3 79 89
drug 16550163_3 90 94
therapy 16550163_3 95 102
and 16550163_3 103 106
also 16550163_3 107 111
because 16550163_3 112 119
TPMT 16550163_3 120 124
has 16550163_3 125 128
provided 16550163_3 129 137
novel 16550163_3 138 143
insights 16550163_3 144 152
into 16550163_3 153 157
molecular 16550163_3 158 167
mechanisms 16550163_3 168 178
responsible 16550163_3 179 190
for 16550163_3 191 194
the 16550163_3 195 198
functional 16550163_3 199 209
effects 16550163_3 210 217
of 16550163_3 218 220
common 16550163_3 221 227
genetic 16550163_3 228 235
polymorphisms 16550163_3 236 249
. 16550163_3 250 251

DFMO 15205357_10 0 4
for 15205357_10 5 8
7 15205357_10 9 10
- 15205357_10 10 11
days 15205357_10 11 15
decreased 15205357_10 16 25
the 15205357_10 26 29
number 15205357_10 30 36
of 15205357_10 37 39
methylated 15205357_10 40 50
CpG 15205357_10 51 54
sites 15205357_10 55 60
in 15205357_10 61 63
the 15205357_10 64 67
ER 15205357_10 68 70
- 15205357_10 70 71
alpha 15205357_10 71 76
gene 15205357_10 77 81
from 15205357_10 82 86
5 15205357_10 87 88
. 15205357_10 88 89
00 15205357_10 89 91
+ 15205357_10 92 93
/ 15205357_10 94 95
- 15205357_10 96 97
0 15205357_10 98 99
. 15205357_10 99 100
95 15205357_10 100 102
to 15205357_10 103 105
3 15205357_10 106 107
. 15205357_10 107 108
83 15205357_10 108 110
+ 15205357_10 111 112
/ 15205357_10 113 114
- 15205357_10 115 116
0 15205357_10 117 118
. 15205357_10 118 119
75 15205357_10 119 121
and 15205357_10 122 125
1 15205357_10 126 127
. 15205357_10 127 128
75 15205357_10 128 130
+ 15205357_10 131 132
/ 15205357_10 133 134
- 15205357_10 135 136
0 15205357_10 137 138
. 15205357_10 138 139
49 15205357_10 139 141
these 15205357_10 142 147
levels 15205357_10 148 154
were 15205357_10 155 159
further 15205357_10 160 167
reduced 15205357_10 168 175
to 15205357_10 176 178
0 15205357_10 179 180
. 15205357_10 180 181
50 15205357_10 181 183
+ 15205357_10 184 185
/ 15205357_10 186 187
- 15205357_10 188 189
0 15205357_10 190 191
. 15205357_10 191 192
26 15205357_10 192 194
following 15205357_10 195 204
administration 15205357_10 205 219
of 15205357_10 220 222
1000 15205357_10 223 227
mg 15205357_10 228 230
/ 15205357_10 230 231
kg 15205357_10 231 233
for 15205357_10 234 237
28 15205357_10 238 240
days 15205357_10 241 245
. 15205357_10 246 247

Brain 10585223_5 0 5
concentration 10585223_5 6 19
- 10585223_5 19 20
time 10585223_5 20 24
profiles 10585223_5 25 33
in 10585223_5 34 36
mdr 10585223_5 37 40
1 10585223_5 40 41
a 10585223_5 41 42
( 10585223_5 43 44
+ 10585223_5 45 46
/ 10585223_5 47 48
+ 10585223_5 49 50
) 10585223_5 51 52
and 10585223_5 53 56
mdr 10585223_5 57 60
1 10585223_5 60 61
a 10585223_5 61 62
( 10585223_5 63 64
- 10585223_5 65 66
/ 10585223_5 67 68
- 10585223_5 69 70
) 10585223_5 71 72
mice 10585223_5 73 77
showed 10585223_5 78 84
a 10585223_5 85 86
different 10585223_5 87 96
pattern 10585223_5 97 104
from 10585223_5 105 109
those 10585223_5 110 115
in 10585223_5 116 118
plasma 10585223_5 119 125
and 10585223_5 126 129
other 10585223_5 130 135
tissues 10585223_5 136 143
, 10585223_5 144 145
indicating 10585223_5 146 156
digoxin 10585223_5 157 164
accumulation 10585223_5 165 177
in 10585223_5 178 180
the 10585223_5 181 184
brain 10585223_5 185 190
tissue 10585223_5 191 197
. 10585223_5 198 199

CONCLUSION 17178263_13 0 10
: 17178263_13 11 12
The 17178263_13 13 16
PTGS 17178263_13 17 21
2 17178263_13 21 22
- 17178263_13 23 24
765 17178263_13 24 27
G 17178263_13 27 28
> 17178263_13 28 29
C 17178263_13 29 30
single 17178263_13 31 37
- 17178263_13 37 38
nucleotide 17178263_13 38 48
polymorphism 17178263_13 49 61
does 17178263_13 62 66
not 17178263_13 67 70
modulate 17178263_13 71 79
COX 17178263_13 80 83
- 17178263_13 83 84
2 17178263_13 84 85
inhibitory 17178263_13 86 96
effects 17178263_13 97 104
of 17178263_13 105 107
celecoxib 17178263_13 108 117
as 17178263_13 118 120
assessed 17178263_13 121 129
by 17178263_13 130 132
an 17178263_13 133 135
ex 17178263_13 136 138
vivo 17178263_13 139 143
whole 17178263_13 144 149
blood 17178263_13 150 155
assay 17178263_13 156 161
. 17178263_13 162 163

The 24769646_6 0 3
level 24769646_6 4 9
of 24769646_6 10 12
dimethyl 24769646_6 13 21
histone 24769646_6 22 29
H 24769646_6 30 31
3 24769646_6 31 32
lysine 24769646_6 33 39
4 24769646_6 40 41
( 24769646_6 42 43
H 24769646_6 44 45
3 24769646_6 45 46
K 24769646_6 46 47
4 24769646_6 47 48
me 24769646_6 48 50
2 24769646_6 50 51
) 24769646_6 52 53
in 24769646_6 54 56
the 24769646_6 57 60
RARa 24769646_6 61 65
gene 24769646_6 66 70
- 24769646_6 70 71
promoter 24769646_6 71 79
region 24769646_6 80 86
, 24769646_6 87 88
PU 24769646_6 89 91
. 24769646_6 91 92
1 24769646_6 92 93
upstream 24769646_6 94 102
regulatory 24769646_6 103 113
region 24769646_6 114 120
( 24769646_6 121 122
URE 24769646_6 123 126
) 24769646_6 127 128
and 24769646_6 129 132
RUNX 24769646_6 133 137
1 24769646_6 137 138
+ 24769646_6 139 140
24 24769646_6 140 142
/ 24769646_6 143 144
+ 24769646_6 145 146
25 24769646_6 146 148
intronic 24769646_6 149 157
enhancer 24769646_6 158 166
was 24769646_6 167 170
higher 24769646_6 171 177
in 24769646_6 178 180
MLL 24769646_6 181 184
- 24769646_6 185 186
AF 24769646_6 187 189
9 24769646_6 189 190
- 24769646_6 191 192
positive 24769646_6 192 200
cells 24769646_6 201 206
than 24769646_6 207 211
in 24769646_6 212 214
MLL 24769646_6 215 218
- 24769646_6 219 220
AF 24769646_6 221 223
4 24769646_6 223 224
- 24769646_6 225 226
positive 24769646_6 226 234
cells 24769646_6 235 240
, 24769646_6 241 242
and 24769646_6 243 246
inhibiting 24769646_6 247 257
lysine 24769646_6 258 264
- 24769646_6 265 266
specific 24769646_6 266 274
demethylase 24769646_6 275 286
1 24769646_6 287 288
, 24769646_6 289 290
which 24769646_6 291 296
acts 24769646_6 297 301
as 24769646_6 302 304
a 24769646_6 305 306
histone 24769646_6 307 314
demethylase 24769646_6 315 326
inhibitor 24769646_6 327 336
, 24769646_6 337 338
reactivated 24769646_6 339 350
ATRA 24769646_6 351 355
sensitivity 24769646_6 356 367
in 24769646_6 368 370
MLL 24769646_6 371 374
- 24769646_6 375 376
AF 24769646_6 377 379
4 24769646_6 379 380
- 24769646_6 381 382
positive 24769646_6 382 390
cells 24769646_6 391 396
. 24769646_6 397 398

We 25523423_4 0 2
compared 25523423_4 3 11
learning 25523423_4 12 20
and 25523423_4 21 24
spatial 25523423_4 25 32
memory 25523423_4 33 39
in 25523423_4 40 42
the 25523423_4 43 46
APPswe 25523423_4 47 53
, 25523423_4 54 55
PSEN 25523423_4 56 60
1 25523423_4 60 61
dE 25523423_4 61 63
985 25523423_4 63 66
Dbo 25523423_4 66 69
( 25523423_4 70 71
APP 25523423_4 72 75
/ 25523423_4 75 76
PS 25523423_4 76 78
1 25523423_4 78 79
) 25523423_4 80 81
mouse 25523423_4 82 87
model 25523423_4 88 93
of 25523423_4 94 96
AD 25523423_4 97 99
and 25523423_4 100 103
studied 25523423_4 104 111
the 25523423_4 112 115
ability 25523423_4 116 123
of 25523423_4 124 126
acute 25523423_4 127 132
intraperitoneal 25523423_4 133 148
and 25523423_4 149 152
oral 25523423_4 153 157
Bryostatin 25523423_4 158 168
- 25523423_4 168 169
1 25523423_4 169 170
to 25523423_4 171 173
reverse 25523423_4 174 181
cognitive 25523423_4 182 191
deficits 25523423_4 192 200
in 25523423_4 201 203
this 25523423_4 204 208
model 25523423_4 209 214
. 25523423_4 215 216

Body 23737969_11 0 4
weight 23737969_11 5 11
> 23737969_11 12 13
= 23737969_11 14 15
40 23737969_11 16 18
kg 23737969_11 19 21
and 23737969_11 22 25
homozygosity 23737969_11 26 38
for 23737969_11 39 42
UGT 23737969_11 43 46
1 23737969_11 46 47
A 23737969_11 47 48
1 23737969_11 48 49
* 23737969_11 50 51
6 23737969_11 52 53
were 23737969_11 54 58
risk 23737969_11 59 63
factors 23737969_11 64 71
of 23737969_11 72 74
creatinine 23737969_11 75 85
elevation 23737969_11 86 95
( 23737969_11 96 97
OR 23737969_11 98 100
= 23737969_11 101 102
8 23737969_11 103 104
. 23737969_11 104 105
48 23737969_11 105 107
, 23737969_11 108 109
95 23737969_11 110 112
% 23737969_11 113 114
CI 23737969_11 115 117
= 23737969_11 118 119
1 23737969_11 120 121
. 23737969_11 121 122
7 23737969_11 122 123
- 23737969_11 123 124
43 23737969_11 124 126
. 23737969_11 127 128
57 23737969_11 128 130
, 23737969_11 131 132
P 23737969_11 133 134
= 23737969_11 135 136
0 23737969_11 137 138
. 23737969_11 138 139
010 23737969_11 139 142
and 23737969_11 143 146
OR 23737969_11 147 149
= 23737969_11 150 151
14 23737969_11 152 154
. 23737969_11 154 155
17 23737969_11 155 157
, 23737969_11 158 159
95 23737969_11 160 162
% 23737969_11 163 164
CI 23737969_11 165 167
= 23737969_11 168 169
1 23737969_11 170 171
. 23737969_11 171 172
34 23737969_11 172 174
- 23737969_11 174 175
150 23737969_11 175 178
. 23737969_11 179 180
35 23737969_11 180 182
, 23737969_11 183 184
P 23737969_11 185 186
= 23737969_11 187 188
0 23737969_11 189 190
. 23737969_11 190 191
028 23737969_11 191 194
) 23737969_11 195 196
. 23737969_11 197 198

In 16251483_10 0 2
man 16251483_10 3 6
, 16251483_10 7 8
arsenic 16251483_10 9 16
has 16251483_10 17 20
the 16251483_10 21 24
ability 16251483_10 25 32
to 16251483_10 33 35
alter 16251483_10 36 41
DNA 16251483_10 42 45
methylation 16251483_10 46 57
patterns 16251483_10 58 66
in 16251483_10 67 69
gene 16251483_10 70 74
p 16251483_10 75 76
53 16251483_10 76 78
and 16251483_10 79 82
p 16251483_10 83 84
16 16251483_10 84 86
, 16251483_10 87 88
which 16251483_10 89 94
are 16251483_10 95 98
important 16251483_10 99 108
in 16251483_10 109 111
carcinogenesis 16251483_10 112 126
. 16251483_10 127 128

In 24098690_10 0 2
a 24098690_10 3 4
combined 24098690_10 5 13
analysis 24098690_10 14 22
, 24098690_10 23 24
the 24098690_10 25 28
OR 24098690_10 29 31
for 24098690_10 32 35
post 24098690_10 36 40
- 24098690_10 40 41
PTCA 24098690_10 42 46
restenosis 24098690_10 47 57
of 24098690_10 58 60
the 24098690_10 61 64
ACE 24098690_10 65 68
DD 24098690_10 69 71
genotype 24098690_10 72 80
was 24098690_10 81 84
1 24098690_10 85 86
. 24098690_10 86 87
61 24098690_10 87 89
( 24098690_10 90 91
95 24098690_10 92 94
% 24098690_10 95 96
CI 24098690_10 97 99
: 24098690_10 100 101
1 24098690_10 102 103
. 24098690_10 103 104
27 24098690_10 104 106
- 24098690_10 106 107
2 24098690_10 107 108
. 24098690_10 109 110
04 24098690_10 110 112
; 24098690_10 113 114
P 24098690_10 115 116
< 24098690_10 117 118
10 24098690_10 119 121
( 24098690_10 122 123
- 24098690_10 124 125
5 24098690_10 125 126
) 24098690_10 127 128
) 24098690_10 129 130
. 24098690_10 131 132

BACKGROUND 19414633_2 0 10
: 19414633_2 11 12
Both 19414633_2 13 17
clopidogrel 19414633_2 18 29
and 19414633_2 30 33
prasugrel 19414633_2 34 43
require 19414633_2 44 51
biotransformation 19414633_2 52 69
to 19414633_2 70 72
active 19414633_2 73 79
metabolites 19414633_2 80 91
by 19414633_2 92 94
cytochrome 19414633_2 95 105
P 19414633_2 106 107
450 19414633_2 107 110
( 19414633_2 111 112
CYP 19414633_2 113 116
) 19414633_2 117 118
enzymes 19414633_2 119 126
. 19414633_2 127 128

We 16015387_9 0 2
demonstrate 16015387_9 3 14
that 16015387_9 15 19
KIT 16015387_9 20 23
exon 16015387_9 24 28
8 16015387_9 29 30
mutations 16015387_9 31 40
result 16015387_9 41 47
in 16015387_9 48 50
constitutive 16015387_9 51 63
ligand 16015387_9 64 70
- 16015387_9 70 71
independent 16015387_9 71 82
kinase 16015387_9 83 89
activation 16015387_9 90 100
that 16015387_9 101 105
can 16015387_9 106 109
be 16015387_9 110 112
inhibited 16015387_9 113 122
by 16015387_9 123 125
clinically 16015387_9 126 136
relevant 16015387_9 137 145
concentrations 16015387_9 146 160
of 16015387_9 161 163
imatinib 16015387_9 164 172
. 16015387_9 173 174

Inhibition 15638955_4 0 10
of 15638955_4 11 13
the 15638955_4 14 17
epidermal 15638955_4 18 27
growth 15638955_4 28 34
factor 15638955_4 35 41
receptor 15638955_4 42 50
( 15638955_4 51 52
EGFR 15638955_4 53 57
) 15638955_4 58 59
with 15638955_4 60 64
monoclonal 15638955_4 65 75
antibodies 15638955_4 76 86
or 15638955_4 87 89
small 15638955_4 90 95
- 15638955_4 95 96
molecule 15638955_4 96 104
inhibitors 15638955_4 105 115
of 15638955_4 116 118
the 15638955_4 119 122
tyrosine 15638955_4 123 131
kinase 15638955_4 132 138
( 15638955_4 139 140
TK 15638955_4 141 143
) 15638955_4 144 145
domain 15638955_4 146 152
of 15638955_4 153 155
the 15638955_4 156 159
receptor 15638955_4 160 168
have 15638955_4 169 173
demonstrated 15638955_4 174 186
modest 15638955_4 187 193
, 15638955_4 194 195
albeit 15638955_4 196 202
significant 15638955_4 203 214
, 15638955_4 215 216
antitumor 15638955_4 217 226
activities 15638955_4 227 237
in 15638955_4 238 240
patients 15638955_4 241 249
with 15638955_4 250 254
non 15638955_4 255 258
- 15638955_4 258 259
small 15638955_4 259 264
- 15638955_4 264 265
cell 15638955_4 265 269
lung 15638955_4 270 274
cancer 15638955_4 275 281
( 15638955_4 282 283
NSCLC 15638955_4 284 289
) 15638955_4 290 291
. 15638955_4 292 293

CONCLUSIONS 22521649_12 0 11
: 22521649_12 12 13
Our 22521649_12 14 17
current 22521649_12 18 25
data 22521649_12 26 30
indicate 22521649_12 31 39
that 22521649_12 40 44
lung 22521649_12 45 49
cancer 22521649_12 50 56
patients 22521649_12 57 65
with 22521649_12 66 70
EGFR 22521649_12 71 75
- 22521649_12 76 77
mutations 22521649_12 77 86
had 22521649_12 87 90
longer 22521649_12 91 97
PFS 22521649_12 98 101
with 22521649_12 102 106
taxane 22521649_12 107 113
than 22521649_12 114 118
gemcitabine 22521649_12 119 130
when 22521649_12 131 135
receiving 22521649_12 136 145
a 22521649_12 146 147
platinum 22521649_12 148 156
- 22521649_12 157 158
based 22521649_12 158 163
doublet 22521649_12 164 171
regimen 22521649_12 172 179
. 22521649_12 180 181

RESULTS 17555717_6 0 7
: 17555717_6 8 9
DTNBP 17555717_6 10 15
1 17555717_6 15 16
showed 17555717_6 17 23
significant 17555717_6 24 35
associations 17555717_6 36 48
with 17555717_6 49 53
methamphetamine 17555717_6 54 69
psychosis 17555717_6 70 79
at 17555717_6 80 82
polymorphisms 17555717_6 83 96
of 17555717_6 97 99
P 17555717_6 100 101
1635 17555717_6 101 105
( 17555717_6 106 107
rs 17555717_6 108 110
3213207 17555717_6 110 117
, 17555717_6 118 119
p 17555717_6 120 121
= 17555717_6 122 123
. 17555717_6 124 125
00003 17555717_6 125 130
) 17555717_6 131 132
and 17555717_6 133 136
SNPA 17555717_6 137 141
( 17555717_6 142 143
rs 17555717_6 144 146
2619538 17555717_6 146 153
, 17555717_6 154 155
p 17555717_6 156 157
= 17555717_6 158 159
. 17555717_6 160 161
049 17555717_6 161 164
) 17555717_6 165 166
and 17555717_6 167 170
the 17555717_6 171 174
three 17555717_6 175 180
- 17555717_6 180 181
locus 17555717_6 181 186
haplotype 17555717_6 187 196
of 17555717_6 197 199
P 17555717_6 200 201
1655 17555717_6 201 205
( 17555717_6 206 207
rs 17555717_6 208 210
2619539 17555717_6 210 217
) 17555717_6 218 219
- 17555717_6 220 221
P 17555717_6 222 223
1635 17555717_6 223 227
- 17555717_6 227 228
SNPA 17555717_6 229 233
( 17555717_6 234 235
permutation 17555717_6 236 247
p 17555717_6 248 249
= 17555717_6 250 251
. 17555717_6 252 253
0005 17555717_6 253 257
) 17555717_6 258 259
. 17555717_6 260 261

Using 21672908_11 0 5
the 21672908_11 6 9
automatically 21672908_11 10 23
extracted 21672908_11 24 33
weekly 21672908_11 34 40
doses 21672908_11 41 46
of 21672908_11 47 49
warfarin 21672908_11 50 58
, 21672908_11 59 60
the 21672908_11 61 64
authors 21672908_11 65 72
successfully 21672908_11 73 85
replicated 21672908_11 86 96
the 21672908_11 97 100
previous 21672908_11 101 109
known 21672908_11 110 115
associations 21672908_11 116 128
between 21672908_11 129 136
warfarin 21672908_11 137 145
stable 21672908_11 146 152
dose 21672908_11 153 157
and 21672908_11 158 161
genetic 21672908_11 162 169
variants 21672908_11 170 178
in 21672908_11 179 181
VKORC 21672908_11 182 187
1 21672908_11 187 188
and 21672908_11 189 192
CYP 21672908_11 193 196
2 21672908_11 196 197
C 21672908_11 197 198
9 21672908_11 198 199
. 21672908_11 200 201

CYP 17430486_2 0 3
3 17430486_2 3 4
A 17430486_2 4 5
enzyme 17430486_2 6 12
plays 17430486_2 13 18
a 17430486_2 19 20
pivotal 17430486_2 21 28
role 17430486_2 29 33
in 17430486_2 34 36
TAC 17430486_2 37 40
metabolism 17430486_2 41 51
. 17430486_2 52 53

Hepatic 18467506_7 0 7
SCF 18467506_7 8 11
mRNA 18467506_7 12 16
levels 18467506_7 17 23
after 18467506_7 24 29
APAP 18467506_7 30 34
injury 18467506_7 35 41
were 18467506_7 42 46
also 18467506_7 47 51
increased 18467506_7 52 61
, 18467506_7 62 63
with 18467506_7 64 68
peak 18467506_7 69 73
levels 18467506_7 74 80
seen 18467506_7 81 85
16 18467506_7 86 88
h 18467506_7 89 90
post 18467506_7 91 95
- 18467506_7 95 96
APAP 18467506_7 97 101
. 18467506_7 102 103

Afatinib 26575001_3 0 8
is 26575001_3 9 11
an 26575001_3 12 14
irreversible 26575001_3 15 27
inhibitor 26575001_3 28 37
directed 26575001_3 38 46
against 26575001_3 47 54
EGFR 26575001_3 55 59
, 26575001_3 60 61
ErbB 26575001_3 62 66
- 26575001_3 66 67
2 26575001_3 67 68
, 26575001_3 69 70
and 26575001_3 71 74
ErbB 26575001_3 75 79
- 26575001_3 79 80
4 26575001_3 80 81
, 26575001_3 82 83
whereas 26575001_3 84 91
erlotinib 26575001_3 92 101
is 26575001_3 102 104
a 26575001_3 105 106
reversible 26575001_3 107 117
inhibitor 26575001_3 118 127
directed 26575001_3 128 136
against 26575001_3 137 144
EGFR 26575001_3 145 149
only 26575001_3 150 154
. 26575001_3 155 156

The 22035418_1 0 3
T 22035418_1 4 5
_ 22035418_1 5 6
T 22035418_1 6 7
genotype 22035418_1 8 16
within 22035418_1 17 23
the 22035418_1 24 27
NME 22035418_1 28 31
1 22035418_1 31 32
promoter 22035418_1 33 41
single 22035418_1 42 48
nucleotide 22035418_1 49 59
polymorphism 22035418_1 60 72
- 22035418_1 73 74
835 22035418_1 74 77
C 22035418_1 78 79
/ 22035418_1 79 80
T 22035418_1 80 81
is 22035418_1 82 84
associated 22035418_1 85 95
with 22035418_1 96 100
an 22035418_1 101 103
increased 22035418_1 104 113
risk 22035418_1 114 118
of 22035418_1 119 121
cytarabine 22035418_1 122 132
induced 22035418_1 133 140
neurotoxicity 22035418_1 141 154
in 22035418_1 155 157
patients 22035418_1 158 166
with 22035418_1 167 171
acute 22035418_1 172 177
myeloid 22035418_1 178 185
leukemia 22035418_1 186 194
. 22035418_1 195 196

In 15358623_4 0 2
147 15358623_4 3 6
patients 15358623_4 7 15
followed 15358623_4 16 24
from 15358623_4 25 29
the 15358623_4 30 33
start 15358623_4 34 39
of 15358623_4 40 42
anticoagulation 15358623_4 43 58
with 15358623_4 59 63
warfarin 15358623_4 64 72
, 15358623_4 73 74
we 15358623_4 75 77
have 15358623_4 78 82
investigated 15358623_4 83 95
whether 15358623_4 96 103
VKORC 15358623_4 104 109
1 15358623_4 109 110
gene 15358623_4 111 115
mutations 15358623_4 116 125
have 15358623_4 126 130
affected 15358623_4 131 139
doses 15358623_4 140 145
of 15358623_4 146 148
drug 15358623_4 149 153
prescribed 15358623_4 154 164
to 15358623_4 165 167
acquire 15358623_4 168 175
the 15358623_4 176 179
target 15358623_4 180 186
anticoagulation 15358623_4 187 202
intensity 15358623_4 203 212
. 15358623_4 213 214

Moreover 23302800_3 0 8
, 23302800_3 9 10
the 23302800_3 11 14
marked 23302800_3 15 21
tumour 23302800_3 22 28
regression 23302800_3 29 39
and 23302800_3 40 43
improved 23302800_3 44 52
survival 23302800_3 53 61
of 23302800_3 62 64
late 23302800_3 65 69
- 23302800_3 69 70
stage 23302800_3 70 75
BRAF 23302800_3 76 80
- 23302800_3 81 82
mutated 23302800_3 82 89
melanoma 23302800_3 90 98
patients 23302800_3 99 107
in 23302800_3 108 110
response 23302800_3 111 119
to 23302800_3 120 122
treatment 23302800_3 123 132
with 23302800_3 133 137
vemurafenib 23302800_3 138 149
demonstrates 23302800_3 150 162
the 23302800_3 163 166
essential 23302800_3 167 176
role 23302800_3 177 181
of 23302800_3 182 184
oncogenic 23302800_3 185 194
BRAF 23302800_3 195 199
in 23302800_3 200 202
melanoma 23302800_3 203 211
maintenance 23302800_3 212 223
. 23302800_3 224 225

On 23757001_2 0 2
the 23757001_2 3 6
basis 23757001_2 7 12
of 23757001_2 13 15
the 23757001_2 16 19
converging 23757001_2 20 30
evidence 23757001_2 31 39
showing 23757001_2 40 47
regulation 23757001_2 48 58
of 23757001_2 59 61
drinking 23757001_2 62 70
behavior 23757001_2 71 79
by 23757001_2 80 82
5 23757001_2 83 84
- 23757001_2 84 85
HT 23757001_2 85 87
3 23757001_2 87 88
AB 23757001_2 88 90
receptors 23757001_2 91 100
and 23757001_2 101 104
the 23757001_2 105 108
serotonin 23757001_2 109 118
transporter 23757001_2 119 130
, 23757001_2 131 132
we 23757001_2 133 135
hypothesized 23757001_2 136 148
that 23757001_2 149 153
the 23757001_2 154 157
interactive 23757001_2 158 169
effects 23757001_2 170 177
of 23757001_2 178 180
genetic 23757001_2 181 188
variations 23757001_2 189 199
in 23757001_2 200 202
the 23757001_2 203 206
genes 23757001_2 207 212
HTR 23757001_2 213 216
3 23757001_2 216 217
A 23757001_2 217 218
, 23757001_2 219 220
HTR 23757001_2 221 224
3 23757001_2 224 225
B 23757001_2 225 226
, 23757001_2 227 228
and 23757001_2 229 232
SLC 23757001_2 233 236
6 23757001_2 236 237
A 23757001_2 237 238
4 23757001_2 238 239
confer 23757001_2 240 246
greater 23757001_2 247 254
susceptibility 23757001_2 255 269
to 23757001_2 270 272
alcohol 23757001_2 273 280
dependence 23757001_2 281 291
( 23757001_2 292 293
AD 23757001_2 294 296
) 23757001_2 297 298
than 23757001_2 299 303
do 23757001_2 304 306
their 23757001_2 307 312
effects 23757001_2 313 320
individually 23757001_2 321 333
. 23757001_2 334 335

The 25042383_3 0 3
purpose 25042383_3 4 11
of 25042383_3 12 14
this 25042383_3 15 19
study 25042383_3 20 25
was 25042383_3 26 29
to 25042383_3 30 32
evaluate 25042383_3 33 41
the 25042383_3 42 45
predictive 25042383_3 46 56
value 25042383_3 57 62
of 25042383_3 63 65
TOP 25042383_3 66 69
2 25042383_3 69 70
A 25042383_3 70 71
gene 25042383_3 72 76
for 25042383_3 77 80
the 25042383_3 81 84
efficacy 25042383_3 85 93
of 25042383_3 94 96
neo 25042383_3 97 100
- 25042383_3 100 101
adjuvant 25042383_3 101 109
anthracycline 25042383_3 110 123
in 25042383_3 124 126
a 25042383_3 127 128
population 25042383_3 129 139
with 25042383_3 140 144
locally 25042383_3 145 152
advanced 25042383_3 153 161
breast 25042383_3 162 168
cancer 25042383_3 169 175
. 25042383_3 176 177

Hydrochlorothiazide 12107202_1 0 19
effectively 12107202_1 20 31
reduces 12107202_1 32 39
urinary 12107202_1 40 47
calcium 12107202_1 48 55
excretion 12107202_1 56 65
in 12107202_1 66 68
two 12107202_1 69 72
Japanese 12107202_1 73 81
patients 12107202_1 82 90
with 12107202_1 91 95
gain 12107202_1 96 100
- 12107202_1 100 101
of 12107202_1 101 103
- 12107202_1 103 104
function 12107202_1 104 112
mutations 12107202_1 113 122
of 12107202_1 123 125
the 12107202_1 126 129
calcium 12107202_1 130 137
- 12107202_1 137 138
sensing 12107202_1 138 145
receptor 12107202_1 146 154
gene 12107202_1 155 159
. 12107202_1 160 161

The 20025435_2 0 3
association 20025435_2 4 15
between 20025435_2 16 23
two 20025435_2 24 27
functional 20025435_2 28 38
polymorphisms 20025435_2 39 52
in 20025435_2 53 55
alcohol 20025435_2 56 63
dehydrogenase 20025435_2 64 77
( 20025435_2 78 79
ADH 20025435_2 80 83
2 20025435_2 83 84
/ 20025435_2 85 86
ADH 20025435_2 87 90
1 20025435_2 90 91
B 20025435_2 91 92
) 20025435_2 93 94
and 20025435_2 95 98
aldehyde 20025435_2 99 107
dehydrogenase 20025435_2 108 121
( 20025435_2 122 123
ALDH 20025435_2 124 128
2 20025435_2 128 129
) 20025435_2 130 131
genes 20025435_2 132 137
and 20025435_2 138 141
alcohol 20025435_2 142 149
dependence 20025435_2 150 160
was 20025435_2 161 164
examined 20025435_2 165 173
in 20025435_2 174 176
182 20025435_2 177 180
Chinese 20025435_2 181 188
and 20025435_2 189 192
Indian 20025435_2 193 199
patients 20025435_2 200 208
undergoing 20025435_2 209 219
treatment 20025435_2 220 229
for 20025435_2 230 233
alcohol 20025435_2 234 241
dependence 20025435_2 242 252
and 20025435_2 253 256
184 20025435_2 257 260
screened 20025435_2 261 269
control 20025435_2 270 277
subjects 20025435_2 278 286
from 20025435_2 287 291
Singapore 20025435_2 292 301
. 20025435_2 302 303

Regarding 25495407_5 0 9
paclitaxel 25495407_5 10 20
toxicity 25495407_5 21 29
: 25495407_5 30 31
CYP 25495407_5 32 35
2 25495407_5 35 36
C 25495407_5 36 37
8 25495407_5 37 38
HapC 25495407_5 39 43
and 25495407_5 44 47
CYP 25495407_5 48 51
2 25495407_5 51 52
C 25495407_5 52 53
8 25495407_5 53 54
rs 25495407_5 55 57
1934951 25495407_5 57 64
were 25495407_5 65 69
associated 25495407_5 70 80
with 25495407_5 81 85
anemia 25495407_5 86 92
; 25495407_5 93 94
and 25495407_5 95 98
ERCC 25495407_5 99 103
1 25495407_5 103 104
Gln 25495407_5 105 108
504 25495407_5 108 111
Lys 25495407_5 111 114
with 25495407_5 115 119
neuropathy 25495407_5 120 130
( 25495407_5 131 132
p 25495407_5 133 134
< 25495407_5 135 136
= 25495407_5 137 138
0 25495407_5 139 140
. 25495407_5 140 141
01 25495407_5 141 143
) 25495407_5 144 145
. 25495407_5 146 147

Studies 18852012_19 0 7
on 18852012_19 8 10
the 18852012_19 11 14
eukaryotic 18852012_19 15 25
enzymes 18852012_19 26 33
by 18852012_19 34 36
NMR 18852012_19 37 40
and 18852012_19 41 44
crystallography 18852012_19 45 60
have 18852012_19 61 65
facilitated 18852012_19 66 77
understanding 18852012_19 78 91
substrate 18852012_19 92 101
specificities 18852012_19 102 115
of 18852012_19 116 118
human 18852012_19 119 124
NAT 18852012_19 125 128
1 18852012_19 128 129
( 18852012_19 130 131
5 18852012_19 132 133
- 18852012_19 133 134
aminosalicylate 18852012_19 134 149
and 18852012_19 150 153
p 18852012_19 154 155
- 18852012_19 155 156
aminobenzoic 18852012_19 156 168
acid 18852012_19 169 173
) 18852012_19 174 175
and 18852012_19 176 179
human 18852012_19 180 185
NAT 18852012_19 186 189
2 18852012_19 189 190
( 18852012_19 191 192
sulphamethazine 18852012_19 193 208
) 18852012_19 209 210
. 18852012_19 211 212

CYP 19374522_1 0 3
2 19374522_1 3 4
D 19374522_1 4 5
6 19374522_1 5 6
genotyping 19374522_1 7 17
for 19374522_1 18 21
psychiatric 19374522_1 22 33
patients 19374522_1 34 42
treated 19374522_1 43 50
with 19374522_1 51 55
risperidone 19374522_1 56 67
: 19374522_1 68 69
considerations 19374522_1 70 84
for 19374522_1 85 88
cost 19374522_1 89 93
- 19374522_1 93 94
effectiveness 19374522_1 94 107
studies 19374522_1 108 115
. 19374522_1 116 117

This 19929252_7 0 4
review 19929252_7 5 11
describes 19929252_7 12 21
the 19929252_7 22 25
DRD 19929252_7 26 29
2 19929252_7 29 30
polymorphisms 19929252_7 31 44
, 19929252_7 45 46
their 19929252_7 47 52
functional 19929252_7 53 63
effects 19929252_7 64 71
, 19929252_7 72 73
and 19929252_7 74 77
their 19929252_7 78 83
impact 19929252_7 84 90
on 19929252_7 91 93
susceptibility 19929252_7 94 108
and 19929252_7 109 112
response 19929252_7 113 121
to 19929252_7 122 124
dopamine 19929252_7 125 133
- 19929252_7 134 135
agonists 19929252_7 135 143
treatment 19929252_7 144 153
. 19929252_7 154 155

The 23708314_10 0 3
results 23708314_10 4 11
showed 23708314_10 12 18
that 23708314_10 19 23
CRAd 23708314_10 24 28
, 23708314_10 29 30
in 23708314_10 31 33
combination 23708314_10 34 45
with 23708314_10 46 50
irradiation 23708314_10 51 62
, 23708314_10 63 64
inhibited 23708314_10 65 74
cell 23708314_10 75 79
proliferation 23708314_10 80 93
, 23708314_10 94 95
promoted 23708314_10 96 104
cell 23708314_10 105 109
apoptosis 23708314_10 110 119
and 23708314_10 120 123
significantly 23708314_10 124 137
increased 23708314_10 138 147
the 23708314_10 148 151
expression 23708314_10 152 162
of 23708314_10 163 165
TRAIL 23708314_10 166 171
, 23708314_10 172 173
DR 23708314_10 174 176
5 23708314_10 176 177
, 23708314_10 178 179
caspase 23708314_10 180 187
- 23708314_10 187 188
3 23708314_10 188 189
and 23708314_10 190 193
caspase 23708314_10 194 201
- 23708314_10 201 202
8 23708314_10 202 203
mRNA 23708314_10 204 208
and 23708314_10 209 212
proteins 23708314_10 213 221
in 23708314_10 222 224
MDA 23708314_10 225 228
- 23708314_10 228 229
MB 23708314_10 229 231
- 23708314_10 231 232
231 23708314_10 232 235
cells 23708314_10 236 241
. 23708314_10 242 243

No 12218660_1 0 2
association 12218660_1 3 14
between 12218660_1 15 22
polymorphisms 12218660_1 23 36
in 12218660_1 37 39
the 12218660_1 40 43
serotonin 12218660_1 44 53
transporter 12218660_1 54 65
gene 12218660_1 66 70
and 12218660_1 71 74
susceptibility 12218660_1 75 89
to 12218660_1 90 92
cocaine 12218660_1 93 100
dependence 12218660_1 101 111
among 12218660_1 112 117
African 12218660_1 118 125
- 12218660_1 125 126
American 12218660_1 126 134
individuals 12218660_1 135 146
. 12218660_1 147 148

Maprotiline 8018460_1 0 11
metabolism 8018460_1 12 22
appears 8018460_1 23 30
to 8018460_1 31 33
co 8018460_1 34 36
- 8018460_1 36 37
segregate 8018460_1 37 46
with 8018460_1 47 51
the 8018460_1 52 55
genetically 8018460_1 56 67
- 8018460_1 67 68
determined 8018460_1 68 78
CYP 8018460_1 79 82
2 8018460_1 82 83
D 8018460_1 83 84
6 8018460_1 84 85
polymorphic 8018460_1 86 97
hydroxylation 8018460_1 98 111
of 8018460_1 112 114
debrisoquine 8018460_1 115 127
. 8018460_1 128 129

Serotonin 15322730_3 0 9
reuptake 15322730_3 10 18
is 15322730_3 19 21
controlled 15322730_3 22 32
by 15322730_3 33 35
the 15322730_3 36 39
serotonin 15322730_3 40 49
transporter 15322730_3 50 61
( 15322730_3 62 63
5 15322730_3 64 65
- 15322730_3 65 66
HTT 15322730_3 66 69
) 15322730_3 70 71
and 15322730_3 72 75
by 15322730_3 76 78
a 15322730_3 79 80
common 15322730_3 81 87
functional 15322730_3 88 98
insertion 15322730_3 99 108
/ 15322730_3 108 109
deletion 15322730_3 109 117
polymorphism 15322730_3 118 130
in 15322730_3 131 133
the 15322730_3 134 137
corresponding 15322730_3 138 151
gene 15322730_3 152 156
' 15322730_3 157 158
s 15322730_3 158 159
promoter 15322730_3 160 168
region 15322730_3 169 175
( 15322730_3 176 177
5 15322730_3 178 179
- 15322730_3 179 180
HTTLPR 15322730_3 180 186
) 15322730_3 187 188
. 15322730_3 189 190

MAIN 16818870_9 0 4
OUTCOME 16818870_9 5 12
MEASURES 16818870_9 13 21
: 16818870_9 22 23
Gene 16818870_9 24 28
variants 16818870_9 29 37
of 16818870_9 38 40
dopamine 16818870_9 41 49
system 16818870_9 50 56
components 16818870_9 57 67
( 16818870_9 68 69
the 16818870_9 70 73
dopamine 16818870_9 74 82
transporter 16818870_9 83 94
variable 16818870_9 95 103
nucleotide 16818870_9 104 114
tandem 16818870_9 115 121
repeat 16818870_9 122 128
, 16818870_9 129 130
D 16818870_9 131 132
2 16818870_9 132 133
receptor 16818870_9 134 142
Taq 16818870_9 143 146
A 16818870_9 147 148
1 16818870_9 148 149
/ 16818870_9 149 150
A 16818870_9 150 151
2 16818870_9 151 152
, 16818870_9 153 154
D 16818870_9 155 156
4 16818870_9 156 157
receptor 16818870_9 158 166
variable 16818870_9 167 175
nucleotide 16818870_9 176 186
tandem 16818870_9 187 193
repeat 16818870_9 194 200
, 16818870_9 201 202
and 16818870_9 203 206
catechol 16818870_9 207 215
- 16818870_9 215 216
O 16818870_9 216 217
- 16818870_9 217 218
methyltransferase 16818870_9 218 235
Val 16818870_9 236 239
158 16818870_9 239 242
Met 16818870_9 242 245
polymorphisms 16818870_9 246 259
) 16818870_9 260 261
and 16818870_9 262 265
change 16818870_9 266 272
in 16818870_9 273 275
[ 16818870_9 276 277
11 16818870_9 278 280
C 16818870_9 280 281
] 16818870_9 282 283
raclopride 16818870_9 284 294
binding 16818870_9 295 302
potential 16818870_9 303 312
in 16818870_9 313 315
the 16818870_9 316 319
ventral 16818870_9 320 327
caudate 16818870_9 328 335
/ 16818870_9 335 336
nucleus 16818870_9 336 343
accumbens 16818870_9 344 353
on 16818870_9 354 356
positron 16818870_9 357 365
emission 16818870_9 366 374
tomography 16818870_9 375 385
scans 16818870_9 386 391
. 16818870_9 392 393

We 23846846_3 0 2
therefore 23846846_3 3 12
hypothesized 23846846_3 13 25
that 23846846_3 26 30
DPYSL 23846846_3 31 36
2 23846846_3 36 37
gene 23846846_3 38 42
polymorphisms 23846846_3 43 56
may 23846846_3 57 60
play 23846846_3 61 65
a 23846846_3 66 67
role 23846846_3 68 72
in 23846846_3 73 75
alcohol 23846846_3 76 83
dependence 23846846_3 84 94
( 23846846_3 95 96
AD 23846846_3 97 99
) 23846846_3 100 101
. 23846846_3 102 103

Regulation 25862379_3 0 10
of 25862379_3 11 13
the 25862379_3 14 17
extracellular 25862379_3 18 31
dopamine 25862379_3 32 40
concentration 25862379_3 41 54
is 25862379_3 55 57
driven 25862379_3 58 64
by 25862379_3 65 67
dopamine 25862379_3 68 76
transporter 25862379_3 77 88
. 25862379_3 89 90

PURPOSE 20512075_2 0 7
: 20512075_2 8 9
The 20512075_2 10 13
tyrosine 20512075_2 14 22
kinase 20512075_2 23 29
inhibitors 20512075_2 30 40
( 20512075_2 41 42
TKIs 20512075_2 43 47
) 20512075_2 48 49
gefitinib 20512075_2 50 59
and 20512075_2 60 63
erlotinib 20512075_2 64 73
are 20512075_2 74 77
effective 20512075_2 78 87
in 20512075_2 88 90
non 20512075_2 91 94
- 20512075_2 94 95
small 20512075_2 95 100
cell 20512075_2 101 105
lung 20512075_2 106 110
cancers 20512075_2 111 118
( 20512075_2 119 120
NSCLCs 20512075_2 121 127
) 20512075_2 128 129
with 20512075_2 130 134
epidermal 20512075_2 135 144
growth 20512075_2 145 151
factor 20512075_2 152 158
receptor 20512075_2 159 167
( 20512075_2 168 169
EGFR 20512075_2 170 174
) 20512075_2 175 176
gene 20512075_2 177 181
mutations 20512075_2 182 191
. 20512075_2 192 193

We 25143362_5 0 2
treated 25143362_5 3 10
three 25143362_5 11 16
patients 25143362_5 17 25
with 25143362_5 26 30
muscular 25143362_5 31 39
dystrophy 25143362_5 40 49
due 25143362_5 50 53
to 25143362_5 54 56
a 25143362_5 57 58
homozygous 25143362_5 59 69
Arg 25143362_5 70 73
555 25143362_5 73 76
Trp 25143362_5 76 79
mutation 25143362_5 80 88
in 25143362_5 89 91
dysferlin 25143362_5 92 101
with 25143362_5 102 106
the 25143362_5 107 110
proteasome 25143362_5 111 121
inhibitor 25143362_5 122 131
bortezomib 25143362_5 132 142
and 25143362_5 143 146
monitored 25143362_5 147 156
dysferlin 25143362_5 157 166
expression 25143362_5 167 177
in 25143362_5 178 180
monocytes 25143362_5 181 190
and 25143362_5 191 194
in 25143362_5 195 197
skeletal 25143362_5 198 206
muscle 25143362_5 207 213
by 25143362_5 214 216
repeated 25143362_5 217 225
percutaneous 25143362_5 226 238
muscle 25143362_5 239 245
biopsy 25143362_5 246 252
. 25143362_5 253 254

The 24977443_10 0 3
existence 24977443_10 4 13
of 24977443_10 14 16
a 24977443_10 17 18
French 24977443_10 19 25
laboratories 24977443_10 26 38
network 24977443_10 39 46
performing 24977443_10 47 57
this 24977443_10 58 62
test 24977443_10 63 67
in 24977443_10 68 70
clinical 24977443_10 71 79
routine 24977443_10 80 87
makes 24977443_10 88 93
it 24977443_10 94 96
possible 24977443_10 97 105
to 24977443_10 106 108
generalize 24977443_10 109 119
UGT 24977443_10 120 123
1 24977443_10 123 124
A 24977443_10 124 125
1 24977443_10 125 126
deficiency 24977443_10 127 137
screening 24977443_10 138 147
, 24977443_10 148 149
so 24977443_10 150 152
as 24977443_10 153 155
to 24977443_10 156 158
guarantee 24977443_10 159 168
equal 24977443_10 169 174
access 24977443_10 175 181
to 24977443_10 182 184
safe 24977443_10 185 189
treatment 24977443_10 190 199
and 24977443_10 200 203
optimized 24977443_10 204 213
irinorecan 24977443_10 214 224
- 24977443_10 225 226
based 24977443_10 226 231
therapy 24977443_10 232 239
for 24977443_10 240 243
the 24977443_10 244 247
many 24977443_10 248 252
patients 24977443_10 253 261
receiving 24977443_10 262 271
irinotecan 24977443_10 272 282
- 24977443_10 283 284
based 24977443_10 284 289
therapy 24977443_10 290 297
in 24977443_10 298 300
advanced 24977443_10 301 309
colorectal 24977443_10 310 320
cancer 24977443_10 321 327
. 24977443_10 328 329

CONCLUSIONS 25194407_11 0 11
: 25194407_11 12 13
Our 25194407_11 14 17
study 25194407_11 18 23
shows 25194407_11 24 29
that 25194407_11 30 34
increased 25194407_11 35 44
serum 25194407_11 45 50
level 25194407_11 51 56
of 25194407_11 57 59
PTH 25194407_11 60 63
and 25194407_11 64 67
decreased 25194407_11 68 77
fetuin 25194407_11 78 84
- 25194407_11 84 85
A 25194407_11 85 86
and 25194407_11 87 90
vitamin 25194407_11 91 98
D 25194407_11 99 100
levels 25194407_11 101 107
may 25194407_11 108 111
increase 25194407_11 112 120
susceptibility 25194407_11 121 135
of 25194407_11 136 138
atherosclerosis 25194407_11 139 154
in 25194407_11 155 157
patients 25194407_11 158 166
with 25194407_11 167 171
hemodialysis 25194407_11 172 184
through 25194407_11 185 192
VDR 25194407_11 193 196
gene 25194407_11 197 201
FokI 25194407_11 202 206
and 25194407_11 207 210
ApaI 25194407_11 211 215
polymorphisms 25194407_11 216 229
. 25194407_11 230 231

Mutational 25071141_1 0 10
analysis 25071141_1 11 19
of 25071141_1 20 22
PI 25071141_1 23 25
3 25071141_1 25 26
K 25071141_1 26 27
/ 25071141_1 28 29
AKT 25071141_1 30 33
signaling 25071141_1 34 43
pathway 25071141_1 44 51
in 25071141_1 52 54
tamoxifen 25071141_1 55 64
exemestane 25071141_1 65 75
adjuvant 25071141_1 76 84
multinational 25071141_1 85 98
pathology 25071141_1 99 108
study 25071141_1 109 114
. 25071141_1 115 116

A 24491881_3 0 1
C 24491881_3 2 3
- 24491881_3 3 4
to 24491881_3 4 6
- 24491881_3 6 7
T 24491881_3 7 8
mutation 24491881_3 9 17
in 24491881_3 18 20
the 24491881_3 21 24
methylenetetrahydrofolate 24491881_3 25 50
reductase 24491881_3 51 60
( 24491881_3 61 62
MTHFR 24491881_3 63 68
) 24491881_3 69 70
gene 24491881_3 71 75
results 24491881_3 76 83
in 24491881_3 84 86
a 24491881_3 87 88
thermolabile 24491881_3 89 101
MTHFR 24491881_3 102 107
, 24491881_3 108 109
which 24491881_3 110 115
may 24491881_3 116 119
affect 24491881_3 120 126
homocysteine 24491881_3 127 139
( 24491881_3 140 141
Hcy 24491881_3 142 145
) 24491881_3 146 147
levels 24491881_3 148 154
. 24491881_3 155 156

Epidermal 19095777_1 0 9
growth 19095777_1 10 16
factor 19095777_1 17 23
receptor 19095777_1 24 32
gene 19095777_1 33 37
copy 19095777_1 38 42
number 19095777_1 43 49
, 19095777_1 50 51
K 19095777_1 52 53
- 19095777_1 53 54
ras 19095777_1 54 57
mutation 19095777_1 58 66
and 19095777_1 67 70
pathological 19095777_1 71 83
response 19095777_1 84 92
to 19095777_1 93 95
preoperative 19095777_1 96 108
cetuximab 19095777_1 109 118
, 19095777_1 119 120
5 19095777_1 121 122
- 19095777_1 122 123
FU 19095777_1 123 125
and 19095777_1 126 129
radiation 19095777_1 130 139
therapy 19095777_1 140 147
in 19095777_1 148 150
locally 19095777_1 151 158
advanced 19095777_1 159 167
rectal 19095777_1 168 174
cancer 19095777_1 175 181
. 19095777_1 182 183

While 9592111_5 0 5
investigating 9592111_5 6 19
the 9592111_5 20 23
neuroendocrine 9592111_5 24 38
correlates 9592111_5 39 49
of 9592111_5 50 52
alcohol 9592111_5 53 60
administration 9592111_5 61 75
via 9592111_5 76 79
different 9592111_5 80 89
routes 9592111_5 90 96
( 9592111_5 97 98
intraperitoneal 9592111_5 99 114
vs 9592111_5 115 117
intragastric 9592111_5 118 130
) 9592111_5 131 132
, 9592111_5 133 134
we 9592111_5 135 137
noted 9592111_5 138 143
a 9592111_5 144 145
difference 9592111_5 146 156
in 9592111_5 157 159
the 9592111_5 160 163
time 9592111_5 164 168
course 9592111_5 169 175
of 9592111_5 176 178
NGFI 9592111_5 179 183
- 9592111_5 183 184
B 9592111_5 184 185
mRNA 9592111_5 186 190
expression 9592111_5 191 201
in 9592111_5 202 204
the 9592111_5 205 208
pPVN 9592111_5 209 213
, 9592111_5 214 215
despite 9592111_5 216 223
comparable 9592111_5 224 234
dynamics 9592111_5 235 243
in 9592111_5 244 246
ACTH 9592111_5 247 251
secretion 9592111_5 252 261
. 9592111_5 262 263

A 17286538_5 0 1
reduction 17286538_5 2 11
in 17286538_5 12 14
CYP 17286538_5 15 18
2 17286538_5 18 19
A 17286538_5 19 20
6 17286538_5 20 21
activity 17286538_5 22 30
will 17286538_5 31 35
lead 17286538_5 36 40
to 17286538_5 41 43
shunting 17286538_5 44 52
of 17286538_5 53 55
coumarin 17286538_5 56 64
into 17286538_5 65 69
other 17286538_5 70 75
metabolic 17286538_5 76 85
pathways 17286538_5 86 94
. 17286538_5 95 96

In 21457551_10 0 2
postmenopausal 21457551_10 3 17
women 21457551_10 18 23
who 21457551_10 24 27
were 21457551_10 28 32
using 21457551_10 33 38
combined 21457551_10 39 47
estrogen 21457551_10 48 56
- 21457551_10 57 58
progestin 21457551_10 59 68
therapy 21457551_10 69 76
( 21457551_10 77 78
EPT 21457551_10 79 82
) 21457551_10 83 84
at 21457551_10 85 87
cohort 21457551_10 88 94
enrollment 21457551_10 95 105
, 21457551_10 106 107
the 21457551_10 108 111
OR 21457551_10 112 114
of 21457551_10 115 117
breast 21457551_10 118 124
cancer 21457551_10 125 131
was 21457551_10 132 135
2 21457551_10 136 137
. 21457551_10 137 138
31 21457551_10 138 140
( 21457551_10 141 142
95 21457551_10 143 145
% 21457551_10 146 147
CI 21457551_10 148 150
= 21457551_10 151 152
1 21457551_10 153 154
. 21457551_10 154 155
47 21457551_10 155 157
- 21457551_10 157 158
3 21457551_10 158 159
. 21457551_10 160 161
62 21457551_10 161 163
) 21457551_10 164 165
per 21457551_10 166 169
minor 21457551_10 170 175
allele 21457551_10 176 182
of 21457551_10 183 185
rs 21457551_10 186 188
4149013 21457551_10 188 195
in 21457551_10 196 198
SLCO 21457551_10 199 203
1 21457551_10 203 204
B 21457551_10 204 205
1 21457551_10 205 206
( 21457551_10 207 208
P 21457551_10 209 210
= 21457551_10 211 212
0 21457551_10 213 214
. 21457551_10 214 215
0003 21457551_10 215 219
; 21457551_10 220 221
within 21457551_10 222 228
- 21457551_10 228 229
gene 21457551_10 229 233
PACT 21457551_10 234 238
= 21457551_10 239 240
0 21457551_10 241 242
. 21457551_10 242 243
002 21457551_10 243 246
; 21457551_10 247 248
overall 21457551_10 249 256
PACT 21457551_10 257 261
= 21457551_10 262 263
0 21457551_10 264 265
. 21457551_10 265 266
023 21457551_10 266 269
) 21457551_10 270 271
. 21457551_10 272 273

In 24598368_5 0 2
2011 24598368_5 3 7
, 24598368_5 8 9
regulatory 24598368_5 10 20
entities 24598368_5 21 29
granted 24598368_5 30 37
conditional 24598368_5 38 49
approval 24598368_5 50 58
to 24598368_5 59 61
an 24598368_5 62 64
anaplastic 24598368_5 65 75
lymphoma 24598368_5 76 84
kinase 24598368_5 85 91
inhibitor 24598368_5 92 101
( 24598368_5 102 103
crizotinib 24598368_5 104 114
) 24598368_5 115 116
based 24598368_5 117 122
on 24598368_5 123 125
an 24598368_5 126 128
impressive 24598368_5 129 139
overall 24598368_5 140 147
response 24598368_5 148 156
rate 24598368_5 157 161
in 24598368_5 162 164
previously 24598368_5 165 175
treated 24598368_5 176 183
non 24598368_5 184 187
- 24598368_5 187 188
small 24598368_5 188 193
cell 24598368_5 194 198
lung 24598368_5 199 203
cancer 24598368_5 204 210
patients 24598368_5 211 219
whose 24598368_5 220 225
tumors 24598368_5 226 232
harbored 24598368_5 233 241
EML 24598368_5 242 245
4 24598368_5 245 246
/ 24598368_5 247 248
ALK 24598368_5 249 252
translocations 24598368_5 253 267
. 24598368_5 268 269

Effects 20136445_1 0 7
of 20136445_1 8 10
various 20136445_1 11 18
polyphenolics 20136445_1 19 32
on 20136445_1 33 35
hydrogen 20136445_1 36 44
peroxide 20136445_1 45 53
- 20136445_1 54 55
induced 20136445_1 55 62
p 20136445_1 63 64
53 20136445_1 64 66
activity 20136445_1 67 75
in 20136445_1 76 78
NIH 20136445_1 79 82
3 20136445_1 82 83
T 20136445_1 83 84
3 20136445_1 84 85
cells 20136445_1 86 91
. 20136445_1 92 93

METHODS 26743855_3 0 7
: 26743855_3 8 9
From 26743855_3 10 14
2006 26743855_3 15 19
to 26743855_3 20 22
2013 26743855_3 23 27
, 26743855_3 28 29
we 26743855_3 30 32
retrospectively 26743855_3 33 48
screened 26743855_3 49 57
104 26743855_3 58 61
unresectable 26743855_3 62 74
stage 26743855_3 75 80
III 26743855_3 81 84
adenocarcinoma 26743855_3 85 99
patients 26743855_3 100 108
who 26743855_3 109 112
were 26743855_3 113 117
examined 26743855_3 118 126
for 26743855_3 127 130
EGFR 26743855_3 131 135
mutation 26743855_3 136 144
status 26743855_3 145 151
and 26743855_3 152 155
received 26743855_3 156 164
definitive 26743855_3 165 175
concurrent 26743855_3 176 186
CRT 26743855_3 187 190
consisting 26743855_3 191 201
of 26743855_3 202 204
platinum 26743855_3 205 213
doublet 26743855_3 214 221
chemotherapy 26743855_3 222 234
in 26743855_3 235 237
first 26743855_3 238 243
- 26743855_3 243 244
line 26743855_3 244 248
setting 26743855_3 249 256
and 26743855_3 257 260
compared 26743855_3 261 269
the 26743855_3 270 273
clinical 26743855_3 274 282
outcomes 26743855_3 283 291
and 26743855_3 292 295
recurrence 26743855_3 296 306
patterns 26743855_3 307 315
according 26743855_3 316 325
to 26743855_3 326 328
mutation 26743855_3 329 337
status 26743855_3 338 344
. 26743855_3 345 346

DISCUSSION 15010519_9 0 10
: 15010519_9 11 12
Lansoprazole 15010519_9 13 25
is 15010519_9 26 28
metabolized 15010519_9 29 40
by 15010519_9 41 43
2 15010519_9 44 45
enzymes 15010519_9 46 53
, 15010519_9 54 55
CYP 15010519_9 56 59
2 15010519_9 59 60
C 15010519_9 60 61
19 15010519_9 61 63
and 15010519_9 64 67
CYP 15010519_9 68 71
3 15010519_9 71 72
A 15010519_9 72 73
4 15010519_9 73 74
. 15010519_9 75 76

Protective 20172524_1 0 10
effects 20172524_1 11 18
of 20172524_1 19 21
magnesium 20172524_1 22 31
lithospermate 20172524_1 32 45
B 20172524_1 46 47
against 20172524_1 48 55
diabetic 20172524_1 56 64
atherosclerosis 20172524_1 65 80
via 20172524_1 81 84
Nrf 20172524_1 85 88
2 20172524_1 88 89
- 20172524_1 90 91
ARE 20172524_1 91 94
- 20172524_1 94 95
NQO 20172524_1 96 99
1 20172524_1 99 100
transcriptional 20172524_1 101 116
pathway 20172524_1 117 124
. 20172524_1 125 126

There 19127598_11 0 5
were 19127598_11 6 10
significant 19127598_11 11 22
correlations 19127598_11 23 35
between 19127598_11 36 43
COX 19127598_11 44 47
- 19127598_11 47 48
2 19127598_11 48 49
mRNA 19127598_11 50 54
suppression 19127598_11 55 66
, 19127598_11 67 68
p 19127598_11 69 70
21 19127598_11 70 72
mRNA 19127598_11 73 77
stimulation 19127598_11 78 89
and 19127598_11 90 93
serum 19127598_11 94 99
isoflavone 19127598_11 100 110
levels 19127598_11 111 117
. 19127598_11 118 119

MUC 11561767_10 0 3
1 11561767_10 3 4
levels 11561767_10 5 11
in 11561767_10 12 14
primary 11561767_10 15 22
tumours 11561767_10 23 30
treated 11561767_10 31 38
neoadjunctively 11561767_10 39 54
with 11561767_10 55 59
3 11561767_10 60 61
weeks 11561767_10 62 67
of 11561767_10 68 70
tamoxifen 11561767_10 71 80
were 11561767_10 81 85
lower 11561767_10 86 91
than 11561767_10 92 96
a 11561767_10 97 98
comparison 11561767_10 99 109
group 11561767_10 110 115
which 11561767_10 116 121
did 11561767_10 122 125
not 11561767_10 126 129
receive 11561767_10 130 137
tamoxifen 11561767_10 138 147
. 11561767_10 148 149

Since 26402671_3 0 5
then 26402671_3 6 10
, 26402671_3 11 12
several 26402671_3 13 20
studies 26402671_3 21 28
have 26402671_3 29 33
investigated 26402671_3 34 46
the 26402671_3 47 50
role 26402671_3 51 55
of 26402671_3 56 58
genes 26402671_3 59 64
, 26402671_3 65 66
their 26402671_3 67 72
variants 26402671_3 73 81
( 26402671_3 82 83
i 26402671_3 84 85
. 26402671_3 85 86
e 26402671_3 86 87
. 26402671_3 87 88
, 26402671_3 89 90
polymorphisms 26402671_3 91 104
) 26402671_3 105 106
and 26402671_3 107 110
their 26402671_3 111 116
encoded 26402671_3 117 124
proteins 26402671_3 125 133
in 26402671_3 134 136
the 26402671_3 137 140
pharmacokinetics 26402671_3 141 157
and 26402671_3 158 161
pharmacodynamics 26402671_3 162 178
of 26402671_3 179 181
BCR 26402671_3 182 185
- 26402671_3 186 187
ABL 26402671_3 188 191
1 26402671_3 192 193
tyrosine 26402671_3 194 202
kinase 26402671_3 203 209
activity 26402671_3 210 218
inhibitors 26402671_3 219 229
( 26402671_3 230 231
TKIs 26402671_3 232 236
) 26402671_3 237 238
. 26402671_3 239 240

CONCLUSIONS 12005453_12 0 11
: 12005453_12 12 13
In 12005453_12 14 16
a 12005453_12 17 18
rat 12005453_12 19 22
model 12005453_12 23 28
of 12005453_12 29 31
TPN 12005453_12 32 35
, 12005453_12 36 37
the 12005453_12 38 41
use 12005453_12 42 45
of 12005453_12 46 48
9 12005453_12 49 50
mmol 12005453_12 51 55
/ 12005453_12 55 56
L 12005453_12 56 57
butyrate 12005453_12 58 66
did 12005453_12 67 70
not 12005453_12 71 74
have 12005453_12 75 79
the 12005453_12 80 83
same 12005453_12 84 88
effect 12005453_12 89 95
on 12005453_12 96 98
GLUT 12005453_12 99 103
2 12005453_12 103 104
and 12005453_12 105 108
proglucagon 12005453_12 109 120
expression 12005453_12 121 131
as 12005453_12 132 134
a 12005453_12 135 136
60 12005453_12 137 139
- 12005453_12 139 140
mmol 12005453_12 140 144
/ 12005453_12 144 145
L 12005453_12 145 146
mixture 12005453_12 147 154
of 12005453_12 155 157
SCFAs 12005453_12 158 163
. 12005453_12 164 165

In 21639946_8 0 2
our 21639946_8 3 6
study 21639946_8 7 12
population 21639946_8 13 23
, 21639946_8 24 25
no 21639946_8 26 28
significant 21639946_8 29 40
correlation 21639946_8 41 52
could 21639946_8 53 58
be 21639946_8 59 61
detected 21639946_8 62 70
between 21639946_8 71 78
CYP 21639946_8 79 82
2 21639946_8 82 83
C 21639946_8 83 84
9 21639946_8 84 85
* 21639946_8 86 87
3 21639946_8 88 89
, 21639946_8 90 91
CYP 21639946_8 92 95
2 21639946_8 95 96
C 21639946_8 96 97
9 21639946_8 97 98
C 21639946_8 99 100
- 21639946_8 100 101
65 21639946_8 101 103
( 21639946_8 104 105
rs 21639946_8 106 108
9332127 21639946_8 108 115
) 21639946_8 116 117
, 21639946_8 118 119
CYP 21639946_8 120 123
4 21639946_8 123 124
F 21639946_8 124 125
2 21639946_8 125 126
rs 21639946_8 127 129
2108622 21639946_8 129 136
, 21639946_8 137 138
GGCX 21639946_8 139 143
rs 21639946_8 144 146
12714145 21639946_8 146 154
, 21639946_8 155 156
EPHX 21639946_8 157 161
1 21639946_8 161 162
rs 21639946_8 163 165
4653436 21639946_8 165 172
and 21639946_8 173 176
PROC 21639946_8 177 181
rs 21639946_8 182 184
1799809 21639946_8 184 191
with 21639946_8 192 196
warfarin 21639946_8 197 205
sensitivity 21639946_8 206 217
. 21639946_8 218 219

Common 15900282_1 0 6
genetic 15900282_1 7 14
variants 15900282_1 15 23
of 15900282_1 24 26
microsomal 15900282_1 27 37
epoxide 15900282_1 38 45
hydrolase 15900282_1 46 55
affect 15900282_1 56 62
warfarin 15900282_1 63 71
dose 15900282_1 72 76
requirements 15900282_1 77 89
beyond 15900282_1 90 96
the 15900282_1 97 100
effect 15900282_1 101 107
of 15900282_1 108 110
cytochrome 15900282_1 111 121
P 15900282_1 122 123
450 15900282_1 123 126
2 15900282_1 127 128
C 15900282_1 128 129
9 15900282_1 129 130
. 15900282_1 131 132

We 16759339_3 0 2
analyzed 16759339_3 3 11
the 16759339_3 12 15
- 16759339_3 16 17
141 16759339_3 17 20
C 16759339_3 21 22
Ins 16759339_3 23 26
/ 16759339_3 26 27
Del 16759339_3 27 30
polymorphism 16759339_3 31 43
in 16759339_3 44 46
the 16759339_3 47 50
promoter 16759339_3 51 59
region 16759339_3 60 66
of 16759339_3 67 69
the 16759339_3 70 73
DRD 16759339_3 74 77
2 16759339_3 77 78
gene 16759339_3 79 83
and 16759339_3 84 87
the 16759339_3 88 91
Ser 16759339_3 92 95
9 16759339_3 95 96
Gly 16759339_3 96 99
( 16759339_3 100 101
BalI 16759339_3 102 106
) 16759339_3 107 108
polymorphism 16759339_3 109 121
in 16759339_3 122 124
exon 16759339_3 125 129
1 16759339_3 130 131
of 16759339_3 132 134
the 16759339_3 135 138
DRD 16759339_3 139 142
3 16759339_3 142 143
gene 16759339_3 144 148
in 16759339_3 149 151
74 16759339_3 152 154
alcohol 16759339_3 155 162
- 16759339_3 163 164
dependent 16759339_3 164 173
Caucasian 16759339_3 174 183
men 16759339_3 184 187
with 16759339_3 188 192
or 16759339_3 193 195
without 16759339_3 196 203
genetic 16759339_3 204 211
predisposition 16759339_3 212 226
for 16759339_3 227 230
alcoholism 16759339_3 231 241
. 16759339_3 242 243

These 26437921_9 0 5
genetic 26437921_9 6 13
variants 26437921_9 14 22
were 26437921_9 23 27
not 26437921_9 28 31
significantly 26437921_9 32 45
associated 26437921_9 46 56
with 26437921_9 57 61
continued 26437921_9 62 71
opioid 26437921_9 72 78
use 26437921_9 79 82
while 26437921_9 83 88
on 26437921_9 89 91
methadone 26437921_9 92 101
maintenance 26437921_9 102 113
treatment 26437921_9 114 123
[ 26437921_9 124 125
rs 26437921_9 126 128
6265 26437921_9 128 132
: 26437921_9 133 134
odds 26437921_9 135 139
ratio 26437921_9 140 145
( 26437921_9 146 147
OR 26437921_9 148 150
) 26437921_9 151 152
= 26437921_9 153 154
1 26437921_9 155 156
. 26437921_9 156 157
37 26437921_9 157 159
, 26437921_9 160 161
95 26437921_9 162 164
% 26437921_9 165 166
confidence 26437921_9 167 177
interval 26437921_9 178 186
( 26437921_9 187 188
CI 26437921_9 189 191
) 26437921_9 192 193
= 26437921_9 194 195
0 26437921_9 196 197
. 26437921_9 197 198
792 26437921_9 198 201
, 26437921_9 202 203
2 26437921_9 204 205
. 26437921_9 205 206
371 26437921_9 206 209
, 26437921_9 210 211
p 26437921_9 212 213
= 26437921_9 214 215
0 26437921_9 216 217
. 26437921_9 217 218
264 26437921_9 218 221
; 26437921_9 222 223
rs 26437921_9 224 226
1799978 26437921_9 226 233
: 26437921_9 234 235
OR 26437921_9 236 238
1 26437921_9 239 240
. 26437921_9 240 241
27 26437921_9 241 243
, 26437921_9 244 245
95 26437921_9 246 248
% 26437921_9 249 250
CI 26437921_9 251 253
0 26437921_9 254 255
. 26437921_9 255 256
511 26437921_9 256 259
, 26437921_9 260 261
3 26437921_9 262 263
. 26437921_9 263 264
182 26437921_9 264 267
, 26437921_9 268 269
p 26437921_9 270 271
= 26437921_9 272 273
0 26437921_9 274 275
. 26437921_9 275 276
603 26437921_9 276 279
] 26437921_9 280 281
. 26437921_9 282 283

VKORC 26167638_1 0 5
1 26167638_1 5 6
- 26167638_1 7 8
1639 26167638_1 9 13
G 26167638_1 13 14
/ 26167638_1 14 15
A 26167638_1 15 16
and 26167638_1 17 20
1173 26167638_1 21 25
C 26167638_1 26 27
/ 26167638_1 27 28
T 26167638_1 28 29
Genetic 26167638_1 30 37
Polymorphisms 26167638_1 38 51
Influence 26167638_1 52 61
Individual 26167638_1 62 72
Differences 26167638_1 73 84
in 26167638_1 85 87
Warfarin 26167638_1 88 96
Maintenance 26167638_1 97 108
Dose 26167638_1 109 113
. 26167638_1 114 115

RESULTS 16815314_8 0 7
: 16815314_8 8 9
The 16815314_8 10 13
descent 16815314_8 14 21
of 16815314_8 22 24
systolic 16815314_8 25 33
blood 16815314_8 34 39
pressure 16815314_8 40 48
after 16815314_8 49 54
metoprolol 16815314_8 55 65
administration 16815314_8 66 80
was 16815314_8 81 84
significantly 16815314_8 85 98
different 16815314_8 99 108
among 16815314_8 109 114
genotype 16815314_8 115 123
groups 16815314_8 124 130
( 16815314_8 131 132
10 16815314_8 133 135
. 16815314_8 135 136
4 16815314_8 136 137
% 16815314_8 138 139
+ 16815314_8 140 141
/ 16815314_8 142 143
- 16815314_8 144 145
4 16815314_8 146 147
. 16815314_8 147 148
0 16815314_8 148 149
% 16815314_8 150 151
, 16815314_8 152 153
2 16815314_8 154 155
. 16815314_8 155 156
8 16815314_8 156 157
% 16815314_8 158 159
+ 16815314_8 160 161
/ 16815314_8 162 163
- 16815314_8 164 165
4 16815314_8 166 167
. 16815314_8 167 168
7 16815314_8 168 169
% 16815314_8 170 171
, 16815314_8 172 173
and 16815314_8 174 177
1 16815314_8 178 179
. 16815314_8 179 180
1 16815314_8 180 181
% 16815314_8 182 183
+ 16815314_8 184 185
/ 16815314_8 186 187
- 16815314_8 188 189
1 16815314_8 190 191
. 16815314_8 191 192
5 16815314_8 192 193
% 16815314_8 194 195
for 16815314_8 196 199
Arg 16815314_8 200 203
389 16815314_8 203 206
Arg 16815314_8 206 209
, 16815314_8 210 211
Gly 16815314_8 212 215
389 16815314_8 215 218
Arg 16815314_8 218 221
, 16815314_8 222 223
and 16815314_8 224 227
Gly 16815314_8 228 231
389 16815314_8 231 234
Gly 16815314_8 234 237
patients 16815314_8 238 246
, 16815314_8 247 248
respectively 16815314_8 249 261
; 16815314_8 262 263
P 16815314_8 264 265
< 16815314_8 266 267
. 16815314_8 268 269
001 16815314_8 269 272
) 16815314_8 273 274
. 16815314_8 275 276

CONCLUSION 24120259_13 0 10
: 24120259_13 11 12
Determination 24120259_13 13 26
of 24120259_13 27 29
the 24120259_13 30 33
CYP 24120259_13 34 37
3 24120259_13 37 38
A 24120259_13 38 39
5 24120259_13 39 40
genotype 24120259_13 41 49
would 24120259_13 50 55
be 24120259_13 56 58
helpful 24120259_13 59 66
in 24120259_13 67 69
the 24120259_13 70 73
design 24120259_13 74 80
of 24120259_13 81 83
adequate 24120259_13 84 92
immunosuppressive 24120259_13 93 110
treatment 24120259_13 111 120
and 24120259_13 121 124
in 24120259_13 125 127
lowering 24120259_13 128 136
toxicity 24120259_13 137 145
by 24120259_13 146 148
predicting 24120259_13 149 159
the 24120259_13 160 163
doses 24120259_13 164 169
of 24120259_13 170 172
tacrolimus 24120259_13 173 183
required 24120259_13 184 192
for 24120259_13 193 196
the 24120259_13 197 200
induction 24120259_13 201 210
and 24120259_13 211 214
maintenance 24120259_13 215 226
phases 24120259_13 227 233
in 24120259_13 234 236
individual 24120259_13 237 247
kidney 24120259_13 248 254
transplant 24120259_13 255 265
recipients 24120259_13 266 276
. 24120259_13 277 278

The 17667795_9 0 3
authors 17667795_9 4 11
found 17667795_9 12 17
a 17667795_9 18 19
clear 17667795_9 20 25
correlation 17667795_9 26 37
between 17667795_9 38 45
haloperidol 17667795_9 46 57
plasma 17667795_9 58 64
concentration 17667795_9 65 78
and 17667795_9 79 82
number 17667795_9 83 89
of 17667795_9 90 92
active 17667795_9 93 99
CYP 17667795_9 100 103
2 17667795_9 103 104
D 17667795_9 104 105
6 17667795_9 105 106
alleles 17667795_9 107 114
. 17667795_9 115 116

In 21118736_18 0 2
homozygous 21118736_18 3 13
CYP 21118736_18 14 17
3 21118736_18 17 18
A 21118736_18 18 19
5 21118736_18 19 20
* 21118736_18 21 22
3 21118736_18 23 24
carriers 21118736_18 25 33
( 21118736_18 34 35
n 21118736_18 36 37
= 21118736_18 38 39
252 21118736_18 40 43
) 21118736_18 44 45
, 21118736_18 46 47
mean 21118736_18 48 52
( 21118736_18 53 54
SD 21118736_18 55 57
) 21118736_18 58 59
tacrolimus 21118736_18 60 70
dose 21118736_18 71 75
requirements 21118736_18 76 88
remained 21118736_18 89 97
significantly 21118736_18 98 111
lower 21118736_18 112 117
during 21118736_18 118 124
DGF 21118736_18 125 128
, 21118736_18 129 130
while 21118736_18 131 136
in 21118736_18 137 139
CYP 21118736_18 140 143
3 21118736_18 143 144
A 21118736_18 144 145
5 21118736_18 145 146
* 21118736_18 147 148
1 21118736_18 149 150
carriers 21118736_18 151 159
with 21118736_18 160 164
DGF 21118736_18 165 168
( 21118736_18 169 170
n 21118736_18 171 172
= 21118736_18 173 174
52 21118736_18 175 177
) 21118736_18 178 179
, 21118736_18 180 181
lower 21118736_18 182 187
mean 21118736_18 188 192
dose 21118736_18 193 197
requirements 21118736_18 198 210
were 21118736_18 211 215
observed 21118736_18 216 224
only 21118736_18 225 229
after 21118736_18 230 235
postoperative 21118736_18 236 249
day 21118736_18 250 253
4 21118736_18 254 255
. 21118736_18 256 257

CONCLUSION 25695221_15 0 10
: 25695221_15 11 12
: 25695221_15 13 14
Gefitinib 25695221_15 15 24
in 25695221_15 25 27
combination 25695221_15 28 39
with 25695221_15 40 44
bevacizumab 25695221_15 45 56
as 25695221_15 57 59
first 25695221_15 60 65
- 25695221_15 65 66
line 25695221_15 66 70
therapy 25695221_15 71 78
seems 25695221_15 79 84
to 25695221_15 85 87
be 25695221_15 88 90
a 25695221_15 91 92
favorable 25695221_15 93 102
and 25695221_15 103 106
well 25695221_15 107 111
- 25695221_15 111 112
tolerated 25695221_15 112 121
treatment 25695221_15 122 131
for 25695221_15 132 135
patients 25695221_15 136 144
with 25695221_15 145 149
advanced 25695221_15 150 158
NSCLC 25695221_15 159 164
with 25695221_15 165 169
activating 25695221_15 170 180
EGFR 25695221_15 181 185
gene 25695221_15 186 190
mutations 25695221_15 191 200
, 25695221_15 201 202
especially 25695221_15 203 213
those 25695221_15 214 219
with 25695221_15 220 224
EGFR 25695221_15 225 229
exon 25695221_15 230 234
19 25695221_15 235 237
deletion 25695221_15 238 246
mutations 25695221_15 247 256
, 25695221_15 257 258
although 25695221_15 259 267
the 25695221_15 268 271
primary 25695221_15 272 279
end 25695221_15 280 283
point 25695221_15 284 289
was 25695221_15 290 293
not 25695221_15 294 297
met 25695221_15 298 301
because 25695221_15 302 309
the 25695221_15 310 313
lower 25695221_15 314 319
limit 25695221_15 320 325
of 25695221_15 326 328
the 25695221_15 329 332
CI 25695221_15 333 335
was 25695221_15 336 339
less 25695221_15 340 344
than 25695221_15 345 349
40 25695221_15 350 352
% 25695221_15 353 354
. 25695221_15 355 356

Association 25877443_1 0 11
of 25877443_1 12 14
HLA 25877443_1 15 18
- 25877443_1 18 19
B 25877443_1 19 20
* 25877443_1 21 22
5701 25877443_1 23 27
genotypes 25877443_1 28 37
and 25877443_1 38 41
abacavir 25877443_1 42 50
- 25877443_1 51 52
induced 25877443_1 52 59
hypersensitivity 25877443_1 60 76
reaction 25877443_1 77 85
: 25877443_1 86 87
a 25877443_1 88 89
systematic 25877443_1 90 100
review 25877443_1 101 107
and 25877443_1 108 111
meta 25877443_1 112 116
- 25877443_1 116 117
analysis 25877443_1 117 125
. 25877443_1 126 127

TPMT 23962279_13 0 4
testing 23962279_13 5 12
is 23962279_13 13 15
cost 23962279_13 16 20
- 23962279_13 20 21
effective 23962279_13 21 30
and 23962279_13 31 34
the 23962279_13 35 38
major 23962279_13 39 44
role 23962279_13 45 49
is 23962279_13 50 52
in 23962279_13 53 55
the 23962279_13 56 59
identification 23962279_13 60 74
of 23962279_13 75 77
the 23962279_13 78 81
TPMT 23962279_13 82 86
deficient 23962279_13 87 96
individual 23962279_13 97 107
prior 23962279_13 108 113
to 23962279_13 114 116
the 23962279_13 117 120
start 23962279_13 121 126
of 23962279_13 127 129
thiopurine 23962279_13 130 140
drugs 23962279_13 141 146
. 23962279_13 147 148

This 12563177_9 0 4
combination 12563177_9 5 16
of 12563177_9 17 19
R 12563177_9 20 21
and 12563177_9 22 25
L 12563177_9 26 27
genotypes 12563177_9 28 37
was 12563177_9 38 41
associated 12563177_9 42 52
with 12563177_9 53 57
lower 12563177_9 58 63
PON 12563177_9 64 67
1 12563177_9 67 68
activity 12563177_9 69 77
towards 12563177_9 78 85
diazoxon 12563177_9 86 94
in 12563177_9 95 97
both 12563177_9 98 102
cases 12563177_9 103 108
and 12563177_9 109 112
controls 12563177_9 113 121
. 12563177_9 122 123

Oral 23982599_5 0 4
afatinib 23982599_5 5 13
( 23982599_5 14 15
Gilotrif 23982599_5 16 24
) 23982599_5 25 26
has 23982599_5 27 30
been 23982599_5 31 35
approved 23982599_5 36 44
in 23982599_5 45 47
the 23982599_5 48 51
US 23982599_5 52 54
for 23982599_5 55 58
the 23982599_5 59 62
first 23982599_5 63 68
- 23982599_5 68 69
line 23982599_5 69 73
treatment 23982599_5 74 83
of 23982599_5 84 86
patients 23982599_5 87 95
with 23982599_5 96 100
metastatic 23982599_5 101 111
non 23982599_5 112 115
- 23982599_5 115 116
small 23982599_5 116 121
- 23982599_5 121 122
cell 23982599_5 122 126
lung 23982599_5 127 131
cancer 23982599_5 132 138
( 23982599_5 139 140
NSCLC 23982599_5 141 146
) 23982599_5 147 148
who 23982599_5 149 152
have 23982599_5 153 157
tumours 23982599_5 158 165
with 23982599_5 166 170
EGFR 23982599_5 171 175
exon 23982599_5 176 180
19 23982599_5 181 183
deletions 23982599_5 184 193
or 23982599_5 194 196
exon 23982599_5 197 201
21 23982599_5 202 204
( 23982599_5 205 206
L 23982599_5 207 208
858 23982599_5 208 211
R 23982599_5 211 212
) 23982599_5 213 214
substitution 23982599_5 215 227
mutations 23982599_5 228 237
as 23982599_5 238 240
detected 23982599_5 241 249
by 23982599_5 250 252
a 23982599_5 253 254
US 23982599_5 255 257
FDA 23982599_5 258 261
- 23982599_5 261 262
approved 23982599_5 262 270
test 23982599_5 271 275
. 23982599_5 276 277

We 10945855_3 0 2
demonstrate 10945855_3 3 14
that 10945855_3 15 19
p 10945855_3 20 21
- 10945855_3 21 22
fluorofentanyl 10945855_3 22 36
more 10945855_3 37 41
potently 10945855_3 42 50
activates 10945855_3 51 60
GIRK 10945855_3 61 65
1 10945855_3 65 66
/ 10945855_3 67 68
GIRK 10945855_3 69 73
2 10945855_3 73 74
channels 10945855_3 75 83
through 10945855_3 84 91
opioid 10945855_3 92 98
receptors 10945855_3 99 108
than 10945855_3 109 113
fentanyl 10945855_3 114 122
and 10945855_3 123 126
that 10945855_3 127 131
the 10945855_3 132 135
p 10945855_3 136 137
- 10945855_3 137 138
fluoro 10945855_3 138 144
substitution 10945855_3 145 157
also 10945855_3 158 162
changes 10945855_3 163 170
the 10945855_3 171 174
potency 10945855_3 175 182
profile 10945855_3 183 190
from 10945855_3 191 195
mu 10945855_3 196 198
> 10945855_3 199 200
kappa 10945855_3 201 206
> 10945855_3 207 208
delta 10945855_3 209 214
( 10945855_3 215 216
fentanyl 10945855_3 217 225
) 10945855_3 226 227
to 10945855_3 228 230
mu 10945855_3 231 233
> 10945855_3 234 235
delta 10945855_3 236 241
> 10945855_3 242 243
or 10945855_3 244 246
= 10945855_3 247 248
kappa 10945855_3 249 254
( 10945855_3 255 256
p 10945855_3 257 258
- 10945855_3 258 259
fluorofentanyl 10945855_3 260 274
) 10945855_3 275 276
. 10945855_3 277 278

In 17851539_6 0 2
the 17851539_6 3 6
second 17851539_6 7 13
experiment 17851539_6 14 24
, 17851539_6 25 26
c 17851539_6 27 28
- 17851539_6 28 29
Fos 17851539_6 29 32
activation 17851539_6 33 43
after 17851539_6 44 49
reinstatement 17851539_6 50 63
of 17851539_6 64 66
ethanol 17851539_6 67 74
seeking 17851539_6 75 82
induced 17851539_6 83 90
by 17851539_6 91 93
discrete 17851539_6 94 102
cues 17851539_6 103 107
was 17851539_6 108 111
compared 17851539_6 112 120
with 17851539_6 121 125
the 17851539_6 126 129
activation 17851539_6 130 140
pattern 17851539_6 141 148
of 17851539_6 149 151
its 17851539_6 152 155
putative 17851539_6 156 164
partner 17851539_6 165 172
( 17851539_6 173 174
c 17851539_6 175 176
- 17851539_6 176 177
Jun 17851539_6 177 180
) 17851539_6 181 182
and 17851539_6 183 186
regulators 17851539_6 187 197
( 17851539_6 198 199
extracellular 17851539_6 200 213
signal 17851539_6 214 220
- 17851539_6 220 221
regulated 17851539_6 221 230
kinases 17851539_6 231 238
and 17851539_6 239 242
c 17851539_6 243 244
- 17851539_6 244 245
Jun 17851539_6 245 248
N 17851539_6 249 250
- 17851539_6 251 252
terminal 17851539_6 252 260
kinases 17851539_6 261 268
) 17851539_6 269 270
. 17851539_6 271 272

In 20079691_13 0 2
view 20079691_13 3 7
of 20079691_13 8 10
the 20079691_13 11 14
location 20079691_13 15 23
of 20079691_13 24 26
HER 20079691_13 27 30
2 20079691_13 30 31
/ 20079691_13 32 33
TOP 20079691_13 34 37
2 20079691_13 37 38
A 20079691_13 38 39
on 20079691_13 40 42
chromosome 20079691_13 43 53
17 20079691_13 54 56
, 20079691_13 57 58
Ch 20079691_13 59 61
17 20079691_13 61 63
CEP 20079691_13 63 66
duplication 20079691_13 67 78
might 20079691_13 79 84
explain 20079691_13 85 92
the 20079691_13 93 96
inconsistencies 20079691_13 97 112
in 20079691_13 113 115
previous 20079691_13 116 124
studies 20079691_13 125 132
of 20079691_13 133 135
factors 20079691_13 136 143
predicting 20079691_13 144 154
benefit 20079691_13 155 162
from 20079691_13 163 167
anthracyclines 20079691_13 168 182
. 20079691_13 183 184

Roles 23012624_1 0 5
of 23012624_1 6 8
ITPA 23012624_1 9 13
and 23012624_1 14 17
IL 23012624_1 18 20
28 23012624_1 20 22
B 23012624_1 22 23
genotypes 23012624_1 24 33
in 23012624_1 34 36
chronic 23012624_1 37 44
hepatitis 23012624_1 45 54
C 23012624_1 55 56
patients 23012624_1 57 65
treated 23012624_1 66 73
with 23012624_1 74 78
peginterferon 23012624_1 79 92
plus 23012624_1 93 97
ribavirin 23012624_1 98 107
. 23012624_1 108 109

IFNL 24672032_3 0 4
3 24672032_3 4 5
( 24672032_3 6 7
lambda 24672032_3 8 14
- 24672032_3 14 15
3 24672032_3 15 16
interferon 24672032_3 17 27
gene 24672032_3 28 32
) 24672032_3 33 34
polymorphisms 24672032_3 35 48
and 24672032_3 49 52
the 24672032_3 53 56
expression 24672032_3 57 67
of 24672032_3 68 70
miR 24672032_3 71 74
- 24672032_3 74 75
122 24672032_3 75 78
have 24672032_3 79 83
been 24672032_3 84 88
associated 24672032_3 89 99
with 24672032_3 100 104
sustained 24672032_3 105 114
virological 24672032_3 115 126
response 24672032_3 127 135
( 24672032_3 136 137
SVR 24672032_3 138 141
) 24672032_3 142 143
to 24672032_3 144 146
treatment 24672032_3 147 156
with 24672032_3 157 161
pegylated 24672032_3 162 171
interferon 24672032_3 172 182
plus 24672032_3 183 187
ribavirin 24672032_3 188 197
in 24672032_3 198 200
patients 24672032_3 201 209
with 24672032_3 210 214
chronic 24672032_3 215 222
hepatitis 24672032_3 223 232
C 24672032_3 233 234
( 24672032_3 235 236
CHC 24672032_3 237 240
) 24672032_3 241 242
. 24672032_3 243 244

EXPERIMENTAL 26341921_8 0 12
DESIGN 26341921_8 13 19
: 26341921_8 20 21
Using 26341921_8 22 27
mouse 26341921_8 28 33
models 26341921_8 34 40
of 26341921_8 41 43
EGFR 26341921_8 44 48
- 26341921_8 49 50
mutant 26341921_8 50 56
lung 26341921_8 57 61
cancer 26341921_8 62 68
, 26341921_8 69 70
we 26341921_8 71 73
tested 26341921_8 74 80
whether 26341921_8 81 88
the 26341921_8 89 92
combination 26341921_8 93 104
of 26341921_8 105 107
afatinib 26341921_8 108 116
plus 26341921_8 117 121
cetuximab 26341921_8 122 131
delivered 26341921_8 132 141
upfront 26341921_8 142 149
to 26341921_8 150 152
mice 26341921_8 153 157
with 26341921_8 158 162
TKI 26341921_8 163 166
- 26341921_8 166 167
na 26341921_8 167 169
ve 26341921_8 170 172
EGFR 26341921_8 173 177
( 26341921_8 178 179
L 26341921_8 180 181
858 26341921_8 181 184
R 26341921_8 184 185
) 26341921_8 186 187
- 26341921_8 188 189
induced 26341921_8 190 197
lung 26341921_8 198 202
adenocarcinomas 26341921_8 203 218
delayed 26341921_8 219 226
tumor 26341921_8 227 232
relapse 26341921_8 233 240
and 26341921_8 241 244
drug 26341921_8 245 249
- 26341921_8 249 250
resistance 26341921_8 250 260
compared 26341921_8 261 269
with 26341921_8 270 274
single 26341921_8 275 281
- 26341921_8 281 282
agent 26341921_8 282 287
TKIs 26341921_8 288 292
. 26341921_8 293 294

Conversely 17963417_12 0 10
, 17963417_12 11 12
carriers 17963417_12 13 21
of 17963417_12 22 24
this 17963417_12 25 29
polymorphism 17963417_12 30 42
also 17963417_12 43 47
had 17963417_12 48 51
a 17963417_12 52 53
higher 17963417_12 54 60
conversion 17963417_12 61 71
to 17963417_12 72 74
diabetes 17963417_12 75 83
mellitus 17963417_12 84 92
when 17963417_12 93 97
treated 17963417_12 98 105
with 17963417_12 106 110
acarbose 17963417_12 111 119
; 17963417_12 120 121
this 17963417_12 122 126
effect 17963417_12 127 133
was 17963417_12 134 137
also 17963417_12 138 142
seen 17963417_12 143 147
in 17963417_12 148 150
adiponectin 17963417_12 151 162
( 17963417_12 163 164
ADIPOQ 17963417_12 165 171
) 17963417_12 172 173
gene 17963417_12 174 178
polymorphism 17963417_12 179 191
carriers 17963417_12 192 200
. 17963417_12 201 202

BACKGROUND 27717041_2 0 10
: 27717041_2 11 12
Alcohol 27717041_2 13 20
use 27717041_2 21 24
disorders 27717041_2 25 34
are 27717041_2 35 38
associated 27717041_2 39 49
with 27717041_2 50 54
single 27717041_2 55 61
- 27717041_2 61 62
nucleotide 27717041_2 62 72
polymorphisms 27717041_2 73 86
in 27717041_2 87 89
GABRA 27717041_2 90 95
2 27717041_2 95 96
, 27717041_2 97 98
the 27717041_2 99 102
gene 27717041_2 103 107
encoding 27717041_2 108 116
the 27717041_2 117 120
GABAA 27717041_2 121 126
receptor 27717041_2 127 135
a 27717041_2 136 137
2 27717041_2 137 138
- 27717041_2 138 139
subunit 27717041_2 139 146
in 27717041_2 147 149
humans 27717041_2 150 156
. 27717041_2 157 158

Simultaneously 19843683_7 0 14
in 19843683_7 15 17
the 19843683_7 18 21
same 19843683_7 22 26
group 19843683_7 27 32
, 19843683_7 33 34
an 19843683_7 35 37
increase 19843683_7 38 46
of 19843683_7 47 49
urinary 19843683_7 50 57
8 19843683_7 58 59
- 19843683_7 59 60
oxoGua 19843683_7 60 66
, 19843683_7 67 68
the 19843683_7 69 72
product 19843683_7 73 80
of 19843683_7 81 83
base 19843683_7 84 88
excision 19843683_7 89 97
repair 19843683_7 98 104
( 19843683_7 105 106
hOGG 19843683_7 107 111
1 19843683_7 111 112
glycosylase 19843683_7 113 124
) 19843683_7 125 126
, 19843683_7 127 128
was 19843683_7 129 132
observed 19843683_7 133 141
. 19843683_7 142 143

We 14635204_12 0 2
conclude 14635204_12 3 11
that 14635204_12 12 16
the 14635204_12 17 20
presence 14635204_12 21 29
of 14635204_12 30 32
recognized 14635204_12 33 43
HFE 14635204_12 44 47
coding 14635204_12 48 54
region 14635204_12 55 61
mutations 14635204_12 62 71
do 14635204_12 72 74
not 14635204_12 75 78
seem 14635204_12 79 83
to 14635204_12 84 86
have 14635204_12 87 91
an 14635204_12 92 94
impact 14635204_12 95 101
on 14635204_12 102 104
the 14635204_12 105 108
degree 14635204_12 109 115
of 14635204_12 116 118
iron 14635204_12 119 123
overload 14635204_12 124 132
in 14635204_12 133 135
patients 14635204_12 136 144
with 14635204_12 145 149
SCD 14635204_12 150 153
receiving 14635204_12 154 163
chronic 14635204_12 164 171
transfusion 14635204_12 172 183
therapy 14635204_12 184 191
. 14635204_12 192 193

The 28258422_9 0 3
adverse 28258422_9 4 11
events 28258422_9 12 18
of 28258422_9 19 21
EGFR 28258422_9 22 26
- 28258422_9 27 28
TKI 28258422_9 28 31
rechallenge 28258422_9 32 43
were 28258422_9 44 48
tolerable 28258422_9 49 58
, 28258422_9 59 60
but 28258422_9 61 64
one 28258422_9 65 68
case 28258422_9 69 73
receiving 28258422_9 74 83
EGFR 28258422_9 84 88
- 28258422_9 89 90
TKI 28258422_9 90 93
rechallenge 28258422_9 94 105
with 28258422_9 106 110
the 28258422_9 111 114
suspected 28258422_9 115 124
drug 28258422_9 125 129
exhibited 28258422_9 130 139
the 28258422_9 140 143
recurrence 28258422_9 144 154
of 28258422_9 155 157
grade 28258422_9 158 163
3 28258422_9 164 165
ILD 28258422_9 166 169
after 28258422_9 170 175
the 28258422_9 176 179
discontinuation 28258422_9 180 195
of 28258422_9 196 198
prednisolone 28258422_9 199 211
. 28258422_9 212 213

In 24265036_2 0 2
tamoxifen 24265036_2 3 12
- 24265036_2 13 14
treated 24265036_2 14 21
breast 24265036_2 22 28
cancer 24265036_2 29 35
patients 24265036_2 36 44
the 24265036_2 45 48
occurrence 24265036_2 49 59
of 24265036_2 60 62
hot 24265036_2 63 66
flashes 24265036_2 67 74
may 24265036_2 75 78
be 24265036_2 79 81
associated 24265036_2 82 92
with 24265036_2 93 97
effective 24265036_2 98 107
estrogen 24265036_2 108 116
receptor 24265036_2 117 125
antagonism 24265036_2 126 136
dependent 24265036_2 137 146
on 24265036_2 147 149
genetic 24265036_2 150 157
variations 24265036_2 158 168
of 24265036_2 169 171
metabolic 24265036_2 172 181
enzymes 24265036_2 182 189
and 24265036_2 190 193
the 24265036_2 194 197
estrogen 24265036_2 198 206
receptor 24265036_2 207 215
. 24265036_2 216 217

Phenytoin 15247556_13 0 9
appears 15247556_13 10 17
to 15247556_13 18 20
increase 15247556_13 21 29
LPV 15247556_13 30 33
clearance 15247556_13 34 43
via 15247556_13 44 47
CYP 15247556_13 48 51
3 15247556_13 51 52
A 15247556_13 52 53
4 15247556_13 53 54
induction 15247556_13 55 64
, 15247556_13 65 66
which 15247556_13 67 72
is 15247556_13 73 75
not 15247556_13 76 79
offset 15247556_13 80 86
by 15247556_13 87 89
the 15247556_13 90 93
presence 15247556_13 94 102
of 15247556_13 103 105
low 15247556_13 106 109
- 15247556_13 109 110
dose 15247556_13 110 114
RTV 15247556_13 115 118
. 15247556_13 119 120

Effects 17042920_1 0 7
of 17042920_1 8 10
genetic 17042920_1 11 18
polymorphisms 17042920_1 19 32
of 17042920_1 33 35
CYP 17042920_1 36 39
3 17042920_1 39 40
A 17042920_1 40 41
4 17042920_1 41 42
, 17042920_1 43 44
CYP 17042920_1 45 48
3 17042920_1 48 49
A 17042920_1 49 50
5 17042920_1 50 51
and 17042920_1 52 55
MDR 17042920_1 56 59
1 17042920_1 59 60
on 17042920_1 61 63
cyclosporine 17042920_1 64 76
pharmacokinetics 17042920_1 77 93
after 17042920_1 94 99
renal 17042920_1 100 105
transplantation 17042920_1 106 121
. 17042920_1 122 123

OBJECTIVE 23394127_3 0 9
: 23394127_3 10 11
To 23394127_3 12 14
investigate 23394127_3 15 26
the 23394127_3 27 30
role 23394127_3 31 35
of 23394127_3 36 38
N 23394127_3 39 40
- 23394127_3 40 41
acetyl 23394127_3 41 47
transferase 23394127_3 48 59
2 23394127_3 60 61
( 23394127_3 62 63
NAT 23394127_3 64 67
2 23394127_3 67 68
) 23394127_3 69 70
and 23394127_3 71 74
cytochrome 23394127_3 75 85
P 23394127_3 86 87
450 23394127_3 87 90
2 23394127_3 91 92
E 23394127_3 92 93
1 23394127_3 93 94
( 23394127_3 95 96
CYP 23394127_3 97 100
2 23394127_3 100 101
E 23394127_3 101 102
1 23394127_3 102 103
) 23394127_3 104 105
in 23394127_3 106 108
the 23394127_3 109 112
hepatotoxicity 23394127_3 113 127
of 23394127_3 128 130
patients 23394127_3 131 139
treated 23394127_3 140 147
with 23394127_3 148 152
INH 23394127_3 153 156
in 23394127_3 157 159
an 23394127_3 160 162
Amazonian 23394127_3 163 172
Brazilian 23394127_3 173 182
population 23394127_3 183 193
. 23394127_3 194 195

Modulation 22297576_10 0 10
of 22297576_10 11 13
5 22297576_10 14 15
- 22297576_10 15 16
HT 22297576_10 16 18
neurons 22297576_10 19 26
in 22297576_10 27 29
the 22297576_10 30 33
dorsalraphe 22297576_10 34 45
nucleus 22297576_10 46 53
by 22297576_10 54 56
GABA 22297576_10 57 61
, 22297576_10 62 63
glutamate 22297576_10 64 73
and 22297576_10 74 77
CRF 22297576_10 78 81
profoundly 22297576_10 82 92
regulate 22297576_10 93 101
aggressive 22297576_10 102 112
behaviors 22297576_10 113 122
. 22297576_10 123 124

JAK 27025877_4 0 3
2 27025877_4 3 4
inhibition 27025877_4 5 15
restored 27025877_4 16 24
sensitivity 27025877_4 25 36
to 27025877_4 37 39
the 27025877_4 40 43
EGFR 27025877_4 44 48
inhibitor 27025877_4 49 58
erlotinib 27025877_4 59 68
in 27025877_4 69 71
TKI 27025877_4 72 75
- 27025877_4 76 77
resistant 27025877_4 77 86
cell 27025877_4 87 91
lines 27025877_4 92 97
and 27025877_4 98 101
xenograft 27025877_4 102 111
models 27025877_4 112 118
of 27025877_4 119 121
EGFR 27025877_4 122 126
- 27025877_4 127 128
mutant 27025877_4 128 134
TKI 27025877_4 135 138
- 27025877_4 139 140
resistant 27025877_4 140 149
lung 27025877_4 150 154
cancer 27025877_4 155 161
. 27025877_4 162 163

G 9654649_8 0 1
- 9654649_8 1 2
Rg 9654649_8 2 4
1 9654649_8 4 5
treatment 9654649_8 6 15
also 9654649_8 16 20
led 9654649_8 21 24
to 9654649_8 25 27
the 9654649_8 28 31
down 9654649_8 32 36
- 9654649_8 36 37
regulation 9654649_8 37 47
of 9654649_8 48 50
intracellular 9654649_8 51 64
GR 9654649_8 65 67
content 9654649_8 68 75
, 9654649_8 76 77
which 9654649_8 78 83
was 9654649_8 84 87
similar 9654649_8 88 95
to 9654649_8 96 98
the 9654649_8 99 102
effect 9654649_8 103 109
of 9654649_8 110 112
Dex 9654649_8 113 116
. 9654649_8 117 118

Salmeterol 17030231_1 0 10
response 17030231_1 11 19
is 17030231_1 20 22
not 17030231_1 23 26
affected 17030231_1 27 35
by 17030231_1 36 38
beta 17030231_1 39 43
2 17030231_1 43 44
- 17030231_1 44 45
adrenergic 17030231_1 45 55
receptor 17030231_1 56 64
genotype 17030231_1 65 73
in 17030231_1 74 76
subjects 17030231_1 77 85
with 17030231_1 86 90
persistent 17030231_1 91 101
asthma 17030231_1 102 108
. 17030231_1 109 110

Scientific 26273667_5 0 10
and 26273667_5 11 14
technological 26273667_5 15 28
advances 26273667_5 29 37
have 26273667_5 38 42
witnessed 26273667_5 43 52
the 26273667_5 53 56
development 26273667_5 57 68
of 26273667_5 69 71
newer 26273667_5 72 77
generation 26273667_5 78 88
of 26273667_5 89 91
drugs 26273667_5 92 97
like 26273667_5 98 102
sulphonylureas 26273667_5 103 117
, 26273667_5 118 119
biguanides 26273667_5 120 130
, 26273667_5 131 132
alpha 26273667_5 133 138
glucosidase 26273667_5 139 150
inhibitors 26273667_5 151 161
, 26273667_5 162 163
and 26273667_5 164 167
thiazolidinediones 26273667_5 168 186
with 26273667_5 187 191
significant 26273667_5 192 203
efficacy 26273667_5 204 212
in 26273667_5 213 215
reducing 26273667_5 216 224
hyperglycemia 26273667_5 225 238
. 26273667_5 239 240

Lack 24841934_9 0 4
of 24841934_9 5 7
folic 24841934_9 8 13
acid 24841934_9 14 18
supplement 24841934_9 19 29
use 24841934_9 30 33
in 24841934_9 34 36
combination 24841934_9 37 48
with 24841934_9 49 53
infants 24841934_9 54 61
or 24841934_9 62 64
mothers 24841934_9 65 72
carrying 24841934_9 73 81
the 24841934_9 82 85
MTHFR 24841934_9 86 91
C 24841934_9 92 93
677 24841934_9 93 96
T 24841934_9 96 97
polymorphism 24841934_9 98 110
did 24841934_9 111 114
not 24841934_9 115 118
seem 24841934_9 119 123
to 24841934_9 124 126
increase 24841934_9 127 135
the 24841934_9 136 139
risk 24841934_9 140 144
of 24841934_9 145 147
ARM 24841934_9 148 151
or 24841934_9 152 154
subgroups 24841934_9 155 164
of 24841934_9 165 167
ARM 24841934_9 168 171
. 24841934_9 172 173

Currently 22741564_4 0 9
, 22741564_4 10 11
thiopurine 22741564_4 12 22
S 22741564_4 23 24
- 22741564_4 24 25
methyltransferase 22741564_4 25 42
( 22741564_4 43 44
TPMT 22741564_4 45 49
) 22741564_4 50 51
deficiency 22741564_4 52 62
is 22741564_4 63 65
the 22741564_4 66 69
only 22741564_4 70 74
pharmacogenetic 22741564_4 75 90
factor 22741564_4 91 97
that 22741564_4 98 102
is 22741564_4 103 105
prospectively 22741564_4 106 119
assessed 22741564_4 120 128
before 22741564_4 129 135
azathioprine 22741564_4 136 148
or 22741564_4 149 151
6 22741564_4 152 153
- 22741564_4 153 154
mercaptopurine 22741564_4 154 168
immunomodulation 22741564_4 169 185
is 22741564_4 186 188
commenced 22741564_4 189 198
in 22741564_4 199 201
patients 22741564_4 202 210
with 22741564_4 211 215
Crohn 22741564_4 216 221
' 22741564_4 221 222
s 22741564_4 222 223
disease 22741564_4 224 231
( 22741564_4 232 233
CD 22741564_4 234 236
) 22741564_4 237 238
. 22741564_4 239 240

Another 12958193_8 0 7
novel 12958193_8 8 13
finding 12958193_8 14 21
is 12958193_8 22 24
hepatic 12958193_8 25 32
induction 12958193_8 33 42
of 12958193_8 43 45
CYP 12958193_8 46 49
3 12958193_8 49 50
a 12958193_8 50 51
13 12958193_8 51 53
by 12958193_8 54 56
dexamethasone 12958193_8 57 70
occurring 12958193_8 71 80
only 12958193_8 81 85
in 12958193_8 86 88
pregnane 12958193_8 89 97
X 12958193_8 98 99
receptor 12958193_8 100 108
null 12958193_8 109 113
mice 12958193_8 114 118
. 12958193_8 119 120

Hydralazine 24702251_4 0 11
is 24702251_4 12 14
metabolized 24702251_4 15 26
by 24702251_4 27 29
the 24702251_4 30 33
highly 24702251_4 34 40
polymorphic 24702251_4 41 52
N 24702251_4 53 54
- 24702251_4 54 55
acetyltransferase 24702251_4 55 72
2 24702251_4 73 74
. 24702251_4 75 76

In 14999690_13 0 2
conclusion 14999690_13 3 13
, 14999690_13 14 15
these 14999690_13 16 21
data 14999690_13 22 26
support 14999690_13 27 34
the 14999690_13 35 38
hypotheses 14999690_13 39 49
that 14999690_13 50 54
hepatocellular 14999690_13 55 69
oxidative 14999690_13 70 79
stress 14999690_13 80 86
leads 14999690_13 87 92
to 14999690_13 93 95
cell 14999690_13 96 100
death 14999690_13 101 106
and 14999690_13 107 110
that 14999690_13 111 115
TNFalpha 14999690_13 116 124
- 14999690_13 125 126
induced 14999690_13 126 133
Ras 14999690_13 134 137
activation 14999690_13 138 148
is 14999690_13 149 151
important 14999690_13 152 161
in 14999690_13 162 164
hepatic 14999690_13 165 172
proliferation 14999690_13 173 186
in 14999690_13 187 189
response 14999690_13 190 198
to 14999690_13 199 201
ethanol 14999690_13 202 209
- 14999690_13 210 211
induced 14999690_13 211 218
liver 14999690_13 219 224
injury 14999690_13 225 231
. 14999690_13 232 233

Knockout 16407894_1 0 8
of 16407894_1 9 11
ERK 16407894_1 12 15
1 16407894_1 15 16
enhances 16407894_1 17 25
cocaine 16407894_1 26 33
- 16407894_1 34 35
evoked 16407894_1 35 41
immediate 16407894_1 42 51
early 16407894_1 52 57
gene 16407894_1 58 62
expression 16407894_1 63 73
and 16407894_1 74 77
behavioral 16407894_1 78 88
plasticity 16407894_1 89 99
. 16407894_1 100 101

Thalidomide 22329352_1 0 11
consolidation 22329352_1 12 25
improves 22329352_1 26 34
progression 22329352_1 35 46
- 22329352_1 46 47
free 22329352_1 47 51
survival 22329352_1 52 60
in 22329352_1 61 63
myeloma 22329352_1 64 71
with 22329352_1 72 76
normal 22329352_1 77 83
but 22329352_1 84 87
not 22329352_1 88 91
up 22329352_1 92 94
- 22329352_1 94 95
regulated 22329352_1 95 104
expression 22329352_1 105 115
of 22329352_1 116 118
fibroblast 22329352_1 119 129
growth 22329352_1 130 136
factor 22329352_1 137 143
receptor 22329352_1 144 152
3 22329352_1 153 154
: 22329352_1 155 156
analysis 22329352_1 157 165
from 22329352_1 166 170
the 22329352_1 171 174
Australasian 22329352_1 175 187
Leukaemia 22329352_1 188 197
and 22329352_1 198 201
Lymphoma 22329352_1 202 210
Group 22329352_1 211 216
MM 22329352_1 217 219
6 22329352_1 219 220
clinical 22329352_1 221 229
trial 22329352_1 230 235
. 22329352_1 236 237

IL 26060059_10 0 2
28 26060059_10 2 4
B 26060059_10 4 5
rs 26060059_10 6 8
8099917 26060059_10 8 15
/ 26060059_10 16 17
rs 26060059_10 18 20
12979860 26060059_10 20 28
is 26060059_10 29 31
useful 26060059_10 32 38
in 26060059_10 39 41
the 26060059_10 42 45
treatment 26060059_10 46 55
of 26060059_10 56 58
MC 26060059_10 59 61
- 26060059_10 62 63
positive 26060059_10 63 71
HCV 26060059_10 72 75
patients 26060059_10 76 84
with 26060059_10 85 89
PEG 26060059_10 90 93
- 26060059_10 93 94
IFN 26060059_10 94 97
and 26060059_10 98 101
ribavirin 26060059_10 102 111
; 26060059_10 112 113
the 26060059_10 114 117
TT 26060059_10 118 120
/ 26060059_10 120 121
CC 26060059_10 121 123
genotype 26060059_10 124 132
is 26060059_10 133 135
associated 26060059_10 136 146
with 26060059_10 147 151
SVR 26060059_10 152 155
, 26060059_10 156 157
the 26060059_10 158 161
TG 26060059_10 162 164
/ 26060059_10 164 165
TC 26060059_10 165 167
with 26060059_10 168 172
non 26060059_10 173 176
- 26060059_10 176 177
SVR 26060059_10 177 180
; 26060059_10 181 182
TT 26060059_10 183 185
/ 26060059_10 185 186
CC 26060059_10 186 188
is 26060059_10 189 191
also 26060059_10 192 196
predictive 26060059_10 197 207
of 26060059_10 208 210
MC 26060059_10 211 213
in 26060059_10 214 216
HCV 26060059_10 217 220
patients 26060059_10 221 229
. 26060059_10 230 231

These 11245458_9 0 5
results 11245458_9 6 13
indicate 11245458_9 14 22
that 11245458_9 23 27
p 11245458_9 28 29
53 11245458_9 29 31
and 11245458_9 32 35
MMR 11245458_9 36 39
can 11245458_9 40 43
cooperate 11245458_9 44 53
to 11245458_9 54 56
control 11245458_9 57 64
sensitivity 11245458_9 65 76
to 11245458_9 77 79
the 11245458_9 80 83
cytotoxic 11245458_9 84 93
effect 11245458_9 94 100
of 11245458_9 101 103
DDP 11245458_9 104 107
and 11245458_9 108 111
to 11245458_9 112 114
limit 11245458_9 115 120
its 11245458_9 121 124
mutagenic 11245458_9 125 134
potential 11245458_9 135 144
in 11245458_9 145 147
the 11245458_9 148 151
colon 11245458_9 152 157
cance 11245458_9 158 163
r 11245458_9 164 165
cells 11245458_9 166 171
. 11245458_9 172 173

Conjugation 25145853_6 0 11
of 25145853_6 12 14
TLR 25145853_6 15 18
9 25145853_6 18 19
ligand 25145853_6 20 26
CpG 25145853_6 27 30
to 25145853_6 31 33
LDH 25145853_6 34 37
nanoparticles 25145853_6 38 51
significantly 25145853_6 52 65
enhanced 25145853_6 66 74
the 25145853_6 75 78
antibody 25145853_6 79 87
response 25145853_6 88 96
and 25145853_6 97 100
promoted 25145853_6 101 109
a 25145853_6 110 111
switch 25145853_6 112 118
from 25145853_6 119 123
Th 25145853_6 124 126
2 25145853_6 126 127
toward 25145853_6 128 134
Th 25145853_6 135 137
1 25145853_6 137 138
response 25145853_6 139 147
, 25145853_6 148 149
demonstrated 25145853_6 150 162
by 25145853_6 163 165
a 25145853_6 166 167
change 25145853_6 168 174
in 25145853_6 175 177
the 25145853_6 178 181
IgG 25145853_6 182 185
2 25145853_6 185 186
a 25145853_6 186 187
: 25145853_6 188 189
IgG 25145853_6 190 193
1 25145853_6 193 194
ratio 25145853_6 195 200
. 25145853_6 201 202

The 18991847_9 0 3
present 18991847_9 4 11
findings 18991847_9 12 20
suggest 18991847_9 21 28
that 18991847_9 29 33
having 18991847_9 34 40
a 18991847_9 41 42
genetic 18991847_9 43 50
variant 18991847_9 51 58
of 18991847_9 59 61
the 18991847_9 62 65
CSNK 18991847_9 66 70
1 18991847_9 70 71
E 18991847_9 71 72
gene 18991847_9 73 77
did 18991847_9 78 81
not 18991847_9 82 85
affect 18991847_9 86 92
susceptibility 18991847_9 93 107
to 18991847_9 108 110
methamphetamine 18991847_9 111 126
dependence 18991847_9 127 137
or 18991847_9 138 140
psychosis 18991847_9 141 150
, 18991847_9 151 152
at 18991847_9 153 155
least 18991847_9 156 161
in 18991847_9 162 164
a 18991847_9 165 166
Japanese 18991847_9 167 175
population 18991847_9 176 186
. 18991847_9 187 188

The 16359408_4 0 3
pro 16359408_4 4 7
- 16359408_4 7 8
drug 16359408_4 8 12
AQ 16359408_4 13 15
is 16359408_4 16 18
transformed 16359408_4 19 30
by 16359408_4 31 33
cytochrome 16359408_4 34 44
P 16359408_4 45 46
450 16359408_4 46 49
CYP 16359408_4 50 53
2 16359408_4 53 54
C 16359408_4 54 55
8 16359408_4 55 56
to 16359408_4 57 59
the 16359408_4 60 63
active 16359408_4 64 70
metabolite 16359408_4 71 81
N 16359408_4 82 83
- 16359408_4 83 84
desethylaminodiaquine 16359408_4 84 105
. 16359408_4 106 107

A 22555197_1 0 1
Phase 22555197_1 2 7
II 22555197_1 8 10
study 22555197_1 11 16
of 22555197_1 17 19
clinical 22555197_1 20 28
outcomes 22555197_1 29 37
of 22555197_1 38 40
3 22555197_1 41 42
- 22555197_1 42 43
week 22555197_1 43 47
cycles 22555197_1 48 54
of 22555197_1 55 57
irinotecan 22555197_1 58 68
and 22555197_1 69 72
S 22555197_1 73 74
- 22555197_1 74 75
1 22555197_1 75 76
in 22555197_1 77 79
patients 22555197_1 80 88
with 22555197_1 89 93
previously 22555197_1 94 104
untreated 22555197_1 105 114
metastatic 22555197_1 115 125
colorectal 22555197_1 126 136
cancer 22555197_1 137 143
: 22555197_1 144 145
influence 22555197_1 146 155
of 22555197_1 156 158
the 22555197_1 159 162
UGT 22555197_1 163 166
1 22555197_1 166 167
A 22555197_1 167 168
1 22555197_1 168 169
and 22555197_1 170 173
CYP 22555197_1 174 177
2 22555197_1 177 178
A 22555197_1 178 179
6 22555197_1 179 180
polymorphisms 22555197_1 181 194
on 22555197_1 195 197
clinical 22555197_1 198 206
activity 22555197_1 207 215
. 22555197_1 216 217

Genetic 25366762_3 0 7
polymorphisms 25366762_3 8 21
in 25366762_3 22 24
functional 25366762_3 25 35
regions 25366762_3 36 43
of 25366762_3 44 46
the 25366762_3 47 50
glutamate 25366762_3 51 60
receptor 25366762_3 61 69
, 25366762_3 70 71
N 25366762_3 72 73
- 25366762_3 73 74
methyl 25366762_3 74 80
D 25366762_3 81 82
- 25366762_3 82 83
aspartate 25366762_3 83 92
2 25366762_3 93 94
A 25366762_3 94 95
( 25366762_3 96 97
GRIN 25366762_3 98 102
2 25366762_3 102 103
A 25366762_3 103 104
) 25366762_3 105 106
gene 25366762_3 107 111
, 25366762_3 112 113
which 25366762_3 114 119
encodes 25366762_3 120 127
the 25366762_3 128 131
2 25366762_3 132 133
A 25366762_3 133 134
subunit 25366762_3 135 142
of 25366762_3 143 145
the 25366762_3 146 149
N 25366762_3 150 151
- 25366762_3 151 152
methyl 25366762_3 152 158
D 25366762_3 159 160
- 25366762_3 160 161
aspartate 25366762_3 161 170
( 25366762_3 171 172
NMDA 25366762_3 173 177
) 25366762_3 178 179
receptor 25366762_3 180 188
, 25366762_3 189 190
may 25366762_3 191 194
modulate 25366762_3 195 203
the 25366762_3 204 207
risk 25366762_3 208 212
of 25366762_3 213 215
heroin 25366762_3 216 222
addiction 25366762_3 223 232
. 25366762_3 233 234

The 22716779_2 0 3
SNP 22716779_2 4 7
rs 22716779_2 8 10
1260326 22716779_2 10 17
( 22716779_2 18 19
P 22716779_2 20 21
446 22716779_2 21 24
L 22716779_2 24 25
) 22716779_2 26 27
and 22716779_2 28 31
rs 22716779_2 32 34
1799884 22716779_2 34 41
( 22716779_2 42 43
- 22716779_2 44 45
30 22716779_2 45 47
G 22716779_2 47 48
> 22716779_2 48 49
A 22716779_2 49 50
) 22716779_2 51 52
for 22716779_2 53 56
the 22716779_2 57 60
glucokinase 22716779_2 61 72
regulatory 22716779_2 73 83
protein 22716779_2 84 91
( 22716779_2 92 93
GCKR 22716779_2 94 98
) 22716779_2 99 100
and 22716779_2 101 104
glucokinase 22716779_2 105 116
( 22716779_2 117 118
GCK 22716779_2 119 122
) 22716779_2 123 124
genes 22716779_2 125 130
, 22716779_2 131 132
respectively 22716779_2 133 145
, 22716779_2 146 147
have 22716779_2 148 152
been 22716779_2 153 157
associated 22716779_2 158 168
with 22716779_2 169 173
opposing 22716779_2 174 182
effects 22716779_2 183 190
on 22716779_2 191 193
TAG 22716779_2 194 197
and 22716779_2 198 201
glucose 22716779_2 202 209
concentrations 22716779_2 210 224
. 22716779_2 225 226

In 22088980_6 0 2
total 22088980_6 3 8
, 22088980_6 9 10
247 22088980_6 11 14
noncarriers 22088980_6 15 26
of 22088980_6 27 29
a 22088980_6 30 31
CYP 22088980_6 32 35
2 22088980_6 35 36
C 22088980_6 36 37
19 22088980_6 37 39
* 22088980_6 40 41
2 22088980_6 42 43
loss 22088980_6 44 48
- 22088980_6 48 49
of 22088980_6 49 51
- 22088980_6 51 52
function 22088980_6 52 60
allele 22088980_6 61 67
were 22088980_6 68 72
to 22088980_6 73 75
receive 22088980_6 76 83
75 22088980_6 84 86
and 22088980_6 87 90
150 22088980_6 91 94
mg 22088980_6 95 97
daily 22088980_6 98 103
of 22088980_6 104 106
clopidogrel 22088980_6 107 118
( 22088980_6 119 120
2 22088980_6 121 122
periods 22088980_6 123 130
each 22088980_6 131 135
) 22088980_6 136 137
, 22088980_6 138 139
whereas 22088980_6 140 147
86 22088980_6 148 150
carriers 22088980_6 151 159
( 22088980_6 160 161
80 22088980_6 162 164
heterozygotes 22088980_6 165 178
, 22088980_6 179 180
6 22088980_6 181 182
homozygotes 22088980_6 183 194
) 22088980_6 195 196
were 22088980_6 197 201
to 22088980_6 202 204
receive 22088980_6 205 212
75 22088980_6 213 215
, 22088980_6 216 217
150 22088980_6 218 221
, 22088980_6 222 223
225 22088980_6 224 227
, 22088980_6 228 229
and 22088980_6 230 233
300 22088980_6 234 237
mg 22088980_6 238 240
daily 22088980_6 241 246
. 22088980_6 247 248

RESULTS 24597466_4 0 7
: 24597466_4 8 9
Patients 24597466_4 10 18
carrying 24597466_4 19 27
HLA 24597466_4 28 31
- 24597466_4 31 32
B 24597466_4 32 33
* 24597466_4 34 35
15 24597466_4 36 38
: 24597466_4 38 39
02 24597466_4 39 41
are 24597466_4 42 45
at 24597466_4 46 48
strongly 24597466_4 49 57
increased 24597466_4 58 67
risk 24597466_4 68 72
for 24597466_4 73 76
CBZ 24597466_4 77 80
- 24597466_4 81 82
induced 24597466_4 82 89
Stevens 24597466_4 90 97
- 24597466_4 97 98
Johnson 24597466_4 98 105
syndrome 24597466_4 106 114
/ 24597466_4 115 116
toxic 24597466_4 117 122
epidermal 24597466_4 123 132
necrolysis 24597466_4 133 143
( 24597466_4 144 145
SJS 24597466_4 146 149
/ 24597466_4 150 151
TEN 24597466_4 152 155
) 24597466_4 156 157
in 24597466_4 158 160
populations 24597466_4 161 172
where 24597466_4 173 178
HLA 24597466_4 179 182
- 24597466_4 182 183
B 24597466_4 183 184
* 24597466_4 185 186
15 24597466_4 187 189
: 24597466_4 189 190
02 24597466_4 190 192
is 24597466_4 193 195
common 24597466_4 196 202
, 24597466_4 203 204
but 24597466_4 205 208
not 24597466_4 209 212
CBZ 24597466_4 213 216
- 24597466_4 217 218
induced 24597466_4 218 225
hypersensitivity 24597466_4 226 242
syndrome 24597466_4 243 251
( 24597466_4 252 253
HSS 24597466_4 254 257
) 24597466_4 258 259
or 24597466_4 260 262
maculopapular 24597466_4 263 276
exanthema 24597466_4 277 286
( 24597466_4 287 288
MPE 24597466_4 289 292
) 24597466_4 293 294
. 24597466_4 295 296

Our 23792648_11 0 3
findings 23792648_11 4 12
indicate 23792648_11 13 21
the 23792648_11 22 25
growth 23792648_11 26 32
suppressive 23792648_11 33 44
effects 23792648_11 45 52
of 23792648_11 53 55
doxorubicin 23792648_11 56 67
, 23792648_11 68 69
oxaliplatin 23792648_11 70 81
and 23792648_11 82 85
methotrexate 23792648_11 86 98
treatment 23792648_11 99 108
on 23792648_11 109 111
stomach 23792648_11 112 119
carcinoma 23792648_11 120 129
cells 23792648_11 130 135
and 23792648_11 136 139
the 23792648_11 140 143
implication 23792648_11 144 155
of 23792648_11 156 158
BCL 23792648_11 159 162
2 23792648_11 162 163
L 23792648_11 163 164
12 23792648_11 164 166
, 23792648_11 167 168
BAX 23792648_11 169 172
, 23792648_11 173 174
and 23792648_11 175 178
BCL 23792648_11 179 182
- 23792648_11 182 183
2 23792648_11 183 184
expression 23792648_11 185 195
profiles 23792648_11 196 204
in 23792648_11 205 207
the 23792648_11 208 211
molecular 23792648_11 212 221
signaling 23792648_11 222 231
pathways 23792648_11 232 240
triggered 23792648_11 241 250
by 23792648_11 251 253
chemotherapy 23792648_11 254 266
. 23792648_11 267 268

Neuropeptide 11340648_2 0 12
Y 11340648_2 13 14
( 11340648_2 15 16
NPY 11340648_2 17 20
) 11340648_2 21 22
was 11340648_2 23 26
previously 11340648_2 27 37
shown 11340648_2 38 43
in 11340648_2 44 46
our 11340648_2 47 50
laboratory 11340648_2 51 61
to 11340648_2 62 64
attenuate 11340648_2 65 74
behavioral 11340648_2 75 85
signs 11340648_2 86 91
of 11340648_2 92 94
morphine 11340648_2 95 103
withdrawal 11340648_2 104 114
. 11340648_2 115 116

Insulin 8530458_13 0 7
treatment 8530458_13 8 17
of 8530458_13 18 20
the 8530458_13 21 24
streptozotocin 8530458_13 25 39
- 8530458_13 40 41
diabetic 8530458_13 42 50
mice 8530458_13 51 55
increased 8530458_13 56 65
both 8530458_13 66 70
the 8530458_13 71 74
CAT 8530458_13 75 78
activity 8530458_13 79 87
and 8530458_13 88 91
CAT 8530458_13 92 95
mRNA 8530458_13 96 100
levels 8530458_13 101 107
driven 8530458_13 108 114
by 8530458_13 115 117
the 8530458_13 118 121
rat 8530458_13 122 125
FAS 8530458_13 126 129
promoter 8530458_13 130 138
in 8530458_13 139 141
liver 8530458_13 142 147
and 8530458_13 148 151
white 8530458_13 152 157
adipose 8530458_13 158 165
tissue 8530458_13 166 172
. 8530458_13 173 174

CONCLUSIONS 21445620_10 0 11
: 21445620_10 12 13
In 21445620_10 14 16
conclusion 21445620_10 17 27
, 21445620_10 28 29
the 21445620_10 30 33
COMT 21445620_10 34 38
Val 21445620_10 39 42
( 21445620_10 43 44
158 21445620_10 45 48
/ 21445620_10 48 49
108 21445620_10 49 52
) 21445620_10 53 54
Met 21445620_10 55 58
does 21445620_10 59 63
not 21445620_10 64 67
appear 21445620_10 68 74
to 21445620_10 75 77
have 21445620_10 78 82
a 21445620_10 83 84
dramatic 21445620_10 85 93
influence 21445620_10 94 103
on 21445620_10 104 106
EGCG 21445620_10 107 111
absorption 21445620_10 112 122
and 21445620_10 123 126
elimination 21445620_10 127 138
. 21445620_10 139 140

A 26666244_1 0 1
phase 26666244_1 2 7
I 26666244_1 8 9
study 26666244_1 10 15
of 26666244_1 16 18
selumetinib 26666244_1 19 30
( 26666244_1 31 32
AZD 26666244_1 33 36
6244 26666244_1 36 40
/ 26666244_1 41 42
ARRY 26666244_1 43 47
- 26666244_1 47 48
142866 26666244_1 48 54
) 26666244_1 55 56
, 26666244_1 57 58
a 26666244_1 59 60
MEK 26666244_1 61 64
1 26666244_1 64 65
/ 26666244_1 65 66
2 26666244_1 66 67
inhibitor 26666244_1 68 77
, 26666244_1 78 79
in 26666244_1 80 82
combination 26666244_1 83 94
with 26666244_1 95 99
cetuximab 26666244_1 100 109
in 26666244_1 110 112
refractory 26666244_1 113 123
solid 26666244_1 124 129
tumors 26666244_1 130 136
and 26666244_1 137 140
KRAS 26666244_1 141 145
mutant 26666244_1 146 152
colorectal 26666244_1 153 163
cancer 26666244_1 164 170
. 26666244_1 171 172

An 21503919_2 0 2
association 21503919_2 3 14
between 21503919_2 15 22
a 21503919_2 23 24
single 21503919_2 25 31
nucleotide 21503919_2 32 42
polymorphism 21503919_2 43 55
( 21503919_2 56 57
SNP 21503919_2 58 61
) 21503919_2 62 63
in 21503919_2 64 66
the 21503919_2 67 70
inosine 21503919_2 71 78
triphosphate 21503919_2 79 91
pyrophosphatase 21503919_2 92 107
( 21503919_2 108 109
ITPA 21503919_2 110 114
) 21503919_2 115 116
gene 21503919_2 117 121
and 21503919_2 122 125
reduction 21503919_2 126 135
of 21503919_2 136 138
hemoglobin 21503919_2 139 149
during 21503919_2 150 156
peg 21503919_2 157 160
- 21503919_2 160 161
interferon 21503919_2 161 171
plus 21503919_2 172 176
ribavirin 21503919_2 177 186
combination 21503919_2 187 198
therapy 21503919_2 199 206
for 21503919_2 207 210
patients 21503919_2 211 219
with 21503919_2 220 224
chronic 21503919_2 225 232
hepatitis 21503919_2 233 242
C 21503919_2 243 244
virus 21503919_2 245 250
( 21503919_2 251 252
HCV 21503919_2 252 255
) 21503919_2 255 256
infection 21503919_2 257 266
has 21503919_2 267 270
been 21503919_2 271 275
reported 21503919_2 276 284
. 21503919_2 285 286

Withdrawal 15175841_1 0 10
- 15175841_1 10 11
induced 15175841_1 11 18
c 15175841_1 19 20
- 15175841_1 20 21
Fos 15175841_1 21 24
expression 15175841_1 25 35
in 15175841_1 36 38
the 15175841_1 39 42
rat 15175841_1 43 46
centromedial 15175841_1 47 59
amygdala 15175841_1 60 68
24 15175841_1 69 71
h 15175841_1 72 73
following 15175841_1 74 83
a 15175841_1 84 85
single 15175841_1 86 92
morphine 15175841_1 93 101
exposure 15175841_1 102 110
. 15175841_1 111 112

Tamoxifen 15952058_9 0 9
- 15952058_9 10 11
treated 15952058_9 11 18
patients 15952058_9 19 27
with 15952058_9 28 32
UGT 15952058_9 33 36
2 15952058_9 36 37
B 15952058_9 37 38
15 15952058_9 38 40
high 15952058_9 41 45
activity 15952058_9 46 54
genotypes 15952058_9 55 64
had 15952058_9 65 68
increased 15952058_9 69 78
risk 15952058_9 79 83
of 15952058_9 84 86
recurrence 15952058_9 87 97
and 15952058_9 98 101
poorer 15952058_9 102 108
survival 15952058_9 109 117
. 15952058_9 118 119

The 21507151_2 0 3
mu 21507151_2 4 6
- 21507151_2 6 7
opioid 21507151_2 7 13
receptor 21507151_2 14 22
encoded 21507151_2 23 30
by 21507151_2 31 33
the 21507151_2 34 37
gene 21507151_2 38 42
OPRM 21507151_2 43 47
1 21507151_2 47 48
plays 21507151_2 49 54
a 21507151_2 55 56
primary 21507151_2 57 64
role 21507151_2 65 69
in 21507151_2 70 72
opiate 21507151_2 73 79
, 21507151_2 80 81
alcohol 21507151_2 82 89
, 21507151_2 90 91
cocaine 21507151_2 92 99
and 21507151_2 100 103
nicotine 21507151_2 104 112
addiction 21507151_2 113 122
. 21507151_2 123 124

Our 12517791_13 0 3
data 12517791_13 4 8
strongly 12517791_13 9 17
support 12517791_13 18 25
the 12517791_13 26 29
hypothesis 12517791_13 30 40
that 12517791_13 41 45
AR 12517791_13 46 48
mutation 12517791_13 49 57
is 12517791_13 58 60
one 12517791_13 61 64
possible 12517791_13 65 73
mechanism 12517791_13 74 83
of 12517791_13 84 86
the 12517791_13 87 90
AWS 12517791_13 91 94
and 12517791_13 95 98
suggest 12517791_13 99 106
that 12517791_13 107 111
flutamide 12517791_13 112 121
might 12517791_13 122 127
be 12517791_13 128 130
effective 12517791_13 131 140
as 12517791_13 141 143
a 12517791_13 144 145
second 12517791_13 146 152
- 12517791_13 152 153
line 12517791_13 153 157
therapy 12517791_13 158 165
for 12517791_13 166 169
refractory 12517791_13 170 180
PC 12517791_13 181 183
previously 12517791_13 184 194
treated 12517791_13 195 202
with 12517791_13 203 207
bicalutamide 12517791_13 208 220
. 12517791_13 221 222

However 18708376_7 0 7
, 18708376_7 8 9
neither 18708376_7 10 17
ESR 18708376_7 18 21
1 18708376_7 21 22
promoter 18708376_7 23 31
hypermethylation 18708376_7 32 48
nor 18708376_7 49 52
low 18708376_7 53 56
ER 18708376_7 57 59
expression 18708376_7 60 70
predicted 18708376_7 71 80
persistent 18708376_7 81 91
atypia 18708376_7 92 98
in 18708376_7 99 101
Random 18708376_7 102 108
Periareolar 18708376_7 109 120
Fine 18708376_7 121 125
Needle 18708376_7 126 132
Aspiration 18708376_7 133 143
after 18708376_7 144 149
12 18708376_7 150 152
months 18708376_7 153 159
tamoxifen 18708376_7 160 169
prevention 18708376_7 170 180
. 18708376_7 181 182

However 19251742_7 0 7
, 19251742_7 8 9
these 19251742_7 10 15
spermatozoa 19251742_7 16 27
did 19251742_7 28 31
not 19251742_7 32 35
show 19251742_7 36 40
strong 19251742_7 41 47
damage 19251742_7 48 54
, 19251742_7 55 56
and 19251742_7 57 60
after 19251742_7 61 66
artificial 19251742_7 67 77
activation 19251742_7 78 88
with 19251742_7 89 93
SrCl 19251742_7 94 98
2 19251742_7 98 99
, 19251742_7 100 101
all 19251742_7 102 105
of 19251742_7 106 108
the 19251742_7 109 112
zygotes 19251742_7 113 120
were 19251742_7 121 125
judged 19251742_7 126 132
as 19251742_7 133 135
normal 19251742_7 136 142
by 19251742_7 143 145
immunostaining 19251742_7 146 160
to 19251742_7 161 163
check 19251742_7 164 169
the 19251742_7 170 173
methylation 19251742_7 174 185
status 19251742_7 186 192
of 19251742_7 193 195
histone 19251742_7 196 203
H 19251742_7 204 205
3 19251742_7 205 206
lysine 19251742_7 207 213
9 19251742_7 214 215
, 19251742_7 216 217
low 19251742_7 218 221
chromosome 19251742_7 222 232
damage 19251742_7 233 239
by 19251742_7 240 242
karyotype 19251742_7 243 252
assay 19251742_7 253 258
and 19251742_7 259 262
staining 19251742_7 263 271
with 19251742_7 272 276
DNA 19251742_7 277 280
double 19251742_7 281 287
- 19251742_7 287 288
strand 19251742_7 288 294
breaks 19251742_7 295 301
marker 19251742_7 302 308
, 19251742_7 309 310
gammaH 19251742_7 311 317
2 19251742_7 317 318
AX 19251742_7 318 320
. 19251742_7 321 322

Since 1315265_5 0 5
the 1315265_5 6 9
paraventricular 1315265_5 10 25
nucleus 1315265_5 26 33
contains 1315265_5 34 42
a 1315265_5 43 44
large 1315265_5 45 50
number 1315265_5 51 57
of 1315265_5 58 60
glucocorticoid 1315265_5 61 75
receptor 1315265_5 76 84
immunoreactive 1315265_5 85 99
cells 1315265_5 100 105
, 1315265_5 106 107
the 1315265_5 108 111
effect 1315265_5 112 118
of 1315265_5 119 121
a 1315265_5 122 123
synthetic 1315265_5 124 133
glucocorticoid 1315265_5 134 148
, 1315265_5 149 150
dexamethasone 1315265_5 151 164
, 1315265_5 165 166
on 1315265_5 167 169
the 1315265_5 170 173
induction 1315265_5 174 183
of 1315265_5 184 186
Fos 1315265_5 187 190
- 1315265_5 191 192
LI 1315265_5 192 194
was 1315265_5 195 198
studied 1315265_5 199 206
. 1315265_5 207 208

In 12125044_5 0 2
contrast 12125044_5 3 11
, 12125044_5 12 13
more 12125044_5 14 18
Jun 12125044_5 19 22
and 12125044_5 23 26
35 12125044_5 27 29
- 12125044_5 29 30
kDa 12125044_5 30 33
FRA 12125044_5 34 37
were 12125044_5 38 42
expressed 12125044_5 43 52
in 12125044_5 53 55
the 12125044_5 56 59
ventral 12125044_5 60 67
striatum 12125044_5 68 76
of 12125044_5 77 79
the 12125044_5 80 83
amphetamine 12125044_5 84 95
- 12125044_5 96 97
treated 12125044_5 97 104
group 12125044_5 105 110
than 12125044_5 111 115
in 12125044_5 116 118
the 12125044_5 119 122
controls 12125044_5 123 131
when 12125044_5 132 136
haloperidol 12125044_5 137 148
was 12125044_5 149 152
given 12125044_5 153 158
at 12125044_5 159 161
w 12125044_5 162 163
10 12125044_5 163 165
. 12125044_5 166 167

We 17014716_6 0 2
examined 17014716_6 3 11
resting 17014716_6 12 19
CD 17014716_6 20 22
4 17014716_6 22 23
+ 17014716_6 24 25
T 17014716_6 26 27
cells 17014716_6 28 33
from 17014716_6 34 38
healthy 17014716_6 39 46
donors 17014716_6 47 53
to 17014716_6 54 56
determine 17014716_6 57 66
if 17014716_6 67 69
prostratin 17014716_6 70 80
induces 17014716_6 81 88
Cyclin 17014716_6 89 95
T 17014716_6 96 97
1 17014716_6 97 98
/ 17014716_6 99 100
P 17014716_6 101 102
- 17014716_6 102 103
TEFb 17014716_6 103 107
, 17014716_6 108 109
a 17014716_6 110 111
cellular 17014716_6 112 120
kinase 17014716_6 121 127
composed 17014716_6 128 136
of 17014716_6 137 139
Cyclin 17014716_6 140 146
T 17014716_6 147 148
1 17014716_6 148 149
and 17014716_6 150 153
Cyclin 17014716_6 154 160
- 17014716_6 160 161
dependent 17014716_6 161 170
kinase 17014716_6 171 177
- 17014716_6 177 178
9 17014716_6 178 179
( 17014716_6 180 181
CDK 17014716_6 182 185
9 17014716_6 185 186
) 17014716_6 187 188
that 17014716_6 189 193
mediates 17014716_6 194 202
Tat 17014716_6 203 206
function 17014716_6 207 215
. 17014716_6 216 217

Long 17392718_12 0 4
- 17392718_12 4 5
term 17392718_12 5 9
SJW 17392718_12 10 13
decreased 17392718_12 14 23
talinolol 17392718_12 24 33
AUC 17392718_12 34 37
with 17392718_12 38 42
a 17392718_12 43 44
corresponding 17392718_12 45 58
increase 17392718_12 59 67
in 17392718_12 68 70
intestinal 17392718_12 71 81
MDR 17392718_12 82 85
1 17392718_12 85 86
expression 17392718_12 87 97
, 17392718_12 98 99
suggesting 17392718_12 100 110
that 17392718_12 111 115
SJW 17392718_12 116 119
has 17392718_12 120 123
a 17392718_12 124 125
major 17392718_12 126 131
inductive 17392718_12 132 141
effect 17392718_12 142 148
on 17392718_12 149 151
intestinal 17392718_12 152 162
P 17392718_12 163 164
- 17392718_12 164 165
glycoprotein 17392718_12 165 177
. 17392718_12 178 179

In 16245360_6 0 2
this 16245360_6 3 7
model 16245360_6 8 13
we 16245360_6 14 16
found 16245360_6 17 22
that 16245360_6 23 27
treatment 16245360_6 28 37
with 16245360_6 38 42
CpG 16245360_6 43 46
ODN 16245360_6 47 50
during 16245360_6 51 57
epicutaneous 16245360_6 58 70
sensitization 16245360_6 71 84
in 16245360_6 85 87
previously 16245360_6 88 98
i 16245360_6 99 100
. 16245360_6 100 101
p 16245360_6 101 102
. 16245360_6 102 103
- 16245360_6 103 104
primed 16245360_6 104 110
mice 16245360_6 111 115
prevented 16245360_6 116 125
the 16245360_6 126 129
development 16245360_6 130 141
of 16245360_6 142 144
Th 16245360_6 145 147
2 16245360_6 147 148
- 16245360_6 149 150
mediated 16245360_6 150 158
responses 16245360_6 159 168
. 16245360_6 169 170

These 8963481_9 0 5
pharmacokinetic 8963481_9 6 21
parameters 8963481_9 22 32
were 8963481_9 33 37
also 8963481_9 38 42
investigated 8963481_9 43 55
with 8963481_9 56 60
respect 8963481_9 61 68
to 8963481_9 69 71
the 8963481_9 72 75
CYP 8963481_9 76 79
2 8963481_9 79 80
D 8963481_9 80 81
6 8963481_9 81 82
polymorphism 8963481_9 83 95
, 8963481_9 96 97
i 8963481_9 98 99
. 8963481_9 99 100
e 8963481_9 100 101
. 8963481_9 101 102
via 8963481_9 103 106
dextromethorphan 8963481_9 107 123
phenotyping 8963481_9 124 135
of 8963481_9 136 138
9 8963481_9 139 140
subjects 8963481_9 141 149
, 8963481_9 150 151
3 8963481_9 152 153
subjects 8963481_9 154 162
were 8963481_9 163 167
poor 8963481_9 168 172
metabolizers 8963481_9 173 185
, 8963481_9 186 187
and 8963481_9 188 191
6 8963481_9 192 193
extensive 8963481_9 194 203
metabolizers 8963481_9 204 216
. 8963481_9 217 218

CONCLUSIONS 23337555_13 0 11
: 23337555_13 12 13
Although 23337555_13 14 22
specific 23337555_13 23 31
alleles 23337555_13 32 39
for 23337555_13 40 43
CFH 23337555_13 44 47
, 23337555_13 48 49
ARMS 23337555_13 50 54
2 23337555_13 54 55
, 23337555_13 56 57
HTRA 23337555_13 58 62
1 23337555_13 62 63
, 23337555_13 64 65
and 23337555_13 66 69
C 23337555_13 70 71
3 23337555_13 71 72
may 23337555_13 73 76
predict 23337555_13 77 84
the 23337555_13 85 88
development 23337555_13 89 100
of 23337555_13 101 103
AMD 23337555_13 104 107
, 23337555_13 108 109
they 23337555_13 110 114
did 23337555_13 115 118
not 23337555_13 119 122
predict 23337555_13 123 130
response 23337555_13 131 139
to 23337555_13 140 142
anti 23337555_13 143 147
- 23337555_13 147 148
vascular 23337555_13 149 157
endothelial 23337555_13 158 169
growth 23337555_13 170 176
factor 23337555_13 177 183
therapy 23337555_13 184 191
. 23337555_13 192 193

AZD 26450446_1 0 3
9291 26450446_1 3 7
in 26450446_1 8 10
EGFR 26450446_1 11 15
- 26450446_1 16 17
mutant 26450446_1 17 23
advanced 26450446_1 24 32
non 26450446_1 33 36
- 26450446_1 36 37
small 26450446_1 37 42
- 26450446_1 42 43
cell 26450446_1 43 47
lung 26450446_1 48 52
cancer 26450446_1 53 59
patients 26450446_1 60 68
. 26450446_1 69 70

Combining 25522765_1 0 9
Onartuzumab 25522765_1 10 21
with 25522765_1 22 26
Erlotinib 25522765_1 27 36
Inhibits 25522765_1 37 45
Growth 25522765_1 46 52
of 25522765_1 53 55
Non 25522765_1 56 59
- 25522765_1 59 60
Small 25522765_1 60 65
Cell 25522765_1 66 70
Lung 25522765_1 71 75
Cancer 25522765_1 76 82
with 25522765_1 83 87
Activating 25522765_1 88 98
EGFR 25522765_1 99 103
Mutations 25522765_1 104 113
and 25522765_1 114 117
HGF 25522765_1 118 121
Overexpression 25522765_1 122 136
. 25522765_1 137 138

Four 27590272_3 0 4
important 27590272_3 5 14
transporter 27590272_3 15 26
genes 27590272_3 27 32
are 27590272_3 33 36
expressed 27590272_3 37 46
in 27590272_3 47 49
the 27590272_3 50 53
kidney 27590272_3 54 60
, 27590272_3 61 62
including 27590272_3 63 72
organic 27590272_3 73 80
cation 27590272_3 81 87
transporter 27590272_3 88 99
2 27590272_3 100 101
( 27590272_3 102 103
OCT 27590272_3 104 107
2 27590272_3 107 108
) 27590272_3 109 110
, 27590272_3 111 112
multidrug 27590272_3 113 122
and 27590272_3 123 126
toxin 27590272_3 127 132
extrusion 27590272_3 133 142
1 27590272_3 143 144
( 27590272_3 145 146
MATE 27590272_3 147 151
1 27590272_3 151 152
) 27590272_3 153 154
, 27590272_3 155 156
ATP 27590272_3 157 160
- 27590272_3 160 161
binding 27590272_3 161 168
cassette 27590272_3 169 177
subfamily 27590272_3 178 187
B 27590272_3 188 189
member 27590272_3 190 196
1 27590272_3 197 198
( 27590272_3 199 200
ABCB 27590272_3 201 205
1 27590272_3 205 206
) 27590272_3 207 208
, 27590272_3 209 210
and 27590272_3 211 214
ATP 27590272_3 215 218
- 27590272_3 218 219
binding 27590272_3 219 226
cassette 27590272_3 227 235
subfamily 27590272_3 236 245
C 27590272_3 246 247
member 27590272_3 248 254
2 27590272_3 255 256
( 27590272_3 257 258
ABCC 27590272_3 259 263
2 27590272_3 263 264
) 27590272_3 265 266
, 27590272_3 267 268
and 27590272_3 269 272
genetic 27590272_3 273 280
polymorphisms 27590272_3 281 294
in 27590272_3 295 297
these 27590272_3 298 303
genes 27590272_3 304 309
may 27590272_3 310 313
alter 27590272_3 314 319
the 27590272_3 320 323
efficacy 27590272_3 324 332
and 27590272_3 333 336
adverse 27590272_3 337 344
effects 27590272_3 345 352
of 27590272_3 353 355
platinum 27590272_3 356 364
drugs 27590272_3 365 370
. 27590272_3 371 372

A 22506971_7 0 1
recent 22506971_7 2 8
study 22506971_7 9 14
found 22506971_7 15 20
that 22506971_7 21 25
hypermethylation 22506971_7 26 42
of 22506971_7 43 45
the 22506971_7 46 49
promoter 22506971_7 50 58
of 22506971_7 59 61
the 22506971_7 62 65
dopamine 22506971_7 66 74
transporter 22506971_7 75 86
( 22506971_7 87 88
DAT 22506971_7 89 92
) 22506971_7 93 94
gene 22506971_7 95 99
was 22506971_7 100 103
positively 22506971_7 104 114
correlated 22506971_7 115 125
with 22506971_7 126 130
alcohol 22506971_7 131 138
dependence 22506971_7 139 149
and 22506971_7 150 153
negatively 22506971_7 154 164
correlated 22506971_7 165 175
with 22506971_7 176 180
alcohol 22506971_7 181 188
craving 22506971_7 189 196
. 22506971_7 197 198

However 25486952_12 0 7
in 25486952_12 8 10
PMF 25486952_12 11 14
, 25486952_12 15 16
Adenosine 25486952_12 17 26
Tri 25486952_12 27 30
- 25486952_12 30 31
Phosphate 25486952_12 31 40
( 25486952_12 41 42
ATP 25486952_12 43 46
) 25486952_12 47 48
- 25486952_12 49 50
competitive 25486952_12 51 62
JAK 25486952_12 63 66
2 25486952_12 66 67
inhibitors 25486952_12 68 78
have 25486952_12 79 83
shown 25486952_12 84 89
their 25486952_12 90 95
interest 25486952_12 96 104
, 25486952_12 105 106
but 25486952_12 107 110
also 25486952_12 111 115
their 25486952_12 116 121
important 25486952_12 122 131
limitations 25486952_12 132 143
. 25486952_12 144 145

CONCLUSION 12893983_9 0 10
: 12893983_9 11 12
Genotyping 12893983_9 13 23
for 12893983_9 24 27
the 12893983_9 28 31
GNB 12893983_9 32 35
3 12893983_9 35 36
C 12893983_9 37 38
825 12893983_9 38 41
T 12893983_9 41 42
polymorphism 12893983_9 43 55
is 12893983_9 56 58
highly 12893983_9 59 65
predictive 12893983_9 66 76
for 12893983_9 77 80
the 12893983_9 81 84
identification 12893983_9 85 99
of 12893983_9 100 102
obese 12893983_9 103 108
individuals 12893983_9 109 120
who 12893983_9 121 124
will 12893983_9 125 129
benefit 12893983_9 130 137
from 12893983_9 138 142
sibutramine 12893983_9 143 154
treatment 12893983_9 155 164
. 12893983_9 165 166

WNT 25539912_1 0 3
activation 25539912_1 4 14
by 25539912_1 15 17
lithium 25539912_1 18 25
abrogates 25539912_1 26 35
TP 25539912_1 36 38
53 25539912_1 38 40
mutation 25539912_1 41 49
associated 25539912_1 50 60
radiation 25539912_1 61 70
resistance 25539912_1 71 81
in 25539912_1 82 84
medulloblastoma 25539912_1 85 100
. 25539912_1 101 102

According 12095411_10 0 9
to 12095411_10 10 12
the 12095411_10 13 16
results 12095411_10 17 24
of 12095411_10 25 27
a 12095411_10 28 29
multifactorial 12095411_10 30 44
analysis 12095411_10 45 53
of 12095411_10 54 56
variance 12095411_10 57 65
, 12095411_10 66 67
only 12095411_10 68 72
the 12095411_10 73 76
235 12095411_10 77 80
T 12095411_10 80 81
allele 12095411_10 82 88
of 12095411_10 89 91
the 12095411_10 92 95
angiotensinogen 12095411_10 96 111
gene 12095411_10 112 116
and 12095411_10 117 120
not 12095411_10 121 124
cholesterol 12095411_10 125 136
drug 12095411_10 137 141
therapy 12095411_10 142 149
independently 12095411_10 150 163
affected 12095411_10 164 172
the 12095411_10 173 176
increase 12095411_10 177 185
of 12095411_10 186 188
stenosis 12095411_10 189 197
at 12095411_10 198 200
follow 12095411_10 201 207
- 12095411_10 207 208
up 12095411_10 208 210
angiography 12095411_10 211 222
. 12095411_10 223 224

We 23101464_3 0 2
genotyped 23101464_3 3 12
23 23101464_3 13 15
single 23101464_3 16 22
nucleotide 23101464_3 23 33
polymorphisms 23101464_3 34 47
( 23101464_3 48 49
SNPs 23101464_3 50 54
) 23101464_3 55 56
in 23101464_3 57 59
the 23101464_3 60 63
PDYN 23101464_3 64 68
and 23101464_3 69 72
OPRK 23101464_3 73 77
1 23101464_3 77 78
genes 23101464_3 79 84
in 23101464_3 85 87
816 23101464_3 88 91
alcohol 23101464_3 92 99
- 23101464_3 100 101
dependent 23101464_3 101 110
subjects 23101464_3 111 119
and 23101464_3 120 123
investigated 23101464_3 124 136
their 23101464_3 137 142
association 23101464_3 143 154
with 23101464_3 155 159
: 23101464_3 160 161
( 23101464_3 162 163
1 23101464_3 164 165
) 23101464_3 166 167
negative 23101464_3 168 176
craving 23101464_3 177 184
measured 23101464_3 185 193
by 23101464_3 194 196
a 23101464_3 197 198
subscale 23101464_3 199 207
of 23101464_3 208 210
the 23101464_3 211 214
Inventory 23101464_3 215 224
of 23101464_3 225 227
Drug 23101464_3 228 232
Taking 23101464_3 233 239
Situations 23101464_3 240 250
; 23101464_3 251 252
( 23101464_3 253 254
2 23101464_3 255 256
) 23101464_3 257 258
a 23101464_3 259 260
self 23101464_3 261 265
- 23101464_3 265 266
reported 23101464_3 266 274
history 23101464_3 275 282
of 23101464_3 283 285
depression 23101464_3 286 296
; 23101464_3 297 298
( 23101464_3 299 300
3 23101464_3 301 302
) 23101464_3 303 304
the 23101464_3 305 308
intensity 23101464_3 309 318
of 23101464_3 319 321
depressive 23101464_3 322 332
symptoms 23101464_3 333 341
measured 23101464_3 342 350
by 23101464_3 351 353
the 23101464_3 354 357
Beck 23101464_3 358 362
Depression 23101464_3 363 373
Inventory 23101464_3 374 383
- 23101464_3 383 384
II 23101464_3 384 386
. 23101464_3 387 388

CYP 19067682_10 0 3
3 19067682_10 3 4
A 19067682_10 4 5
5 19067682_10 5 6
genetic 19067682_10 7 14
polymorphism 19067682_10 15 27
was 19067682_10 28 31
not 19067682_10 32 35
associated 19067682_10 36 46
with 19067682_10 47 51
tacrolimus 19067682_10 52 62
- 19067682_10 63 64
related 19067682_10 64 71
nephrotoxicity 19067682_10 72 86
. 19067682_10 87 88

METHODS 21628721_5 0 7
AND 21628721_5 8 11
RESULTS 21628721_5 12 19
: 21628721_5 20 21
CYP 21628721_5 22 25
2 21628721_5 25 26
C 21628721_5 26 27
19 21628721_5 27 29
* 21628721_5 30 31
2 21628721_5 32 33
genotyping 21628721_5 34 44
and 21628721_5 45 48
platelet 21628721_5 49 57
function 21628721_5 58 66
testing 21628721_5 67 74
using 21628721_5 75 80
5 21628721_5 81 82
and 21628721_5 83 86
20 21628721_5 87 89
mol 21628721_5 90 93
/ 21628721_5 93 94
l 21628721_5 94 95
ADP 21628721_5 96 99
- 21628721_5 100 101
induced 21628721_5 101 108
light 21628721_5 109 114
transmittance 21628721_5 115 128
aggregometry 21628721_5 129 141
( 21628721_5 142 143
LTA 21628721_5 144 147
) 21628721_5 148 149
, 21628721_5 150 151
the 21628721_5 152 155
PlateletWorks 21628721_5 156 169
assay 21628721_5 170 175
and 21628721_5 176 179
the 21628721_5 180 183
VerifyNow 21628721_5 184 193
P 21628721_5 194 195
2 21628721_5 195 196
Y 21628721_5 196 197
12 21628721_5 197 199
assay 21628721_5 200 205
, 21628721_5 206 207
were 21628721_5 208 212
performed 21628721_5 213 222
in 21628721_5 223 225
1069 21628721_5 226 230
clopidogrel 21628721_5 231 242
pretreated 21628721_5 243 253
patients 21628721_5 254 262
undergoing 21628721_5 263 273
elective 21628721_5 274 282
coronary 21628721_5 283 291
stenting 21628721_5 292 300
( 21628721_5 301 302
POPular 21628721_5 303 310
study 21628721_5 311 316
, 21628721_5 317 318
http 21628721_5 319 323
: 21628721_5 323 324
/ 21628721_5 324 325
/ 21628721_5 325 326
clinicalTrials 21628721_5 326 340
. 21628721_5 340 341
gov 21628721_5 341 344
/ 21628721_5 344 345
NCT 21628721_5 346 349
00352014 21628721_5 349 357
) 21628721_5 358 359
. 21628721_5 360 361

Lack 21876500_1 0 4
of 21876500_1 5 7
association 21876500_1 8 19
between 21876500_1 20 27
the 21876500_1 28 31
Val 21876500_1 32 35
158 21876500_1 35 38
Met 21876500_1 38 41
catechol 21876500_1 42 50
- 21876500_1 50 51
O 21876500_1 51 52
- 21876500_1 52 53
methyltransferase 21876500_1 53 70
gene 21876500_1 71 75
polymorphism 21876500_1 76 88
and 21876500_1 89 92
methamphetamine 21876500_1 93 108
dependence 21876500_1 109 119
. 21876500_1 120 121

Recent 15897724_4 0 6
studies 15897724_4 7 14
from 15897724_4 15 19
Japan 15897724_4 20 25
revealed 15897724_4 26 34
that 15897724_4 35 39
macrocytosis 15897724_4 40 52
is 15897724_4 53 55
related 15897724_4 56 63
to 15897724_4 64 66
ALDH 15897724_4 67 71
- 15897724_4 71 72
2 15897724_4 72 73
/ 15897724_4 73 74
2 15897724_4 74 75
genotype 15897724_4 76 84
, 15897724_4 85 86
leading 15897724_4 87 94
to 15897724_4 95 97
increased 15897724_4 98 107
acetaldehyde 15897724_4 108 120
accumulation 15897724_4 121 133
. 15897724_4 134 135

METHODS 24611967_4 0 7
: 24611967_4 8 9
Fifty 24611967_4 10 15
- 24611967_4 15 16
two 24611967_4 16 19
patients 24611967_4 20 28
with 24611967_4 29 33
fasting 24611967_4 34 41
glucose 24611967_4 42 49
100 24611967_4 50 53
- 24611967_4 53 54
240 24611967_4 54 57
mg 24611967_4 58 60
/ 24611967_4 60 61
dL 24611967_4 61 63
or 24611967_4 64 66
glycosylated 24611967_4 67 79
hemoglobin 24611967_4 80 90
( 24611967_4 91 92
HbA 24611967_4 93 96
1 24611967_4 96 97
c 24611967_4 97 98
) 24611967_4 99 100
> 24611967_4 101 102
= 24611967_4 103 104
6 24611967_4 105 106
. 24611967_4 106 107
0 24611967_4 107 108
% 24611967_4 109 110
and 24611967_4 111 114
alanine 24611967_4 115 122
aminotransferase 24611967_4 123 139
( 24611967_4 140 141
ALT 24611967_4 142 145
) 24611967_4 146 147
40 24611967_4 148 150
- 24611967_4 150 151
250 24611967_4 151 154
IU 24611967_4 155 157
/ 24611967_4 157 158
L 24611967_4 158 159
were 24611967_4 160 164
randomized 24611967_4 165 175
to 24611967_4 176 178
receive 24611967_4 179 186
metformin 24611967_4 187 196
( 24611967_4 197 198
250 24611967_4 199 202
mg 24611967_4 203 205
t 24611967_4 206 207
. 24611967_4 207 208
i 24611967_4 208 209
. 24611967_4 209 210
d 24611967_4 210 211
. 24611967_4 211 212
) 24611967_4 213 214
, 24611967_4 215 216
or 24611967_4 217 219
metformin 24611967_4 220 229
( 24611967_4 230 231
250 24611967_4 232 235
mg 24611967_4 236 238
t 24611967_4 239 240
. 24611967_4 240 241
i 24611967_4 241 242
. 24611967_4 242 243
d 24611967_4 243 244
. 24611967_4 244 245
) 24611967_4 246 247
and 24611967_4 248 251
carnitine 24611967_4 252 261
- 24611967_4 262 263
orotate 24611967_4 263 270
complex 24611967_4 271 278
( 24611967_4 279 280
300 24611967_4 281 284
mg 24611967_4 285 287
t 24611967_4 288 289
. 24611967_4 289 290
i 24611967_4 290 291
. 24611967_4 291 292
d 24611967_4 292 293
. 24611967_4 293 294
) 24611967_4 295 296
for 24611967_4 297 300
12 24611967_4 301 303
weeks 24611967_4 304 309
( 24611967_4 310 311
n 24611967_4 312 313
= 24611967_4 314 315
26 24611967_4 316 318
per 24611967_4 319 322
group 24611967_4 323 328
) 24611967_4 329 330
. 24611967_4 331 332

Liver 26518936_1 0 5
Transplant 26518936_1 6 16
Patient 26518936_1 17 24
Carriers 26518936_1 25 33
of 26518936_1 34 36
Polymorphism 26518936_1 37 49
Cyp 26518936_1 50 53
3 26518936_1 53 54
a 26518936_1 54 55
5 26518936_1 55 56
* 26518936_1 57 58
1 26518936_1 59 60
Donors 26518936_1 61 67
May 26518936_1 68 71
Need 26518936_1 72 76
More 26518936_1 77 81
Doses 26518936_1 82 87
of 26518936_1 88 90
Tacrolimus 26518936_1 91 101
From 26518936_1 102 106
the 26518936_1 107 110
First 26518936_1 111 116
Month 26518936_1 117 122
After 26518936_1 123 128
Transplantation 26518936_1 129 144
. 26518936_1 145 146

Modelling 17404720_1 0 9
the 17404720_1 10 13
influence 17404720_1 14 23
of 17404720_1 24 26
MDR 17404720_1 27 30
1 17404720_1 30 31
polymorphism 17404720_1 32 44
on 17404720_1 45 47
digoxin 17404720_1 48 55
pharmacokinetic 17404720_1 56 71
parameters 17404720_1 72 82
. 17404720_1 83 84

PURPOSE 8998185_4 0 7
: 8998185_4 8 9
We 8998185_4 10 12
assessed 8998185_4 13 21
the 8998185_4 22 25
prognostic 8998185_4 26 36
value 8998185_4 37 42
of 8998185_4 43 45
identifying 8998185_4 46 57
abnormal 8998185_4 58 66
p 8998185_4 67 68
53 8998185_4 68 70
protein 8998185_4 71 78
expression 8998185_4 79 89
in 8998185_4 90 92
the 8998185_4 93 96
tumors 8998185_4 97 103
of 8998185_4 104 106
patients 8998185_4 107 115
with 8998185_4 116 120
locally 8998185_4 121 128
advanced 8998185_4 129 137
prostate 8998185_4 138 146
cancer 8998185_4 147 153
who 8998185_4 154 157
were 8998185_4 158 162
treated 8998185_4 163 170
with 8998185_4 171 175
either 8998185_4 176 182
external 8998185_4 183 191
- 8998185_4 191 192
beam 8998185_4 192 196
radiation 8998185_4 197 206
therapy 8998185_4 207 214
alone 8998185_4 215 220
or 8998185_4 221 223
total 8998185_4 224 229
androgen 8998185_4 230 238
blockade 8998185_4 239 247
before 8998185_4 248 254
and 8998185_4 255 258
during 8998185_4 259 265
the 8998185_4 266 269
radiation 8998185_4 270 279
therapy 8998185_4 280 287
. 8998185_4 288 289

Instead 19748123_12 0 7
we 19748123_12 8 10
observed 19748123_12 11 19
that 19748123_12 20 24
WY 19748123_12 25 27
14 19748123_12 27 29
, 19748123_12 29 30
643 19748123_12 30 33
consistently 19748123_12 34 46
reduces 19748123_12 47 54
the 19748123_12 55 58
protein 19748123_12 59 66
and 19748123_12 67 70
mRNA 19748123_12 71 75
expression 19748123_12 76 86
of 19748123_12 87 89
Cyclin 19748123_12 90 96
B 19748123_12 97 98
1 19748123_12 98 99
. 19748123_12 100 101

We 24905729_3 0 2
characterized 24905729_3 3 16
patients 24905729_3 17 25
with 24905729_3 26 30
severe 24905729_3 31 37
persistent 24905729_3 38 48
hepatocellular 24905729_3 49 63
secretory 24905729_3 64 73
failure 24905729_3 74 81
( 24905729_3 82 83
PHSF 24905729_3 84 88
) 24905729_3 89 90
and 24905729_3 91 94
treated 24905729_3 95 102
them 24905729_3 103 107
with 24905729_3 108 112
the 24905729_3 113 116
pregnane 24905729_3 117 125
X 24905729_3 126 127
receptor 24905729_3 128 136
( 24905729_3 137 138
PXR 24905729_3 139 142
) 24905729_3 143 144
agonist 24905729_3 145 152
, 24905729_3 153 154
rifampicin 24905729_3 155 165
. 24905729_3 166 167

A 26807589_1 0 1
Single 26807589_1 2 8
- 26807589_1 8 9
Nucleotide 26807589_1 9 19
Polymorphism 26807589_1 20 32
in 26807589_1 33 35
ABCC 26807589_1 36 40
4 26807589_1 40 41
Is 26807589_1 42 44
Associated 26807589_1 45 55
with 26807589_1 56 60
Tenofovir 26807589_1 61 70
- 26807589_1 71 72
Related 26807589_1 72 79
Beta 26807589_1 80 84
2 26807589_1 84 85
- 26807589_1 86 87
Microglobulinuria 26807589_1 87 104
in 26807589_1 105 107
Thai 26807589_1 108 112
Patients 26807589_1 113 121
with 26807589_1 122 126
HIV 26807589_1 127 130
- 26807589_1 130 131
1 26807589_1 131 132
Infection 26807589_1 133 142
. 26807589_1 143 144

CONCLUSION 22735459_10 0 10
: 22735459_10 11 12
These 22735459_10 13 18
results 22735459_10 19 26
suggest 22735459_10 27 34
that 22735459_10 35 39
CYP 22735459_10 40 43
2 22735459_10 43 44
C 22735459_10 44 45
9 22735459_10 45 46
* 22735459_10 47 48
1 22735459_10 49 50
/ 22735459_10 51 52
* 22735459_10 53 54
3 22735459_10 55 56
and 22735459_10 57 60
CYP 22735459_10 61 64
2 22735459_10 64 65
C 22735459_10 65 66
9 22735459_10 66 67
* 22735459_10 68 69
1 22735459_10 70 71
/ 22735459_10 72 73
* 22735459_10 74 75
13 22735459_10 76 78
are 22735459_10 79 82
similarly 22735459_10 83 92
associated 22735459_10 93 103
with 22735459_10 104 108
decreased 22735459_10 109 118
formation 22735459_10 119 128
of 22735459_10 129 131
E 22735459_10 132 133
- 22735459_10 133 134
3174 22735459_10 134 138
from 22735459_10 139 143
losartan 22735459_10 144 152
, 22735459_10 153 154
but 22735459_10 155 158
the 22735459_10 159 162
clinical 22735459_10 163 171
effects 22735459_10 172 179
of 22735459_10 180 182
losartan 22735459_10 183 191
may 22735459_10 192 195
not 22735459_10 196 199
be 22735459_10 200 202
reduced 22735459_10 203 210
by 22735459_10 211 213
CYP 22735459_10 214 217
2 22735459_10 217 218
C 22735459_10 218 219
9 22735459_10 219 220
* 22735459_10 221 222
1 22735459_10 223 224
/ 22735459_10 225 226
* 22735459_10 227 228
3 22735459_10 229 230
and 22735459_10 231 234
CYP 22735459_10 235 238
2 22735459_10 238 239
C 22735459_10 239 240
9 22735459_10 240 241
* 22735459_10 242 243
1 22735459_10 244 245
/ 22735459_10 246 247
* 22735459_10 248 249
13 22735459_10 250 252
. 22735459_10 253 254

There 14515062_8 0 5
were 14515062_8 6 10
no 14515062_8 11 13
differences 14515062_8 14 25
between 14515062_8 26 33
IL 14515062_8 34 36
- 14515062_8 36 37
1 14515062_8 37 38
B 14515062_8 38 39
allele 14515062_8 40 46
2 14515062_8 47 48
carriers 14515062_8 49 57
( 14515062_8 58 59
A 14515062_8 60 61
2 14515062_8 61 62
+ 14515062_8 63 64
) 14515062_8 65 66
and 14515062_8 67 70
non 14515062_8 71 74
- 14515062_8 74 75
carriers 14515062_8 75 83
( 14515062_8 84 85
A 14515062_8 86 87
2 14515062_8 87 88
- 14515062_8 89 90
) 14515062_8 91 92
in 14515062_8 93 95
basal 14515062_8 96 101
or 14515062_8 102 104
adenosine 14515062_8 105 114
- 14515062_8 115 116
stimulated 14515062_8 116 126
myocardial 14515062_8 127 137
flow 14515062_8 138 142
( 14515062_8 143 144
ASMF 14515062_8 145 149
) 14515062_8 150 151
, 14515062_8 152 153
at 14515062_8 154 156
baseline 14515062_8 157 165
. 14515062_8 166 167

This 18666383_4 0 4
review 18666383_4 5 11
highlights 18666383_4 12 22
the 18666383_4 23 26
polymorphisms 18666383_4 27 40
of 18666383_4 41 43
TPMT 18666383_4 44 48
gene 18666383_4 49 53
and 18666383_4 54 57
their 18666383_4 58 63
clinical 18666383_4 64 72
impact 18666383_4 73 79
on 18666383_4 80 82
the 18666383_4 83 86
use 18666383_4 87 90
of 18666383_4 91 93
thiopurine 18666383_4 94 104
drugs 18666383_4 105 110
. 18666383_4 111 112

Participants 18187595_3 0 12
with 18187595_3 13 17
SLCO 18187595_3 18 22
1 18187595_3 22 23
B 18187595_3 23 24
1 18187595_3 24 25
c 18187595_3 26 27
. 18187595_3 27 28
521 18187595_3 29 32
CC 18187595_3 33 35
genotype 18187595_3 36 44
( 18187595_3 45 46
n 18187595_3 47 48
= 18187595_3 49 50
4 18187595_3 51 52
) 18187595_3 53 54
had 18187595_3 55 58
a 18187595_3 59 60
59 18187595_3 61 63
% 18187595_3 64 65
( 18187595_3 66 67
P 18187595_3 68 69
= 18187595_3 70 71
0 18187595_3 72 73
. 18187595_3 73 74
001 18187595_3 74 77
) 18187595_3 78 79
or 18187595_3 80 82
72 18187595_3 83 85
% 18187595_3 86 87
( 18187595_3 88 89
P 18187595_3 90 91
< 18187595_3 92 93
0 18187595_3 94 95
. 18187595_3 95 96
001 18187595_3 96 99
) 18187595_3 100 101
greater 18187595_3 102 109
mean 18187595_3 110 114
area 18187595_3 115 119
under 18187595_3 120 125
the 18187595_3 126 129
plasma 18187595_3 130 136
repaglinide 18187595_3 137 148
concentration 18187595_3 149 162
- 18187595_3 162 163
time 18187595_3 163 167
curve 18187595_3 168 173
( 18187595_3 174 175
AUC 18187595_3 176 179
( 18187595_3 180 181
0 18187595_3 182 183
- 18187595_3 183 184
infinity 18187595_3 184 192
) 18187595_3 193 194
) 18187595_3 195 196
than 18187595_3 197 201
participants 18187595_3 202 214
with 18187595_3 215 219
c 18187595_3 220 221
. 18187595_3 221 222
521 18187595_3 223 226
TC 18187595_3 226 228
( 18187595_3 229 230
n 18187595_3 231 232
= 18187595_3 233 234
12 18187595_3 235 237
) 18187595_3 238 239
or 18187595_3 240 242
c 18187595_3 243 244
. 18187595_3 244 245
521 18187595_3 246 249
TT 18187595_3 249 251
( 18187595_3 252 253
n 18187595_3 254 255
= 18187595_3 256 257
16 18187595_3 258 260
) 18187595_3 261 262
genotypes 18187595_3 263 272
. 18187595_3 273 274

Also 25637161_10 0 4
, 25637161_10 5 6
overexpression 25637161_10 7 21
of 25637161_10 22 24
antiapoptotic 25637161_10 25 38
BCL 25637161_10 39 42
- 25637161_10 42 43
2 25637161_10 43 44
leads 25637161_10 45 50
to 25637161_10 51 53
a 25637161_10 54 55
significant 25637161_10 56 67
reduction 25637161_10 68 77
of 25637161_10 78 80
BEZ 25637161_10 81 84
235 25637161_10 84 87
/ 25637161_10 88 89
CQ 25637161_10 90 92
- 25637161_10 93 94
induced 25637161_10 94 101
apoptosis 25637161_10 102 111
, 25637161_10 112 113
emphasizing 25637161_10 114 125
that 25637161_10 126 130
an 25637161_10 131 133
intact 25637161_10 134 140
mitochondrial 25637161_10 141 154
pathway 25637161_10 155 162
of 25637161_10 163 165
apoptosis 25637161_10 166 175
is 25637161_10 176 178
required 25637161_10 179 187
for 25637161_10 188 191
BEZ 25637161_10 192 195
235 25637161_10 195 198
/ 25637161_10 199 200
CQ 25637161_10 201 203
- 25637161_10 204 205
induced 25637161_10 205 212
cell 25637161_10 213 217
death 25637161_10 218 223
. 25637161_10 224 225

The 27217047_12 0 3
decrement 27217047_12 4 13
for 27217047_12 14 17
daily 27217047_12 18 23
dosage 27217047_12 24 30
of 27217047_12 31 33
Tac 27217047_12 34 37
- 27217047_12 38 39
QD 27217047_12 39 41
was 27217047_12 42 45
significantly 27217047_12 46 59
greater 27217047_12 60 67
in 27217047_12 68 70
patients 27217047_12 71 79
expressing 27217047_12 80 90
the 27217047_12 91 94
CYP 27217047_12 95 98
3 27217047_12 98 99
A 27217047_12 99 100
5 27217047_12 100 101
* 27217047_12 102 103
3 27217047_12 104 105
/ 27217047_12 106 107
* 27217047_12 108 109
3 27217047_12 110 111
than 27217047_12 112 116
the 27217047_12 117 120
CYP 27217047_12 121 124
3 27217047_12 124 125
A 27217047_12 125 126
5 27217047_12 126 127
* 27217047_12 128 129
1 27217047_12 130 131
allele 27217047_12 132 138
. 27217047_12 139 140

The 15180166_10 0 3
metabolic 15180166_10 4 13
ratios 15180166_10 14 20
unchanged 15180166_10 21 30
acetaminophen 15180166_10 31 44
/ 15180166_10 45 46
acetaminophen 15180166_10 47 60
glucuronide 15180166_10 61 72
in 15180166_10 73 75
UGT 15180166_10 76 79
1 15180166_10 79 80
A 15180166_10 80 81
1 15180166_10 81 82
- 15180166_10 83 84
wildtypes 15180166_10 84 93
, 15180166_10 94 95
heterozygotes 15180166_10 96 109
and 15180166_10 110 113
mutants 15180166_10 114 121
showed 15180166_10 122 128
no 15180166_10 129 131
statistically 15180166_10 132 145
significant 15180166_10 146 157
differences 15180166_10 158 169
. 15180166_10 170 171

A 12700947_8 0 1
single 12700947_8 2 8
immunization 12700947_8 9 21
of 12700947_8 22 24
3 12700947_8 25 26
H 12700947_8 26 27
1 12700947_8 27 28
mixed 12700947_8 29 34
with 12700947_8 35 39
CpG 12700947_8 40 43
ODN 12700947_8 44 47
1826 12700947_8 48 52
was 12700947_8 53 56
sufficient 12700947_8 57 67
to 12700947_8 68 70
induce 12700947_8 71 77
measurable 12700947_8 78 88
anti 12700947_8 89 93
- 12700947_8 93 94
CEA 12700947_8 95 98
immunity 12700947_8 99 107
in 12700947_8 108 110
na 12700947_8 111 113
ve 12700947_8 114 116
mice 12700947_8 117 121
. 12700947_8 122 123

Human 2753981_6 0 5
PTH 2753981_6 6 9
- 2753981_6 10 11
( 2753981_6 12 13
1 2753981_6 14 15
- 2753981_6 15 16
34 2753981_6 16 18
) 2753981_6 19 20
caused 2753981_6 21 27
a 2753981_6 28 29
rise 2753981_6 30 34
in 2753981_6 35 37
serum 2753981_6 38 43
calcium 2753981_6 44 51
, 2753981_6 52 53
a 2753981_6 54 55
rise 2753981_6 56 60
in 2753981_6 61 63
nephrogenous 2753981_6 64 76
cAMP 2753981_6 77 81
, 2753981_6 82 83
a 2753981_6 84 85
fall 2753981_6 86 90
in 2753981_6 91 93
renal 2753981_6 94 99
phosphate 2753981_6 100 109
reabsorption 2753981_6 110 122
, 2753981_6 123 124
and 2753981_6 125 128
, 2753981_6 129 130
in 2753981_6 131 133
particular 2753981_6 134 144
, 2753981_6 145 146
a 2753981_6 147 148
rise 2753981_6 149 153
in 2753981_6 154 156
serum 2753981_6 157 162
1 2753981_6 163 164
, 2753981_6 164 165
25 2753981_6 165 167
- 2753981_6 167 168
( 2753981_6 168 169
OH 2753981_6 169 171
) 2753981_6 171 172
2 2753981_6 172 173
D 2753981_6 173 174
. 2753981_6 175 176

RESULTS 25978827_4 0 7
: 25978827_4 8 9
Two 25978827_4 10 13
single 25978827_4 14 20
- 25978827_4 20 21
nucleotide 25978827_4 21 31
polymorphisms 25978827_4 32 45
were 25978827_4 46 50
significantly 25978827_4 51 64
associated 25978827_4 65 75
with 25978827_4 76 80
alcohol 25978827_4 81 88
dependence 25978827_4 89 99
in 25978827_4 100 102
European 25978827_4 103 111
Americans 25978827_4 112 121
using 25978827_4 122 127
the 25978827_4 128 131
Nyholt 25978827_4 132 138
corrected 25978827_4 139 148
p 25978827_4 149 150
value 25978827_4 151 156
of 25978827_4 157 159
. 25978827_4 160 161
007 25978827_4 161 164
: 25978827_4 165 166
rs 25978827_4 167 169
886003 25978827_4 169 175
( 25978827_4 176 177
b 25978827_4 178 179
= 25978827_4 180 181
- 25978827_4 182 183
. 25978827_4 183 184
212 25978827_4 184 187
, 25978827_4 188 189
p 25978827_4 190 191
= 25978827_4 192 193
. 25978827_4 194 195
0002 25978827_4 195 199
) 25978827_4 200 201
and 25978827_4 202 205
rs 25978827_4 206 208
17862325 25978827_4 208 216
( 25978827_4 217 218
b 25978827_4 219 220
= 25978827_4 221 222
- 25978827_4 223 224
. 25978827_4 224 225
234 25978827_4 225 228
, 25978827_4 229 230
p 25978827_4 231 232
< 25978827_4 233 234
. 25978827_4 235 236
0001 25978827_4 236 240
) 25978827_4 241 242
, 25978827_4 243 244
but 25978827_4 245 248
not 25978827_4 249 252
in 25978827_4 253 255
African 25978827_4 256 263
Americans 25978827_4 264 273
, 25978827_4 274 275
likely 25978827_4 276 282
because 25978827_4 283 290
of 25978827_4 291 293
the 25978827_4 294 297
lower 25978827_4 298 303
power 25978827_4 304 309
to 25978827_4 310 312
detect 25978827_4 313 319
association 25978827_4 320 331
in 25978827_4 332 334
this 25978827_4 335 339
group 25978827_4 340 345
. 25978827_4 346 347

Findings 15902904_2 0 8
obtained 15902904_2 9 17
from 15902904_2 18 22
several 15902904_2 23 30
studies 15902904_2 31 38
indicate 15902904_2 39 47
that 15902904_2 48 52
ethanol 15902904_2 53 60
enhances 15902904_2 61 69
the 15902904_2 70 73
activity 15902904_2 74 82
of 15902904_2 83 85
alpha 15902904_2 86 91
4 15902904_2 91 92
beta 15902904_2 92 96
2 15902904_2 96 97
neuronal 15902904_2 98 106
nicotinic 15902904_2 107 116
acetylcholine 15902904_2 117 130
receptor 15902904_2 131 139
and 15902904_2 140 143
support 15902904_2 144 151
the 15902904_2 152 155
possibility 15902904_2 156 167
that 15902904_2 168 172
a 15902904_2 173 174
polymorphism 15902904_2 175 187
of 15902904_2 188 190
the 15902904_2 191 194
nicotinic 15902904_2 195 204
acetylcholine 15902904_2 205 218
receptor 15902904_2 219 227
alpha 15902904_2 228 233
4 15902904_2 233 234
subunit 15902904_2 235 242
gene 15902904_2 243 247
( 15902904_2 248 249
CHRNA 15902904_2 250 255
4 15902904_2 255 256
) 15902904_2 257 258
modulates 15902904_2 259 268
enhancement 15902904_2 269 280
of 15902904_2 281 283
nicotinic 15902904_2 284 293
receptor 15902904_2 294 302
function 15902904_2 303 311
by 15902904_2 312 314
ethanol 15902904_2 315 322
. 15902904_2 323 324

CONCLUSION 17949449_9 0 10
: 17949449_9 11 12
In 17949449_9 13 15
patients 17949449_9 16 24
with 17949449_9 25 29
Dukes 17949449_9 30 35
' 17949449_9 36 37
C 17949449_9 38 39
colorectal 17949449_9 40 50
cancer 17949449_9 51 57
who 17949449_9 58 61
underwent 17949449_9 62 71
curative 17949449_9 72 80
surgical 17949449_9 81 89
resection 17949449_9 90 99
of 17949449_9 100 102
the 17949449_9 103 106
primary 17949449_9 107 114
tumour 17949449_9 115 121
, 17949449_9 122 123
followed 17949449_9 124 132
by 17949449_9 133 135
5 17949449_9 136 137
- 17949449_9 137 138
FU 17949449_9 138 140
- 17949449_9 141 142
based 17949449_9 142 147
adjuvant 17949449_9 148 156
chemotherapy 17949449_9 157 169
, 17949449_9 170 171
p 17949449_9 172 173
53 17949449_9 173 175
mutation 17949449_9 176 184
status 17949449_9 185 191
as 17949449_9 192 194
assessed 17949449_9 195 203
by 17949449_9 204 206
gene 17949449_9 207 211
sequencing 17949449_9 212 222
is 17949449_9 223 225
a 17949449_9 226 227
significant 17949449_9 228 239
predictor 17949449_9 240 249
of 17949449_9 250 252
overall 17949449_9 253 260
and 17949449_9 261 264
metastasis 17949449_9 265 275
- 17949449_9 275 276
free 17949449_9 276 280
survival 17949449_9 281 289
. 17949449_9 290 291

CONCLUSIONS 17636396_11 0 11
: 17636396_11 12 13
Current 17636396_11 14 21
evidence 17636396_11 22 30
supports 17636396_11 31 39
the 17636396_11 40 43
conclusion 17636396_11 44 54
that 17636396_11 55 59
the 17636396_11 60 63
benefit 17636396_11 64 71
of 17636396_11 72 74
both 17636396_11 75 79
anthracycline 17636396_11 80 93
- 17636396_11 94 95
based 17636396_11 95 100
and 17636396_11 101 104
taxane 17636396_11 105 111
- 17636396_11 112 113
based 17636396_11 113 118
adjuvant 17636396_11 119 127
chemotherapy 17636396_11 128 140
is 17636396_11 141 143
associated 17636396_11 144 154
on 17636396_11 155 157
HER 17636396_11 158 161
2 17636396_11 161 162
/ 17636396_11 163 164
neu 17636396_11 164 167
status 17636396_11 168 174
, 17636396_11 175 176
with 17636396_11 177 181
patients 17636396_11 182 190
with 17636396_11 191 195
HER 17636396_11 196 199
2 17636396_11 199 200
/ 17636396_11 201 202
neu 17636396_11 202 205
- 17636396_11 206 207
positive 17636396_11 207 215
cancers 17636396_11 216 223
benefiting 17636396_11 224 234
more 17636396_11 235 239
from 17636396_11 240 244
these 17636396_11 245 250
therapies 17636396_11 251 260
than 17636396_11 261 265
those 17636396_11 266 271
with 17636396_11 272 276
HER 17636396_11 277 280
2 17636396_11 280 281
/ 17636396_11 282 283
neu 17636396_11 283 286
- 17636396_11 287 288
negative 17636396_11 288 296
cancers 17636396_11 297 304
. 17636396_11 305 306

The 11893774_7 0 3
region 11893774_7 4 10
of 11893774_7 11 13
estrogen 11893774_7 14 22
responsiveness 11893774_7 23 37
was 11893774_7 38 41
localized 11893774_7 42 51
to 11893774_7 52 54
- 11893774_7 55 56
1557 11893774_7 56 60
/ 11893774_7 61 62
- 11893774_7 63 64
1175 11893774_7 64 68
of 11893774_7 69 71
the 11893774_7 72 75
HL 11893774_7 76 78
promoter 11893774_7 79 87
by 11893774_7 88 90
deletion 11893774_7 91 99
analysis 11893774_7 100 108
. 11893774_7 109 110

Viruses 17116677_8 0 7
containing 17116677_8 8 18
additional 17116677_8 19 29
mutations 17116677_8 30 39
of 17116677_8 40 42
D 17116677_8 43 44
123 17116677_8 44 47
G 17116677_8 47 48
, 17116677_8 49 50
F 17116677_8 51 52
227 17116677_8 52 55
L 17116677_8 55 56
, 17116677_8 57 58
and 17116677_8 59 62
T 17116677_8 63 64
369 17116677_8 64 67
I 17116677_8 67 68
emerged 17116677_8 69 76
when 17116677_8 77 81
the 17116677_8 82 85
cultures 17116677_8 86 94
were 17116677_8 95 99
incubated 17116677_8 100 109
with 17116677_8 110 114
increasing 17116677_8 115 125
concentrations 17116677_8 126 140
of 17116677_8 141 143
VRX 17116677_8 144 147
- 17116677_8 147 148
480773 17116677_8 148 154
. 17116677_8 155 156

RESULTS 16485141_7 0 7
: 16485141_7 8 9
We 16485141_7 10 12
found 16485141_7 13 18
that 16485141_7 19 23
F 16485141_7 24 25
2 16485141_7 25 26
male 16485141_7 27 31
high 16485141_7 32 36
- 16485141_7 36 37
nic 16485141_7 38 41
o 16485141_7 42 43
tine 16485141_7 44 48
( 16485141_7 49 50
n 16485141_7 51 52
= 16485141_7 53 54
8 16485141_7 55 56
; 16485141_7 57 58
25 16485141_7 59 61
. 16485141_7 61 62
1 16485141_7 62 63
+ 16485141_7 64 65
/ 16485141_7 66 67
- 16485141_7 68 69
1 16485141_7 69 70
. 16485141_7 70 71
2 16485141_7 71 72
microg 16485141_7 73 79
nicotine 16485141_7 80 88
/ 16485141_7 89 90
day 16485141_7 90 93
) 16485141_7 94 95
consumers 16485141_7 96 105
had 16485141_7 106 109
more 16485141_7 110 114
CYP 16485141_7 115 118
2 16485141_7 118 119
A 16485141_7 119 120
5 16485141_7 120 121
protein 16485141_7 122 129
, 16485141_7 130 131
compared 16485141_7 132 140
to 16485141_7 141 143
low 16485141_7 144 147
( 16485141_7 148 149
n 16485141_7 150 151
= 16485141_7 152 153
11 16485141_7 154 156
; 16485141_7 157 158
3 16485141_7 159 160
. 16485141_7 160 161
8 16485141_7 161 162
+ 16485141_7 163 164
/ 16485141_7 165 166
- 16485141_7 167 168
1 16485141_7 168 169
. 16485141_7 169 170
4 16485141_7 170 171
microg 16485141_7 172 178
nicotine 16485141_7 179 187
/ 16485141_7 188 189
day 16485141_7 189 192
) 16485141_7 193 194
consumers 16485141_7 195 204
( 16485141_7 205 206
10 16485141_7 207 209
. 16485141_7 209 210
2 16485141_7 210 211
+ 16485141_7 212 213
/ 16485141_7 214 215
- 16485141_7 216 217
1 16485141_7 217 218
. 16485141_7 218 219
0 16485141_7 219 220
vs 16485141_7 221 223
6 16485141_7 224 225
. 16485141_7 225 226
5 16485141_7 226 227
+ 16485141_7 228 229
/ 16485141_7 230 231
- 16485141_7 232 233
1 16485141_7 233 234
. 16485141_7 234 235
3 16485141_7 235 236
CYP 16485141_7 237 240
2 16485141_7 240 241
A 16485141_7 241 242
5 16485141_7 242 243
units 16485141_7 244 249
) 16485141_7 250 251
. 16485141_7 252 253

OBJECTIVES 20101393_3 0 10
: 20101393_3 11 12
The 20101393_3 13 16
current 20101393_3 17 24
study 20101393_3 25 30
aimed 20101393_3 31 36
to 20101393_3 37 39
determine 20101393_3 40 49
the 20101393_3 50 53
relationship 20101393_3 54 66
between 20101393_3 67 74
ecstasy 20101393_3 75 82
use 20101393_3 83 86
and 20101393_3 87 90
depressive 20101393_3 91 101
/ 20101393_3 102 103
anxiety 20101393_3 104 111
symptomatology 20101393_3 112 126
after 20101393_3 127 132
controlling 20101393_3 133 144
for 20101393_3 145 148
known 20101393_3 149 154
environmental 20101393_3 155 168
and 20101393_3 169 172
genetic 20101393_3 173 180
( 20101393_3 181 182
polymorphism 20101393_3 183 195
of 20101393_3 196 198
the 20101393_3 199 202
serotonin 20101393_3 203 212
transporter 20101393_3 213 224
gene 20101393_3 225 229
) 20101393_3 230 231
risk 20101393_3 232 236
factors 20101393_3 237 244
for 20101393_3 245 248
depression 20101393_3 249 259
and 20101393_3 260 263
anxiety 20101393_3 264 271
disorders 20101393_3 272 281
. 20101393_3 282 283

CFTR 24204751_5 0 4
- 24204751_5 5 6
dependent 24204751_5 6 15
secretion 24204751_5 16 25
( 24204751_5 26 27
C 24204751_5 28 29
- 24204751_5 29 30
sweat 24204751_5 30 35
) 24204751_5 36 37
was 24204751_5 38 41
stimulated 24204751_5 42 52
with 24204751_5 53 57
a 24204751_5 58 59
b 24204751_5 60 61
- 24204751_5 61 62
adrenergic 24204751_5 62 72
cocktail 24204751_5 73 81
that 24204751_5 82 86
elevates 24204751_5 87 95
cytosolic 24204751_5 96 105
cAMP 24204751_5 106 110
while 24204751_5 111 116
blocking 24204751_5 117 125
muscarinic 24204751_5 126 136
receptors 24204751_5 137 146
. 24204751_5 147 148

Interestingly 12509456_18 0 13
, 12509456_18 14 15
BRCA 12509456_18 16 20
1 12509456_18 20 21
mRNA 12509456_18 22 26
expression 12509456_18 27 37
in 12509456_18 38 40
HCC 12509456_18 41 44
- 12509456_18 44 45
1937 12509456_18 45 49
breast 12509456_18 50 56
cancer 12509456_18 57 63
cells 12509456_18 64 69
, 12509456_18 70 71
which 12509456_18 72 77
express 12509456_18 78 85
C 12509456_18 86 87
- 12509456_18 88 89
terminally 12509456_18 89 99
truncated 12509456_18 100 109
BRCA 12509456_18 110 114
1 12509456_18 114 115
, 12509456_18 116 117
was 12509456_18 118 121
not 12509456_18 122 125
affected 12509456_18 126 134
by 12509456_18 135 137
either 12509456_18 138 144
LAM 12509456_18 145 148
or 12509456_18 149 151
CL 12509456_18 152 154
4 12509456_18 154 155
. 12509456_18 156 157

RATIONALE 16163519_2 0 9
: 16163519_2 10 11
Dopamine 16163519_2 12 20
beta 16163519_2 21 25
- 16163519_2 25 26
hydroxylase 16163519_2 26 37
( 16163519_2 38 39
DBH 16163519_2 40 43
) 16163519_2 44 45
converts 16163519_2 46 54
dopamine 16163519_2 55 63
( 16163519_2 64 65
DA 16163519_2 66 68
) 16163519_2 69 70
to 16163519_2 71 73
norepinephrine 16163519_2 74 88
( 16163519_2 89 90
NE 16163519_2 91 93
) 16163519_2 94 95
, 16163519_2 96 97
thus 16163519_2 98 102
playing 16163519_2 103 110
a 16163519_2 111 112
critical 16163519_2 113 121
role 16163519_2 122 126
in 16163519_2 127 129
catecholamine 16163519_2 130 143
metabolism 16163519_2 144 154
. 16163519_2 155 156

CONCLUSIONS 19398669_11 0 11
: 19398669_11 12 13
Genetic 19398669_11 14 21
polymorphism 19398669_11 22 34
677 19398669_11 35 38
C 19398669_11 39 40
> 19398669_11 40 41
T 19398669_11 41 42
on 19398669_11 43 45
MTHFR 19398669_11 46 51
affects 19398669_11 52 59
vascular 19398669_11 60 68
5 19398669_11 69 70
- 19398669_11 70 71
MTHF 19398669_11 71 75
( 19398669_11 76 77
but 19398669_11 78 81
not 19398669_11 82 85
homocysteine 19398669_11 86 98
) 19398669_11 99 100
and 19398669_11 101 104
can 19398669_11 105 108
be 19398669_11 109 111
used 19398669_11 112 116
as 19398669_11 117 119
a 19398669_11 120 121
model 19398669_11 122 127
to 19398669_11 128 130
distinguish 19398669_11 131 142
the 19398669_11 143 146
chronic 19398669_11 147 154
effects 19398669_11 155 162
of 19398669_11 163 165
vascular 19398669_11 166 174
5 19398669_11 175 176
- 19398669_11 176 177
MTHF 19398669_11 177 181
from 19398669_11 182 186
homocysteine 19398669_11 187 199
on 19398669_11 200 202
vascular 19398669_11 203 211
wall 19398669_11 212 216
. 19398669_11 217 218

RESULTS 23225895_8 0 7
: 23225895_8 8 9
Reinfecting 23225895_8 10 21
parasites 23225895_8 22 31
with 23225895_8 32 36
the 23225895_8 37 40
pfmdr 23225895_8 41 46
1 23225895_8 46 47
N 23225895_8 48 49
86 23225895_8 49 51
/ 23225895_8 51 52
184 23225895_8 52 55
F 23225895_8 55 56
/ 23225895_8 56 57
D 23225895_8 57 58
1246 23225895_8 58 62
haplotype 23225895_8 63 72
were 23225895_8 73 77
able 23225895_8 78 82
to 23225895_8 83 85
withstand 23225895_8 86 95
lumefantrine 23225895_8 96 108
blood 23225895_8 109 114
concentrations 23225895_8 115 129
15 23225895_8 130 132
- 23225895_8 132 133
fold 23225895_8 133 137
higher 23225895_8 138 144
than 23225895_8 145 149
those 23225895_8 150 155
with 23225895_8 156 160
the 23225895_8 161 164
86 23225895_8 165 167
Y 23225895_8 167 168
/ 23225895_8 168 169
Y 23225895_8 169 170
184 23225895_8 170 173
/ 23225895_8 173 174
1246 23225895_8 174 178
Y 23225895_8 178 179
haplotype 23225895_8 180 189
. 23225895_8 190 191

Although 16773681_6 0 8
pharmacogenetics 16773681_6 9 25
is 16773681_6 26 28
a 16773681_6 29 30
promising 16773681_6 31 40
field 16773681_6 41 46
that 16773681_6 47 51
already 16773681_6 52 59
contributed 16773681_6 60 71
to 16773681_6 72 74
a 16773681_6 75 76
better 16773681_6 77 83
understanding 16773681_6 84 97
of 16773681_6 98 100
some 16773681_6 101 105
of 16773681_6 106 108
the 16773681_6 109 112
underlying 16773681_6 113 123
mechanisms 16773681_6 124 134
of 16773681_6 135 137
action 16773681_6 138 144
of 16773681_6 145 147
drugs 16773681_6 148 153
used 16773681_6 154 158
in 16773681_6 159 161
IBD 16773681_6 162 165
, 16773681_6 166 167
the 16773681_6 168 171
only 16773681_6 172 176
discovery 16773681_6 177 186
translated 16773681_6 187 197
until 16773681_6 198 203
now 16773681_6 204 207
into 16773681_6 208 212
daily 16773681_6 213 218
practice 16773681_6 219 227
is 16773681_6 228 230
the 16773681_6 231 234
relation 16773681_6 235 243
between 16773681_6 244 251
thiopurine 16773681_6 252 262
S 16773681_6 263 264
- 16773681_6 264 265
methyltransferase 16773681_6 265 282
( 16773681_6 283 284
TPMT 16773681_6 285 289
) 16773681_6 290 291
gene 16773681_6 292 296
polymorphisms 16773681_6 297 310
and 16773681_6 311 314
hematological 16773681_6 315 328
toxicity 16773681_6 329 337
of 16773681_6 338 340
thiopurine 16773681_6 341 351
treatment 16773681_6 352 361
. 16773681_6 362 363

On 10102685_7 0 2
day 10102685_7 3 6
21 10102685_7 7 9
after 10102685_7 10 15
the 10102685_7 16 19
first 10102685_7 20 25
streptozotocin 10102685_7 26 40
( 10102685_7 41 42
STZ 10102685_7 43 46
) 10102685_7 47 48
injection 10102685_7 49 58
, 10102685_7 59 60
75 10102685_7 61 63
% 10102685_7 64 65
of 10102685_7 66 68
the 10102685_7 69 72
C 10102685_7 73 74
57 10102685_7 74 76
BL 10102685_7 76 78
/ 10102685_7 78 79
6 10102685_7 79 80
mice 10102685_7 81 85
and 10102685_7 86 89
100 10102685_7 90 93
% 10102685_7 94 95
of 10102685_7 96 98
the 10102685_7 99 102
129 10102685_7 103 106
SvEv 10102685_7 106 110
mice 10102685_7 111 115
had 10102685_7 116 119
blood 10102685_7 120 125
glucose 10102685_7 126 133
levels 10102685_7 134 140
> 10102685_7 141 142
11 10102685_7 143 145
mmol 10102685_7 146 150
/ 10102685_7 150 151
l 10102685_7 151 152
, 10102685_7 153 154
whereas 10102685_7 155 162
the 10102685_7 163 166
corresponding 10102685_7 167 180
number 10102685_7 181 187
for 10102685_7 188 191
iNOS 10102685_7 192 196
- 10102685_7 197 198
/ 10102685_7 199 200
- 10102685_7 201 202
mice 10102685_7 203 207
was 10102685_7 208 211
only 10102685_7 212 216
23 10102685_7 217 219
% 10102685_7 220 221
. 10102685_7 222 223

The 18161298_22 0 3
expression 18161298_22 4 14
of 18161298_22 15 17
cleaved 18161298_22 18 25
Caspase 18161298_22 26 33
- 18161298_22 33 34
3 18161298_22 34 35
in 18161298_22 36 38
WCA 18161298_22 39 42
group 18161298_22 43 48
and 18161298_22 49 52
5 18161298_22 53 54
- 18161298_22 54 55
FU 18161298_22 55 57
group 18161298_22 58 63
was 18161298_22 64 67
significantly 18161298_22 68 81
increased 18161298_22 82 91
compared 18161298_22 92 100
with 18161298_22 101 105
the 18161298_22 106 109
control 18161298_22 110 117
group 18161298_22 118 123
respectively 18161298_22 124 136
. 18161298_22 137 138

Nigrostriatal 10864974_1 0 13
lesions 10864974_1 14 21
alter 10864974_1 22 27
oral 10864974_1 28 32
dyskinesia 10864974_1 33 43
and 10864974_1 44 47
c 10864974_1 48 49
- 10864974_1 49 50
Fos 10864974_1 50 53
expression 10864974_1 54 64
induced 10864974_1 65 72
by 10864974_1 73 75
the 10864974_1 76 79
serotonin 10864974_1 80 89
agonist 10864974_1 90 97
1 10864974_1 98 99
- 10864974_1 99 100
( 10864974_1 100 101
m 10864974_1 101 102
- 10864974_1 102 103
chlorophenyl 10864974_1 103 115
) 10864974_1 115 116
piperazine 10864974_1 116 126
in 10864974_1 127 129
adult 10864974_1 130 135
rats 10864974_1 136 140
. 10864974_1 141 142

In 9563874_17 0 2
fact 9563874_17 3 7
, 9563874_17 8 9
the 9563874_17 10 13
combined 9563874_17 14 22
interference 9563874_17 23 35
with 9563874_17 36 40
both 9563874_17 41 45
EGFR 9563874_17 46 50
and 9563874_17 51 54
PKAI 9563874_17 55 59
with 9563874_17 60 64
specific 9563874_17 65 73
pharmacological 9563874_17 74 89
agents 9563874_17 90 96
, 9563874_17 97 98
such 9563874_17 99 103
as 9563874_17 104 106
anti 9563874_17 107 111
- 9563874_17 111 112
EGFR 9563874_17 113 117
blocking 9563874_17 118 126
MAbs 9563874_17 127 131
and 9563874_17 132 135
cAMP 9563874_17 136 140
analogues 9563874_17 141 150
, 9563874_17 151 152
has 9563874_17 153 156
a 9563874_17 157 158
cooperative 9563874_17 159 170
antiproliferative 9563874_17 171 188
effect 9563874_17 189 195
on 9563874_17 196 198
human 9563874_17 199 204
cancer 9563874_17 205 211
cell 9563874_17 212 216
lines 9563874_17 217 222
in 9563874_17 223 225
vitro 9563874_17 226 231
and 9563874_17 232 235
in 9563874_17 236 238
vivo 9563874_17 239 243
. 9563874_17 244 245

Human 23115637_2 0 5
genetic 23115637_2 6 13
studies 23115637_2 14 21
have 23115637_2 22 26
suggested 23115637_2 27 36
that 23115637_2 37 41
polymorphisms 23115637_2 42 55
of 23115637_2 56 58
the 23115637_2 59 62
GABRA 23115637_2 63 68
2 23115637_2 68 69
gene 23115637_2 70 74
encoding 23115637_2 75 83
the 23115637_2 84 87
GABA 23115637_2 88 92
( 23115637_2 93 94
A 23115637_2 95 96
) 23115637_2 97 98
a 23115637_2 99 100
2 23115637_2 100 101
- 23115637_2 101 102
subunit 23115637_2 102 109
are 23115637_2 110 113
associated 23115637_2 114 124
with 23115637_2 125 129
ethanol 23115637_2 130 137
dependence 23115637_2 138 148
. 23115637_2 149 150

Crizotinib 22989574_5 0 10
continued 22989574_5 11 20
to 22989574_5 21 23
be 22989574_5 24 26
developed 22989574_5 27 36
as 22989574_5 37 39
an 22989574_5 40 42
ALK 22989574_5 43 46
and 22989574_5 47 50
MET 22989574_5 51 54
inhibitor 22989574_5 55 64
in 22989574_5 65 67
other 22989574_5 68 73
tumor 22989574_5 74 79
types 22989574_5 80 85
driven 22989574_5 86 92
by 22989574_5 93 95
alteration 22989574_5 96 106
in 22989574_5 107 109
ALK 22989574_5 110 113
and 22989574_5 114 117
MET 22989574_5 118 121
. 22989574_5 122 123

RESULTS 21366650_6 0 7
: 21366650_6 8 9
There 21366650_6 10 15
were 21366650_6 16 20
no 21366650_6 21 23
significant 21366650_6 24 35
differences 21366650_6 36 47
in 21366650_6 48 50
the 21366650_6 51 54
dose 21366650_6 55 59
- 21366650_6 59 60
adjusted 21366650_6 60 68
area 21366650_6 69 73
under 21366650_6 74 79
the 21366650_6 80 83
plasma 21366650_6 84 90
concentration 21366650_6 91 104
- 21366650_6 104 105
time 21366650_6 105 109
curve 21366650_6 110 115
( 21366650_6 116 117
AUC 21366650_6 118 121
( 21366650_6 122 123
0 21366650_6 124 125
- 21366650_6 125 126
12 21366650_6 126 128
) 21366650_6 129 130
) 21366650_6 131 132
and 21366650_6 133 136
maximum 21366650_6 137 144
plasma 21366650_6 145 151
concentration 21366650_6 152 165
( 21366650_6 166 167
C 21366650_6 168 169
( 21366650_6 170 171
max 21366650_6 172 175
) 21366650_6 176 177
) 21366650_6 178 179
of 21366650_6 180 182
tacrolimus 21366650_6 183 193
between 21366650_6 194 201
CYP 21366650_6 202 205
2 21366650_6 205 206
C 21366650_6 206 207
19 21366650_6 207 209
genotype 21366650_6 210 218
groups 21366650_6 219 225
, 21366650_6 226 227
but 21366650_6 228 231
there 21366650_6 232 237
were 21366650_6 238 242
significant 21366650_6 243 254
differences 21366650_6 255 266
between 21366650_6 267 274
CYP 21366650_6 275 278
3 21366650_6 278 279
A 21366650_6 279 280
5 21366650_6 280 281
genotypes 21366650_6 282 291
groups 21366650_6 292 298
( 21366650_6 299 300
* 21366650_6 301 302
1 21366650_6 303 304
/ 21366650_6 305 306
* 21366650_6 307 308
1 21366650_6 309 310
+ 21366650_6 311 312
* 21366650_6 313 314
1 21366650_6 315 316
/ 21366650_6 317 318
* 21366650_6 319 320
3 21366650_6 321 322
vs 21366650_6 323 325
. 21366650_6 325 326
* 21366650_6 327 328
3 21366650_6 329 330
/ 21366650_6 331 332
* 21366650_6 333 334
3 21366650_6 335 336
= 21366650_6 337 338
45 21366650_6 339 341
2 21366650_6 342 343
20 21366650_6 344 346
0 21366650_6 347 348
vs 21366650_6 349 351
. 21366650_6 351 352
71 21366650_6 353 355
0 21366650_6 356 357
34 21366650_6 358 360
1 21366650_6 361 362
ng 21366650_6 363 365
h 21366650_6 366 367
/ 21366650_6 367 368
mL 21366650_6 368 370
/ 21366650_6 370 371
mg 21366650_6 371 373
, 21366650_6 374 375
P 21366650_6 376 377
< 21366650_6 378 379
0 21366650_6 380 381
0001 21366650_6 382 386
and 21366650_6 387 390
6 21366650_6 391 392
3 21366650_6 393 394
2 21366650_6 395 396
6 21366650_6 397 398
vs 21366650_6 399 401
. 21366650_6 401 402
9 21366650_6 403 404
3 21366650_6 405 406
7 21366650_6 407 408
0 21366650_6 409 410
ng 21366650_6 411 413
/ 21366650_6 413 414
mL 21366650_6 414 416
/ 21366650_6 416 417
mg 21366650_6 417 419
, 21366650_6 420 421
P 21366650_6 422 423
= 21366650_6 424 425
0 21366650_6 426 427
0017 21366650_6 428 432
, 21366650_6 433 434
respectively 21366650_6 435 447
) 21366650_6 448 449
and 21366650_6 450 453
between 21366650_6 454 461
co 21366650_6 462 464
- 21366650_6 464 465
administration 21366650_6 465 479
with 21366650_6 480 484
and 21366650_6 485 488
without 21366650_6 489 496
lansoprazole 21366650_6 497 509
( 21366650_6 510 511
74 21366650_6 512 514
5 21366650_6 515 516
34 21366650_6 517 519
0 21366650_6 520 521
vs 21366650_6 522 524
. 21366650_6 524 525
52 21366650_6 526 528
4 21366650_6 529 530
27 21366650_6 531 533
4 21366650_6 534 535
ng 21366650_6 536 538
h 21366650_6 539 540
/ 21366650_6 540 541
mL 21366650_6 541 543
/ 21366650_6 543 544
mg 21366650_6 544 546
, 21366650_6 547 548
P 21366650_6 549 550
= 21366650_6 551 552
0 21366650_6 553 554
0054 21366650_6 555 559
and 21366650_6 560 563
10 21366650_6 564 566
9 21366650_6 567 568
8 21366650_6 569 570
8 21366650_6 571 572
vs 21366650_6 573 575
. 21366650_6 575 576
6 21366650_6 577 578
7 21366650_6 579 580
3 21366650_6 581 582
0 21366650_6 583 584
ng 21366650_6 585 587
/ 21366650_6 587 588
mL 21366650_6 588 590
/ 21366650_6 590 591
mg 21366650_6 591 593
, 21366650_6 594 595
P 21366650_6 596 597
= 21366650_6 598 599
0 21366650_6 600 601
0024 21366650_6 602 606
, 21366650_6 607 608
respectively 21366650_6 609 621
) 21366650_6 622 623
. 21366650_6 624 625

Thus 16115938_12 0 4
, 16115938_12 5 6
antisense 16115938_12 7 16
PKA 16115938_12 17 20
RIalpha 16115938_12 21 28
and 16115938_12 29 32
CpG 16115938_12 33 36
immunomer 16115938_12 37 46
in 16115938_12 47 49
combination 16115938_12 50 61
work 16115938_12 62 66
cooperatively 16115938_12 67 80
and 16115938_12 81 84
as 16115938_12 85 87
tumor 16115938_12 88 93
- 16115938_12 94 95
targeted 16115938_12 95 103
therapeutics 16115938_12 104 116
to 16115938_12 117 119
treat 16115938_12 120 125
human 16115938_12 126 131
cancer 16115938_12 132 138
. 16115938_12 139 140

Omacetaxine 22896000_13 0 11
may 22896000_13 12 15
provide 22896000_13 16 23
a 22896000_13 24 25
safe 22896000_13 26 30
and 22896000_13 31 34
effective 22896000_13 35 44
treatment 22896000_13 45 54
for 22896000_13 55 58
CML 22896000_13 59 62
patients 22896000_13 63 71
with 22896000_13 72 76
T 22896000_13 77 78
315 22896000_13 78 81
I 22896000_13 81 82
mutation 22896000_13 83 91
. 22896000_13 92 93

HLA 21676164_1 0 3
- 21676164_1 3 4
B 21676164_1 4 5
* 21676164_1 6 7
1502 21676164_1 8 12
strongly 21676164_1 13 21
predicts 21676164_1 22 30
carbamazepine 21676164_1 31 44
- 21676164_1 45 46
induced 21676164_1 46 53
Stevens 21676164_1 54 61
- 21676164_1 61 62
Johnson 21676164_1 62 69
syndrome 21676164_1 70 78
and 21676164_1 79 82
toxic 21676164_1 83 88
epidermal 21676164_1 89 98
necrolysis 21676164_1 99 109
in 21676164_1 110 112
Thai 21676164_1 113 117
patients 21676164_1 118 126
with 21676164_1 127 131
neuropathic 21676164_1 132 143
pain 21676164_1 144 148
. 21676164_1 149 150

The 19391036_8 0 3
present 19391036_8 4 11
study 19391036_8 12 17
suggests 19391036_8 18 26
that 19391036_8 27 31
A 19391036_8 32 33
1298 19391036_8 33 37
C 19391036_8 37 38
gene 19391036_8 39 43
, 19391036_8 44 45
but 19391036_8 46 49
not 19391036_8 50 53
C 19391036_8 54 55
677 19391036_8 55 58
T 19391036_8 58 59
polymorphism 19391036_8 60 72
is 19391036_8 73 75
associated 19391036_8 76 86
with 19391036_8 87 91
MTX 19391036_8 92 95
- 19391036_8 96 97
related 19391036_8 97 104
toxicity 19391036_8 105 113
. 19391036_8 114 115

C 18385200_4 0 1
- 18385200_4 1 2
MYC 18385200_4 2 5
and 18385200_4 6 9
DHFR 18385200_4 10 14
protein 18385200_4 15 22
levels 18385200_4 23 29
at 18385200_4 30 32
diagnosis 18385200_4 33 42
were 18385200_4 43 47
assessed 18385200_4 48 56
by 18385200_4 57 59
immunohistochemistry 18385200_4 60 80
on 18385200_4 81 83
series 18385200_4 84 90
of 18385200_4 91 93
patients 18385200_4 94 102
treated 18385200_4 103 110
with 18385200_4 111 115
either 18385200_4 116 122
a 18385200_4 123 124
MTX 18385200_4 125 128
- 18385200_4 129 130
based 18385200_4 130 135
protocol 18385200_4 136 144
( 18385200_4 145 146
IOR 18385200_4 147 150
/ 18385200_4 150 151
OS 18385200_4 151 153
- 18385200_4 153 154
1 18385200_4 154 155
; 18385200_4 156 157
72 18385200_4 158 160
patients 18385200_4 161 169
) 18385200_4 170 171
or 18385200_4 172 174
with 18385200_4 175 179
a 18385200_4 180 181
standard 18385200_4 182 190
four 18385200_4 191 195
- 18385200_4 195 196
drug 18385200_4 196 200
regimen 18385200_4 201 208
( 18385200_4 209 210
ISG 18385200_4 211 214
/ 18385200_4 214 215
SSG 18385200_4 216 219
1 18385200_4 220 221
; 18385200_4 222 223
61 18385200_4 224 226
patients 18385200_4 227 235
) 18385200_4 236 237
. 18385200_4 238 239

In 21801714_9 0 2
Nrf 21801714_9 3 6
2 21801714_9 6 7
knock 21801714_9 8 13
- 21801714_9 13 14
out 21801714_9 14 17
cells 21801714_9 18 23
, 21801714_9 24 25
Cln 21801714_9 26 29
could 21801714_9 30 35
not 21801714_9 36 39
elevate 21801714_9 40 47
UGT 21801714_9 48 51
1 21801714_9 51 52
A 21801714_9 52 53
1 21801714_9 53 54
activity 21801714_9 55 63
indicating 21801714_9 64 74
Nrf 21801714_9 75 78
2 21801714_9 78 79
to 21801714_9 80 82
be 21801714_9 83 85
its 21801714_9 86 89
target 21801714_9 90 96
. 21801714_9 97 98

The 24355137_1 0 3
association 24355137_1 4 15
of 24355137_1 16 18
5 24355137_1 19 20
- 24355137_1 20 21
HTR 24355137_1 21 24
2 24355137_1 24 25
A 24355137_1 25 26
- 24355137_1 27 28
1438 24355137_1 28 32
A 24355137_1 32 33
/ 24355137_1 33 34
G 24355137_1 34 35
, 24355137_1 36 37
COMT 24355137_1 38 42
Val 24355137_1 43 46
158 24355137_1 46 49
Met 24355137_1 49 52
, 24355137_1 53 54
MAOA 24355137_1 55 59
- 24355137_1 60 61
LPR 24355137_1 61 64
, 24355137_1 65 66
DAT 24355137_1 67 70
VNTR 24355137_1 71 75
and 24355137_1 76 79
5 24355137_1 80 81
- 24355137_1 81 82
HTT 24355137_1 82 85
VNTR 24355137_1 86 90
gene 24355137_1 91 95
polymorphisms 24355137_1 96 109
and 24355137_1 110 113
borderline 24355137_1 114 124
personality 24355137_1 125 136
disorder 24355137_1 137 145
in 24355137_1 146 148
female 24355137_1 149 155
heroin 24355137_1 156 162
- 24355137_1 163 164
dependent 24355137_1 164 173
Chinese 24355137_1 174 181
subjects 24355137_1 182 190
. 24355137_1 191 192

The 10949117_3 0 3
present 10949117_3 4 11
association 10949117_3 12 23
study 10949117_3 24 29
tested 10949117_3 30 36
the 10949117_3 37 40
hypothesis 10949117_3 41 51
that 10949117_3 52 56
hMOR 10949117_3 57 61
exon 10949117_3 62 66
1 10949117_3 67 68
variants 10949117_3 69 77
elicit 10949117_3 78 84
susceptibility 10949117_3 85 99
to 10949117_3 100 102
alcohol 10949117_3 103 110
dependence 10949117_3 111 121
. 10949117_3 122 123

The 9761125_9 0 3
incidence 9761125_9 4 13
and 9761125_9 14 17
type 9761125_9 18 22
of 9761125_9 23 25
p 9761125_9 26 27
53 9761125_9 27 29
mutation 9761125_9 30 38
did 9761125_9 39 42
not 9761125_9 43 46
differ 9761125_9 47 53
significantly 9761125_9 54 67
in 9761125_9 68 70
patients 9761125_9 71 79
with 9761125_9 80 84
a 9761125_9 85 86
history 9761125_9 87 94
of 9761125_9 95 97
phenacetin 9761125_9 98 108
abuse 9761125_9 109 114
, 9761125_9 115 116
smoking 9761125_9 117 124
or 9761125_9 125 127
neither 9761125_9 128 135
of 9761125_9 136 138
these 9761125_9 139 144
habits 9761125_9 145 151
. 9761125_9 152 153

In 18480244_5 0 2
these 18480244_5 3 8
experiments 18480244_5 9 20
, 18480244_5 21 22
we 18480244_5 23 25
used 18480244_5 26 30
a 18480244_5 31 32
potent 18480244_5 33 39
synthetic 18480244_5 40 49
TLR 18480244_5 50 53
7 18480244_5 53 54
ligand 18480244_5 55 61
, 18480244_5 62 63
9 18480244_5 64 65
- 18480244_5 65 66
benzyl 18480244_5 66 72
- 18480244_5 72 73
8 18480244_5 73 74
- 18480244_5 74 75
hydroxy 18480244_5 75 82
- 18480244_5 82 83
2 18480244_5 83 84
- 18480244_5 84 85
( 18480244_5 85 86
2 18480244_5 86 87
- 18480244_5 87 88
methoxyethoxy 18480244_5 88 101
) 18480244_5 101 102
adenine 18480244_5 102 109
( 18480244_5 110 111
SM 18480244_5 112 114
360320 18480244_5 114 120
; 18480244_5 121 122
1 18480244_5 123 124
V 18480244_5 124 125
136 18480244_5 125 128
) 18480244_5 129 130
, 18480244_5 131 132
to 18480244_5 133 135
investigate 18480244_5 136 147
the 18480244_5 148 151
consequences 18480244_5 152 164
of 18480244_5 165 167
TLR 18480244_5 168 171
7 18480244_5 171 172
activation 18480244_5 173 183
in 18480244_5 184 186
genetically 18480244_5 187 198
defined 18480244_5 199 206
strains 18480244_5 207 214
of 18480244_5 215 217
mice 18480244_5 218 222
. 18480244_5 223 224

This 27096382_17 0 4
response 27096382_17 5 13
was 27096382_17 14 17
independent 27096382_17 18 29
of 27096382_17 30 32
IL 27096382_17 33 35
36 27096382_17 35 37
RN 27096382_17 37 39
mutations 27096382_17 40 49
and 27096382_17 50 53
consolidated 27096382_17 54 66
by 27096382_17 67 69
combination 27096382_17 70 81
with 27096382_17 82 86
low 27096382_17 87 90
doses 27096382_17 91 96
of 27096382_17 97 99
the 27096382_17 100 103
retinoid 27096382_17 104 112
acitretin 27096382_17 113 122
. 27096382_17 123 124

The 17919354_6 0 3
pertinence 17919354_6 4 14
of 17919354_6 15 17
HFE 17919354_6 18 21
mutations 17919354_6 22 31
, 17919354_6 32 33
anastrozole 17919354_6 34 45
and 17919354_6 46 49
tamoxifen 17919354_6 50 59
treatment 17919354_6 60 69
, 17919354_6 70 71
and 17919354_6 72 75
chemotherapy 17919354_6 76 88
to 17919354_6 89 91
the 17919354_6 92 95
development 17919354_6 96 107
and 17919354_6 108 111
management 17919354_6 112 122
of 17919354_6 123 125
PCT 17919354_6 126 129
in 17919354_6 130 132
women 17919354_6 133 138
with 17919354_6 139 143
breast 17919354_6 144 150
cancer 17919354_6 151 157
is 17919354_6 158 160
discussed 17919354_6 161 170
. 17919354_6 171 172

Impact 23778325_1 0 6
of 23778325_1 7 9
genetic 23778325_1 10 17
polymorphisms 23778325_1 18 31
on 23778325_1 32 34
adenoma 23778325_1 35 42
recurrence 23778325_1 43 53
and 23778325_1 54 57
toxicity 23778325_1 58 66
in 23778325_1 67 69
a 23778325_1 70 71
COX 23778325_1 72 75
2 23778325_1 75 76
inhibitor 23778325_1 77 86
( 23778325_1 87 88
celecoxib 23778325_1 89 98
) 23778325_1 99 100
trial 23778325_1 101 106
: 23778325_1 107 108
results 23778325_1 109 116
from 23778325_1 117 121
a 23778325_1 122 123
pilot 23778325_1 124 129
study 23778325_1 130 135
. 23778325_1 136 137

CONCLUSIONS 17998284_10 0 11
: 17998284_10 12 13
KRAS 17998284_10 14 18
WT 17998284_10 19 21
status 17998284_10 22 28
is 17998284_10 29 31
associated 17998284_10 32 42
to 17998284_10 43 45
survival 17998284_10 46 54
benefit 17998284_10 55 62
in 17998284_10 63 65
CTX 17998284_10 66 69
treated 17998284_10 70 77
mCRC 17998284_10 78 82
. 17998284_10 83 84

PURPOSE 18349392_2 0 7
: 18349392_2 8 9
Regulation 18349392_2 10 20
of 18349392_2 21 23
epidermal 18349392_2 24 33
growth 18349392_2 34 40
factor 18349392_2 41 47
receptor 18349392_2 48 56
( 18349392_2 57 58
EGFR 18349392_2 59 63
) 18349392_2 64 65
signaling 18349392_2 66 75
pathways 18349392_2 76 84
may 18349392_2 85 88
play 18349392_2 89 93
a 18349392_2 94 95
relevant 18349392_2 96 104
role 18349392_2 105 109
in 18349392_2 110 112
determining 18349392_2 113 124
the 18349392_2 125 128
activity 18349392_2 129 137
of 18349392_2 138 140
cetuximab 18349392_2 141 150
therapy 18349392_2 151 158
in 18349392_2 159 161
patients 18349392_2 162 170
with 18349392_2 171 175
metastatic 18349392_2 176 186
colorectal 18349392_2 187 197
cancer 18349392_2 198 204
( 18349392_2 205 206
MCRC 18349392_2 207 211
) 18349392_2 212 213
. 18349392_2 214 215

Genetic 23918539_1 0 7
variation 23918539_1 8 17
in 23918539_1 18 20
NOS 23918539_1 21 24
2 23918539_1 24 25
A 23918539_1 25 26
is 23918539_1 27 29
associated 23918539_1 30 40
with 23918539_1 41 45
a 23918539_1 46 47
sustained 23918539_1 48 57
virological 23918539_1 58 69
response 23918539_1 70 78
to 23918539_1 79 81
peginterferon 23918539_1 82 95
plus 23918539_1 96 100
ribavirin 23918539_1 101 110
therapy 23918539_1 111 118
for 23918539_1 119 122
chronic 23918539_1 123 130
hepatitis 23918539_1 131 140
C 23918539_1 141 142
in 23918539_1 143 145
Taiwanese 23918539_1 146 155
Chinese 23918539_1 156 163
. 23918539_1 164 165

Pdyn 19559544_5 0 4
gene 19559544_5 5 9
deficiency 19559544_5 10 20
potentiates 19559544_5 21 32
nalbuphine 19559544_5 33 43
- 19559544_5 44 45
induced 19559544_5 45 52
behavioral 19559544_5 53 63
sensitization 19559544_5 64 77
of 19559544_5 78 80
locomotor 19559544_5 81 90
activity 19559544_5 91 99
and 19559544_5 100 103
accumbal 19559544_5 104 112
c 19559544_5 113 114
- 19559544_5 114 115
Fos 19559544_5 115 118
expression 19559544_5 119 129
. 19559544_5 130 131

Resistance 15259893_9 0 10
during 15259893_9 11 17
exposure 15259893_9 18 26
to 15259893_9 27 29
amprenavir 15259893_9 30 40
can 15259893_9 41 44
follow 15259893_9 45 51
development 15259893_9 52 63
of 15259893_9 64 66
I 15259893_9 67 68
50 15259893_9 68 70
V 15259893_9 70 71
, 15259893_9 72 73
which 15259893_9 74 79
also 15259893_9 80 84
may 15259893_9 85 88
confer 15259893_9 89 95
resistance 15259893_9 96 106
to 15259893_9 107 109
lopinavir 15259893_9 110 119
. 15259893_9 120 121

Posaconazole 23147740_1 0 12
pharmacodynamic 23147740_1 13 28
target 23147740_1 29 35
determination 23147740_1 36 49
against 23147740_1 50 57
wild 23147740_1 58 62
- 23147740_1 62 63
type 23147740_1 63 67
and 23147740_1 68 71
Cyp 23147740_1 72 75
51 23147740_1 75 77
mutant 23147740_1 78 84
isolates 23147740_1 85 93
of 23147740_1 94 96
Aspergillus 23147740_1 97 108
fumigatus 23147740_1 109 118
in 23147740_1 119 121
an 23147740_1 122 124
in 23147740_1 125 127
vivo 23147740_1 128 132
model 23147740_1 133 138
of 23147740_1 139 141
invasive 23147740_1 142 150
pulmonary 23147740_1 151 160
aspergillosis 23147740_1 161 174
. 23147740_1 175 176

BACKGROUND 27525598_2 0 10
: 27525598_2 11 12
A 27525598_2 13 14
polymorphism 27525598_2 15 27
upstream 27525598_2 28 36
of 27525598_2 37 39
interleukin 27525598_2 40 51
( 27525598_2 52 53
IL 27525598_2 53 55
) 27525598_2 55 56
- 27525598_2 56 57
28 27525598_2 57 59
B 27525598_2 59 60
was 27525598_2 61 64
recently 27525598_2 65 73
identified 27525598_2 74 84
to 27525598_2 85 87
be 27525598_2 88 90
associated 27525598_2 91 101
with 27525598_2 102 106
a 27525598_2 107 108
2 27525598_2 109 110
- 27525598_2 110 111
fold 27525598_2 111 115
difference 27525598_2 116 126
in 27525598_2 127 129
sustained 27525598_2 130 139
virologic 27525598_2 140 149
response 27525598_2 150 158
( 27525598_2 159 160
SVR 27525598_2 161 164
) 27525598_2 165 166
to 27525598_2 167 169
pegylated 27525598_2 170 179
interferon 27525598_2 180 190
- 27525598_2 190 191
alpha 27525598_2 191 196
and 27525598_2 197 200
ribavirin 27525598_2 201 210
therapy 27525598_2 211 218
in 27525598_2 219 221
a 27525598_2 222 223
large 27525598_2 224 229
cohort 27525598_2 230 236
of 27525598_2 237 239
treatment 27525598_2 240 249
- 27525598_2 249 250
naive 27525598_2 250 255
, 27525598_2 256 257
adherent 27525598_2 258 266
patients 27525598_2 267 275
with 27525598_2 276 280
chronic 27525598_2 281 288
hepatitis 27525598_2 289 298
C 27525598_2 299 300
( 27525598_2 301 302
CHC 27525598_2 303 306
) 27525598_2 307 308
virus 27525598_2 309 314
genotype 27525598_2 315 323
1 27525598_2 324 325
( 27525598_2 326 327
HCV 27525598_2 328 331
- 27525598_2 331 332
1 27525598_2 332 333
) 27525598_2 334 335
infection 27525598_2 336 345
. 27525598_2 346 347

We 12456499_2 0 2
hypothesized 12456499_2 3 15
that 12456499_2 16 20
possession 12456499_2 21 31
of 12456499_2 32 34
either 12456499_2 35 41
of 12456499_2 42 44
2 12456499_2 45 46
functional 12456499_2 47 57
coagulation 12456499_2 58 69
factor 12456499_2 70 76
XIII 12456499_2 77 81
polymorphisms 12456499_2 82 95
, 12456499_2 96 97
one 12456499_2 98 101
within 12456499_2 102 108
subunit 12456499_2 109 116
A 12456499_2 117 118
( 12456499_2 119 120
Val 12456499_2 121 124
34 12456499_2 124 126
Leu 12456499_2 126 129
) 12456499_2 130 131
and 12456499_2 132 135
one 12456499_2 136 139
within 12456499_2 140 146
subunit 12456499_2 147 154
B 12456499_2 155 156
( 12456499_2 157 158
His 12456499_2 159 162
95 12456499_2 162 164
Arg 12456499_2 164 167
) 12456499_2 168 169
, 12456499_2 170 171
might 12456499_2 172 177
modulate 12456499_2 178 186
the 12456499_2 187 190
prothrombotic 12456499_2 191 204
effects 12456499_2 205 212
of 12456499_2 213 215
estrogen 12456499_2 216 224
and 12456499_2 225 228
help 12456499_2 229 233
to 12456499_2 234 236
explain 12456499_2 237 244
the 12456499_2 245 248
variation 12456499_2 249 258
in 12456499_2 259 261
incidence 12456499_2 262 271
of 12456499_2 272 274
arterial 12456499_2 275 283
thrombotic 12456499_2 284 294
events 12456499_2 295 301
among 12456499_2 302 307
postmenopausal 12456499_2 308 322
women 12456499_2 323 328
using 12456499_2 329 334
hormone 12456499_2 335 342
replacement 12456499_2 343 354
therapy 12456499_2 355 362
. 12456499_2 363 364

We 22030088_4 0 2
examined 22030088_4 3 11
the 22030088_4 12 15
effect 22030088_4 16 22
of 22030088_4 23 25
combining 22030088_4 26 35
aspirin 22030088_4 36 43
and 22030088_4 44 47
celecoxib 22030088_4 48 57
in 22030088_4 58 60
relation 22030088_4 61 69
to 22030088_4 70 72
UGT 22030088_4 73 76
1 22030088_4 76 77
A 22030088_4 77 78
6 22030088_4 78 79
T 22030088_4 80 81
181 22030088_4 81 84
A 22030088_4 84 85
and 22030088_4 86 89
R 22030088_4 90 91
184 22030088_4 91 94
S 22030088_4 94 95
variants 22030088_4 96 104
among 22030088_4 105 110
1 22030088_4 111 112
, 22030088_4 112 113
647 22030088_4 113 116
patients 22030088_4 117 125
in 22030088_4 126 128
the 22030088_4 129 132
Adenoma 22030088_4 133 140
Prevention 22030088_4 141 151
with 22030088_4 152 156
Celecoxib 22030088_4 157 166
( 22030088_4 167 168
APC 22030088_4 169 172
) 22030088_4 173 174
trial 22030088_4 175 180
who 22030088_4 181 184
were 22030088_4 185 189
stratified 22030088_4 190 200
according 22030088_4 201 210
to 22030088_4 211 213
the 22030088_4 214 217
use 22030088_4 218 221
of 22030088_4 222 224
low 22030088_4 225 228
- 22030088_4 228 229
dose 22030088_4 229 233
aspirin 22030088_4 234 241
after 22030088_4 242 247
removal 22030088_4 248 255
of 22030088_4 256 258
adenomas 22030088_4 259 267
and 22030088_4 268 271
randomized 22030088_4 272 282
to 22030088_4 283 285
placebo 22030088_4 286 293
, 22030088_4 294 295
200 22030088_4 296 299
- 22030088_4 299 300
mg 22030088_4 300 302
twice 22030088_4 303 308
daily 22030088_4 309 314
, 22030088_4 315 316
or 22030088_4 317 319
400 22030088_4 320 323
- 22030088_4 323 324
mg 22030088_4 324 326
twice 22030088_4 327 332
daily 22030088_4 333 338
celecoxib 22030088_4 339 348
for 22030088_4 349 352
3 22030088_4 353 354
years 22030088_4 355 360
. 22030088_4 361 362

In 18695635_12 0 2
conclusion 18695635_12 3 13
, 18695635_12 14 15
our 18695635_12 16 19
findings 18695635_12 20 28
showed 18695635_12 29 35
that 18695635_12 36 40
MPAG 18695635_12 41 45
pharmacokinetics 18695635_12 46 62
were 18695635_12 63 67
significantly 18695635_12 68 81
influenced 18695635_12 82 92
by 18695635_12 93 95
SLCO 18695635_12 96 100
1 18695635_12 100 101
B 18695635_12 101 102
1 18695635_12 102 103
and 18695635_12 104 107
SLCO 18695635_12 108 112
1 18695635_12 112 113
B 18695635_12 113 114
3 18695635_12 114 115
polymorphisms 18695635_12 116 129
and 18695635_12 130 133
not 18695635_12 134 137
by 18695635_12 138 140
UGT 18695635_12 141 144
polymorphisms 18695635_12 145 158
. 18695635_12 159 160

This 1225820_10 0 4
present 1225820_10 5 12
study 1225820_10 13 18
provides 1225820_10 19 27
an 1225820_10 28 30
additional 1225820_10 31 41
piece 1225820_10 42 47
of 1225820_10 48 50
support 1225820_10 51 58
to 1225820_10 59 61
the 1225820_10 62 65
hypothesis 1225820_10 66 76
that 1225820_10 77 81
the 1225820_10 82 85
ChF 1225820_10 86 89
1 1225820_10 89 90
and 1225820_10 91 94
ChS 1225820_10 95 98
1 1225820_10 98 99
are 1225820_10 100 103
alleles 1225820_10 104 111
determining 1225820_10 112 123
the 1225820_10 124 127
synthesis 1225820_10 128 137
of 1225820_10 138 140
usual 1225820_10 141 146
and 1225820_10 147 150
atypical 1225820_10 151 159
cholinesterase 1225820_10 160 174
together 1225820_10 175 183
with 1225820_10 184 188
the 1225820_10 189 192
likelihood 1225820_10 193 203
of 1225820_10 204 206
ChU 1225820_10 207 210
1 1225820_10 210 211
ChD 1225820_10 212 215
1 1225820_10 215 216
heterozygotes 1225820_10 217 230
having 1225820_10 231 237
occasional 1225820_10 238 248
suxamethonium 1225820_10 249 262
apnoea 1225820_10 263 269
. 1225820_10 270 271

In 8524236_7 0 2
plasmid 8524236_7 3 10
constructs 8524236_7 11 21
which 8524236_7 22 27
contained 8524236_7 28 37
a 8524236_7 38 39
chloramphenicol 8524236_7 40 55
acetyltransferase 8524236_7 56 73
reporter 8524236_7 74 82
gene 8524236_7 83 87
and 8524236_7 88 91
the 8524236_7 92 95
wild 8524236_7 96 100
- 8524236_7 100 101
type 8524236_7 101 105
ER 8524236_7 106 108
/ 8524236_7 108 109
Sp 8524236_7 110 112
1 8524236_7 112 113
promoter 8524236_7 114 122
sequence 8524236_7 123 131
, 8524236_7 132 133
E 8524236_7 134 135
2 8524236_7 135 136
- 8524236_7 137 138
induced 8524236_7 138 145
chloramphenicol 8524236_7 146 161
acetyltransferase 8524236_7 162 179
activity 8524236_7 180 188
and 8524236_7 189 192
mRNA 8524236_7 193 197
levels 8524236_7 198 204
were 8524236_7 205 209
inhibited 8524236_7 210 219
by 8524236_7 220 222
TCDD 8524236_7 223 227
whereas 8524236_7 228 235
no 8524236_7 236 238
inhibition 8524236_7 239 249
was 8524236_7 250 253
observed 8524236_7 254 262
with 8524236_7 263 267
the 8524236_7 268 271
mutant 8524236_7 272 278
ER 8524236_7 279 281
/ 8524236_7 281 282
Sp 8524236_7 283 285
1 8524236_7 285 286
- 8524236_7 287 288
" 8524236_7 289 290
XRE 8524236_7 291 294
" 8524236_7 295 296
plasmids 8524236_7 297 305
. 8524236_7 306 307

The 21389156_11 0 3
rs 21389156_11 4 6
8099917 21389156_11 6 13
polymorphism 21389156_11 14 26
should 21389156_11 27 33
be 21389156_11 34 36
the 21389156_11 37 40
best 21389156_11 41 45
predictor 21389156_11 46 55
for 21389156_11 56 59
the 21389156_11 60 63
response 21389156_11 64 72
to 21389156_11 73 75
the 21389156_11 76 79
PEG 21389156_11 80 83
- 21389156_11 84 85
IFN 21389156_11 85 88
/ 21389156_11 89 90
RBV 21389156_11 91 94
treatment 21389156_11 95 104
among 21389156_11 105 110
Japanese 21389156_11 111 119
chronic 21389156_11 120 127
hepatitis 21389156_11 128 137
C 21389156_11 138 139
patients 21389156_11 140 148
. 21389156_11 149 150

Cholestyramine 20034695_6 0 14
is 20034695_6 15 17
essential 20034695_6 18 27
in 20034695_6 28 30
the 20034695_6 31 34
treatment 20034695_6 35 44
of 20034695_6 45 47
sitosterolemia 20034695_6 48 62
( 20034695_6 63 64
ABCG 20034695_6 65 69
5 20034695_6 69 70
/ 20034695_6 71 72
8 20034695_6 72 73
deficiency 20034695_6 74 84
) 20034695_6 85 86
. 20034695_6 87 88

METHODS 17009149_5 0 7
: 17009149_5 8 9
Paraffin 17009149_5 10 18
- 17009149_5 19 20
embedded 17009149_5 20 28
tissues 17009149_5 29 36
from 17009149_5 37 41
54 17009149_5 42 44
patients 17009149_5 45 53
with 17009149_5 54 58
unresectable 17009149_5 59 71
metastases 17009149_5 72 82
from 17009149_5 83 87
colorectal 17009149_5 88 98
cancer 17009149_5 99 105
who 17009149_5 106 109
had 17009149_5 110 113
undergone 17009149_5 114 123
chemotherapy 17009149_5 124 136
with 17009149_5 137 141
the 17009149_5 142 145
FOLFOX 17009149_5 146 152
regimen 17009149_5 153 160
were 17009149_5 161 165
analyzed 17009149_5 166 174
for 17009149_5 175 178
MTHFR 17009149_5 179 184
polymorphisms 17009149_5 185 198
in 17009149_5 199 201
the 17009149_5 202 205
MTHFR 17009149_5 206 211
gene 17009149_5 212 216
( 17009149_5 217 218
677 17009149_5 219 222
C 17009149_5 222 223
- 17009149_5 223 224
- 17009149_5 224 225
> 17009149_5 225 226
T 17009149_5 226 227
, 17009149_5 228 229
Ala 17009149_5 230 233
- 17009149_5 233 234
- 17009149_5 234 235
> 17009149_5 235 236
Val 17009149_5 236 239
mutation 17009149_5 240 248
) 17009149_5 249 250
and 17009149_5 251 254
XRCC 17009149_5 255 259
1 17009149_5 259 260
gene 17009149_5 261 265
( 17009149_5 266 267
Arg 17009149_5 268 271
- 17009149_5 271 272
- 17009149_5 272 273
> 17009149_5 273 274
Gln 17009149_5 274 277
substitution 17009149_5 278 290
in 17009149_5 291 293
exon 17009149_5 294 298
10 17009149_5 299 301
) 17009149_5 302 303
. 17009149_5 304 305

The 19182535_2 0 3
tyrosine 19182535_2 4 12
kinase 19182535_2 13 19
( 19182535_2 20 21
TK 19182535_2 22 24
) 19182535_2 25 26
inhibitor 19182535_2 27 36
, 19182535_2 37 38
imatinib 19182535_2 39 47
, 19182535_2 48 49
has 19182535_2 50 53
revolutionized 19182535_2 54 68
therapy 19182535_2 69 76
of 19182535_2 77 79
malignancies 19182535_2 80 92
that 19182535_2 93 97
are 19182535_2 98 101
addicted 19182535_2 102 110
to 19182535_2 111 113
one 19182535_2 114 117
of 19182535_2 118 120
its 19182535_2 121 124
target 19182535_2 125 131
kinases 19182535_2 132 139
, 19182535_2 140 141
c 19182535_2 142 143
- 19182535_2 143 144
abl 19182535_2 144 147
, 19182535_2 148 149
c 19182535_2 150 151
- 19182535_2 151 152
kit 19182535_2 152 155
and 19182535_2 156 159
PDGF 19182535_2 160 164
- 19182535_2 164 165
R 19182535_2 165 166
. 19182535_2 167 168

Trastuzumab 21135276_3 0 11
, 21135276_3 12 13
the 21135276_3 14 17
humanized 21135276_3 18 27
human 21135276_3 28 33
epidermal 21135276_3 34 43
growth 21135276_3 44 50
factor 21135276_3 51 57
receptor 21135276_3 58 66
2 21135276_3 67 68
( 21135276_3 69 70
HER 21135276_3 71 74
2 21135276_3 74 75
) 21135276_3 76 77
monoclonal 21135276_3 78 88
antibody 21135276_3 89 97
, 21135276_3 98 99
and 21135276_3 100 103
lapatinib 21135276_3 104 113
, 21135276_3 114 115
an 21135276_3 116 118
epidermal 21135276_3 119 128
growth 21135276_3 129 135
factor 21135276_3 136 142
receptor 21135276_3 143 151
/ 21135276_3 152 153
HER 21135276_3 154 157
2 21135276_3 157 158
tyrosine 21135276_3 159 167
kinase 21135276_3 168 174
inhibitor 21135276_3 175 184
, 21135276_3 185 186
are 21135276_3 187 190
both 21135276_3 191 195
established 21135276_3 196 207
treatments 21135276_3 208 218
for 21135276_3 219 222
HER 21135276_3 223 226
2 21135276_3 226 227
- 21135276_3 228 229
overexpressing 21135276_3 229 243
breast 21135276_3 244 250
cancers 21135276_3 251 258
. 21135276_3 259 260

Upfront 26603945_15 0 7
screening 26603945_15 8 17
for 26603945_15 18 21
these 26603945_15 22 27
variants 26603945_15 28 36
, 26603945_15 37 38
in 26603945_15 39 41
addition 26603945_15 42 50
to 26603945_15 51 53
the 26603945_15 54 57
established 26603945_15 58 69
variants 26603945_15 70 78
DPYD 26603945_15 79 83
* 26603945_15 84 85
2 26603945_15 86 87
A 26603945_15 87 88
and 26603945_15 89 92
c 26603945_15 93 94
. 26603945_15 94 95
2846 26603945_15 95 99
A 26603945_15 99 100
> 26603945_15 100 101
T 26603945_15 101 102
, 26603945_15 103 104
is 26603945_15 105 107
recommended 26603945_15 108 119
to 26603945_15 120 122
improve 26603945_15 123 130
the 26603945_15 131 134
safety 26603945_15 135 141
of 26603945_15 142 144
patients 26603945_15 145 153
with 26603945_15 154 158
cancer 26603945_15 159 165
treated 26603945_15 166 173
with 26603945_15 174 178
fluoropyrimidines 26603945_15 179 196
. 26603945_15 197 198

Impact 17089107_1 0 6
of 17089107_1 7 9
CYP 17089107_1 10 13
2 17089107_1 13 14
D 17089107_1 14 15
6 17089107_1 15 16
* 17089107_1 17 18
10 17089107_1 19 21
on 17089107_1 22 24
H 17089107_1 25 26
1 17089107_1 26 27
- 17089107_1 27 28
antihistamine 17089107_1 28 41
- 17089107_1 42 43
induced 17089107_1 43 50
hypersomnia 17089107_1 51 62
. 17089107_1 63 64

The 20122728_2 0 3
role 20122728_2 4 8
of 20122728_2 9 11
TNF 20122728_2 12 15
- 20122728_2 15 16
a 20122728_2 16 17
promoter 20122728_2 18 26
polymorphisms 20122728_2 27 40
in 20122728_2 41 43
the 20122728_2 44 47
development 20122728_2 48 59
of 20122728_2 60 62
multiple 20122728_2 63 71
myeloma 20122728_2 72 79
( 20122728_2 80 81
MM 20122728_2 82 84
) 20122728_2 85 86
were 20122728_2 87 91
tested 20122728_2 92 98
in 20122728_2 99 101
210 20122728_2 102 105
patients 20122728_2 106 114
and 20122728_2 115 118
218 20122728_2 119 122
healthy 20122728_2 123 130
individuals 20122728_2 131 142
and 20122728_2 143 146
their 20122728_2 147 152
impact 20122728_2 153 159
on 20122728_2 160 162
the 20122728_2 163 166
clinical 20122728_2 167 175
outcome 20122728_2 176 183
were 20122728_2 184 188
evaluated 20122728_2 189 198
in 20122728_2 199 201
98 20122728_2 202 204
patients 20122728_2 205 213
treated 20122728_2 214 221
with 20122728_2 222 226
thalidomide 20122728_2 227 238
and 20122728_2 239 242
dexamethasone 20122728_2 243 256
( 20122728_2 257 258
Thal 20122728_2 259 263
+ 20122728_2 264 265
Dex 20122728_2 266 269
) 20122728_2 270 271
regimen 20122728_2 272 279
. 20122728_2 280 281

CONCLUSION 27382939_13 0 10
: 27382939_13 11 12
IL 27382939_13 13 15
28 27382939_13 15 17
B 27382939_13 17 18
predicts 27382939_13 19 27
the 27382939_13 28 31
PEG 27382939_13 32 35
- 27382939_13 35 36
IFN 27382939_13 36 39
response 27382939_13 40 48
in 27382939_13 49 51
patients 27382939_13 52 60
with 27382939_13 61 65
CHD 27382939_13 66 69
infection 27382939_13 70 79
. 27382939_13 80 81

In 10430972_10 0 2
conclusion 10430972_10 3 13
, 10430972_10 14 15
with 10430972_10 16 20
high 10430972_10 21 25
- 10430972_10 25 26
dose 10430972_10 26 30
folate 10430972_10 31 37
supplementation 10430972_10 38 53
, 10430972_10 54 55
the 10430972_10 56 59
hyperhomocysteinemia 10430972_10 60 80
in 10430972_10 81 83
patients 10430972_10 84 92
with 10430972_10 93 97
ESRD 10430972_10 98 102
does 10430972_10 103 107
not 10430972_10 108 111
seem 10430972_10 112 116
to 10430972_10 117 119
be 10430972_10 120 122
caused 10430972_10 123 129
by 10430972_10 130 132
the 10430972_10 133 136
677 10430972_10 137 140
C 10430972_10 140 141
- 10430972_10 141 142
- 10430972_10 142 143
> 10430972_10 143 144
T 10430972_10 144 145
mutation 10430972_10 146 154
in 10430972_10 155 157
the 10430972_10 158 161
MTHFR 10430972_10 162 167
gene 10430972_10 168 172
. 10430972_10 173 174

Before 19578241_10 0 6
ADV 19578241_10 7 10
treatment 19578241_10 11 20
, 19578241_10 21 22
apart 19578241_10 23 28
from 19578241_10 29 33
3 19578241_10 34 35
TC 19578241_10 35 37
resistance 19578241_10 38 48
signature 19578241_10 49 58
mutations 19578241_10 59 68
, 19578241_10 69 70
additional 19578241_10 71 81
changes 19578241_10 82 89
were 19578241_10 90 94
found 19578241_10 95 100
, 19578241_10 101 102
including 19578241_10 103 112
the 19578241_10 113 116
rtA 19578241_10 117 120
181 19578241_10 121 124
T 19578241_10 124 125
mutation 19578241_10 126 134
, 19578241_10 135 136
which 19578241_10 137 142
was 19578241_10 143 146
already 19578241_10 147 154
present 19578241_10 155 162
in 19578241_10 163 165
2 19578241_10 166 167
/ 19578241_10 167 168
14 19578241_10 168 170
ADV 19578241_10 171 174
- 19578241_10 175 176
resistant 19578241_10 176 185
patients 19578241_10 186 194
. 19578241_10 195 196

HLA 19514905_1 0 3
- 19514905_1 3 4
B 19514905_1 4 5
* 19514905_1 6 7
5701 19514905_1 8 12
screening 19514905_1 13 22
prior 19514905_1 23 28
to 19514905_1 29 31
abacavir 19514905_1 32 40
prescription 19514905_1 41 53
: 19514905_1 54 55
clinical 19514905_1 56 64
and 19514905_1 65 68
laboratory 19514905_1 69 79
aspects 19514905_1 80 87
. 19514905_1 88 89

There 10580024_9 0 5
were 10580024_9 6 10
no 10580024_9 11 13
sex 10580024_9 14 17
differences 10580024_9 18 29
in 10580024_9 30 32
thioguanine 10580024_9 33 44
nucleotide 10580024_9 45 55
concentrations 10580024_9 56 70
( 10580024_9 71 72
P 10580024_9 73 74
= 10580024_9 75 76
. 10580024_9 77 78
24 10580024_9 78 80
) 10580024_9 81 82
, 10580024_9 83 84
TPMT 10580024_9 85 89
enzyme 10580024_9 90 96
activity 10580024_9 97 105
( 10580024_9 106 107
P 10580024_9 108 109
= 10580024_9 110 111
. 10580024_9 112 113
22 10580024_9 113 115
) 10580024_9 116 117
, 10580024_9 118 119
or 10580024_9 120 122
average 10580024_9 123 130
weekly 10580024_9 131 137
prescribed 10580024_9 138 148
dose 10580024_9 149 153
of 10580024_9 154 156
6 10580024_9 157 158
- 10580024_9 158 159
mercaptopurine 10580024_9 159 173
( 10580024_9 174 175
P 10580024_9 176 177
= 10580024_9 178 179
. 10580024_9 180 181
49 10580024_9 181 183
) 10580024_9 184 185
. 10580024_9 186 187

MEK 18282182_12 0 3
1 18282182_12 3 4
/ 18282182_12 4 5
2 18282182_12 5 6
is 18282182_12 7 9
immediately 18282182_12 10 21
upstream 18282182_12 22 30
of 18282182_12 31 33
ERK 18282182_12 34 37
1 18282182_12 37 38
/ 18282182_12 38 39
2 18282182_12 39 40
and 18282182_12 41 44
the 18282182_12 45 48
MEK 18282182_12 49 52
1 18282182_12 52 53
inhibitor 18282182_12 54 63
PD 18282182_12 64 66
98059 18282182_12 66 71
failed 18282182_12 72 78
to 18282182_12 79 81
attenuate 18282182_12 82 91
COX 18282182_12 92 95
- 18282182_12 95 96
2 18282182_12 96 97
expression 18282182_12 98 108
while 18282182_12 109 114
the 18282182_12 115 118
MEK 18282182_12 119 122
1 18282182_12 122 123
/ 18282182_12 123 124
2 18282182_12 124 125
inhibitor 18282182_12 126 135
U 18282182_12 136 137
0126 18282182_12 137 141
induced 18282182_12 142 149
a 18282182_12 150 151
slight 18282182_12 152 158
decrease 18282182_12 159 167
in 18282182_12 168 170
COX 18282182_12 171 174
- 18282182_12 174 175
2 18282182_12 175 176
expression 18282182_12 177 187
. 18282182_12 188 189

Furthermore 22461642_7 0 11
, 22461642_7 12 13
oridonin 22461642_7 14 22
inhibited 22461642_7 23 32
the 22461642_7 33 36
activity 22461642_7 37 45
of 22461642_7 46 48
c 22461642_7 49 50
- 22461642_7 50 51
Kit 22461642_7 51 54
( 22461642_7 55 56
+ 22461642_7 57 58
) 22461642_7 59 60
leukemia 22461642_7 61 69
- 22461642_7 70 71
initiating 22461642_7 71 81
cells 22461642_7 82 87
. 22461642_7 88 89

OBJECTIVE 21873787_2 0 9
: 21873787_2 10 11
To 21873787_2 12 14
explore 21873787_2 15 22
the 21873787_2 23 26
relation 21873787_2 27 35
between 21873787_2 36 43
methylation 21873787_2 44 55
status 21873787_2 56 62
of 21873787_2 63 65
RAS 21873787_2 66 69
association 21873787_2 70 81
domain 21873787_2 82 88
family 21873787_2 89 95
1 21873787_2 96 97
A 21873787_2 97 98
( 21873787_2 99 100
RASSF 21873787_2 101 106
1 21873787_2 106 107
A 21873787_2 107 108
) 21873787_2 109 110
in 21873787_2 111 113
patients 21873787_2 114 122
with 21873787_2 123 127
advanced 21873787_2 128 136
epithelial 21873787_2 137 147
ovarian 21873787_2 148 155
cancer 21873787_2 156 162
and 21873787_2 163 166
the 21873787_2 167 170
clinical 21873787_2 171 179
efficacy 21873787_2 180 188
of 21873787_2 189 191
cisplatin 21873787_2 192 201
based 21873787_2 202 207
neoadjuvant 21873787_2 208 219
therapy 21873787_2 220 227
. 21873787_2 228 229

Our 27430334_6 0 3
results 27430334_6 4 11
revealed 27430334_6 12 20
that 27430334_6 21 25
AZD 27430334_6 26 29
4619 27430334_6 29 33
increased 27430334_6 34 43
ALT 27430334_6 44 47
1 27430334_6 47 48
protein 27430334_6 49 56
expression 27430334_6 57 67
in 27430334_6 68 70
a 27430334_6 71 72
dose 27430334_6 73 77
- 27430334_6 77 78
dependent 27430334_6 78 87
manner 27430334_6 88 94
in 27430334_6 95 97
human 27430334_6 98 103
, 27430334_6 104 105
but 27430334_6 106 109
not 27430334_6 110 113
in 27430334_6 114 116
rat 27430334_6 117 120
primary 27430334_6 121 128
hepatocytes 27430334_6 129 140
. 27430334_6 141 142

Warfarin 15341704_2 0 8
, 15341704_2 9 10
the 15341704_2 11 14
principal 15341704_2 15 24
oral 15341704_2 25 29
anticoagulant 15341704_2 30 43
used 15341704_2 44 48
in 15341704_2 49 51
the 15341704_2 52 55
treatment 15341704_2 56 65
and 15341704_2 66 69
prevention 15341704_2 70 80
of 15341704_2 81 83
thromboembolic 15341704_2 84 98
disease 15341704_2 99 106
, 15341704_2 107 108
is 15341704_2 109 111
primarily 15341704_2 112 121
metabolized 15341704_2 122 133
by 15341704_2 134 136
CYP 15341704_2 137 140
2 15341704_2 140 141
C 15341704_2 141 142
9 15341704_2 142 143
, 15341704_2 144 145
one 15341704_2 146 149
of 15341704_2 150 152
the 15341704_2 153 156
hepatic 15341704_2 157 164
microsomal 15341704_2 165 175
enzymes 15341704_2 176 183
. 15341704_2 184 185

The 23149441_14 0 3
effect 23149441_14 4 10
was 23149441_14 11 14
influenced 23149441_14 15 25
by 23149441_14 26 28
CYP 23149441_14 29 32
3 23149441_14 32 33
A 23149441_14 33 34
5 23149441_14 34 35
polymorphism 23149441_14 36 48
, 23149441_14 49 50
although 23149441_14 51 59
the 23149441_14 60 63
tacrolimus 23149441_14 64 74
variability 23149441_14 75 86
itself 23149441_14 87 93
was 23149441_14 94 97
not 23149441_14 98 101
determined 23149441_14 102 112
by 23149441_14 113 115
the 23149441_14 116 119
CYP 23149441_14 120 123
3 23149441_14 123 124
A 23149441_14 124 125
5 23149441_14 125 126
polymorphism 23149441_14 127 139
. 23149441_14 140 141

In 25487141_10 0 2
a 25487141_10 3 4
simple 25487141_10 5 11
linear 25487141_10 12 18
regression 25487141_10 19 29
model 25487141_10 30 35
, 25487141_10 36 37
age 25487141_10 38 41
, 25487141_10 42 43
hemoglobin 25487141_10 44 54
( 25487141_10 55 56
Hb 25487141_10 57 59
) 25487141_10 60 61
, 25487141_10 62 63
CYP 25487141_10 64 67
3 25487141_10 67 68
A 25487141_10 68 69
5 25487141_10 69 70
gene 25487141_10 71 75
polymorphisms 25487141_10 76 89
, 25487141_10 90 91
and 25487141_10 92 95
IL 25487141_10 96 98
- 25487141_10 98 99
18 25487141_10 99 101
A 25487141_10 102 103
- 25487141_10 103 104
607 25487141_10 104 107
C 25487141_10 107 108
gene 25487141_10 109 113
polymorphisms 25487141_10 114 127
were 25487141_10 128 132
associated 25487141_10 133 143
with 25487141_10 144 148
log 25487141_10 149 152
- 25487141_10 152 153
transformed 25487141_10 153 164
tacrolimus 25487141_10 165 175
C 25487141_10 176 177
/ 25487141_10 177 178
D 25487141_10 178 179
ratios 25487141_10 180 186
( 25487141_10 187 188
P 25487141_10 189 190
< 25487141_10 191 192
0 25487141_10 193 194
. 25487141_10 194 195
05 25487141_10 195 197
) 25487141_10 198 199
. 25487141_10 200 201

Recent 21182896_4 0 6
studies 21182896_4 7 14
of 21182896_4 15 17
the 21182896_4 18 21
tryptophan 21182896_4 22 32
hydroxylase 21182896_4 33 44
2 21182896_4 45 46
showed 21182896_4 47 53
mild 21182896_4 54 58
or 21182896_4 59 61
no 21182896_4 62 64
association 21182896_4 65 76
with 21182896_4 77 81
suicide 21182896_4 82 89
and 21182896_4 90 93
alcohol 21182896_4 94 101
- 21182896_4 102 103
related 21182896_4 103 110
suicide 21182896_4 111 118
. 21182896_4 119 120

HPMA 9724909_1 0 4
copolymer 9724909_1 5 14
bound 9724909_1 15 20
adriamycin 9724909_1 21 31
overcomes 9724909_1 32 41
MDR 9724909_1 42 45
1 9724909_1 45 46
gene 9724909_1 47 51
encoded 9724909_1 52 59
resistance 9724909_1 60 70
in 9724909_1 71 73
a 9724909_1 74 75
human 9724909_1 76 81
ovarian 9724909_1 82 89
carcinoma 9724909_1 90 99
cell 9724909_1 100 104
line 9724909_1 105 109
. 9724909_1 110 111

CONCLUSIONS 9164419_8 0 11
: 9164419_8 12 13
These 9164419_8 14 19
results 9164419_8 20 27
suggest 9164419_8 28 35
that 9164419_8 36 40
the 9164419_8 41 44
hydroxylation 9164419_8 45 58
of 9164419_8 59 61
lansoprazole 9164419_8 62 74
cosegregates 9164419_8 75 87
with 9164419_8 88 92
the 9164419_8 93 96
genetically 9164419_8 97 108
determined 9164419_8 109 119
S 9164419_8 120 121
- 9164419_8 121 122
mephenytoin 9164419_8 122 133
4 9164419_8 134 135
' 9164419_8 135 136
- 9164419_8 136 137
hydroxylation 9164419_8 137 150
( 9164419_8 151 152
CYP 9164419_8 153 156
2 9164419_8 156 157
C 9164419_8 157 158
19 9164419_8 158 160
) 9164419_8 161 162
polymorphism 9164419_8 163 175
in 9164419_8 176 178
the 9164419_8 179 182
Korean 9164419_8 183 189
subjects 9164419_8 190 198
. 9164419_8 199 200

The 11238813_6 0 3
diallyl 11238813_6 4 11
disulfide 11238813_6 12 21
- 11238813_6 22 23
mediated 11238813_6 23 31
inhibition 11238813_6 32 42
of 11238813_6 43 45
H 11238813_6 46 47
- 11238813_6 47 48
ras 11238813_6 48 51
oncogene 11238813_6 52 60
transformed 11238813_6 61 72
tumor 11238813_6 73 78
growth 11238813_6 79 85
correlated 11238813_6 86 96
with 11238813_6 97 101
the 11238813_6 102 105
inhibition 11238813_6 106 116
of 11238813_6 117 119
p 11238813_6 120 121
21 11238813_6 121 123
( 11238813_6 124 125
H 11238813_6 126 127
- 11238813_6 127 128
ras 11238813_6 128 131
) 11238813_6 132 133
membrane 11238813_6 134 142
association 11238813_6 143 154
. 11238813_6 155 156

METHODS 23991619_3 0 7
: 23991619_3 8 9
One 23991619_3 10 13
APL 23991619_3 14 17
patient 23991619_3 18 25
overexpressed 23991619_3 26 39
PML 23991619_3 40 43
/ 23991619_3 44 45
RARa 23991619_3 46 50
( 23991619_3 51 52
bcr 23991619_3 53 56
1 23991619_3 56 57
) 23991619_3 58 59
and 23991619_3 60 63
WT 23991619_3 64 66
1 23991619_3 66 67
genes 23991619_3 68 73
in 23991619_3 74 76
the 23991619_3 77 80
presence 23991619_3 81 89
of 23991619_3 90 92
the 23991619_3 93 96
Fms 23991619_3 97 100
- 23991619_3 100 101
like 23991619_3 101 105
tyrosine 23991619_3 106 114
kinase 23991619_3 115 121
- 23991619_3 122 123
internal 23991619_3 123 131
tandem 23991619_3 132 138
duplication 23991619_3 139 150
mutation 23991619_3 151 159
, 23991619_3 160 161
while 23991619_3 162 167
cytogenetics 23991619_3 168 180
showed 23991619_3 181 187
t 23991619_3 188 189
( 23991619_3 190 191
2 23991619_3 192 193
; 23991619_3 194 195
3 23991619_3 196 197
) 23991619_3 198 199
( 23991619_3 200 201
p 23991619_3 202 203
25 23991619_3 203 205
; 23991619_3 206 207
q 23991619_3 208 209
21 23991619_3 209 211
) 23991619_3 212 213
and 23991619_3 214 217
t 23991619_3 218 219
( 23991619_3 220 221
15 23991619_3 222 224
; 23991619_3 225 226
17 23991619_3 227 229
) 23991619_3 230 231
( 23991619_3 232 233
q 23991619_3 234 235
22 23991619_3 235 237
; 23991619_3 238 239
q 23991619_3 240 241
21 23991619_3 241 243
) 23991619_3 244 245
. 23991619_3 246 247

It 18926911_12 0 2
was 18926911_12 3 6
also 18926911_12 7 11
observed 18926911_12 12 20
that 18926911_12 21 25
subjects 18926911_12 26 34
whose 18926911_12 35 40
genotype 18926911_12 41 49
presented 18926911_12 50 59
one 18926911_12 60 63
synonymous 18926911_12 64 74
substitution 18926911_12 75 87
( 18926911_12 88 89
S 18926911_12 90 91
) 18926911_12 92 93
in 18926911_12 94 96
one 18926911_12 97 100
HLA 18926911_12 101 104
- 18926911_12 104 105
G 18926911_12 105 106
allele 18926911_12 107 113
in 18926911_12 114 116
the 18926911_12 117 120
HLA 18926911_12 121 124
- 18926911_12 124 125
G 18926911_12 125 126
0101 18926911_12 127 131
group 18926911_12 132 137
of 18926911_12 138 140
alleles 18926911_12 141 148
and 18926911_12 149 152
another 18926911_12 153 160
allele 18926911_12 161 167
with 18926911_12 168 172
a 18926911_12 173 174
non 18926911_12 175 178
- 18926911_12 178 179
synonymous 18926911_12 179 189
substitution 18926911_12 190 202
( 18926911_12 203 204
N 18926911_12 205 206
/ 18926911_12 206 207
S 18926911_12 207 208
) 18926911_12 209 210
on 18926911_12 211 213
HLA 18926911_12 214 217
- 18926911_12 217 218
G 18926911_12 219 220
0103 18926911_12 220 224
, 18926911_12 225 226
HLA 18926911_12 227 230
- 18926911_12 230 231
G 18926911_12 232 233
010401 18926911_12 233 239
, 18926911_12 240 241
HLA 18926911_12 242 245
- 18926911_12 245 246
G 18926911_12 246 247
010403 18926911_12 247 253
or 18926911_12 254 256
HLA 18926911_12 257 260
- 18926911_12 260 261
G 18926911_12 262 263
0105 18926911_12 263 267
N 18926911_12 267 268
alleles 18926911_12 269 276
, 18926911_12 277 278
apparently 18926911_12 279 289
had 18926911_12 290 293
a 18926911_12 294 295
greater 18926911_12 296 303
chance 18926911_12 304 310
of 18926911_12 311 313
rejection 18926911_12 314 323
episodes 18926911_12 324 332
. 18926911_12 333 334

Gefitinib 18281523_8 0 9
showed 18281523_8 10 16
analogous 18281523_8 17 26
PK 18281523_8 27 29
properties 18281523_8 30 40
in 18281523_8 41 43
each 18281523_8 44 48
tumor 18281523_8 49 54
type 18281523_8 55 59
yet 18281523_8 60 63
different 18281523_8 64 73
PD 18281523_8 74 76
characteristics 18281523_8 77 92
consistent 18281523_8 93 103
with 18281523_8 104 108
the 18281523_8 109 112
EGFR 18281523_8 113 117
status 18281523_8 118 124
of 18281523_8 125 127
the 18281523_8 128 131
tumors 18281523_8 132 138
. 18281523_8 139 140

The 25367959_2 0 3
combination 25367959_2 4 15
of 25367959_2 16 18
erlotinib 25367959_2 19 28
and 25367959_2 29 32
bevacizumab 25367959_2 33 44
prolongs 25367959_2 45 53
PFS 25367959_2 54 57
in 25367959_2 58 60
patients 25367959_2 61 69
with 25367959_2 70 74
EGFR 25367959_2 75 79
- 25367959_2 80 81
mutant 25367959_2 81 87
NSCLC 25367959_2 88 93
. 25367959_2 94 95

The 18364363_1 0 3
short 18364363_1 4 9
allele 18364363_1 10 16
of 18364363_1 17 19
the 18364363_1 20 23
serotonin 18364363_1 24 33
transporter 18364363_1 34 45
promote 18364363_1 46 53
r 18364363_1 54 55
polymorphism 18364363_1 56 68
influences 18364363_1 69 79
relapse 18364363_1 80 87
in 18364363_1 88 90
alcohol 18364363_1 91 98
dependence 18364363_1 99 109
. 18364363_1 110 111

In 20205700_9 0 2
both 20205700_9 3 7
populations 20205700_9 8 19
, 20205700_9 20 21
a 20205700_9 22 23
common 20205700_9 24 30
SNP 20205700_9 31 34
encoding 20205700_9 35 43
ALDH 20205700_9 44 48
1 20205700_9 48 49
b 20205700_9 49 50
1 20205700_9 50 51
( 20205700_9 52 53
rs 20205700_9 54 56
2228093 20205700_9 56 63
) 20205700_9 64 65
was 20205700_9 66 69
found 20205700_9 70 75
to 20205700_9 76 78
be 20205700_9 79 81
significantly 20205700_9 82 95
associated 20205700_9 96 106
with 20205700_9 107 111
alcohol 20205700_9 112 119
- 20205700_9 120 121
induced 20205700_9 121 128
hypersensitivity 20205700_9 129 145
( 20205700_9 146 147
odds 20205700_9 148 152
ratio 20205700_9 153 158
TT 20205700_9 159 161
vs 20205700_9 162 164
. 20205700_9 164 165
CC 20205700_9 166 168
in 20205700_9 169 171
combined 20205700_9 172 180
populations 20205700_9 181 192
: 20205700_9 193 194
2 20205700_9 195 196
. 20205700_9 196 197
53 20205700_9 197 199
, 20205700_9 200 201
95 20205700_9 202 204
% 20205700_9 205 206
CI 20205700_9 207 209
1 20205700_9 210 211
. 20205700_9 211 212
31 20205700_9 212 214
- 20205700_9 214 215
4 20205700_9 215 216
. 20205700_9 217 218
90 20205700_9 218 220
) 20205700_9 221 222
. 20205700_9 223 224

PURPOSE 22771883_2 0 7
: 22771883_2 8 9
To 22771883_2 10 12
determine 22771883_2 13 22
if 22771883_2 23 25
genetic 22771883_2 26 33
polymorphisms 22771883_2 34 47
of 22771883_2 48 50
liver 22771883_2 51 56
- 22771883_2 56 57
specific 22771883_2 57 65
human 22771883_2 66 71
organic 22771883_2 72 79
anion 22771883_2 80 85
transporting 22771883_2 86 98
polypeptide 22771883_2 99 110
( 22771883_2 111 112
OATP 22771883_2 113 117
) 22771883_2 118 119
1 22771883_2 120 121
B 22771883_2 121 122
1 22771883_2 122 123
and 22771883_2 124 127
OATP 22771883_2 128 132
1 22771883_2 132 133
B 22771883_2 133 134
3 22771883_2 134 135
influence 22771883_2 136 145
cellular 22771883_2 146 154
uptake 22771883_2 155 161
of 22771883_2 162 164
gadoxetic 22771883_2 165 174
acid 22771883_2 175 179
in 22771883_2 180 182
vitro 22771883_2 183 188
and 22771883_2 189 192
if 22771883_2 193 195
functionally 22771883_2 196 208
relevant 22771883_2 209 217
polymorphisms 22771883_2 218 231
are 22771883_2 232 235
confounders 22771883_2 236 247
for 22771883_2 248 251
liver 22771883_2 252 257
enhancement 22771883_2 258 269
by 22771883_2 270 272
gadoxetic 22771883_2 273 282
acid 22771883_2 283 287
in 22771883_2 288 290
healthy 22771883_2 291 298
subjects 22771883_2 299 307
. 22771883_2 308 309

Multivariate 19014491_7 0 12
regressions 19014491_7 13 24
analyses 19014491_7 25 33
with 19014491_7 34 38
adjustment 19014491_7 39 49
for 19014491_7 50 53
relevant 19014491_7 54 62
covariates 19014491_7 63 73
were 19014491_7 74 78
performed 19014491_7 79 88
to 19014491_7 89 91
detect 19014491_7 92 98
associations 19014491_7 99 111
of 19014491_7 112 114
SIRT 19014491_7 115 119
1 19014491_7 119 120
variants 19014491_7 121 129
with 19014491_7 130 134
the 19014491_7 135 138
changes 19014491_7 139 146
in 19014491_7 147 149
anthropometrics 19014491_7 150 165
, 19014491_7 166 167
weight 19014491_7 168 174
, 19014491_7 175 176
body 19014491_7 177 181
fat 19014491_7 182 185
or 19014491_7 186 188
metabolic 19014491_7 189 198
characteristics 19014491_7 199 214
( 19014491_7 215 216
blood 19014491_7 217 222
glucose 19014491_7 223 230
, 19014491_7 231 232
insulin 19014491_7 233 240
sensitivity 19014491_7 241 252
, 19014491_7 253 254
insulin 19014491_7 255 262
secretion 19014491_7 263 272
and 19014491_7 273 276
liver 19014491_7 277 282
fat 19014491_7 283 286
, 19014491_7 287 288
measured 19014491_7 289 297
by 19014491_7 298 300
magnetic 19014491_7 301 309
resonance 19014491_7 310 319
techniques 19014491_7 320 330
) 19014491_7 331 332
after 19014491_7 333 338
the 19014491_7 339 342
9 19014491_7 343 344
- 19014491_7 344 345
month 19014491_7 345 350
follow 19014491_7 351 357
- 19014491_7 357 358
up 19014491_7 358 360
test 19014491_7 361 365
in 19014491_7 366 368
the 19014491_7 369 372
TULIP 19014491_7 373 378
study 19014491_7 379 384
. 19014491_7 385 386

RESULTS 10223777_10 0 7
: 10223777_10 8 9
No 10223777_10 10 12
significant 10223777_10 13 24
difference 10223777_10 25 35
in 10223777_10 36 38
plasma 10223777_10 39 45
concentration 10223777_10 46 59
profile 10223777_10 60 67
or 10223777_10 68 70
urinary 10223777_10 71 78
alpha 10223777_10 79 84
- 10223777_10 84 85
hydroxymetoprolol 10223777_10 85 102
excretion 10223777_10 103 112
could 10223777_10 113 118
be 10223777_10 119 121
found 10223777_10 122 127
among 10223777_10 128 133
subjects 10223777_10 134 142
with 10223777_10 143 147
R 10223777_10 148 149
296 10223777_10 149 152
C 10223777_10 152 153
polymorphism 10223777_10 154 166
( 10223777_10 167 168
CYP 10223777_10 169 172
2 10223777_10 172 173
D 10223777_10 173 174
6 10223777_10 174 175
* 10223777_10 176 177
1 10223777_10 178 179
/ 10223777_10 180 181
CYP 10223777_10 182 185
2 10223777_10 185 186
D 10223777_10 186 187
6 10223777_10 187 188
* 10223777_10 189 190
2 10223777_10 191 192
) 10223777_10 193 194
. 10223777_10 195 196

The 25940539_9 0 3
anticancer 25940539_9 4 14
effect 25940539_9 15 21
of 25940539_9 22 24
CUDC 25940539_9 25 29
- 25940539_9 29 30
101 25940539_9 30 33
was 25940539_9 34 37
associated 25940539_9 38 48
with 25940539_9 49 53
increased 25940539_9 54 63
expression 25940539_9 64 74
of 25940539_9 75 77
p 25940539_9 78 79
21 25940539_9 79 81
and 25940539_9 82 85
E 25940539_9 86 87
- 25940539_9 87 88
cadherin 25940539_9 88 96
, 25940539_9 97 98
and 25940539_9 99 102
reduced 25940539_9 103 110
expression 25940539_9 111 121
of 25940539_9 122 124
survivin 25940539_9 125 133
, 25940539_9 134 135
XIAP 25940539_9 136 140
, 25940539_9 141 142
b 25940539_9 143 144
- 25940539_9 144 145
catenin 25940539_9 145 152
, 25940539_9 153 154
N 25940539_9 155 156
- 25940539_9 156 157
cadherin 25940539_9 157 165
, 25940539_9 166 167
and 25940539_9 168 171
Vimentin 25940539_9 172 180
. 25940539_9 181 182

17 22329763_1 0 2
- 22329763_1 2 3
Hydroxysteroid 22329763_1 3 17
dehydrogenase 22329763_1 18 31
type 22329763_1 32 36
5 22329763_1 37 38
gene 22329763_1 39 43
polymorphism 22329763_1 44 56
( 22329763_1 57 58
- 22329763_1 59 60
71 22329763_1 60 62
A 22329763_1 63 64
/ 22329763_1 64 65
G 22329763_1 65 66
HSD 22329763_1 67 70
17 22329763_1 70 72
B 22329763_1 72 73
5 22329763_1 73 74
SNP 22329763_1 75 78
) 22329763_1 79 80
and 22329763_1 81 84
treatment 22329763_1 85 94
with 22329763_1 95 99
oral 22329763_1 100 104
contraceptive 22329763_1 105 118
pills 22329763_1 119 124
in 22329763_1 125 127
PCOS 22329763_1 128 132
women 22329763_1 133 138
without 22329763_1 139 146
metabolic 22329763_1 147 156
comorbidities 22329763_1 157 170
. 22329763_1 171 172

After 22588607_3 0 5
the 22588607_3 6 9
screening 22588607_3 10 19
of 22588607_3 20 22
860 22588607_3 23 26
healthy 22588607_3 27 34
Finnish 22588607_3 35 42
volunteers 22588607_3 43 53
for 22588607_3 54 57
the 22588607_3 58 61
CES 22588607_3 62 65
1 22588607_3 65 66
c 22588607_3 67 68
. 22588607_3 68 69
428 22588607_3 69 72
G 22588607_3 72 73
> 22588607_3 73 74
A 22588607_3 74 75
( 22588607_3 76 77
p 22588607_3 78 79
. 22588607_3 79 80
Gly 22588607_3 80 83
143 22588607_3 83 86
Glu 22588607_3 86 89
, 22588607_3 90 91
rs 22588607_3 92 94
121912777 22588607_3 94 103
) 22588607_3 104 105
polymorphism 22588607_3 106 118
, 22588607_3 119 120
a 22588607_3 121 122
pharmacokinetic 22588607_3 123 138
study 22588607_3 139 144
with 22588607_3 145 149
75 22588607_3 150 152
mg 22588607_3 153 155
oseltamivir 22588607_3 156 167
was 22588607_3 168 171
carried 22588607_3 172 179
out 22588607_3 180 183
in 22588607_3 184 186
c 22588607_3 187 188
. 22588607_3 188 189
428 22588607_3 189 192
G 22588607_3 192 193
> 22588607_3 193 194
A 22588607_3 194 195
carriers 22588607_3 196 204
and 22588607_3 205 208
noncarriers 22588607_3 209 220
. 22588607_3 221 222

Findings 25137520_6 0 8
of 25137520_6 9 11
potential 25137520_6 12 21
gene 25137520_6 22 26
- 25137520_6 26 27
environment 25137520_6 27 38
interactions 25137520_6 39 51
between 25137520_6 52 59
SNPs 25137520_6 60 64
in 25137520_6 65 67
TNF 25137520_6 68 71
- 25137520_6 71 72
a 25137520_6 72 73
, 25137520_6 74 75
TNF 25137520_6 76 79
- 25137520_6 79 80
b 25137520_6 80 81
, 25137520_6 82 83
TCA 25137520_6 84 87
- 25137520_6 87 88
b 25137520_6 88 89
, 25137520_6 90 91
VDR 25137520_6 92 95
, 25137520_6 96 97
MBP 25137520_6 98 101
, 25137520_6 102 103
and 25137520_6 104 107
APOE 25137520_6 108 112
, 25137520_6 113 114
and 25137520_6 115 118
lead 25137520_6 119 123
, 25137520_6 124 125
mercury 25137520_6 126 133
, 25137520_6 134 135
or 25137520_6 136 138
solvents 25137520_6 139 147
should 25137520_6 148 154
be 25137520_6 155 157
considered 25137520_6 158 168
cautiously 25137520_6 169 179
due 25137520_6 180 183
to 25137520_6 184 186
limited 25137520_6 187 194
sample 25137520_6 195 201
size 25137520_6 202 206
. 25137520_6 207 208

Inhibition 26313006_9 0 10
of 26313006_9 11 13
CyclinB 26313006_9 14 21
1 26313006_9 21 22
induction 26313006_9 23 32
by 26313006_9 33 35
Cycloheximide 26313006_9 36 49
or 26313006_9 50 52
CDK 26313006_9 53 56
1 26313006_9 56 57
activity 26313006_9 58 66
by 26313006_9 67 69
Roscovitine 26313006_9 70 81
significantly 26313006_9 82 95
prevented 26313006_9 96 105
FQI 26313006_9 106 109
- 26313006_9 110 111
induced 26313006_9 111 118
mitotic 26313006_9 119 126
arrest 26313006_9 127 133
. 26313006_9 134 135

The 22495427_3 0 3
aim 22495427_3 4 7
of 22495427_3 8 10
this 22495427_3 11 15
study 22495427_3 16 21
was 22495427_3 22 25
to 22495427_3 26 28
investigate 22495427_3 29 40
single 22495427_3 41 47
nucleotide 22495427_3 48 58
polymorphisms 22495427_3 59 72
( 22495427_3 73 74
SNPs 22495427_3 75 79
) 22495427_3 80 81
in 22495427_3 82 84
XDH 22495427_3 85 88
, 22495427_3 89 90
AOX 22495427_3 91 94
1 22495427_3 94 95
, 22495427_3 96 97
and 22495427_3 98 101
MOCOS 22495427_3 102 107
genes 22495427_3 108 113
in 22495427_3 114 116
relation 22495427_3 117 125
to 22495427_3 126 128
clinical 22495427_3 129 137
parameters 22495427_3 138 148
and 22495427_3 149 152
risk 22495427_3 153 157
of 22495427_3 158 160
drug 22495427_3 161 165
side 22495427_3 166 170
effects 22495427_3 171 178
in 22495427_3 179 181
a 22495427_3 182 183
cohort 22495427_3 184 190
of 22495427_3 191 193
kidney 22495427_3 194 200
transplant 22495427_3 201 211
recipients 22495427_3 212 222
treated 22495427_3 223 230
with 22495427_3 231 235
azathioprine 22495427_3 236 248
( 22495427_3 249 250
AZA 22495427_3 251 254
) 22495427_3 255 256
as 22495427_3 257 259
a 22495427_3 260 261
part 22495427_3 262 266
of 22495427_3 267 269
standard 22495427_3 270 278
immunosuppressive 22495427_3 279 296
regimen 22495427_3 297 304
. 22495427_3 305 306

The 25122903_3 0 3
current 25122903_3 4 11
study 25122903_3 12 17
identifies 25122903_3 18 28
an 25122903_3 29 31
association 25122903_3 32 43
of 25122903_3 44 46
an 25122903_3 47 49
intronic 25122903_3 50 58
SNP 25122903_3 59 62
( 25122903_3 63 64
rs 25122903_3 65 67
9479757 25122903_3 67 74
) 25122903_3 75 76
with 25122903_3 77 81
the 25122903_3 82 85
severity 25122903_3 86 94
of 25122903_3 95 97
heroin 25122903_3 98 104
addiction 25122903_3 105 114
among 25122903_3 115 120
Han 25122903_3 121 124
- 25122903_3 124 125
Chinese 25122903_3 125 132
male 25122903_3 133 137
heroin 25122903_3 138 144
addicts 25122903_3 145 152
. 25122903_3 153 154

CONCLUSIONS 17452407_12 0 11
: 17452407_12 12 13
Female 17452407_12 14 20
, 17452407_12 21 22
but 17452407_12 23 26
not 17452407_12 27 30
male 17452407_12 31 35
ESRD 17452407_12 36 40
patients 17452407_12 41 49
with 17452407_12 50 54
the 17452407_12 55 58
ERalpha 17452407_12 59 66
Ser 17452407_12 67 70
10 17452407_12 70 72
Ser 17452407_12 72 75
CC 17452407_12 76 78
genotype 17452407_12 79 87
had 17452407_12 88 91
lower 17452407_12 92 97
prevalence 17452407_12 98 108
of 17452407_12 109 111
PEW 17452407_12 112 115
, 17452407_12 116 117
lower 17452407_12 118 123
serum 17452407_12 124 129
triglyceride 17452407_12 130 142
, 17452407_12 143 144
higher 17452407_12 145 151
serum 17452407_12 152 157
albumin 17452407_12 158 165
and 17452407_12 166 169
lower 17452407_12 170 175
hsCRP 17452407_12 176 181
levels 17452407_12 182 188
. 17452407_12 189 190

AIMS 22379998_2 0 4
: 22379998_2 5 6
An 22379998_2 7 9
association 22379998_2 10 21
between 22379998_2 22 29
carbamazepine 22379998_2 30 43
- 22379998_2 44 45
induced 22379998_2 45 52
hypersensitivity 22379998_2 53 69
and 22379998_2 70 73
HLA 22379998_2 74 77
- 22379998_2 77 78
A 22379998_2 78 79
* 22379998_2 80 81
3101 22379998_2 82 86
has 22379998_2 87 90
been 22379998_2 91 95
reported 22379998_2 96 104
in 22379998_2 105 107
populations 22379998_2 108 119
of 22379998_2 120 122
both 22379998_2 123 127
European 22379998_2 128 136
and 22379998_2 137 140
Asian 22379998_2 141 146
descent 22379998_2 147 154
. 22379998_2 155 156

We 22015057_6 0 2
assessed 22015057_6 3 11
RECIST 22015057_6 12 18
response 22015057_6 19 27
, 22015057_6 28 29
progression 22015057_6 30 41
- 22015057_6 41 42
free 22015057_6 42 46
survival 22015057_6 47 55
( 22015057_6 56 57
PFS 22015057_6 58 61
) 22015057_6 62 63
, 22015057_6 64 65
overall 22015057_6 66 73
survival 22015057_6 74 82
, 22015057_6 83 84
and 22015057_6 85 88
toxicity 22015057_6 89 97
of 22015057_6 98 100
sunitinib 22015057_6 101 110
with 22015057_6 111 115
16 22015057_6 116 118
key 22015057_6 119 122
polymorphisms 22015057_6 123 136
in 22015057_6 137 139
nine 22015057_6 140 144
genes 22015057_6 145 150
: 22015057_6 151 152
VEGFR 22015057_6 153 158
2 22015057_6 158 159
( 22015057_6 160 161
rs 22015057_6 162 164
2305948 22015057_6 164 171
and 22015057_6 172 175
rs 22015057_6 176 178
1870377 22015057_6 178 185
) 22015057_6 186 187
, 22015057_6 188 189
VEGFR 22015057_6 190 195
3 22015057_6 195 196
( 22015057_6 197 198
rs 22015057_6 199 201
307826 22015057_6 201 207
, 22015057_6 208 209
rs 22015057_6 210 212
448012 22015057_6 212 218
, 22015057_6 219 220
and 22015057_6 221 224
rs 22015057_6 225 227
307821 22015057_6 227 233
) 22015057_6 234 235
, 22015057_6 236 237
PDGFR 22015057_6 238 243
- 22015057_6 243 244
a 22015057_6 244 245
( 22015057_6 246 247
rs 22015057_6 248 250
35597368 22015057_6 250 258
) 22015057_6 259 260
, 22015057_6 261 262
VEGF 22015057_6 263 267
- 22015057_6 267 268
A 22015057_6 268 269
( 22015057_6 270 271
rs 22015057_6 272 274
2010963 22015057_6 274 281
, 22015057_6 282 283
rs 22015057_6 284 286
699947 22015057_6 286 292
, 22015057_6 293 294
and 22015057_6 295 298
rs 22015057_6 299 301
1570360 22015057_6 301 308
) 22015057_6 309 310
, 22015057_6 311 312
IL 22015057_6 313 315
8 22015057_6 315 316
( 22015057_6 317 318
rs 22015057_6 319 321
1126647 22015057_6 321 328
) 22015057_6 329 330
, 22015057_6 331 332
CYP 22015057_6 333 336
3 22015057_6 336 337
A 22015057_6 337 338
4 22015057_6 338 339
( 22015057_6 340 341
rs 22015057_6 342 344
2740574 22015057_6 344 351
) 22015057_6 352 353
, 22015057_6 354 355
CYP 22015057_6 356 359
3 22015057_6 359 360
A 22015057_6 360 361
5 22015057_6 361 362
( 22015057_6 363 364
rs 22015057_6 365 367
776746 22015057_6 367 373
) 22015057_6 374 375
, 22015057_6 376 377
ABCB 22015057_6 378 382
1 22015057_6 382 383
( 22015057_6 384 385
rs 22015057_6 386 388
1045642 22015057_6 388 395
, 22015057_6 396 397
rs 22015057_6 398 400
1128503 22015057_6 400 407
, 22015057_6 408 409
and 22015057_6 410 413
rs 22015057_6 414 416
2032582 22015057_6 416 423
) 22015057_6 424 425
, 22015057_6 426 427
and 22015057_6 428 431
ABCB 22015057_6 432 436
2 22015057_6 436 437
( 22015057_6 438 439
rs 22015057_6 440 442
2231142 22015057_6 442 449
) 22015057_6 450 451
. 22015057_6 452 453

Preclinical 21508389_3 0 11
work 21508389_3 12 16
has 21508389_3 17 20
shown 21508389_3 21 26
that 21508389_3 27 31
the 21508389_3 32 35
Kirsten 21508389_3 36 43
ras 21508389_3 44 47
( 21508389_3 48 49
KRAS 21508389_3 50 54
) 21508389_3 55 56
oncogene 21508389_3 57 65
sensitizes 21508389_3 66 76
colorectal 21508389_3 77 87
tumour 21508389_3 88 94
cells 21508389_3 95 100
to 21508389_3 101 103
oxaliplatin 21508389_3 104 115
and 21508389_3 116 119
capecitabine 21508389_3 120 132
in 21508389_3 133 135
a 21508389_3 136 137
wild 21508389_3 138 142
- 21508389_3 142 143
type 21508389_3 143 147
tumour 21508389_3 148 154
suppressor 21508389_3 155 165
p 21508389_3 166 167
53 21508389_3 167 169
( 21508389_3 170 171
TP 21508389_3 172 174
53 21508389_3 174 176
) 21508389_3 177 178
- 21508389_3 179 180
dependent 21508389_3 181 190
manner 21508389_3 191 197
. 21508389_3 198 199

DPYD 19530960_6 0 4
haplotypes 19530960_6 5 15
were 19530960_6 16 20
inferred 19530960_6 21 29
and 19530960_6 30 33
their 19530960_6 34 39
associations 19530960_6 40 52
with 19530960_6 53 57
severe 19530960_6 58 64
5 19530960_6 65 66
- 19530960_6 66 67
FU 19530960_6 67 69
toxicity 19530960_6 70 78
were 19530960_6 79 83
assessed 19530960_6 84 92
. 19530960_6 93 94

The 14604772_9 0 3
TNF 14604772_9 4 7
- 14604772_9 7 8
alpha 14604772_9 8 13
immunoreactive 14604772_9 14 28
glia 14604772_9 29 33
decreased 14604772_9 34 43
in 14604772_9 44 46
number 14604772_9 47 53
in 14604772_9 54 56
the 14604772_9 57 60
60 14604772_9 61 63
mg 14604772_9 64 66
/ 14604772_9 66 67
kg 14604772_9 67 69
ibudilast 14604772_9 70 79
- 14604772_9 80 81
treated 14604772_9 81 88
group 14604772_9 89 94
as 14604772_9 95 97
compared 14604772_9 98 106
to 14604772_9 107 109
the 14604772_9 110 113
vehicle 14604772_9 114 121
- 14604772_9 121 122
treated 14604772_9 122 129
group 14604772_9 130 135
( 14604772_9 136 137
p 14604772_9 138 139
< 14604772_9 140 141
0 14604772_9 142 143
. 14604772_9 143 144
001 14604772_9 144 147
) 14604772_9 148 149
. 14604772_9 150 151

Haloperidol 10628896_8 0 11
is 10628896_8 12 14
a 10628896_8 15 16
substrate 10628896_8 17 26
of 10628896_8 27 29
CYP 10628896_8 30 33
3 10628896_8 33 34
A 10628896_8 34 35
4 10628896_8 35 36
and 10628896_8 37 40
an 10628896_8 41 43
inhibitor 10628896_8 44 53
, 10628896_8 54 55
as 10628896_8 56 58
well 10628896_8 59 63
as 10628896_8 64 66
a 10628896_8 67 68
stimulator 10628896_8 69 79
, 10628896_8 80 81
of 10628896_8 82 84
CYP 10628896_8 85 88
2 10628896_8 88 89
D 10628896_8 89 90
6 10628896_8 90 91
. 10628896_8 92 93

Microsomal 2134689_3 0 10
4 2134689_3 11 12
' 2134689_3 13 14
- 2134689_3 15 16
hydroxylation 2134689_3 17 30
of 2134689_3 31 33
S 2134689_3 34 35
- 2134689_3 35 36
mephenytoin 2134689_3 36 47
, 2134689_3 48 49
but 2134689_3 50 53
not 2134689_3 54 57
of 2134689_3 58 60
R 2134689_3 61 62
- 2134689_3 62 63
mephenytoin 2134689_3 64 75
, 2134689_3 76 77
was 2134689_3 78 81
correlated 2134689_3 82 92
to 2134689_3 93 95
the 2134689_3 96 99
content 2134689_3 100 107
of 2134689_3 108 110
cytochrome 2134689_3 111 121
P 2134689_3 122 123
- 2134689_3 123 124
450 2134689_3 124 127
human 2134689_3 128 133
- 2134689_3 133 134
2 2134689_3 134 135
. 2134689_3 136 137

RESULTS 26086347_5 0 7
: 26086347_5 8 9
Patients 26086347_5 10 18
with 26086347_5 19 23
ABCG 26086347_5 24 28
2 26086347_5 28 29
421 26086347_5 30 33
CA 26086347_5 34 36
or 26086347_5 37 39
AA 26086347_5 40 42
genotypes 26086347_5 43 52
had 26086347_5 53 56
2 26086347_5 57 58
. 26086347_5 58 59
9 26086347_5 59 60
times 26086347_5 61 66
greater 26086347_5 67 74
odds 26086347_5 75 79
of 26086347_5 80 82
developing 26086347_5 83 93
atorvastatin 26086347_5 94 106
dose 26086347_5 107 111
- 26086347_5 111 112
dependent 26086347_5 112 121
ADRs 26086347_5 122 126
( 26086347_5 127 128
OR 26086347_5 129 131
: 26086347_5 132 133
2 26086347_5 134 135
. 26086347_5 135 136
91 26086347_5 136 138
; 26086347_5 139 140
95 26086347_5 141 143
% 26086347_5 144 145
CI 26086347_5 146 148
: 26086347_5 149 150
1 26086347_5 151 152
. 26086347_5 152 153
22 26086347_5 153 155
- 26086347_5 155 156
6 26086347_5 156 157
. 26086347_5 158 159
95 26086347_5 159 161
; 26086347_5 162 163
p 26086347_5 164 165
= 26086347_5 166 167
0 26086347_5 168 169
. 26086347_5 169 170
016 26086347_5 170 173
) 26086347_5 174 175
than 26086347_5 176 180
those 26086347_5 181 186
with 26086347_5 187 191
ABCG 26086347_5 192 196
2 26086347_5 196 197
421 26086347_5 198 201
CC 26086347_5 201 203
genotype 26086347_5 204 212
. 26086347_5 213 214

Thus 21149285_6 0 4
, 21149285_6 5 6
we 21149285_6 7 9
genotyped 21149285_6 10 19
the 21149285_6 20 23
individual 21149285_6 24 34
HLA 21149285_6 35 38
- 21149285_6 38 39
A 21149285_6 39 40
alleles 21149285_6 41 48
in 21149285_6 49 51
61 21149285_6 52 54
cases 21149285_6 55 60
and 21149285_6 61 64
376 21149285_6 65 68
patients 21149285_6 69 77
who 21149285_6 78 81
showed 21149285_6 82 88
no 21149285_6 89 91
cADRs 21149285_6 92 97
by 21149285_6 98 100
administration 21149285_6 101 115
of 21149285_6 116 118
CBZ 21149285_6 119 122
( 21149285_6 123 124
CBZ 21149285_6 125 128
- 21149285_6 129 130
tolerant 21149285_6 130 138
controls 21149285_6 139 147
) 21149285_6 148 149
and 21149285_6 150 153
found 21149285_6 154 159
that 21149285_6 160 164
HLA 21149285_6 165 168
- 21149285_6 168 169
A 21149285_6 169 170
* 21149285_6 171 172
3101 21149285_6 173 177
was 21149285_6 178 181
present 21149285_6 182 189
in 21149285_6 190 192
60 21149285_6 193 195
. 21149285_6 195 196
7 21149285_6 196 197
% 21149285_6 198 199
( 21149285_6 200 201
37 21149285_6 202 204
/ 21149285_6 204 205
61 21149285_6 205 207
) 21149285_6 208 209
of 21149285_6 210 212
the 21149285_6 213 216
patients 21149285_6 217 225
with 21149285_6 226 230
CBZ 21149285_6 231 234
- 21149285_6 235 236
induced 21149285_6 236 243
cADRs 21149285_6 244 249
, 21149285_6 250 251
but 21149285_6 252 255
in 21149285_6 256 258
only 21149285_6 259 263
12 21149285_6 264 266
. 21149285_6 266 267
5 21149285_6 267 268
% 21149285_6 269 270
( 21149285_6 271 272
47 21149285_6 273 275
/ 21149285_6 275 276
376 21149285_6 276 279
) 21149285_6 280 281
of 21149285_6 282 284
the 21149285_6 285 288
CBZ 21149285_6 289 292
- 21149285_6 293 294
tolerant 21149285_6 294 302
controls 21149285_6 303 311
( 21149285_6 312 313
odds 21149285_6 314 318
ratio 21149285_6 319 324
= 21149285_6 325 326
10 21149285_6 327 329
. 21149285_6 329 330
8 21149285_6 330 331
, 21149285_6 332 333
95 21149285_6 334 336
% 21149285_6 337 338
confidence 21149285_6 339 349
interval 21149285_6 350 358
5 21149285_6 359 360
. 21149285_6 360 361
9 21149285_6 361 362
- 21149285_6 362 363
19 21149285_6 363 365
. 21149285_6 366 367
6 21149285_6 367 368
, 21149285_6 369 370
P 21149285_6 371 372
= 21149285_6 373 374
3 21149285_6 375 376
. 21149285_6 376 377
64 21149285_6 377 379
10 21149285_6 380 382
) 21149285_6 383 384
, 21149285_6 385 386
implying 21149285_6 387 395
that 21149285_6 396 400
this 21149285_6 401 405
allele 21149285_6 406 412
has 21149285_6 413 416
the 21149285_6 417 420
60 21149285_6 421 423
. 21149285_6 423 424
7 21149285_6 424 425
% 21149285_6 426 427
sensitivity 21149285_6 428 439
and 21149285_6 440 443
87 21149285_6 444 446
. 21149285_6 446 447
5 21149285_6 447 448
% 21149285_6 449 450
specificity 21149285_6 451 462
when 21149285_6 463 467
we 21149285_6 468 470
apply 21149285_6 471 476
HLA 21149285_6 477 480
- 21149285_6 480 481
A 21149285_6 481 482
* 21149285_6 483 484
3101 21149285_6 485 489
as 21149285_6 490 492
a 21149285_6 493 494
risk 21149285_6 495 499
predictor 21149285_6 500 509
for 21149285_6 510 513
CBZ 21149285_6 514 517
- 21149285_6 518 519
induced 21149285_6 519 526
cADRs 21149285_6 527 532
. 21149285_6 533 534

PNA 17968354_8 0 3
and 17968354_8 4 7
PNA 17968354_8 8 11
- 17968354_8 11 12
AAV 17968354_8 12 15
6 17968354_8 15 16
, 17968354_8 17 18
PNA 17968354_8 19 22
- 17968354_8 22 23
AAV 17968354_8 23 26
8 17968354_8 26 27
conjugates 17968354_8 28 38
induced 17968354_8 39 46
dystrophin 17968354_8 47 57
expression 17968354_8 58 68
in 17968354_8 69 71
a 17968354_8 72 73
dose 17968354_8 74 78
- 17968354_8 78 79
dependent 17968354_8 79 88
manner 17968354_8 89 95
. 17968354_8 96 97

RESULTS 18784465_9 0 7
: 18784465_9 8 9
Abacavir 18784465_9 10 18
- 18784465_9 19 20
based 18784465_9 20 25
treatment 18784465_9 26 35
without 18784465_9 36 43
HLA 18784465_9 44 47
- 18784465_9 47 48
B 18784465_9 48 49
* 18784465_9 50 51
5701 18784465_9 52 56
testing 18784465_9 57 64
resulted 18784465_9 65 73
in 18784465_9 74 76
a 18784465_9 77 78
projected 18784465_9 79 88
30 18784465_9 89 91
. 18784465_9 91 92
93 18784465_9 92 94
years 18784465_9 95 100
life 18784465_9 101 105
expectancy 18784465_9 106 116
, 18784465_9 117 118
16 18784465_9 119 121
. 18784465_9 121 122
23 18784465_9 122 124
discounted 18784465_9 125 135
quality 18784465_9 136 143
- 18784465_9 143 144
adjusted 18784465_9 144 152
life 18784465_9 153 157
years 18784465_9 158 163
, 18784465_9 164 165
and 18784465_9 166 169
472 18784465_9 170 173
, 18784465_9 173 174
200 18784465_9 174 177
discounted 18784465_9 178 188
lifetime 18784465_9 189 197
cost 18784465_9 198 202
per 18784465_9 203 206
person 18784465_9 207 213
. 18784465_9 214 215

Dabrafenib 24901049_9 0 10
decreased 24901049_9 11 20
the 24901049_9 21 24
RIP 24901049_9 25 28
3 24901049_9 28 29
- 24901049_9 30 31
mediated 24901049_9 31 39
Ser 24901049_9 40 43
358 24901049_9 43 46
phosphorylation 24901049_9 47 62
of 24901049_9 63 65
mixed 24901049_9 66 71
lineage 24901049_9 72 79
kinase 24901049_9 80 86
domain 24901049_9 87 93
- 24901049_9 93 94
like 24901049_9 94 98
protein 24901049_9 99 106
( 24901049_9 107 108
MLKL 24901049_9 109 113
) 24901049_9 114 115
and 24901049_9 116 119
disrupted 24901049_9 120 129
the 24901049_9 130 133
interaction 24901049_9 134 145
between 24901049_9 146 153
RIP 24901049_9 154 157
3 24901049_9 157 158
and 24901049_9 159 162
MLKL 24901049_9 163 167
. 24901049_9 168 169

Intriguingly 24055295_8 0 12
, 24055295_8 13 14
JTC 24055295_8 15 18
801 24055295_8 18 21
promoted 24055295_8 22 30
the 24055295_8 31 34
mRNA 24055295_8 35 39
and 24055295_8 40 43
protein 24055295_8 44 51
expression 24055295_8 52 62
levels 24055295_8 63 69
of 24055295_8 70 72
FLG 24055295_8 73 76
but 24055295_8 77 80
not 24055295_8 81 84
the 24055295_8 85 88
mRNA 24055295_8 89 93
levels 24055295_8 94 100
of 24055295_8 101 103
other 24055295_8 104 109
makers 24055295_8 110 116
for 24055295_8 117 120
keratinocyte 24055295_8 121 133
differentiation 24055295_8 134 149
, 24055295_8 150 151
including 24055295_8 152 161
loricrin 24055295_8 162 170
, 24055295_8 171 172
keratin 24055295_8 173 180
10 24055295_8 181 183
, 24055295_8 184 185
and 24055295_8 186 189
transglutaminase 24055295_8 190 206
1 24055295_8 207 208
, 24055295_8 209 210
in 24055295_8 211 213
a 24055295_8 214 215
human 24055295_8 216 221
skin 24055295_8 222 226
equivalent 24055295_8 227 237
model 24055295_8 238 243
. 24055295_8 244 245

The 19695401_14 0 3
risk 19695401_14 4 8
for 19695401_14 9 12
azathioprine 19695401_14 13 25
- 19695401_14 26 27
induced 19695401_14 27 34
myelosuppression 19695401_14 35 51
in 19695401_14 52 54
the 19695401_14 55 58
patients 19695401_14 59 67
with 19695401_14 68 72
the 19695401_14 73 76
heterozygous 19695401_14 77 89
TPMT 19695401_14 90 94
* 19695401_14 95 96
1 19695401_14 97 98
/ 19695401_14 99 100
* 19695401_14 101 102
3 19695401_14 103 104
C 19695401_14 104 105
genotype 19695401_14 106 114
was 19695401_14 115 118
significantly 19695401_14 119 132
higher 19695401_14 133 139
than 19695401_14 140 144
that 19695401_14 145 149
in 19695401_14 150 152
patients 19695401_14 153 161
with 19695401_14 162 166
the 19695401_14 167 170
wild 19695401_14 171 175
- 19695401_14 175 176
type 19695401_14 176 180
genotype 19695401_14 181 189
( 19695401_14 190 191
adjusted 19695401_14 192 200
OR 19695401_14 201 203
, 19695401_14 204 205
14 19695401_14 206 208
. 19695401_14 208 209
18 19695401_14 209 211
[ 19695401_14 212 213
95 19695401_14 214 216
% 19695401_14 217 218
CI 19695401_14 219 221
, 19695401_14 222 223
3 19695401_14 224 225
. 19695401_14 225 226
07 19695401_14 226 228
- 19695401_14 228 229
65 19695401_14 229 231
. 19695401_14 232 233
40 19695401_14 233 235
] 19695401_14 236 237
; 19695401_14 238 239
P 19695401_14 240 241
< 19695401_14 242 243
0 19695401_14 244 245
. 19695401_14 245 246
005 19695401_14 246 249
) 19695401_14 250 251
. 19695401_14 252 253

In 25350163_8 0 2
a 25350163_8 3 4
pilot 25350163_8 5 10
clinical 25350163_8 11 19
trial 25350163_8 20 25
involving 25350163_8 26 35
10 25350163_8 36 38
F 25350163_8 39 40
508 25350163_8 40 43
del 25350163_8 43 46
- 25350163_8 47 48
CFTR 25350163_8 49 53
homozygous 25350163_8 54 64
CF 25350163_8 65 67
patients 25350163_8 68 76
, 25350163_8 77 78
the 25350163_8 79 82
combination 25350163_8 83 94
of 25350163_8 95 97
cysteamine 25350163_8 98 108
and 25350163_8 109 112
EGCG 25350163_8 113 117
restored 25350163_8 118 126
BECN 25350163_8 127 131
1 25350163_8 131 132
, 25350163_8 133 134
reduced 25350163_8 135 142
SQSTM 25350163_8 143 148
1 25350163_8 148 149
levels 25350163_8 150 156
and 25350163_8 157 160
improved 25350163_8 161 169
CFTR 25350163_8 170 174
function 25350163_8 175 183
from 25350163_8 184 188
nasal 25350163_8 189 194
epithelial 25350163_8 195 205
cells 25350163_8 206 211
in 25350163_8 212 214
vivo 25350163_8 215 219
, 25350163_8 220 221
correlating 25350163_8 222 233
with 25350163_8 234 238
a 25350163_8 239 240
decrease 25350163_8 241 249
of 25350163_8 250 252
chloride 25350163_8 253 261
concentrations 25350163_8 262 276
in 25350163_8 277 279
sweat 25350163_8 280 285
, 25350163_8 286 287
as 25350163_8 288 290
well 25350163_8 291 295
as 25350163_8 296 298
with 25350163_8 299 303
a 25350163_8 304 305
reduction 25350163_8 306 315
of 25350163_8 316 318
the 25350163_8 319 322
abundance 25350163_8 323 332
of 25350163_8 333 335
TNF 25350163_8 336 339
/ 25350163_8 340 341
TNF 25350163_8 342 345
- 25350163_8 345 346
alpha 25350163_8 346 351
( 25350163_8 352 353
tumor 25350163_8 354 359
necrosis 25350163_8 360 368
factor 25350163_8 369 375
) 25350163_8 376 377
and 25350163_8 378 381
CXCL 25350163_8 382 386
8 25350163_8 386 387
( 25350163_8 388 389
chemokine 25350163_8 390 399
[ 25350163_8 400 401
C 25350163_8 401 402
- 25350163_8 402 403
X 25350163_8 403 404
- 25350163_8 404 405
C 25350163_8 405 406
motif 25350163_8 407 412
] 25350163_8 412 413
ligand 25350163_8 414 420
8 25350163_8 421 422
) 25350163_8 423 424
transcripts 25350163_8 425 436
in 25350163_8 437 439
nasal 25350163_8 440 445
brushing 25350163_8 446 454
and 25350163_8 455 458
TNF 25350163_8 459 462
and 25350163_8 463 466
CXCL 25350163_8 467 471
8 25350163_8 471 472
protein 25350163_8 473 480
levels 25350163_8 481 487
in 25350163_8 488 490
the 25350163_8 491 494
sputum 25350163_8 495 501
. 25350163_8 502 503

To 22892524_4 0 2
assess 22892524_4 3 9
the 22892524_4 10 13
clinical 22892524_4 14 22
relevance 22892524_4 23 32
of 22892524_4 33 35
this 22892524_4 36 40
cross 22892524_4 41 46
- 22892524_4 46 47
resistance 22892524_4 47 57
, 22892524_4 58 59
we 22892524_4 60 62
studied 22892524_4 63 70
the 22892524_4 71 74
evolution 22892524_4 75 84
of 22892524_4 85 87
HBV 22892524_4 88 91
polymerase 22892524_4 92 102
gene 22892524_4 103 107
variants 22892524_4 108 116
in 22892524_4 117 119
patients 22892524_4 120 128
with 22892524_4 129 133
genotypic 22892524_4 134 143
resistance 22892524_4 144 154
against 22892524_4 155 162
ADV 22892524_4 163 166
( 22892524_4 167 168
rt 22892524_4 169 171
N 22892524_4 172 173
236 22892524_4 173 176
T 22892524_4 176 177
and 22892524_4 178 181
/ 22892524_4 181 182
or 22892524_4 182 184
rt 22892524_4 185 187
A 22892524_4 188 189
181 22892524_4 189 192
V 22892524_4 192 193
/ 22892524_4 193 194
T 22892524_4 194 195
) 22892524_4 196 197
during 22892524_4 198 204
TDF 22892524_4 205 208
treatment 22892524_4 209 218
. 22892524_4 219 220

Long 16153394_11 0 4
- 16153394_11 4 5
term 16153394_11 5 9
terbutaline 16153394_11 10 21
treatment 16153394_11 22 31
desensitizes 16153394_11 32 44
venous 16153394_11 45 51
beta 16153394_11 52 56
2 16153394_11 56 57
- 16153394_11 57 58
AR 16153394_11 58 60
in 16153394_11 61 63
a 16153394_11 64 65
haplotype 16153394_11 66 75
- 16153394_11 75 76
dependent 16153394_11 76 85
manner 16153394_11 86 92
, 16153394_11 93 94
with 16153394_11 95 99
haplotype 16153394_11 100 109
A 16153394_11 110 111
( 16153394_11 112 113
Arg 16153394_11 114 117
16 16153394_11 118 120
Gln 16153394_11 120 123
27 16153394_11 123 125
Thr 16153394_11 125 128
164 16153394_11 128 131
) 16153394_11 132 133
showing 16153394_11 134 141
greater 16153394_11 142 149
desensitization 16153394_11 150 165
than 16153394_11 166 170
haplotype 16153394_11 171 180
B 16153394_11 181 182
( 16153394_11 183 184
Gly 16153394_11 185 188
16 16153394_11 188 190
Gln 16153394_11 190 193
27 16153394_11 193 195
Thr 16153394_11 195 198
164 16153394_11 198 201
) 16153394_11 202 203
, 16153394_11 204 205
which 16153394_11 206 211
shows 16153394_11 212 217
greater 16153394_11 218 225
desensitization 16153394_11 226 241
than 16153394_11 242 246
haplotype 16153394_11 247 256
C 16153394_11 257 258
( 16153394_11 259 260
Gly 16153394_11 261 264
16 16153394_11 264 266
Glu 16153394_11 266 269
27 16153394_11 269 271
Thr 16153394_11 271 274
164 16153394_11 274 277
) 16153394_11 278 279
. 16153394_11 280 281

Women 19021634_8 0 5
with 19021634_8 6 10
a 19021634_8 11 12
CHEK 19021634_8 13 17
2 19021634_8 17 18
mutation 19021634_8 19 27
face 19021634_8 28 32
a 19021634_8 33 34
fourfold 19021634_8 35 43
increase 19021634_8 44 52
in 19021634_8 53 55
the 19021634_8 56 59
risk 19021634_8 60 64
of 19021634_8 65 67
ER 19021634_8 68 70
- 19021634_8 71 72
positive 19021634_8 72 80
breast 19021634_8 81 87
cancer 19021634_8 88 94
and 19021634_8 95 98
might 19021634_8 99 104
be 19021634_8 105 107
candidates 19021634_8 108 118
for 19021634_8 119 122
tamoxifen 19021634_8 123 132
chemoprevention 19021634_8 133 148
. 19021634_8 149 150

The 17190370_3 0 3
purpose 17190370_3 4 11
of 17190370_3 12 14
this 17190370_3 15 19
study 17190370_3 20 25
was 17190370_3 26 29
to 17190370_3 30 32
investigate 17190370_3 33 44
the 17190370_3 45 48
implication 17190370_3 49 60
of 17190370_3 61 63
the 17190370_3 64 67
ABCB 17190370_3 68 72
1 17190370_3 72 73
C 17190370_3 74 75
3435 17190370_3 75 79
Tpolymorphism 17190370_3 79 92
on 17190370_3 93 95
the 17190370_3 96 99
pharmacokinetics 17190370_3 100 116
of 17190370_3 117 119
( 17190370_3 120 121
R 17190370_3 122 123
) 17190370_3 124 125
- 17190370_3 126 127
lansoprazole 17190370_3 128 140
, 17190370_3 141 142
the 17190370_3 143 146
major 17190370_3 147 152
enantiomer 17190370_3 153 163
, 17190370_3 164 165
in 17190370_3 166 168
CYP 17190370_3 169 172
2 17190370_3 172 173
C 17190370_3 173 174
19 17190370_3 174 176
extensive 17190370_3 177 186
metabolizers 17190370_3 187 199
( 17190370_3 200 201
EMs 17190370_3 202 205
) 17190370_3 206 207
and 17190370_3 208 211
on 17190370_3 212 214
gastroesophageal 17190370_3 215 231
symptoms 17190370_3 232 240
in 17190370_3 241 243
renal 17190370_3 244 249
transplant 17190370_3 250 260
recipients 17190370_3 261 271
receiving 17190370_3 272 281
tacrolimus 17190370_3 282 292
. 17190370_3 293 294

None 7635999_7 0 4
had 7635999_7 5 8
a 7635999_7 9 10
CYP 7635999_7 11 14
2 7635999_7 14 15
D 7635999_7 15 16
6 7635999_7 16 17
genotype 7635999_7 18 26
indicative 7635999_7 27 37
of 7635999_7 38 40
ultrarapid 7635999_7 41 51
debrisoquine 7635999_7 52 64
hydroxylation 7635999_7 65 78
capacity 7635999_7 79 87
. 7635999_7 88 89

Proenkephalin 2755460_1 0 13
gene 2755460_1 14 18
expression 2755460_1 19 29
in 2755460_1 30 32
the 2755460_1 33 36
primate 2755460_1 37 44
uterus 2755460_1 45 51
: 2755460_1 52 53
regulation 2755460_1 54 64
by 2755460_1 65 67
estradiol 2755460_1 68 77
in 2755460_1 78 80
the 2755460_1 81 84
endometrium 2755460_1 85 96
. 2755460_1 97 98

GSTP 18797455_1 0 4
1 18797455_1 4 5
Ile 18797455_1 6 9
105 18797455_1 9 12
Val 18797455_1 12 15
polymorphism 18797455_1 16 28
correlates 18797455_1 29 39
with 18797455_1 40 44
progression 18797455_1 45 56
- 18797455_1 56 57
free 18797455_1 57 61
survival 18797455_1 62 70
in 18797455_1 71 73
MCRC 18797455_1 74 78
patients 18797455_1 79 87
treated 18797455_1 88 95
with 18797455_1 96 100
or 18797455_1 101 103
without 18797455_1 104 111
irinotecan 18797455_1 112 122
: 18797455_1 123 124
a 18797455_1 125 126
study 18797455_1 127 132
of 18797455_1 133 135
the 18797455_1 136 139
Dutch 18797455_1 140 145
Colorectal 18797455_1 146 156
Cancer 18797455_1 157 163
Group 18797455_1 164 169
. 18797455_1 170 171

In 14506398_11 0 2
an 14506398_11 3 5
African 14506398_11 6 13
American 14506398_11 14 22
population 14506398_11 23 33
, 14506398_11 34 35
a 14506398_11 36 37
trend 14506398_11 38 43
for 14506398_11 44 47
higher 14506398_11 48 54
frequencies 14506398_11 55 66
of 14506398_11 67 69
the 14506398_11 70 73
ALDH 14506398_11 74 78
1 14506398_11 78 79
A 14506398_11 79 80
1 14506398_11 80 81
* 14506398_11 82 83
2 14506398_11 84 85
and 14506398_11 86 89
ALDH 14506398_11 90 94
1 14506398_11 94 95
A 14506398_11 95 96
1 14506398_11 96 97
* 14506398_11 98 99
3 14506398_11 100 101
alleles 14506398_11 102 109
was 14506398_11 110 113
observed 14506398_11 114 122
in 14506398_11 123 125
a 14506398_11 126 127
population 14506398_11 128 138
of 14506398_11 139 141
alcoholics 14506398_11 142 152
( 14506398_11 153 154
p 14506398_11 155 156
= 14506398_11 157 158
0 14506398_11 159 160
. 14506398_11 160 161
03 14506398_11 161 163
and 14506398_11 164 167
f 14506398_11 168 169
= 14506398_11 170 171
0 14506398_11 172 173
. 14506398_11 173 174
12 14506398_11 174 176
, 14506398_11 177 178
respectively 14506398_11 179 191
) 14506398_11 192 193
compared 14506398_11 194 202
with 14506398_11 203 207
the 14506398_11 208 211
control 14506398_11 212 219
population 14506398_11 220 230
. 14506398_11 231 232

Potential 26418006_3 0 9
biomarkers 26418006_3 10 20
for 26418006_3 21 24
gemcitabine 26418006_3 25 36
response 26418006_3 37 45
include 26418006_3 46 53
the 26418006_3 54 57
activities 26418006_3 58 68
of 26418006_3 69 71
cytidine 26418006_3 72 80
deaminase 26418006_3 81 90
( 26418006_3 91 92
CDA 26418006_3 93 96
) 26418006_3 97 98
, 26418006_3 99 100
human 26418006_3 101 106
equilibrative 26418006_3 107 120
nucleoside 26418006_3 121 131
transporter 26418006_3 132 143
1 26418006_3 144 145
( 26418006_3 146 147
hENT 26418006_3 148 152
1 26418006_3 152 153
) 26418006_3 154 155
, 26418006_3 156 157
deoxycytidine 26418006_3 158 171
kinase 26418006_3 172 178
( 26418006_3 179 180
DCK 26418006_3 181 184
) 26418006_3 185 186
, 26418006_3 187 188
and 26418006_3 189 192
ribonucleotide 26418006_3 193 207
reductase 26418006_3 208 217
M 26418006_3 218 219
1 26418006_3 219 220
( 26418006_3 221 222
RRM 26418006_3 223 226
1 26418006_3 226 227
) 26418006_3 228 229
. 26418006_3 230 231

OBJECTIVE 12153842_2 0 9
: 12153842_2 10 11
Jews 12153842_2 12 16
drink 12153842_2 17 22
less 12153842_2 23 27
than 12153842_2 28 32
other 12153842_2 33 38
Caucasians 12153842_2 39 49
and 12153842_2 50 53
have 12153842_2 54 58
a 12153842_2 59 60
higher 12153842_2 61 67
prevalence 12153842_2 68 78
of 12153842_2 79 81
ADH 12153842_2 82 85
2 12153842_2 85 86
* 12153842_2 87 88
2 12153842_2 89 90
, 12153842_2 91 92
an 12153842_2 93 95
allele 12153842_2 96 102
of 12153842_2 103 105
an 12153842_2 106 108
alcohol 12153842_2 109 116
dehydrogenase 12153842_2 117 130
gene 12153842_2 131 135
that 12153842_2 136 140
protects 12153842_2 141 149
against 12153842_2 150 157
heavy 12153842_2 158 163
drinking 12153842_2 164 172
. 12153842_2 173 174

METHODS 17980418_4 0 7
: 17980418_4 8 9
We 17980418_4 10 12
resequenced 17980418_4 13 24
, 17980418_4 25 26
then 17980418_4 27 31
genotyped 17980418_4 32 41
10 17980418_4 42 44
FCER 17980418_4 45 49
2 17980418_4 49 50
single 17980418_4 51 57
nucleotide 17980418_4 58 68
polymorphisms 17980418_4 69 82
( 17980418_4 83 84
SNPs 17980418_4 85 89
) 17980418_4 90 91
in 17980418_4 92 94
311 17980418_4 95 98
children 17980418_4 99 107
randomized 17980418_4 108 118
to 17980418_4 119 121
inhaled 17980418_4 122 129
budesonide 17980418_4 130 140
as 17980418_4 141 143
part 17980418_4 144 148
of 17980418_4 149 151
the 17980418_4 152 155
Childhood 17980418_4 156 165
Asthma 17980418_4 166 172
Management 17980418_4 173 183
Program 17980418_4 184 191
. 17980418_4 192 193

In 25261422_8 0 2
vivo 25261422_8 3 7
, 25261422_8 8 9
virological 25261422_8 10 21
outcome 25261422_8 22 29
of 25261422_8 30 32
first 25261422_8 33 38
- 25261422_8 38 39
line 25261422_8 39 43
regimens 25261422_8 44 52
containing 25261422_8 53 63
tenofovir 25261422_8 64 73
and 25261422_8 74 77
emtricitabine 25261422_8 78 91
was 25261422_8 92 95
comparable 25261422_8 96 106
between 25261422_8 107 114
patients 25261422_8 115 123
diagnosed 25261422_8 124 133
with 25261422_8 134 138
HIV 25261422_8 139 142
- 25261422_8 142 143
1 25261422_8 143 144
harbouring 25261422_8 145 155
M 25261422_8 156 157
41 25261422_8 157 159
L 25261422_8 159 160
( 25261422_8 161 162
n 25261422_8 163 164
= 25261422_8 165 166
17 25261422_8 167 169
, 25261422_8 170 171
16 25261422_8 172 174
were 25261422_8 175 179
part 25261422_8 180 184
of 25261422_8 185 187
one 25261422_8 188 191
transmission 25261422_8 192 204
cluster 25261422_8 205 212
) 25261422_8 213 214
and 25261422_8 215 218
WT 25261422_8 219 221
virus 25261422_8 222 227
( 25261422_8 228 229
n 25261422_8 230 231
= 25261422_8 232 233
248 25261422_8 234 237
) 25261422_8 238 239
. 25261422_8 240 241

Neither 10568834_5 0 7
p 10568834_5 8 9
53 10568834_5 9 11
overexpression 10568834_5 12 26
nor 10568834_5 27 30
mutation 10568834_5 31 39
were 10568834_5 40 44
associated 10568834_5 45 55
with 10568834_5 56 60
significantly 10568834_5 61 74
worse 10568834_5 75 80
patient 10568834_5 81 88
survival 10568834_5 89 97
in 10568834_5 98 100
the 10568834_5 101 104
overall 10568834_5 105 112
group 10568834_5 113 118
or 10568834_5 119 121
in 10568834_5 122 124
the 10568834_5 125 128
subgroup 10568834_5 129 137
of 10568834_5 138 140
35 10568834_5 141 143
patients 10568834_5 144 152
who 10568834_5 153 156
received 10568834_5 157 165
standard 10568834_5 166 174
post 10568834_5 175 179
- 10568834_5 179 180
operative 10568834_5 180 189
chemotherapy 10568834_5 190 202
with 10568834_5 203 207
5 10568834_5 208 209
- 10568834_5 209 210
fluorouracil 10568834_5 210 222
and 10568834_5 223 226
levamisole 10568834_5 227 237
. 10568834_5 238 239

Norepinephrine 10377355_6 0 14
( 10377355_6 15 16
NE 10377355_6 17 19
) 10377355_6 20 21
is 10377355_6 22 24
a 10377355_6 25 26
well 10377355_6 27 31
known 10377355_6 32 37
neurotransmitter 10377355_6 38 54
that 10377355_6 55 59
regulates 10377355_6 60 69
CRH 10377355_6 70 73
neurons 10377355_6 74 81
in 10377355_6 82 84
the 10377355_6 85 88
PVN 10377355_6 89 92
. 10377355_6 93 94

In 18485328_10 0 2
vitro 18485328_10 3 8
functional 18485328_10 9 19
studies 18485328_10 20 27
demonstrated 18485328_10 28 40
the 18485328_10 41 44
catalytic 18485328_10 45 54
functions 18485328_10 55 64
of 18485328_10 65 67
both 18485328_10 68 72
p 18485328_10 73 74
. 18485328_10 74 75
Gly 18485328_10 75 78
143 18485328_10 78 81
Glu 18485328_10 81 84
and 18485328_10 85 88
p 18485328_10 89 90
. 18485328_10 90 91
Asp 18485328_10 91 94
260 18485328_10 94 97
fs 18485328_10 97 99
are 18485328_10 100 103
substantially 18485328_10 104 117
impaired 18485328_10 118 126
, 18485328_10 127 128
resulting 18485328_10 129 138
in 18485328_10 139 141
a 18485328_10 142 143
complete 18485328_10 144 152
loss 18485328_10 153 157
of 18485328_10 158 160
hydrolytic 18485328_10 161 171
activity 18485328_10 172 180
toward 18485328_10 181 187
methylphenidate 18485328_10 188 203
. 18485328_10 204 205

Pharmacogenetics 19019258_1 0 16
and 19019258_1 17 20
breast 19019258_1 21 27
cancer 19019258_1 28 34
endocrine 19019258_1 35 44
therapy 19019258_1 45 52
: 19019258_1 53 54
CYP 19019258_1 55 58
2 19019258_1 58 59
D 19019258_1 59 60
6 19019258_1 60 61
as 19019258_1 62 64
a 19019258_1 65 66
predictive 19019258_1 67 77
factor 19019258_1 78 84
for 19019258_1 85 88
tamoxifen 19019258_1 89 98
metabolism 19019258_1 99 109
and 19019258_1 110 113
drug 19019258_1 114 118
response 19019258_1 119 127
? 19019258_1 128 129

Breast 18519658_5 0 6
cancer 18519658_5 7 13
patients 18519658_5 14 22
harboring 18519658_5 23 32
the 18519658_5 33 36
loss 18519658_5 37 41
- 18519658_5 41 42
of 18519658_5 42 44
- 18519658_5 44 45
function 18519658_5 45 53
Asp 18519658_5 54 57
299 18519658_5 57 60
Gly 18519658_5 60 63
polymorphism 18519658_5 64 76
of 18519658_5 77 79
TLR 18519658_5 80 83
4 18519658_5 83 84
relapsed 18519658_5 85 93
earlier 18519658_5 94 101
after 18519658_5 102 107
receiving 18519658_5 108 117
anthracycline 18519658_5 118 131
- 18519658_5 132 133
based 18519658_5 133 138
chemotherapy 18519658_5 139 151
. 18519658_5 152 153

The 16731130_12 0 3
expression 16731130_12 4 14
of 16731130_12 15 17
Bcl 16731130_12 18 21
- 16731130_12 21 22
2 16731130_12 22 23
was 16731130_12 24 27
also 16731130_12 28 32
significantly 16731130_12 33 46
higher 16731130_12 47 53
in 16731130_12 54 56
the 16731130_12 57 60
CoCl 16731130_12 61 65
2 16731130_12 65 66
group 16731130_12 67 72
( 16731130_12 73 74
0 16731130_12 75 76
. 16731130_12 76 77
15 16731130_12 77 79
+ 16731130_12 80 81
/ 16731130_12 82 83
- 16731130_12 84 85
0 16731130_12 86 87
. 16731130_12 87 88
02 16731130_12 88 90
) 16731130_12 91 92
versus 16731130_12 93 99
control 16731130_12 100 107
( 16731130_12 108 109
0 16731130_12 110 111
. 16731130_12 111 112
11 16731130_12 112 114
+ 16731130_12 115 116
/ 16731130_12 117 118
- 16731130_12 119 120
0 16731130_12 121 122
. 16731130_12 122 123
01 16731130_12 123 125
, 16731130_12 126 127
p 16731130_12 128 129
= 16731130_12 130 131
0 16731130_12 132 133
. 16731130_12 133 134
007 16731130_12 134 137
) 16731130_12 138 139
, 16731130_12 140 141
whereas 16731130_12 142 149
Bax 16731130_12 150 153
expression 16731130_12 154 164
was 16731130_12 165 168
lower 16731130_12 169 174
( 16731130_12 175 176
0 16731130_12 177 178
. 16731130_12 178 179
34 16731130_12 179 181
+ 16731130_12 182 183
/ 16731130_12 184 185
- 16731130_12 186 187
0 16731130_12 188 189
. 16731130_12 189 190
04 16731130_12 190 192
versus 16731130_12 193 199
0 16731130_12 200 201
. 16731130_12 201 202
54 16731130_12 202 204
+ 16731130_12 205 206
/ 16731130_12 207 208
- 16731130_12 209 210
0 16731130_12 211 212
. 16731130_12 212 213
03 16731130_12 213 215
for 16731130_12 216 219
control 16731130_12 220 227
, 16731130_12 228 229
p 16731130_12 230 231
< 16731130_12 232 233
0 16731130_12 234 235
. 16731130_12 235 236
001 16731130_12 236 239
) 16731130_12 240 241
. 16731130_12 242 243

Effects 11882352_1 0 7
of 11882352_1 8 10
src 11882352_1 11 14
- 11882352_1 15 16
deficiency 11882352_1 16 26
on 11882352_1 27 29
the 11882352_1 30 33
expression 11882352_1 34 44
of 11882352_1 45 47
in 11882352_1 48 50
vivo 11882352_1 51 55
toxicity 11882352_1 56 64
of 11882352_1 65 67
TCDD 11882352_1 68 72
in 11882352_1 73 75
a 11882352_1 76 77
strain 11882352_1 78 84
of 11882352_1 85 87
c 11882352_1 88 89
- 11882352_1 89 90
src 11882352_1 91 94
knockout 11882352_1 95 103
mice 11882352_1 104 108
procured 11882352_1 109 117
through 11882352_1 118 125
six 11882352_1 126 129
generations 11882352_1 130 141
of 11882352_1 142 144
backcrossings 11882352_1 145 158
to 11882352_1 159 161
C 11882352_1 162 163
57 11882352_1 163 165
BL 11882352_1 165 167
/ 11882352_1 167 168
6 11882352_1 168 169
mice 11882352_1 170 174
. 11882352_1 175 176

RESULTS 18024866_6 0 7
: 18024866_6 8 9
Tamoxifen 18024866_6 10 19
- 18024866_6 20 21
treated 18024866_6 21 28
patients 18024866_6 29 37
carrying 18024866_6 38 46
the 18024866_6 47 50
CYP 18024866_6 51 54
2 18024866_6 54 55
D 18024866_6 55 56
6 18024866_6 56 57
alleles 18024866_6 58 65
* 18024866_6 66 67
4 18024866_6 68 69
, 18024866_6 70 71
* 18024866_6 72 73
5 18024866_6 74 75
, 18024866_6 76 77
* 18024866_6 78 79
10 18024866_6 80 82
, 18024866_6 83 84
* 18024866_6 85 86
41 18024866_6 87 89
- 18024866_6 90 91
all 18024866_6 91 94
associated 18024866_6 95 105
with 18024866_6 106 110
impaired 18024866_6 111 119
formation 18024866_6 120 129
of 18024866_6 130 132
antiestrogenic 18024866_6 133 147
metabolites 18024866_6 148 159
- 18024866_6 160 161
had 18024866_6 161 164
significantly 18024866_6 165 178
more 18024866_6 179 183
recurrences 18024866_6 184 195
of 18024866_6 196 198
breast 18024866_6 199 205
cancer 18024866_6 206 212
, 18024866_6 213 214
shorter 18024866_6 215 222
relapse 18024866_6 223 230
- 18024866_6 230 231
free 18024866_6 231 235
periods 18024866_6 236 243
( 18024866_6 244 245
hazard 18024866_6 246 252
ratio 18024866_6 253 258
[ 18024866_6 259 260
HR 18024866_6 261 263
] 18024866_6 264 265
, 18024866_6 266 267
2 18024866_6 268 269
. 18024866_6 269 270
24 18024866_6 270 272
; 18024866_6 273 274
95 18024866_6 275 277
% 18024866_6 278 279
CI 18024866_6 280 282
, 18024866_6 283 284
1 18024866_6 285 286
. 18024866_6 286 287
16 18024866_6 287 289
to 18024866_6 290 292
4 18024866_6 293 294
. 18024866_6 294 295
33 18024866_6 295 297
; 18024866_6 298 299
P 18024866_6 300 301
= 18024866_6 302 303
. 18024866_6 304 305
02 18024866_6 305 307
) 18024866_6 308 309
, 18024866_6 310 311
and 18024866_6 312 315
worse 18024866_6 316 321
event 18024866_6 322 327
- 18024866_6 327 328
free 18024866_6 328 332
survival 18024866_6 333 341
rates 18024866_6 342 347
( 18024866_6 348 349
HR 18024866_6 350 352
, 18024866_6 353 354
1 18024866_6 355 356
. 18024866_6 356 357
89 18024866_6 357 359
; 18024866_6 360 361
95 18024866_6 362 364
% 18024866_6 365 366
CI 18024866_6 367 369
, 18024866_6 370 371
1 18024866_6 372 373
. 18024866_6 373 374
10 18024866_6 374 376
to 18024866_6 377 379
3 18024866_6 380 381
. 18024866_6 381 382
25 18024866_6 382 384
; 18024866_6 385 386
P 18024866_6 387 388
= 18024866_6 389 390
. 18024866_6 391 392
02 18024866_6 392 394
) 18024866_6 395 396
compared 18024866_6 397 405
with 18024866_6 406 410
carriers 18024866_6 411 419
of 18024866_6 420 422
functional 18024866_6 423 433
alleles 18024866_6 434 441
. 18024866_6 442 443

Here 11455387_7 0 4
we 11455387_7 5 7
show 11455387_7 8 12
that 11455387_7 13 17
an 11455387_7 18 20
exposure 11455387_7 21 29
of 11455387_7 30 32
mice 11455387_7 33 37
to 11455387_7 38 40
PAHs 11455387_7 41 45
induces 11455387_7 46 53
the 11455387_7 54 57
expression 11455387_7 58 68
of 11455387_7 69 71
Bax 11455387_7 72 75
in 11455387_7 76 78
oocytes 11455387_7 79 86
, 11455387_7 87 88
followed 11455387_7 89 97
by 11455387_7 98 100
apoptosis 11455387_7 101 110
. 11455387_7 111 112

Purified 25941087_7 0 8
SULT 25941087_7 9 13
1 25941087_7 13 14
A 25941087_7 14 15
3 25941087_7 15 16
allozymes 25941087_7 17 26
were 25941087_7 27 31
shown 25941087_7 32 37
to 25941087_7 38 40
exhibit 25941087_7 41 48
differential 25941087_7 49 61
sulfating 25941087_7 62 71
activity 25941087_7 72 80
toward 25941087_7 81 87
ritodrine 25941087_7 88 97
. 25941087_7 98 99

When 17477907_6 0 4
incubated 17477907_6 5 14
with 17477907_6 15 19
P 17477907_6 20 21
- 17477907_6 21 22
gp 17477907_6 22 24
- 17477907_6 25 26
expressing 17477907_6 26 36
MDR 17477907_6 37 40
cell 17477907_6 41 45
lines 17477907_6 46 51
, 17477907_6 52 53
serum 17477907_6 54 59
from 17477907_6 60 64
immunized 17477907_6 65 74
mice 17477907_6 75 79
restored 17477907_6 80 88
sensitivity 17477907_6 89 100
to 17477907_6 101 103
either 17477907_6 104 110
doxorubicin 17477907_6 111 122
or 17477907_6 123 125
vinblastine 17477907_6 126 137
, 17477907_6 138 139
or 17477907_6 140 142
had 17477907_6 143 146
no 17477907_6 147 149
effect 17477907_6 150 156
in 17477907_6 157 159
a 17477907_6 160 161
cell 17477907_6 162 166
type 17477907_6 167 171
specific 17477907_6 172 180
manner 17477907_6 181 187
, 17477907_6 188 189
suggesting 17477907_6 190 200
that 17477907_6 201 205
several 17477907_6 206 213
mechanisms 17477907_6 214 224
may 17477907_6 225 228
occur 17477907_6 229 234
in 17477907_6 235 237
the 17477907_6 238 241
establishment 17477907_6 242 255
of 17477907_6 256 258
the 17477907_6 259 262
MDR 17477907_6 263 266
phenotype 17477907_6 267 276
. 17477907_6 277 278

The 14683587_2 0 3
aim 14683587_2 4 7
of 14683587_2 8 10
our 14683587_2 11 14
study 14683587_2 15 20
was 14683587_2 21 24
to 14683587_2 25 27
evaluate 14683587_2 28 36
electrogenetherapy 14683587_2 37 55
with 14683587_2 56 60
p 14683587_2 61 62
53 14683587_2 62 64
wt 14683587_2 65 67
alone 14683587_2 68 73
or 14683587_2 74 76
combined 14683587_2 77 85
with 14683587_2 86 90
cisplatin 14683587_2 91 100
on 14683587_2 101 103
two 14683587_2 104 107
colorectal 14683587_2 108 118
( 14683587_2 119 120
HT 14683587_2 121 123
- 14683587_2 123 124
29 14683587_2 124 126
and 14683587_2 127 130
LoVo 14683587_2 131 135
) 14683587_2 136 137
and 14683587_2 138 141
two 14683587_2 142 145
prostatic 14683587_2 146 155
( 14683587_2 156 157
PC 14683587_2 158 160
- 14683587_2 160 161
3 14683587_2 161 162
and 14683587_2 163 166
Du 14683587_2 167 169
145 14683587_2 169 172
) 14683587_2 173 174
carcinoma 14683587_2 175 184
cell 14683587_2 185 189
lines 14683587_2 190 195
with 14683587_2 196 200
different 14683587_2 201 210
p 14683587_2 211 212
53 14683587_2 212 214
status 14683587_2 215 221
. 14683587_2 222 223

The 26736037_7 0 3
CREB 26736037_7 4 8
signaling 26736037_7 9 18
pathway 26736037_7 19 26
is 26736037_7 27 29
involved 26736037_7 30 38
in 26736037_7 39 41
gene 26736037_7 42 46
expression 26736037_7 47 57
changes 26736037_7 58 65
related 26736037_7 66 73
to 26736037_7 74 76
chronic 26736037_7 77 84
use 26736037_7 85 88
of 26736037_7 89 91
multiple 26736037_7 92 100
drugs 26736037_7 101 106
of 26736037_7 107 109
abuse 26736037_7 110 115
including 26736037_7 116 125
methamphetamine 26736037_7 126 141
and 26736037_7 142 145
these 26736037_7 146 151
results 26736037_7 152 159
suggest 26736037_7 160 167
that 26736037_7 168 172
variability 26736037_7 173 184
in 26736037_7 185 187
CREB 26736037_7 188 192
signaling 26736037_7 193 202
may 26736037_7 203 206
influence 26736037_7 207 216
pretreatment 26736037_7 217 229
frequency 26736037_7 230 239
of 26736037_7 240 242
methamphetamine 26736037_7 243 258
use 26736037_7 259 262
as 26736037_7 263 265
well 26736037_7 266 270
as 26736037_7 271 273
outcomes 26736037_7 274 282
of 26736037_7 283 285
outpatient 26736037_7 286 296
treatment 26736037_7 297 306
. 26736037_7 307 308

In 20424113_3 0 2
this 20424113_3 3 7
study 20424113_3 8 13
, 20424113_3 14 15
we 20424113_3 16 18
showed 20424113_3 19 25
that 20424113_3 26 30
in 20424113_3 31 33
the 20424113_3 34 37
presence 20424113_3 38 46
of 20424113_3 47 49
copper 20424113_3 50 56
( 20424113_3 57 58
Cu 20424113_3 59 61
) 20424113_3 62 63
, 20424113_3 64 65
disulfiram 20424113_3 66 76
( 20424113_3 77 78
DSF 20424113_3 79 82
) 20424113_3 83 84
, 20424113_3 85 86
a 20424113_3 87 88
clinically 20424113_3 89 99
used 20424113_3 100 104
antialcoholism 20424113_3 105 119
drug 20424113_3 120 124
, 20424113_3 125 126
could 20424113_3 127 132
potently 20424113_3 133 141
inhibit 20424113_3 142 149
breast 20424113_3 150 156
cancer 20424113_3 157 163
cell 20424113_3 164 168
growth 20424113_3 169 175
regardless 20424113_3 176 186
of 20424113_3 187 189
the 20424113_3 190 193
PIK 20424113_3 194 197
3 20424113_3 197 198
CA 20424113_3 198 200
status 20424113_3 201 207
. 20424113_3 208 209

In 21388237_3 0 2
the 21388237_3 3 6
multicentre 21388237_3 7 18
clinical 21388237_3 19 27
and 21388237_3 28 31
pharmacogenetic 21388237_3 32 47
GENDEP 21388237_3 48 54
study 21388237_3 55 60
( 21388237_3 61 62
Genome 21388237_3 63 69
- 21388237_3 69 70
based 21388237_3 70 75
Therapeutic 21388237_3 76 87
Drugs 21388237_3 88 93
for 21388237_3 94 97
Depression 21388237_3 98 108
) 21388237_3 109 110
, 21388237_3 111 112
the 21388237_3 113 116
effect 21388237_3 117 123
of 21388237_3 124 126
the 21388237_3 127 130
serotonin 21388237_3 131 140
transporter 21388237_3 141 152
gene 21388237_3 153 157
promoter 21388237_3 158 166
polymorphism 21388237_3 167 179
5 21388237_3 180 181
- 21388237_3 181 182
HTTLPR 21388237_3 182 188
on 21388237_3 189 191
sexual 21388237_3 192 198
function 21388237_3 199 207
was 21388237_3 208 211
investigated 21388237_3 212 224
during 21388237_3 225 231
treatment 21388237_3 232 241
with 21388237_3 242 246
escitalopram 21388237_3 247 259
( 21388237_3 260 261
SSRI 21388237_3 262 266
) 21388237_3 267 268
and 21388237_3 269 272
nortriptyline 21388237_3 273 286
( 21388237_3 287 288
tricyclic 21388237_3 289 298
antidepressant 21388237_3 299 313
) 21388237_3 314 315
. 21388237_3 316 317

Using 19176891_5 0 5
confocal 19176891_5 6 14
microscopy 19176891_5 15 25
, 19176891_5 26 27
we 19176891_5 28 30
demonstrate 19176891_5 31 42
that 19176891_5 43 47
intraperitoneal 19176891_5 48 63
CCK 19176891_5 64 67
administration 19176891_5 68 82
increases 19176891_5 83 92
the 19176891_5 93 96
number 19176891_5 97 103
of 19176891_5 104 106
neurons 19176891_5 107 114
that 19176891_5 115 119
express 19176891_5 120 127
phosphorylated 19176891_5 128 142
ERK 19176891_5 143 146
1 19176891_5 146 147
/ 19176891_5 147 148
2 19176891_5 148 149
( 19176891_5 150 151
pERK 19176891_5 152 156
1 19176891_5 156 157
/ 19176891_5 157 158
2 19176891_5 158 159
) 19176891_5 160 161
in 19176891_5 162 164
the 19176891_5 165 168
medial 19176891_5 169 175
and 19176891_5 176 179
commissural 19176891_5 180 191
subnuclei 19176891_5 192 201
of 19176891_5 202 204
the 19176891_5 205 208
NTS 19176891_5 209 212
and 19176891_5 213 216
that 19176891_5 217 221
CCK 19176891_5 222 225
- 19176891_5 226 227
induced 19176891_5 227 234
expression 19176891_5 235 245
of 19176891_5 246 248
ERK 19176891_5 249 252
1 19176891_5 252 253
/ 19176891_5 253 254
2 19176891_5 254 255
is 19176891_5 256 258
increased 19176891_5 259 268
in 19176891_5 269 271
tyrosine 19176891_5 272 280
hydroxylase 19176891_5 281 292
- 19176891_5 293 294
immunoreactive 19176891_5 294 308
neurons 19176891_5 309 316
. 19176891_5 317 318

Levels 8923461_9 0 6
of 8923461_9 7 9
c 8923461_9 10 11
- 8923461_9 11 12
fos 8923461_9 12 15
and 8923461_9 16 19
c 8923461_9 20 21
- 8923461_9 21 22
jun 8923461_9 22 25
proteins 8923461_9 26 34
also 8923461_9 35 39
were 8923461_9 40 44
increased 8923461_9 45 54
by 8923461_9 55 57
TNF 8923461_9 58 61
alpha 8923461_9 62 67
or 8923461_9 68 70
ceramide 8923461_9 71 79
in 8923461_9 80 82
the 8923461_9 83 86
presence 8923461_9 87 95
of 8923461_9 96 98
DEX 8923461_9 99 102
. 8923461_9 103 104

Genetic 15864124_1 0 7
polymorphism 15864124_1 8 20
in 15864124_1 21 23
the 15864124_1 24 27
phenobarbital 15864124_1 28 41
- 15864124_1 42 43
responsive 15864124_1 43 53
enhancer 15864124_1 54 62
module 15864124_1 63 69
of 15864124_1 70 72
the 15864124_1 73 76
UDP 15864124_1 77 80
- 15864124_1 80 81
glucuronosyltransferase 15864124_1 81 104
1 15864124_1 105 106
A 15864124_1 106 107
1 15864124_1 107 108
gene 15864124_1 109 113
and 15864124_1 114 117
irinotecan 15864124_1 118 128
toxicity 15864124_1 129 137
. 15864124_1 138 139

CONCLUSION 26220844_12 0 10
: 26220844_12 11 12
Rare 26220844_12 13 17
TT 26220844_12 18 20
genotype 26220844_12 21 29
of 26220844_12 30 32
STMN 26220844_12 33 37
1 26220844_12 37 38
gene 26220844_12 39 43
may 26220844_12 44 47
be 26220844_12 48 50
an 26220844_12 51 53
unfavorable 26220844_12 54 65
predictive 26220844_12 66 76
factor 26220844_12 77 83
of 26220844_12 84 86
chemotherapy 26220844_12 87 99
based 26220844_12 100 105
on 26220844_12 106 108
platinum 26220844_12 109 117
compounds 26220844_12 118 127
and 26220844_12 128 131
vinorelbine 26220844_12 132 143
, 26220844_12 144 145
in 26220844_12 146 148
patients 26220844_12 149 157
with 26220844_12 158 162
NSCLC 26220844_12 163 168
. 26220844_12 169 170

Pharmacogenetics 19655247_7 0 16
studies 19655247_7 17 24
illustrate 19655247_7 25 35
the 19655247_7 36 39
potential 19655247_7 40 49
of 19655247_7 50 52
genetics 19655247_7 53 61
to 19655247_7 62 64
impact 19655247_7 65 71
on 19655247_7 72 74
response 19655247_7 75 83
to 19655247_7 84 86
therapy 19655247_7 87 94
, 19655247_7 95 96
as 19655247_7 97 99
observed 19655247_7 100 108
with 19655247_7 109 113
SLC 19655247_7 114 117
6 19655247_7 117 118
A 19655247_7 118 119
4 19655247_7 119 120
and 19655247_7 121 124
responses 19655247_7 125 134
to 19655247_7 135 137
the 19655247_7 138 141
5 19655247_7 142 143
- 19655247_7 143 144
HT 19655247_7 144 146
3 19655247_7 146 147
antagonist 19655247_7 148 158
alosetron 19655247_7 159 168
and 19655247_7 169 172
the 19655247_7 173 176
5 19655247_7 177 178
- 19655247_7 178 179
HT 19655247_7 179 181
4 19655247_7 181 182
agonist 19655247_7 183 190
, 19655247_7 191 192
tegaserod 19655247_7 193 202
. 19655247_7 203 204

Specifically 10864974_5 0 12
, 10864974_5 13 14
the 10864974_5 15 18
effects 10864974_5 19 26
of 10864974_5 27 29
unilateral 10864974_5 30 40
lesions 10864974_5 41 48
of 10864974_5 49 51
nigrostriatal 10864974_5 52 65
DA 10864974_5 66 68
neurons 10864974_5 69 76
on 10864974_5 77 79
oral 10864974_5 80 84
dyskinesia 10864974_5 85 95
and 10864974_5 96 99
Fos 10864974_5 100 103
protein 10864974_5 104 111
expression 10864974_5 112 122
induced 10864974_5 123 130
by 10864974_5 131 133
the 10864974_5 134 137
non 10864974_5 138 141
- 10864974_5 141 142
selective 10864974_5 142 151
5 10864974_5 152 153
- 10864974_5 153 154
HT 10864974_5 154 156
( 10864974_5 156 157
2 10864974_5 157 158
C 10864974_5 158 159
) 10864974_5 160 161
agonist 10864974_5 162 169
1 10864974_5 170 171
- 10864974_5 171 172
( 10864974_5 172 173
m 10864974_5 173 174
- 10864974_5 174 175
chlorophenyl 10864974_5 175 187
) 10864974_5 187 188
piperazine 10864974_5 188 198
( 10864974_5 199 200
m 10864974_5 201 202
- 10864974_5 202 203
CPP 10864974_5 203 206
) 10864974_5 207 208
were 10864974_5 209 213
examined 10864974_5 214 222
. 10864974_5 223 224

RESULTS 27097961_8 0 7
: 27097961_8 8 9
No 27097961_8 10 12
marked 27097961_8 13 19
difference 27097961_8 20 30
in 27097961_8 31 33
NAA 27097961_8 34 37
, 27097961_8 38 39
Cr 27097961_8 40 42
, 27097961_8 43 44
or 27097961_8 45 47
Cho 27097961_8 48 51
levels 27097961_8 52 58
was 27097961_8 59 62
detected 27097961_8 63 71
before 27097961_8 72 78
and 27097961_8 79 82
after 27097961_8 83 88
MPH 27097961_8 89 92
administration 27097961_8 93 107
with 27097961_8 108 112
respect 27097961_8 113 120
to 27097961_8 121 123
the 27097961_8 124 127
DAT 27097961_8 128 131
1 27097961_8 131 132
gene 27097961_8 133 137
VNTR 27097961_8 138 142
polymorphisms 27097961_8 143 156
. 27097961_8 157 158

The 23159001_11 0 3
efficacy 23159001_11 4 12
of 23159001_11 13 15
icotinib 23159001_11 16 24
hydrochloride 23159001_11 25 38
were 23159001_11 39 43
related 23159001_11 44 51
to 23159001_11 52 54
the 23159001_11 55 58
ECOG 23159001_11 59 63
performance 23159001_11 64 75
status 23159001_11 76 82
, 23159001_11 83 84
smoking 23159001_11 85 92
history 23159001_11 93 100
, 23159001_11 101 102
EGFR 23159001_11 103 107
mutation 23159001_11 108 116
and 23159001_11 117 120
rash 23159001_11 121 125
significantly 23159001_11 126 139
( 23159001_11 140 141
P 23159001_11 142 143
< 23159001_11 144 145
0 23159001_11 146 147
. 23159001_11 147 148
05 23159001_11 148 150
) 23159001_11 151 152
. 23159001_11 153 154

Molecular 10785598_1 0 9
downstream 10785598_1 10 20
events 10785598_1 21 27
and 10785598_1 28 31
induction 10785598_1 32 41
of 10785598_1 42 44
thymidylate 10785598_1 45 56
synthase 10785598_1 57 65
in 10785598_1 66 68
mutant 10785598_1 69 75
and 10785598_1 76 79
wild 10785598_1 80 84
- 10785598_1 84 85
type 10785598_1 85 89
p 10785598_1 90 91
53 10785598_1 91 93
colon 10785598_1 94 99
cancer 10785598_1 100 106
cell 10785598_1 107 111
lines 10785598_1 112 117
after 10785598_1 118 123
treatment 10785598_1 124 133
with 10785598_1 134 138
5 10785598_1 139 140
- 10785598_1 140 141
fluorouracil 10785598_1 141 153
and 10785598_1 154 157
the 10785598_1 158 161
thymidylate 10785598_1 162 173
synthase 10785598_1 174 182
inhibitor 10785598_1 183 192
raltitrexed 10785598_1 193 204
. 10785598_1 205 206

CONCLUSION 22401810_16 0 10
( 22401810_16 11 12
S 22401810_16 13 14
) 22401810_16 15 16
: 22401810_16 17 18
FSHR 22401810_16 19 23
gene 22401810_16 24 28
variations 22401810_16 29 39
such 22401810_16 40 44
as 22401810_16 45 47
Asn 22401810_16 48 51
680 22401810_16 51 54
Ser 22401810_16 54 57
, 22401810_16 58 59
Ala 22401810_16 60 63
189 22401810_16 63 66
Val 22401810_16 66 69
, 22401810_16 70 71
Thr 22401810_16 72 75
449 22401810_16 75 78
Ile 22401810_16 78 81
, 22401810_16 82 83
and 22401810_16 84 87
Ile 22401810_16 88 91
160 22401810_16 91 94
Thr 22401810_16 94 97
did 22401810_16 98 101
not 22401810_16 102 105
seem 22401810_16 106 110
to 22401810_16 111 113
be 22401810_16 114 116
a 22401810_16 117 118
decisive 22401810_16 119 127
factor 22401810_16 128 134
of 22401810_16 135 137
poor 22401810_16 138 142
response 22401810_16 143 151
to 22401810_16 152 154
fertility 22401810_16 155 164
treatment 22401810_16 165 174
, 22401810_16 175 176
whereas 22401810_16 177 184
the 22401810_16 185 188
low 22401810_16 189 192
ovarian 22401810_16 193 200
reserve 22401810_16 201 208
determined 22401810_16 209 219
by 22401810_16 220 222
AMH 22401810_16 223 226
is 22401810_16 227 229
considered 22401810_16 230 240
more 22401810_16 241 245
crucial 22401810_16 246 253
. 22401810_16 254 255

Total 22811313_10 0 5
androgen 22811313_10 6 14
concentrations 22811313_10 15 29
were 22811313_10 30 34
not 22811313_10 35 38
associated 22811313_10 39 49
with 22811313_10 50 54
pregnancy 22811313_10 55 64
; 22811313_10 65 66
however 22811313_10 67 74
, 22811313_10 75 76
in 22811313_10 77 79
women 22811313_10 80 85
with 22811313_10 86 90
abnormal 22811313_10 91 99
FMR 22811313_10 100 103
1 22811313_10 103 104
genotypes 22811313_10 105 114
, 22811313_10 115 116
but 22811313_10 117 120
not 22811313_10 121 124
those 22811313_10 125 130
with 22811313_10 131 135
the 22811313_10 136 139
normal 22811313_10 140 146
genotype 22811313_10 147 155
, 22811313_10 156 157
free 22811313_10 158 162
testosterone 22811313_10 163 175
significantly 22811313_10 176 189
affected 22811313_10 190 198
clinical 22811313_10 199 207
pregnancy 22811313_10 208 217
potential 22811313_10 218 227
( 22811313_10 228 229
b 22811313_10 230 231
= 22811313_10 232 233
1 22811313_10 234 235
. 22811313_10 235 236
101 22811313_10 236 239
, 22811313_10 240 241
SE 22811313_10 242 244
0 22811313_10 245 246
. 22811313_10 246 247
508 22811313_10 247 250
, 22811313_10 251 252
P 22811313_10 253 254
= 22811313_10 255 256
0 22811313_10 257 258
. 22811313_10 258 259
03 22811313_10 259 261
) 22811313_10 262 263
. 22811313_10 264 265

Our 17094454_10 0 3
data 17094454_10 4 8
indicate 17094454_10 9 17
that 17094454_10 18 22
the 17094454_10 23 26
PSA 17094454_10 27 30
- 17094454_10 31 32
158 17094454_10 32 35
G 17094454_10 36 37
/ 17094454_10 37 38
A 17094454_10 38 39
polymorphism 17094454_10 40 52
has 17094454_10 53 56
no 17094454_10 57 59
effect 17094454_10 60 66
on 17094454_10 67 69
the 17094454_10 70 73
PSA 17094454_10 74 77
promoter 17094454_10 78 86
activity 17094454_10 87 95
in 17094454_10 96 98
vitro 17094454_10 99 104
and 17094454_10 105 108
no 17094454_10 109 111
association 17094454_10 112 123
with 17094454_10 124 128
the 17094454_10 129 132
serum 17094454_10 133 138
PSA 17094454_10 139 142
level 17094454_10 143 148
in 17094454_10 149 151
Japanese 17094454_10 152 160
men 17094454_10 161 164
, 17094454_10 165 166
however 17094454_10 167 174
suggest 17094454_10 175 182
that 17094454_10 183 187
the 17094454_10 188 191
patients 17094454_10 192 200
with 17094454_10 201 205
GG 17094454_10 206 208
genotype 17094454_10 209 217
of 17094454_10 218 220
ARE 17094454_10 221 224
1 17094454_10 224 225
may 17094454_10 226 229
be 17094454_10 230 232
more 17094454_10 233 237
sensitive 17094454_10 238 247
to 17094454_10 248 250
androgen 17094454_10 251 259
ablation 17094454_10 260 268
therapy 17094454_10 269 276
. 17094454_10 277 278

Heterozygous 12835613_12 0 12
individuals 12835613_12 13 24
with 12835613_12 25 29
the 12835613_12 30 33
CYP 12835613_12 34 37
2 12835613_12 37 38
C 12835613_12 38 39
19 12835613_12 39 41
* 12835613_12 42 43
1 12835613_12 44 45
/ 12835613_12 46 47
* 12835613_12 48 49
2 12835613_12 50 51
genotype 12835613_12 52 60
have 12835613_12 61 65
a 12835613_12 66 67
reduced 12835613_12 68 75
capacity 12835613_12 76 84
for 12835613_12 85 88
metabolizing 12835613_12 89 101
carisoprodol 12835613_12 102 114
, 12835613_12 115 116
and 12835613_12 117 120
should 12835613_12 121 127
probably 12835613_12 128 136
be 12835613_12 137 139
regarded 12835613_12 140 148
as 12835613_12 149 151
intermediate 12835613_12 152 164
metabolizers 12835613_12 165 177
of 12835613_12 178 180
this 12835613_12 181 185
drug 12835613_12 186 190
. 12835613_12 191 192

Ectopic 12668130_5 0 7
expression 12668130_5 8 18
of 12668130_5 19 21
both 12668130_5 22 26
MnSOD 12668130_5 27 32
and 12668130_5 33 36
Cu 12668130_5 37 39
/ 12668130_5 39 40
ZnSOD 12668130_5 40 45
afforded 12668130_5 46 54
protection 12668130_5 55 65
from 12668130_5 66 70
I 12668130_5 71 72
/ 12668130_5 72 73
R 12668130_5 73 74
injury 12668130_5 75 81
, 12668130_5 82 83
as 12668130_5 84 86
evidenced 12668130_5 87 96
by 12668130_5 97 99
a 12668130_5 100 101
significant 12668130_5 102 113
reduction 12668130_5 114 123
in 12668130_5 124 126
serum 12668130_5 127 132
creatine 12668130_5 133 141
kinase 12668130_5 142 148
levels 12668130_5 149 155
, 12668130_5 156 157
infarct 12668130_5 158 165
size 12668130_5 166 170
, 12668130_5 171 172
malondialdehyde 12668130_5 173 188
levels 12668130_5 189 195
, 12668130_5 196 197
and 12668130_5 198 201
apoptotic 12668130_5 202 211
cell 12668130_5 212 216
death 12668130_5 217 222
in 12668130_5 223 225
comparison 12668130_5 226 236
to 12668130_5 237 239
controls 12668130_5 240 248
. 12668130_5 249 250

Combination 19549911_9 0 11
of 19549911_9 12 14
fludarabine 19549911_9 15 26
with 19549911_9 27 31
SYK 19549911_9 32 35
Inhibitor 19549911_9 36 45
II 19549911_9 46 48
or 19549911_9 49 51
R 19549911_9 52 53
406 19549911_9 53 56
increased 19549911_9 57 66
cytotoxicity 19549911_9 67 79
compared 19549911_9 80 88
with 19549911_9 89 93
fludarabine 19549911_9 94 105
therapy 19549911_9 106 113
alone 19549911_9 114 119
. 19549911_9 120 121

Association 21916909_1 0 11
of 21916909_1 12 14
ABCB 21916909_1 15 19
1 21916909_1 19 20
, 21916909_1 21 22
CYP 21916909_1 23 26
3 21916909_1 26 27
A 21916909_1 27 28
4 21916909_1 28 29
* 21916909_1 30 31
18 21916909_1 32 34
B 21916909_1 34 35
and 21916909_1 36 39
CYP 21916909_1 40 43
3 21916909_1 43 44
A 21916909_1 44 45
5 21916909_1 45 46
* 21916909_1 47 48
3 21916909_1 49 50
genotypes 21916909_1 51 60
with 21916909_1 61 65
the 21916909_1 66 69
pharmacokinetics 21916909_1 70 86
of 21916909_1 87 89
tacrolimus 21916909_1 90 100
in 21916909_1 101 103
healthy 21916909_1 104 111
Chinese 21916909_1 112 119
subjects 21916909_1 120 128
: 21916909_1 129 130
a 21916909_1 131 132
population 21916909_1 133 143
pharmacokinetic 21916909_1 144 159
analysis 21916909_1 160 168
. 21916909_1 169 170

Whereas 15717164_13 0 7
GST 15717164_13 8 11
- 15717164_13 11 12
M 15717164_13 12 13
1 15717164_13 13 14
null 15717164_13 15 19
will 15717164_13 20 24
increase 15717164_13 25 33
cyclophosphamide 15717164_13 34 50
efficacy 15717164_13 51 59
, 15717164_13 60 61
GST 15717164_13 62 65
- 15717164_13 65 66
P 15717164_13 66 67
1 15717164_13 67 68
polymorphism 15717164_13 69 81
seems 15717164_13 82 87
to 15717164_13 88 90
be 15717164_13 91 93
related 15717164_13 94 101
to 15717164_13 102 104
enhanced 15717164_13 105 113
susceptibility 15717164_13 114 128
to 15717164_13 129 131
further 15717164_13 132 139
relapses 15717164_13 140 148
. 15717164_13 149 150

Our 27378608_9 0 3
study 27378608_9 4 9
provides 27378608_9 10 18
evidence 27378608_9 19 27
for 27378608_9 28 31
a 27378608_9 32 33
FcyRIIIa 27378608_9 34 42
V 27378608_9 43 44
allele 27378608_9 45 51
- 27378608_9 51 52
restricted 27378608_9 52 62
pCR 27378608_9 63 66
benefit 27378608_9 67 74
from 27378608_9 75 79
neoadjuvant 27378608_9 80 91
trastuzumab 27378608_9 92 103
plus 27378608_9 104 108
lapatinib 27378608_9 109 118
in 27378608_9 119 121
HER 27378608_9 122 125
2 27378608_9 125 126
+ 27378608_9 127 128
BC 27378608_9 129 131
. 27378608_9 132 133
The 27378608_9 133 136
Pharmacogenomics 27378608_9 137 153
Journal 27378608_9 154 161
advance 27378608_9 162 169
online 27378608_9 170 176
publication 27378608_9 177 188
, 27378608_9 189 190
5 27378608_9 191 192
July 27378608_9 193 197
2016 27378608_9 198 202
; 27378608_9 203 204
doi 27378608_9 205 208
: 27378608_9 209 210
10 27378608_9 210 212
. 27378608_9 212 213
1038 27378608_9 213 217
/ 27378608_9 218 219
tpj 27378608_9 220 223
. 27378608_9 224 225
2016 27378608_9 225 229
. 27378608_9 229 230
51 27378608_9 230 232
. 27378608_9 233 234

Successful 20487194_4 0 10
results 20487194_4 11 18
that 20487194_4 19 23
have 20487194_4 24 28
been 20487194_4 29 33
achieved 20487194_4 34 42
within 20487194_4 43 49
the 20487194_4 50 53
field 20487194_4 54 59
of 20487194_4 60 62
pharmacogenomics 20487194_4 63 79
so 20487194_4 80 82
far 20487194_4 83 86
are 20487194_4 87 90
, 20487194_4 91 92
to 20487194_4 93 95
name 20487194_4 96 100
a 20487194_4 101 102
few 20487194_4 103 106
, 20487194_4 107 108
HLA 20487194_4 109 112
- 20487194_4 112 113
B 20487194_4 113 114
* 20487194_4 115 116
5701 20487194_4 117 121
screening 20487194_4 122 131
to 20487194_4 132 134
avoid 20487194_4 135 140
hypersensitivity 20487194_4 141 157
to 20487194_4 158 160
the 20487194_4 161 164
antiretroviral 20487194_4 165 179
abacavir 20487194_4 180 188
, 20487194_4 189 190
thiopurine 20487194_4 191 201
S 20487194_4 202 203
- 20487194_4 203 204
methyltransferase 20487194_4 204 221
( 20487194_4 222 223
TPMT 20487194_4 224 228
) 20487194_4 229 230
genotyping 20487194_4 231 241
to 20487194_4 242 244
avoid 20487194_4 245 250
thiopurine 20487194_4 251 261
toxicity 20487194_4 262 270
, 20487194_4 271 272
and 20487194_4 273 276
CYP 20487194_4 277 280
2 20487194_4 280 281
C 20487194_4 281 282
9 20487194_4 282 283
and 20487194_4 284 287
VKORC 20487194_4 288 293
1 20487194_4 293 294
genotyping 20487194_4 295 305
for 20487194_4 306 309
better 20487194_4 310 316
dosing 20487194_4 317 323
of 20487194_4 324 326
the 20487194_4 327 330
anticoagulant 20487194_4 331 344
warfarin 20487194_4 345 353
. 20487194_4 354 355

In 17143476_3 0 2
this 17143476_3 3 7
study 17143476_3 8 13
, 17143476_3 14 15
we 17143476_3 16 18
investigated 17143476_3 19 31
the 17143476_3 32 35
relationship 17143476_3 36 48
between 17143476_3 49 56
aberrant 17143476_3 57 65
hypermethylation 17143476_3 66 82
of 17143476_3 83 85
the 17143476_3 86 89
CHFR 17143476_3 90 94
( 17143476_3 95 96
checkpoint 17143476_3 97 107
with 17143476_3 108 112
forkhead 17143476_3 113 121
- 17143476_3 121 122
associated 17143476_3 122 132
and 17143476_3 133 136
ring 17143476_3 137 141
finger 17143476_3 142 148
) 17143476_3 149 150
mitotic 17143476_3 151 158
checkpoint 17143476_3 159 169
gene 17143476_3 170 174
and 17143476_3 175 178
sensitivity 17143476_3 179 190
to 17143476_3 191 193
taxanes 17143476_3 194 201
in 17143476_3 202 204
endometrial 17143476_3 205 216
cancer 17143476_3 217 223
. 17143476_3 224 225

CONCLUSION 24948056_9 0 10
: 24948056_9 11 12
This 24948056_9 13 17
work 24948056_9 18 22
shows 24948056_9 23 28
that 24948056_9 29 33
EC 24948056_9 34 36
immunization 24948056_9 37 49
with 24948056_9 50 54
PC 24948056_9 55 57
- 24948056_9 57 58
BSA 24948056_9 58 61
plus 24948056_9 62 66
TLR 24948056_9 67 70
9 24948056_9 70 71
ligand 24948056_9 72 78
CpG 24948056_9 79 82
may 24948056_9 83 86
be 24948056_9 87 89
a 24948056_9 90 91
potential 24948056_9 92 101
tool 24948056_9 102 106
to 24948056_9 107 109
boost 24948056_9 110 115
immunity 24948056_9 116 124
to 24948056_9 125 127
S 24948056_9 128 129
. 24948056_9 129 130
pneumoniae 24948056_9 131 141
. 24948056_9 142 143

This 23645737_3 0 4
study 23645737_3 5 10
investigates 23645737_3 11 23
the 23645737_3 24 27
role 23645737_3 28 32
of 23645737_3 33 35
adenosine 23645737_3 36 45
deaminase 23645737_3 46 55
- 23645737_3 55 56
like 23645737_3 56 60
( 23645737_3 61 62
ADAL 23645737_3 63 67
) 23645737_3 68 69
protein 23645737_3 70 77
in 23645737_3 78 80
the 23645737_3 81 84
intracellular 23645737_3 85 98
activation 23645737_3 99 109
of 23645737_3 110 112
GS 23645737_3 113 115
- 23645737_3 115 116
9219 23645737_3 116 120
. 23645737_3 121 122

Possible 16821082_1 0 8
involvement 16821082_1 9 20
of 16821082_1 21 23
CCT 16821082_1 24 27
5 16821082_1 27 28
, 16821082_1 29 30
RGS 16821082_1 31 34
3 16821082_1 34 35
, 16821082_1 36 37
and 16821082_1 38 41
YKT 16821082_1 42 45
6 16821082_1 45 46
genes 16821082_1 47 52
up 16821082_1 53 55
- 16821082_1 55 56
regulated 16821082_1 56 65
in 16821082_1 66 68
p 16821082_1 69 70
53 16821082_1 70 72
- 16821082_1 73 74
mutated 16821082_1 74 81
tumors 16821082_1 82 88
in 16821082_1 89 91
resistance 16821082_1 92 102
to 16821082_1 103 105
docetaxel 16821082_1 106 115
in 16821082_1 116 118
human 16821082_1 119 124
breast 16821082_1 125 131
cancers 16821082_1 132 139
. 16821082_1 140 141

Folate 21731042_5 0 6
intake 21731042_5 7 13
was 21731042_5 14 17
estimated 21731042_5 18 27
by 21731042_5 28 30
a 21731042_5 31 32
semiquantitative 21731042_5 33 49
food 21731042_5 50 54
frequency 21731042_5 55 64
questionnaire 21731042_5 65 78
and 21731042_5 79 82
DNA 21731042_5 83 86
extracted 21731042_5 87 96
from 21731042_5 97 101
blood 21731042_5 102 107
samples 21731042_5 108 115
for 21731042_5 116 119
MTHFR 21731042_5 120 125
C 21731042_5 126 127
677 21731042_5 127 130
T 21731042_5 130 131
genotyping 21731042_5 132 142
. 21731042_5 143 144

Is 25872644_1 0 2
there 25872644_1 3 8
a 25872644_1 9 10
role 25872644_1 11 15
for 25872644_1 16 19
ADORA 25872644_1 20 25
2 25872644_1 25 26
A 25872644_1 26 27
polymorphisms 25872644_1 28 41
in 25872644_1 42 44
levodopa 25872644_1 45 53
- 25872644_1 54 55
induced 25872644_1 55 62
dyskinesia 25872644_1 63 73
in 25872644_1 74 76
Parkinson 25872644_1 77 86
' 25872644_1 86 87
s 25872644_1 87 88
disease 25872644_1 89 96
patients 25872644_1 97 105
? 25872644_1 106 107

These 26091798_14 0 5
results 26091798_14 6 13
demonstrate 26091798_14 14 25
that 26091798_14 26 30
p 26091798_14 31 32
53 26091798_14 32 34
is 26091798_14 35 37
able 26091798_14 38 42
to 26091798_14 43 45
respond 26091798_14 46 53
to 26091798_14 54 56
exposure 26091798_14 57 65
of 26091798_14 66 68
arsenic 26091798_14 69 76
or 26091798_14 77 79
Cr 26091798_14 80 82
( 26091798_14 82 83
VI 26091798_14 83 85
) 26091798_14 85 86
, 26091798_14 87 88
suggesting 26091798_14 89 99
that 26091798_14 100 104
BEAS 26091798_14 105 109
- 26091798_14 109 110
2 26091798_14 110 111
B 26091798_14 111 112
cells 26091798_14 113 118
are 26091798_14 119 122
an 26091798_14 123 125
appropriate 26091798_14 126 137
in 26091798_14 138 140
vitro 26091798_14 141 146
model 26091798_14 147 152
to 26091798_14 153 155
investigate 26091798_14 156 167
arsenic 26091798_14 168 175
or 26091798_14 176 178
Cr 26091798_14 179 181
( 26091798_14 181 182
VI 26091798_14 182 184
) 26091798_14 184 185
induced 26091798_14 186 193
lung 26091798_14 194 198
cancer 26091798_14 199 205
. 26091798_14 206 207

In 12768192_8 0 2
contrast 12768192_8 3 11
, 12768192_8 12 13
nonfunctional 12768192_8 14 27
ICAM 12768192_8 28 32
- 12768192_8 32 33
1 12768192_8 33 34
lacking 12768192_8 35 42
the 12768192_8 43 46
N 12768192_8 47 48
- 12768192_8 49 50
terminal 12768192_8 50 58
ligand 12768192_8 59 65
- 12768192_8 65 66
binding 12768192_8 66 73
Ig 12768192_8 74 76
domain 12768192_8 77 83
failed 12768192_8 84 90
to 12768192_8 91 93
generate 12768192_8 94 102
antitumor 12768192_8 103 112
immunity 12768192_8 113 121
, 12768192_8 122 123
even 12768192_8 124 128
in 12768192_8 129 131
the 12768192_8 132 135
presence 12768192_8 136 144
of 12768192_8 145 147
DMXAA 12768192_8 148 153
. 12768192_8 154 155

Association 21388909_1 0 11
between 21388909_1 12 19
ABCB 21388909_1 20 24
1 21388909_1 24 25
polymorphism 21388909_1 26 38
and 21388909_1 39 42
response 21388909_1 43 51
to 21388909_1 52 54
sodium 21388909_1 55 61
valproate 21388909_1 62 71
treatment 21388909_1 72 81
in 21388909_1 82 84
Malaysian 21388909_1 85 94
epilepsy 21388909_1 95 103
patients 21388909_1 104 112
. 21388909_1 113 114

Similarly 17250611_11 0 9
, 17250611_11 10 11
the 17250611_11 12 15
allele 17250611_11 16 22
of 17250611_11 23 25
TAS 17250611_11 26 29
2 17250611_11 29 30
R 17250611_11 30 31
16 17250611_11 31 33
that 17250611_11 34 38
is 17250611_11 39 41
associated 17250611_11 42 52
with 17250611_11 53 57
a 17250611_11 58 59
lower 17250611_11 60 65
risk 17250611_11 66 70
for 17250611_11 71 74
alcohol 17250611_11 75 82
dependence 17250611_11 83 93
is 17250611_11 94 96
also 17250611_11 97 101
associated 17250611_11 102 112
with 17250611_11 113 117
lower 17250611_11 118 123
mean 17250611_11 124 128
Maxdrinks 17250611_11 129 138
scores 17250611_11 139 145
in 17250611_11 146 148
African 17250611_11 149 156
- 17250611_11 156 157
American 17250611_11 157 165
families 17250611_11 166 174
. 17250611_11 175 176

BACKGROUND 23407558_2 0 10
: 23407558_2 11 12
Development 23407558_2 13 24
of 23407558_2 25 27
acquired 23407558_2 28 36
resistance 23407558_2 37 47
limits 23407558_2 48 54
the 23407558_2 55 58
utility 23407558_2 59 66
of 23407558_2 67 69
epidermal 23407558_2 70 79
growth 23407558_2 80 86
factor 23407558_2 87 93
receptor 23407558_2 94 102
( 23407558_2 103 104
EGFR 23407558_2 105 109
) 23407558_2 110 111
tyrosine 23407558_2 112 120
kinase 23407558_2 121 127
inhibitors 23407558_2 128 138
( 23407558_2 139 140
TKI 23407558_2 141 144
) 23407558_2 145 146
for 23407558_2 147 150
the 23407558_2 151 154
treatment 23407558_2 155 164
of 23407558_2 165 167
EGFR 23407558_2 168 172
- 23407558_2 173 174
mutant 23407558_2 174 180
lung 23407558_2 181 185
cancers 23407558_2 186 193
. 23407558_2 194 195

Combination 27522730_20 0 11
of 27522730_20 12 14
blood 27522730_20 15 20
group 27522730_20 21 26
specificity 27522730_20 27 38
and 27522730_20 39 42
interleukin 27522730_20 43 54
28 27522730_20 55 57
B 27522730_20 57 58
gene 27522730_20 59 63
polymorphism 27522730_20 64 76
is 27522730_20 77 79
a 27522730_20 80 81
simple 27522730_20 82 88
and 27522730_20 89 92
reliable 27522730_20 93 101
predictor 27522730_20 102 111
of 27522730_20 112 114
SVR 27522730_20 115 118
and 27522730_20 119 122
dynamics 27522730_20 123 131
of 27522730_20 132 134
fibrosis 27522730_20 135 143
in 27522730_20 144 146
patients 27522730_20 147 155
with 27522730_20 156 160
CHC 27522730_20 161 164
- 27522730_20 164 165
I 27522730_20 165 166
receiving 27522730_20 167 176
AVT 27522730_20 177 180
with 27522730_20 181 185
pegylated 27522730_20 186 195
interferon 27522730_20 196 206
a 27522730_20 207 208
- 27522730_20 208 209
2 27522730_20 209 210
and 27522730_20 211 214
ribavirin 27522730_20 215 224
; 27522730_20 225 226
also 27522730_20 227 231
, 27522730_20 232 233
it 27522730_20 234 236
may 27522730_20 237 240
be 27522730_20 241 243
an 27522730_20 244 246
instrument 27522730_20 247 257
of 27522730_20 258 260
selection 27522730_20 261 270
of 27522730_20 271 273
patients 27522730_20 274 282
for 27522730_20 283 286
interferon 27522730_20 287 297
- 27522730_20 297 298
free 27522730_20 298 302
therapy 27522730_20 303 310
. 27522730_20 311 312

Additionally 21187469_5 0 12
, 21187469_5 13 14
RT 21187469_5 15 17
- 21187469_5 17 18
PCR 21187469_5 18 21
analysis 21187469_5 22 30
of 21187469_5 31 33
MiaPaca 21187469_5 34 41
2 21187469_5 41 42
cells 21187469_5 43 48
treated 21187469_5 49 56
with 21187469_5 57 61
1 21187469_5 62 63
, 21187469_5 64 65
10 21187469_5 66 68
or 21187469_5 69 71
100 21187469_5 72 75
M 21187469_5 76 77
of 21187469_5 78 80
I 21187469_5 81 82
3 21187469_5 82 83
C 21187469_5 83 84
showed 21187469_5 85 91
that 21187469_5 92 96
I 21187469_5 97 98
3 21187469_5 98 99
C 21187469_5 99 100
reactivated 21187469_5 101 112
the 21187469_5 113 116
tumor 21187469_5 117 122
suppressor 21187469_5 123 133
gene 21187469_5 134 138
p 21187469_5 139 140
16 21187469_5 140 142
INK 21187469_5 142 145
4 21187469_5 145 146
a 21187469_5 146 147
in 21187469_5 148 150
pancreatic 21187469_5 151 161
cancer 21187469_5 162 168
cells 21187469_5 169 174
. 21187469_5 175 176

OBJECTIVE 7944879_2 0 9
: 7944879_2 10 11
To 7944879_2 12 14
test 7944879_2 15 19
the 7944879_2 20 23
hypothesis 7944879_2 24 34
that 7944879_2 35 39
interindividual 7944879_2 40 55
differences 7944879_2 56 67
in 7944879_2 68 70
response 7944879_2 71 79
to 7944879_2 80 82
clozapine 7944879_2 83 92
therapy 7944879_2 93 100
might 7944879_2 101 106
be 7944879_2 107 109
attributable 7944879_2 110 122
to 7944879_2 123 125
the 7944879_2 126 129
D 7944879_2 130 131
4 7944879_2 131 132
dopamine 7944879_2 133 141
receptor 7944879_2 142 150
( 7944879_2 151 152
DRD 7944879_2 153 156
4 7944879_2 156 157
) 7944879_2 158 159
alleles 7944879_2 160 167
they 7944879_2 168 172
carry 7944879_2 173 178
. 7944879_2 179 180

PTH 23515284_5 0 3
infusion 23515284_5 4 12
for 23515284_5 13 16
8 23515284_5 17 18
days 23515284_5 19 23
caused 23515284_5 24 30
a 23515284_5 31 32
rapid 23515284_5 33 38
and 23515284_5 39 42
persistent 23515284_5 43 53
decrease 23515284_5 54 62
in 23515284_5 63 65
serum 23515284_5 66 71
Pi 23515284_5 72 74
in 23515284_5 75 77
Wt 23515284_5 78 80
mice 23515284_5 81 85
, 23515284_5 86 87
whereas 23515284_5 88 95
serum 23515284_5 96 101
Pi 23515284_5 102 104
in 23515284_5 105 107
DD 23515284_5 108 110
mice 23515284_5 111 115
fell 23515284_5 116 120
only 23515284_5 121 125
transiently 23515284_5 126 137
for 23515284_5 138 141
the 23515284_5 142 145
first 23515284_5 146 151
2 23515284_5 152 153
days 23515284_5 154 158
. 23515284_5 159 160

Intercellular 12504868_8 0 13
adhesion 12504868_8 14 22
molecule 12504868_8 23 31
- 12504868_8 31 32
1 12504868_8 32 33
gene 12504868_8 34 38
expression 12504868_8 39 49
also 12504868_8 50 54
was 12504868_8 55 58
upregulated 12504868_8 59 70
in 12504868_8 71 73
a 12504868_8 74 75
synergistic 12504868_8 76 87
manner 12504868_8 88 94
in 12504868_8 95 97
cortical 12504868_8 98 106
, 12504868_8 107 108
striatal 12504868_8 109 117
, 12504868_8 118 119
and 12504868_8 120 123
hippocampal 12504868_8 124 135
regions 12504868_8 136 143
in 12504868_8 144 146
mice 12504868_8 147 151
which 12504868_8 152 157
received 12504868_8 158 166
injections 12504868_8 167 177
of 12504868_8 178 180
Tat 12504868_8 181 184
combined 12504868_8 185 193
with 12504868_8 194 198
METH 12504868_8 199 203
compared 12504868_8 204 212
to 12504868_8 213 215
the 12504868_8 216 219
effects 12504868_8 220 227
of 12504868_8 228 230
these 12504868_8 231 236
agents 12504868_8 237 243
alone 12504868_8 244 249
. 12504868_8 250 251

rs 26505400_7 0 2
2115819 26505400_7 2 9
, 26505400_7 10 11
rs 26505400_7 12 14
9934438 26505400_7 14 21
, 26505400_7 22 23
and 26505400_7 24 27
rs 26505400_7 28 30
689466 26505400_7 30 36
, 26505400_7 37 38
located 26505400_7 39 46
in 26505400_7 47 49
the 26505400_7 50 53
ALOX 26505400_7 54 58
5 26505400_7 58 59
( 26505400_7 60 61
arachidonate 26505400_7 62 74
5 26505400_7 75 76
- 26505400_7 76 77
lipoxygenase 26505400_7 77 89
) 26505400_7 90 91
, 26505400_7 92 93
VKORC 26505400_7 94 99
1 26505400_7 99 100
( 26505400_7 101 102
vitamin 26505400_7 103 110
K 26505400_7 111 112
epoxide 26505400_7 113 120
reductase 26505400_7 121 130
complex 26505400_7 131 138
, 26505400_7 139 140
subunit 26505400_7 141 148
1 26505400_7 149 150
) 26505400_7 151 152
and 26505400_7 153 156
PTGS 26505400_7 157 161
2 26505400_7 161 162
( 26505400_7 163 164
prostaglandin 26505400_7 165 178
- 26505400_7 178 179
endoperoxide 26505400_7 179 191
synthase 26505400_7 192 200
2 26505400_7 201 202
) 26505400_7 203 204
genes 26505400_7 205 210
, 26505400_7 211 212
respectively 26505400_7 213 225
, 26505400_7 226 227
in 26505400_7 228 230
the 26505400_7 231 234
Tibetan 26505400_7 235 242
population 26505400_7 243 253
were 26505400_7 254 258
different 26505400_7 259 268
from 26505400_7 269 273
those 26505400_7 274 279
in 26505400_7 280 282
most 26505400_7 283 287
of 26505400_7 288 290
the 26505400_7 291 294
populations 26505400_7 295 306
. 26505400_7 307 308

RESULTS 22995156_8 0 7
: 22995156_8 8 9
Higher 22995156_8 10 16
B 22995156_8 17 18
- 22995156_8 18 19
Cd 22995156_8 19 21
( 22995156_8 22 23
natural 22995156_8 24 31
log 22995156_8 32 35
- 22995156_8 35 36
transformed 22995156_8 36 47
) 22995156_8 48 49
with 22995156_8 50 54
increasing 22995156_8 55 65
number 22995156_8 66 72
of 22995156_8 73 75
MT 22995156_8 76 78
1 22995156_8 78 79
A 22995156_8 79 80
rs 22995156_8 81 83
11076161 22995156_8 83 91
A 22995156_8 92 93
- 22995156_8 93 94
alleles 22995156_8 94 101
was 22995156_8 102 105
found 22995156_8 106 111
in 22995156_8 112 114
the 22995156_8 115 118
highly 22995156_8 119 125
polluted 22995156_8 126 134
group 22995156_8 135 140
( 22995156_8 141 142
p 22995156_8 143 144
- 22995156_8 144 145
value 22995156_8 145 150
trend 22995156_8 151 156
= 22995156_8 157 158
0 22995156_8 159 160
. 22995156_8 160 161
033 22995156_8 161 164
; 22995156_8 165 166
all 22995156_8 167 170
p 22995156_8 171 172
- 22995156_8 172 173
values 22995156_8 173 179
adjusted 22995156_8 180 188
for 22995156_8 189 192
age 22995156_8 193 196
, 22995156_8 197 198
sex 22995156_8 199 202
, 22995156_8 203 204
and 22995156_8 205 208
smoking 22995156_8 209 216
) 22995156_8 217 218
. 22995156_8 219 220

To 24673480_4 0 2
reach 24673480_4 3 8
an 24673480_4 9 11
effective 24673480_4 12 21
dose 24673480_4 22 26
while 24673480_4 27 32
avoiding 24673480_4 33 41
adverse 24673480_4 42 49
drug 24673480_4 50 54
reactions 24673480_4 55 64
( 24673480_4 65 66
ADRs 24673480_4 67 71
) 24673480_4 72 73
, 24673480_4 74 75
testing 24673480_4 76 83
of 24673480_4 84 86
CYP 24673480_4 87 90
2 24673480_4 90 91
D 24673480_4 91 92
6 24673480_4 92 93
genotype 24673480_4 94 102
prior 24673480_4 103 108
to 24673480_4 109 111
carvedilol 24673480_4 112 122
initiation 24673480_4 123 133
may 24673480_4 134 137
be 24673480_4 138 140
considered 24673480_4 141 151
. 24673480_4 152 153

CONCLUSIONS 21709633_9 0 11
: 21709633_9 12 13
Our 21709633_9 14 17
results 21709633_9 18 25
suggest 21709633_9 26 33
that 21709633_9 34 38
the 21709633_9 39 42
magnitude 21709633_9 43 52
of 21709633_9 53 55
FPG 21709633_9 56 59
reduction 21709633_9 60 69
after 21709633_9 70 75
6 21709633_9 76 77
- 21709633_9 77 78
month 21709633_9 78 83
sulphonylurea 21709633_9 84 97
treatment 21709633_9 98 107
in 21709633_9 108 110
addition 21709633_9 111 119
to 21709633_9 120 122
metformin 21709633_9 123 132
in 21709633_9 133 135
patients 21709633_9 136 144
with 21709633_9 145 149
type 21709633_9 150 154
2 21709633_9 155 156
diabetes 21709633_9 157 165
is 21709633_9 166 168
related 21709633_9 169 176
to 21709633_9 177 179
the 21709633_9 180 183
variation 21709633_9 184 193
in 21709633_9 194 196
KCNQ 21709633_9 197 201
1 21709633_9 201 202
. 21709633_9 203 204

However 24809685_11 0 7
, 24809685_11 8 9
the 24809685_11 10 13
presently 24809685_11 14 23
observed 24809685_11 24 32
trend 24809685_11 33 38
towards 24809685_11 39 46
CpG 24809685_11 47 50
- 24809685_11 51 52
specific 24809685_11 52 60
MAO 24809685_11 61 64
- 24809685_11 64 65
A 24809685_11 65 66
gene 24809685_11 67 71
hypomethylation 24809685_11 72 87
- 24809685_11 88 89
possibly 24809685_11 89 97
via 24809685_11 98 101
increased 24809685_11 102 111
gene 24809685_11 112 116
expression 24809685_11 117 127
and 24809685_11 128 131
consecutively 24809685_11 132 145
decreased 24809685_11 146 155
serotonin 24809685_11 156 165
and 24809685_11 166 169
/ 24809685_11 169 170
or 24809685_11 170 172
norepinephrine 24809685_11 173 187
availability 24809685_11 188 200
- 24809685_11 201 202
to 24809685_11 202 204
potentially 24809685_11 205 216
drive 24809685_11 217 222
impaired 24809685_11 223 231
antidepressant 24809685_11 232 246
treatment 24809685_11 247 256
response 24809685_11 257 265
in 24809685_11 266 268
female 24809685_11 269 275
patients 24809685_11 276 284
might 24809685_11 285 290
be 24809685_11 291 293
worthwhile 24809685_11 294 304
to 24809685_11 305 307
be 24809685_11 308 310
followed 24809685_11 311 319
up 24809685_11 320 322
in 24809685_11 323 325
larger 24809685_11 326 332
pharmacoepigenetic 24809685_11 333 351
studies 24809685_11 352 359
. 24809685_11 360 361

beta 15470329_7 0 4
1 15470329_7 5 6
- 15470329_7 7 8
Adrenergic 15470329_7 8 18
receptor 15470329_7 19 27
polymorphisms 15470329_7 28 41
Ser 15470329_7 42 45
49 15470329_7 45 47
Gly 15470329_7 47 50
and 15470329_7 51 54
Arg 15470329_7 55 58
389 15470329_7 59 62
Gly 15470329_7 62 65
were 15470329_7 66 70
included 15470329_7 71 79
as 15470329_7 80 82
factors 15470329_7 83 90
possibly 15470329_7 91 99
interfering 15470329_7 100 111
with 15470329_7 112 116
the 15470329_7 117 120
pharmacokinetic 15470329_7 121 136
- 15470329_7 137 138
pharmacodynamic 15470329_7 139 154
relationship 15470329_7 155 167
of 15470329_7 168 170
metoprolol 15470329_7 171 181
. 15470329_7 182 183

Molecular 11320258_1 0 9
mechanisms 11320258_1 10 20
of 11320258_1 21 23
cocaine 11320258_1 24 31
reward 11320258_1 32 38
: 11320258_1 39 40
combined 11320258_1 41 49
dopamine 11320258_1 50 58
and 11320258_1 59 62
serotonin 11320258_1 63 72
transporter 11320258_1 73 84
knockouts 11320258_1 85 94
eliminate 11320258_1 95 104
cocaine 11320258_1 105 112
place 11320258_1 113 118
preference 11320258_1 119 129
. 11320258_1 130 131

Male 15589566_1 0 4
- 15589566_1 4 5
specific 15589566_1 5 13
association 15589566_1 14 25
between 15589566_1 26 33
the 15589566_1 34 37
5 15589566_1 38 39
- 15589566_1 39 40
HTTLPR 15589566_1 40 46
S 15589566_1 47 48
allele 15589566_1 49 55
and 15589566_1 56 59
suicide 15589566_1 60 67
attempts 15589566_1 68 76
in 15589566_1 77 79
alcohol 15589566_1 80 87
- 15589566_1 88 89
dependent 15589566_1 89 98
subjects 15589566_1 99 107
. 15589566_1 108 109

Evaluation 20043790_1 0 10
of 20043790_1 11 13
the 20043790_1 14 17
safety 20043790_1 18 24
of 20043790_1 25 27
spinosad 20043790_1 28 36
and 20043790_1 37 40
milbemycin 20043790_1 41 51
5 20043790_1 52 53
- 20043790_1 53 54
oxime 20043790_1 54 59
orally 20043790_1 60 66
administered 20043790_1 67 79
to 20043790_1 80 82
Collies 20043790_1 83 90
with 20043790_1 91 95
the 20043790_1 96 99
MDR 20043790_1 100 103
1 20043790_1 103 104
gene 20043790_1 105 109
mutation 20043790_1 110 118
. 20043790_1 119 120

PURPOSE 21498394_2 0 7
: 21498394_2 8 9
To 21498394_2 10 12
explore 21498394_2 13 20
the 21498394_2 21 24
effect 21498394_2 25 31
of 21498394_2 32 34
dihydropyrimidine 21498394_2 35 52
dehydrogenase 21498394_2 53 66
( 21498394_2 67 68
DPD 21498394_2 69 72
) 21498394_2 73 74
single 21498394_2 75 81
nucleotide 21498394_2 82 92
polymorphisms 21498394_2 93 106
( 21498394_2 107 108
SNP 21498394_2 109 112
) 21498394_2 113 114
and 21498394_2 115 118
haplotypes 21498394_2 119 129
on 21498394_2 130 132
outcome 21498394_2 133 140
of 21498394_2 141 143
capecitabine 21498394_2 144 156
. 21498394_2 157 158

Recurrence 16721582_1 0 10
of 16721582_1 11 13
proteinuria 16721582_1 14 25
10 16721582_1 26 28
years 16721582_1 29 34
post 16721582_1 35 39
- 16721582_1 39 40
transplant 16721582_1 41 51
in 16721582_1 52 54
NPHS 16721582_1 55 59
2 16721582_1 59 60
- 16721582_1 61 62
associated 16721582_1 62 72
focal 16721582_1 73 78
segmental 16721582_1 79 88
glomerulosclerosis 16721582_1 89 107
after 16721582_1 108 113
conversion 16721582_1 114 124
from 16721582_1 125 129
cyclosporin 16721582_1 130 141
A 16721582_1 142 143
to 16721582_1 144 146
sirolimus 16721582_1 147 156
. 16721582_1 157 158

A 15975707_3 0 1
reporter 15975707_3 2 10
system 15975707_3 11 17
controlled 15975707_3 18 28
by 15975707_3 29 31
hTERT 15975707_3 32 37
promoter 15975707_3 38 46
was 15975707_3 47 50
constructed 15975707_3 51 62
to 15975707_3 63 65
evaluate 15975707_3 66 74
the 15975707_3 75 78
effects 15975707_3 79 86
of 15975707_3 87 89
tea 15975707_3 90 93
polyphenols 15975707_3 94 105
, 15975707_3 106 107
( 15975707_3 108 109
- 15975707_3 109 110
) 15975707_3 110 111
- 15975707_3 111 112
epigallocatechin 15975707_3 112 128
- 15975707_3 128 129
3 15975707_3 129 130
- 15975707_3 130 131
gallate 15975707_3 131 138
( 15975707_3 139 140
EGCG 15975707_3 141 145
) 15975707_3 146 147
and 15975707_3 148 151
( 15975707_3 152 153
- 15975707_3 153 154
) 15975707_3 154 155
- 15975707_3 155 156
epigallocatechin 15975707_3 156 172
( 15975707_3 173 174
EGC 15975707_3 175 178
) 15975707_3 179 180
on 15975707_3 181 183
the 15975707_3 184 187
repression 15975707_3 188 198
of 15975707_3 199 201
hTERT 15975707_3 202 207
transcription 15975707_3 208 221
. 15975707_3 222 223

The 18589174_8 0 3
median 18589174_8 4 10
C 18589174_8 11 12
/ 18589174_8 12 13
D 18589174_8 13 14
ratio 18589174_8 15 20
was 18589174_8 21 24
higher 18589174_8 25 31
for 18589174_8 32 35
TAC 18589174_8 36 39
- 18589174_8 40 41
treated 18589174_8 41 48
patients 18589174_8 49 57
with 18589174_8 58 62
MDR 18589174_8 63 66
- 18589174_8 66 67
1 18589174_8 67 68
- 18589174_8 69 70
3435 18589174_8 70 74
CC 18589174_8 74 76
( 18589174_8 77 78
14 18589174_8 79 81
. 18589174_8 81 82
1 18589174_8 82 83
, 18589174_8 84 85
7 18589174_8 86 87
. 18589174_8 87 88
3 18589174_8 88 89
, 18589174_8 90 91
and 18589174_8 92 95
2 18589174_8 96 97
. 18589174_8 97 98
2 18589174_8 98 99
ng 18589174_8 100 102
/ 18589174_8 102 103
mL 18589174_8 103 105
per 18589174_8 106 109
0 18589174_8 110 111
. 18589174_8 111 112
1 18589174_8 112 113
mg 18589174_8 114 116
/ 18589174_8 116 117
kg 18589174_8 117 119
/ 18589174_8 119 120
d 18589174_8 120 121
for 18589174_8 122 125
CC 18589174_8 126 128
, 18589174_8 129 130
CT 18589174_8 131 133
, 18589174_8 134 135
and 18589174_8 136 139
TT 18589174_8 140 142
, 18589174_8 143 144
respectively 18589174_8 145 157
; 18589174_8 158 159
P 18589174_8 160 161
= 18589174_8 162 163
. 18589174_8 164 165
023 18589174_8 165 168
) 18589174_8 169 170
. 18589174_8 171 172

The 26086150_9 0 3
risks 26086150_9 4 9
for 26086150_9 10 13
co 26086150_9 14 16
- 26086150_9 16 17
trimoxazole 26086150_9 17 28
- 26086150_9 29 30
induced 26086150_9 30 37
SJS 26086150_9 38 41
/ 26086150_9 42 43
TEN 26086150_9 44 47
in 26086150_9 48 50
patients 26086150_9 51 59
with 26086150_9 60 64
the 26086150_9 65 68
HLA 26086150_9 69 72
- 26086150_9 72 73
B 26086150_9 73 74
* 26086150_9 75 76
15 26086150_9 77 79
: 26086150_9 79 80
02 26086150_9 80 82
, 26086150_9 83 84
HLA 26086150_9 85 88
- 26086150_9 88 89
C 26086150_9 89 90
* 26086150_9 91 92
06 26086150_9 93 95
: 26086150_9 95 96
02 26086150_9 96 98
, 26086150_9 99 100
or 26086150_9 101 103
HLA 26086150_9 104 107
- 26086150_9 107 108
C 26086150_9 108 109
* 26086150_9 110 111
08 26086150_9 112 114
: 26086150_9 114 115
01 26086150_9 115 117
allele 26086150_9 118 124
were 26086150_9 125 129
about 26086150_9 130 135
3 26086150_9 136 137
- 26086150_9 137 138
11 26086150_9 138 140
- 26086150_9 140 141
fold 26086150_9 141 145
higher 26086150_9 146 152
when 26086150_9 153 157
compared 26086150_9 158 166
with 26086150_9 167 171
those 26086150_9 172 177
who 26086150_9 178 181
did 26086150_9 182 185
not 26086150_9 186 189
carry 26086150_9 190 195
one 26086150_9 196 199
of 26086150_9 200 202
these 26086150_9 203 208
alleles 26086150_9 209 216
. 26086150_9 217 218

A 20005399_5 0 1
reduction 20005399_5 2 11
in 20005399_5 12 14
basal 20005399_5 15 20
nitric 20005399_5 21 27
oxide 20005399_5 28 33
( 20005399_5 34 35
NO 20005399_5 36 38
) 20005399_5 39 40
release 20005399_5 41 48
as 20005399_5 49 51
a 20005399_5 52 53
result 20005399_5 54 60
of 20005399_5 61 63
genetic 20005399_5 64 71
variation 20005399_5 72 81
in 20005399_5 82 84
endothelial 20005399_5 85 96
NO 20005399_5 97 99
synthase 20005399_5 100 108
( 20005399_5 109 110
eNOS 20005399_5 111 115
) 20005399_5 116 117
function 20005399_5 118 126
may 20005399_5 127 130
predispose 20005399_5 131 141
to 20005399_5 142 144
hypertension 20005399_5 145 157
, 20005399_5 158 159
thrombosis 20005399_5 160 170
, 20005399_5 171 172
vasospasm 20005399_5 173 182
, 20005399_5 183 184
and 20005399_5 185 188
atherosclerosis 20005399_5 189 204
, 20005399_5 205 206
all 20005399_5 207 210
contributing 20005399_5 211 223
to 20005399_5 224 226
the 20005399_5 227 230
development 20005399_5 231 242
of 20005399_5 243 245
CAN 20005399_5 246 249
. 20005399_5 250 251

[ 15813023_1 0 1
Effect 15813023_1 2 8
of 15813023_1 9 11
MDR 15813023_1 12 15
1 15813023_1 15 16
polymorphic 15813023_1 17 28
expression 15813023_1 29 39
on 15813023_1 40 42
oral 15813023_1 43 47
disposition 15813023_1 48 59
of 15813023_1 60 62
cyclosporine 15813023_1 63 75
A 15813023_1 76 77
] 15813023_1 78 79
. 15813023_1 80 81

AIM 21734808_2 0 3
: 21734808_2 4 5
To 21734808_2 6 8
evaluate 21734808_2 9 17
bacterial 21734808_2 18 27
cytosine 21734808_2 28 36
deaminase 21734808_2 37 46
( 21734808_2 47 48
bCD 21734808_2 49 52
) 21734808_2 53 54
mutant 21734808_2 55 61
D 21734808_2 62 63
314 21734808_2 63 66
A 21734808_2 66 67
and 21734808_2 68 71
5 21734808_2 72 73
- 21734808_2 73 74
fluorocytosine 21734808_2 74 88
( 21734808_2 89 90
5 21734808_2 91 92
- 21734808_2 92 93
FC 21734808_2 93 95
) 21734808_2 96 97
for 21734808_2 98 101
treatment 21734808_2 102 111
of 21734808_2 112 114
colon 21734808_2 115 120
cancer 21734808_2 121 127
in 21734808_2 128 130
a 21734808_2 131 132
mouse 21734808_2 133 138
model 21734808_2 139 144
. 21734808_2 145 146

Furthermore 26385865_6 0 11
, 26385865_6 12 13
knockdown 26385865_6 14 23
of 26385865_6 24 26
the 26385865_6 27 30
human 26385865_6 31 36
ortholog 26385865_6 37 45
POLG 26385865_6 46 50
of 26385865_6 51 53
S 26385865_6 54 55
. 26385865_6 55 56
pombe 26385865_6 57 62
POG 26385865_6 63 66
1 26385865_6 66 67
in 26385865_6 68 70
human 26385865_6 71 76
cells 26385865_6 77 82
significantly 26385865_6 83 96
increased 26385865_6 97 106
the 26385865_6 107 110
cytotoxicity 26385865_6 111 123
of 26385865_6 124 126
sunitinib 26385865_6 127 136
. 26385865_6 137 138

BACKGROUND 21869714_2 0 10
: 21869714_2 11 12
Several 21869714_2 13 20
randomized 21869714_2 21 31
phase 21869714_2 32 37
III 21869714_2 38 41
studies 21869714_2 42 49
in 21869714_2 50 52
advanced 21869714_2 53 61
stage 21869714_2 62 67
non 21869714_2 68 71
- 21869714_2 71 72
small 21869714_2 72 77
cell 21869714_2 78 82
lung 21869714_2 83 87
cancer 21869714_2 88 94
( 21869714_2 95 96
NSCLC 21869714_2 97 102
) 21869714_2 103 104
confirmed 21869714_2 105 114
the 21869714_2 115 118
superior 21869714_2 119 127
response 21869714_2 128 136
rate 21869714_2 137 141
and 21869714_2 142 145
progression 21869714_2 146 157
- 21869714_2 157 158
free 21869714_2 158 162
survival 21869714_2 163 171
of 21869714_2 172 174
using 21869714_2 175 180
epidermal 21869714_2 181 190
growth 21869714_2 191 197
factor 21869714_2 198 204
receptor 21869714_2 205 213
( 21869714_2 214 215
EGFR 21869714_2 216 220
) 21869714_2 221 222
tyrosine 21869714_2 223 231
kinase 21869714_2 232 238
inhibitor 21869714_2 239 248
as 21869714_2 249 251
first 21869714_2 252 257
- 21869714_2 257 258
line 21869714_2 258 262
therapy 21869714_2 263 270
compared 21869714_2 271 279
with 21869714_2 280 284
chemotherapy 21869714_2 285 297
in 21869714_2 298 300
patients 21869714_2 301 309
with 21869714_2 310 314
activating 21869714_2 315 325
EGFR 21869714_2 326 330
mutations 21869714_2 331 340
. 21869714_2 341 342

We 23598060_11 0 2
find 23598060_11 3 7
that 23598060_11 8 12
P 23598060_11 13 14
50 23598060_11 14 16
and 23598060_11 17 20
PPI 23598060_11 21 24
may 23598060_11 25 28
be 23598060_11 29 31
influenced 23598060_11 32 42
by 23598060_11 43 45
COMT 23598060_11 46 50
rs 23598060_11 51 53
4680 23598060_11 53 57
polymorphisms 23598060_11 58 71
in 23598060_11 72 74
schizophrenia 23598060_11 75 88
; 23598060_11 89 90
more 23598060_11 91 95
excitingly 23598060_11 96 106
, 23598060_11 107 108
we 23598060_11 109 111
find 23598060_11 112 116
that 23598060_11 117 121
P 23598060_11 122 123
50 23598060_11 123 125
might 23598060_11 126 131
be 23598060_11 132 134
influenced 23598060_11 135 145
by 23598060_11 146 148
COMT 23598060_11 149 153
rs 23598060_11 154 156
737865 23598060_11 156 162
polymorphisms 23598060_11 163 176
and 23598060_11 177 180
PPI 23598060_11 181 184
may 23598060_11 185 188
be 23598060_11 189 191
influenced 23598060_11 192 202
by 23598060_11 203 205
COMT 23598060_11 206 210
rs 23598060_11 211 213
165599 23598060_11 213 219
polymorphisms 23598060_11 220 233
in 23598060_11 234 236
schizophrenia 23598060_11 237 250
, 23598060_11 251 252
and 23598060_11 253 256
their 23598060_11 257 262
mutations 23598060_11 263 272
are 23598060_11 273 276
associated 23598060_11 277 287
with 23598060_11 288 292
the 23598060_11 293 296
reduction 23598060_11 297 306
of 23598060_11 307 309
the 23598060_11 310 313
risk 23598060_11 314 318
of 23598060_11 319 321
P 23598060_11 322 323
50 23598060_11 323 325
or 23598060_11 326 328
PPI 23598060_11 329 332
defects 23598060_11 333 340
in 23598060_11 341 343
schizophrenia 23598060_11 344 357
. 23598060_11 358 359

Our 21747412_7 0 3
results 21747412_7 4 11
indicate 21747412_7 12 20
that 21747412_7 21 25
analysis 21747412_7 26 34
of 21747412_7 35 37
the 21747412_7 38 41
MTHFR 21747412_7 42 47
genotype 21747412_7 48 56
is 21747412_7 57 59
a 21747412_7 60 61
useful 21747412_7 62 68
tool 21747412_7 69 73
to 21747412_7 74 76
optimise 21747412_7 77 85
MTX 21747412_7 86 89
therapy 21747412_7 90 97
in 21747412_7 98 100
childhood 21747412_7 101 110
patients 21747412_7 111 119
with 21747412_7 120 124
ALL 21747412_7 125 128
. 21747412_7 129 130

Immunoglobulin 27378608_1 0 14
G 27378608_1 15 16
fragment 27378608_1 17 25
C 27378608_1 26 27
receptor 27378608_1 28 36
polymorphisms 27378608_1 37 50
and 27378608_1 51 54
efficacy 27378608_1 55 63
of 27378608_1 64 66
preoperative 27378608_1 67 79
chemotherapy 27378608_1 80 92
plus 27378608_1 93 97
trastuzumab 27378608_1 98 109
and 27378608_1 110 113
lapatinib 27378608_1 114 123
in 27378608_1 124 126
HER 27378608_1 127 130
2 27378608_1 130 131
- 27378608_1 132 133
positive 27378608_1 133 141
breast 27378608_1 142 148
cancer 27378608_1 149 155
. 27378608_1 156 157

Association 23103366_1 0 11
of 23103366_1 12 14
the 23103366_1 15 18
Arg 23103366_1 19 22
194 23103366_1 22 25
Trp 23103366_1 25 28
and 23103366_1 29 32
the 23103366_1 33 36
Arg 23103366_1 37 40
399 23103366_1 40 43
Gln 23103366_1 43 46
polymorphisms 23103366_1 47 60
of 23103366_1 61 63
the 23103366_1 64 67
XRCC 23103366_1 68 72
1 23103366_1 72 73
gene 23103366_1 74 78
with 23103366_1 79 83
risk 23103366_1 84 88
occurrence 23103366_1 89 99
and 23103366_1 100 103
the 23103366_1 104 107
response 23103366_1 108 116
to 23103366_1 117 119
adjuvant 23103366_1 120 128
therapy 23103366_1 129 136
among 23103366_1 137 142
Polish 23103366_1 143 149
women 23103366_1 150 155
with 23103366_1 156 160
breast 23103366_1 161 167
cancer 23103366_1 168 174
. 23103366_1 175 176

Following 16799968_5 0 9
the 16799968_5 10 13
administration 16799968_5 14 28
of 16799968_5 29 31
Jo 16799968_5 32 34
2 16799968_5 34 35
, 16799968_5 36 37
hepatocyte 16799968_5 38 48
apoptosis 16799968_5 49 58
, 16799968_5 59 60
liver 16799968_5 61 66
injury 16799968_5 67 73
, 16799968_5 74 75
and 16799968_5 76 79
animal 16799968_5 80 86
fatalities 16799968_5 87 97
were 16799968_5 98 102
abated 16799968_5 103 109
in 16799968_5 110 112
TCPOBOP 16799968_5 113 120
- 16799968_5 121 122
treated 16799968_5 122 129
CAR 16799968_5 130 133
+ 16799968_5 134 135
/ 16799968_5 136 137
+ 16799968_5 138 139
but 16799968_5 140 143
not 16799968_5 144 147
in 16799968_5 148 150
CAR 16799968_5 151 154
- 16799968_5 155 156
/ 16799968_5 157 158
- 16799968_5 159 160
mice 16799968_5 161 165
. 16799968_5 166 167

PMH 22027477_9 0 3
therapy 22027477_9 4 11
was 22027477_9 12 15
not 22027477_9 16 19
significantly 22027477_9 20 33
associated 22027477_9 34 44
with 22027477_9 45 49
the 22027477_9 50 53
MSI 22027477_9 54 57
- 22027477_9 58 59
H 22027477_9 59 60
, 22027477_9 61 62
CIMP 22027477_9 63 67
- 22027477_9 67 68
positive 22027477_9 68 76
or 22027477_9 77 79
BRAF 22027477_9 80 84
- 22027477_9 85 86
mutated 22027477_9 86 93
CRC 22027477_9 94 97
subtypes 22027477_9 98 106
. 22027477_9 107 108

This 22234350_11 0 4
is 22234350_11 5 7
a 22234350_11 8 9
tagging 22234350_11 10 17
SNP 22234350_11 18 21
for 22234350_11 22 25
one 22234350_11 26 29
of 22234350_11 30 32
the 22234350_11 33 36
five 22234350_11 37 41
dominant 22234350_11 42 50
NFATc 22234350_11 51 56
4 22234350_11 56 57
haplotypes 22234350_11 58 68
, 22234350_11 69 70
T 22234350_11 71 72
- 22234350_11 72 73
T 22234350_11 73 74
- 22234350_11 74 75
T 22234350_11 75 76
- 22234350_11 76 77
T 22234350_11 77 78
- 22234350_11 78 79
G 22234350_11 79 80
, 22234350_11 81 82
and 22234350_11 83 86
CNI 22234350_11 87 90
- 22234350_11 90 91
treated 22234350_11 92 99
recipients 22234350_11 100 110
with 22234350_11 111 115
this 22234350_11 116 120
haplotype 22234350_11 121 130
had 22234350_11 131 134
a 22234350_11 135 136
reduced 22234350_11 137 144
adjusted 22234350_11 145 153
risk 22234350_11 154 158
for 22234350_11 159 162
NODAT 22234350_11 163 168
( 22234350_11 169 170
hazard 22234350_11 171 177
ratio 22234350_11 178 183
: 22234350_11 184 185
0 22234350_11 186 187
. 22234350_11 187 188
45 22234350_11 188 190
; 22234350_11 191 192
95 22234350_11 193 195
% 22234350_11 196 197
confidence 22234350_11 198 208
interval 22234350_11 209 217
: 22234350_11 218 219
0 22234350_11 220 221
. 22234350_11 221 222
19 22234350_11 222 224
- 22234350_11 224 225
1 22234350_11 225 226
. 22234350_11 227 228
01 22234350_11 228 230
) 22234350_11 231 232
. 22234350_11 233 234

DISCUSSION 19344737_12 0 10
: 19344737_12 11 12
These 19344737_12 13 18
results 19344737_12 19 26
suggest 19344737_12 27 34
that 19344737_12 35 39
the 19344737_12 40 43
well 19344737_12 44 48
documented 19344737_12 49 59
relationship 19344737_12 60 72
between 19344737_12 73 80
conduct 19344737_12 81 88
disorder 19344737_12 89 97
, 19344737_12 98 99
the 19344737_12 100 103
behavioral 19344737_12 104 114
phenotype 19344737_12 115 124
of 19344737_12 125 127
impulsivity 19344737_12 128 139
, 19344737_12 140 141
and 19344737_12 142 145
problematic 19344737_12 146 157
alcohol 19344737_12 158 165
/ 19344737_12 166 167
drug 19344737_12 168 172
use 19344737_12 173 176
among 19344737_12 177 182
adolescents 19344737_12 183 194
may 19344737_12 195 198
be 19344737_12 199 201
moderated 19344737_12 202 211
by 19344737_12 212 214
A 19344737_12 215 216
1 19344737_12 216 217
carrier 19344737_12 218 225
status 19344737_12 226 232
of 19344737_12 233 235
the 19344737_12 236 239
DRD 19344737_12 240 243
2 19344737_12 243 244
gene 19344737_12 245 249
. 19344737_12 250 251

In 22072145_4 0 2
this 22072145_4 3 7
study 22072145_4 8 13
, 22072145_4 14 15
the 22072145_4 16 19
authors 22072145_4 20 27
investigated 22072145_4 28 40
the 22072145_4 41 44
association 22072145_4 45 56
of 22072145_4 57 59
MMP 22072145_4 60 63
- 22072145_4 63 64
2 22072145_4 64 65
polymorphisms 22072145_4 66 79
with 22072145_4 80 84
treatment 22072145_4 85 94
efficacy 22072145_4 95 103
and 22072145_4 104 107
the 22072145_4 108 111
occurrence 22072145_4 112 122
of 22072145_4 123 125
severe 22072145_4 126 132
toxicity 22072145_4 133 141
in 22072145_4 142 144
patients 22072145_4 145 153
with 22072145_4 154 158
nonsmall 22072145_4 159 167
cell 22072145_4 168 172
lung 22072145_4 173 177
cancer 22072145_4 178 184
( 22072145_4 185 186
NSCLC 22072145_4 187 192
) 22072145_4 193 194
who 22072145_4 195 198
were 22072145_4 199 203
receiving 22072145_4 204 213
first 22072145_4 214 219
- 22072145_4 219 220
line 22072145_4 220 224
, 22072145_4 225 226
platinum 22072145_4 227 235
- 22072145_4 236 237
based 22072145_4 237 242
chemotherapy 22072145_4 243 255
. 22072145_4 256 257

CONCLUSION 23091097_11 0 10
: 23091097_11 11 12
The 23091097_11 13 16
combination 23091097_11 17 28
of 23091097_11 29 31
11 23091097_11 32 34
q 23091097_11 34 35
deletion 23091097_11 36 44
and 23091097_11 45 48
ATM 23091097_11 49 52
mutation 23091097_11 53 61
in 23091097_11 62 64
CLL 23091097_11 65 68
is 23091097_11 69 71
associated 23091097_11 72 82
with 23091097_11 83 87
significantly 23091097_11 88 101
shorter 23091097_11 102 109
progression 23091097_11 110 121
- 23091097_11 121 122
free 23091097_11 122 126
and 23091097_11 127 130
overall 23091097_11 131 138
survival 23091097_11 139 147
following 23091097_11 148 157
first 23091097_11 158 163
- 23091097_11 163 164
line 23091097_11 164 168
treatment 23091097_11 169 178
with 23091097_11 179 183
alkylating 23091097_11 184 194
agents 23091097_11 195 201
and 23091097_11 202 205
purine 23091097_11 206 212
analogs 23091097_11 213 220
. 23091097_11 221 222

Pharmacogenetic 25043824_3 0 15
aspects 25043824_3 16 23
of 25043824_3 24 26
the 25043824_3 27 30
serotonin 25043824_3 31 40
metabolism 25043824_3 41 51
, 25043824_3 52 53
specifically 25043824_3 54 66
variation 25043824_3 67 76
in 25043824_3 77 79
the 25043824_3 80 83
5 25043824_3 84 85
- 25043824_3 85 86
HTTLPR 25043824_3 86 92
may 25043824_3 93 96
be 25043824_3 97 99
involved 25043824_3 100 108
. 25043824_3 109 110

Therefore 22501025_4 0 9
, 22501025_4 10 11
we 22501025_4 12 14
examined 22501025_4 15 23
whether 22501025_4 24 31
individual 22501025_4 32 42
differences 22501025_4 43 54
in 22501025_4 55 57
SRs 22501025_4 58 61
, 22501025_4 62 63
which 22501025_4 64 69
reflect 22501025_4 70 77
sensitivity 22501025_4 78 89
to 22501025_4 90 92
the 22501025_4 93 96
effects 22501025_4 97 104
of 22501025_4 105 107
alcohol 22501025_4 108 115
, 22501025_4 116 117
are 22501025_4 118 121
associated 22501025_4 122 132
with 22501025_4 133 137
variation 22501025_4 138 147
in 22501025_4 148 150
GABRA 22501025_4 151 156
2 22501025_4 156 157
. 22501025_4 158 159

Inhibiting 10911933_12 0 10
CYP 10911933_12 11 14
2 10911933_12 14 15
A 10911933_12 15 16
6 10911933_12 16 17
( 10911933_12 18 19
e 10911933_12 20 21
. 10911933_12 21 22
g 10911933_12 22 23
. 10911933_12 23 24
tranylcypromine 10911933_12 25 40
, 10911933_12 41 42
methoxsalen 10911933_12 43 54
) 10911933_12 55 56
decreases 10911933_12 57 66
smoking 10911933_12 67 74
and 10911933_12 75 78
the 10911933_12 79 82
activation 10911933_12 83 93
of 10911933_12 94 96
procarcinogens 10911933_12 97 111
. 10911933_12 112 113

Accordingly 17042920_15 0 11
, 17042920_15 12 13
cyclosporine 17042920_15 14 26
dose 17042920_15 27 31
- 17042920_15 31 32
adjusted 17042920_15 32 40
C 17042920_15 41 42
0 17042920_15 42 43
was 17042920_15 44 47
larger 17042920_15 48 54
in 17042920_15 55 57
CYP 17042920_15 58 61
3 17042920_15 61 62
A 17042920_15 62 63
5 17042920_15 63 64
non 17042920_15 65 68
- 17042920_15 68 69
expressors 17042920_15 69 79
than 17042920_15 80 84
expressors 17042920_15 85 95
in 17042920_15 96 98
the 17042920_15 99 102
first 17042920_15 103 108
week 17042920_15 109 113
after 17042920_15 114 119
renal 17042920_15 120 125
transplantation 17042920_15 126 141
. 17042920_15 142 143

Functional 24293093_1 0 10
polymorphism 24293093_1 11 23
of 24293093_1 24 26
CYP 24293093_1 27 30
2 24293093_1 30 31
B 24293093_1 31 32
6 24293093_1 32 33
G 24293093_1 34 35
15631 24293093_1 35 40
T 24293093_1 40 41
is 24293093_1 42 44
associated 24293093_1 45 55
with 24293093_1 56 60
hematologic 24293093_1 61 72
and 24293093_1 73 76
cytogenetic 24293093_1 77 88
response 24293093_1 89 97
in 24293093_1 98 100
chronic 24293093_1 101 108
myeloid 24293093_1 109 116
leukemia 24293093_1 117 125
patients 24293093_1 126 134
treated 24293093_1 135 142
with 24293093_1 143 147
imatinib 24293093_1 148 156
. 24293093_1 157 158

CD 22961402_1 0 2
55 22961402_1 2 4
polymorphisms 22961402_1 5 18
and 22961402_1 19 22
risk 22961402_1 23 27
of 22961402_1 28 30
aspirin 22961402_1 31 38
- 22961402_1 39 40
exacerbated 22961402_1 41 52
respiratory 22961402_1 53 64
disease 22961402_1 65 72
. 22961402_1 73 74

This 25666034_12 0 4
finding 25666034_12 5 12
supports 25666034_12 13 21
involvement 25666034_12 22 33
of 25666034_12 34 36
TRb 25666034_12 37 40
signaling 25666034_12 41 50
in 25666034_12 51 53
the 25666034_12 54 57
effect 25666034_12 58 64
of 25666034_12 65 67
acute 25666034_12 68 73
nicotine 25666034_12 74 82
on 25666034_12 83 85
hippocampus 25666034_12 86 97
- 25666034_12 97 98
dependent 25666034_12 98 107
memory 25666034_12 108 114
. 25666034_12 115 116

The 15608594_4 0 3
goal 15608594_4 4 8
of 15608594_4 9 11
this 15608594_4 12 16
study 15608594_4 17 22
was 15608594_4 23 26
to 15608594_4 27 29
test 15608594_4 30 34
whether 15608594_4 35 42
the 15608594_4 43 46
A 15608594_4 47 48
118 15608594_4 48 51
G 15608594_4 51 52
polymorphism 15608594_4 53 65
is 15608594_4 66 68
associated 15608594_4 69 79
with 15608594_4 80 84
sensitivity 15608594_4 85 96
to 15608594_4 97 99
the 15608594_4 100 103
effects 15608594_4 104 111
of 15608594_4 112 114
alcohol 15608594_4 115 122
. 15608594_4 123 124

Intracerebroventricular 25251606_7 0 23
infusion 25251606_7 24 32
of 25251606_7 33 35
a 25251606_7 36 37
peptide 25251606_7 38 45
that 25251606_7 46 50
mimics 25251606_7 51 57
the 25251606_7 58 61
effector 25251606_7 62 70
domain 25251606_7 71 77
of 25251606_7 78 80
MARCKS 25251606_7 81 87
increases 25251606_7 88 97
the 25251606_7 98 101
content 25251606_7 102 109
of 25251606_7 110 112
PI 25251606_7 113 115
( 25251606_7 115 116
4 25251606_7 116 117
, 25251606_7 117 118
5 25251606_7 118 119
) 25251606_7 119 120
P 25251606_7 120 121
2 25251606_7 121 122
in 25251606_7 123 125
the 25251606_7 126 129
synaptic 25251606_7 130 138
membrane 25251606_7 139 147
and 25251606_7 148 151
ameliorates 25251606_7 152 163
behavioral 25251606_7 164 174
abnormalities 25251606_7 175 188
in 25251606_7 189 191
ASMko 25251606_7 192 197
mice 25251606_7 198 202
. 25251606_7 203 204

